data_1wvo_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1wvo _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.786 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 84.7 p -129.14 151.32 49.94 Favored 'General case' 0 C--O 1.24 0.593 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -75.24 105.69 4.41 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 O-C-N 122.014 -0.429 . . . . 0.0 111.109 -179.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.0 m -102.86 152.82 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-O 122.654 1.216 . . . . 0.0 107.769 178.088 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.58 128.28 35.31 Favored 'General case' 0 C--N 1.319 -0.722 0 C-N-CA 124.958 1.303 . . . . 0.0 107.94 178.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.488 ' HE2' ' HB ' ' A' ' 27' ' ' THR . 20.1 ttmm -75.86 -23.92 55.69 Favored 'General case' 0 C--N 1.327 -0.378 0 O-C-N 121.012 -1.055 . . . . 0.0 111.099 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.7 m -148.15 173.25 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 C-N-CA 126.589 1.956 . . . . 0.0 107.678 -179.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 54.5 tttp -67.42 127.87 34.3 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 177.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.3 mt -111.48 96.43 31.73 Favored Pre-proline 0 C--N 1.331 -0.206 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -61.09 145.29 99.1 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 121.576 1.518 . . . . 0.0 110.496 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -50.77 146.2 6.11 Favored 'General case' 0 C--O 1.238 0.486 0 C-N-CA 124.936 1.294 . . . . 0.0 110.799 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.55 -3.64 81.6 Favored Glycine 0 CA--C 1.531 1.051 0 CA-C-O 119.327 -0.707 . . . . 0.0 113.153 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 20.0 m -88.22 143.78 26.84 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 118.956 1.378 . . . . 0.0 110.704 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 13.2 mm -83.98 140.24 16.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 71.0 mt -73.83 149.4 41.64 Favored 'General case' 0 C--O 1.238 0.489 0 C-N-CA 123.515 0.726 . . . . 0.0 112.452 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 22.6 p -146.94 157.4 43.62 Favored 'General case' 0 C--O 1.238 0.49 0 C-N-CA 127.526 2.33 . . . . 0.0 107.073 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 19.9 mmt -67.58 -24.15 65.47 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 118.826 0.739 . . . . 0.0 110.571 179.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -67.72 -12.67 61.01 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.476 -0.765 . . . . 0.0 112.207 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 47.7 mtm -115.45 10.78 15.83 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.078 0.951 . . . . 0.0 110.915 179.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -132.16 161.77 32.52 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 119.655 1.116 . . . . 0.0 112.53 -179.026 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.488 ' HB ' ' HE2' ' A' ' 12' ' ' LYS . 12.6 t -159.31 170.93 20.76 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 127.847 2.459 . . . . 0.0 107.294 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -125.36 110.87 25.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 178.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -76.68 91.73 3.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.8 p -54.53 125.54 9.43 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 C-N-CA 126.288 1.835 . . . . 0.0 106.591 178.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.65 -61.73 0.28 Allowed Glycine 0 N--CA 1.45 -0.417 0 CA-C-O 119.687 -0.507 . . . . 0.0 112.155 -179.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -148.7 148.65 28.63 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-N 118.313 1.056 . . . . 0.0 110.419 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -80.47 44.02 1.65 Allowed 'Trans proline' 0 CA--C 1.548 1.191 0 C-N-CA 123.645 2.896 . . . . 0.0 110.729 179.358 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 24.5 ttmt -84.85 92.8 8.35 Favored 'General case' 0 CA--C 1.521 -0.16 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.14 -132.59 6.74 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 179.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.444 ' CD2' ' HD2' ' A' ' 37' ' ' PRO . 0.6 OUTLIER -94.02 139.93 22.75 Favored Pre-proline 0 C--O 1.238 0.462 0 C-N-CA 124.805 1.242 . . . . 0.0 110.215 -179.727 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.444 ' HD2' ' CD2' ' A' ' 36' ' ' TYR . 83.9 Cg_endo -75.17 148.77 35.1 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.022 1.815 . . . . 0.0 112.104 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -75.99 -0.82 10.7 Favored 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 122.962 2.441 . . . . 0.0 111.709 178.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -81.55 -49.79 10.14 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.629 1.572 . . . . 0.0 108.794 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 -85.65 6.28 28.21 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.767 1.227 . . . . 0.0 111.344 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.0 tt -44.1 -41.66 1.81 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 C-N-CA 126.506 1.922 . . . . 0.0 114.607 -178.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -60.49 -32.61 71.6 Favored 'General case' 0 C--N 1.333 -0.138 0 O-C-N 121.575 -0.703 . . . . 0.0 112.003 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 33.7 m-80 -63.63 -30.42 71.53 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 123.377 0.671 . . . . 0.0 110.95 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.3 mt -71.93 -42.57 66.51 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 123.377 0.671 . . . . 0.0 109.828 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.2 t -67.2 93.73 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-O 122.212 1.006 . . . . 0.0 109.18 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 137.05 -11.7 3.88 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 126.202 1.858 . . . . 0.0 112.286 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -84.39 166.4 17.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 118.924 1.362 . . . . 0.0 109.069 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -110.3 139.58 45.35 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.5 m -81.99 150.35 4.49 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 O-C-N 123.583 0.552 . . . . 0.0 110.301 179.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 91.9 mt -101.01 -10.43 20.55 Favored 'General case' 0 C--O 1.233 0.226 0 C-N-CA 125.364 1.466 . . . . 0.0 111.88 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.4 160.56 14.99 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 C-N-CA 124.529 1.132 . . . . 0.0 109.154 178.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 11.6 m -78.65 99.88 6.77 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 14.9 t -73.2 150.41 7.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 179.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -102.55 168.12 9.49 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 123.589 0.756 . . . . 0.0 109.265 178.358 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 72.4 tt0 -61.51 144.18 54.7 Favored 'General case' 0 CA--C 1.538 0.495 0 O-C-N 121.413 -0.804 . . . . 0.0 108.834 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . 0.349 0.1 OUTLIER 56.92 13.06 1.35 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 128.077 2.551 . . . . 0.0 114.543 179.699 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -78.33 153.72 31.46 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 124.077 0.951 . . . . 0.0 112.403 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 20.0 m -81.43 113.07 19.25 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 124.75 1.22 . . . . 0.0 111.771 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.4 mm -76.88 144.31 11.83 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 3.0 mmt -134.53 161.21 35.7 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 125.877 1.671 . . . . 0.0 110.637 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -67.46 -29.15 68.53 Favored 'General case' 0 N--CA 1.467 0.378 0 O-C-N 121.354 -0.841 . . . . 0.0 111.773 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -74.01 -11.31 60.29 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 119.305 0.957 . . . . 0.0 112.486 179.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 69.6 mt -94.56 -4.43 47.94 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.341 1.057 . . . . 0.0 111.646 -179.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 m -122.54 140.36 46.59 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-N 120.162 1.346 . . . . 0.0 108.642 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 48.1 t0 . . . . . 0 C--O 1.24 0.59 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.902 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.5 p -139.83 161.46 37.52 Favored 'General case' 0 C--O 1.241 0.617 0 C-N-CA 125.758 1.623 . . . . 0.0 109.303 -179.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.2 t -85.88 133.17 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.8 m -129.38 160.62 40.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 178.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.4 118.78 12.71 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 126.38 1.872 . . . . 0.0 109.106 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.8 ttmm -68.01 -28.41 67.39 Favored 'General case' 0 N--CA 1.469 0.524 0 O-C-N 120.937 -1.102 . . . . 0.0 111.011 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.9 m -145.75 168.14 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 C-N-CA 127.778 2.431 . . . . 0.0 106.98 -179.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 80.9 tttt -68.81 128.78 37.88 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 8.2 mt -111.61 103.88 55.54 Favored Pre-proline 0 CA--C 1.538 0.507 0 C-N-CA 124.967 1.307 . . . . 0.0 108.552 -178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -69.96 147.74 62.21 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 121.949 1.766 . . . . 0.0 110.704 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 7.3 tm-20 -49.22 139.65 10.83 Favored 'General case' 0 C--O 1.237 0.425 0 C-N-CA 123.909 0.884 . . . . 0.0 111.413 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.04 -3.57 84.56 Favored Glycine 0 CA--C 1.523 0.551 0 CA-C-N 115.571 -0.74 . . . . 0.0 112.942 179.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.4 m -82.53 140.37 33.34 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 118.756 1.278 . . . . 0.0 109.591 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.4 mm -78.73 135.35 26.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 105.424 -2.065 . . . . 0.0 105.424 178.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 32.2 mt -75.35 131.52 40.31 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.751 0.82 . . . . 0.0 109.304 179.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.4 p -127.83 161.36 29.21 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 13.2 mmt -61.76 -27.49 68.77 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 121.878 -0.514 . . . . 0.0 111.257 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -74.58 -7.9 54.62 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.884 0.874 . . . . 0.0 113.06 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 70.4 mtm -113.94 7.7 16.99 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 119.27 0.941 . . . . 0.0 111.25 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -123.64 152.68 41.71 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 124.368 1.067 . . . . 0.0 109.36 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.9 t -150.3 161.73 41.89 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 98.5 t -111.67 103.73 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 -178.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 9.5 tppt? -78.15 102.84 7.73 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 178.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.0 t -67.1 122.99 19.21 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 N-CA-C 104.438 -2.431 . . . . 0.0 104.438 178.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 170.18 -64.19 0.17 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-O 118.89 -0.95 . . . . 0.0 114.397 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -147.94 156.92 44.07 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 118.852 1.326 . . . . 0.0 110.421 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -79.31 0.72 9.79 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 123.666 2.911 . . . . 0.0 113.532 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.6 ttmt -60.44 106.99 0.6 Allowed 'General case' 0 CA--C 1.529 0.155 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 142.37 -105.56 0.41 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 123.758 0.694 . . . . 0.0 111.819 179.683 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -144.67 143.05 20.04 Favored Pre-proline 0 C--O 1.238 0.485 0 N-CA-C 106.347 -1.723 . . . . 0.0 106.347 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.45 132.11 23.13 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.735 2.29 . . . . 0.0 113.162 -178.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -71.15 -19.49 29.61 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 122.193 1.929 . . . . 0.0 112.257 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 24.5 mp0 -65.04 -31.92 73.38 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 119.586 1.085 . . . . 0.0 110.191 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -106.28 17.57 23.26 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 125.148 1.379 . . . . 0.0 111.998 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.8 tt -50.33 -32.84 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 125.146 1.379 . . . . 0.0 112.366 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -56.73 -25.01 53.62 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 124.193 0.997 . . . . 0.0 112.089 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 74.2 m-80 -81.39 -17.33 49.35 Favored 'General case' 0 C--N 1.339 0.127 0 C-N-CA 123.487 0.715 . . . . 0.0 112.101 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 72.3 mt -76.65 -34.55 58.27 Favored 'General case' 0 C--O 1.225 -0.221 0 CA-C-N 119.219 0.918 . . . . 0.0 108.701 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 63.3 t -62.7 128.98 25.46 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 98.1 -16.78 59.64 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 125.484 1.516 . . . . 0.0 111.09 -178.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 82.6 mttt -75.4 168.75 19.4 Favored 'General case' 0 C--N 1.344 0.354 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 178.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.451 ' HB2' ' HZ1' ' A' ' 48' ' ' LYS . 3.5 ttmp? -125.69 135.01 51.65 Favored 'General case' 0 CA--C 1.508 -0.656 0 O-C-N 121.236 -0.915 . . . . 0.0 108.785 -179.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.7 m -67.7 141.13 18.12 Favored 'Isoleucine or valine' 0 C--O 1.24 0.602 0 O-C-N 123.97 0.794 . . . . 0.0 110.113 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 86.5 mt -93.74 -14.44 26.28 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 126.12 1.768 . . . . 0.0 112.256 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 22.7 m -146.63 158.85 10.51 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 C-N-CA 126.317 1.847 . . . . 0.0 108.2 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 88.6 m -70.84 101.36 2.11 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 178.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 45.5 t -79.77 119.81 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -72.36 166.9 21.59 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 122.399 1.095 . . . . 0.0 109.401 178.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 52.6 tt0 -61.03 143.77 54.71 Favored 'General case' 0 N--CA 1.449 -0.52 0 O-C-N 121.438 -0.789 . . . . 0.0 109.521 -179.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.8 t70 64.15 3.71 1.84 Allowed 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.52 1.928 . . . . 0.0 113.587 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -71.71 155.12 40.83 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.866 0.841 . . . . 0.0 109.338 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.2 m -71.83 127.0 31.17 Favored 'General case' 0 N--CA 1.436 -1.151 0 C-N-CA 126.057 1.743 . . . . 0.0 110.797 -178.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.4 mm -90.7 137.58 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 N-CA-C 103.812 -2.662 . . . . 0.0 103.812 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 34.7 mtp -140.92 -170.89 3.13 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 123.662 0.785 . . . . 0.0 110.501 -178.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -86.27 -37.58 18.43 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 6.2 pm0 -64.45 -11.76 36.71 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.446 1.098 . . . . 0.0 112.779 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 71.4 mt -101.19 2.4 40.02 Favored 'General case' 0 C--O 1.227 -0.124 0 C-N-CA 125.436 1.494 . . . . 0.0 112.319 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 10.3 m -135.35 155.13 36.7 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-N 121.435 1.925 . . . . 0.0 114.399 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 49.9 p30 . . . . . 0 C--O 1.236 0.394 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.394 178.269 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.293 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 79.5 p -144.31 159.04 43.38 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-N 117.853 0.826 . . . . 0.0 111.353 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 97.6 t -71.73 133.31 32.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.6 m -136.02 157.88 38.48 Favored 'Isoleucine or valine' 0 C--O 1.24 0.601 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.87 124.46 24.38 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 44.2 tttt -77.14 -27.11 53.77 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 121.911 -0.493 . . . . 0.0 111.653 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.4 m -144.29 168.15 10.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 C-N-CA 127.602 2.361 . . . . 0.0 106.824 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 78.6 tttt -69.06 117.81 11.17 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 178.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 19.9 mt -102.75 112.26 65.53 Favored Pre-proline 0 CA--C 1.533 0.307 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.93 148.95 32.41 Favored 'Trans proline' 0 N--CA 1.445 -1.342 0 C-N-CA 121.7 1.6 . . . . 0.0 109.428 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 tm-20 -51.68 145.61 9.0 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 124.135 0.974 . . . . 0.0 110.384 179.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.38 -3.58 86.47 Favored Glycine 0 CA--C 1.529 0.927 0 CA-C-O 119.105 -0.83 . . . . 0.0 114.89 178.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.6 m -89.78 152.4 21.32 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 118.389 1.095 . . . . 0.0 110.054 -179.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 48.7 mm -90.01 141.54 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 65.9 mt -75.9 139.29 41.56 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.373 0.606 . . . . 0.0 111.489 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 68.3 p -134.28 155.59 49.94 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 126.12 1.768 . . . . 0.0 106.393 178.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 25.8 mtp -67.47 -12.45 60.32 Favored 'General case' 0 CA--C 1.545 0.766 0 CA-C-N 119.594 1.088 . . . . 0.0 110.16 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.6 m-20 -72.84 -19.9 61.23 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 120.828 -1.17 . . . . 0.0 112.147 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 56.1 mtm -115.08 10.37 16.15 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 124.691 1.196 . . . . 0.0 111.59 -178.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 36.0 mt -130.82 148.74 52.63 Favored 'General case' 0 CA--C 1.515 -0.37 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -178.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.8 t -157.14 179.14 9.56 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.4 t -124.56 113.52 36.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 118.826 0.739 . . . . 0.0 109.76 -178.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 2.7 ttpp -79.37 93.4 5.33 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 179.118 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 t -59.63 98.62 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -172.17 -46.13 0.04 OUTLIER Glycine 0 C--N 1.339 0.716 0 CA-C-O 117.494 -1.725 . . . . 0.0 115.559 -178.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -151.43 154.33 33.41 Favored Pre-proline 0 N--CA 1.464 0.241 0 CA-C-N 120.251 2.026 . . . . 0.0 110.6 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -76.49 -3.89 14.36 Favored 'Trans proline' 0 CA--C 1.534 0.504 0 C-N-CA 123.195 2.597 . . . . 0.0 113.066 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 3.6 tmmm? -63.73 107.05 1.09 Allowed 'General case' 0 CA--C 1.518 -0.252 0 O-C-N 121.132 -0.98 . . . . 0.0 108.419 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.418 ' HA2' ' SD ' ' A' ' 60' ' ' MET . . . 131.36 178.49 15.5 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 126.26 1.886 . . . . 0.0 109.889 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 7.3 t80 -57.07 134.02 80.45 Favored Pre-proline 0 C--O 1.24 0.603 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -61.98 131.04 33.13 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.168 1.912 . . . . 0.0 108.997 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.64 -19.06 48.39 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.261 1.974 . . . . 0.0 112.351 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -70.67 -10.85 60.32 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 113.304 0.853 . . . . 0.0 113.304 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -121.33 10.92 10.66 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 126.044 1.738 . . . . 0.0 111.582 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.5 tt -41.33 -37.42 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 C-N-CA 128.194 2.598 . . . . 0.0 113.792 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -60.39 -34.99 74.7 Favored 'General case' 0 CA--C 1.528 0.133 0 C-N-CA 125.58 1.552 . . . . 0.0 113.927 -179.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -59.46 -38.96 82.13 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 119.675 1.125 . . . . 0.0 112.044 -178.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 85.0 mt -72.55 -33.93 67.17 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 124.681 1.192 . . . . 0.0 111.9 -179.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 69.3 t -67.68 91.29 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 124.521 1.128 . . . . 0.0 108.302 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 139.12 -9.38 3.29 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 126.437 1.97 . . . . 0.0 112.629 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 92.1 mttt -82.41 171.14 14.5 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 119.039 1.419 . . . . 0.0 108.437 178.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 33.8 ttmt -110.15 136.93 48.61 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 178.117 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.4 m -80.74 146.27 7.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 O-C-N 121.786 -0.572 . . . . 0.0 109.961 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 92.8 mt -97.21 -14.19 21.57 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 125.906 1.682 . . . . 0.0 113.453 -178.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 16.7 m -146.32 158.0 11.41 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.0 m -77.23 101.6 6.29 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 70.8 t -80.23 138.89 19.04 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -85.12 170.03 13.32 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-O 122.054 0.93 . . . . 0.0 110.283 178.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -71.22 138.99 49.94 Favored 'General case' 0 N--CA 1.447 -0.597 0 O-C-N 121.184 -0.947 . . . . 0.0 109.678 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.8 t70 72.3 4.18 4.92 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 127.671 2.389 . . . . 0.0 113.337 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -67.44 145.46 54.99 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.594 1.158 . . . . 0.0 109.387 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 25.4 m -73.24 129.0 37.09 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 179.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 26.2 mm -87.1 131.05 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' MET . . . . . 0.418 ' SD ' ' HA2' ' A' ' 35' ' ' GLY . 82.0 mmm -124.55 161.02 27.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 126.235 1.814 . . . . 0.0 106.948 179.255 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -72.31 -27.25 62.32 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.825 1.65 . . . . 0.0 111.332 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.41 -14.42 62.91 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 124.419 1.088 . . . . 0.0 112.816 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 19.8 mt -93.29 -1.09 56.43 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 126.203 1.801 . . . . 0.0 112.148 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.4 m -126.68 160.47 34.76 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 CA-C-N 119.707 1.14 . . . . 0.0 113.22 -178.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.541 0.606 0 C-N-CA 125.345 1.458 . . . . 0.0 109.091 178.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.301 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 10.7 p -94.02 134.12 36.76 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 118.264 1.032 . . . . 0.0 113.224 -178.373 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 98.9 t -68.27 132.67 32.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 176.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.29 155.6 40.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.533 0 C-N-CA 124.048 0.939 . . . . 0.0 109.174 179.098 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.72 117.04 12.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 177.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 42.6 tttp -63.58 -31.57 72.78 Favored 'General case' 0 C--N 1.33 -0.25 0 O-C-N 121.426 -0.796 . . . . 0.0 112.498 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m -142.3 169.99 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 C-N-CA 126.567 1.947 . . . . 0.0 107.012 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 39.1 tttt -64.17 127.18 30.33 Favored 'General case' 0 N--CA 1.454 -0.265 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.3 mt -111.89 100.69 49.54 Favored Pre-proline 0 CA--C 1.532 0.278 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 -179.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -65.16 151.43 85.54 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 N-CA-C 109.062 -1.168 . . . . 0.0 109.062 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -50.75 151.81 2.28 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.27 1.028 . . . . 0.0 111.384 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.62 -3.67 62.97 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 123.962 0.791 . . . . 0.0 113.971 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 99.1 m -81.42 145.89 30.56 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 118.191 0.995 . . . . 0.0 109.524 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.5 mm -88.74 130.86 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 178.045 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 30.7 mt -69.33 137.24 52.76 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 124.399 1.079 . . . . 0.0 110.734 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 73.4 p -135.39 159.03 42.86 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.383 1.073 . . . . 0.0 108.621 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 12.0 mmt -64.15 -17.86 63.89 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 118.114 0.415 . . . . 0.0 110.523 179.083 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -79.07 -16.45 56.77 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.966 0.906 . . . . 0.0 112.177 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 75.3 mtm -118.94 15.09 13.36 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.378 1.071 . . . . 0.0 109.971 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 42.9 mt -137.0 154.46 50.4 Favored 'General case' 0 CA--C 1.511 -0.553 0 O-C-N 120.959 -1.088 . . . . 0.0 110.034 -178.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.6 t -164.33 -179.54 6.14 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 1.2 p -134.01 112.6 16.7 Favored 'Isoleucine or valine' 0 C--O 1.234 0.287 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -73.99 114.86 12.78 Favored 'General case' 0 CA--C 1.511 -0.556 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.1 p -51.81 139.75 7.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 O-C-N 124.196 0.935 . . . . 0.0 109.702 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 138.0 -131.34 5.4 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.2 pm0 -75.66 133.92 73.09 Favored Pre-proline 0 CA--C 1.541 0.602 0 C-N-CA 125.211 1.404 . . . . 0.0 112.847 -179.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.06 61.3 7.17 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 124.673 3.582 . . . . 0.0 111.123 179.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -88.24 172.06 9.73 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 125.122 1.369 . . . . 0.0 107.866 178.38 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.05 -77.0 1.18 Allowed Glycine 0 N--CA 1.445 -0.715 0 N-CA-C 113.822 0.289 . . . . 0.0 113.822 178.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -149.07 139.97 13.87 Favored Pre-proline 0 N--CA 1.443 -0.789 0 C-N-CA 126.315 1.846 . . . . 0.0 107.016 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.38 136.91 48.95 Favored 'Trans proline' 0 N--CA 1.451 -0.98 0 N-CA-C 109.106 -1.152 . . . . 0.0 109.106 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -68.76 -15.25 40.55 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 122.479 2.119 . . . . 0.0 113.354 -179.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -69.47 -27.49 65.26 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 119.959 1.254 . . . . 0.0 109.85 178.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -98.27 10.43 40.67 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.644 1.578 . . . . 0.0 111.382 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.8 tt -52.54 -38.87 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 C-N-CA 124.831 1.252 . . . . 0.0 111.672 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -68.91 -21.14 64.24 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.74 1.216 . . . . 0.0 112.661 -179.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -79.88 -38.04 33.53 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 119.087 0.858 . . . . 0.0 110.746 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.54 -30.0 70.36 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 123.032 0.533 . . . . 0.0 110.078 178.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 45.3 t -66.52 107.13 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.47 -11.95 10.37 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 126.503 2.002 . . . . 0.0 112.696 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.0 mttm -79.91 156.87 27.09 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-N 118.562 1.181 . . . . 0.0 109.215 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -101.51 138.57 38.34 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.182 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.7 m -78.05 138.77 19.68 Favored 'Isoleucine or valine' 0 C--O 1.24 0.605 0 N-CA-C 109.082 -0.711 . . . . 0.0 109.082 178.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 82.6 mt -84.85 -16.77 40.17 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.587 1.555 . . . . 0.0 111.636 179.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 15.3 m -149.69 163.5 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.175 0 C-N-CA 126.342 1.857 . . . . 0.0 108.648 -178.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 16.7 m -72.45 125.94 28.64 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 177.693 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 87.6 t -105.03 131.12 54.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -76.25 170.43 16.34 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-O 122.413 1.102 . . . . 0.0 112.759 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -65.67 136.91 56.91 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 63.14 7.98 3.06 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 126.035 1.734 . . . . 0.0 112.803 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -72.45 157.28 37.93 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 119.428 1.013 . . . . 0.0 111.286 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.1 m -79.75 119.34 22.53 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 123.944 0.898 . . . . 0.0 111.27 -178.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.6 mm -76.13 139.82 18.29 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 178.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 26.8 mtp -138.88 160.49 39.6 Favored 'General case' 0 C--O 1.231 0.094 0 C-N-CA 123.655 0.782 . . . . 0.0 109.474 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -60.77 -40.77 93.77 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 123.304 0.641 . . . . 0.0 109.456 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -65.66 4.33 0.6 Allowed 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 126.215 1.806 . . . . 0.0 114.551 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 34.9 mt -118.28 0.01 11.61 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.113 1.365 . . . . 0.0 109.694 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.5 m -131.23 162.58 39.01 Favored 'Isoleucine or valine' 0 C--N 1.343 0.285 0 C-N-CA 124.321 1.048 . . . . 0.0 111.148 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 36.4 t0 . . . . . 0 C--O 1.239 0.526 0 C-N-CA 124.975 1.31 . . . . 0.0 112.056 179.726 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.669 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 45.4 p -142.57 159.02 43.05 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.472 0.709 . . . . 0.0 109.794 -178.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 78.2 t -84.11 124.55 39.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 178.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.9 m -123.07 148.71 26.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.535 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.5 111.73 4.28 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 125.686 1.595 . . . . 0.0 107.997 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 81.1 tttt -64.95 -24.8 67.63 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 123.434 0.694 . . . . 0.0 112.714 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.6 m -148.92 165.79 3.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 127.116 2.167 . . . . 0.0 106.944 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -64.69 130.58 44.11 Favored 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 178.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 32.2 mt -118.78 101.27 50.59 Favored Pre-proline 0 CA--C 1.533 0.311 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -67.35 153.15 77.81 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 121.944 1.763 . . . . 0.0 112.346 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.6 tm-20 -58.17 146.03 35.02 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 122.289 1.042 . . . . 0.0 108.617 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.95 19.99 56.52 Favored Glycine 0 CA--C 1.53 0.995 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.953 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.1 m -117.44 156.25 28.27 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 125.976 1.71 . . . . 0.0 107.734 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 34.1 mm -101.5 143.25 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 C-N-CA 123.867 0.867 . . . . 0.0 108.716 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 23.0 mt -76.03 135.88 39.94 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 67.1 p -130.57 158.15 40.76 Favored 'General case' 0 C--O 1.238 0.477 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 13.4 mmt -63.22 -20.51 65.5 Favored 'General case' 0 CA--C 1.536 0.408 0 O-C-N 121.926 -0.484 . . . . 0.0 109.713 178.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -79.99 -18.41 50.36 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 126.27 1.828 . . . . 0.0 114.185 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 69.8 mtm -112.46 16.15 19.95 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 119.162 0.892 . . . . 0.0 111.697 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.1 mt -133.64 147.92 51.49 Favored 'General case' 0 C--O 1.238 0.456 0 C-N-CA 124.019 0.927 . . . . 0.0 110.666 -179.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.9 t -147.7 144.62 28.45 Favored 'General case' 0 CA--C 1.54 0.572 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 56.8 t -89.06 117.52 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 31.7 ttpt -59.84 -29.63 68.4 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 115.01 1.485 . . . . 0.0 115.01 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.6 t 47.65 66.42 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 CA-C-O 122.665 1.221 . . . . 0.0 109.278 -179.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.97 -66.24 0.01 OUTLIER Glycine 0 CA--C 1.521 0.435 0 C-N-CA 124.647 1.118 . . . . 0.0 111.042 -179.482 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -133.9 152.8 79.28 Favored Pre-proline 0 CA--C 1.529 0.158 0 C-N-CA 123.583 0.753 . . . . 0.0 111.598 -178.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.18 5.4 4.59 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 123.686 2.924 . . . . 0.0 113.131 179.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -72.26 115.12 11.13 Favored 'General case' 0 CA--C 1.518 -0.251 0 O-C-N 119.946 -1.721 . . . . 0.0 106.413 178.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.36 171.71 15.73 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -54.94 135.71 66.59 Favored Pre-proline 0 CA--C 1.541 0.61 0 CA-C-O 118.993 -0.527 . . . . 0.0 110.716 -179.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -67.94 150.73 78.26 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.806 2.337 . . . . 0.0 113.557 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -79.41 -4.34 13.6 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 123.437 2.758 . . . . 0.0 114.93 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 24.2 tp10 -82.43 -46.14 13.89 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 119.918 1.235 . . . . 0.0 108.124 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -79.71 7.38 8.62 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 125.86 1.664 . . . . 0.0 111.63 -179.575 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.7 tt -46.82 -43.13 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 C-N-CA 126.19 1.796 . . . . 0.0 112.909 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -58.91 -27.95 65.74 Favored 'General case' 0 C--O 1.227 -0.126 0 C-N-CA 123.1 0.56 . . . . 0.0 111.657 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -73.35 -36.82 66.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 49.2 mt -66.65 -38.96 87.94 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 119.123 0.874 . . . . 0.0 109.705 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 73.5 t -61.63 131.45 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.09 -11.09 69.69 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 118.792 -1.004 . . . . 0.0 111.699 -178.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 26.5 mttm -84.05 154.36 23.28 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-N 119.556 1.678 . . . . 0.0 110.615 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 39.4 ttmt -95.04 131.08 41.41 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 178.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.4 m -66.76 168.66 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 176.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 46.3 mt -114.28 -7.08 12.97 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 123.913 0.885 . . . . 0.0 112.44 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.8 m -156.83 162.31 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 126.952 2.101 . . . . 0.0 108.418 -178.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.9 m -72.94 109.66 6.66 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 57.4 t -85.96 131.04 35.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 179.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -78.05 167.49 21.37 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 123.652 0.781 . . . . 0.0 109.721 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -69.92 149.86 47.35 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 177.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 60.94 10.01 2.58 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 127.948 2.499 . . . . 0.0 111.59 -179.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -75.73 153.33 37.11 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 178.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 99.2 m -88.47 121.88 31.34 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.179 0.514 . . . . 0.0 110.932 -178.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 mm -74.18 138.51 21.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 178.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -131.37 157.92 42.13 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 124.368 1.067 . . . . 0.0 108.595 179.31 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -59.35 -27.8 66.26 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 124.715 1.206 . . . . 0.0 111.669 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -89.26 -4.15 58.27 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 119.173 0.897 . . . . 0.0 113.095 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 57.4 mt -96.57 15.8 20.61 Favored 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 124.352 1.061 . . . . 0.0 109.4 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.1 m -139.22 140.84 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 37.2 t70 . . . . . 0 C--N 1.327 -0.389 0 C-N-CA 125.598 1.559 . . . . 0.0 110.387 179.787 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.321 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -146.91 162.0 39.58 Favored 'General case' 0 C--O 1.239 0.513 0 C-N-CA 126.081 1.753 . . . . 0.0 110.963 179.046 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.2 t -70.0 140.47 18.54 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 C-N-CA 126.188 1.795 . . . . 0.0 112.282 -178.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.7 m -139.59 159.53 27.8 Favored 'Isoleucine or valine' 0 C--O 1.24 0.584 0 C-N-CA 126.601 1.961 . . . . 0.0 107.078 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -81.25 138.28 35.78 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.455 ' HE3' ' HB ' ' A' ' 27' ' ' THR . 8.6 ttmt -81.6 -22.33 37.78 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 123.447 0.699 . . . . 0.0 111.567 179.551 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.8 m -145.76 170.38 5.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 124.842 1.257 . . . . 0.0 108.254 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.6 tttm -72.41 104.05 3.65 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 105.549 -2.019 . . . . 0.0 105.549 177.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 7.3 mt -88.32 109.04 25.54 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-O 118.122 -0.942 . . . . 0.0 109.063 -178.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -69.67 149.39 67.4 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 CA-C-N 120.981 1.386 . . . . 0.0 109.983 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -51.14 143.88 10.11 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.454 1.102 . . . . 0.0 110.565 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.38 2.0 90.27 Favored Glycine 0 C--N 1.338 0.641 0 CA-C-O 118.979 -0.901 . . . . 0.0 114.53 179.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 65.4 m -91.03 142.63 27.57 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 118.741 1.271 . . . . 0.0 109.708 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 5.0 mm -78.7 135.45 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 50.4 mt -74.29 141.85 45.26 Favored 'General case' 0 C--O 1.237 0.446 0 C-N-CA 124.774 1.23 . . . . 0.0 109.352 178.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 41.7 p -141.36 165.51 27.31 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 106.951 -1.499 . . . . 0.0 106.951 178.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -65.02 -22.2 66.96 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-N 118.116 0.416 . . . . 0.0 110.459 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -67.93 -30.5 69.82 Favored 'General case' 0 N--CA 1.464 0.263 0 C-N-CA 124.48 1.112 . . . . 0.0 111.495 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 71.1 mtm -105.92 10.52 32.37 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.491 1.117 . . . . 0.0 112.67 -177.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.0 mt -131.93 162.51 30.48 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 123.958 0.903 . . . . 0.0 109.013 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.455 ' HB ' ' HE3' ' A' ' 12' ' ' LYS . 6.5 t -169.84 174.86 5.45 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.4 t -114.99 156.75 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 177.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 23.8 ttpp -126.98 111.68 14.37 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 103.423 -2.806 . . . . 0.0 103.423 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.7 m -62.63 158.88 3.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 120.238 -0.585 . . . . 0.0 110.209 -179.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 130.76 -96.69 0.35 Allowed Glycine 0 C--N 1.333 0.371 0 CA-C-O 119.078 -0.846 . . . . 0.0 112.277 179.168 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -115.76 157.28 44.97 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 125.559 1.544 . . . . 0.0 113.486 -177.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -77.32 15.19 1.24 Allowed 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 124.562 3.508 . . . . 0.0 113.366 179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 25.6 tptp -55.68 113.55 1.51 Allowed 'General case' 0 N--CA 1.465 0.311 0 O-C-N 120.699 -1.251 . . . . 0.0 108.5 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.33 -170.47 21.43 Favored Glycine 0 N--CA 1.451 -0.348 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.4 t80 -58.02 130.32 82.98 Favored Pre-proline 0 CA--C 1.544 0.719 0 CA-C-O 118.505 -0.76 . . . . 0.0 110.257 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -66.05 153.12 79.39 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.897 2.398 . . . . 0.0 111.797 -178.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_endo -77.23 -22.96 10.7 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 121.606 1.537 . . . . 0.0 113.893 -178.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -63.12 -40.92 99.01 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 119.83 1.195 . . . . 0.0 109.933 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -82.96 4.34 26.26 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-O 117.906 -1.045 . . . . 0.0 113.313 -178.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.6 tt -48.25 -35.03 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 CA-C-N 120.719 1.6 . . . . 0.0 113.763 -178.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -58.82 -28.49 66.07 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.508 0.723 . . . . 0.0 111.701 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 30.0 m-80 -71.53 -41.99 68.5 Favored 'General case' 0 CA--C 1.521 -0.161 0 C-N-CA 124.001 0.921 . . . . 0.0 109.234 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 38.1 mt -65.0 -42.17 94.73 Favored 'General case' 0 CA--C 1.519 -0.216 0 C-N-CA 123.054 0.541 . . . . 0.0 110.171 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.78 98.7 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 C-N-CA 124.345 1.058 . . . . 0.0 108.786 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.99 -14.19 6.65 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 126.321 1.915 . . . . 0.0 114.178 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -79.62 167.79 20.24 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 118.861 1.331 . . . . 0.0 110.426 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.05 137.82 42.22 Favored 'General case' 0 CA--C 1.512 -0.516 0 CA-C-O 118.075 -0.964 . . . . 0.0 109.599 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.3 m -77.02 138.14 21.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 78.3 mt -85.33 -15.88 41.84 Favored 'General case' 0 N--CA 1.462 0.148 0 C-N-CA 123.452 0.701 . . . . 0.0 112.182 179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.2 m -148.04 164.47 5.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 30.7 m -69.66 140.86 53.68 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 84.9 t -115.14 152.8 16.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -110.71 166.69 10.81 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 123.966 0.907 . . . . 0.0 111.194 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -63.26 128.57 36.43 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 30.6 t70 68.73 8.21 6.61 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 128.09 2.556 . . . . 0.0 112.908 -179.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -67.25 162.6 22.28 Favored 'General case' 0 CA--C 1.533 0.298 0 O-C-N 121.005 -1.059 . . . . 0.0 108.438 179.26 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 77.7 m -95.08 123.0 38.32 Favored 'General case' 0 N--CA 1.468 0.435 0 O-C-N 120.131 -1.606 . . . . 0.0 113.181 -178.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 13.3 mm -74.38 146.41 9.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 3.3 mmt -140.26 158.56 43.85 Favored 'General case' 0 C--O 1.233 0.214 0 C-N-CA 126.404 1.882 . . . . 0.0 107.299 179.235 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.34 -32.32 73.71 Favored 'General case' 0 CA--C 1.528 0.123 0 O-C-N 122.141 -0.349 . . . . 0.0 111.762 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -72.07 -5.27 34.07 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -179.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 56.7 mt -103.77 9.57 36.99 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 124.24 1.016 . . . . 0.0 111.05 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.5 m -131.93 155.28 41.45 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 CA-C-N 119.758 1.163 . . . . 0.0 112.3 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 . . . . . 0 C--O 1.234 0.285 0 C-N-CA 125.608 1.563 . . . . 0.0 113.85 -179.547 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 CA-C-O 121.053 0.252 . . . . 0.0 113.234 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -122.52 134.32 54.56 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 127.245 2.218 . . . . 0.0 111.997 -177.877 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 61.2 t -67.73 129.44 32.29 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 28.2 m -132.88 151.42 34.31 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.23 128.4 36.11 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.493 ' HE3' ' HB ' ' A' ' 27' ' ' THR . 6.7 ttmt -72.75 -28.15 62.46 Favored 'General case' 0 C--N 1.327 -0.377 0 O-C-N 121.399 -0.813 . . . . 0.0 111.695 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.71 169.88 18.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 C-N-CA 125.762 1.625 . . . . 0.0 107.093 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 58.7 tttt -71.88 114.91 10.48 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 49.8 mt -100.2 106.77 43.88 Favored Pre-proline 0 CA--C 1.534 0.339 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -66.55 148.7 83.96 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 121.569 1.513 . . . . 0.0 110.72 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 52.0 tt0 -48.54 142.29 6.06 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 126.168 1.787 . . . . 0.0 110.38 179.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.36 0.46 86.76 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-O 118.012 -1.438 . . . . 0.0 113.768 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.1 m -91.3 154.88 18.93 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 120.355 2.078 . . . . 0.0 107.857 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.8 mm -89.29 145.91 6.82 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-N 119.509 1.05 . . . . 0.0 109.097 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 15.2 mt -80.36 137.7 36.59 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.245 0.618 . . . . 0.0 109.811 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 29.0 p -131.22 154.95 47.89 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 125.952 1.701 . . . . 0.0 107.342 179.261 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 12.4 mmt -60.82 -35.46 76.58 Favored 'General case' 0 CA--C 1.538 0.484 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -61.2 -19.16 61.29 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 127.987 2.515 . . . . 0.0 113.051 178.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.6 mtm -115.66 16.31 16.45 Favored 'General case' 0 N--CA 1.466 0.355 0 O-C-N 121.195 -0.941 . . . . 0.0 110.979 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 70.7 mt -129.26 170.5 13.53 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 121.998 0.904 . . . . 0.0 113.263 -179.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.493 ' HB ' ' HE3' ' A' ' 12' ' ' LYS . 4.3 t -171.88 173.26 4.54 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 128.343 2.657 . . . . 0.0 107.221 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -129.88 110.56 19.83 Favored 'Isoleucine or valine' 0 C--O 1.24 0.568 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 178.571 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.406 ' HZ1' ' CG ' ' A' ' 56' ' ' ASP . 20.6 ttpt -69.8 112.6 6.36 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.192 1.397 . . . . 0.0 107.498 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.8 p -66.93 130.96 32.76 Favored 'Isoleucine or valine' 0 C--O 1.239 0.513 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 178.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.64 -89.27 0.1 OUTLIER Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 -179.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -134.5 158.5 75.01 Favored Pre-proline 0 CA--C 1.539 0.553 0 CA-C-O 118.532 -0.747 . . . . 0.0 110.698 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -73.3 31.65 0.31 Allowed 'Trans proline' 0 CA--C 1.544 0.981 1 C-N-CA 126.149 4.566 . . . . 0.0 116.093 -179.152 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -60.6 139.04 57.96 Favored 'General case' 0 C--O 1.225 -0.225 0 O-C-N 120.676 -1.265 . . . . 0.0 110.968 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.41 -72.67 0.78 Allowed Glycine 0 CA--C 1.524 0.62 0 CA-C-O 118.526 -1.152 . . . . 0.0 115.754 178.497 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -151.09 147.77 21.31 Favored Pre-proline 0 CA--C 1.544 0.737 0 CA-C-N 119.596 1.698 . . . . 0.0 114.82 -176.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -83.99 163.4 13.67 Favored 'Trans proline' 0 C--N 1.354 0.868 0 C-N-CA 124.203 3.269 . . . . 0.0 114.347 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -79.61 -10.36 14.5 Favored 'Trans proline' 0 C--N 1.349 0.605 0 C-N-CA 122.482 2.121 . . . . 0.0 111.873 179.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -76.73 -19.85 57.2 Favored 'General case' 0 CA--C 1.535 0.39 0 O-C-N 121.248 -0.907 . . . . 0.0 110.922 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -117.47 8.78 13.07 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 124.04 0.936 . . . . 0.0 112.69 -178.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.6 tt -51.45 -35.5 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 124.041 0.936 . . . . 0.0 111.569 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -61.83 -28.17 69.29 Favored 'General case' 0 N--CA 1.461 0.123 0 C-N-CA 125.245 1.418 . . . . 0.0 111.74 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 37.7 m-80 -78.37 -30.26 47.86 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-O 118.977 -0.535 . . . . 0.0 109.622 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.4 mt -76.03 -37.47 58.33 Favored 'General case' 0 C--N 1.339 0.12 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.1 t -63.54 121.28 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 104.617 -2.364 . . . . 0.0 104.617 178.241 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.45 -9.72 38.59 Favored Glycine 0 CA--C 1.534 1.266 0 CA-C-O 118.846 -0.975 . . . . 0.0 111.404 -178.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 72.2 mttt -85.18 169.16 14.12 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-N 119.721 1.761 . . . . 0.0 107.751 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.1 ttmp? -116.01 130.07 56.65 Favored 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 125.813 1.645 . . . . 0.0 108.027 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.9 m -73.2 144.02 13.21 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 55.7 mt -90.59 -13.88 33.58 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 124.198 0.999 . . . . 0.0 112.093 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 31.6 m -147.99 162.88 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 125.89 1.676 . . . . 0.0 107.208 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 51.5 m -72.85 133.83 44.6 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 96.9 t -112.61 124.48 69.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 125.808 1.643 . . . . 0.0 107.519 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -78.65 171.85 14.54 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.49 0.662 . . . . 0.0 111.866 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 49.1 tt0 -63.25 143.68 57.59 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 105.389 -2.078 . . . . 0.0 105.389 177.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.406 ' CG ' ' HZ1' ' A' ' 29' ' ' LYS . 25.8 t0 61.36 8.23 2.06 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.334 2.254 . . . . 0.0 112.883 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.82 150.52 32.28 Favored 'General case' 0 C--N 1.344 0.365 0 O-C-N 120.905 -1.122 . . . . 0.0 110.287 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.5 118.02 17.92 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 125.124 1.369 . . . . 0.0 113.961 -176.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 mm -75.87 146.32 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 104.564 -2.384 . . . . 0.0 104.564 177.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 10.0 mtt -141.92 157.19 45.26 Favored 'General case' 0 CA--C 1.518 -0.272 0 C-N-CA 123.956 0.903 . . . . 0.0 109.207 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -67.63 -14.74 63.2 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 122.473 0.309 . . . . 0.0 111.267 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 20.5 tt0 -84.52 -33.02 23.61 Favored 'General case' 0 CA--C 1.535 0.4 0 O-C-N 121.127 -0.983 . . . . 0.0 110.89 179.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 43.5 mt -81.33 6.27 14.83 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.722 1.609 . . . . 0.0 113.826 -178.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.6 m -126.66 154.26 36.28 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 CA-C-N 119.267 0.94 . . . . 0.0 110.997 -179.224 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 . . . . . 0 C--O 1.238 0.46 0 C-N-CA 125.351 1.46 . . . . 0.0 109.618 179.108 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.878 0 N-CA-C 107.262 -2.335 . . . . 0.0 107.262 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.1 t -141.94 174.03 10.97 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 118.377 1.089 . . . . 0.0 112.506 -178.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 68.3 t -78.33 119.78 27.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 C-N-CA 127.664 2.386 . . . . 0.0 108.578 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.6 m -128.96 147.5 33.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.17 115.43 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 124.356 1.062 . . . . 0.0 108.267 179.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 41.0 tttm -64.68 -30.55 71.56 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.7 m -147.74 168.67 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 128.413 2.685 . . . . 0.0 105.804 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 65.9 tttt -63.64 130.47 44.42 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 9.4 mt -114.63 101.14 54.18 Favored Pre-proline 0 N--CA 1.454 -0.26 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -70.56 148.3 59.6 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 122.381 2.054 . . . . 0.0 109.235 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 -51.9 146.25 8.65 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.678 1.191 . . . . 0.0 113.228 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 79.74 -2.87 71.78 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 125.059 1.314 . . . . 0.0 113.525 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.4 m -82.19 151.68 26.78 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 119.0 1.4 . . . . 0.0 109.637 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 17.4 mm -91.31 128.5 43.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 178.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 63.3 mt -67.56 146.91 53.44 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.084 1.354 . . . . 0.0 108.964 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 64.9 p -141.27 160.29 40.43 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.9 mmt -64.27 -26.86 68.68 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 178.043 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -63.69 -16.0 59.91 Favored 'General case' 0 CA--C 1.536 0.426 0 O-C-N 121.494 -0.754 . . . . 0.0 112.48 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 38.0 mtm -120.09 4.99 10.84 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 124.878 1.271 . . . . 0.0 112.375 -179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 92.1 mt -124.94 118.82 27.12 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 120.006 1.275 . . . . 0.0 109.163 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 t -123.82 171.77 9.4 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 124.921 1.288 . . . . 0.0 109.369 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 17.9 t -119.81 151.4 22.36 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 39.1 mmtm -109.83 -172.22 2.0 Allowed 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 124.995 1.318 . . . . 0.0 109.795 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 23.2 m -131.57 16.77 1.82 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 C-N-CA 124.979 1.312 . . . . 0.0 111.565 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -78.64 -92.42 0.32 Allowed Glycine 0 C--N 1.334 0.451 0 C-N-CA 124.107 0.86 . . . . 0.0 113.255 -179.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -133.54 157.59 77.63 Favored Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 126.279 1.831 . . . . 0.0 109.004 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -73.05 -1.99 11.35 Favored 'Trans proline' 0 CA--C 1.535 0.55 0 C-N-CA 123.873 3.048 . . . . 0.0 114.233 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.4 ttpt -52.49 127.78 23.67 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.97 -170.74 13.44 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 -178.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -64.61 128.45 93.49 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -64.3 134.85 43.9 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.247 1.965 . . . . 0.0 111.337 -179.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -68.55 -17.65 43.28 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 121.631 1.554 . . . . 0.0 113.482 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -64.39 -25.62 68.1 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 120.311 1.414 . . . . 0.0 110.241 179.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -109.04 12.51 25.17 Favored 'General case' 0 N--CA 1.464 0.237 0 O-C-N 121.15 -0.969 . . . . 0.0 112.121 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.5 tt -48.6 -35.48 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 124.847 1.259 . . . . 0.0 111.895 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 40.0 m-85 -51.81 -30.17 22.22 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 126.111 1.764 . . . . 0.0 112.144 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 67.4 m-80 -81.96 -21.39 37.23 Favored 'General case' 0 CA--C 1.519 -0.214 0 C-N-CA 124.327 1.051 . . . . 0.0 113.093 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 96.2 mt -78.05 -35.53 49.51 Favored 'General case' 0 CA--C 1.521 -0.145 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.85 125.49 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.41 -11.5 68.71 Favored Glycine 0 CA--C 1.529 0.949 0 CA-C-O 117.842 -1.532 . . . . 0.0 113.369 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 43.1 mtmt -83.42 164.24 20.05 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 120.814 2.307 . . . . 0.0 109.558 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.7 ttmp? -102.54 145.52 29.48 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.8 m -85.36 140.23 16.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 O-C-N 123.346 0.404 . . . . 0.0 110.397 179.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 16.9 mt -86.89 -18.07 31.75 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-O 117.718 -1.134 . . . . 0.0 111.527 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 17.7 m -150.02 165.36 3.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 C-N-CA 123.958 0.903 . . . . 0.0 109.052 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.0 m -74.76 143.2 44.18 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 105.609 -1.997 . . . . 0.0 105.609 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 75.1 t -129.08 123.26 58.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 C-N-CA 125.8 1.64 . . . . 0.0 106.664 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -72.54 160.98 31.39 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 122.626 1.203 . . . . 0.0 108.867 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -65.76 134.32 52.9 Favored 'General case' 0 C--O 1.24 0.581 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.2 t70 82.87 1.2 1.17 Allowed 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 128.886 2.874 . . . . 0.0 113.901 179.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -71.76 156.97 38.74 Favored 'General case' 0 C--N 1.341 0.226 0 CA-C-N 118.228 0.467 . . . . 0.0 110.631 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.3 m -80.67 116.9 20.92 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 125.965 1.706 . . . . 0.0 109.775 179.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 16.0 mm -73.95 143.53 13.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 N-CA-C 107.243 -1.391 . . . . 0.0 107.243 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -135.47 153.75 51.65 Favored 'General case' 0 CA--C 1.521 -0.147 0 C-N-CA 125.574 1.55 . . . . 0.0 107.411 179.177 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -60.72 -29.34 69.3 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -179.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 22.2 tp10 -67.65 -22.7 65.3 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 122.714 0.406 . . . . 0.0 111.252 -179.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 17.4 mt -86.52 4.06 41.53 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 124.759 1.224 . . . . 0.0 112.276 -178.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.4 m -131.4 117.25 35.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 120.182 1.355 . . . . 0.0 112.292 -178.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 11.3 t70 . . . . . 0 C--O 1.238 0.488 0 C-N-CA 125.651 1.58 . . . . 0.0 108.263 179.263 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.548 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 48.4 t -136.95 154.92 50.31 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 123.823 0.849 . . . . 0.0 110.916 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 99.2 t -75.76 142.52 14.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.3 m -141.83 161.81 20.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.568 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 178.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.91 121.72 20.47 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 54.1 tttm -74.8 -21.7 59.16 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 118.862 -0.59 . . . . 0.0 110.96 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.4 m -145.31 168.04 8.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 C-N-CA 125.873 1.669 . . . . 0.0 108.765 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -73.34 113.68 10.7 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 178.037 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.3 mt -105.56 104.12 46.68 Favored Pre-proline 0 CA--C 1.533 0.299 0 C-N-CA 124.977 1.311 . . . . 0.0 108.311 -178.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -67.82 155.39 70.06 Favored 'Trans proline' 0 N--CA 1.454 -0.83 0 C-N-CA 121.559 1.506 . . . . 0.0 110.382 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.8 tm-20 -52.08 147.34 7.53 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-O 121.899 0.856 . . . . 0.0 111.164 179.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.27 -4.1 82.36 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 123.77 0.7 . . . . 0.0 114.151 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 26.9 m -84.98 144.76 28.1 Favored 'General case' 0 CA--C 1.538 0.485 0 CA-C-N 118.9 1.35 . . . . 0.0 111.355 -179.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 27.5 mm -87.13 129.85 37.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.859 1.664 . . . . 0.0 107.712 178.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 38.6 mt -71.33 150.49 45.07 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.808 1.243 . . . . 0.0 112.323 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 46.5 p -145.57 161.72 39.13 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 126.826 2.05 . . . . 0.0 107.396 179.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 21.6 mmt -62.11 -38.51 89.17 Favored 'General case' 0 C--O 1.223 -0.327 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 178.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.9 t0 -59.32 -23.61 62.62 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 125.014 1.326 . . . . 0.0 112.651 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 25.5 mtm -104.36 7.71 35.71 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 121.34 -0.85 . . . . 0.0 111.919 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.1 mt -126.19 151.19 47.69 Favored 'General case' 0 CA--C 1.521 -0.135 0 O-C-N 120.948 -1.095 . . . . 0.0 109.124 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.3 t -149.28 174.06 12.81 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 179.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.1 t -128.77 122.78 57.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 22.5 mmmt -92.84 116.46 29.05 Favored 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 p -65.2 136.03 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 178.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 154.76 -87.48 0.13 Allowed Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.5 pm0 -145.11 156.78 54.56 Favored Pre-proline 0 CA--C 1.54 0.591 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -82.35 57.35 6.12 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 124.965 3.777 . . . . 0.0 111.589 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.51 10.26 3.31 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 124.642 1.177 . . . . 0.0 113.254 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.48 -155.6 7.57 Favored Glycine 0 CA--C 1.524 0.633 0 C-N-CA 125.12 1.343 . . . . 0.0 109.98 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 20.1 t80 -59.66 141.03 89.04 Favored Pre-proline 0 CA--C 1.547 0.85 0 C-N-CA 123.669 0.788 . . . . 0.0 109.926 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.25 143.34 58.41 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 123.728 2.952 . . . . 0.0 115.287 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -76.17 -9.06 19.07 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.145 1.896 . . . . 0.0 113.144 179.124 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -79.23 -59.81 2.62 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -71.13 6.58 1.57 Allowed 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 125.817 1.647 . . . . 0.0 113.35 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 15.6 tt -47.65 -33.41 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 C-N-CA 126.385 1.874 . . . . 0.0 112.767 -179.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -57.53 -26.34 61.22 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 123.687 0.795 . . . . 0.0 111.753 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -78.01 -28.2 49.13 Favored 'General case' 0 CA--C 1.528 0.11 0 C-N-CA 123.532 0.733 . . . . 0.0 111.437 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.8 mt -70.58 -37.33 73.93 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 118.679 0.672 . . . . 0.0 109.458 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 43.1 t -61.44 109.29 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 C-N-CA 124.794 1.238 . . . . 0.0 109.382 -179.319 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.14 -14.44 18.88 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 125.582 1.563 . . . . 0.0 111.389 -178.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.2 mttt -74.64 156.0 37.19 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 118.76 1.28 . . . . 0.0 108.318 179.048 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.7 ttmp? -103.45 133.2 48.9 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 6.5 m -73.89 141.59 15.97 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 178.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 93.3 mt -87.37 -20.77 26.24 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 125.658 1.583 . . . . 0.0 110.806 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.6 m -142.29 166.42 16.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.241 0 C-N-CA 125.076 1.35 . . . . 0.0 110.18 -178.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 54.4 m -74.11 106.74 5.92 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 91.3 t -90.22 136.1 24.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 178.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -92.69 175.31 6.86 Favored 'General case' 0 C--O 1.226 -0.18 0 O-C-N 121.618 -0.676 . . . . 0.0 111.853 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -70.13 136.87 50.59 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.0 t70 67.22 9.46 6.98 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 126.952 2.101 . . . . 0.0 111.508 -178.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.9 t0 -70.96 147.67 48.46 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 178.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 39.4 m -81.31 115.09 20.52 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.888 0.851 . . . . 0.0 110.535 -178.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.8 mm -72.14 111.47 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -106.79 152.61 23.62 Favored 'General case' 0 C--O 1.238 0.481 0 N-CA-C 104.409 -2.441 . . . . 0.0 104.409 177.33 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -62.93 -24.45 67.87 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.606 -0.684 . . . . 0.0 111.707 -179.646 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -75.13 -6.01 47.32 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 46.3 mt -95.6 -2.79 47.6 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 119.501 1.046 . . . . 0.0 111.437 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.8 m -130.5 151.5 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 125.251 1.42 . . . . 0.0 107.574 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 13.6 t0 . . . . . 0 CA--C 1.541 0.6 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.767 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.394 0 N-CA-C 107.019 -2.432 . . . . 0.0 107.019 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 96.8 p -138.55 151.19 47.09 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 118.701 1.25 . . . . 0.0 110.924 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.6 t -76.57 125.83 36.69 Favored 'Isoleucine or valine' 0 C--O 1.234 0.259 0 O-C-N 121.307 -0.87 . . . . 0.0 110.159 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 33.3 m -124.9 155.8 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-O 122.445 1.117 . . . . 0.0 108.355 177.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.71 118.7 10.63 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 125.204 1.402 . . . . 0.0 107.43 178.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 34.8 tttp -69.84 -27.31 64.75 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.4 m -151.75 169.77 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 125.729 1.612 . . . . 0.0 107.71 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -61.28 135.27 57.67 Favored 'General case' 0 C--O 1.241 0.62 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.06 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.1 mt -123.09 114.92 29.21 Favored Pre-proline 0 C--O 1.237 0.427 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -68.35 145.46 65.61 Favored 'Trans proline' 0 N--CA 1.448 -1.174 0 C-N-CA 120.752 0.968 . . . . 0.0 109.993 178.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.6 tt0 -57.27 146.07 29.82 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.442 0.697 . . . . 0.0 110.8 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.36 -0.05 88.48 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 123.849 0.738 . . . . 0.0 112.854 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.6 m -91.71 155.34 18.36 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 118.311 1.055 . . . . 0.0 111.742 -178.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 37.1 mm -89.77 130.12 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 125.332 1.453 . . . . 0.0 108.634 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 29.8 mt -70.25 151.99 44.72 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 124.486 1.114 . . . . 0.0 109.047 178.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 74.2 p -140.63 163.22 33.47 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 124.205 1.002 . . . . 0.0 108.458 -179.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 6.2 mmt -63.58 -40.44 96.97 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 177.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -57.71 -30.75 65.77 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 125.683 1.593 . . . . 0.0 113.801 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 63.7 mtm -101.12 13.96 33.48 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 120.379 1.445 . . . . 0.0 112.737 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.4 mt -126.75 136.65 52.7 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -179.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.3 t -140.43 131.2 25.82 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.6 m -90.01 125.82 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 CA-C-N 120.179 1.354 . . . . 0.0 107.881 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 11.1 mttp -84.64 105.33 15.36 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 178.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 8.0 p -59.48 143.03 14.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.517 0 C-N-CA 123.922 0.889 . . . . 0.0 108.966 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 143.7 -81.36 0.22 Allowed Glycine 0 N--CA 1.448 -0.541 0 CA-C-N 118.081 0.4 . . . . 0.0 113.645 179.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -125.6 151.0 69.86 Favored Pre-proline 0 CA--C 1.533 0.293 0 C-N-CA 124.439 1.095 . . . . 0.0 113.102 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -77.8 28.8 0.44 Allowed 'Trans proline' 0 CA--C 1.545 1.051 0 C-N-CA 124.762 3.642 . . . . 0.0 111.936 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 47.7 tttm -80.52 92.99 5.97 Favored 'General case' 0 C--O 1.237 0.444 0 O-C-N 119.826 -1.796 . . . . 0.0 106.944 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 142.66 -149.42 21.27 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 108.501 -1.84 . . . . 0.0 108.501 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -84.68 140.5 38.12 Favored Pre-proline 0 C--O 1.24 0.596 0 C-N-CA 126.328 1.851 . . . . 0.0 108.76 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -55.58 136.05 72.21 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.191 2.594 . . . . 0.0 111.942 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -75.55 -11.02 20.51 Favored 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 123.364 2.709 . . . . 0.0 113.878 -178.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -87.99 -40.02 14.22 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 124.375 1.07 . . . . 0.0 110.074 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -74.36 4.53 5.72 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 124.523 1.129 . . . . 0.0 112.077 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.0 tt -44.5 -39.48 1.72 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 128.049 2.54 . . . . 0.0 112.756 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -53.64 -30.6 43.7 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 123.791 0.836 . . . . 0.0 112.15 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 73.6 m-80 -75.38 -44.97 41.95 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.803 179.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 36.6 mt -56.58 -42.63 78.97 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 79.9 t -60.6 107.55 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 179.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.74 -15.12 26.73 Favored Glycine 0 CA--C 1.528 0.847 0 C-N-CA 125.019 1.295 . . . . 0.0 112.692 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -76.76 157.42 31.65 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-N 120.157 1.979 . . . . 0.0 108.086 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 4.0 ttmp? -98.69 137.96 36.55 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 105.217 -2.142 . . . . 0.0 105.217 177.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 9.2 m -68.13 171.75 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 177.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 61.1 mt -116.46 -11.38 11.15 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 125.019 1.328 . . . . 0.0 111.097 178.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.8 m -153.3 166.68 1.35 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.372 0 C-N-CA 125.91 1.684 . . . . 0.0 107.958 -178.312 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.3 m -74.13 135.96 42.91 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 104.843 -2.281 . . . . 0.0 104.843 178.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 95.2 t -121.06 150.83 24.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -106.96 168.18 9.37 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.114 1.366 . . . . 0.0 108.85 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -65.65 147.94 52.57 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 50.1 m-20 72.47 -6.18 1.65 Allowed 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 128.377 2.671 . . . . 0.0 113.236 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -64.62 152.51 41.98 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-O 121.924 0.868 . . . . 0.0 112.652 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -84.0 99.16 10.24 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 123.827 0.851 . . . . 0.0 110.903 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 10.5 mm -67.26 93.73 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 29.9 mtp -96.05 160.96 14.19 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 119.363 0.983 . . . . 0.0 109.577 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -60.36 -22.4 63.23 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.712 0.805 . . . . 0.0 113.107 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -74.97 -16.02 60.65 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.041 0.936 . . . . 0.0 111.865 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 27.8 mt -99.16 9.07 44.18 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 126.447 1.899 . . . . 0.0 113.959 -178.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.92 149.8 33.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 120.138 1.335 . . . . 0.0 112.38 -179.095 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 15.7 t0 . . . . . 0 C--O 1.236 0.379 0 C-N-CA 126.036 1.734 . . . . 0.0 107.659 178.681 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.849 0 N-CA-C 112.091 -0.403 . . . . 0.0 112.091 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 23.0 t -102.32 156.73 17.39 Favored 'General case' 0 C--O 1.244 0.779 0 C-N-CA 123.94 0.896 . . . . 0.0 110.732 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 85.9 t -75.52 127.86 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.2 m -127.69 146.59 33.13 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.073 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.25 124.02 18.61 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 124.429 1.092 . . . . 0.0 109.054 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 46.6 tttm -67.92 -31.71 71.66 Favored 'General case' 0 C--O 1.225 -0.23 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.421 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.3 m -147.02 174.87 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 126.48 1.912 . . . . 0.0 107.585 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 81.1 tttt -69.38 138.38 53.59 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 178.097 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 23.8 mt -129.25 107.35 17.7 Favored Pre-proline 0 CA--C 1.532 0.262 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -178.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.52 155.51 66.53 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 121.661 1.574 . . . . 0.0 110.532 179.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -53.39 147.27 10.84 Favored 'General case' 0 C--O 1.238 0.466 0 C-N-CA 124.942 1.297 . . . . 0.0 109.88 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.0 0.27 75.35 Favored Glycine 0 CA--C 1.53 0.989 0 CA-C-O 118.825 -0.986 . . . . 0.0 113.926 179.187 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 28.5 m -86.67 137.7 32.25 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 119.608 1.704 . . . . 0.0 108.956 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 11.4 mm -80.51 128.71 38.46 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 178.394 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 74.6 mt -67.19 145.18 55.51 Favored 'General case' 0 C--O 1.237 0.442 0 C-N-CA 125.28 1.432 . . . . 0.0 110.307 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.6 p -143.25 152.35 41.6 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.371 1.468 . . . . 0.0 107.457 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -56.65 -27.09 57.88 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 118.869 0.758 . . . . 0.0 109.319 178.559 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -56.39 -29.27 61.28 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 126.418 1.887 . . . . 0.0 111.574 177.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 48.6 mtm -114.04 3.01 15.14 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 124.616 1.166 . . . . 0.0 111.168 -178.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 70.7 mt -105.52 147.89 27.85 Favored 'General case' 0 C--N 1.343 0.296 0 CA-C-N 120.081 1.31 . . . . 0.0 109.188 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.0 t -159.74 171.97 18.56 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 125.241 1.417 . . . . 0.0 107.613 178.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 77.0 t -125.57 152.19 32.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 8.3 mmmt -127.45 109.49 11.8 Favored 'General case' 0 CA--C 1.508 -0.646 0 N-CA-C 105.797 -1.927 . . . . 0.0 105.797 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 29.5 m -59.52 151.43 5.12 Favored 'Isoleucine or valine' 0 C--O 1.24 0.563 0 O-C-N 123.573 0.545 . . . . 0.0 109.532 179.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 152.09 -95.24 0.15 Allowed Glycine 0 N--CA 1.442 -0.925 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.53 163.38 50.02 Favored Pre-proline 0 C--N 1.326 -0.419 0 C-N-CA 126.562 1.945 . . . . 0.0 110.147 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -85.88 53.87 3.37 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 122.761 2.307 . . . . 0.0 110.16 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 32.9 pttt -73.81 70.65 1.44 Allowed 'General case' 0 C--O 1.221 -0.417 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 178.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.69 -152.8 18.07 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -178.366 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -55.07 134.17 68.07 Favored Pre-proline 0 CA--C 1.545 0.766 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -178.17 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -74.17 156.36 46.78 Favored 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 123.367 2.711 . . . . 0.0 111.251 179.306 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -71.18 -24.72 23.09 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.045 1.83 . . . . 0.0 113.942 -178.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 18.8 mp0 -83.68 2.32 38.22 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 -177.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -124.79 -5.46 7.5 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 119.949 1.25 . . . . 0.0 111.957 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 18.2 tt -40.38 -34.8 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 128.401 2.68 . . . . 0.0 114.327 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -57.91 -11.96 2.81 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.43 1.492 . . . . 0.0 114.139 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -97.4 -24.8 15.46 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 120.298 1.408 . . . . 0.0 110.82 178.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 85.8 mt -64.23 -37.94 89.27 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -68.08 118.88 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 179.556 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.82 -16.78 23.21 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 125.325 1.44 . . . . 0.0 112.337 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -85.6 158.68 20.05 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 119.034 1.417 . . . . 0.0 107.593 178.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt -103.45 139.74 38.42 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.793 -0.818 . . . . 0.0 108.793 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.2 m -77.29 135.12 27.16 Favored 'Isoleucine or valine' 0 C--O 1.236 0.347 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 24.1 mt -81.27 -15.3 55.92 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 124.227 1.011 . . . . 0.0 112.028 179.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.2 m -146.92 164.03 7.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 127.059 2.144 . . . . 0.0 108.796 -178.353 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 24.0 m -77.34 132.28 38.5 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.025 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.3 t -98.5 -178.48 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 C-N-CA 126.512 1.925 . . . . 0.0 106.803 178.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -135.64 164.76 27.11 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 127.377 2.271 . . . . 0.0 107.73 177.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -65.91 141.43 58.24 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 105.7 -1.963 . . . . 0.0 105.7 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 68.22 4.88 4.37 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.168 1.787 . . . . 0.0 114.946 179.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -76.19 155.35 34.59 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 119.633 1.106 . . . . 0.0 109.515 179.005 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 29.7 m -77.32 135.74 38.41 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 121.166 -0.959 . . . . 0.0 109.871 -179.338 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 16.7 mm -97.5 133.94 37.42 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 N-CA-C 104.808 -2.293 . . . . 0.0 104.808 177.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 82.7 mtp -139.93 160.86 38.96 Favored 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 123.579 0.752 . . . . 0.0 110.703 -178.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -57.44 -33.62 68.12 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 124.778 1.231 . . . . 0.0 113.231 -179.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -75.32 -2.25 27.4 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.319 1.448 . . . . 0.0 113.601 -178.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 36.9 mt -108.92 3.59 22.45 Favored 'General case' 0 C--O 1.232 0.148 0 C-N-CA 125.06 1.344 . . . . 0.0 110.78 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.4 m -129.59 144.53 37.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 C-N-CA 124.174 0.99 . . . . 0.0 111.234 -179.385 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 27.3 t0 . . . . . 0 CA--C 1.535 0.394 0 C-N-CA 125.57 1.548 . . . . 0.0 110.704 -179.947 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.005 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 90.7 p -145.22 158.8 43.74 Favored 'General case' 0 C--O 1.237 0.431 0 O-C-N 121.764 -0.845 . . . . 0.0 111.412 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.11 137.17 24.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.083 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.4 m -136.49 160.62 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 C-N-CA 125.722 1.609 . . . . 0.0 107.778 178.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.74 118.27 18.38 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 178.566 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -62.48 -31.77 72.56 Favored 'General case' 0 N--CA 1.467 0.411 0 O-C-N 121.341 -0.85 . . . . 0.0 110.953 179.762 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m -138.32 172.0 14.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 126.708 2.003 . . . . 0.0 107.715 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.1 tttm -70.56 134.09 47.34 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 73.9 mt -120.82 110.11 35.36 Favored Pre-proline 0 CA--C 1.53 0.208 0 C-N-CA 123.756 0.822 . . . . 0.0 110.031 -178.419 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -69.54 148.97 67.65 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 121.882 1.721 . . . . 0.0 111.086 178.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 60.4 tt0 -55.27 151.12 10.13 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 124.403 1.081 . . . . 0.0 110.166 178.429 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 68.99 30.47 72.22 Favored Glycine 0 CA--C 1.524 0.652 0 CA-C-O 119.441 -0.644 . . . . 0.0 113.847 178.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 59.9 m -118.04 150.87 38.58 Favored 'General case' 0 C--O 1.239 0.511 0 C-N-CA 125.737 1.615 . . . . 0.0 107.446 179.195 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 32.7 mm -92.4 123.93 44.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 CA-C-N 118.933 0.788 . . . . 0.0 109.443 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 62.2 mt -63.65 147.13 52.36 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.557 1.143 . . . . 0.0 110.858 -179.484 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.3 p -140.55 164.03 31.26 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 124.754 1.222 . . . . 0.0 107.715 178.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 5.7 mmt -62.82 -32.35 73.52 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.462 0.574 . . . . 0.0 110.281 179.211 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -59.24 -27.87 66.18 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 125.021 1.329 . . . . 0.0 113.357 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 57.9 mtm -105.08 9.2 34.39 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.528 1.131 . . . . 0.0 112.733 -178.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 78.5 mt -127.68 146.22 50.63 Favored 'General case' 0 CA--C 1.518 -0.28 0 O-C-N 120.85 -1.156 . . . . 0.0 110.579 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.6 t -153.48 177.92 10.38 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.66 119.52 38.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 179.163 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 47.8 mtpt -91.63 108.8 20.16 Favored 'General case' 0 CA--C 1.511 -0.527 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 179.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 31.9 t -58.64 133.86 23.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 N-CA-C 105.609 -1.997 . . . . 0.0 105.609 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.42 -83.4 0.12 Allowed Glycine 0 C--N 1.334 0.441 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -124.25 150.61 64.28 Favored Pre-proline 0 CA--C 1.532 0.252 0 C-N-CA 123.501 0.72 . . . . 0.0 111.025 -179.597 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -71.14 -15.59 31.98 Favored 'Trans proline' 0 N--CA 1.456 -0.715 0 C-N-CA 122.486 2.124 . . . . 0.0 113.192 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 18.7 ttmm -48.54 106.15 0.09 Allowed 'General case' 0 C--O 1.234 0.272 0 C-N-CA 126.314 1.846 . . . . 0.0 109.982 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.76 -173.51 20.88 Favored Glycine 0 CA--C 1.525 0.715 0 C-N-CA 126.314 1.911 . . . . 0.0 108.93 -179.043 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.5 t80 -65.79 140.19 97.2 Favored Pre-proline 0 CA--C 1.543 0.703 0 O-C-N 121.973 -0.722 . . . . 0.0 109.509 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -66.19 134.29 36.04 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 122.713 2.275 . . . . 0.0 111.579 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -71.56 -16.47 30.47 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.756 2.304 . . . . 0.0 115.215 -179.199 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -70.94 -22.5 62.21 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.555 1.07 . . . . 0.0 111.927 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -114.88 13.28 17.08 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 124.855 1.262 . . . . 0.0 113.269 -178.224 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 20.5 tt -45.44 -36.39 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 125.365 1.466 . . . . 0.0 113.79 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -58.73 -23.59 60.05 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.336 1.054 . . . . 0.0 113.518 -178.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -78.42 -32.94 48.89 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 120.385 1.448 . . . . 0.0 111.504 179.224 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.2 mt -62.87 -35.37 79.77 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.016 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 77.5 t -60.32 117.03 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.08 -6.71 51.4 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 118.302 -1.277 . . . . 0.0 113.91 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.0 mttm -86.52 158.63 19.5 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 120.717 2.258 . . . . 0.0 108.725 178.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -95.77 135.22 37.78 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 179.107 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.2 m -77.51 139.74 18.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 CA-C-N 118.239 0.472 . . . . 0.0 110.077 179.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 23.1 mt -85.08 -17.22 38.06 Favored 'General case' 0 N--CA 1.462 0.154 0 C-N-CA 125.278 1.431 . . . . 0.0 112.066 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.18 163.52 7.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 C-N-CA 124.816 1.247 . . . . 0.0 110.582 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 22.5 m -78.51 122.4 25.82 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 105.116 -2.179 . . . . 0.0 105.116 178.079 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 76.2 t -106.59 139.29 28.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 106.126 -1.805 . . . . 0.0 106.126 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -86.1 176.21 8.12 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 122.079 0.942 . . . . 0.0 112.211 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -71.32 132.37 44.78 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 123.648 0.779 . . . . 0.0 110.09 -179.153 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 68.02 9.75 7.37 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 126.252 1.821 . . . . 0.0 110.127 -179.112 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 35.1 t0 -73.54 153.38 40.29 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.573 1.149 . . . . 0.0 109.466 179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 23.1 m -78.51 129.59 35.04 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 124.969 1.308 . . . . 0.0 111.809 -177.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 13.0 mm -90.39 148.01 4.84 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 179.013 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 38.1 mtp -142.17 163.56 32.54 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 124.777 1.231 . . . . 0.0 108.238 178.511 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -65.02 -26.35 68.24 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 124.128 0.971 . . . . 0.0 111.039 179.768 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -73.04 -14.84 61.49 Favored 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 123.62 0.768 . . . . 0.0 112.226 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 12.2 mt -94.11 6.59 48.1 Favored 'General case' 0 C--N 1.334 -0.069 0 CA-C-O 118.115 -0.945 . . . . 0.0 113.325 -177.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.4 m -127.88 125.33 64.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 120.139 1.336 . . . . 0.0 112.586 -178.632 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 50.5 t0 . . . . . 0 C--O 1.237 0.395 0 C-N-CA 125.779 1.632 . . . . 0.0 108.556 179.679 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.61 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.0 p -110.21 133.7 52.97 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.339 1.455 . . . . 0.0 110.78 -179.566 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.5 t -68.89 127.33 30.57 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 179.366 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.1 m -122.86 149.86 26.6 Favored 'Isoleucine or valine' 0 C--O 1.241 0.625 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.13 119.06 12.82 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 60.5 tttm -70.29 -21.53 62.94 Favored 'General case' 0 C--N 1.331 -0.206 0 O-C-N 121.529 -0.732 . . . . 0.0 112.099 -179.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.2 m -148.17 167.7 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 126.546 1.938 . . . . 0.0 107.501 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.3 tttm -76.43 99.8 5.0 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 178.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 7.6 mt -87.25 109.93 29.43 Favored Pre-proline 0 C--N 1.326 -0.431 0 C-N-CA 125.747 1.619 . . . . 0.0 107.677 -177.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.77 155.12 66.7 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 C-N-CA 121.387 1.391 . . . . 0.0 110.906 -179.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 61.8 tt0 -51.72 141.16 17.38 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 125.653 1.581 . . . . 0.0 109.399 179.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.1 -0.29 87.67 Favored Glycine 0 CA--C 1.535 1.3 0 CA-C-O 119.181 -0.788 . . . . 0.0 114.458 179.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.3 m -84.28 147.77 27.05 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 120.282 2.041 . . . . 0.0 109.668 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.5 mm -86.47 131.26 35.13 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 17.8 mt -68.98 148.16 50.55 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-O 121.607 0.717 . . . . 0.0 110.54 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.3 p -143.34 157.47 44.45 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 127.065 2.146 . . . . 0.0 107.331 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 15.9 mmt -64.98 -24.87 67.64 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -65.17 -14.73 61.3 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 128.791 2.837 . . . . 0.0 112.002 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 25.7 mtm -124.16 10.19 8.7 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.388 1.475 . . . . 0.0 111.933 -179.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 83.4 mt -128.66 152.86 47.9 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 119.728 1.149 . . . . 0.0 110.714 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.0 t -160.54 -179.15 7.41 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 105.434 -2.062 . . . . 0.0 105.434 178.133 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.47 131.11 39.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 O-C-N 120.766 -1.209 . . . . 0.0 108.07 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 2.4 tppp? -84.28 105.45 15.13 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 101.698 -3.445 . . . . 0.0 101.698 177.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.0 m -66.99 89.99 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 O-C-N 121.597 -0.689 . . . . 0.0 110.534 -179.154 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -145.06 -87.15 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 124.984 1.278 . . . . 0.0 110.565 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.9 148.44 39.92 Favored Pre-proline 0 C--N 1.326 -0.418 0 C-N-CA 125.884 1.674 . . . . 0.0 111.695 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -82.5 71.6 6.42 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.176 2.584 . . . . 0.0 108.166 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 40.1 tttp -114.24 166.2 11.9 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 123.537 0.735 . . . . 0.0 109.726 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 74.41 -87.65 0.71 Allowed Glycine 0 N--CA 1.444 -0.828 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -139.84 144.58 39.23 Favored Pre-proline 0 C--O 1.238 0.448 0 C-N-CA 124.919 1.288 . . . . 0.0 108.117 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.9 148.05 85.66 Favored 'Trans proline' 0 CA--C 1.539 0.75 0 C-N-CA 121.543 1.495 . . . . 0.0 109.358 179.065 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.05 -18.8 14.24 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.145 1.897 . . . . 0.0 111.989 -178.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -66.17 -33.09 74.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.46 -0.775 . . . . 0.0 111.391 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -92.24 10.78 28.13 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.18 1.792 . . . . 0.0 111.864 -178.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 13.9 tt -53.98 -34.65 26.5 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.718 0 O-C-N 119.801 -1.812 . . . . 0.0 111.201 179.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -60.64 -20.93 62.07 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.805 1.242 . . . . 0.0 113.605 179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -99.24 -17.99 17.83 Favored 'General case' 0 CA--C 1.515 -0.383 0 CA-C-N 119.732 1.151 . . . . 0.0 111.733 178.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 25.4 mt -68.27 -32.74 73.12 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 177.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 41.7 t -64.24 138.79 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 178.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 91.58 -16.2 59.68 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-O 118.823 -0.987 . . . . 0.0 112.277 -179.055 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.3 mttm -76.63 171.98 13.77 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-N 119.586 1.693 . . . . 0.0 107.368 178.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 24.7 ttmt -122.85 133.44 54.43 Favored 'General case' 0 CA--C 1.516 -0.355 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 1.8 m -74.6 148.47 7.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 O-C-N 124.258 0.974 . . . . 0.0 110.675 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 65.5 mt -97.93 -14.15 20.79 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 126.013 1.725 . . . . 0.0 112.696 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 15.7 m -144.42 161.81 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 C-N-CA 126.064 1.746 . . . . 0.0 108.461 179.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.1 m -74.98 96.0 3.1 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 87.0 t -70.79 127.13 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 178.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -74.29 170.28 15.91 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.584 0.707 . . . . 0.0 110.162 179.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -74.87 138.25 42.34 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 104.788 -2.301 . . . . 0.0 104.788 177.414 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 34.7 t0 72.34 10.94 5.85 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.781 2.032 . . . . 0.0 113.132 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -72.96 149.6 43.21 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 177.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 90.7 m -79.12 122.71 26.58 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 179.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.2 mm -76.51 126.52 37.26 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 48.7 mtp -128.09 155.43 44.4 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 122.469 1.128 . . . . 0.0 110.425 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -62.28 -20.18 64.02 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 126.696 1.998 . . . . 0.0 114.029 -179.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -89.21 -10.35 47.36 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 123.876 0.87 . . . . 0.0 111.687 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 84.1 mt -90.4 11.0 22.87 Favored 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 124.823 1.249 . . . . 0.0 110.729 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.5 m -133.34 151.2 33.27 Favored 'Isoleucine or valine' 0 C--O 1.232 0.166 0 CA-C-N 120.427 1.467 . . . . 0.0 114.239 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 35.1 t0 . . . . . 0 C--O 1.239 0.537 0 C-N-CA 124.641 1.176 . . . . 0.0 109.129 178.712 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.378 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 76.5 p -137.26 157.19 47.18 Favored 'General case' 0 C--O 1.238 0.451 0 C-N-CA 123.793 0.837 . . . . 0.0 109.704 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 28.9 t -75.57 130.75 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.3 m -128.98 157.85 41.76 Favored 'Isoleucine or valine' 0 C--O 1.24 0.593 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 178.023 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.31 130.99 42.77 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 178.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 64.7 tttt -75.59 -32.91 60.52 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 121.366 -0.834 . . . . 0.0 110.754 179.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 22.6 m -144.58 170.71 7.34 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 129.601 3.16 . . . . 0.0 108.945 -179.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 20.6 tttm -68.78 116.58 9.43 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 119.762 1.165 . . . . 0.0 108.79 179.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 40.2 mt -98.9 105.19 29.84 Favored Pre-proline 0 CA--C 1.534 0.365 0 C-N-CA 125.168 1.387 . . . . 0.0 110.983 -179.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.99 145.39 67.6 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 121.609 1.539 . . . . 0.0 108.937 177.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -53.69 152.9 4.85 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 124.151 0.98 . . . . 0.0 110.966 178.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.87 24.89 76.15 Favored Glycine 0 CA--C 1.524 0.61 0 CA-C-O 118.543 -1.143 . . . . 0.0 113.892 178.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 56.9 m -118.62 143.82 46.55 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 119.112 1.456 . . . . 0.0 108.266 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 18.6 mm -74.39 136.26 25.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.363 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 25.4 mt -80.51 141.47 35.13 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 126.099 1.76 . . . . 0.0 107.805 179.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.0 p -135.92 165.32 25.93 Favored 'General case' 0 C--O 1.237 0.425 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 179.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -61.26 -25.87 67.38 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.55 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -78.17 -10.4 59.62 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.347 1.059 . . . . 0.0 113.164 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 58.9 mtm -119.97 16.07 12.51 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 126.029 1.731 . . . . 0.0 110.566 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.8 mt -141.55 137.88 32.3 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 179.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.1 t -148.28 155.08 40.89 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 t -111.25 102.04 13.41 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 27.7 ttpp -75.01 112.78 11.59 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.236 0.614 . . . . 0.0 109.794 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 90.1 t -61.83 121.92 11.28 Favored 'Isoleucine or valine' 0 C--O 1.239 0.504 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 176.19 -82.77 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -138.56 158.68 69.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 C-N-CA 123.442 0.697 . . . . 0.0 110.768 -179.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -74.63 11.63 1.3 Allowed 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.344 2.696 . . . . 0.0 113.182 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -67.47 95.32 0.45 Allowed 'General case' 0 C--O 1.232 0.155 0 O-C-N 120.281 -1.512 . . . . 0.0 108.136 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.7 -167.89 23.78 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 128.095 2.76 . . . . 0.0 109.316 -178.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -67.77 144.35 97.35 Favored Pre-proline 0 CA--C 1.545 0.752 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -72.35 154.35 56.07 Favored 'Trans proline' 0 CA--C 1.544 1.016 0 C-N-CA 122.432 2.088 . . . . 0.0 113.406 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_endo -66.2 -27.42 48.76 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 123.416 2.744 . . . . 0.0 116.223 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -75.99 -25.06 55.44 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 120.233 1.379 . . . . 0.0 112.179 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -88.86 -2.55 58.64 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.919 0.781 . . . . 0.0 112.563 -179.184 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.4 tt -51.12 -34.38 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 O-C-N 120.616 -1.302 . . . . 0.0 112.557 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -59.43 -22.9 62.15 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -95.29 -19.09 20.28 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-O 117.76 -1.115 . . . . 0.0 111.308 178.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 61.0 mt -72.68 -34.32 67.12 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 73.1 t -64.83 130.64 30.2 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 N-CA-C 105.62 -1.993 . . . . 0.0 105.62 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 93.82 -12.64 69.0 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-O 118.054 -1.414 . . . . 0.0 112.514 -179.305 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -75.49 173.14 11.36 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 119.565 1.682 . . . . 0.0 109.602 178.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.5 tppt? -127.07 101.58 6.6 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.204 1.402 . . . . 0.0 108.941 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 6.1 m -43.06 140.84 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 123.73 0.812 . . . . 0.0 112.508 -178.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 92.8 mt -86.84 -19.48 28.9 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.486 1.114 . . . . 0.0 112.307 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.1 m -143.89 165.69 13.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 C-N-CA 126.222 1.809 . . . . 0.0 107.974 -179.021 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.2 m -76.26 138.56 40.64 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 178.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 79.0 t -119.85 128.43 75.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -75.38 173.89 10.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 122.101 0.953 . . . . 0.0 110.565 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -69.83 145.53 52.02 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . 0.338 0.7 OUTLIER 58.63 8.29 0.88 Allowed 'General case' 0 C--O 1.236 0.348 0 C-N-CA 125.291 1.436 . . . . 0.0 114.374 179.333 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -74.38 158.78 33.32 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 178.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 18.4 m -84.77 126.82 33.75 Favored 'General case' 0 C--N 1.321 -0.638 0 O-C-N 120.69 -1.256 . . . . 0.0 112.131 -177.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.9 mm -84.04 134.9 25.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 N-CA-C 104.328 -2.471 . . . . 0.0 104.328 178.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 69.7 mtp -141.48 159.83 41.4 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 122.885 0.474 . . . . 0.0 110.642 -178.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -61.54 -20.68 63.52 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 125.057 1.343 . . . . 0.0 112.697 179.765 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -81.68 -12.68 58.57 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.457 1.103 . . . . 0.0 112.245 179.546 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 25.0 mt -103.34 0.23 31.08 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.345 1.058 . . . . 0.0 111.463 -179.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.6 m -132.24 147.23 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 CA-C-O 122.302 1.049 . . . . 0.0 112.368 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 20.4 t0 . . . . . 0 N--CA 1.445 -0.718 0 C-N-CA 126.692 1.997 . . . . 0.0 110.104 179.559 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.675 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -144.23 164.99 29.11 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 124.916 1.286 . . . . 0.0 109.665 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.0 t -81.41 134.05 27.95 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.6 m -133.23 159.39 43.01 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.77 120.35 17.23 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 178.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 75.5 tttt -69.04 -29.5 67.65 Favored 'General case' 0 C--N 1.327 -0.372 0 O-C-N 121.787 -0.571 . . . . 0.0 109.761 179.209 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.2 m -151.0 163.12 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 C-N-CA 128.081 2.552 . . . . 0.0 107.569 178.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -56.23 141.07 42.52 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 124.701 1.2 . . . . 0.0 108.718 178.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 8.3 mt -129.68 105.4 17.16 Favored Pre-proline 0 N--CA 1.465 0.281 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -178.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.79 146.06 82.48 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 121.47 1.446 . . . . 0.0 111.263 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 60.5 tt0 -56.71 141.97 41.91 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.561 0.696 . . . . 0.0 111.036 -179.335 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 90.91 2.77 71.32 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-O 119.137 -0.813 . . . . 0.0 113.376 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 30.0 m -97.38 151.26 20.12 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 125.603 1.561 . . . . 0.0 109.143 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 14.4 mm -91.98 141.15 14.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 37.6 mt -73.49 149.56 42.21 Favored 'General case' 0 C--O 1.238 0.468 0 C-N-CA 124.667 1.187 . . . . 0.0 110.69 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.9 p -144.51 158.11 43.91 Favored 'General case' 0 C--N 1.328 -0.361 0 C-N-CA 127.176 2.19 . . . . 0.0 108.096 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.6 mmt -63.74 -31.7 72.96 Favored 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -59.43 -17.44 30.93 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.987 1.315 . . . . 0.0 111.914 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 49.5 mtm -119.88 11.08 11.73 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.122 1.369 . . . . 0.0 111.849 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.5 mt -130.33 146.88 51.97 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 119.373 0.988 . . . . 0.0 110.256 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.7 t -152.95 163.83 39.08 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 55.3 t -107.75 101.49 12.6 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 1.1 mmtm -72.65 129.7 38.86 Favored 'General case' 0 N--CA 1.453 -0.287 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.3 m -73.24 123.04 27.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 168.33 -93.64 0.1 Allowed Glycine 0 C--N 1.335 0.473 0 C-N-CA 119.918 -1.134 . . . . 0.0 112.985 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -138.09 153.83 73.65 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 117.484 0.642 . . . . 0.0 111.577 -179.098 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -70.48 14.7 0.3 Allowed 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 124.588 3.525 . . . . 0.0 115.08 -179.032 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.42 114.2 6.65 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 105.31 -2.108 . . . . 0.0 105.31 178.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 119.74 -166.39 13.42 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -178.725 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -69.83 138.66 87.99 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-O 118.909 -0.567 . . . . 0.0 112.207 -178.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -60.79 135.18 58.26 Favored 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.643 2.229 . . . . 0.0 110.162 179.281 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.42 -13.84 36.19 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 121.963 1.775 . . . . 0.0 115.299 -179.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -78.23 -31.17 49.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 119.494 1.043 . . . . 0.0 108.929 179.021 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -81.39 3.98 22.5 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.379 1.072 . . . . 0.0 111.647 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.1 tt -53.2 -32.26 18.93 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 124.658 1.183 . . . . 0.0 112.244 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -57.27 -43.79 83.36 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 123.232 0.613 . . . . 0.0 109.384 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 18.3 m-80 -64.79 -36.76 85.36 Favored 'General case' 0 CA--C 1.522 -0.114 0 C-N-CA 124.176 0.991 . . . . 0.0 110.633 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 71.7 mt -64.42 -34.07 77.32 Favored 'General case' 0 C--O 1.227 -0.108 0 CA-C-O 118.837 -0.602 . . . . 0.0 110.495 179.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 96.8 t -71.98 82.11 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 CA-C-O 123.031 1.396 . . . . 0.0 109.245 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 147.24 -4.95 1.0 Allowed Glycine 0 CA--C 1.527 0.844 0 C-N-CA 127.032 2.253 . . . . 0.0 112.653 -179.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 78.7 mttt -91.92 156.33 17.54 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 119.427 1.613 . . . . 0.0 109.118 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -99.42 138.67 36.19 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 179.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 6.1 m -75.33 137.37 23.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 95.6 mt -88.81 -12.85 40.84 Favored 'General case' 0 C--N 1.334 -0.106 0 C-N-CA 124.575 1.15 . . . . 0.0 111.592 179.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 32.6 m -143.53 160.2 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.25 0 C-N-CA 124.343 1.057 . . . . 0.0 108.65 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 33.4 m -74.23 105.58 5.48 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 104.735 -2.32 . . . . 0.0 104.735 177.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 41.1 t -80.23 143.46 12.37 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 179.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -90.62 169.74 10.75 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 121.774 0.797 . . . . 0.0 109.08 178.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -69.35 136.91 52.4 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 178.053 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.6 t0 65.06 13.79 8.92 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 124.796 1.239 . . . . 0.0 113.813 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -77.01 157.14 31.35 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 124.004 0.922 . . . . 0.0 109.048 178.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.0 m -78.47 128.75 34.03 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 121.517 -0.74 . . . . 0.0 109.596 -179.264 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.0 mm -87.93 129.08 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 N-CA-C 103.143 -2.91 . . . . 0.0 103.143 177.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 46.6 mtp -133.24 159.92 38.8 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -63.4 -34.13 77.06 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 123.372 0.669 . . . . 0.0 109.904 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -60.75 -19.5 59.18 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 126.662 1.985 . . . . 0.0 110.741 179.699 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 10.7 mt -100.86 6.91 43.88 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 125.149 1.38 . . . . 0.0 112.532 -179.209 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.4 m -132.55 147.2 31.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 120.749 1.613 . . . . 0.0 111.814 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.237 0.398 0 C-N-CA 125.413 1.485 . . . . 0.0 109.57 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.623 0 N-CA-C 112.34 -0.304 . . . . 0.0 112.34 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 36.7 p -136.87 143.75 43.2 Favored 'General case' 0 C--O 1.234 0.255 0 C-N-CA 125.627 1.571 . . . . 0.0 110.872 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.7 t -69.24 123.07 21.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 CA-C-N 119.15 0.886 . . . . 0.0 110.869 179.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 35.5 m -125.41 154.64 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 125.043 1.337 . . . . 0.0 108.065 177.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.37 118.91 12.07 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -70.36 -29.93 66.72 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.389 -0.819 . . . . 0.0 110.85 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.6 m -147.21 161.85 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 127.816 2.447 . . . . 0.0 106.932 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 78.3 tttt -62.85 143.44 57.59 Favored 'General case' 0 C--O 1.24 0.577 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.1 mt -127.33 110.85 21.25 Favored Pre-proline 0 CA--C 1.538 0.486 0 C-N-CA 124.956 1.302 . . . . 0.0 109.201 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -66.35 149.5 84.9 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 121.663 1.575 . . . . 0.0 109.704 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.6 tm-20 -53.56 148.55 9.26 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 124.293 1.037 . . . . 0.0 110.905 179.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.22 -0.52 87.46 Favored Glycine 0 CA--C 1.526 0.747 0 C-N-CA 124.617 1.103 . . . . 0.0 115.219 178.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 72.5 m -83.6 144.53 29.39 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 118.213 1.006 . . . . 0.0 110.768 -179.07 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 30.0 mm -85.65 135.58 24.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 177.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 42.4 mt -72.29 151.98 42.43 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 124.008 0.923 . . . . 0.0 112.033 -179.123 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 47.7 p -144.0 159.02 43.32 Favored 'General case' 0 C--O 1.238 0.455 0 C-N-CA 127.285 2.234 . . . . 0.0 106.533 178.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.69 -30.89 71.64 Favored 'General case' 0 C--O 1.224 -0.273 0 CA-C-N 119.377 0.99 . . . . 0.0 108.483 178.605 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -58.14 -30.58 66.45 Favored 'General case' 0 C--O 1.225 -0.209 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -179.436 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.8 mtm -95.69 9.67 39.53 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 118.861 0.755 . . . . 0.0 111.518 179.565 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.3 mt -130.83 158.22 40.76 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 123.898 0.879 . . . . 0.0 111.843 -178.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 t -159.32 152.06 21.7 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.351 -2.092 . . . . 0.0 105.351 177.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 m -103.01 120.51 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 119.828 1.194 . . . . 0.0 108.596 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 27.5 ttpp -68.84 113.67 6.48 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 104.784 -2.302 . . . . 0.0 104.784 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 60.7 t -74.56 85.73 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -144.02 -77.13 0.03 OUTLIER Glycine 0 CA--C 1.52 0.358 0 C-N-CA 125.395 1.474 . . . . 0.0 111.311 -179.118 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -147.62 161.59 34.98 Favored Pre-proline 0 CA--C 1.537 0.464 0 C-N-CA 124.88 1.272 . . . . 0.0 109.493 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -73.82 36.23 0.39 Allowed 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 124.61 3.54 . . . . 0.0 113.249 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -62.7 164.24 8.06 Favored 'General case' 0 N--CA 1.462 0.16 0 O-C-N 120.567 -1.333 . . . . 0.0 108.912 178.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 53.41 -132.09 42.7 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 179.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -86.45 135.88 35.89 Favored Pre-proline 0 CA--C 1.542 0.658 0 C-N-CA 125.026 1.33 . . . . 0.0 110.848 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.16 151.48 66.63 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.273 2.649 . . . . 0.0 112.592 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -80.04 -24.81 5.48 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.654 2.236 . . . . 0.0 112.989 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -65.48 -43.24 90.84 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 119.253 0.933 . . . . 0.0 110.638 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -71.05 8.33 0.97 Allowed 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 127.771 2.428 . . . . 0.0 114.15 -178.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.1 tt -50.27 -36.17 12.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 CA-C-N 119.3 0.955 . . . . 0.0 112.498 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -58.89 -32.37 69.44 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-O 118.976 -0.535 . . . . 0.0 111.706 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 70.9 m-80 -70.3 -49.6 47.98 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 20.8 mt -57.03 -46.23 82.54 Favored 'General case' 0 CA--C 1.515 -0.385 0 C-N-CA 123.52 0.728 . . . . 0.0 109.957 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 74.8 t -68.05 99.19 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.693 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 131.46 -12.48 5.45 Favored Glycine 0 CA--C 1.529 0.926 0 C-N-CA 127.18 2.324 . . . . 0.0 110.687 -179.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 55.8 mttm -84.21 169.19 15.03 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 120.021 1.911 . . . . 0.0 108.053 178.273 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 20.4 ttmm -111.85 138.45 48.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 118.1 -0.952 . . . . 0.0 109.287 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.8 m -74.52 137.14 23.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.508 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 38.3 mt -83.2 -18.84 37.91 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 125.678 1.591 . . . . 0.0 112.268 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 22.8 m -145.21 167.94 9.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 126.198 1.799 . . . . 0.0 108.496 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.6 m -76.88 109.46 10.7 Favored 'General case' 0 N--CA 1.456 -0.149 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 178.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 86.7 t -86.48 126.07 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 C-N-CA 124.632 1.173 . . . . 0.0 107.863 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -77.45 172.8 12.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 122.18 0.991 . . . . 0.0 111.298 178.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -71.79 148.63 46.08 Favored 'General case' 0 N--CA 1.443 -0.782 0 O-C-N 121.616 -0.678 . . . . 0.0 109.509 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 29.2 t70 61.36 7.36 1.7 Allowed 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 127.554 2.342 . . . . 0.0 112.169 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -67.82 150.99 47.9 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.234 1.014 . . . . 0.0 108.895 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 47.3 m -82.64 111.84 18.97 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.048 -1.094 . . . . 0.0 108.048 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.8 mm -70.27 129.68 34.47 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 105.712 -1.959 . . . . 0.0 105.712 178.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 59.1 mtp -132.8 161.02 35.19 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 123.897 0.879 . . . . 0.0 109.316 -179.203 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -62.25 -30.55 71.19 Favored 'General case' 0 N--CA 1.466 0.329 0 C-N-CA 123.498 0.719 . . . . 0.0 111.031 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 19.2 pt-20 -66.51 -15.84 63.69 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 123.613 0.765 . . . . 0.0 111.474 179.339 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 38.5 mt -100.32 5.29 44.46 Favored 'General case' 0 C--N 1.341 0.234 0 C-N-CA 126.419 1.887 . . . . 0.0 112.692 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.06 140.41 47.97 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-N 121.665 2.029 . . . . 0.0 114.687 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 46.4 t0 . . . . . 0 C--O 1.239 0.514 0 C-N-CA 127.191 2.197 . . . . 0.0 108.869 178.893 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.742 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 46.4 p -136.33 163.04 31.37 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 117.251 0.525 . . . . 0.0 109.887 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 62.3 t -68.74 142.89 15.65 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.4 m -140.87 164.36 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 127.021 2.129 . . . . 0.0 106.547 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -81.13 133.15 35.42 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.062 -1.458 . . . . 0.0 107.062 177.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -75.51 -29.31 59.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 118.898 -0.572 . . . . 0.0 111.371 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.6 m -144.96 168.97 8.51 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 127.199 2.2 . . . . 0.0 107.854 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.4 tttm -71.86 123.86 23.6 Favored 'General case' 0 C--O 1.238 0.457 0 C-N-CA 124.966 1.306 . . . . 0.0 108.766 178.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 74.9 mt -115.64 119.82 37.06 Favored Pre-proline 0 CA--C 1.538 0.517 0 C-N-CA 125.111 1.365 . . . . 0.0 110.112 -178.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.6 152.03 53.28 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 121.783 1.655 . . . . 0.0 110.633 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -50.49 146.9 4.95 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.797 1.639 . . . . 0.0 110.844 179.435 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.12 -4.44 66.8 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 115.341 0.896 . . . . 0.0 115.341 178.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.5 m -82.6 149.65 27.32 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 118.561 1.18 . . . . 0.0 109.438 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.05 141.86 13.77 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 76.3 mt -82.98 144.35 30.04 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 123.607 0.763 . . . . 0.0 110.589 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 77.1 p -133.67 162.25 32.46 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 126.876 2.071 . . . . 0.0 108.114 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.0 mmt -63.03 -26.57 68.91 Favored 'General case' 0 N--CA 1.465 0.294 0 O-C-N 121.781 -0.574 . . . . 0.0 110.75 179.172 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -68.91 -43.92 74.19 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-O 117.82 -1.086 . . . . 0.0 112.782 -179.139 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 29.6 mtm -87.76 18.17 4.25 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 120.671 1.578 . . . . 0.0 111.58 -177.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 64.8 mt -125.65 133.61 52.14 Favored 'General case' 0 CA--C 1.516 -0.337 0 C-N-CA 126.169 1.788 . . . . 0.0 109.856 -179.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.0 t -146.77 174.08 11.8 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 178.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 40.9 t -129.86 100.22 5.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 CA-C-N 119.36 0.982 . . . . 0.0 108.585 -178.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.438 ' HE2' ' HA ' ' A' ' 29' ' ' LYS . 6.2 mmpt? -67.41 131.32 45.46 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.7 m -62.31 125.87 19.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 178.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.37 -134.0 3.13 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -99.66 156.19 35.64 Favored Pre-proline 0 C--O 1.236 0.374 0 C-N-CA 123.995 0.918 . . . . 0.0 112.781 -179.335 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -79.84 51.7 4.0 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 124.474 3.449 . . . . 0.0 111.526 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.0 pttt -72.21 -56.47 5.48 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 120.83 -1.169 . . . . 0.0 110.486 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -70.83 -169.61 8.86 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 125.3 1.428 . . . . 0.0 112.075 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -57.12 144.18 70.17 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 118.209 -0.9 . . . . 0.0 111.316 179.64 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -64.4 142.5 79.04 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.838 2.359 . . . . 0.0 112.089 179.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -77.26 7.82 3.55 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 123.638 2.892 . . . . 0.0 112.051 178.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -94.62 -43.09 8.45 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 126.405 1.882 . . . . 0.0 109.845 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -94.45 8.53 41.76 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 124.113 0.965 . . . . 0.0 111.193 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.2 tt -45.89 -35.78 2.16 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 126.644 1.977 . . . . 0.0 111.874 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -59.67 -25.15 64.49 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 125.374 1.47 . . . . 0.0 112.223 179.535 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -77.88 -36.14 50.07 Favored 'General case' 0 CA--C 1.518 -0.253 0 C-N-CA 124.068 0.947 . . . . 0.0 109.977 179.278 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 84.9 mt -57.38 -40.69 78.71 Favored 'General case' 0 CA--C 1.516 -0.335 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.227 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 94.4 t -60.39 104.71 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 178.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 118.67 -14.95 11.56 Favored Glycine 0 CA--C 1.526 0.748 0 CA-C-O 117.957 -1.468 . . . . 0.0 113.187 -179.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -81.06 168.5 18.57 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 119.564 1.682 . . . . 0.0 108.39 179.23 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -114.83 138.11 51.16 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 124.15 0.98 . . . . 0.0 109.316 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.1 m -74.06 151.94 7.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.596 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 13.1 mt -100.39 -13.99 18.53 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 126.018 1.727 . . . . 0.0 113.643 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 10.4 m -151.14 163.85 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 126.974 2.109 . . . . 0.0 107.915 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.6 m -73.25 102.53 3.68 Favored 'General case' 0 CA--C 1.534 0.349 0 O-C-N 121.085 -1.009 . . . . 0.0 108.665 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 64.1 t -78.4 144.28 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 N-CA-C 107.167 -1.419 . . . . 0.0 107.167 179.226 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 34.9 mm-40 -88.65 174.73 7.87 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 122.094 0.95 . . . . 0.0 110.082 179.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -77.14 143.35 39.19 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 177.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 69.63 -1.07 2.4 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 125.436 1.495 . . . . 0.0 112.698 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -67.2 151.34 47.72 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 127.177 2.191 . . . . 0.0 110.976 -178.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.6 m -80.51 127.58 32.6 Favored 'General case' 0 C--N 1.324 -0.535 0 C-N-CA 123.272 0.629 . . . . 0.0 110.431 -178.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.2 mm -85.08 96.4 4.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.264 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 179.113 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' MET . . . . . 0.426 ' H ' HD11 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -82.79 170.2 15.29 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 177.37 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.426 ' CD ' ' H ' ' A' ' 61' ' ' GLU . 17.8 mp0 -76.18 -34.69 59.33 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 125.198 1.399 . . . . 0.0 109.658 -179.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -64.56 -29.03 70.06 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 123.09 0.556 . . . . 0.0 111.334 179.144 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.426 HD11 ' H ' ' A' ' 60' ' ' MET . 73.9 mt -76.1 -0.18 21.01 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.79 1.236 . . . . 0.0 113.229 -179.385 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.36 147.2 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 121.466 1.939 . . . . 0.0 110.751 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.239 0.507 0 CA-C-O 123.256 1.503 . . . . 0.0 114.079 -179.014 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.439 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.4 t -137.37 163.17 31.69 Favored 'General case' 0 C--O 1.239 0.532 0 C-N-CA 123.94 0.896 . . . . 0.0 109.324 179.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.0 t -74.06 136.19 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.1 m -130.37 158.95 42.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 C-N-CA 125.426 1.49 . . . . 0.0 107.805 178.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.96 107.2 5.2 Favored 'General case' 0 N--CA 1.443 -0.797 0 N-CA-C 104.733 -2.321 . . . . 0.0 104.733 177.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 37.6 tttt -59.75 -24.09 63.76 Favored 'General case' 0 N--CA 1.464 0.239 0 O-C-N 121.6 -0.687 . . . . 0.0 111.857 -179.265 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.1 m -145.86 169.52 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 C-N-CA 125.679 1.592 . . . . 0.0 109.123 -178.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 36.8 tttm -72.71 128.32 35.19 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 103.386 -2.82 . . . . 0.0 103.386 176.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.5 mt -122.69 115.22 29.64 Favored Pre-proline 0 C--N 1.333 -0.143 0 C-N-CA 125.09 1.356 . . . . 0.0 111.122 -176.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -70.65 153.98 64.49 Favored 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 121.077 1.185 . . . . 0.0 110.463 178.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -54.2 149.36 9.81 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.671 1.588 . . . . 0.0 111.436 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.13 -2.7 64.54 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 123.798 0.714 . . . . 0.0 114.431 179.47 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 12.8 m -81.76 143.63 31.67 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 119.179 1.49 . . . . 0.0 109.809 -179.601 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 39.9 mm -84.41 125.99 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.916 -1.883 . . . . 0.0 105.916 178.07 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 45.4 mt -66.38 144.83 56.3 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 124.434 1.094 . . . . 0.0 110.893 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 40.1 p -139.3 165.88 26.02 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 178.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.6 mmt -67.08 -9.82 43.46 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.914 -0.492 . . . . 0.0 110.507 178.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -88.83 -2.83 58.78 Favored 'General case' 0 N--CA 1.471 0.579 0 O-C-N 120.353 -1.467 . . . . 0.0 110.88 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 36.7 mtm -125.11 4.81 7.89 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 124.944 1.298 . . . . 0.0 110.961 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.8 mt -135.8 147.33 48.29 Favored 'General case' 0 CA--C 1.512 -0.506 0 O-C-N 121.163 -0.961 . . . . 0.0 109.326 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.9 t -159.46 177.98 10.39 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 178.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.1 132.82 68.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 178.713 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.451 ' HZ2' ' CG ' ' A' ' 56' ' ' ASP . 25.1 mmtp -91.51 -173.04 3.44 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.86 96.83 4.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 O-C-N 120.948 -1.095 . . . . 0.0 108.856 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.16 -82.71 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -157.02 160.7 30.51 Favored Pre-proline 0 CA--C 1.546 0.816 0 C-N-CA 125.529 1.532 . . . . 0.0 109.132 -179.04 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -66.46 13.02 0.14 Allowed 'Trans proline' 0 CA--C 1.54 0.781 1 C-N-CA 126.321 4.681 . . . . 0.0 116.94 -179.039 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.0 ptmt -54.06 114.38 1.58 Allowed 'General case' 0 C--O 1.221 -0.412 0 CA-C-N 119.287 0.949 . . . . 0.0 110.853 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 116.56 -81.03 0.3 Allowed Glycine 0 C--N 1.332 0.321 0 CA-C-N 119.625 1.102 . . . . 0.0 112.366 179.125 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -151.17 138.36 11.99 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 123.147 0.579 . . . . 0.0 111.822 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -68.13 134.77 32.6 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.357 2.038 . . . . 0.0 111.707 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -63.71 -22.49 69.76 Favored 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 122.439 2.093 . . . . 0.0 113.191 179.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -69.4 -8.6 48.0 Favored 'General case' 0 CA--C 1.534 0.341 0 CA-C-N 119.323 0.965 . . . . 0.0 112.404 179.461 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -119.78 10.39 11.62 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 124.794 1.238 . . . . 0.0 112.414 -178.508 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.3 tt -51.84 -31.17 13.05 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 O-C-N 121.326 -0.859 . . . . 0.0 113.078 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -54.63 -37.49 65.71 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 125.248 1.419 . . . . 0.0 112.278 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -77.95 -29.28 49.77 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 118.467 0.576 . . . . 0.0 111.042 179.182 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 78.0 mt -66.46 -34.54 78.18 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 179.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.1 t -69.58 105.18 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -179.004 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 119.81 -10.08 11.32 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.894 1.711 . . . . 0.0 112.587 -179.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 3.3 mtpp -82.16 154.39 25.52 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 119.228 1.514 . . . . 0.0 108.026 178.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.2 ttmt -95.69 135.15 37.76 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 5.1 m -75.81 143.45 13.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 177.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 73.4 mt -89.27 -14.94 34.71 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 124.399 1.08 . . . . 0.0 111.248 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.4 m -145.9 163.81 10.55 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 C-N-CA 126.395 1.878 . . . . 0.0 109.309 -178.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 4.9 m -75.76 127.4 32.96 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 105.731 -1.951 . . . . 0.0 105.731 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 89.2 t -105.93 148.74 10.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -98.66 170.55 8.71 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 123.626 0.77 . . . . 0.0 111.603 -179.066 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -67.78 132.75 48.01 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.451 ' CG ' ' HZ2' ' A' ' 29' ' ' LYS . 7.4 t70 67.91 9.39 7.1 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 129.327 3.051 . . . . 0.0 114.201 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -68.06 154.64 41.23 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 123.429 0.692 . . . . 0.0 110.253 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -84.81 124.97 32.18 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 123.246 0.618 . . . . 0.0 110.97 -178.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.9 mm -85.84 146.95 5.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 178.073 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 32.9 mtp -134.01 151.76 51.57 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 105.47 -2.048 . . . . 0.0 105.47 178.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.26 -26.96 61.63 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 123.562 0.745 . . . . 0.0 112.885 -178.765 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -76.62 -0.58 23.91 Favored 'General case' 0 N--CA 1.451 -0.408 0 C-N-CA 126.0 1.72 . . . . 0.0 114.768 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 61.6 mt -113.53 3.18 15.63 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.204 1.402 . . . . 0.0 112.364 -179.402 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.2 m -132.52 152.9 37.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-N 119.462 1.028 . . . . 0.0 112.453 -178.025 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.531 0.217 0 C-N-CA 123.594 0.758 . . . . 0.0 110.109 179.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.387 0 N-CA-C 111.995 -0.442 . . . . 0.0 111.995 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 55.7 p -137.74 155.58 48.92 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 124.224 1.01 . . . . 0.0 110.842 179.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 43.4 t -75.93 130.61 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 178.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 m -129.74 157.68 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 N-CA-C 105.122 -2.177 . . . . 0.0 105.122 177.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.05 128.9 36.62 Favored 'General case' 0 N--CA 1.444 -0.731 0 O-C-N 121.356 -0.84 . . . . 0.0 109.38 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 52.6 tttt -72.44 -27.49 62.36 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.075 0.55 . . . . 0.0 111.309 179.686 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.6 m -146.87 171.65 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 C-N-CA 127.092 2.157 . . . . 0.0 108.083 -179.473 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.3 tttt -70.58 124.67 24.79 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 178.58 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.3 mt -116.16 101.81 53.82 Favored Pre-proline 0 C--N 1.327 -0.384 0 N-CA-C 105.788 -1.93 . . . . 0.0 105.788 -178.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -63.31 159.05 41.53 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 120.896 1.064 . . . . 0.0 110.627 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 71.4 tt0 -54.83 149.03 11.96 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 179.512 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.94 4.89 73.46 Favored Glycine 0 CA--C 1.533 1.212 0 CA-C-O 119.045 -0.864 . . . . 0.0 114.576 179.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 18.9 m -92.11 150.85 20.71 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 119.667 1.734 . . . . 0.0 109.425 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 36.5 mm -89.5 135.97 24.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.439 0 C-N-CA 124.149 0.98 . . . . 0.0 110.108 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 25.9 mt -75.56 143.4 42.43 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.172 0.51 . . . . 0.0 109.808 178.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 33.2 p -138.55 154.13 48.74 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 17.4 mmt -59.71 -34.48 72.97 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-O 121.834 0.826 . . . . 0.0 110.332 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -64.81 -12.45 48.16 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 126.633 1.973 . . . . 0.0 114.055 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 33.1 mtm -117.74 6.26 12.34 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.22 1.008 . . . . 0.0 111.238 179.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.9 mt -119.41 153.21 35.56 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 179.429 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.7 t -151.93 172.59 16.0 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 105.558 -2.015 . . . . 0.0 105.558 178.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.65 122.0 46.21 Favored 'Isoleucine or valine' 0 C--O 1.237 0.424 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.203 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 15.3 ttmm -87.39 103.57 15.62 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.072 -2.196 . . . . 0.0 105.072 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 14.8 m -65.55 132.96 31.19 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.52 -64.62 0.27 Allowed Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -145.4 157.69 52.17 Favored Pre-proline 0 N--CA 1.453 -0.3 0 CA-C-O 118.604 -0.712 . . . . 0.0 111.712 -178.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -78.93 11.97 2.39 Favored 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 123.433 2.755 . . . . 0.0 112.599 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -51.74 110.07 0.43 Allowed 'General case' 0 N--CA 1.463 0.202 0 C-N-CA 125.455 1.502 . . . . 0.0 110.126 179.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.63 -99.33 0.56 Allowed Glycine 0 C--N 1.333 0.374 0 CA-C-N 119.193 0.906 . . . . 0.0 111.931 179.164 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -139.18 134.76 16.86 Favored Pre-proline 0 C--O 1.239 0.543 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -61.0 133.44 47.33 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.557 2.838 . . . . 0.0 111.554 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -72.52 -16.22 27.35 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 123.466 2.777 . . . . 0.0 113.408 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -67.42 -23.39 65.54 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 119.399 1.0 . . . . 0.0 110.028 178.301 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 47.1 m-20 -99.71 7.86 44.77 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 126.125 1.77 . . . . 0.0 111.167 -179.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.4 tt -51.72 -33.84 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 CA-C-N 120.395 1.452 . . . . 0.0 112.712 -179.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -60.98 -19.26 60.92 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 123.97 0.908 . . . . 0.0 112.006 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 -92.43 -27.58 17.39 Favored 'General case' 0 CA--C 1.52 -0.189 0 C-N-CA 124.701 1.2 . . . . 0.0 110.364 179.189 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 19.5 mt -67.97 -37.77 81.92 Favored 'General case' 0 CA--C 1.52 -0.188 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.1 t -58.98 137.72 21.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.09 -14.02 63.25 Favored Glycine 0 CA--C 1.53 0.996 0 CA-C-O 118.121 -1.377 . . . . 0.0 112.824 -179.188 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 40.8 mttm -75.41 166.66 23.25 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 120.458 2.129 . . . . 0.0 108.812 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -119.76 132.42 55.62 Favored 'General case' 0 CA--C 1.521 -0.165 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.333 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -74.99 157.12 6.09 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-N 118.438 0.563 . . . . 0.0 112.461 179.81 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.08 -19.14 16.64 Favored 'General case' 0 C--O 1.225 -0.229 0 C-N-CA 126.628 1.971 . . . . 0.0 110.49 178.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 35.4 m -142.43 158.74 19.46 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 124.208 1.003 . . . . 0.0 109.445 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 58.0 m -72.23 99.51 2.39 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.919 1.688 . . . . 0.0 109.562 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 47.4 t -78.83 151.99 5.01 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 179.294 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -100.86 169.44 8.98 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 126.072 1.749 . . . . 0.0 110.655 179.371 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -69.33 141.62 54.22 Favored 'General case' 0 C--O 1.239 0.52 0 N-CA-C 106.001 -1.851 . . . . 0.0 106.001 176.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 67.13 1.22 2.3 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 128.182 2.593 . . . . 0.0 112.413 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.44 149.55 48.2 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.15 0.98 . . . . 0.0 109.938 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 94.6 m -85.26 124.51 31.97 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-O 122.326 1.06 . . . . 0.0 110.94 -177.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 mm -82.18 142.01 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 33.6 mtp -142.25 155.14 45.22 Favored 'General case' 0 C--O 1.237 0.399 0 C-N-CA 125.018 1.327 . . . . 0.0 108.008 179.072 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -61.22 -34.7 75.53 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 124.519 1.128 . . . . 0.0 112.388 -179.106 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -69.56 -2.85 12.56 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 113.688 0.996 . . . . 0.0 113.688 -179.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 54.3 mt -105.04 5.77 32.8 Favored 'General case' 0 C--O 1.234 0.285 0 C-N-CA 125.696 1.598 . . . . 0.0 112.827 -178.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 36.0 m -124.79 160.35 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 120.272 1.396 . . . . 0.0 112.068 -179.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 46.7 t0 . . . . . 0 C--O 1.238 0.49 0 C-N-CA 127.079 2.151 . . . . 0.0 110.434 -179.21 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.709 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.2 m -146.61 145.19 29.99 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.206 0.527 . . . . 0.0 111.982 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 21.8 t -69.88 128.82 33.79 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 C-N-CA 123.994 0.918 . . . . 0.0 109.837 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.3 m -123.62 152.68 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 178.178 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.01 111.57 4.49 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 178.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 18.6 tttp -59.59 -30.56 68.76 Favored 'General case' 0 CA--C 1.536 0.426 0 O-C-N 121.068 -1.02 . . . . 0.0 113.561 -178.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.8 m -141.98 170.82 11.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 128.747 2.819 . . . . 0.0 106.91 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 42.9 tttm -66.59 137.77 56.99 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 178.401 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.1 mt -121.7 103.43 40.61 Favored Pre-proline 0 N--CA 1.462 0.155 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -179.304 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -66.65 149.99 83.82 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 121.085 1.19 . . . . 0.0 109.561 179.281 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -52.32 146.17 9.84 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 125.448 1.499 . . . . 0.0 110.749 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.65 3.13 86.68 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 123.724 0.678 . . . . 0.0 114.508 178.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 22.6 m -91.49 147.67 22.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 118.361 1.081 . . . . 0.0 109.779 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 49.3 mm -87.09 135.59 24.89 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 C-N-CA 123.982 0.913 . . . . 0.0 108.611 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 13.9 mt -74.16 147.09 42.94 Favored 'General case' 0 CA--C 1.519 -0.226 0 C-N-CA 125.288 1.435 . . . . 0.0 110.841 179.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 53.8 p -140.96 157.69 44.99 Favored 'General case' 0 C--O 1.238 0.47 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.167 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 7.6 mmt -62.93 -20.43 65.19 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.266 0.939 . . . . 0.0 110.881 178.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -72.0 -21.28 61.58 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.226 0.921 . . . . 0.0 110.25 178.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.7 mtm -105.51 4.98 31.08 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 126.328 1.851 . . . . 0.0 111.62 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 80.3 mt -122.94 141.26 52.12 Favored 'General case' 0 CA--C 1.516 -0.339 0 O-C-N 121.135 -0.978 . . . . 0.0 108.647 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.6 t -153.22 115.48 4.39 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.729 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 9' ' ' VAL . 0.2 OUTLIER -71.4 139.04 20.52 Favored 'Isoleucine or valine' 0 C--O 1.238 0.479 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.16 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.53 112.33 25.38 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 104.542 -2.392 . . . . 0.0 104.542 177.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.79 127.83 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 178.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 171.27 -85.86 0.08 OUTLIER Glycine 0 C--N 1.334 0.468 0 C-N-CA 119.955 -1.117 . . . . 0.0 113.356 -179.04 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -138.91 160.78 61.48 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 118.162 0.981 . . . . 0.0 111.562 -178.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -72.78 5.85 2.72 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.406 2.737 . . . . 0.0 114.818 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 23.7 tttp -68.63 92.91 0.48 Allowed 'General case' 0 C--O 1.233 0.21 0 C-N-CA 124.928 1.291 . . . . 0.0 109.476 179.377 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 148.21 -91.78 0.15 Allowed Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -157.27 141.38 11.67 Favored Pre-proline 0 C--O 1.238 0.454 0 C-N-CA 124.974 1.31 . . . . 0.0 110.308 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -68.64 150.39 74.59 Favored 'Trans proline' 0 CA--C 1.538 0.699 0 C-N-CA 122.447 2.098 . . . . 0.0 112.737 -179.403 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 80.7 Cg_endo -79.59 -3.28 12.82 Favored 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 123.098 2.532 . . . . 0.0 113.639 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -73.15 -59.11 2.86 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -71.31 4.95 2.49 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 128.762 2.825 . . . . 0.0 113.748 -179.395 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.4 tt -48.88 -37.11 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.568 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -178.153 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -63.38 -13.95 44.95 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.083 0.953 . . . . 0.0 113.49 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -87.29 -30.38 20.91 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 123.381 0.672 . . . . 0.0 110.989 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 21.2 mt -67.66 -44.54 77.59 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.331 1.052 . . . . 0.0 108.775 -179.13 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 1.4 p -66.4 124.01 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.68 -15.47 29.21 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 125.664 1.602 . . . . 0.0 112.3 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 61.7 mttm -81.84 158.25 24.11 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 119.073 1.437 . . . . 0.0 110.469 179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -97.89 142.55 29.49 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 177.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.0 m -86.1 144.0 10.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 CA-C-N 119.397 0.999 . . . . 0.0 109.228 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 62.2 mt -92.92 -3.84 53.83 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 125.446 1.498 . . . . 0.0 112.96 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 28.7 m -148.93 161.98 5.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 C-N-CA 125.81 1.644 . . . . 0.0 109.715 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.4 m -85.28 100.64 11.93 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 104.118 -2.549 . . . . 0.0 104.118 176.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 44.7 t -82.4 143.34 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 179.389 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -88.94 176.52 6.98 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 123.73 0.812 . . . . 0.0 110.605 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -72.41 143.42 48.53 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.496 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 59.23 11.58 2.17 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 128.946 2.898 . . . . 0.0 113.806 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -75.04 154.25 38.06 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.09 1.356 . . . . 0.0 109.099 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.0 m -82.61 132.86 35.18 Favored 'General case' 0 C--N 1.33 -0.276 0 O-C-N 120.886 -1.134 . . . . 0.0 112.379 -178.329 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 41.4 mm -100.2 127.52 53.08 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.72 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 30.9 mtp -122.58 167.37 13.47 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -61.09 -23.65 65.64 Favored 'General case' 0 CA--C 1.538 0.505 0 O-C-N 120.929 -1.107 . . . . 0.0 113.95 -179.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -76.56 -4.79 44.7 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 125.54 1.536 . . . . 0.0 113.065 -179.538 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 19.1 mt -107.61 2.08 23.69 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.721 0.809 . . . . 0.0 112.249 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.4 m -127.22 159.05 37.98 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 CA-C-N 119.37 0.986 . . . . 0.0 111.704 -178.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 C--O 1.239 0.504 0 C-N-CA 125.622 1.569 . . . . 0.0 113.569 -179.396 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.97 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -80.82 -55.65 4.67 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.441 0.697 . . . . 0.0 110.099 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.6 t -53.12 132.02 37.6 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 124.006 0.922 . . . . 0.0 109.318 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -158.3 90.12 0.11 Allowed Glycine 0 N--CA 1.442 -0.952 0 N-CA-C 107.546 -2.222 . . . . 0.0 107.546 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 74.3 m -75.04 41.0 0.16 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.184 1.394 . . . . 0.0 109.797 178.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.3 p -45.06 -38.23 4.77 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 127.584 2.353 . . . . 0.0 111.683 -179.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.15 -173.77 30.6 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 124.001 0.81 . . . . 0.0 111.1 179.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 84.7 p -129.14 151.32 49.94 Favored 'General case' 0 C--O 1.24 0.593 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -75.24 105.69 4.41 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 O-C-N 122.014 -0.429 . . . . 0.0 111.109 -179.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.0 m -102.86 152.82 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-O 122.654 1.216 . . . . 0.0 107.769 178.088 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.58 128.28 35.31 Favored 'General case' 0 C--N 1.319 -0.722 0 C-N-CA 124.958 1.303 . . . . 0.0 107.94 178.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.488 ' HE2' ' HB ' ' A' ' 27' ' ' THR . 20.1 ttmm -75.86 -23.92 55.69 Favored 'General case' 0 C--N 1.327 -0.378 0 O-C-N 121.012 -1.055 . . . . 0.0 111.099 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.7 m -148.15 173.25 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 C-N-CA 126.589 1.956 . . . . 0.0 107.678 -179.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 54.5 tttp -67.42 127.87 34.3 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 177.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.3 mt -111.48 96.43 31.73 Favored Pre-proline 0 C--N 1.331 -0.206 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -61.09 145.29 99.1 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 121.576 1.518 . . . . 0.0 110.496 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -50.77 146.2 6.11 Favored 'General case' 0 C--O 1.238 0.486 0 C-N-CA 124.936 1.294 . . . . 0.0 110.799 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.55 -3.64 81.6 Favored Glycine 0 CA--C 1.531 1.051 0 CA-C-O 119.327 -0.707 . . . . 0.0 113.153 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 20.0 m -88.22 143.78 26.84 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 118.956 1.378 . . . . 0.0 110.704 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 13.2 mm -83.98 140.24 16.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 71.0 mt -73.83 149.4 41.64 Favored 'General case' 0 C--O 1.238 0.489 0 C-N-CA 123.515 0.726 . . . . 0.0 112.452 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 22.6 p -146.94 157.4 43.62 Favored 'General case' 0 C--O 1.238 0.49 0 C-N-CA 127.526 2.33 . . . . 0.0 107.073 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 19.9 mmt -67.58 -24.15 65.47 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 118.826 0.739 . . . . 0.0 110.571 179.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -67.72 -12.67 61.01 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.476 -0.765 . . . . 0.0 112.207 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 47.7 mtm -115.45 10.78 15.83 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.078 0.951 . . . . 0.0 110.915 179.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -132.16 161.77 32.52 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 119.655 1.116 . . . . 0.0 112.53 -179.026 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.488 ' HB ' ' HE2' ' A' ' 12' ' ' LYS . 12.6 t -159.31 170.93 20.76 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 127.847 2.459 . . . . 0.0 107.294 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -125.36 110.87 25.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 178.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -76.68 91.73 3.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.8 p -54.53 125.54 9.43 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 C-N-CA 126.288 1.835 . . . . 0.0 106.591 178.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.65 -61.73 0.28 Allowed Glycine 0 N--CA 1.45 -0.417 0 CA-C-O 119.687 -0.507 . . . . 0.0 112.155 -179.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -148.7 148.65 28.63 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-N 118.313 1.056 . . . . 0.0 110.419 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -80.47 44.02 1.65 Allowed 'Trans proline' 0 CA--C 1.548 1.191 0 C-N-CA 123.645 2.896 . . . . 0.0 110.729 179.358 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 24.5 ttmt -84.85 92.8 8.35 Favored 'General case' 0 CA--C 1.521 -0.16 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.14 -132.59 6.74 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 179.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.444 ' CD2' ' HD2' ' A' ' 37' ' ' PRO . 0.6 OUTLIER -94.02 139.93 22.75 Favored Pre-proline 0 C--O 1.238 0.462 0 C-N-CA 124.805 1.242 . . . . 0.0 110.215 -179.727 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.444 ' HD2' ' CD2' ' A' ' 36' ' ' TYR . 83.9 Cg_endo -75.17 148.77 35.1 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.022 1.815 . . . . 0.0 112.104 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -75.99 -0.82 10.7 Favored 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 122.962 2.441 . . . . 0.0 111.709 178.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -81.55 -49.79 10.14 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.629 1.572 . . . . 0.0 108.794 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 -85.65 6.28 28.21 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.767 1.227 . . . . 0.0 111.344 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.0 tt -44.1 -41.66 1.81 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 C-N-CA 126.506 1.922 . . . . 0.0 114.607 -178.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -60.49 -32.61 71.6 Favored 'General case' 0 C--N 1.333 -0.138 0 O-C-N 121.575 -0.703 . . . . 0.0 112.003 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 33.7 m-80 -63.63 -30.42 71.53 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 123.377 0.671 . . . . 0.0 110.95 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.3 mt -71.93 -42.57 66.51 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 123.377 0.671 . . . . 0.0 109.828 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.2 t -67.2 93.73 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-O 122.212 1.006 . . . . 0.0 109.18 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 137.05 -11.7 3.88 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 126.202 1.858 . . . . 0.0 112.286 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -84.39 166.4 17.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 118.924 1.362 . . . . 0.0 109.069 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -110.3 139.58 45.35 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.5 m -81.99 150.35 4.49 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 O-C-N 123.583 0.552 . . . . 0.0 110.301 179.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 91.9 mt -101.01 -10.43 20.55 Favored 'General case' 0 C--O 1.233 0.226 0 C-N-CA 125.364 1.466 . . . . 0.0 111.88 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.4 160.56 14.99 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 C-N-CA 124.529 1.132 . . . . 0.0 109.154 178.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 11.6 m -78.65 99.88 6.77 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 14.9 t -73.2 150.41 7.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 179.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -102.55 168.12 9.49 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 123.589 0.756 . . . . 0.0 109.265 178.358 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 72.4 tt0 -61.51 144.18 54.7 Favored 'General case' 0 CA--C 1.538 0.495 0 O-C-N 121.413 -0.804 . . . . 0.0 108.834 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . 0.349 0.1 OUTLIER 56.92 13.06 1.35 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 128.077 2.551 . . . . 0.0 114.543 179.699 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -78.33 153.72 31.46 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 124.077 0.951 . . . . 0.0 112.403 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 20.0 m -81.43 113.07 19.25 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 124.75 1.22 . . . . 0.0 111.771 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.4 mm -76.88 144.31 11.83 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 3.0 mmt -134.53 161.21 35.7 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 125.877 1.671 . . . . 0.0 110.637 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -67.46 -29.15 68.53 Favored 'General case' 0 N--CA 1.467 0.378 0 O-C-N 121.354 -0.841 . . . . 0.0 111.773 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -74.01 -11.31 60.29 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 119.305 0.957 . . . . 0.0 112.486 179.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 69.6 mt -94.56 -4.43 47.94 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.341 1.057 . . . . 0.0 111.646 -179.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 m -122.54 140.36 46.59 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-N 120.162 1.346 . . . . 0.0 108.642 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 48.1 t0 -74.32 165.23 25.53 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -68.78 170.11 10.12 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 124.49 1.116 . . . . 0.0 108.192 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -68.12 151.49 46.93 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -116.78 59.07 0.47 Allowed Glycine 0 CA--C 1.518 0.271 0 N-CA-C 105.916 -2.873 . . . . 0.0 105.916 179.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 17.6 tppt? -99.14 -65.03 0.99 Allowed 'General case' 0 CA--C 1.52 -0.187 0 C-N-CA 124.164 0.986 . . . . 0.0 110.908 -178.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 42.1 tptt -50.07 122.04 6.23 Favored 'General case' 0 CA--C 1.514 -0.414 0 C-N-CA 124.379 1.072 . . . . 0.0 112.792 -177.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 28.0 pt -74.93 39.6 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 126.387 1.875 . . . . 0.0 110.78 178.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 19.6 tptm -151.67 142.03 22.47 Favored 'General case' 0 C--N 1.346 0.427 0 O-C-N 119.829 -1.794 . . . . 0.0 113.418 -178.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 32.6 m -79.98 100.09 7.94 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.534 1.134 . . . . 0.0 110.129 178.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 44.8 m -163.04 159.35 23.2 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 126.5 1.92 . . . . 0.0 106.825 178.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 112.22 93.04 2.1 Favored Glycine 0 C--N 1.335 0.477 0 CA-C-O 117.855 -1.525 . . . . 0.0 109.843 179.491 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -74.78 150.18 38.9 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.7 2.267 . . . . 0.0 109.293 179.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 32.9 t -61.98 143.66 56.21 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 116.643 -0.253 . . . . 0.0 110.902 -179.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 81.1 p -94.34 -10.33 33.04 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 123.672 0.789 . . . . 0.0 108.872 177.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.012 0 N-CA-C 106.562 -2.615 . . . . 0.0 106.562 179.177 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.599 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.6 p -85.23 124.84 32.33 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.71 1.604 . . . . 0.0 107.938 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 58.0 p -71.41 176.39 4.69 Favored 'General case' 0 C--O 1.243 0.749 0 CA-C-N 119.279 0.945 . . . . 0.0 110.918 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 137.7 86.43 0.17 Allowed Glycine 0 C--N 1.333 0.401 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.062 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.3 t -125.5 163.27 23.03 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.1 p -137.31 9.34 2.95 Favored 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 114.072 1.138 . . . . 0.0 114.072 -179.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -171.1 -164.0 26.08 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 120.09 1.313 . . . . 0.0 111.515 -179.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.5 p -139.83 161.46 37.52 Favored 'General case' 0 C--O 1.241 0.617 0 C-N-CA 125.758 1.623 . . . . 0.0 109.303 -179.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.2 t -85.88 133.17 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.8 m -129.38 160.62 40.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 178.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.4 118.78 12.71 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 126.38 1.872 . . . . 0.0 109.106 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.8 ttmm -68.01 -28.41 67.39 Favored 'General case' 0 N--CA 1.469 0.524 0 O-C-N 120.937 -1.102 . . . . 0.0 111.011 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.9 m -145.75 168.14 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 C-N-CA 127.778 2.431 . . . . 0.0 106.98 -179.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 80.9 tttt -68.81 128.78 37.88 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 8.2 mt -111.61 103.88 55.54 Favored Pre-proline 0 CA--C 1.538 0.507 0 C-N-CA 124.967 1.307 . . . . 0.0 108.552 -178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -69.96 147.74 62.21 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 121.949 1.766 . . . . 0.0 110.704 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 7.3 tm-20 -49.22 139.65 10.83 Favored 'General case' 0 C--O 1.237 0.425 0 C-N-CA 123.909 0.884 . . . . 0.0 111.413 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.04 -3.57 84.56 Favored Glycine 0 CA--C 1.523 0.551 0 CA-C-N 115.571 -0.74 . . . . 0.0 112.942 179.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.4 m -82.53 140.37 33.34 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 118.756 1.278 . . . . 0.0 109.591 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.4 mm -78.73 135.35 26.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 105.424 -2.065 . . . . 0.0 105.424 178.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 32.2 mt -75.35 131.52 40.31 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.751 0.82 . . . . 0.0 109.304 179.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.4 p -127.83 161.36 29.21 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 13.2 mmt -61.76 -27.49 68.77 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 121.878 -0.514 . . . . 0.0 111.257 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -74.58 -7.9 54.62 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.884 0.874 . . . . 0.0 113.06 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 70.4 mtm -113.94 7.7 16.99 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 119.27 0.941 . . . . 0.0 111.25 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -123.64 152.68 41.71 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 124.368 1.067 . . . . 0.0 109.36 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.9 t -150.3 161.73 41.89 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 98.5 t -111.67 103.73 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 -178.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 9.5 tppt? -78.15 102.84 7.73 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 178.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.0 t -67.1 122.99 19.21 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 N-CA-C 104.438 -2.431 . . . . 0.0 104.438 178.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 170.18 -64.19 0.17 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-O 118.89 -0.95 . . . . 0.0 114.397 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -147.94 156.92 44.07 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 118.852 1.326 . . . . 0.0 110.421 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -79.31 0.72 9.79 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 123.666 2.911 . . . . 0.0 113.532 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.6 ttmt -60.44 106.99 0.6 Allowed 'General case' 0 CA--C 1.529 0.155 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 142.37 -105.56 0.41 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 123.758 0.694 . . . . 0.0 111.819 179.683 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -144.67 143.05 20.04 Favored Pre-proline 0 C--O 1.238 0.485 0 N-CA-C 106.347 -1.723 . . . . 0.0 106.347 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.45 132.11 23.13 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.735 2.29 . . . . 0.0 113.162 -178.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -71.15 -19.49 29.61 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 122.193 1.929 . . . . 0.0 112.257 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 24.5 mp0 -65.04 -31.92 73.38 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 119.586 1.085 . . . . 0.0 110.191 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -106.28 17.57 23.26 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 125.148 1.379 . . . . 0.0 111.998 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.8 tt -50.33 -32.84 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 125.146 1.379 . . . . 0.0 112.366 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -56.73 -25.01 53.62 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 124.193 0.997 . . . . 0.0 112.089 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 74.2 m-80 -81.39 -17.33 49.35 Favored 'General case' 0 C--N 1.339 0.127 0 C-N-CA 123.487 0.715 . . . . 0.0 112.101 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 72.3 mt -76.65 -34.55 58.27 Favored 'General case' 0 C--O 1.225 -0.221 0 CA-C-N 119.219 0.918 . . . . 0.0 108.701 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 63.3 t -62.7 128.98 25.46 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 98.1 -16.78 59.64 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 125.484 1.516 . . . . 0.0 111.09 -178.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 82.6 mttt -75.4 168.75 19.4 Favored 'General case' 0 C--N 1.344 0.354 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 178.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.451 ' HB2' ' HZ1' ' A' ' 48' ' ' LYS . 3.5 ttmp? -125.69 135.01 51.65 Favored 'General case' 0 CA--C 1.508 -0.656 0 O-C-N 121.236 -0.915 . . . . 0.0 108.785 -179.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.7 m -67.7 141.13 18.12 Favored 'Isoleucine or valine' 0 C--O 1.24 0.602 0 O-C-N 123.97 0.794 . . . . 0.0 110.113 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 86.5 mt -93.74 -14.44 26.28 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 126.12 1.768 . . . . 0.0 112.256 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 22.7 m -146.63 158.85 10.51 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 C-N-CA 126.317 1.847 . . . . 0.0 108.2 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 88.6 m -70.84 101.36 2.11 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 178.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 45.5 t -79.77 119.81 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -72.36 166.9 21.59 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 122.399 1.095 . . . . 0.0 109.401 178.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 52.6 tt0 -61.03 143.77 54.71 Favored 'General case' 0 N--CA 1.449 -0.52 0 O-C-N 121.438 -0.789 . . . . 0.0 109.521 -179.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.8 t70 64.15 3.71 1.84 Allowed 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.52 1.928 . . . . 0.0 113.587 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -71.71 155.12 40.83 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.866 0.841 . . . . 0.0 109.338 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.2 m -71.83 127.0 31.17 Favored 'General case' 0 N--CA 1.436 -1.151 0 C-N-CA 126.057 1.743 . . . . 0.0 110.797 -178.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.4 mm -90.7 137.58 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 N-CA-C 103.812 -2.662 . . . . 0.0 103.812 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 34.7 mtp -140.92 -170.89 3.13 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 123.662 0.785 . . . . 0.0 110.501 -178.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -86.27 -37.58 18.43 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 6.2 pm0 -64.45 -11.76 36.71 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.446 1.098 . . . . 0.0 112.779 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 71.4 mt -101.19 2.4 40.02 Favored 'General case' 0 C--O 1.227 -0.124 0 C-N-CA 125.436 1.494 . . . . 0.0 112.319 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 10.3 m -135.35 155.13 36.7 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-N 121.435 1.925 . . . . 0.0 114.399 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 49.9 p30 -76.87 164.49 25.76 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.394 178.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -70.89 121.62 18.44 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -50.77 -32.03 18.61 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 114.326 1.232 . . . . 0.0 114.326 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -62.82 -31.63 80.97 Favored Glycine 0 CA--C 1.529 0.937 0 CA-C-O 119.012 -0.882 . . . . 0.0 114.983 -179.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -175.97 153.86 1.39 Allowed 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 119.024 1.412 . . . . 0.0 109.807 178.597 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.0 ptmm? -98.08 128.48 44.62 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 7.9 pt -139.02 62.12 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 123.91 0.884 . . . . 0.0 111.175 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 15.3 mmmt -71.3 95.02 1.26 Allowed 'General case' 0 N--CA 1.47 0.575 0 N-CA-C 106.166 -1.79 . . . . 0.0 106.166 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.5 m -141.86 177.56 8.1 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 124.556 1.142 . . . . 0.0 111.66 -179.188 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.23 86.81 1.93 Allowed 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 127.85 2.46 . . . . 0.0 109.484 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 177.71 164.82 31.75 Favored Glycine 0 CA--C 1.529 0.956 0 C-N-CA 123.647 0.642 . . . . 0.0 111.649 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 75.4 Cg_endo -71.36 170.24 18.87 Favored 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.93 2.42 . . . . 0.0 111.184 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 46.6 p -104.3 -122.9 0.21 Allowed 'General case' 0 C--O 1.235 0.298 0 C-N-CA 124.723 1.209 . . . . 0.0 110.332 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -171.08 170.62 6.1 Favored 'General case' 0 N--CA 1.441 -0.892 0 C-N-CA 129.111 2.964 . . . . 0.0 106.371 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.035 0 N-CA-C 106.413 -2.675 . . . . 0.0 106.413 179.882 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.643 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.96 130.08 41.24 Favored 'General case' 0 C--O 1.236 0.367 0 C-N-CA 124.015 0.926 . . . . 0.0 111.065 -178.302 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 34.3 t -69.28 143.64 53.8 Favored 'General case' 0 C--O 1.237 0.414 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 179.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 68.9 40.13 84.81 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 119.557 -0.58 . . . . 0.0 112.122 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.7 m -82.8 90.27 6.89 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 117.72 0.76 . . . . 0.0 109.752 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.0 m -53.28 -67.2 0.27 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 125.666 1.586 . . . . 0.0 113.32 -179.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 77.68 178.66 48.66 Favored Glycine 0 CA--C 1.535 1.293 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 79.5 p -144.31 159.04 43.38 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-N 117.853 0.826 . . . . 0.0 111.353 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 97.6 t -71.73 133.31 32.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.6 m -136.02 157.88 38.48 Favored 'Isoleucine or valine' 0 C--O 1.24 0.601 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.87 124.46 24.38 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 44.2 tttt -77.14 -27.11 53.77 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 121.911 -0.493 . . . . 0.0 111.653 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.4 m -144.29 168.15 10.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 C-N-CA 127.602 2.361 . . . . 0.0 106.824 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 78.6 tttt -69.06 117.81 11.17 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 178.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 19.9 mt -102.75 112.26 65.53 Favored Pre-proline 0 CA--C 1.533 0.307 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.93 148.95 32.41 Favored 'Trans proline' 0 N--CA 1.445 -1.342 0 C-N-CA 121.7 1.6 . . . . 0.0 109.428 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 tm-20 -51.68 145.61 9.0 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 124.135 0.974 . . . . 0.0 110.384 179.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.38 -3.58 86.47 Favored Glycine 0 CA--C 1.529 0.927 0 CA-C-O 119.105 -0.83 . . . . 0.0 114.89 178.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.6 m -89.78 152.4 21.32 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 118.389 1.095 . . . . 0.0 110.054 -179.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 48.7 mm -90.01 141.54 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 65.9 mt -75.9 139.29 41.56 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.373 0.606 . . . . 0.0 111.489 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 68.3 p -134.28 155.59 49.94 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 126.12 1.768 . . . . 0.0 106.393 178.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 25.8 mtp -67.47 -12.45 60.32 Favored 'General case' 0 CA--C 1.545 0.766 0 CA-C-N 119.594 1.088 . . . . 0.0 110.16 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.6 m-20 -72.84 -19.9 61.23 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 120.828 -1.17 . . . . 0.0 112.147 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 56.1 mtm -115.08 10.37 16.15 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 124.691 1.196 . . . . 0.0 111.59 -178.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 36.0 mt -130.82 148.74 52.63 Favored 'General case' 0 CA--C 1.515 -0.37 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -178.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.8 t -157.14 179.14 9.56 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.4 t -124.56 113.52 36.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 118.826 0.739 . . . . 0.0 109.76 -178.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 2.7 ttpp -79.37 93.4 5.33 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 179.118 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 t -59.63 98.62 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -172.17 -46.13 0.04 OUTLIER Glycine 0 C--N 1.339 0.716 0 CA-C-O 117.494 -1.725 . . . . 0.0 115.559 -178.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -151.43 154.33 33.41 Favored Pre-proline 0 N--CA 1.464 0.241 0 CA-C-N 120.251 2.026 . . . . 0.0 110.6 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -76.49 -3.89 14.36 Favored 'Trans proline' 0 CA--C 1.534 0.504 0 C-N-CA 123.195 2.597 . . . . 0.0 113.066 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 3.6 tmmm? -63.73 107.05 1.09 Allowed 'General case' 0 CA--C 1.518 -0.252 0 O-C-N 121.132 -0.98 . . . . 0.0 108.419 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.418 ' HA2' ' SD ' ' A' ' 60' ' ' MET . . . 131.36 178.49 15.5 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 126.26 1.886 . . . . 0.0 109.889 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 7.3 t80 -57.07 134.02 80.45 Favored Pre-proline 0 C--O 1.24 0.603 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -61.98 131.04 33.13 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.168 1.912 . . . . 0.0 108.997 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.64 -19.06 48.39 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.261 1.974 . . . . 0.0 112.351 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -70.67 -10.85 60.32 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 113.304 0.853 . . . . 0.0 113.304 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -121.33 10.92 10.66 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 126.044 1.738 . . . . 0.0 111.582 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.5 tt -41.33 -37.42 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 C-N-CA 128.194 2.598 . . . . 0.0 113.792 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -60.39 -34.99 74.7 Favored 'General case' 0 CA--C 1.528 0.133 0 C-N-CA 125.58 1.552 . . . . 0.0 113.927 -179.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -59.46 -38.96 82.13 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 119.675 1.125 . . . . 0.0 112.044 -178.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 85.0 mt -72.55 -33.93 67.17 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 124.681 1.192 . . . . 0.0 111.9 -179.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 69.3 t -67.68 91.29 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 124.521 1.128 . . . . 0.0 108.302 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 139.12 -9.38 3.29 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 126.437 1.97 . . . . 0.0 112.629 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 92.1 mttt -82.41 171.14 14.5 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 119.039 1.419 . . . . 0.0 108.437 178.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 33.8 ttmt -110.15 136.93 48.61 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 178.117 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.4 m -80.74 146.27 7.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 O-C-N 121.786 -0.572 . . . . 0.0 109.961 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 92.8 mt -97.21 -14.19 21.57 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 125.906 1.682 . . . . 0.0 113.453 -178.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 16.7 m -146.32 158.0 11.41 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.0 m -77.23 101.6 6.29 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 70.8 t -80.23 138.89 19.04 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -85.12 170.03 13.32 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-O 122.054 0.93 . . . . 0.0 110.283 178.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -71.22 138.99 49.94 Favored 'General case' 0 N--CA 1.447 -0.597 0 O-C-N 121.184 -0.947 . . . . 0.0 109.678 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.8 t70 72.3 4.18 4.92 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 127.671 2.389 . . . . 0.0 113.337 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -67.44 145.46 54.99 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.594 1.158 . . . . 0.0 109.387 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 25.4 m -73.24 129.0 37.09 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 179.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 26.2 mm -87.1 131.05 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' MET . . . . . 0.418 ' SD ' ' HA2' ' A' ' 35' ' ' GLY . 82.0 mmm -124.55 161.02 27.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 126.235 1.814 . . . . 0.0 106.948 179.255 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -72.31 -27.25 62.32 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.825 1.65 . . . . 0.0 111.332 179.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.41 -14.42 62.91 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 124.419 1.088 . . . . 0.0 112.816 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 19.8 mt -93.29 -1.09 56.43 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 126.203 1.801 . . . . 0.0 112.148 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.4 m -126.68 160.47 34.76 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 CA-C-N 119.707 1.14 . . . . 0.0 113.22 -178.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.78 -172.02 3.14 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.345 1.458 . . . . 0.0 109.091 178.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 17.2 t-20 -128.35 129.56 46.44 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 106.028 -1.841 . . . . 0.0 106.028 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -43.66 110.87 0.23 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 124.342 1.057 . . . . 0.0 111.452 -179.108 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 166.59 -150.15 16.86 Favored Glycine 0 N--CA 1.443 -0.876 0 C-N-CA 119.8 -1.191 . . . . 0.0 113.417 -178.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.34 166.26 10.78 Favored 'General case' 0 CA--C 1.516 -0.347 0 C-N-CA 124.44 1.096 . . . . 0.0 111.119 -179.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 8.1 pttm -152.66 162.16 41.62 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 123.951 0.9 . . . . 0.0 108.926 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 8.1 pt -88.75 170.22 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 122.119 0.962 . . . . 0.0 110.087 179.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.402 ' HD2' ' H ' ' A' ' 72' ' ' LYS . 0.0 OUTLIER -81.29 127.48 32.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 104.865 -2.272 . . . . 0.0 104.865 177.691 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 26.8 m -172.76 154.34 2.94 Favored 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 127.753 2.421 . . . . 0.0 107.209 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 7.0 t -114.22 -170.37 1.71 Allowed 'General case' 0 C--O 1.241 0.608 0 C-N-CA 124.547 1.139 . . . . 0.0 108.565 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -74.12 -179.06 39.72 Favored Glycine 0 CA--C 1.533 1.167 0 C-N-CA 124.485 1.04 . . . . 0.0 111.293 179.036 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -67.52 165.49 27.08 Favored 'Trans proline' 0 N--CA 1.45 -1.06 0 C-N-CA 121.951 1.767 . . . . 0.0 109.54 179.078 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.4 m -131.37 14.48 5.05 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.645 0.778 . . . . 0.0 110.534 179.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.3 t -144.71 153.07 41.33 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 124.642 1.177 . . . . 0.0 109.946 -178.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.223 0 N-CA-C 106.192 -2.763 . . . . 0.0 106.192 -179.706 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.971 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.4 m -72.67 166.41 22.84 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 117.714 0.757 . . . . 0.0 110.176 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.5 m -86.43 -28.05 23.77 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 123.925 0.89 . . . . 0.0 110.431 179.05 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 132.58 163.22 10.56 Favored Glycine 0 CA--C 1.522 0.526 0 C-N-CA 127.725 2.583 . . . . 0.0 109.197 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.5 p -80.69 167.82 19.56 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 117.581 0.691 . . . . 0.0 109.266 179.098 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 m -154.5 147.6 24.71 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.451 1.5 . . . . 0.0 107.006 179.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 166.07 -170.12 40.62 Favored Glycine 0 CA--C 1.519 0.301 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 10.7 p -94.02 134.12 36.76 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 118.264 1.032 . . . . 0.0 113.224 -178.373 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 98.9 t -68.27 132.67 32.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 176.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.29 155.6 40.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.533 0 C-N-CA 124.048 0.939 . . . . 0.0 109.174 179.098 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.72 117.04 12.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 177.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 42.6 tttp -63.58 -31.57 72.78 Favored 'General case' 0 C--N 1.33 -0.25 0 O-C-N 121.426 -0.796 . . . . 0.0 112.498 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m -142.3 169.99 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 C-N-CA 126.567 1.947 . . . . 0.0 107.012 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 39.1 tttt -64.17 127.18 30.33 Favored 'General case' 0 N--CA 1.454 -0.265 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.3 mt -111.89 100.69 49.54 Favored Pre-proline 0 CA--C 1.532 0.278 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 -179.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -65.16 151.43 85.54 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 N-CA-C 109.062 -1.168 . . . . 0.0 109.062 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -50.75 151.81 2.28 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.27 1.028 . . . . 0.0 111.384 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.62 -3.67 62.97 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 123.962 0.791 . . . . 0.0 113.971 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 99.1 m -81.42 145.89 30.56 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 118.191 0.995 . . . . 0.0 109.524 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.5 mm -88.74 130.86 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 178.045 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 30.7 mt -69.33 137.24 52.76 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 124.399 1.079 . . . . 0.0 110.734 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 73.4 p -135.39 159.03 42.86 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.383 1.073 . . . . 0.0 108.621 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 12.0 mmt -64.15 -17.86 63.89 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 118.114 0.415 . . . . 0.0 110.523 179.083 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -79.07 -16.45 56.77 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.966 0.906 . . . . 0.0 112.177 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 75.3 mtm -118.94 15.09 13.36 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.378 1.071 . . . . 0.0 109.971 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 42.9 mt -137.0 154.46 50.4 Favored 'General case' 0 CA--C 1.511 -0.553 0 O-C-N 120.959 -1.088 . . . . 0.0 110.034 -178.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.6 t -164.33 -179.54 6.14 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 1.2 p -134.01 112.6 16.7 Favored 'Isoleucine or valine' 0 C--O 1.234 0.287 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -73.99 114.86 12.78 Favored 'General case' 0 CA--C 1.511 -0.556 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.1 p -51.81 139.75 7.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 O-C-N 124.196 0.935 . . . . 0.0 109.702 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 138.0 -131.34 5.4 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.2 pm0 -75.66 133.92 73.09 Favored Pre-proline 0 CA--C 1.541 0.602 0 C-N-CA 125.211 1.404 . . . . 0.0 112.847 -179.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.06 61.3 7.17 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 124.673 3.582 . . . . 0.0 111.123 179.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -88.24 172.06 9.73 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 125.122 1.369 . . . . 0.0 107.866 178.38 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.05 -77.0 1.18 Allowed Glycine 0 N--CA 1.445 -0.715 0 N-CA-C 113.822 0.289 . . . . 0.0 113.822 178.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -149.07 139.97 13.87 Favored Pre-proline 0 N--CA 1.443 -0.789 0 C-N-CA 126.315 1.846 . . . . 0.0 107.016 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.38 136.91 48.95 Favored 'Trans proline' 0 N--CA 1.451 -0.98 0 N-CA-C 109.106 -1.152 . . . . 0.0 109.106 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -68.76 -15.25 40.55 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 122.479 2.119 . . . . 0.0 113.354 -179.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -69.47 -27.49 65.26 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 119.959 1.254 . . . . 0.0 109.85 178.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -98.27 10.43 40.67 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.644 1.578 . . . . 0.0 111.382 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.8 tt -52.54 -38.87 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 C-N-CA 124.831 1.252 . . . . 0.0 111.672 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -68.91 -21.14 64.24 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.74 1.216 . . . . 0.0 112.661 -179.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -79.88 -38.04 33.53 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 119.087 0.858 . . . . 0.0 110.746 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.54 -30.0 70.36 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 123.032 0.533 . . . . 0.0 110.078 178.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 45.3 t -66.52 107.13 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.47 -11.95 10.37 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 126.503 2.002 . . . . 0.0 112.696 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.0 mttm -79.91 156.87 27.09 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-N 118.562 1.181 . . . . 0.0 109.215 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -101.51 138.57 38.34 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.182 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.7 m -78.05 138.77 19.68 Favored 'Isoleucine or valine' 0 C--O 1.24 0.605 0 N-CA-C 109.082 -0.711 . . . . 0.0 109.082 178.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 82.6 mt -84.85 -16.77 40.17 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.587 1.555 . . . . 0.0 111.636 179.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 15.3 m -149.69 163.5 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.175 0 C-N-CA 126.342 1.857 . . . . 0.0 108.648 -178.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 16.7 m -72.45 125.94 28.64 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 177.693 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 87.6 t -105.03 131.12 54.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -76.25 170.43 16.34 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-O 122.413 1.102 . . . . 0.0 112.759 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -65.67 136.91 56.91 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 63.14 7.98 3.06 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 126.035 1.734 . . . . 0.0 112.803 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -72.45 157.28 37.93 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 119.428 1.013 . . . . 0.0 111.286 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.1 m -79.75 119.34 22.53 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 123.944 0.898 . . . . 0.0 111.27 -178.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.6 mm -76.13 139.82 18.29 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 178.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 26.8 mtp -138.88 160.49 39.6 Favored 'General case' 0 C--O 1.231 0.094 0 C-N-CA 123.655 0.782 . . . . 0.0 109.474 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -60.77 -40.77 93.77 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 123.304 0.641 . . . . 0.0 109.456 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -65.66 4.33 0.6 Allowed 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 126.215 1.806 . . . . 0.0 114.551 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 34.9 mt -118.28 0.01 11.61 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.113 1.365 . . . . 0.0 109.694 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.5 m -131.23 162.58 39.01 Favored 'Isoleucine or valine' 0 C--N 1.343 0.285 0 C-N-CA 124.321 1.048 . . . . 0.0 111.148 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -77.82 99.69 6.02 Favored 'General case' 0 C--O 1.239 0.526 0 C-N-CA 124.975 1.31 . . . . 0.0 112.056 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 179.73 135.55 0.1 Allowed 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 126.731 2.012 . . . . 0.0 108.002 178.138 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 27.6 m-70 -138.24 106.6 5.8 Favored 'General case' 0 CA--C 1.519 -0.213 0 N-CA-C 105.406 -2.072 . . . . 0.0 105.406 178.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -111.29 -115.75 3.56 Favored Glycine 0 N--CA 1.45 -0.408 0 O-C-N 123.184 0.303 . . . . 0.0 113.155 -178.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 54.7 tptt -101.59 100.82 11.28 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 106.006 -1.85 . . . . 0.0 106.006 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 36.1 tttp -145.26 171.64 14.28 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 25.8 pt -132.87 168.91 23.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 C-N-CA 124.989 1.315 . . . . 0.0 109.796 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 2.4 mmmp? -71.55 146.51 48.42 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 178.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 46.11 45.32 12.5 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 125.112 1.365 . . . . 0.0 111.627 -179.395 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.1 t -62.85 123.09 17.57 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 178.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 170.41 154.86 9.79 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 119.019 -0.878 . . . . 0.0 111.542 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -68.72 -39.78 8.25 Favored 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 123.51 2.807 . . . . 0.0 111.389 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 6.7 t -156.89 157.87 35.65 Favored 'General case' 0 N--CA 1.442 -0.851 0 C-N-CA 127.42 2.288 . . . . 0.0 105.564 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 1.7 t -159.89 -178.36 6.98 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 126.041 1.737 . . . . 0.0 106.855 179.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.675 0 N-CA-C 107.983 -2.047 . . . . 0.0 107.983 -178.924 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.431 0 N-CA-C 112.471 -0.251 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 6.0 t -155.2 152.25 29.13 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 179.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -163.75 168.2 20.0 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-O 121.827 0.822 . . . . 0.0 112.922 -179.115 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.72 -168.43 12.57 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 106.53 -2.628 . . . . 0.0 106.53 178.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.5 m -147.16 149.03 32.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 118.276 1.038 . . . . 0.0 108.846 178.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 69.7 m -125.25 118.49 26.12 Favored 'General case' 0 CA--C 1.516 -0.353 0 N-CA-C 105.828 -1.915 . . . . 0.0 105.828 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.06 -174.45 36.94 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 45.4 p -142.57 159.02 43.05 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.472 0.709 . . . . 0.0 109.794 -178.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 78.2 t -84.11 124.55 39.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 178.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.9 m -123.07 148.71 26.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.535 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.5 111.73 4.28 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 125.686 1.595 . . . . 0.0 107.997 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 81.1 tttt -64.95 -24.8 67.63 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 123.434 0.694 . . . . 0.0 112.714 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.6 m -148.92 165.79 3.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 127.116 2.167 . . . . 0.0 106.944 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -64.69 130.58 44.11 Favored 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 178.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 32.2 mt -118.78 101.27 50.59 Favored Pre-proline 0 CA--C 1.533 0.311 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -67.35 153.15 77.81 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 121.944 1.763 . . . . 0.0 112.346 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.6 tm-20 -58.17 146.03 35.02 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 122.289 1.042 . . . . 0.0 108.617 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.95 19.99 56.52 Favored Glycine 0 CA--C 1.53 0.995 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.953 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.1 m -117.44 156.25 28.27 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 125.976 1.71 . . . . 0.0 107.734 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 34.1 mm -101.5 143.25 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 C-N-CA 123.867 0.867 . . . . 0.0 108.716 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 23.0 mt -76.03 135.88 39.94 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 67.1 p -130.57 158.15 40.76 Favored 'General case' 0 C--O 1.238 0.477 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 13.4 mmt -63.22 -20.51 65.5 Favored 'General case' 0 CA--C 1.536 0.408 0 O-C-N 121.926 -0.484 . . . . 0.0 109.713 178.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -79.99 -18.41 50.36 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 126.27 1.828 . . . . 0.0 114.185 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 69.8 mtm -112.46 16.15 19.95 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 119.162 0.892 . . . . 0.0 111.697 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.1 mt -133.64 147.92 51.49 Favored 'General case' 0 C--O 1.238 0.456 0 C-N-CA 124.019 0.927 . . . . 0.0 110.666 -179.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.9 t -147.7 144.62 28.45 Favored 'General case' 0 CA--C 1.54 0.572 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 56.8 t -89.06 117.52 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 31.7 ttpt -59.84 -29.63 68.4 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 115.01 1.485 . . . . 0.0 115.01 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.6 t 47.65 66.42 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 CA-C-O 122.665 1.221 . . . . 0.0 109.278 -179.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.97 -66.24 0.01 OUTLIER Glycine 0 CA--C 1.521 0.435 0 C-N-CA 124.647 1.118 . . . . 0.0 111.042 -179.482 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -133.9 152.8 79.28 Favored Pre-proline 0 CA--C 1.529 0.158 0 C-N-CA 123.583 0.753 . . . . 0.0 111.598 -178.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.18 5.4 4.59 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 123.686 2.924 . . . . 0.0 113.131 179.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -72.26 115.12 11.13 Favored 'General case' 0 CA--C 1.518 -0.251 0 O-C-N 119.946 -1.721 . . . . 0.0 106.413 178.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.36 171.71 15.73 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -54.94 135.71 66.59 Favored Pre-proline 0 CA--C 1.541 0.61 0 CA-C-O 118.993 -0.527 . . . . 0.0 110.716 -179.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -67.94 150.73 78.26 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.806 2.337 . . . . 0.0 113.557 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -79.41 -4.34 13.6 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 123.437 2.758 . . . . 0.0 114.93 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 24.2 tp10 -82.43 -46.14 13.89 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 119.918 1.235 . . . . 0.0 108.124 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -79.71 7.38 8.62 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 125.86 1.664 . . . . 0.0 111.63 -179.575 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.7 tt -46.82 -43.13 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 C-N-CA 126.19 1.796 . . . . 0.0 112.909 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -58.91 -27.95 65.74 Favored 'General case' 0 C--O 1.227 -0.126 0 C-N-CA 123.1 0.56 . . . . 0.0 111.657 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -73.35 -36.82 66.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 49.2 mt -66.65 -38.96 87.94 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 119.123 0.874 . . . . 0.0 109.705 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 73.5 t -61.63 131.45 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.09 -11.09 69.69 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 118.792 -1.004 . . . . 0.0 111.699 -178.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 26.5 mttm -84.05 154.36 23.28 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-N 119.556 1.678 . . . . 0.0 110.615 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 39.4 ttmt -95.04 131.08 41.41 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 178.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.4 m -66.76 168.66 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 176.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 46.3 mt -114.28 -7.08 12.97 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 123.913 0.885 . . . . 0.0 112.44 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.8 m -156.83 162.31 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 126.952 2.101 . . . . 0.0 108.418 -178.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.9 m -72.94 109.66 6.66 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 57.4 t -85.96 131.04 35.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 179.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -78.05 167.49 21.37 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 123.652 0.781 . . . . 0.0 109.721 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -69.92 149.86 47.35 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 177.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 60.94 10.01 2.58 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 127.948 2.499 . . . . 0.0 111.59 -179.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -75.73 153.33 37.11 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 178.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 99.2 m -88.47 121.88 31.34 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.179 0.514 . . . . 0.0 110.932 -178.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 mm -74.18 138.51 21.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 178.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -131.37 157.92 42.13 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 124.368 1.067 . . . . 0.0 108.595 179.31 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -59.35 -27.8 66.26 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 124.715 1.206 . . . . 0.0 111.669 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -89.26 -4.15 58.27 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 119.173 0.897 . . . . 0.0 113.095 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 57.4 mt -96.57 15.8 20.61 Favored 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 124.352 1.061 . . . . 0.0 109.4 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.1 m -139.22 140.84 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -75.46 66.82 1.92 Allowed 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 125.598 1.559 . . . . 0.0 110.387 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -147.64 141.36 25.65 Favored 'General case' 0 CA--C 1.516 -0.338 0 C-N-CA 125.215 1.406 . . . . 0.0 108.372 -179.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . 0.263 5.5 m-70 64.43 -67.28 0.11 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 126.518 1.927 . . . . 0.0 109.057 -178.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -76.55 168.55 54.8 Favored Glycine 0 CA--C 1.538 1.506 0 N-CA-C 106.455 -2.658 . . . . 0.0 106.455 176.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 154.68 -4.48 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 130.186 3.394 . . . . 0.0 112.07 -179.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -79.8 106.45 11.84 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 120.665 -1.272 . . . . 0.0 107.696 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 23.4 pt -73.56 5.21 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 CA-C-N 118.295 0.498 . . . . 0.0 111.859 179.201 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -87.75 97.31 10.83 Favored 'General case' 0 N--CA 1.449 -0.483 0 O-C-N 120.724 -1.235 . . . . 0.0 108.498 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 2.2 p -62.4 92.87 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 126.655 1.982 . . . . 0.0 108.396 178.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 7.2 t -162.08 132.75 4.95 Favored 'General case' 0 C--O 1.236 0.394 0 O-C-N 120.709 -1.245 . . . . 0.0 110.749 -179.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.35 137.47 23.77 Favored Glycine 0 CA--C 1.534 1.224 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 179.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -73.0 168.05 25.76 Favored 'Trans proline' 0 N--CA 1.462 -0.38 0 C-N-CA 123.325 2.683 . . . . 0.0 111.784 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 50.3 m -64.95 109.19 2.02 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 177.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 12.7 m -154.62 80.34 1.09 Allowed 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 -178.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.967 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.615 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.755 0 N-CA-C 107.794 -2.122 . . . . 0.0 107.794 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.1 t -132.04 -9.32 3.43 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.495 1.518 . . . . 0.0 109.333 177.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.5 m -74.78 160.74 30.33 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 124.545 1.138 . . . . 0.0 109.671 178.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.75 161.27 28.52 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 108.041 -2.024 . . . . 0.0 108.041 179.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.1 p -140.79 24.92 2.18 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.292 1.437 . . . . 0.0 111.709 -178.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.1 m -54.74 127.26 27.51 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 124.173 0.989 . . . . 0.0 110.214 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.66 -171.75 24.26 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 126.917 2.199 . . . . 0.0 109.869 -178.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -146.91 162.0 39.58 Favored 'General case' 0 C--O 1.239 0.513 0 C-N-CA 126.081 1.753 . . . . 0.0 110.963 179.046 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.2 t -70.0 140.47 18.54 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 C-N-CA 126.188 1.795 . . . . 0.0 112.282 -178.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.7 m -139.59 159.53 27.8 Favored 'Isoleucine or valine' 0 C--O 1.24 0.584 0 C-N-CA 126.601 1.961 . . . . 0.0 107.078 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -81.25 138.28 35.78 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.455 ' HE3' ' HB ' ' A' ' 27' ' ' THR . 8.6 ttmt -81.6 -22.33 37.78 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 123.447 0.699 . . . . 0.0 111.567 179.551 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.8 m -145.76 170.38 5.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 124.842 1.257 . . . . 0.0 108.254 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.6 tttm -72.41 104.05 3.65 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 105.549 -2.019 . . . . 0.0 105.549 177.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 7.3 mt -88.32 109.04 25.54 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-O 118.122 -0.942 . . . . 0.0 109.063 -178.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -69.67 149.39 67.4 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 CA-C-N 120.981 1.386 . . . . 0.0 109.983 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -51.14 143.88 10.11 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.454 1.102 . . . . 0.0 110.565 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.38 2.0 90.27 Favored Glycine 0 C--N 1.338 0.641 0 CA-C-O 118.979 -0.901 . . . . 0.0 114.53 179.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 65.4 m -91.03 142.63 27.57 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 118.741 1.271 . . . . 0.0 109.708 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 5.0 mm -78.7 135.45 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 50.4 mt -74.29 141.85 45.26 Favored 'General case' 0 C--O 1.237 0.446 0 C-N-CA 124.774 1.23 . . . . 0.0 109.352 178.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 41.7 p -141.36 165.51 27.31 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 106.951 -1.499 . . . . 0.0 106.951 178.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -65.02 -22.2 66.96 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-N 118.116 0.416 . . . . 0.0 110.459 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -67.93 -30.5 69.82 Favored 'General case' 0 N--CA 1.464 0.263 0 C-N-CA 124.48 1.112 . . . . 0.0 111.495 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 71.1 mtm -105.92 10.52 32.37 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.491 1.117 . . . . 0.0 112.67 -177.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.0 mt -131.93 162.51 30.48 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 123.958 0.903 . . . . 0.0 109.013 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.455 ' HB ' ' HE3' ' A' ' 12' ' ' LYS . 6.5 t -169.84 174.86 5.45 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.4 t -114.99 156.75 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 177.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 23.8 ttpp -126.98 111.68 14.37 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 103.423 -2.806 . . . . 0.0 103.423 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.7 m -62.63 158.88 3.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 120.238 -0.585 . . . . 0.0 110.209 -179.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 130.76 -96.69 0.35 Allowed Glycine 0 C--N 1.333 0.371 0 CA-C-O 119.078 -0.846 . . . . 0.0 112.277 179.168 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -115.76 157.28 44.97 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 125.559 1.544 . . . . 0.0 113.486 -177.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -77.32 15.19 1.24 Allowed 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 124.562 3.508 . . . . 0.0 113.366 179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 25.6 tptp -55.68 113.55 1.51 Allowed 'General case' 0 N--CA 1.465 0.311 0 O-C-N 120.699 -1.251 . . . . 0.0 108.5 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.33 -170.47 21.43 Favored Glycine 0 N--CA 1.451 -0.348 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.4 t80 -58.02 130.32 82.98 Favored Pre-proline 0 CA--C 1.544 0.719 0 CA-C-O 118.505 -0.76 . . . . 0.0 110.257 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -66.05 153.12 79.39 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.897 2.398 . . . . 0.0 111.797 -178.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_endo -77.23 -22.96 10.7 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 121.606 1.537 . . . . 0.0 113.893 -178.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -63.12 -40.92 99.01 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 119.83 1.195 . . . . 0.0 109.933 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -82.96 4.34 26.26 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-O 117.906 -1.045 . . . . 0.0 113.313 -178.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.6 tt -48.25 -35.03 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 CA-C-N 120.719 1.6 . . . . 0.0 113.763 -178.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -58.82 -28.49 66.07 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.508 0.723 . . . . 0.0 111.701 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 30.0 m-80 -71.53 -41.99 68.5 Favored 'General case' 0 CA--C 1.521 -0.161 0 C-N-CA 124.001 0.921 . . . . 0.0 109.234 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 38.1 mt -65.0 -42.17 94.73 Favored 'General case' 0 CA--C 1.519 -0.216 0 C-N-CA 123.054 0.541 . . . . 0.0 110.171 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.78 98.7 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 C-N-CA 124.345 1.058 . . . . 0.0 108.786 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.99 -14.19 6.65 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 126.321 1.915 . . . . 0.0 114.178 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -79.62 167.79 20.24 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 118.861 1.331 . . . . 0.0 110.426 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.05 137.82 42.22 Favored 'General case' 0 CA--C 1.512 -0.516 0 CA-C-O 118.075 -0.964 . . . . 0.0 109.599 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.3 m -77.02 138.14 21.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 78.3 mt -85.33 -15.88 41.84 Favored 'General case' 0 N--CA 1.462 0.148 0 C-N-CA 123.452 0.701 . . . . 0.0 112.182 179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.2 m -148.04 164.47 5.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 30.7 m -69.66 140.86 53.68 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 84.9 t -115.14 152.8 16.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -110.71 166.69 10.81 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 123.966 0.907 . . . . 0.0 111.194 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -63.26 128.57 36.43 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 30.6 t70 68.73 8.21 6.61 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 128.09 2.556 . . . . 0.0 112.908 -179.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -67.25 162.6 22.28 Favored 'General case' 0 CA--C 1.533 0.298 0 O-C-N 121.005 -1.059 . . . . 0.0 108.438 179.26 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 77.7 m -95.08 123.0 38.32 Favored 'General case' 0 N--CA 1.468 0.435 0 O-C-N 120.131 -1.606 . . . . 0.0 113.181 -178.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 13.3 mm -74.38 146.41 9.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 3.3 mmt -140.26 158.56 43.85 Favored 'General case' 0 C--O 1.233 0.214 0 C-N-CA 126.404 1.882 . . . . 0.0 107.299 179.235 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.34 -32.32 73.71 Favored 'General case' 0 CA--C 1.528 0.123 0 O-C-N 122.141 -0.349 . . . . 0.0 111.762 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -72.07 -5.27 34.07 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -179.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 56.7 mt -103.77 9.57 36.99 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 124.24 1.016 . . . . 0.0 111.05 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.5 m -131.93 155.28 41.45 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 CA-C-N 119.758 1.163 . . . . 0.0 112.3 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -62.15 167.67 3.84 Favored 'General case' 0 C--O 1.234 0.285 0 C-N-CA 125.608 1.563 . . . . 0.0 113.85 -179.547 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -85.8 84.13 7.65 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 106.633 -1.618 . . . . 0.0 106.633 178.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -63.33 -9.57 12.56 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 125.973 1.709 . . . . 0.0 112.598 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -146.58 -167.33 12.8 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 126.203 1.859 . . . . 0.0 109.926 179.235 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 48.7 tttp -89.39 111.11 21.89 Favored 'General case' 0 N--CA 1.443 -0.795 0 C-N-CA 127.557 2.343 . . . . 0.0 107.993 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 7.8 ptmm? -133.07 -177.86 4.7 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 36.9 mm -117.37 169.78 7.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 105.6 -2.0 . . . . 0.0 105.6 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 35.2 pttt -60.86 108.89 0.92 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.842 1.257 . . . . 0.0 108.045 178.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.1 t -154.89 147.34 24.07 Favored 'General case' 0 C--O 1.233 0.187 0 C-N-CA 124.036 0.934 . . . . 0.0 109.645 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.5 p -90.43 -2.65 57.95 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 126.28 1.832 . . . . 0.0 113.031 179.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 45.34 61.7 3.5 Favored Glycine 0 CA--C 1.536 1.368 0 CA-C-O 118.302 -1.277 . . . . 0.0 110.544 -179.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -57.49 -36.02 98.77 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 123.209 2.606 . . . . 0.0 114.734 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 9.7 p -153.51 -172.55 4.27 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-N 119.272 0.942 . . . . 0.0 109.456 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -155.04 134.28 12.43 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.254 1.394 0 CA-C-O 118.074 -1.403 . . . . 0.0 110.407 -179.706 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.725 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 34.7 t -131.41 -67.12 0.71 Allowed 'General case' 0 CA--C 1.53 0.199 0 N-CA-C 105.423 -2.066 . . . . 0.0 105.423 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.2 p -90.65 93.41 9.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 178.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 130.56 134.52 3.68 Favored Glycine 0 N--CA 1.453 -0.216 0 N-CA-C 107.318 -2.313 . . . . 0.0 107.318 -179.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.7 p -153.97 79.44 1.13 Allowed 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 -179.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.1 t -81.51 103.19 11.07 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 102.146 -3.279 . . . . 0.0 102.146 178.077 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -161.75 177.62 37.93 Favored Glycine 0 C--N 1.333 0.366 0 O-C-N 121.284 -0.885 . . . . 0.0 113.234 -178.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -122.52 134.32 54.56 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 127.245 2.218 . . . . 0.0 111.997 -177.877 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 61.2 t -67.73 129.44 32.29 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 28.2 m -132.88 151.42 34.31 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.23 128.4 36.11 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.493 ' HE3' ' HB ' ' A' ' 27' ' ' THR . 6.7 ttmt -72.75 -28.15 62.46 Favored 'General case' 0 C--N 1.327 -0.377 0 O-C-N 121.399 -0.813 . . . . 0.0 111.695 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.71 169.88 18.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 C-N-CA 125.762 1.625 . . . . 0.0 107.093 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 58.7 tttt -71.88 114.91 10.48 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 49.8 mt -100.2 106.77 43.88 Favored Pre-proline 0 CA--C 1.534 0.339 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -66.55 148.7 83.96 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 121.569 1.513 . . . . 0.0 110.72 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 52.0 tt0 -48.54 142.29 6.06 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 126.168 1.787 . . . . 0.0 110.38 179.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.36 0.46 86.76 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-O 118.012 -1.438 . . . . 0.0 113.768 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.1 m -91.3 154.88 18.93 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 120.355 2.078 . . . . 0.0 107.857 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.8 mm -89.29 145.91 6.82 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-N 119.509 1.05 . . . . 0.0 109.097 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 15.2 mt -80.36 137.7 36.59 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.245 0.618 . . . . 0.0 109.811 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 29.0 p -131.22 154.95 47.89 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 125.952 1.701 . . . . 0.0 107.342 179.261 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 12.4 mmt -60.82 -35.46 76.58 Favored 'General case' 0 CA--C 1.538 0.484 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -61.2 -19.16 61.29 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 127.987 2.515 . . . . 0.0 113.051 178.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.6 mtm -115.66 16.31 16.45 Favored 'General case' 0 N--CA 1.466 0.355 0 O-C-N 121.195 -0.941 . . . . 0.0 110.979 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 70.7 mt -129.26 170.5 13.53 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 121.998 0.904 . . . . 0.0 113.263 -179.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.493 ' HB ' ' HE3' ' A' ' 12' ' ' LYS . 4.3 t -171.88 173.26 4.54 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 128.343 2.657 . . . . 0.0 107.221 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -129.88 110.56 19.83 Favored 'Isoleucine or valine' 0 C--O 1.24 0.568 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 178.571 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.406 ' HZ1' ' CG ' ' A' ' 56' ' ' ASP . 20.6 ttpt -69.8 112.6 6.36 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.192 1.397 . . . . 0.0 107.498 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.8 p -66.93 130.96 32.76 Favored 'Isoleucine or valine' 0 C--O 1.239 0.513 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 178.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.64 -89.27 0.1 OUTLIER Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 -179.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -134.5 158.5 75.01 Favored Pre-proline 0 CA--C 1.539 0.553 0 CA-C-O 118.532 -0.747 . . . . 0.0 110.698 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -73.3 31.65 0.31 Allowed 'Trans proline' 0 CA--C 1.544 0.981 1 C-N-CA 126.149 4.566 . . . . 0.0 116.093 -179.152 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -60.6 139.04 57.96 Favored 'General case' 0 C--O 1.225 -0.225 0 O-C-N 120.676 -1.265 . . . . 0.0 110.968 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.41 -72.67 0.78 Allowed Glycine 0 CA--C 1.524 0.62 0 CA-C-O 118.526 -1.152 . . . . 0.0 115.754 178.497 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -151.09 147.77 21.31 Favored Pre-proline 0 CA--C 1.544 0.737 0 CA-C-N 119.596 1.698 . . . . 0.0 114.82 -176.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -83.99 163.4 13.67 Favored 'Trans proline' 0 C--N 1.354 0.868 0 C-N-CA 124.203 3.269 . . . . 0.0 114.347 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -79.61 -10.36 14.5 Favored 'Trans proline' 0 C--N 1.349 0.605 0 C-N-CA 122.482 2.121 . . . . 0.0 111.873 179.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -76.73 -19.85 57.2 Favored 'General case' 0 CA--C 1.535 0.39 0 O-C-N 121.248 -0.907 . . . . 0.0 110.922 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -117.47 8.78 13.07 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 124.04 0.936 . . . . 0.0 112.69 -178.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.6 tt -51.45 -35.5 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 124.041 0.936 . . . . 0.0 111.569 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -61.83 -28.17 69.29 Favored 'General case' 0 N--CA 1.461 0.123 0 C-N-CA 125.245 1.418 . . . . 0.0 111.74 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 37.7 m-80 -78.37 -30.26 47.86 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-O 118.977 -0.535 . . . . 0.0 109.622 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.4 mt -76.03 -37.47 58.33 Favored 'General case' 0 C--N 1.339 0.12 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.1 t -63.54 121.28 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 104.617 -2.364 . . . . 0.0 104.617 178.241 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.45 -9.72 38.59 Favored Glycine 0 CA--C 1.534 1.266 0 CA-C-O 118.846 -0.975 . . . . 0.0 111.404 -178.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 72.2 mttt -85.18 169.16 14.12 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-N 119.721 1.761 . . . . 0.0 107.751 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.1 ttmp? -116.01 130.07 56.65 Favored 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 125.813 1.645 . . . . 0.0 108.027 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.9 m -73.2 144.02 13.21 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 55.7 mt -90.59 -13.88 33.58 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 124.198 0.999 . . . . 0.0 112.093 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 31.6 m -147.99 162.88 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 125.89 1.676 . . . . 0.0 107.208 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 51.5 m -72.85 133.83 44.6 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 96.9 t -112.61 124.48 69.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 125.808 1.643 . . . . 0.0 107.519 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -78.65 171.85 14.54 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.49 0.662 . . . . 0.0 111.866 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 49.1 tt0 -63.25 143.68 57.59 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 105.389 -2.078 . . . . 0.0 105.389 177.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.406 ' CG ' ' HZ1' ' A' ' 29' ' ' LYS . 25.8 t0 61.36 8.23 2.06 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.334 2.254 . . . . 0.0 112.883 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.82 150.52 32.28 Favored 'General case' 0 C--N 1.344 0.365 0 O-C-N 120.905 -1.122 . . . . 0.0 110.287 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.5 118.02 17.92 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 125.124 1.369 . . . . 0.0 113.961 -176.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 mm -75.87 146.32 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 104.564 -2.384 . . . . 0.0 104.564 177.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 10.0 mtt -141.92 157.19 45.26 Favored 'General case' 0 CA--C 1.518 -0.272 0 C-N-CA 123.956 0.903 . . . . 0.0 109.207 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -67.63 -14.74 63.2 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 122.473 0.309 . . . . 0.0 111.267 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 20.5 tt0 -84.52 -33.02 23.61 Favored 'General case' 0 CA--C 1.535 0.4 0 O-C-N 121.127 -0.983 . . . . 0.0 110.89 179.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 43.5 mt -81.33 6.27 14.83 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.722 1.609 . . . . 0.0 113.826 -178.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.6 m -126.66 154.26 36.28 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 CA-C-N 119.267 0.94 . . . . 0.0 110.997 -179.224 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -74.38 -179.1 3.78 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 125.351 1.46 . . . . 0.0 109.618 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -73.63 144.99 45.69 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 120.982 -1.074 . . . . 0.0 110.52 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 17.6 t-80 -63.63 94.34 0.09 Allowed 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 178.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.98 155.72 11.05 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 125.176 1.37 . . . . 0.0 110.718 -178.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 80.6 tttt -132.24 122.92 25.96 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 125.867 1.667 . . . . 0.0 106.607 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.94 143.49 17.01 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 118.164 0.438 . . . . 0.0 110.807 -179.685 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 29.1 pt -79.23 158.12 4.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 106.63 -1.618 . . . . 0.0 106.63 177.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 5.1 ptpt -105.42 152.66 22.71 Favored 'General case' 0 C--O 1.234 0.248 0 C-N-CA 123.613 0.765 . . . . 0.0 109.326 179.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.8 m -95.78 164.37 12.78 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 123.299 0.64 . . . . 0.0 109.879 179.546 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 5.7 t -170.23 -170.7 1.0 Allowed 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 127.338 2.255 . . . . 0.0 105.909 179.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -123.31 163.59 16.72 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -76.91 1.79 8.24 Favored 'Trans proline' 0 CA--C 1.54 0.805 0 C-N-CA 123.64 2.893 . . . . 0.0 112.775 179.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 9.0 t -146.57 156.16 43.03 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 105.839 -1.911 . . . . 0.0 105.839 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 57.4 m -158.32 177.66 11.02 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 126.055 1.742 . . . . 0.0 107.528 179.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.257 1.552 0 C-N-CA 128.211 2.815 . . . . 0.0 106.527 179.797 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.51 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.0 m -142.23 -168.4 2.71 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 124.433 1.093 . . . . 0.0 108.844 -179.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.2 t -138.96 157.78 45.39 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.454 1.102 . . . . 0.0 108.191 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 70.77 48.08 36.65 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 108.886 -1.686 . . . . 0.0 108.886 -179.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.4 p -60.58 157.73 13.8 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.421 1.488 . . . . 0.0 112.438 -179.312 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 43.9 t -102.83 -105.42 0.27 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 124.856 1.262 . . . . 0.0 108.292 179.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -175.94 -165.06 31.24 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 107.262 -2.335 . . . . 0.0 107.262 -179.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.1 t -141.94 174.03 10.97 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 118.377 1.089 . . . . 0.0 112.506 -178.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 68.3 t -78.33 119.78 27.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 C-N-CA 127.664 2.386 . . . . 0.0 108.578 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.6 m -128.96 147.5 33.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.17 115.43 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 124.356 1.062 . . . . 0.0 108.267 179.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 41.0 tttm -64.68 -30.55 71.56 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.7 m -147.74 168.67 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 128.413 2.685 . . . . 0.0 105.804 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 65.9 tttt -63.64 130.47 44.42 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 9.4 mt -114.63 101.14 54.18 Favored Pre-proline 0 N--CA 1.454 -0.26 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -70.56 148.3 59.6 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 122.381 2.054 . . . . 0.0 109.235 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 -51.9 146.25 8.65 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.678 1.191 . . . . 0.0 113.228 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 79.74 -2.87 71.78 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 125.059 1.314 . . . . 0.0 113.525 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.4 m -82.19 151.68 26.78 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 119.0 1.4 . . . . 0.0 109.637 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 17.4 mm -91.31 128.5 43.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 178.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 63.3 mt -67.56 146.91 53.44 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.084 1.354 . . . . 0.0 108.964 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 64.9 p -141.27 160.29 40.43 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.9 mmt -64.27 -26.86 68.68 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 178.043 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -63.69 -16.0 59.91 Favored 'General case' 0 CA--C 1.536 0.426 0 O-C-N 121.494 -0.754 . . . . 0.0 112.48 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 38.0 mtm -120.09 4.99 10.84 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 124.878 1.271 . . . . 0.0 112.375 -179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 92.1 mt -124.94 118.82 27.12 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 120.006 1.275 . . . . 0.0 109.163 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 t -123.82 171.77 9.4 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 124.921 1.288 . . . . 0.0 109.369 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 17.9 t -119.81 151.4 22.36 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 39.1 mmtm -109.83 -172.22 2.0 Allowed 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 124.995 1.318 . . . . 0.0 109.795 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 23.2 m -131.57 16.77 1.82 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 C-N-CA 124.979 1.312 . . . . 0.0 111.565 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -78.64 -92.42 0.32 Allowed Glycine 0 C--N 1.334 0.451 0 C-N-CA 124.107 0.86 . . . . 0.0 113.255 -179.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -133.54 157.59 77.63 Favored Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 126.279 1.831 . . . . 0.0 109.004 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -73.05 -1.99 11.35 Favored 'Trans proline' 0 CA--C 1.535 0.55 0 C-N-CA 123.873 3.048 . . . . 0.0 114.233 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.4 ttpt -52.49 127.78 23.67 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.97 -170.74 13.44 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 -178.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -64.61 128.45 93.49 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -64.3 134.85 43.9 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.247 1.965 . . . . 0.0 111.337 -179.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -68.55 -17.65 43.28 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 121.631 1.554 . . . . 0.0 113.482 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -64.39 -25.62 68.1 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 120.311 1.414 . . . . 0.0 110.241 179.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -109.04 12.51 25.17 Favored 'General case' 0 N--CA 1.464 0.237 0 O-C-N 121.15 -0.969 . . . . 0.0 112.121 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.5 tt -48.6 -35.48 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 124.847 1.259 . . . . 0.0 111.895 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 40.0 m-85 -51.81 -30.17 22.22 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 126.111 1.764 . . . . 0.0 112.144 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 67.4 m-80 -81.96 -21.39 37.23 Favored 'General case' 0 CA--C 1.519 -0.214 0 C-N-CA 124.327 1.051 . . . . 0.0 113.093 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 96.2 mt -78.05 -35.53 49.51 Favored 'General case' 0 CA--C 1.521 -0.145 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.85 125.49 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.41 -11.5 68.71 Favored Glycine 0 CA--C 1.529 0.949 0 CA-C-O 117.842 -1.532 . . . . 0.0 113.369 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 43.1 mtmt -83.42 164.24 20.05 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 120.814 2.307 . . . . 0.0 109.558 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.7 ttmp? -102.54 145.52 29.48 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.8 m -85.36 140.23 16.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 O-C-N 123.346 0.404 . . . . 0.0 110.397 179.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 16.9 mt -86.89 -18.07 31.75 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-O 117.718 -1.134 . . . . 0.0 111.527 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 17.7 m -150.02 165.36 3.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 C-N-CA 123.958 0.903 . . . . 0.0 109.052 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.0 m -74.76 143.2 44.18 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 105.609 -1.997 . . . . 0.0 105.609 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 75.1 t -129.08 123.26 58.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 C-N-CA 125.8 1.64 . . . . 0.0 106.664 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -72.54 160.98 31.39 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 122.626 1.203 . . . . 0.0 108.867 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -65.76 134.32 52.9 Favored 'General case' 0 C--O 1.24 0.581 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.2 t70 82.87 1.2 1.17 Allowed 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 128.886 2.874 . . . . 0.0 113.901 179.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -71.76 156.97 38.74 Favored 'General case' 0 C--N 1.341 0.226 0 CA-C-N 118.228 0.467 . . . . 0.0 110.631 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.3 m -80.67 116.9 20.92 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 125.965 1.706 . . . . 0.0 109.775 179.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 16.0 mm -73.95 143.53 13.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 N-CA-C 107.243 -1.391 . . . . 0.0 107.243 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -135.47 153.75 51.65 Favored 'General case' 0 CA--C 1.521 -0.147 0 C-N-CA 125.574 1.55 . . . . 0.0 107.411 179.177 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -60.72 -29.34 69.3 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -179.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 22.2 tp10 -67.65 -22.7 65.3 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 122.714 0.406 . . . . 0.0 111.252 -179.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 17.4 mt -86.52 4.06 41.53 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 124.759 1.224 . . . . 0.0 112.276 -178.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.4 m -131.4 117.25 35.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 120.182 1.355 . . . . 0.0 112.292 -178.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -72.89 118.55 15.98 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 125.651 1.58 . . . . 0.0 108.263 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 173.18 114.94 0.02 OUTLIER 'General case' 0 C--O 1.233 0.226 0 C-N-CA 126.054 1.742 . . . . 0.0 110.108 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 72.7 m-70 -79.42 61.44 3.47 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 46.5 -139.61 7.07 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 126.227 1.87 . . . . 0.0 110.58 -179.169 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 25.4 ttpp -101.85 142.7 32.76 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 178.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 60.5 tttp -155.64 124.59 6.11 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 106.345 -1.724 . . . . 0.0 106.345 178.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 62.7 mt -60.5 153.98 4.47 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 20.8 mmtp -111.82 -39.83 4.45 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 125.21 1.404 . . . . 0.0 109.529 179.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.3 t -75.47 -168.36 0.81 Allowed 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.151 1.381 . . . . 0.0 110.032 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -144.51 170.25 16.41 Favored 'General case' 0 C--O 1.237 0.42 0 C-N-CA 127.296 2.238 . . . . 0.0 108.432 179.325 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 130.65 -72.9 0.47 Allowed Glycine 0 CA--C 1.525 0.7 0 CA-C-O 117.919 -1.489 . . . . 0.0 111.839 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -74.68 158.71 43.19 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 122.028 1.818 . . . . 0.0 112.734 -179.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 6.5 m -63.34 157.7 22.34 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 125.451 1.5 . . . . 0.0 110.005 178.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 5.7 m -51.55 -37.78 51.22 Favored 'General case' 0 C--O 1.228 -0.067 0 C-N-CA 125.101 1.36 . . . . 0.0 113.156 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.983 0 N-CA-C 104.378 -3.489 . . . . 0.0 104.378 -179.863 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.98 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.9 m -75.16 122.81 24.18 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.9 t -74.48 69.39 1.67 Allowed 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 119.535 1.061 . . . . 0.0 110.091 -179.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.0 160.27 31.44 Favored Glycine 0 N--CA 1.45 -0.372 0 O-C-N 120.789 -1.195 . . . . 0.0 114.053 -179.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -161.46 -68.11 0.06 Allowed 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 129.124 2.969 . . . . 0.0 105.984 178.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.9 m -75.99 97.32 3.98 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 124.714 1.206 . . . . 0.0 108.303 178.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 178.85 -168.79 39.92 Favored Glycine 0 CA--C 1.523 0.548 0 O-C-N 120.238 -1.539 . . . . 0.0 111.44 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 48.4 t -136.95 154.92 50.31 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 123.823 0.849 . . . . 0.0 110.916 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 99.2 t -75.76 142.52 14.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.3 m -141.83 161.81 20.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.568 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 178.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.91 121.72 20.47 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 54.1 tttm -74.8 -21.7 59.16 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 118.862 -0.59 . . . . 0.0 110.96 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.4 m -145.31 168.04 8.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 C-N-CA 125.873 1.669 . . . . 0.0 108.765 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -73.34 113.68 10.7 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 178.037 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.3 mt -105.56 104.12 46.68 Favored Pre-proline 0 CA--C 1.533 0.299 0 C-N-CA 124.977 1.311 . . . . 0.0 108.311 -178.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -67.82 155.39 70.06 Favored 'Trans proline' 0 N--CA 1.454 -0.83 0 C-N-CA 121.559 1.506 . . . . 0.0 110.382 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.8 tm-20 -52.08 147.34 7.53 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-O 121.899 0.856 . . . . 0.0 111.164 179.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.27 -4.1 82.36 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 123.77 0.7 . . . . 0.0 114.151 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 26.9 m -84.98 144.76 28.1 Favored 'General case' 0 CA--C 1.538 0.485 0 CA-C-N 118.9 1.35 . . . . 0.0 111.355 -179.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 27.5 mm -87.13 129.85 37.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.859 1.664 . . . . 0.0 107.712 178.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 38.6 mt -71.33 150.49 45.07 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.808 1.243 . . . . 0.0 112.323 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 46.5 p -145.57 161.72 39.13 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 126.826 2.05 . . . . 0.0 107.396 179.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 21.6 mmt -62.11 -38.51 89.17 Favored 'General case' 0 C--O 1.223 -0.327 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 178.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.9 t0 -59.32 -23.61 62.62 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 125.014 1.326 . . . . 0.0 112.651 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 25.5 mtm -104.36 7.71 35.71 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 121.34 -0.85 . . . . 0.0 111.919 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.1 mt -126.19 151.19 47.69 Favored 'General case' 0 CA--C 1.521 -0.135 0 O-C-N 120.948 -1.095 . . . . 0.0 109.124 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.3 t -149.28 174.06 12.81 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 179.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.1 t -128.77 122.78 57.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 22.5 mmmt -92.84 116.46 29.05 Favored 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 p -65.2 136.03 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 178.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 154.76 -87.48 0.13 Allowed Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.5 pm0 -145.11 156.78 54.56 Favored Pre-proline 0 CA--C 1.54 0.591 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -82.35 57.35 6.12 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 124.965 3.777 . . . . 0.0 111.589 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.51 10.26 3.31 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 124.642 1.177 . . . . 0.0 113.254 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.48 -155.6 7.57 Favored Glycine 0 CA--C 1.524 0.633 0 C-N-CA 125.12 1.343 . . . . 0.0 109.98 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 20.1 t80 -59.66 141.03 89.04 Favored Pre-proline 0 CA--C 1.547 0.85 0 C-N-CA 123.669 0.788 . . . . 0.0 109.926 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.25 143.34 58.41 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 123.728 2.952 . . . . 0.0 115.287 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -76.17 -9.06 19.07 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.145 1.896 . . . . 0.0 113.144 179.124 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -79.23 -59.81 2.62 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -71.13 6.58 1.57 Allowed 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 125.817 1.647 . . . . 0.0 113.35 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 15.6 tt -47.65 -33.41 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 C-N-CA 126.385 1.874 . . . . 0.0 112.767 -179.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -57.53 -26.34 61.22 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 123.687 0.795 . . . . 0.0 111.753 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -78.01 -28.2 49.13 Favored 'General case' 0 CA--C 1.528 0.11 0 C-N-CA 123.532 0.733 . . . . 0.0 111.437 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.8 mt -70.58 -37.33 73.93 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 118.679 0.672 . . . . 0.0 109.458 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 43.1 t -61.44 109.29 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 C-N-CA 124.794 1.238 . . . . 0.0 109.382 -179.319 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.14 -14.44 18.88 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 125.582 1.563 . . . . 0.0 111.389 -178.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.2 mttt -74.64 156.0 37.19 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 118.76 1.28 . . . . 0.0 108.318 179.048 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.7 ttmp? -103.45 133.2 48.9 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 6.5 m -73.89 141.59 15.97 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 178.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 93.3 mt -87.37 -20.77 26.24 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 125.658 1.583 . . . . 0.0 110.806 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.6 m -142.29 166.42 16.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.241 0 C-N-CA 125.076 1.35 . . . . 0.0 110.18 -178.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 54.4 m -74.11 106.74 5.92 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 91.3 t -90.22 136.1 24.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 178.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -92.69 175.31 6.86 Favored 'General case' 0 C--O 1.226 -0.18 0 O-C-N 121.618 -0.676 . . . . 0.0 111.853 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -70.13 136.87 50.59 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.0 t70 67.22 9.46 6.98 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 126.952 2.101 . . . . 0.0 111.508 -178.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.9 t0 -70.96 147.67 48.46 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 178.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 39.4 m -81.31 115.09 20.52 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.888 0.851 . . . . 0.0 110.535 -178.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.8 mm -72.14 111.47 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -106.79 152.61 23.62 Favored 'General case' 0 C--O 1.238 0.481 0 N-CA-C 104.409 -2.441 . . . . 0.0 104.409 177.33 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -62.93 -24.45 67.87 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.606 -0.684 . . . . 0.0 111.707 -179.646 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -75.13 -6.01 47.32 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 46.3 mt -95.6 -2.79 47.6 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 119.501 1.046 . . . . 0.0 111.437 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.8 m -130.5 151.5 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 125.251 1.42 . . . . 0.0 107.574 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -70.34 166.54 20.03 Favored 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -61.04 -52.39 65.18 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 179.086 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -149.55 160.25 43.64 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 126.491 1.916 . . . . 0.0 107.245 178.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -114.84 167.63 12.36 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 108.19 -1.964 . . . . 0.0 108.19 178.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.06 -2.79 4.56 Favored 'General case' 0 N--CA 1.466 0.375 0 O-C-N 121.571 -0.958 . . . . 0.0 111.269 178.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 51.4 tttm -59.08 109.38 0.83 Allowed 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 106.113 -1.81 . . . . 0.0 106.113 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.3 pp -67.43 175.55 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 124.681 1.193 . . . . 0.0 110.789 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 30.5 ttmt -96.36 146.37 24.81 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.219 1.008 . . . . 0.0 109.986 179.574 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.9 p -78.6 -77.7 0.16 Allowed 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 105.504 -2.036 . . . . 0.0 105.504 178.106 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.8 m -137.92 171.52 14.3 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 125.864 1.666 . . . . 0.0 108.153 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -128.35 -149.65 7.05 Favored Glycine 0 CA--C 1.531 1.092 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -68.88 9.65 0.44 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 123.564 2.843 . . . . 0.0 113.445 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.4 p -63.07 137.86 58.38 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 119.904 1.229 . . . . 0.0 107.929 178.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 35.9 t -169.92 -26.01 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.074 1.75 . . . . 0.0 109.287 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.2 0 C-N-CA 128.785 3.088 . . . . 0.0 105.918 179.494 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.636 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.2 p -76.81 171.5 14.62 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 178.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.2 p -147.29 142.32 27.05 Favored 'General case' 0 C--O 1.235 0.338 0 O-C-N 121.17 -0.956 . . . . 0.0 110.524 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -110.21 120.87 5.77 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 106.34 -2.704 . . . . 0.0 106.34 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.7 108.08 5.55 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 -178.38 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 89.6 p -139.86 154.4 47.29 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.96 -146.63 11.23 Favored Glycine 0 CA--C 1.52 0.394 0 N-CA-C 107.019 -2.432 . . . . 0.0 107.019 -178.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 96.8 p -138.55 151.19 47.09 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 118.701 1.25 . . . . 0.0 110.924 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.6 t -76.57 125.83 36.69 Favored 'Isoleucine or valine' 0 C--O 1.234 0.259 0 O-C-N 121.307 -0.87 . . . . 0.0 110.159 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 33.3 m -124.9 155.8 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-O 122.445 1.117 . . . . 0.0 108.355 177.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.71 118.7 10.63 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 125.204 1.402 . . . . 0.0 107.43 178.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 34.8 tttp -69.84 -27.31 64.75 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.4 m -151.75 169.77 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 125.729 1.612 . . . . 0.0 107.71 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -61.28 135.27 57.67 Favored 'General case' 0 C--O 1.241 0.62 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.06 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.1 mt -123.09 114.92 29.21 Favored Pre-proline 0 C--O 1.237 0.427 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -68.35 145.46 65.61 Favored 'Trans proline' 0 N--CA 1.448 -1.174 0 C-N-CA 120.752 0.968 . . . . 0.0 109.993 178.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.6 tt0 -57.27 146.07 29.82 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.442 0.697 . . . . 0.0 110.8 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.36 -0.05 88.48 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 123.849 0.738 . . . . 0.0 112.854 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.6 m -91.71 155.34 18.36 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 118.311 1.055 . . . . 0.0 111.742 -178.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 37.1 mm -89.77 130.12 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 125.332 1.453 . . . . 0.0 108.634 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 29.8 mt -70.25 151.99 44.72 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 124.486 1.114 . . . . 0.0 109.047 178.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 74.2 p -140.63 163.22 33.47 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 124.205 1.002 . . . . 0.0 108.458 -179.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 6.2 mmt -63.58 -40.44 96.97 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 177.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -57.71 -30.75 65.77 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 125.683 1.593 . . . . 0.0 113.801 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 63.7 mtm -101.12 13.96 33.48 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 120.379 1.445 . . . . 0.0 112.737 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.4 mt -126.75 136.65 52.7 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -179.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.3 t -140.43 131.2 25.82 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.6 m -90.01 125.82 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 CA-C-N 120.179 1.354 . . . . 0.0 107.881 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 11.1 mttp -84.64 105.33 15.36 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 178.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 8.0 p -59.48 143.03 14.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.517 0 C-N-CA 123.922 0.889 . . . . 0.0 108.966 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 143.7 -81.36 0.22 Allowed Glycine 0 N--CA 1.448 -0.541 0 CA-C-N 118.081 0.4 . . . . 0.0 113.645 179.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -125.6 151.0 69.86 Favored Pre-proline 0 CA--C 1.533 0.293 0 C-N-CA 124.439 1.095 . . . . 0.0 113.102 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -77.8 28.8 0.44 Allowed 'Trans proline' 0 CA--C 1.545 1.051 0 C-N-CA 124.762 3.642 . . . . 0.0 111.936 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 47.7 tttm -80.52 92.99 5.97 Favored 'General case' 0 C--O 1.237 0.444 0 O-C-N 119.826 -1.796 . . . . 0.0 106.944 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 142.66 -149.42 21.27 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 108.501 -1.84 . . . . 0.0 108.501 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -84.68 140.5 38.12 Favored Pre-proline 0 C--O 1.24 0.596 0 C-N-CA 126.328 1.851 . . . . 0.0 108.76 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -55.58 136.05 72.21 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.191 2.594 . . . . 0.0 111.942 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -75.55 -11.02 20.51 Favored 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 123.364 2.709 . . . . 0.0 113.878 -178.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -87.99 -40.02 14.22 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 124.375 1.07 . . . . 0.0 110.074 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -74.36 4.53 5.72 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 124.523 1.129 . . . . 0.0 112.077 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.0 tt -44.5 -39.48 1.72 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 128.049 2.54 . . . . 0.0 112.756 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -53.64 -30.6 43.7 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 123.791 0.836 . . . . 0.0 112.15 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 73.6 m-80 -75.38 -44.97 41.95 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.803 179.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 36.6 mt -56.58 -42.63 78.97 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 79.9 t -60.6 107.55 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 179.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.74 -15.12 26.73 Favored Glycine 0 CA--C 1.528 0.847 0 C-N-CA 125.019 1.295 . . . . 0.0 112.692 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -76.76 157.42 31.65 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-N 120.157 1.979 . . . . 0.0 108.086 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 4.0 ttmp? -98.69 137.96 36.55 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 105.217 -2.142 . . . . 0.0 105.217 177.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 9.2 m -68.13 171.75 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 177.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 61.1 mt -116.46 -11.38 11.15 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 125.019 1.328 . . . . 0.0 111.097 178.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.8 m -153.3 166.68 1.35 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.372 0 C-N-CA 125.91 1.684 . . . . 0.0 107.958 -178.312 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.3 m -74.13 135.96 42.91 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 104.843 -2.281 . . . . 0.0 104.843 178.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 95.2 t -121.06 150.83 24.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -106.96 168.18 9.37 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.114 1.366 . . . . 0.0 108.85 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -65.65 147.94 52.57 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 50.1 m-20 72.47 -6.18 1.65 Allowed 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 128.377 2.671 . . . . 0.0 113.236 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -64.62 152.51 41.98 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-O 121.924 0.868 . . . . 0.0 112.652 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -84.0 99.16 10.24 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 123.827 0.851 . . . . 0.0 110.903 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 10.5 mm -67.26 93.73 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 29.9 mtp -96.05 160.96 14.19 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 119.363 0.983 . . . . 0.0 109.577 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -60.36 -22.4 63.23 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.712 0.805 . . . . 0.0 113.107 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -74.97 -16.02 60.65 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.041 0.936 . . . . 0.0 111.865 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 27.8 mt -99.16 9.07 44.18 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 126.447 1.899 . . . . 0.0 113.959 -178.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.92 149.8 33.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 120.138 1.335 . . . . 0.0 112.38 -179.095 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -100.32 164.05 12.11 Favored 'General case' 0 C--O 1.236 0.379 0 C-N-CA 126.036 1.734 . . . . 0.0 107.659 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -71.43 139.98 49.9 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -69.81 -0.03 6.5 Favored 'General case' 0 CA--C 1.545 0.768 0 O-C-N 121.35 -0.844 . . . . 0.0 112.255 179.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -64.58 165.37 32.71 Favored Glycine 0 CA--C 1.531 1.039 0 O-C-N 119.684 -1.885 . . . . 0.0 109.69 178.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.18 5.52 51.49 Favored 'General case' 0 C--O 1.239 0.542 0 O-C-N 121.646 -0.914 . . . . 0.0 112.9 -179.366 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.7 tptp -59.79 159.01 9.45 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 119.059 0.845 . . . . 0.0 109.254 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 40.9 pt -82.48 167.32 2.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 178.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 20.7 ttmm -60.26 151.48 27.35 Favored 'General case' 0 C--O 1.239 0.527 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -153.5 170.52 20.56 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-O 122.125 0.964 . . . . 0.0 112.861 179.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.2 p -78.21 56.83 1.74 Allowed 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 128.999 2.92 . . . . 0.0 109.245 179.279 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.66 80.07 0.48 Allowed Glycine 0 CA--C 1.523 0.566 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -68.36 -15.9 42.79 Favored 'Trans proline' 0 CA--C 1.534 0.519 0 C-N-CA 122.424 2.083 . . . . 0.0 111.895 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.5 m -160.85 173.71 14.94 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 125.827 1.651 . . . . 0.0 107.331 179.139 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 43.4 m -118.1 113.9 22.29 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 104.918 -2.253 . . . . 0.0 104.918 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.74 0 CA-C-O 116.921 -2.044 . . . . 0.0 110.252 -179.957 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.862 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -135.15 153.68 51.9 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 124.689 1.196 . . . . 0.0 108.385 -179.567 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.9 m -145.04 171.13 14.91 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 125.507 1.523 . . . . 0.0 109.019 -179.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.16 -9.42 42.69 Favored Glycine 0 CA--C 1.523 0.587 0 CA-C-O 117.976 -1.458 . . . . 0.0 113.638 179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.6 t -171.71 127.91 0.63 Allowed 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.828 1.314 . . . . 0.0 108.254 178.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -121.31 81.16 1.75 Allowed 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 103.955 -2.609 . . . . 0.0 103.955 178.355 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.81 -179.99 16.53 Favored Glycine 0 CA--C 1.528 0.849 0 CA-C-N 114.666 -1.152 . . . . 0.0 112.091 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 23.0 t -102.32 156.73 17.39 Favored 'General case' 0 C--O 1.244 0.779 0 C-N-CA 123.94 0.896 . . . . 0.0 110.732 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 85.9 t -75.52 127.86 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.2 m -127.69 146.59 33.13 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.073 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.25 124.02 18.61 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 124.429 1.092 . . . . 0.0 109.054 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 46.6 tttm -67.92 -31.71 71.66 Favored 'General case' 0 C--O 1.225 -0.23 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.421 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.3 m -147.02 174.87 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 126.48 1.912 . . . . 0.0 107.585 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 81.1 tttt -69.38 138.38 53.59 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 178.097 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 23.8 mt -129.25 107.35 17.7 Favored Pre-proline 0 CA--C 1.532 0.262 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -178.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.52 155.51 66.53 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 121.661 1.574 . . . . 0.0 110.532 179.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -53.39 147.27 10.84 Favored 'General case' 0 C--O 1.238 0.466 0 C-N-CA 124.942 1.297 . . . . 0.0 109.88 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.0 0.27 75.35 Favored Glycine 0 CA--C 1.53 0.989 0 CA-C-O 118.825 -0.986 . . . . 0.0 113.926 179.187 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 28.5 m -86.67 137.7 32.25 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 119.608 1.704 . . . . 0.0 108.956 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 11.4 mm -80.51 128.71 38.46 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 178.394 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 74.6 mt -67.19 145.18 55.51 Favored 'General case' 0 C--O 1.237 0.442 0 C-N-CA 125.28 1.432 . . . . 0.0 110.307 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.6 p -143.25 152.35 41.6 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.371 1.468 . . . . 0.0 107.457 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -56.65 -27.09 57.88 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 118.869 0.758 . . . . 0.0 109.319 178.559 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -56.39 -29.27 61.28 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 126.418 1.887 . . . . 0.0 111.574 177.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 48.6 mtm -114.04 3.01 15.14 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 124.616 1.166 . . . . 0.0 111.168 -178.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 70.7 mt -105.52 147.89 27.85 Favored 'General case' 0 C--N 1.343 0.296 0 CA-C-N 120.081 1.31 . . . . 0.0 109.188 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.0 t -159.74 171.97 18.56 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 125.241 1.417 . . . . 0.0 107.613 178.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 77.0 t -125.57 152.19 32.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 8.3 mmmt -127.45 109.49 11.8 Favored 'General case' 0 CA--C 1.508 -0.646 0 N-CA-C 105.797 -1.927 . . . . 0.0 105.797 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 29.5 m -59.52 151.43 5.12 Favored 'Isoleucine or valine' 0 C--O 1.24 0.563 0 O-C-N 123.573 0.545 . . . . 0.0 109.532 179.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 152.09 -95.24 0.15 Allowed Glycine 0 N--CA 1.442 -0.925 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.53 163.38 50.02 Favored Pre-proline 0 C--N 1.326 -0.419 0 C-N-CA 126.562 1.945 . . . . 0.0 110.147 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -85.88 53.87 3.37 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 122.761 2.307 . . . . 0.0 110.16 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 32.9 pttt -73.81 70.65 1.44 Allowed 'General case' 0 C--O 1.221 -0.417 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 178.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.69 -152.8 18.07 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -178.366 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -55.07 134.17 68.07 Favored Pre-proline 0 CA--C 1.545 0.766 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -178.17 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -74.17 156.36 46.78 Favored 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 123.367 2.711 . . . . 0.0 111.251 179.306 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -71.18 -24.72 23.09 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.045 1.83 . . . . 0.0 113.942 -178.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 18.8 mp0 -83.68 2.32 38.22 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 -177.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -124.79 -5.46 7.5 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 119.949 1.25 . . . . 0.0 111.957 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 18.2 tt -40.38 -34.8 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 128.401 2.68 . . . . 0.0 114.327 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -57.91 -11.96 2.81 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.43 1.492 . . . . 0.0 114.139 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -97.4 -24.8 15.46 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 120.298 1.408 . . . . 0.0 110.82 178.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 85.8 mt -64.23 -37.94 89.27 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -68.08 118.88 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 179.556 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.82 -16.78 23.21 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 125.325 1.44 . . . . 0.0 112.337 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -85.6 158.68 20.05 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 119.034 1.417 . . . . 0.0 107.593 178.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt -103.45 139.74 38.42 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.793 -0.818 . . . . 0.0 108.793 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.2 m -77.29 135.12 27.16 Favored 'Isoleucine or valine' 0 C--O 1.236 0.347 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 24.1 mt -81.27 -15.3 55.92 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 124.227 1.011 . . . . 0.0 112.028 179.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.2 m -146.92 164.03 7.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 127.059 2.144 . . . . 0.0 108.796 -178.353 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 24.0 m -77.34 132.28 38.5 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.025 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 54.3 t -98.5 -178.48 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 C-N-CA 126.512 1.925 . . . . 0.0 106.803 178.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -135.64 164.76 27.11 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 127.377 2.271 . . . . 0.0 107.73 177.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -65.91 141.43 58.24 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 105.7 -1.963 . . . . 0.0 105.7 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 68.22 4.88 4.37 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.168 1.787 . . . . 0.0 114.946 179.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -76.19 155.35 34.59 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 119.633 1.106 . . . . 0.0 109.515 179.005 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 29.7 m -77.32 135.74 38.41 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 121.166 -0.959 . . . . 0.0 109.871 -179.338 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 16.7 mm -97.5 133.94 37.42 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 N-CA-C 104.808 -2.293 . . . . 0.0 104.808 177.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 82.7 mtp -139.93 160.86 38.96 Favored 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 123.579 0.752 . . . . 0.0 110.703 -178.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -57.44 -33.62 68.12 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 124.778 1.231 . . . . 0.0 113.231 -179.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -75.32 -2.25 27.4 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.319 1.448 . . . . 0.0 113.601 -178.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 36.9 mt -108.92 3.59 22.45 Favored 'General case' 0 C--O 1.232 0.148 0 C-N-CA 125.06 1.344 . . . . 0.0 110.78 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.4 m -129.59 144.53 37.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 C-N-CA 124.174 0.99 . . . . 0.0 111.234 -179.385 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -91.07 173.66 7.82 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.57 1.548 . . . . 0.0 110.704 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 31.5 t30 -57.04 157.39 5.9 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 125.036 1.334 . . . . 0.0 110.056 178.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 50.7 p-80 -119.45 166.85 12.56 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 124.14 0.976 . . . . 0.0 113.268 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 120.4 -164.36 13.92 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 125.864 1.697 . . . . 0.0 109.076 -179.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -114.62 166.14 12.04 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 125.847 1.659 . . . . 0.0 108.155 179.589 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.9 157.75 43.29 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 125.851 1.66 . . . . 0.0 106.785 177.358 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 8.2 pt -68.38 124.62 24.38 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 CA-C-N 118.635 0.652 . . . . 0.0 109.454 179.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.6 tptm -82.05 58.16 3.82 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.073 1.349 . . . . 0.0 111.002 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 5.0 t -141.89 145.61 34.8 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.3 t -68.43 170.95 8.04 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-O 122.061 0.934 . . . . 0.0 112.258 -179.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -155.02 -164.14 12.73 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 126.908 2.194 . . . . 0.0 109.277 -179.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -64.3 172.65 6.15 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 122.568 2.178 . . . . 0.0 112.344 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 10.9 t -136.42 149.0 48.06 Favored 'General case' 0 C--O 1.238 0.453 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 179.34 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -87.75 178.92 6.6 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 121.597 0.713 . . . . 0.0 109.978 179.548 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.735 0 N-CA-C 105.095 -3.202 . . . . 0.0 105.095 178.76 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.895 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 6.4 t -148.32 -48.69 0.16 Allowed 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 118.177 -0.915 . . . . 0.0 110.537 179.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.2 t -64.0 154.66 33.46 Favored 'General case' 0 C--O 1.238 0.451 0 CA-C-N 119.118 0.872 . . . . 0.0 111.148 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 101.17 132.31 7.71 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 106.664 -2.574 . . . . 0.0 106.664 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.1 m -153.61 162.6 41.1 Favored 'General case' 0 C--O 1.238 0.483 0 O-C-N 121.213 -1.169 . . . . 0.0 108.723 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.2 m -119.47 4.59 11.16 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 124.95 1.3 . . . . 0.0 112.04 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 75.03 -159.24 51.78 Favored Glycine 0 CA--C 1.53 1.005 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 90.7 p -145.22 158.8 43.74 Favored 'General case' 0 C--O 1.237 0.431 0 O-C-N 121.764 -0.845 . . . . 0.0 111.412 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.11 137.17 24.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.083 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.4 m -136.49 160.62 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 C-N-CA 125.722 1.609 . . . . 0.0 107.778 178.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.74 118.27 18.38 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 178.566 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -62.48 -31.77 72.56 Favored 'General case' 0 N--CA 1.467 0.411 0 O-C-N 121.341 -0.85 . . . . 0.0 110.953 179.762 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m -138.32 172.0 14.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 126.708 2.003 . . . . 0.0 107.715 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.1 tttm -70.56 134.09 47.34 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 73.9 mt -120.82 110.11 35.36 Favored Pre-proline 0 CA--C 1.53 0.208 0 C-N-CA 123.756 0.822 . . . . 0.0 110.031 -178.419 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -69.54 148.97 67.65 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 121.882 1.721 . . . . 0.0 111.086 178.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 60.4 tt0 -55.27 151.12 10.13 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 124.403 1.081 . . . . 0.0 110.166 178.429 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 68.99 30.47 72.22 Favored Glycine 0 CA--C 1.524 0.652 0 CA-C-O 119.441 -0.644 . . . . 0.0 113.847 178.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 59.9 m -118.04 150.87 38.58 Favored 'General case' 0 C--O 1.239 0.511 0 C-N-CA 125.737 1.615 . . . . 0.0 107.446 179.195 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 32.7 mm -92.4 123.93 44.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 CA-C-N 118.933 0.788 . . . . 0.0 109.443 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 62.2 mt -63.65 147.13 52.36 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.557 1.143 . . . . 0.0 110.858 -179.484 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.3 p -140.55 164.03 31.26 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 124.754 1.222 . . . . 0.0 107.715 178.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 5.7 mmt -62.82 -32.35 73.52 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.462 0.574 . . . . 0.0 110.281 179.211 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -59.24 -27.87 66.18 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 125.021 1.329 . . . . 0.0 113.357 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 57.9 mtm -105.08 9.2 34.39 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.528 1.131 . . . . 0.0 112.733 -178.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 78.5 mt -127.68 146.22 50.63 Favored 'General case' 0 CA--C 1.518 -0.28 0 O-C-N 120.85 -1.156 . . . . 0.0 110.579 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.6 t -153.48 177.92 10.38 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.66 119.52 38.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 179.163 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 47.8 mtpt -91.63 108.8 20.16 Favored 'General case' 0 CA--C 1.511 -0.527 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 179.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 31.9 t -58.64 133.86 23.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 N-CA-C 105.609 -1.997 . . . . 0.0 105.609 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.42 -83.4 0.12 Allowed Glycine 0 C--N 1.334 0.441 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -124.25 150.61 64.28 Favored Pre-proline 0 CA--C 1.532 0.252 0 C-N-CA 123.501 0.72 . . . . 0.0 111.025 -179.597 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -71.14 -15.59 31.98 Favored 'Trans proline' 0 N--CA 1.456 -0.715 0 C-N-CA 122.486 2.124 . . . . 0.0 113.192 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 18.7 ttmm -48.54 106.15 0.09 Allowed 'General case' 0 C--O 1.234 0.272 0 C-N-CA 126.314 1.846 . . . . 0.0 109.982 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.76 -173.51 20.88 Favored Glycine 0 CA--C 1.525 0.715 0 C-N-CA 126.314 1.911 . . . . 0.0 108.93 -179.043 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.5 t80 -65.79 140.19 97.2 Favored Pre-proline 0 CA--C 1.543 0.703 0 O-C-N 121.973 -0.722 . . . . 0.0 109.509 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -66.19 134.29 36.04 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 122.713 2.275 . . . . 0.0 111.579 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -71.56 -16.47 30.47 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.756 2.304 . . . . 0.0 115.215 -179.199 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -70.94 -22.5 62.21 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.555 1.07 . . . . 0.0 111.927 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -114.88 13.28 17.08 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 124.855 1.262 . . . . 0.0 113.269 -178.224 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 20.5 tt -45.44 -36.39 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 125.365 1.466 . . . . 0.0 113.79 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -58.73 -23.59 60.05 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.336 1.054 . . . . 0.0 113.518 -178.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -78.42 -32.94 48.89 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 120.385 1.448 . . . . 0.0 111.504 179.224 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.2 mt -62.87 -35.37 79.77 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.016 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 77.5 t -60.32 117.03 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.08 -6.71 51.4 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 118.302 -1.277 . . . . 0.0 113.91 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.0 mttm -86.52 158.63 19.5 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 120.717 2.258 . . . . 0.0 108.725 178.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -95.77 135.22 37.78 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 179.107 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.2 m -77.51 139.74 18.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 CA-C-N 118.239 0.472 . . . . 0.0 110.077 179.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 23.1 mt -85.08 -17.22 38.06 Favored 'General case' 0 N--CA 1.462 0.154 0 C-N-CA 125.278 1.431 . . . . 0.0 112.066 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.18 163.52 7.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 C-N-CA 124.816 1.247 . . . . 0.0 110.582 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 22.5 m -78.51 122.4 25.82 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 105.116 -2.179 . . . . 0.0 105.116 178.079 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 76.2 t -106.59 139.29 28.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 106.126 -1.805 . . . . 0.0 106.126 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -86.1 176.21 8.12 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 122.079 0.942 . . . . 0.0 112.211 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -71.32 132.37 44.78 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 123.648 0.779 . . . . 0.0 110.09 -179.153 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 68.02 9.75 7.37 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 126.252 1.821 . . . . 0.0 110.127 -179.112 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 35.1 t0 -73.54 153.38 40.29 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.573 1.149 . . . . 0.0 109.466 179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 23.1 m -78.51 129.59 35.04 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 124.969 1.308 . . . . 0.0 111.809 -177.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 13.0 mm -90.39 148.01 4.84 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 179.013 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 38.1 mtp -142.17 163.56 32.54 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 124.777 1.231 . . . . 0.0 108.238 178.511 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -65.02 -26.35 68.24 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 124.128 0.971 . . . . 0.0 111.039 179.768 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -73.04 -14.84 61.49 Favored 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 123.62 0.768 . . . . 0.0 112.226 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 12.2 mt -94.11 6.59 48.1 Favored 'General case' 0 C--N 1.334 -0.069 0 CA-C-O 118.115 -0.945 . . . . 0.0 113.325 -177.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.4 m -127.88 125.33 64.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 120.139 1.336 . . . . 0.0 112.586 -178.632 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -75.26 102.39 5.01 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 125.779 1.632 . . . . 0.0 108.556 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -169.32 158.8 8.36 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 123.087 0.555 . . . . 0.0 110.747 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -147.2 -55.72 0.24 Allowed 'General case' 0 N--CA 1.465 0.325 0 C-N-CA 124.067 0.947 . . . . 0.0 111.085 179.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 164.94 107.96 0.21 Allowed Glycine 0 C--N 1.337 0.626 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.58 -57.36 0.79 Allowed 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 123.864 0.866 . . . . 0.0 110.328 -179.634 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 44.8 mttm -70.37 -21.13 62.9 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 118.795 0.725 . . . . 0.0 112.847 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 3.3 mp -136.06 152.49 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 179.753 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 12.5 ptmm? -124.16 172.74 8.8 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 123.498 0.719 . . . . 0.0 110.56 179.096 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -70.44 96.85 1.2 Allowed 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 126.938 2.095 . . . . 0.0 107.113 178.791 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.8 p -88.54 169.61 11.59 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 74.88 -169.83 54.38 Favored Glycine 0 CA--C 1.528 0.896 0 O-C-N 121.188 -0.945 . . . . 0.0 112.218 179.539 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -67.73 15.36 0.14 Allowed 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 125.095 3.863 . . . . 0.0 115.644 -178.632 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 73.19 3.37 4.62 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.513 1.525 . . . . 0.0 113.69 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.26 157.33 22.88 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.501 1.12 . . . . 0.0 108.719 179.512 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.898 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.704 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.698 0 CA-C-O 119.248 -0.751 . . . . 0.0 111.692 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -120.03 18.88 12.4 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 119.092 1.446 . . . . 0.0 113.231 -179.409 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 m -59.66 145.2 45.62 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 119.313 0.96 . . . . 0.0 109.989 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.66 -72.7 0.27 Allowed Glycine 0 C--O 1.237 0.343 0 N-CA-C 108.389 -1.884 . . . . 0.0 108.389 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 32.4 p -154.12 178.78 9.59 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.28 1.032 . . . . 0.0 111.684 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 26.8 t -167.32 169.39 12.46 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 128.82 2.848 . . . . 0.0 106.655 179.054 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 166.31 -164.4 37.57 Favored Glycine 0 CA--C 1.524 0.61 0 O-C-N 120.757 -1.214 . . . . 0.0 110.864 -179.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.0 p -110.21 133.7 52.97 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.339 1.455 . . . . 0.0 110.78 -179.566 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.5 t -68.89 127.33 30.57 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 179.366 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.1 m -122.86 149.86 26.6 Favored 'Isoleucine or valine' 0 C--O 1.241 0.625 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.13 119.06 12.82 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 60.5 tttm -70.29 -21.53 62.94 Favored 'General case' 0 C--N 1.331 -0.206 0 O-C-N 121.529 -0.732 . . . . 0.0 112.099 -179.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.2 m -148.17 167.7 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 126.546 1.938 . . . . 0.0 107.501 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.3 tttm -76.43 99.8 5.0 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 178.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 7.6 mt -87.25 109.93 29.43 Favored Pre-proline 0 C--N 1.326 -0.431 0 C-N-CA 125.747 1.619 . . . . 0.0 107.677 -177.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.77 155.12 66.7 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 C-N-CA 121.387 1.391 . . . . 0.0 110.906 -179.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 61.8 tt0 -51.72 141.16 17.38 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 125.653 1.581 . . . . 0.0 109.399 179.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.1 -0.29 87.67 Favored Glycine 0 CA--C 1.535 1.3 0 CA-C-O 119.181 -0.788 . . . . 0.0 114.458 179.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.3 m -84.28 147.77 27.05 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 120.282 2.041 . . . . 0.0 109.668 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.5 mm -86.47 131.26 35.13 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 17.8 mt -68.98 148.16 50.55 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-O 121.607 0.717 . . . . 0.0 110.54 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.3 p -143.34 157.47 44.45 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 127.065 2.146 . . . . 0.0 107.331 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 15.9 mmt -64.98 -24.87 67.64 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -65.17 -14.73 61.3 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 128.791 2.837 . . . . 0.0 112.002 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 25.7 mtm -124.16 10.19 8.7 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.388 1.475 . . . . 0.0 111.933 -179.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 83.4 mt -128.66 152.86 47.9 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 119.728 1.149 . . . . 0.0 110.714 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.0 t -160.54 -179.15 7.41 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 105.434 -2.062 . . . . 0.0 105.434 178.133 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.47 131.11 39.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 O-C-N 120.766 -1.209 . . . . 0.0 108.07 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 2.4 tppp? -84.28 105.45 15.13 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 101.698 -3.445 . . . . 0.0 101.698 177.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.0 m -66.99 89.99 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 O-C-N 121.597 -0.689 . . . . 0.0 110.534 -179.154 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -145.06 -87.15 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 124.984 1.278 . . . . 0.0 110.565 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.9 148.44 39.92 Favored Pre-proline 0 C--N 1.326 -0.418 0 C-N-CA 125.884 1.674 . . . . 0.0 111.695 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -82.5 71.6 6.42 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.176 2.584 . . . . 0.0 108.166 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 40.1 tttp -114.24 166.2 11.9 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 123.537 0.735 . . . . 0.0 109.726 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 74.41 -87.65 0.71 Allowed Glycine 0 N--CA 1.444 -0.828 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -139.84 144.58 39.23 Favored Pre-proline 0 C--O 1.238 0.448 0 C-N-CA 124.919 1.288 . . . . 0.0 108.117 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.9 148.05 85.66 Favored 'Trans proline' 0 CA--C 1.539 0.75 0 C-N-CA 121.543 1.495 . . . . 0.0 109.358 179.065 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.05 -18.8 14.24 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.145 1.897 . . . . 0.0 111.989 -178.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -66.17 -33.09 74.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.46 -0.775 . . . . 0.0 111.391 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -92.24 10.78 28.13 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.18 1.792 . . . . 0.0 111.864 -178.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 13.9 tt -53.98 -34.65 26.5 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.718 0 O-C-N 119.801 -1.812 . . . . 0.0 111.201 179.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -60.64 -20.93 62.07 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.805 1.242 . . . . 0.0 113.605 179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -99.24 -17.99 17.83 Favored 'General case' 0 CA--C 1.515 -0.383 0 CA-C-N 119.732 1.151 . . . . 0.0 111.733 178.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 25.4 mt -68.27 -32.74 73.12 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 177.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 41.7 t -64.24 138.79 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 178.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 91.58 -16.2 59.68 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-O 118.823 -0.987 . . . . 0.0 112.277 -179.055 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.3 mttm -76.63 171.98 13.77 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-N 119.586 1.693 . . . . 0.0 107.368 178.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 24.7 ttmt -122.85 133.44 54.43 Favored 'General case' 0 CA--C 1.516 -0.355 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 1.8 m -74.6 148.47 7.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 O-C-N 124.258 0.974 . . . . 0.0 110.675 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 65.5 mt -97.93 -14.15 20.79 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 126.013 1.725 . . . . 0.0 112.696 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 15.7 m -144.42 161.81 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 C-N-CA 126.064 1.746 . . . . 0.0 108.461 179.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.1 m -74.98 96.0 3.1 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 87.0 t -70.79 127.13 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 178.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -74.29 170.28 15.91 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.584 0.707 . . . . 0.0 110.162 179.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -74.87 138.25 42.34 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 104.788 -2.301 . . . . 0.0 104.788 177.414 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 34.7 t0 72.34 10.94 5.85 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.781 2.032 . . . . 0.0 113.132 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -72.96 149.6 43.21 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 177.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 90.7 m -79.12 122.71 26.58 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 179.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.2 mm -76.51 126.52 37.26 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 48.7 mtp -128.09 155.43 44.4 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 122.469 1.128 . . . . 0.0 110.425 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -62.28 -20.18 64.02 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 126.696 1.998 . . . . 0.0 114.029 -179.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -89.21 -10.35 47.36 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 123.876 0.87 . . . . 0.0 111.687 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 84.1 mt -90.4 11.0 22.87 Favored 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 124.823 1.249 . . . . 0.0 110.729 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.5 m -133.34 151.2 33.27 Favored 'Isoleucine or valine' 0 C--O 1.232 0.166 0 CA-C-N 120.427 1.467 . . . . 0.0 114.239 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 35.1 t0 -90.85 169.99 10.46 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 124.641 1.176 . . . . 0.0 109.129 178.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -72.09 136.85 46.73 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 121.753 -0.592 . . . . 0.0 109.793 178.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 54.0 t-80 -60.11 134.96 57.55 Favored 'General case' 0 C--O 1.24 0.592 0 C-N-CA 124.025 0.93 . . . . 0.0 111.751 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.44 -178.12 15.07 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 124.428 1.013 . . . . 0.0 111.586 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.17 -8.71 1.32 Allowed 'General case' 0 N--CA 1.47 0.538 0 O-C-N 121.986 -0.714 . . . . 0.0 112.655 178.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -54.51 155.62 3.9 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.961 1.305 . . . . 0.0 110.67 179.027 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 33.1 pt -111.95 28.8 2.1 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 C-N-CA 125.712 1.605 . . . . 0.0 111.442 -179.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 48.2 tttp -66.63 -34.55 78.12 Favored 'General case' 0 C--O 1.237 0.414 0 O-C-N 120.852 -1.155 . . . . 0.0 110.805 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 33.1 t -77.41 150.64 35.02 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 125.102 1.361 . . . . 0.0 109.487 179.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 21.9 t -71.11 -67.8 0.48 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 104.452 -2.425 . . . . 0.0 104.452 177.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -172.99 147.91 10.05 Favored Glycine 0 CA--C 1.53 1.001 0 N-CA-C 106.791 -2.524 . . . . 0.0 106.791 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -71.63 -17.16 29.98 Favored 'Trans proline' 0 CA--C 1.534 0.477 0 C-N-CA 123.073 2.516 . . . . 0.0 113.835 -179.118 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.6 m 66.64 8.71 6.08 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.037 1.335 . . . . 0.0 114.133 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 39.0 p -79.12 -167.57 1.2 Allowed 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.493 1.517 . . . . 0.0 109.857 179.108 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.858 0 N-CA-C 106.761 -2.536 . . . . 0.0 106.761 178.639 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.356 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.5 p -67.5 177.85 1.81 Allowed 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 126.908 2.083 . . . . 0.0 111.274 178.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 65.1 m -105.06 97.6 7.43 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 101.248 -3.612 . . . . 0.0 101.248 177.332 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.2 120.33 0.7 Allowed Glycine 0 CA--C 1.527 0.837 0 N-CA-C 106.854 -2.499 . . . . 0.0 106.854 -177.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 79.7 p -126.6 175.23 8.09 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 124.687 1.195 . . . . 0.0 109.977 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 48.7 m -119.44 178.32 4.59 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 124.776 1.231 . . . . 0.0 109.162 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -140.74 -158.48 7.57 Favored Glycine 0 N--CA 1.45 -0.378 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 -179.317 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 76.5 p -137.26 157.19 47.18 Favored 'General case' 0 C--O 1.238 0.451 0 C-N-CA 123.793 0.837 . . . . 0.0 109.704 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 28.9 t -75.57 130.75 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.3 m -128.98 157.85 41.76 Favored 'Isoleucine or valine' 0 C--O 1.24 0.593 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 178.023 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.31 130.99 42.77 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 178.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 64.7 tttt -75.59 -32.91 60.52 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 121.366 -0.834 . . . . 0.0 110.754 179.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 22.6 m -144.58 170.71 7.34 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 129.601 3.16 . . . . 0.0 108.945 -179.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 20.6 tttm -68.78 116.58 9.43 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 119.762 1.165 . . . . 0.0 108.79 179.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 40.2 mt -98.9 105.19 29.84 Favored Pre-proline 0 CA--C 1.534 0.365 0 C-N-CA 125.168 1.387 . . . . 0.0 110.983 -179.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.99 145.39 67.6 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 121.609 1.539 . . . . 0.0 108.937 177.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -53.69 152.9 4.85 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 124.151 0.98 . . . . 0.0 110.966 178.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.87 24.89 76.15 Favored Glycine 0 CA--C 1.524 0.61 0 CA-C-O 118.543 -1.143 . . . . 0.0 113.892 178.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 56.9 m -118.62 143.82 46.55 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 119.112 1.456 . . . . 0.0 108.266 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 18.6 mm -74.39 136.26 25.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.363 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 25.4 mt -80.51 141.47 35.13 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 126.099 1.76 . . . . 0.0 107.805 179.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.0 p -135.92 165.32 25.93 Favored 'General case' 0 C--O 1.237 0.425 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 179.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -61.26 -25.87 67.38 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.55 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -78.17 -10.4 59.62 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.347 1.059 . . . . 0.0 113.164 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 58.9 mtm -119.97 16.07 12.51 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 126.029 1.731 . . . . 0.0 110.566 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.8 mt -141.55 137.88 32.3 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 179.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.1 t -148.28 155.08 40.89 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 t -111.25 102.04 13.41 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 27.7 ttpp -75.01 112.78 11.59 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.236 0.614 . . . . 0.0 109.794 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 90.1 t -61.83 121.92 11.28 Favored 'Isoleucine or valine' 0 C--O 1.239 0.504 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 176.19 -82.77 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -138.56 158.68 69.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 C-N-CA 123.442 0.697 . . . . 0.0 110.768 -179.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -74.63 11.63 1.3 Allowed 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.344 2.696 . . . . 0.0 113.182 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -67.47 95.32 0.45 Allowed 'General case' 0 C--O 1.232 0.155 0 O-C-N 120.281 -1.512 . . . . 0.0 108.136 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.7 -167.89 23.78 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 128.095 2.76 . . . . 0.0 109.316 -178.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -67.77 144.35 97.35 Favored Pre-proline 0 CA--C 1.545 0.752 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -72.35 154.35 56.07 Favored 'Trans proline' 0 CA--C 1.544 1.016 0 C-N-CA 122.432 2.088 . . . . 0.0 113.406 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_endo -66.2 -27.42 48.76 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 123.416 2.744 . . . . 0.0 116.223 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -75.99 -25.06 55.44 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 120.233 1.379 . . . . 0.0 112.179 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -88.86 -2.55 58.64 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.919 0.781 . . . . 0.0 112.563 -179.184 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.4 tt -51.12 -34.38 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 O-C-N 120.616 -1.302 . . . . 0.0 112.557 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -59.43 -22.9 62.15 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -95.29 -19.09 20.28 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-O 117.76 -1.115 . . . . 0.0 111.308 178.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 61.0 mt -72.68 -34.32 67.12 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 73.1 t -64.83 130.64 30.2 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 N-CA-C 105.62 -1.993 . . . . 0.0 105.62 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 93.82 -12.64 69.0 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-O 118.054 -1.414 . . . . 0.0 112.514 -179.305 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -75.49 173.14 11.36 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 119.565 1.682 . . . . 0.0 109.602 178.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.5 tppt? -127.07 101.58 6.6 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.204 1.402 . . . . 0.0 108.941 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 6.1 m -43.06 140.84 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 123.73 0.812 . . . . 0.0 112.508 -178.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 92.8 mt -86.84 -19.48 28.9 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.486 1.114 . . . . 0.0 112.307 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.1 m -143.89 165.69 13.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 C-N-CA 126.222 1.809 . . . . 0.0 107.974 -179.021 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.2 m -76.26 138.56 40.64 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 178.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 79.0 t -119.85 128.43 75.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -75.38 173.89 10.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 122.101 0.953 . . . . 0.0 110.565 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -69.83 145.53 52.02 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . 0.338 0.7 OUTLIER 58.63 8.29 0.88 Allowed 'General case' 0 C--O 1.236 0.348 0 C-N-CA 125.291 1.436 . . . . 0.0 114.374 179.333 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -74.38 158.78 33.32 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 178.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 18.4 m -84.77 126.82 33.75 Favored 'General case' 0 C--N 1.321 -0.638 0 O-C-N 120.69 -1.256 . . . . 0.0 112.131 -177.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.9 mm -84.04 134.9 25.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 N-CA-C 104.328 -2.471 . . . . 0.0 104.328 178.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 69.7 mtp -141.48 159.83 41.4 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 122.885 0.474 . . . . 0.0 110.642 -178.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -61.54 -20.68 63.52 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 125.057 1.343 . . . . 0.0 112.697 179.765 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -81.68 -12.68 58.57 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.457 1.103 . . . . 0.0 112.245 179.546 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 25.0 mt -103.34 0.23 31.08 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.345 1.058 . . . . 0.0 111.463 -179.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.6 m -132.24 147.23 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 CA-C-O 122.302 1.049 . . . . 0.0 112.368 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -81.67 163.08 22.76 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 126.692 1.997 . . . . 0.0 110.104 179.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -67.5 149.23 50.46 Favored 'General case' 0 N--CA 1.444 -0.755 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.115 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -148.85 135.31 19.49 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 178.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.38 75.65 0.42 Allowed Glycine 0 CA--C 1.529 0.921 0 C-N-CA 123.567 0.603 . . . . 0.0 112.827 179.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 51.8 tptt -142.65 165.98 25.92 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 126.617 1.967 . . . . 0.0 107.451 178.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.1 ptpm? -149.56 121.62 8.27 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 179.565 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 98.0 mt -69.26 158.6 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 4.7 ttpm? -155.41 101.32 2.19 Favored 'General case' 0 CA--C 1.517 -0.317 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 14.5 p -65.53 -31.51 72.6 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 122.653 0.381 . . . . 0.0 111.796 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.1 m -62.14 115.84 4.46 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 124.81 1.244 . . . . 0.0 112.821 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 88.08 174.86 47.87 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.069 0.842 . . . . 0.0 114.085 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -61.72 148.69 92.48 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 123.372 2.715 . . . . 0.0 110.878 -179.467 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 24.1 m -79.66 -178.22 6.25 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 125.107 1.363 . . . . 0.0 110.839 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -57.76 -58.57 7.77 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 123.628 0.771 . . . . 0.0 109.142 178.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.961 0 N-CA-C 106.81 -2.516 . . . . 0.0 106.81 -179.417 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.947 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.1 t -54.09 -71.18 0.08 Allowed 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.76 1.224 . . . . 0.0 111.196 -179.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -74.96 163.9 27.13 Favored 'General case' 0 C--O 1.237 0.421 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.406 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 101.14 137.72 9.9 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 -179.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.5 m -63.32 163.49 10.49 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 117.338 0.569 . . . . 0.0 110.929 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.3 t -80.16 -175.71 5.19 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-O 121.7 0.762 . . . . 0.0 109.19 178.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -153.91 -172.51 22.02 Favored Glycine 0 CA--C 1.525 0.675 0 C-N-CA 125.412 1.482 . . . . 0.0 109.507 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -144.23 164.99 29.11 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 124.916 1.286 . . . . 0.0 109.665 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.0 t -81.41 134.05 27.95 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.6 m -133.23 159.39 43.01 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.77 120.35 17.23 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 178.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 75.5 tttt -69.04 -29.5 67.65 Favored 'General case' 0 C--N 1.327 -0.372 0 O-C-N 121.787 -0.571 . . . . 0.0 109.761 179.209 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.2 m -151.0 163.12 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 C-N-CA 128.081 2.552 . . . . 0.0 107.569 178.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -56.23 141.07 42.52 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 124.701 1.2 . . . . 0.0 108.718 178.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 8.3 mt -129.68 105.4 17.16 Favored Pre-proline 0 N--CA 1.465 0.281 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -178.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.79 146.06 82.48 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 121.47 1.446 . . . . 0.0 111.263 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 60.5 tt0 -56.71 141.97 41.91 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.561 0.696 . . . . 0.0 111.036 -179.335 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 90.91 2.77 71.32 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-O 119.137 -0.813 . . . . 0.0 113.376 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 30.0 m -97.38 151.26 20.12 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 125.603 1.561 . . . . 0.0 109.143 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 14.4 mm -91.98 141.15 14.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 37.6 mt -73.49 149.56 42.21 Favored 'General case' 0 C--O 1.238 0.468 0 C-N-CA 124.667 1.187 . . . . 0.0 110.69 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.9 p -144.51 158.11 43.91 Favored 'General case' 0 C--N 1.328 -0.361 0 C-N-CA 127.176 2.19 . . . . 0.0 108.096 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.6 mmt -63.74 -31.7 72.96 Favored 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -59.43 -17.44 30.93 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.987 1.315 . . . . 0.0 111.914 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 49.5 mtm -119.88 11.08 11.73 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.122 1.369 . . . . 0.0 111.849 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.5 mt -130.33 146.88 51.97 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 119.373 0.988 . . . . 0.0 110.256 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.7 t -152.95 163.83 39.08 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 55.3 t -107.75 101.49 12.6 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 1.1 mmtm -72.65 129.7 38.86 Favored 'General case' 0 N--CA 1.453 -0.287 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.3 m -73.24 123.04 27.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 168.33 -93.64 0.1 Allowed Glycine 0 C--N 1.335 0.473 0 C-N-CA 119.918 -1.134 . . . . 0.0 112.985 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -138.09 153.83 73.65 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 117.484 0.642 . . . . 0.0 111.577 -179.098 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -70.48 14.7 0.3 Allowed 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 124.588 3.525 . . . . 0.0 115.08 -179.032 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.42 114.2 6.65 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 105.31 -2.108 . . . . 0.0 105.31 178.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 119.74 -166.39 13.42 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -178.725 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -69.83 138.66 87.99 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-O 118.909 -0.567 . . . . 0.0 112.207 -178.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -60.79 135.18 58.26 Favored 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.643 2.229 . . . . 0.0 110.162 179.281 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.42 -13.84 36.19 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 121.963 1.775 . . . . 0.0 115.299 -179.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -78.23 -31.17 49.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 119.494 1.043 . . . . 0.0 108.929 179.021 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -81.39 3.98 22.5 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.379 1.072 . . . . 0.0 111.647 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.1 tt -53.2 -32.26 18.93 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 124.658 1.183 . . . . 0.0 112.244 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -57.27 -43.79 83.36 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 123.232 0.613 . . . . 0.0 109.384 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 18.3 m-80 -64.79 -36.76 85.36 Favored 'General case' 0 CA--C 1.522 -0.114 0 C-N-CA 124.176 0.991 . . . . 0.0 110.633 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 71.7 mt -64.42 -34.07 77.32 Favored 'General case' 0 C--O 1.227 -0.108 0 CA-C-O 118.837 -0.602 . . . . 0.0 110.495 179.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 96.8 t -71.98 82.11 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 CA-C-O 123.031 1.396 . . . . 0.0 109.245 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 147.24 -4.95 1.0 Allowed Glycine 0 CA--C 1.527 0.844 0 C-N-CA 127.032 2.253 . . . . 0.0 112.653 -179.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 78.7 mttt -91.92 156.33 17.54 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 119.427 1.613 . . . . 0.0 109.118 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -99.42 138.67 36.19 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 179.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 6.1 m -75.33 137.37 23.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 95.6 mt -88.81 -12.85 40.84 Favored 'General case' 0 C--N 1.334 -0.106 0 C-N-CA 124.575 1.15 . . . . 0.0 111.592 179.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 32.6 m -143.53 160.2 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.25 0 C-N-CA 124.343 1.057 . . . . 0.0 108.65 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 33.4 m -74.23 105.58 5.48 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 104.735 -2.32 . . . . 0.0 104.735 177.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 41.1 t -80.23 143.46 12.37 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 179.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -90.62 169.74 10.75 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 121.774 0.797 . . . . 0.0 109.08 178.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -69.35 136.91 52.4 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 178.053 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.6 t0 65.06 13.79 8.92 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 124.796 1.239 . . . . 0.0 113.813 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -77.01 157.14 31.35 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 124.004 0.922 . . . . 0.0 109.048 178.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.0 m -78.47 128.75 34.03 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 121.517 -0.74 . . . . 0.0 109.596 -179.264 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.0 mm -87.93 129.08 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 N-CA-C 103.143 -2.91 . . . . 0.0 103.143 177.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 46.6 mtp -133.24 159.92 38.8 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -63.4 -34.13 77.06 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 123.372 0.669 . . . . 0.0 109.904 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -60.75 -19.5 59.18 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 126.662 1.985 . . . . 0.0 110.741 179.699 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 10.7 mt -100.86 6.91 43.88 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 125.149 1.38 . . . . 0.0 112.532 -179.209 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.4 m -132.55 147.2 31.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 120.749 1.613 . . . . 0.0 111.814 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -57.45 143.1 41.73 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 125.413 1.485 . . . . 0.0 109.57 179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -61.42 -35.27 77.09 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 124.325 1.05 . . . . 0.0 112.102 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -147.78 174.5 11.76 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 124.793 1.237 . . . . 0.0 108.082 178.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.46 108.3 0.37 Allowed Glycine 0 N--CA 1.452 -0.237 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.43 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 19.3 ptmt -138.04 155.34 48.91 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 123.541 0.737 . . . . 0.0 109.179 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 6.2 ttpm? -161.67 105.98 1.26 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.4 pp -76.79 -2.36 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 N-CA-C 113.595 0.961 . . . . 0.0 113.595 -179.344 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -70.81 97.98 1.48 Allowed 'General case' 0 C--N 1.342 0.27 0 CA-C-N 119.996 1.271 . . . . 0.0 110.381 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 19.5 t -123.38 -67.64 0.93 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 20.1 m -68.27 167.56 14.16 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 124.17 0.988 . . . . 0.0 111.914 -179.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -169.98 172.94 44.02 Favored Glycine 0 CA--C 1.533 1.167 0 C-N-CA 125.558 1.551 . . . . 0.0 109.269 179.46 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -74.29 -10.22 22.28 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 123.02 2.48 . . . . 0.0 111.4 179.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.4 p -73.79 48.86 0.3 Allowed 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 129.265 3.026 . . . . 0.0 110.681 179.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 51.1 m -145.69 84.03 1.66 Allowed 'General case' 0 N--CA 1.453 -0.314 0 O-C-N 120.573 -1.329 . . . . 0.0 108.085 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.775 0 C-N-CA 129.649 3.5 . . . . 0.0 106.159 179.716 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.891 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.1 t -129.44 136.94 50.55 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.333 1.453 . . . . 0.0 107.937 179.74 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 m -75.39 128.18 34.8 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.37 0.668 . . . . 0.0 109.863 179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -100.89 -172.91 29.06 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 73.3 m -86.37 124.44 32.72 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 178.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -52.89 139.11 28.2 Favored 'General case' 0 C--O 1.237 0.408 0 C-N-CA 123.863 0.865 . . . . 0.0 111.23 -179.061 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -175.98 -168.32 36.08 Favored Glycine 0 CA--C 1.524 0.623 0 O-C-N 121.613 -0.68 . . . . 0.0 112.34 -179.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 36.7 p -136.87 143.75 43.2 Favored 'General case' 0 C--O 1.234 0.255 0 C-N-CA 125.627 1.571 . . . . 0.0 110.872 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.7 t -69.24 123.07 21.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 CA-C-N 119.15 0.886 . . . . 0.0 110.869 179.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 35.5 m -125.41 154.64 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 125.043 1.337 . . . . 0.0 108.065 177.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.37 118.91 12.07 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -70.36 -29.93 66.72 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.389 -0.819 . . . . 0.0 110.85 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.6 m -147.21 161.85 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 127.816 2.447 . . . . 0.0 106.932 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 78.3 tttt -62.85 143.44 57.59 Favored 'General case' 0 C--O 1.24 0.577 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.1 mt -127.33 110.85 21.25 Favored Pre-proline 0 CA--C 1.538 0.486 0 C-N-CA 124.956 1.302 . . . . 0.0 109.201 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -66.35 149.5 84.9 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 121.663 1.575 . . . . 0.0 109.704 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.6 tm-20 -53.56 148.55 9.26 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 124.293 1.037 . . . . 0.0 110.905 179.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.22 -0.52 87.46 Favored Glycine 0 CA--C 1.526 0.747 0 C-N-CA 124.617 1.103 . . . . 0.0 115.219 178.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 72.5 m -83.6 144.53 29.39 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 118.213 1.006 . . . . 0.0 110.768 -179.07 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 30.0 mm -85.65 135.58 24.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 177.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 42.4 mt -72.29 151.98 42.43 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 124.008 0.923 . . . . 0.0 112.033 -179.123 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 47.7 p -144.0 159.02 43.32 Favored 'General case' 0 C--O 1.238 0.455 0 C-N-CA 127.285 2.234 . . . . 0.0 106.533 178.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.69 -30.89 71.64 Favored 'General case' 0 C--O 1.224 -0.273 0 CA-C-N 119.377 0.99 . . . . 0.0 108.483 178.605 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -58.14 -30.58 66.45 Favored 'General case' 0 C--O 1.225 -0.209 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -179.436 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.8 mtm -95.69 9.67 39.53 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 118.861 0.755 . . . . 0.0 111.518 179.565 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.3 mt -130.83 158.22 40.76 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 123.898 0.879 . . . . 0.0 111.843 -178.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 t -159.32 152.06 21.7 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.351 -2.092 . . . . 0.0 105.351 177.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 m -103.01 120.51 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 119.828 1.194 . . . . 0.0 108.596 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 27.5 ttpp -68.84 113.67 6.48 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 104.784 -2.302 . . . . 0.0 104.784 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 60.7 t -74.56 85.73 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -144.02 -77.13 0.03 OUTLIER Glycine 0 CA--C 1.52 0.358 0 C-N-CA 125.395 1.474 . . . . 0.0 111.311 -179.118 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -147.62 161.59 34.98 Favored Pre-proline 0 CA--C 1.537 0.464 0 C-N-CA 124.88 1.272 . . . . 0.0 109.493 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -73.82 36.23 0.39 Allowed 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 124.61 3.54 . . . . 0.0 113.249 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -62.7 164.24 8.06 Favored 'General case' 0 N--CA 1.462 0.16 0 O-C-N 120.567 -1.333 . . . . 0.0 108.912 178.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 53.41 -132.09 42.7 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 179.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -86.45 135.88 35.89 Favored Pre-proline 0 CA--C 1.542 0.658 0 C-N-CA 125.026 1.33 . . . . 0.0 110.848 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.16 151.48 66.63 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.273 2.649 . . . . 0.0 112.592 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -80.04 -24.81 5.48 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.654 2.236 . . . . 0.0 112.989 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -65.48 -43.24 90.84 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 119.253 0.933 . . . . 0.0 110.638 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -71.05 8.33 0.97 Allowed 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 127.771 2.428 . . . . 0.0 114.15 -178.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.1 tt -50.27 -36.17 12.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 CA-C-N 119.3 0.955 . . . . 0.0 112.498 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -58.89 -32.37 69.44 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-O 118.976 -0.535 . . . . 0.0 111.706 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 70.9 m-80 -70.3 -49.6 47.98 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 20.8 mt -57.03 -46.23 82.54 Favored 'General case' 0 CA--C 1.515 -0.385 0 C-N-CA 123.52 0.728 . . . . 0.0 109.957 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 74.8 t -68.05 99.19 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.693 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 131.46 -12.48 5.45 Favored Glycine 0 CA--C 1.529 0.926 0 C-N-CA 127.18 2.324 . . . . 0.0 110.687 -179.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 55.8 mttm -84.21 169.19 15.03 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 120.021 1.911 . . . . 0.0 108.053 178.273 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 20.4 ttmm -111.85 138.45 48.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 118.1 -0.952 . . . . 0.0 109.287 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.8 m -74.52 137.14 23.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.508 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 38.3 mt -83.2 -18.84 37.91 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 125.678 1.591 . . . . 0.0 112.268 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 22.8 m -145.21 167.94 9.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 126.198 1.799 . . . . 0.0 108.496 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.6 m -76.88 109.46 10.7 Favored 'General case' 0 N--CA 1.456 -0.149 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 178.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 86.7 t -86.48 126.07 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 C-N-CA 124.632 1.173 . . . . 0.0 107.863 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -77.45 172.8 12.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 122.18 0.991 . . . . 0.0 111.298 178.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -71.79 148.63 46.08 Favored 'General case' 0 N--CA 1.443 -0.782 0 O-C-N 121.616 -0.678 . . . . 0.0 109.509 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 29.2 t70 61.36 7.36 1.7 Allowed 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 127.554 2.342 . . . . 0.0 112.169 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -67.82 150.99 47.9 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.234 1.014 . . . . 0.0 108.895 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 47.3 m -82.64 111.84 18.97 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.048 -1.094 . . . . 0.0 108.048 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.8 mm -70.27 129.68 34.47 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 105.712 -1.959 . . . . 0.0 105.712 178.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 59.1 mtp -132.8 161.02 35.19 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 123.897 0.879 . . . . 0.0 109.316 -179.203 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -62.25 -30.55 71.19 Favored 'General case' 0 N--CA 1.466 0.329 0 C-N-CA 123.498 0.719 . . . . 0.0 111.031 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 19.2 pt-20 -66.51 -15.84 63.69 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 123.613 0.765 . . . . 0.0 111.474 179.339 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 38.5 mt -100.32 5.29 44.46 Favored 'General case' 0 C--N 1.341 0.234 0 C-N-CA 126.419 1.887 . . . . 0.0 112.692 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.06 140.41 47.97 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-N 121.665 2.029 . . . . 0.0 114.687 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -101.01 161.15 13.8 Favored 'General case' 0 C--O 1.239 0.514 0 C-N-CA 127.191 2.197 . . . . 0.0 108.869 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -64.92 143.43 57.96 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 127.183 2.193 . . . . 0.0 111.598 179.568 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 34.5 t-80 -76.88 107.8 9.47 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 178.531 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -76.24 178.11 49.87 Favored Glycine 0 CA--C 1.532 1.154 0 N-CA-C 109.289 -1.525 . . . . 0.0 109.289 178.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.6 ttmp? -125.89 -77.2 0.58 Allowed 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 179.161 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -78.33 72.45 4.86 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 178.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 30.2 pt -79.91 175.01 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 125.407 1.483 . . . . 0.0 110.718 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 24.0 tptp -147.14 113.2 5.82 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 107.046 -1.464 . . . . 0.0 107.046 178.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.9 t -57.4 104.43 0.17 Allowed 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 125.256 1.422 . . . . 0.0 110.418 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.1 p -74.54 -58.36 3.34 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 178.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 163.42 161.61 12.97 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 127.019 2.247 . . . . 0.0 108.962 179.522 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -81.5 -179.02 4.62 Favored 'Trans proline' 0 CA--C 1.538 0.69 0 C-N-CA 123.402 2.735 . . . . 0.0 109.48 179.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 38.0 p -130.91 134.9 47.18 Favored 'General case' 0 C--O 1.236 0.383 0 O-C-N 121.194 -0.941 . . . . 0.0 109.263 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 44.1 t -84.66 -65.35 1.02 Allowed 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 105.913 -1.884 . . . . 0.0 105.913 178.314 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.579 0 N-CA-C 106.392 -2.683 . . . . 0.0 106.392 -179.207 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.669 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.0 p -64.4 147.97 51.48 Favored 'General case' 0 CA--C 1.535 0.367 0 CA-C-N 118.629 1.215 . . . . 0.0 109.177 179.044 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.5 m -54.32 -38.78 66.38 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 123.623 0.769 . . . . 0.0 113.074 -179.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.71 124.78 15.66 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 111.524 -0.631 . . . . 0.0 111.524 -179.426 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.2 m -83.19 76.51 9.87 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 124.142 0.977 . . . . 0.0 109.885 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.9 p -80.99 72.57 8.02 Favored 'General case' 0 CA--C 1.542 0.661 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 178.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 124.33 -175.79 16.98 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 127.251 2.358 . . . . 0.0 109.188 -179.16 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 46.4 p -136.33 163.04 31.37 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 117.251 0.525 . . . . 0.0 109.887 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 62.3 t -68.74 142.89 15.65 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.4 m -140.87 164.36 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 127.021 2.129 . . . . 0.0 106.547 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -81.13 133.15 35.42 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.062 -1.458 . . . . 0.0 107.062 177.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -75.51 -29.31 59.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 118.898 -0.572 . . . . 0.0 111.371 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.6 m -144.96 168.97 8.51 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 127.199 2.2 . . . . 0.0 107.854 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.4 tttm -71.86 123.86 23.6 Favored 'General case' 0 C--O 1.238 0.457 0 C-N-CA 124.966 1.306 . . . . 0.0 108.766 178.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 74.9 mt -115.64 119.82 37.06 Favored Pre-proline 0 CA--C 1.538 0.517 0 C-N-CA 125.111 1.365 . . . . 0.0 110.112 -178.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.6 152.03 53.28 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 121.783 1.655 . . . . 0.0 110.633 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -50.49 146.9 4.95 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.797 1.639 . . . . 0.0 110.844 179.435 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.12 -4.44 66.8 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 115.341 0.896 . . . . 0.0 115.341 178.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.5 m -82.6 149.65 27.32 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 118.561 1.18 . . . . 0.0 109.438 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.05 141.86 13.77 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 76.3 mt -82.98 144.35 30.04 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 123.607 0.763 . . . . 0.0 110.589 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 77.1 p -133.67 162.25 32.46 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 126.876 2.071 . . . . 0.0 108.114 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.0 mmt -63.03 -26.57 68.91 Favored 'General case' 0 N--CA 1.465 0.294 0 O-C-N 121.781 -0.574 . . . . 0.0 110.75 179.172 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -68.91 -43.92 74.19 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-O 117.82 -1.086 . . . . 0.0 112.782 -179.139 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 29.6 mtm -87.76 18.17 4.25 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 120.671 1.578 . . . . 0.0 111.58 -177.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 64.8 mt -125.65 133.61 52.14 Favored 'General case' 0 CA--C 1.516 -0.337 0 C-N-CA 126.169 1.788 . . . . 0.0 109.856 -179.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.0 t -146.77 174.08 11.8 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 178.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 40.9 t -129.86 100.22 5.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 CA-C-N 119.36 0.982 . . . . 0.0 108.585 -178.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.438 ' HE2' ' HA ' ' A' ' 29' ' ' LYS . 6.2 mmpt? -67.41 131.32 45.46 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.7 m -62.31 125.87 19.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 178.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.37 -134.0 3.13 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -99.66 156.19 35.64 Favored Pre-proline 0 C--O 1.236 0.374 0 C-N-CA 123.995 0.918 . . . . 0.0 112.781 -179.335 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -79.84 51.7 4.0 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 124.474 3.449 . . . . 0.0 111.526 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.0 pttt -72.21 -56.47 5.48 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 120.83 -1.169 . . . . 0.0 110.486 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -70.83 -169.61 8.86 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 125.3 1.428 . . . . 0.0 112.075 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -57.12 144.18 70.17 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 118.209 -0.9 . . . . 0.0 111.316 179.64 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -64.4 142.5 79.04 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.838 2.359 . . . . 0.0 112.089 179.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -77.26 7.82 3.55 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 123.638 2.892 . . . . 0.0 112.051 178.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -94.62 -43.09 8.45 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 126.405 1.882 . . . . 0.0 109.845 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -94.45 8.53 41.76 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 124.113 0.965 . . . . 0.0 111.193 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.2 tt -45.89 -35.78 2.16 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 126.644 1.977 . . . . 0.0 111.874 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -59.67 -25.15 64.49 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 125.374 1.47 . . . . 0.0 112.223 179.535 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -77.88 -36.14 50.07 Favored 'General case' 0 CA--C 1.518 -0.253 0 C-N-CA 124.068 0.947 . . . . 0.0 109.977 179.278 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 84.9 mt -57.38 -40.69 78.71 Favored 'General case' 0 CA--C 1.516 -0.335 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.227 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 94.4 t -60.39 104.71 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 178.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 118.67 -14.95 11.56 Favored Glycine 0 CA--C 1.526 0.748 0 CA-C-O 117.957 -1.468 . . . . 0.0 113.187 -179.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -81.06 168.5 18.57 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 119.564 1.682 . . . . 0.0 108.39 179.23 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -114.83 138.11 51.16 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 124.15 0.98 . . . . 0.0 109.316 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.1 m -74.06 151.94 7.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.596 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 13.1 mt -100.39 -13.99 18.53 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 126.018 1.727 . . . . 0.0 113.643 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 10.4 m -151.14 163.85 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 126.974 2.109 . . . . 0.0 107.915 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.6 m -73.25 102.53 3.68 Favored 'General case' 0 CA--C 1.534 0.349 0 O-C-N 121.085 -1.009 . . . . 0.0 108.665 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 64.1 t -78.4 144.28 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 N-CA-C 107.167 -1.419 . . . . 0.0 107.167 179.226 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 34.9 mm-40 -88.65 174.73 7.87 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 122.094 0.95 . . . . 0.0 110.082 179.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -77.14 143.35 39.19 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 177.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 69.63 -1.07 2.4 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 125.436 1.495 . . . . 0.0 112.698 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -67.2 151.34 47.72 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 127.177 2.191 . . . . 0.0 110.976 -178.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.6 m -80.51 127.58 32.6 Favored 'General case' 0 C--N 1.324 -0.535 0 C-N-CA 123.272 0.629 . . . . 0.0 110.431 -178.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.2 mm -85.08 96.4 4.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.264 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 179.113 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' MET . . . . . 0.426 ' H ' HD11 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -82.79 170.2 15.29 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 177.37 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.426 ' CD ' ' H ' ' A' ' 61' ' ' GLU . 17.8 mp0 -76.18 -34.69 59.33 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 125.198 1.399 . . . . 0.0 109.658 -179.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -64.56 -29.03 70.06 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 123.09 0.556 . . . . 0.0 111.334 179.144 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.426 HD11 ' H ' ' A' ' 60' ' ' MET . 73.9 mt -76.1 -0.18 21.01 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.79 1.236 . . . . 0.0 113.229 -179.385 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.36 147.2 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 121.466 1.939 . . . . 0.0 110.751 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.45 164.43 11.54 Favored 'General case' 0 C--O 1.239 0.507 0 CA-C-O 123.256 1.503 . . . . 0.0 114.079 -179.014 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -81.49 96.55 7.45 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.117 179.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 52.7 t-80 -71.18 88.17 0.81 Allowed 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 124.061 0.944 . . . . 0.0 108.821 179.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -178.95 142.02 5.16 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 107.593 -2.203 . . . . 0.0 107.593 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -157.01 -24.91 0.09 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 179.212 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 22.4 ttmm -70.11 134.43 48.17 Favored 'General case' 0 C--O 1.236 0.342 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 80.1 mt -130.98 149.52 33.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -142.67 74.29 1.44 Allowed 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 125.706 1.602 . . . . 0.0 106.939 179.556 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 11.4 m -72.38 63.77 0.56 Allowed 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.05 1.34 . . . . 0.0 110.527 179.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 34.4 t -158.96 174.09 15.5 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 125.35 1.46 . . . . 0.0 108.03 -179.535 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -173.35 177.39 45.77 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 127.203 2.335 . . . . 0.0 107.693 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -68.76 155.36 68.98 Favored 'Trans proline' 0 N--CA 1.456 -0.706 0 C-N-CA 121.683 1.588 . . . . 0.0 109.342 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 67.3 m -152.3 35.67 0.52 Allowed 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.318 1.047 . . . . 0.0 109.718 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 12.2 m -154.16 169.47 23.5 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 126.01 1.724 . . . . 0.0 107.175 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.452 0 C-N-CA 127.589 2.519 . . . . 0.0 106.918 -179.756 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.698 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.5 t -67.99 -178.64 1.04 Allowed 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.419 1.488 . . . . 0.0 112.077 -179.532 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.2 t -70.79 131.42 43.79 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 125.279 1.431 . . . . 0.0 109.827 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.16 149.28 20.4 Favored Glycine 0 N--CA 1.446 -0.693 0 N-CA-C 107.703 -2.159 . . . . 0.0 107.703 178.599 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.0 p -106.78 -6.28 17.87 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 126.006 1.722 . . . . 0.0 113.012 -179.251 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.7 t -66.29 -10.55 43.6 Favored 'General case' 0 CA--C 1.535 0.381 0 N-CA-C 115.848 1.796 . . . . 0.0 115.848 -178.625 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.2 -160.47 36.49 Favored Glycine 0 CA--C 1.521 0.439 0 CA-C-N 119.636 1.107 . . . . 0.0 110.753 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.4 t -137.37 163.17 31.69 Favored 'General case' 0 C--O 1.239 0.532 0 C-N-CA 123.94 0.896 . . . . 0.0 109.324 179.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.0 t -74.06 136.19 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.1 m -130.37 158.95 42.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 C-N-CA 125.426 1.49 . . . . 0.0 107.805 178.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.96 107.2 5.2 Favored 'General case' 0 N--CA 1.443 -0.797 0 N-CA-C 104.733 -2.321 . . . . 0.0 104.733 177.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 37.6 tttt -59.75 -24.09 63.76 Favored 'General case' 0 N--CA 1.464 0.239 0 O-C-N 121.6 -0.687 . . . . 0.0 111.857 -179.265 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.1 m -145.86 169.52 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 C-N-CA 125.679 1.592 . . . . 0.0 109.123 -178.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 36.8 tttm -72.71 128.32 35.19 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 103.386 -2.82 . . . . 0.0 103.386 176.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.5 mt -122.69 115.22 29.64 Favored Pre-proline 0 C--N 1.333 -0.143 0 C-N-CA 125.09 1.356 . . . . 0.0 111.122 -176.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -70.65 153.98 64.49 Favored 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 121.077 1.185 . . . . 0.0 110.463 178.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -54.2 149.36 9.81 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.671 1.588 . . . . 0.0 111.436 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.13 -2.7 64.54 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 123.798 0.714 . . . . 0.0 114.431 179.47 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 12.8 m -81.76 143.63 31.67 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 119.179 1.49 . . . . 0.0 109.809 -179.601 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 39.9 mm -84.41 125.99 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.916 -1.883 . . . . 0.0 105.916 178.07 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 45.4 mt -66.38 144.83 56.3 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 124.434 1.094 . . . . 0.0 110.893 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 40.1 p -139.3 165.88 26.02 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 178.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.6 mmt -67.08 -9.82 43.46 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.914 -0.492 . . . . 0.0 110.507 178.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -88.83 -2.83 58.78 Favored 'General case' 0 N--CA 1.471 0.579 0 O-C-N 120.353 -1.467 . . . . 0.0 110.88 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 36.7 mtm -125.11 4.81 7.89 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 124.944 1.298 . . . . 0.0 110.961 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.8 mt -135.8 147.33 48.29 Favored 'General case' 0 CA--C 1.512 -0.506 0 O-C-N 121.163 -0.961 . . . . 0.0 109.326 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.9 t -159.46 177.98 10.39 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 178.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.1 132.82 68.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 178.713 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.451 ' HZ2' ' CG ' ' A' ' 56' ' ' ASP . 25.1 mmtp -91.51 -173.04 3.44 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 178.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.86 96.83 4.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 O-C-N 120.948 -1.095 . . . . 0.0 108.856 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.16 -82.71 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -157.02 160.7 30.51 Favored Pre-proline 0 CA--C 1.546 0.816 0 C-N-CA 125.529 1.532 . . . . 0.0 109.132 -179.04 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -66.46 13.02 0.14 Allowed 'Trans proline' 0 CA--C 1.54 0.781 1 C-N-CA 126.321 4.681 . . . . 0.0 116.94 -179.039 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.0 ptmt -54.06 114.38 1.58 Allowed 'General case' 0 C--O 1.221 -0.412 0 CA-C-N 119.287 0.949 . . . . 0.0 110.853 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 116.56 -81.03 0.3 Allowed Glycine 0 C--N 1.332 0.321 0 CA-C-N 119.625 1.102 . . . . 0.0 112.366 179.125 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -151.17 138.36 11.99 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 123.147 0.579 . . . . 0.0 111.822 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -68.13 134.77 32.6 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.357 2.038 . . . . 0.0 111.707 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -63.71 -22.49 69.76 Favored 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 122.439 2.093 . . . . 0.0 113.191 179.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -69.4 -8.6 48.0 Favored 'General case' 0 CA--C 1.534 0.341 0 CA-C-N 119.323 0.965 . . . . 0.0 112.404 179.461 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -119.78 10.39 11.62 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 124.794 1.238 . . . . 0.0 112.414 -178.508 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.3 tt -51.84 -31.17 13.05 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 O-C-N 121.326 -0.859 . . . . 0.0 113.078 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -54.63 -37.49 65.71 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 125.248 1.419 . . . . 0.0 112.278 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -77.95 -29.28 49.77 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 118.467 0.576 . . . . 0.0 111.042 179.182 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 78.0 mt -66.46 -34.54 78.18 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 179.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.1 t -69.58 105.18 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -179.004 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 119.81 -10.08 11.32 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.894 1.711 . . . . 0.0 112.587 -179.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 3.3 mtpp -82.16 154.39 25.52 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 119.228 1.514 . . . . 0.0 108.026 178.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.2 ttmt -95.69 135.15 37.76 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 5.1 m -75.81 143.45 13.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 177.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 73.4 mt -89.27 -14.94 34.71 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 124.399 1.08 . . . . 0.0 111.248 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.4 m -145.9 163.81 10.55 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 C-N-CA 126.395 1.878 . . . . 0.0 109.309 -178.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 4.9 m -75.76 127.4 32.96 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 105.731 -1.951 . . . . 0.0 105.731 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 89.2 t -105.93 148.74 10.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -98.66 170.55 8.71 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 123.626 0.77 . . . . 0.0 111.603 -179.066 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -67.78 132.75 48.01 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.451 ' CG ' ' HZ2' ' A' ' 29' ' ' LYS . 7.4 t70 67.91 9.39 7.1 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 129.327 3.051 . . . . 0.0 114.201 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -68.06 154.64 41.23 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 123.429 0.692 . . . . 0.0 110.253 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -84.81 124.97 32.18 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 123.246 0.618 . . . . 0.0 110.97 -178.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.9 mm -85.84 146.95 5.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 178.073 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 32.9 mtp -134.01 151.76 51.57 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 105.47 -2.048 . . . . 0.0 105.47 178.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.26 -26.96 61.63 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 123.562 0.745 . . . . 0.0 112.885 -178.765 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -76.62 -0.58 23.91 Favored 'General case' 0 N--CA 1.451 -0.408 0 C-N-CA 126.0 1.72 . . . . 0.0 114.768 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 61.6 mt -113.53 3.18 15.63 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.204 1.402 . . . . 0.0 112.364 -179.402 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.2 m -132.52 152.9 37.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-N 119.462 1.028 . . . . 0.0 112.453 -178.025 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -61.8 150.78 36.08 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.594 0.758 . . . . 0.0 110.109 179.292 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -95.88 -42.48 8.29 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 116.453 2.02 . . . . 0.0 116.453 -177.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 -136.05 73.2 1.45 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 124.266 1.026 . . . . 0.0 112.237 -177.712 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -75.38 169.17 54.75 Favored Glycine 0 CA--C 1.526 0.764 0 C-N-CA 124.227 0.918 . . . . 0.0 113.356 -178.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.02 144.6 20.18 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 126.855 2.062 . . . . 0.0 106.234 178.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 51.1 tttp -148.44 130.4 15.29 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 177.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 31.7 pt -60.76 152.68 5.46 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.46 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 3.0 ttmp? -149.72 153.56 37.12 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 126.958 2.103 . . . . 0.0 107.236 178.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 73.3 m -140.8 126.08 18.62 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 104.131 -2.544 . . . . 0.0 104.131 178.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 12.4 m -91.91 168.54 11.35 Favored 'General case' 0 C--O 1.239 0.511 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 179.39 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.91 78.38 0.25 Allowed Glycine 0 CA--C 1.527 0.818 0 CA-C-O 118.055 -1.414 . . . . 0.0 112.265 -179.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -69.99 167.96 23.24 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.695 2.263 . . . . 0.0 110.18 179.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 46.5 t -143.56 -173.27 3.91 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.81 1.644 . . . . 0.0 107.344 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 33.7 m -129.35 16.48 6.04 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 127.02 2.128 . . . . 0.0 109.898 179.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.254 1.346 0 C-N-CA 130.388 3.851 . . . . 0.0 106.108 179.736 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.358 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 42.7 p -80.33 109.07 14.47 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 179.245 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.3 t -64.86 174.83 1.7 Allowed 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.933 0.873 . . . . 0.0 110.713 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 153.08 89.46 0.07 OUTLIER Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 105.618 -2.993 . . . . 0.0 105.618 -179.37 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.9 m -123.49 95.38 4.56 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 125.331 1.452 . . . . 0.0 108.786 -179.208 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.4 m -168.6 173.82 7.14 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 127.861 2.464 . . . . 0.0 108.301 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 81.25 -164.74 46.13 Favored Glycine 0 C--N 1.336 0.541 0 C-N-CA 123.939 0.781 . . . . 0.0 111.995 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 55.7 p -137.74 155.58 48.92 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 124.224 1.01 . . . . 0.0 110.842 179.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 43.4 t -75.93 130.61 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 178.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 m -129.74 157.68 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 N-CA-C 105.122 -2.177 . . . . 0.0 105.122 177.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.05 128.9 36.62 Favored 'General case' 0 N--CA 1.444 -0.731 0 O-C-N 121.356 -0.84 . . . . 0.0 109.38 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 52.6 tttt -72.44 -27.49 62.36 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.075 0.55 . . . . 0.0 111.309 179.686 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.6 m -146.87 171.65 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 C-N-CA 127.092 2.157 . . . . 0.0 108.083 -179.473 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.3 tttt -70.58 124.67 24.79 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 178.58 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.3 mt -116.16 101.81 53.82 Favored Pre-proline 0 C--N 1.327 -0.384 0 N-CA-C 105.788 -1.93 . . . . 0.0 105.788 -178.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -63.31 159.05 41.53 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 120.896 1.064 . . . . 0.0 110.627 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 71.4 tt0 -54.83 149.03 11.96 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 179.512 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.94 4.89 73.46 Favored Glycine 0 CA--C 1.533 1.212 0 CA-C-O 119.045 -0.864 . . . . 0.0 114.576 179.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 18.9 m -92.11 150.85 20.71 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 119.667 1.734 . . . . 0.0 109.425 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 36.5 mm -89.5 135.97 24.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.439 0 C-N-CA 124.149 0.98 . . . . 0.0 110.108 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 25.9 mt -75.56 143.4 42.43 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.172 0.51 . . . . 0.0 109.808 178.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 33.2 p -138.55 154.13 48.74 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 17.4 mmt -59.71 -34.48 72.97 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-O 121.834 0.826 . . . . 0.0 110.332 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -64.81 -12.45 48.16 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 126.633 1.973 . . . . 0.0 114.055 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 33.1 mtm -117.74 6.26 12.34 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.22 1.008 . . . . 0.0 111.238 179.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.9 mt -119.41 153.21 35.56 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 179.429 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.7 t -151.93 172.59 16.0 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 105.558 -2.015 . . . . 0.0 105.558 178.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.65 122.0 46.21 Favored 'Isoleucine or valine' 0 C--O 1.237 0.424 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.203 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 15.3 ttmm -87.39 103.57 15.62 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.072 -2.196 . . . . 0.0 105.072 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 14.8 m -65.55 132.96 31.19 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.52 -64.62 0.27 Allowed Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -145.4 157.69 52.17 Favored Pre-proline 0 N--CA 1.453 -0.3 0 CA-C-O 118.604 -0.712 . . . . 0.0 111.712 -178.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -78.93 11.97 2.39 Favored 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 123.433 2.755 . . . . 0.0 112.599 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -51.74 110.07 0.43 Allowed 'General case' 0 N--CA 1.463 0.202 0 C-N-CA 125.455 1.502 . . . . 0.0 110.126 179.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.63 -99.33 0.56 Allowed Glycine 0 C--N 1.333 0.374 0 CA-C-N 119.193 0.906 . . . . 0.0 111.931 179.164 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -139.18 134.76 16.86 Favored Pre-proline 0 C--O 1.239 0.543 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -61.0 133.44 47.33 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.557 2.838 . . . . 0.0 111.554 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -72.52 -16.22 27.35 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 123.466 2.777 . . . . 0.0 113.408 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -67.42 -23.39 65.54 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 119.399 1.0 . . . . 0.0 110.028 178.301 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 47.1 m-20 -99.71 7.86 44.77 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 126.125 1.77 . . . . 0.0 111.167 -179.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.4 tt -51.72 -33.84 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 CA-C-N 120.395 1.452 . . . . 0.0 112.712 -179.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -60.98 -19.26 60.92 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 123.97 0.908 . . . . 0.0 112.006 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 -92.43 -27.58 17.39 Favored 'General case' 0 CA--C 1.52 -0.189 0 C-N-CA 124.701 1.2 . . . . 0.0 110.364 179.189 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 19.5 mt -67.97 -37.77 81.92 Favored 'General case' 0 CA--C 1.52 -0.188 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.1 t -58.98 137.72 21.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.09 -14.02 63.25 Favored Glycine 0 CA--C 1.53 0.996 0 CA-C-O 118.121 -1.377 . . . . 0.0 112.824 -179.188 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 40.8 mttm -75.41 166.66 23.25 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 120.458 2.129 . . . . 0.0 108.812 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -119.76 132.42 55.62 Favored 'General case' 0 CA--C 1.521 -0.165 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.333 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -74.99 157.12 6.09 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-N 118.438 0.563 . . . . 0.0 112.461 179.81 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.08 -19.14 16.64 Favored 'General case' 0 C--O 1.225 -0.229 0 C-N-CA 126.628 1.971 . . . . 0.0 110.49 178.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 35.4 m -142.43 158.74 19.46 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 124.208 1.003 . . . . 0.0 109.445 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 58.0 m -72.23 99.51 2.39 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.919 1.688 . . . . 0.0 109.562 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 47.4 t -78.83 151.99 5.01 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 179.294 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -100.86 169.44 8.98 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 126.072 1.749 . . . . 0.0 110.655 179.371 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -69.33 141.62 54.22 Favored 'General case' 0 C--O 1.239 0.52 0 N-CA-C 106.001 -1.851 . . . . 0.0 106.001 176.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 67.13 1.22 2.3 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 128.182 2.593 . . . . 0.0 112.413 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.44 149.55 48.2 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.15 0.98 . . . . 0.0 109.938 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 94.6 m -85.26 124.51 31.97 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-O 122.326 1.06 . . . . 0.0 110.94 -177.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 mm -82.18 142.01 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 33.6 mtp -142.25 155.14 45.22 Favored 'General case' 0 C--O 1.237 0.399 0 C-N-CA 125.018 1.327 . . . . 0.0 108.008 179.072 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -61.22 -34.7 75.53 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 124.519 1.128 . . . . 0.0 112.388 -179.106 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -69.56 -2.85 12.56 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 113.688 0.996 . . . . 0.0 113.688 -179.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 54.3 mt -105.04 5.77 32.8 Favored 'General case' 0 C--O 1.234 0.285 0 C-N-CA 125.696 1.598 . . . . 0.0 112.827 -178.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 36.0 m -124.79 160.35 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 120.272 1.396 . . . . 0.0 112.068 -179.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -124.71 173.05 8.81 Favored 'General case' 0 C--O 1.238 0.49 0 C-N-CA 127.079 2.151 . . . . 0.0 110.434 -179.21 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 53.7 t-20 -62.85 135.5 57.36 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.409 1.884 . . . . 0.0 109.402 179.215 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -56.51 -40.31 74.79 Favored 'General case' 0 CA--C 1.537 0.474 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.451 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -123.95 81.07 0.35 Allowed Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 126.386 1.946 . . . . 0.0 109.337 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -72.22 38.21 0.07 Allowed 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 124.982 1.313 . . . . 0.0 111.487 179.052 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 20.7 ptmt -66.73 170.97 5.67 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 120.561 -1.337 . . . . 0.0 109.838 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 4.7 mp -125.59 147.53 30.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 C-N-CA 123.509 0.723 . . . . 0.0 109.377 -178.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 80.6 tttt -131.77 -78.32 0.51 Allowed 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 127.203 2.201 . . . . 0.0 105.246 179.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -67.8 153.59 43.39 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 124.484 1.114 . . . . 0.0 110.193 179.386 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.7 t -65.73 -37.73 87.21 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 89.92 93.13 1.19 Allowed Glycine 0 CA--C 1.527 0.789 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_endo -76.9 15.38 1.12 Allowed 'Trans proline' 0 CA--C 1.543 0.967 0 C-N-CA 123.676 2.917 . . . . 0.0 112.473 179.512 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.7 t -59.43 162.15 5.1 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 125.141 1.376 . . . . 0.0 111.06 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.8 t -149.21 173.33 13.58 Favored 'General case' 0 N--CA 1.447 -0.609 0 C-N-CA 124.832 1.253 . . . . 0.0 108.521 179.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.175 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 -179.884 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.668 0 N-CA-C 109.971 -1.252 . . . . 0.0 109.971 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.4 m -136.16 52.33 1.98 Allowed 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.774 1.23 . . . . 0.0 109.871 -179.574 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 m -64.24 173.04 2.15 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 125.41 1.484 . . . . 0.0 112.392 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -74.97 -37.96 42.26 Favored Glycine 0 CA--C 1.53 0.986 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 179.182 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 62.9 m -63.0 160.93 13.95 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 125.507 1.523 . . . . 0.0 112.253 -179.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.5 t 166.5 160.35 0.03 OUTLIER 'General case' 0 C--O 1.236 0.358 1 C-N-CA 132.101 4.161 . . . . 0.0 103.372 179.627 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 73.38 175.86 31.09 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.23 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.2 m -146.61 145.19 29.99 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.206 0.527 . . . . 0.0 111.982 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 21.8 t -69.88 128.82 33.79 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 C-N-CA 123.994 0.918 . . . . 0.0 109.837 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.3 m -123.62 152.68 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 178.178 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.01 111.57 4.49 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 178.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 18.6 tttp -59.59 -30.56 68.76 Favored 'General case' 0 CA--C 1.536 0.426 0 O-C-N 121.068 -1.02 . . . . 0.0 113.561 -178.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.8 m -141.98 170.82 11.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 128.747 2.819 . . . . 0.0 106.91 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 42.9 tttm -66.59 137.77 56.99 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 178.401 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.1 mt -121.7 103.43 40.61 Favored Pre-proline 0 N--CA 1.462 0.155 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -179.304 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -66.65 149.99 83.82 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 121.085 1.19 . . . . 0.0 109.561 179.281 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -52.32 146.17 9.84 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 125.448 1.499 . . . . 0.0 110.749 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.65 3.13 86.68 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 123.724 0.678 . . . . 0.0 114.508 178.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 22.6 m -91.49 147.67 22.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 118.361 1.081 . . . . 0.0 109.779 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 49.3 mm -87.09 135.59 24.89 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 C-N-CA 123.982 0.913 . . . . 0.0 108.611 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 13.9 mt -74.16 147.09 42.94 Favored 'General case' 0 CA--C 1.519 -0.226 0 C-N-CA 125.288 1.435 . . . . 0.0 110.841 179.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 53.8 p -140.96 157.69 44.99 Favored 'General case' 0 C--O 1.238 0.47 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.167 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 7.6 mmt -62.93 -20.43 65.19 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.266 0.939 . . . . 0.0 110.881 178.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -72.0 -21.28 61.58 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.226 0.921 . . . . 0.0 110.25 178.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.7 mtm -105.51 4.98 31.08 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 126.328 1.851 . . . . 0.0 111.62 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 80.3 mt -122.94 141.26 52.12 Favored 'General case' 0 CA--C 1.516 -0.339 0 O-C-N 121.135 -0.978 . . . . 0.0 108.647 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.6 t -153.22 115.48 4.39 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.729 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 9' ' ' VAL . 0.2 OUTLIER -71.4 139.04 20.52 Favored 'Isoleucine or valine' 0 C--O 1.238 0.479 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.16 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.53 112.33 25.38 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 104.542 -2.392 . . . . 0.0 104.542 177.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.79 127.83 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 178.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 171.27 -85.86 0.08 OUTLIER Glycine 0 C--N 1.334 0.468 0 C-N-CA 119.955 -1.117 . . . . 0.0 113.356 -179.04 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -138.91 160.78 61.48 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 118.162 0.981 . . . . 0.0 111.562 -178.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -72.78 5.85 2.72 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.406 2.737 . . . . 0.0 114.818 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 23.7 tttp -68.63 92.91 0.48 Allowed 'General case' 0 C--O 1.233 0.21 0 C-N-CA 124.928 1.291 . . . . 0.0 109.476 179.377 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 148.21 -91.78 0.15 Allowed Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -157.27 141.38 11.67 Favored Pre-proline 0 C--O 1.238 0.454 0 C-N-CA 124.974 1.31 . . . . 0.0 110.308 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -68.64 150.39 74.59 Favored 'Trans proline' 0 CA--C 1.538 0.699 0 C-N-CA 122.447 2.098 . . . . 0.0 112.737 -179.403 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 80.7 Cg_endo -79.59 -3.28 12.82 Favored 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 123.098 2.532 . . . . 0.0 113.639 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -73.15 -59.11 2.86 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -71.31 4.95 2.49 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 128.762 2.825 . . . . 0.0 113.748 -179.395 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.4 tt -48.88 -37.11 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.568 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -178.153 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -63.38 -13.95 44.95 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.083 0.953 . . . . 0.0 113.49 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -87.29 -30.38 20.91 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 123.381 0.672 . . . . 0.0 110.989 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 21.2 mt -67.66 -44.54 77.59 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.331 1.052 . . . . 0.0 108.775 -179.13 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 1.4 p -66.4 124.01 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.68 -15.47 29.21 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 125.664 1.602 . . . . 0.0 112.3 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 61.7 mttm -81.84 158.25 24.11 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 119.073 1.437 . . . . 0.0 110.469 179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -97.89 142.55 29.49 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 177.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.0 m -86.1 144.0 10.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 CA-C-N 119.397 0.999 . . . . 0.0 109.228 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 62.2 mt -92.92 -3.84 53.83 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 125.446 1.498 . . . . 0.0 112.96 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 28.7 m -148.93 161.98 5.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 C-N-CA 125.81 1.644 . . . . 0.0 109.715 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.4 m -85.28 100.64 11.93 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 104.118 -2.549 . . . . 0.0 104.118 176.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 44.7 t -82.4 143.34 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 179.389 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -88.94 176.52 6.98 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 123.73 0.812 . . . . 0.0 110.605 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -72.41 143.42 48.53 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.496 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 59.23 11.58 2.17 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 128.946 2.898 . . . . 0.0 113.806 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -75.04 154.25 38.06 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.09 1.356 . . . . 0.0 109.099 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.0 m -82.61 132.86 35.18 Favored 'General case' 0 C--N 1.33 -0.276 0 O-C-N 120.886 -1.134 . . . . 0.0 112.379 -178.329 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 41.4 mm -100.2 127.52 53.08 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.72 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 30.9 mtp -122.58 167.37 13.47 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -61.09 -23.65 65.64 Favored 'General case' 0 CA--C 1.538 0.505 0 O-C-N 120.929 -1.107 . . . . 0.0 113.95 -179.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -76.56 -4.79 44.7 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 125.54 1.536 . . . . 0.0 113.065 -179.538 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 19.1 mt -107.61 2.08 23.69 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.721 0.809 . . . . 0.0 112.249 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.4 m -127.22 159.05 37.98 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 CA-C-N 119.37 0.986 . . . . 0.0 111.704 -178.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -70.99 159.66 34.34 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 125.622 1.569 . . . . 0.0 113.569 -179.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 21.2 t30 -95.55 105.53 17.51 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 105.23 -2.137 . . . . 0.0 105.23 177.602 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 31.2 p-80 -39.58 -45.04 1.55 Allowed 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 127.503 2.321 . . . . 0.0 110.2 179.088 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.85 82.45 0.18 Allowed Glycine 0 C--N 1.337 0.639 0 C-N-CA 123.804 0.716 . . . . 0.0 112.004 178.521 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 18.0 ttmt -116.79 50.14 1.1 Allowed 'General case' 0 CA--C 1.518 -0.253 0 O-C-N 122.132 -0.628 . . . . 0.0 111.064 179.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 5.0 tmmm? -149.12 123.07 9.38 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 104.141 -2.54 . . . . 0.0 104.141 177.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 97.4 mt -139.0 136.29 42.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 104.685 -2.339 . . . . 0.0 104.685 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -140.58 150.15 43.27 Favored 'General case' 0 C--O 1.235 0.301 0 C-N-CA 124.847 1.259 . . . . 0.0 108.092 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.0 p -146.43 69.46 1.19 Allowed 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 179.142 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 61.41 8.75 2.3 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.571 1.548 . . . . 0.0 114.78 -179.154 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.4 177.98 52.73 Favored Glycine 0 CA--C 1.534 1.271 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 178.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -69.29 163.62 37.21 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 123.157 2.571 . . . . 0.0 113.108 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.8 p -83.43 73.18 10.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.358 1.463 . . . . 0.0 109.803 179.472 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 34.2 p -62.52 -18.23 61.48 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 123.113 0.565 . . . . 0.0 110.887 178.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.439 -1.123 0 C-N-CA 130.294 3.807 . . . . 0.0 105.121 179.512 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.786 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 84.7 p -129.14 151.32 49.94 Favored 'General case' 0 C--O 1.24 0.593 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -75.24 105.69 4.41 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 O-C-N 122.014 -0.429 . . . . 0.0 111.109 -179.434 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.0 m -102.86 152.82 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-O 122.654 1.216 . . . . 0.0 107.769 178.088 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.58 128.28 35.31 Favored 'General case' 0 C--N 1.319 -0.722 0 C-N-CA 124.958 1.303 . . . . 0.0 107.94 178.097 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.52 ' HE2' ' HB ' ' A' ' 27' ' ' THR . 20.1 ttmm -75.86 -23.92 55.69 Favored 'General case' 0 C--N 1.327 -0.378 0 O-C-N 121.012 -1.055 . . . . 0.0 111.099 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.7 m -148.15 173.25 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 C-N-CA 126.589 1.956 . . . . 0.0 107.678 -179.329 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 54.5 tttp -67.42 127.87 34.3 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 177.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.3 mt -111.48 96.43 31.73 Favored Pre-proline 0 C--N 1.331 -0.206 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -61.09 145.29 99.1 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 121.576 1.518 . . . . 0.0 110.496 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.588 ' HA ' HG23 ' A' ' 49' ' ' VAL . 4.9 tm-20 -50.77 146.2 6.11 Favored 'General case' 0 C--O 1.238 0.486 0 C-N-CA 124.936 1.294 . . . . 0.0 110.799 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.55 -3.64 81.6 Favored Glycine 0 CA--C 1.531 1.051 0 CA-C-O 119.327 -0.707 . . . . 0.0 113.153 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 20.0 m -88.22 143.78 26.84 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 118.956 1.378 . . . . 0.0 110.704 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 13.2 mm -83.98 140.24 16.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 71.0 mt -73.83 149.4 41.64 Favored 'General case' 0 C--O 1.238 0.489 0 C-N-CA 123.515 0.726 . . . . 0.0 112.452 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 22.6 p -146.94 157.4 43.62 Favored 'General case' 0 C--O 1.238 0.49 0 C-N-CA 127.526 2.33 . . . . 0.0 107.073 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 19.9 mmt -67.58 -24.15 65.47 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 118.826 0.739 . . . . 0.0 110.571 179.179 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -67.72 -12.67 61.01 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.476 -0.765 . . . . 0.0 112.207 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 47.7 mtm -115.45 10.78 15.83 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.078 0.951 . . . . 0.0 110.915 179.181 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -132.16 161.77 32.52 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 119.655 1.116 . . . . 0.0 112.53 -179.026 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.52 ' HB ' ' HE2' ' A' ' 12' ' ' LYS . 12.6 t -159.31 170.93 20.76 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 127.847 2.459 . . . . 0.0 107.294 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -125.36 110.87 25.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 178.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -76.68 91.73 3.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.8 p -54.53 125.54 9.43 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 C-N-CA 126.288 1.835 . . . . 0.0 106.591 178.713 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.65 -61.73 0.28 Allowed Glycine 0 N--CA 1.45 -0.417 0 CA-C-O 119.687 -0.507 . . . . 0.0 112.155 -179.513 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -148.7 148.65 28.63 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-N 118.313 1.056 . . . . 0.0 110.419 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -80.47 44.02 1.65 Allowed 'Trans proline' 0 CA--C 1.548 1.191 0 C-N-CA 123.645 2.896 . . . . 0.0 110.729 179.358 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 24.5 ttmt -84.85 92.8 8.35 Favored 'General case' 0 CA--C 1.521 -0.16 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.14 -132.59 6.74 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 179.633 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.462 ' CD2' ' HD2' ' A' ' 37' ' ' PRO . 0.6 OUTLIER -94.02 139.93 22.75 Favored Pre-proline 0 C--O 1.238 0.462 0 C-N-CA 124.805 1.242 . . . . 0.0 110.215 -179.727 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.462 ' HD2' ' CD2' ' A' ' 36' ' ' TYR . 83.9 Cg_endo -75.17 148.77 35.1 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.022 1.815 . . . . 0.0 112.104 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -75.99 -0.82 10.7 Favored 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 122.962 2.441 . . . . 0.0 111.709 178.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -81.55 -49.79 10.14 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.629 1.572 . . . . 0.0 108.794 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 -85.65 6.28 28.21 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.767 1.227 . . . . 0.0 111.344 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.0 tt -44.1 -41.66 1.81 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 C-N-CA 126.506 1.922 . . . . 0.0 114.607 -178.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -60.49 -32.61 71.6 Favored 'General case' 0 C--N 1.333 -0.138 0 O-C-N 121.575 -0.703 . . . . 0.0 112.003 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 33.7 m-80 -63.63 -30.42 71.53 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 123.377 0.671 . . . . 0.0 110.95 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.3 mt -71.93 -42.57 66.51 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 123.377 0.671 . . . . 0.0 109.828 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.2 t -67.2 93.73 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-O 122.212 1.006 . . . . 0.0 109.18 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 137.05 -11.7 3.88 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 126.202 1.858 . . . . 0.0 112.286 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -84.39 166.4 17.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 118.924 1.362 . . . . 0.0 109.069 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -110.3 139.58 45.35 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.588 HG23 ' HA ' ' A' ' 17' ' ' GLU . 13.5 m -81.99 150.35 4.49 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 O-C-N 123.583 0.552 . . . . 0.0 110.301 179.046 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 91.9 mt -101.01 -10.43 20.55 Favored 'General case' 0 C--O 1.233 0.226 0 C-N-CA 125.364 1.466 . . . . 0.0 111.88 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.4 160.56 14.99 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 C-N-CA 124.529 1.132 . . . . 0.0 109.154 178.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 11.6 m -78.65 99.88 6.77 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 14.9 t -73.2 150.41 7.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 179.036 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -102.55 168.12 9.49 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 123.589 0.756 . . . . 0.0 109.265 178.358 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 72.4 tt0 -61.51 144.18 54.7 Favored 'General case' 0 CA--C 1.538 0.495 0 O-C-N 121.413 -0.804 . . . . 0.0 108.834 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . 0.349 0.1 OUTLIER 56.92 13.06 1.35 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 128.077 2.551 . . . . 0.0 114.543 179.699 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -78.33 153.72 31.46 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 124.077 0.951 . . . . 0.0 112.403 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 20.0 m -81.43 113.07 19.25 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 124.75 1.22 . . . . 0.0 111.771 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.4 mm -76.88 144.31 11.83 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 3.0 mmt -134.53 161.21 35.7 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 125.877 1.671 . . . . 0.0 110.637 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -67.46 -29.15 68.53 Favored 'General case' 0 N--CA 1.467 0.378 0 O-C-N 121.354 -0.841 . . . . 0.0 111.773 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -74.01 -11.31 60.29 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 119.305 0.957 . . . . 0.0 112.486 179.527 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 69.6 mt -94.56 -4.43 47.94 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.341 1.057 . . . . 0.0 111.646 -179.339 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 m -122.54 140.36 46.59 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-N 120.162 1.346 . . . . 0.0 108.642 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 48.1 t0 . . . . . 0 C--O 1.24 0.59 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.902 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.5 p -139.83 161.46 37.52 Favored 'General case' 0 C--O 1.241 0.617 0 C-N-CA 125.758 1.623 . . . . 0.0 109.303 -179.62 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.2 t -85.88 133.17 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.8 m -129.38 160.62 40.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 178.184 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.4 118.78 12.71 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 126.38 1.872 . . . . 0.0 109.106 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.8 ttmm -68.01 -28.41 67.39 Favored 'General case' 0 N--CA 1.469 0.524 0 O-C-N 120.937 -1.102 . . . . 0.0 111.011 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.9 m -145.75 168.14 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 C-N-CA 127.778 2.431 . . . . 0.0 106.98 -179.399 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 80.9 tttt -68.81 128.78 37.88 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.76 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 8.2 mt -111.61 103.88 55.54 Favored Pre-proline 0 CA--C 1.538 0.507 0 C-N-CA 124.967 1.307 . . . . 0.0 108.552 -178.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -69.96 147.74 62.21 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 121.949 1.766 . . . . 0.0 110.704 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 7.3 tm-20 -49.22 139.65 10.83 Favored 'General case' 0 C--O 1.237 0.425 0 C-N-CA 123.909 0.884 . . . . 0.0 111.413 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.04 -3.57 84.56 Favored Glycine 0 CA--C 1.523 0.551 0 CA-C-N 115.571 -0.74 . . . . 0.0 112.942 179.575 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.4 m -82.53 140.37 33.34 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 118.756 1.278 . . . . 0.0 109.591 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.4 mm -78.73 135.35 26.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 105.424 -2.065 . . . . 0.0 105.424 178.119 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 32.2 mt -75.35 131.52 40.31 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.751 0.82 . . . . 0.0 109.304 179.628 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.4 p -127.83 161.36 29.21 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.759 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 13.2 mmt -61.76 -27.49 68.77 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 121.878 -0.514 . . . . 0.0 111.257 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -74.58 -7.9 54.62 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.884 0.874 . . . . 0.0 113.06 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 70.4 mtm -113.94 7.7 16.99 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 119.27 0.941 . . . . 0.0 111.25 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -123.64 152.68 41.71 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 124.368 1.067 . . . . 0.0 109.36 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.9 t -150.3 161.73 41.89 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 98.5 t -111.67 103.73 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 -178.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 9.5 tppt? -78.15 102.84 7.73 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 178.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.0 t -67.1 122.99 19.21 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 N-CA-C 104.438 -2.431 . . . . 0.0 104.438 178.131 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 170.18 -64.19 0.17 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-O 118.89 -0.95 . . . . 0.0 114.397 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -147.94 156.92 44.07 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 118.852 1.326 . . . . 0.0 110.421 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -79.31 0.72 9.79 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 123.666 2.911 . . . . 0.0 113.532 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.6 ttmt -60.44 106.99 0.6 Allowed 'General case' 0 CA--C 1.529 0.155 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 142.37 -105.56 0.41 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 123.758 0.694 . . . . 0.0 111.819 179.683 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -144.67 143.05 20.04 Favored Pre-proline 0 C--O 1.238 0.485 0 N-CA-C 106.347 -1.723 . . . . 0.0 106.347 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.45 132.11 23.13 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.735 2.29 . . . . 0.0 113.162 -178.474 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -71.15 -19.49 29.61 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 122.193 1.929 . . . . 0.0 112.257 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 24.5 mp0 -65.04 -31.92 73.38 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 119.586 1.085 . . . . 0.0 110.191 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -106.28 17.57 23.26 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 125.148 1.379 . . . . 0.0 111.998 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.8 tt -50.33 -32.84 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 125.146 1.379 . . . . 0.0 112.366 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -56.73 -25.01 53.62 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 124.193 0.997 . . . . 0.0 112.089 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -81.39 -17.33 49.35 Favored 'General case' 0 C--N 1.339 0.127 0 C-N-CA 123.487 0.715 . . . . 0.0 112.101 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 72.3 mt -76.65 -34.55 58.27 Favored 'General case' 0 C--O 1.225 -0.221 0 CA-C-N 119.219 0.918 . . . . 0.0 108.701 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 63.3 t -62.7 128.98 25.46 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 98.1 -16.78 59.64 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 125.484 1.516 . . . . 0.0 111.09 -178.391 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 82.6 mttt -75.4 168.75 19.4 Favored 'General case' 0 C--N 1.344 0.354 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 178.617 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.5 ttmp? -125.69 135.01 51.65 Favored 'General case' 0 CA--C 1.508 -0.656 0 O-C-N 121.236 -0.915 . . . . 0.0 108.785 -179.627 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.7 m -67.7 141.13 18.12 Favored 'Isoleucine or valine' 0 C--O 1.24 0.602 0 O-C-N 123.97 0.794 . . . . 0.0 110.113 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 86.5 mt -93.74 -14.44 26.28 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 126.12 1.768 . . . . 0.0 112.256 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 22.7 m -146.63 158.85 10.51 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 C-N-CA 126.317 1.847 . . . . 0.0 108.2 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 88.6 m -70.84 101.36 2.11 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 178.235 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 45.5 t -79.77 119.81 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -72.36 166.9 21.59 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 122.399 1.095 . . . . 0.0 109.401 178.633 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 52.6 tt0 -61.03 143.77 54.71 Favored 'General case' 0 N--CA 1.449 -0.52 0 O-C-N 121.438 -0.789 . . . . 0.0 109.521 -179.392 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.8 t70 64.15 3.71 1.84 Allowed 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.52 1.928 . . . . 0.0 113.587 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -71.71 155.12 40.83 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.866 0.841 . . . . 0.0 109.338 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.2 m -71.83 127.0 31.17 Favored 'General case' 0 N--CA 1.436 -1.151 0 C-N-CA 126.057 1.743 . . . . 0.0 110.797 -178.595 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.4 mm -90.7 137.58 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 N-CA-C 103.812 -2.662 . . . . 0.0 103.812 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 34.7 mtp -140.92 -170.89 3.13 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 123.662 0.785 . . . . 0.0 110.501 -178.67 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -86.27 -37.58 18.43 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 6.2 pm0 -64.45 -11.76 36.71 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.446 1.098 . . . . 0.0 112.779 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 71.4 mt -101.19 2.4 40.02 Favored 'General case' 0 C--O 1.227 -0.124 0 C-N-CA 125.436 1.494 . . . . 0.0 112.319 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 10.3 m -135.35 155.13 36.7 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-N 121.435 1.925 . . . . 0.0 114.399 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 49.9 p30 . . . . . 0 C--O 1.236 0.394 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.394 178.269 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.293 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 79.5 p -144.31 159.04 43.38 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-N 117.853 0.826 . . . . 0.0 111.353 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 97.6 t -71.73 133.31 32.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.37 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.496 HG11 ' HE3' ' A' ' 29' ' ' LYS . 14.6 m -136.02 157.88 38.48 Favored 'Isoleucine or valine' 0 C--O 1.24 0.601 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 178.283 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.87 124.46 24.38 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 44.2 tttt -77.14 -27.11 53.77 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 121.911 -0.493 . . . . 0.0 111.653 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.4 m -144.29 168.15 10.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 C-N-CA 127.602 2.361 . . . . 0.0 106.824 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 78.6 tttt -69.06 117.81 11.17 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 178.076 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 19.9 mt -102.75 112.26 65.53 Favored Pre-proline 0 CA--C 1.533 0.307 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.509 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.93 148.95 32.41 Favored 'Trans proline' 0 N--CA 1.445 -1.342 0 C-N-CA 121.7 1.6 . . . . 0.0 109.428 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 tm-20 -51.68 145.61 9.0 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 124.135 0.974 . . . . 0.0 110.384 179.101 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.38 -3.58 86.47 Favored Glycine 0 CA--C 1.529 0.927 0 CA-C-O 119.105 -0.83 . . . . 0.0 114.89 178.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.6 m -89.78 152.4 21.32 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 118.389 1.095 . . . . 0.0 110.054 -179.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 48.7 mm -90.01 141.54 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.478 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 65.9 mt -75.9 139.29 41.56 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.373 0.606 . . . . 0.0 111.489 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 68.3 p -134.28 155.59 49.94 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 126.12 1.768 . . . . 0.0 106.393 178.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 25.8 mtp -67.47 -12.45 60.32 Favored 'General case' 0 CA--C 1.545 0.766 0 CA-C-N 119.594 1.088 . . . . 0.0 110.16 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.6 m-20 -72.84 -19.9 61.23 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 120.828 -1.17 . . . . 0.0 112.147 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 56.1 mtm -115.08 10.37 16.15 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 124.691 1.196 . . . . 0.0 111.59 -178.732 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 36.0 mt -130.82 148.74 52.63 Favored 'General case' 0 CA--C 1.515 -0.37 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -178.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.8 t -157.14 179.14 9.56 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.4 t -124.56 113.52 36.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 118.826 0.739 . . . . 0.0 109.76 -178.742 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.496 ' HE3' HG11 ' A' ' 10' ' ' VAL . 2.7 ttpp -79.37 93.4 5.33 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 179.118 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 t -59.63 98.62 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -172.17 -46.13 0.04 OUTLIER Glycine 0 C--N 1.339 0.716 0 CA-C-O 117.494 -1.725 . . . . 0.0 115.559 -178.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -151.43 154.33 33.41 Favored Pre-proline 0 N--CA 1.464 0.241 0 CA-C-N 120.251 2.026 . . . . 0.0 110.6 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -76.49 -3.89 14.36 Favored 'Trans proline' 0 CA--C 1.534 0.504 0 C-N-CA 123.195 2.597 . . . . 0.0 113.066 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 3.6 tmmm? -63.73 107.05 1.09 Allowed 'General case' 0 CA--C 1.518 -0.252 0 O-C-N 121.132 -0.98 . . . . 0.0 108.419 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.429 ' HA2' ' SD ' ' A' ' 60' ' ' MET . . . 131.36 178.49 15.5 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 126.26 1.886 . . . . 0.0 109.889 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.526 ' CG ' HD11 ' A' ' 44' ' ' LEU . 7.3 t80 -57.07 134.02 80.45 Favored Pre-proline 0 C--O 1.24 0.603 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -61.98 131.04 33.13 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.168 1.912 . . . . 0.0 108.997 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.64 -19.06 48.39 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.261 1.974 . . . . 0.0 112.351 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -70.67 -10.85 60.32 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 113.304 0.853 . . . . 0.0 113.304 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -121.33 10.92 10.66 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 126.044 1.738 . . . . 0.0 111.582 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.5 tt -41.33 -37.42 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 C-N-CA 128.194 2.598 . . . . 0.0 113.792 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -60.39 -34.99 74.7 Favored 'General case' 0 CA--C 1.528 0.133 0 C-N-CA 125.58 1.552 . . . . 0.0 113.927 -179.165 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -59.46 -38.96 82.13 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 119.675 1.125 . . . . 0.0 112.044 -178.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.526 HD11 ' CG ' ' A' ' 36' ' ' TYR . 85.0 mt -72.55 -33.93 67.17 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 124.681 1.192 . . . . 0.0 111.9 -179.026 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 69.3 t -67.68 91.29 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 124.521 1.128 . . . . 0.0 108.302 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 139.12 -9.38 3.29 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 126.437 1.97 . . . . 0.0 112.629 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 92.1 mttt -82.41 171.14 14.5 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 119.039 1.419 . . . . 0.0 108.437 178.712 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 33.8 ttmt -110.15 136.93 48.61 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 178.117 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.4 m -80.74 146.27 7.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 O-C-N 121.786 -0.572 . . . . 0.0 109.961 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 92.8 mt -97.21 -14.19 21.57 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 125.906 1.682 . . . . 0.0 113.453 -178.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 16.7 m -146.32 158.0 11.41 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.0 m -77.23 101.6 6.29 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 70.8 t -80.23 138.89 19.04 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -85.12 170.03 13.32 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-O 122.054 0.93 . . . . 0.0 110.283 178.664 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -71.22 138.99 49.94 Favored 'General case' 0 N--CA 1.447 -0.597 0 O-C-N 121.184 -0.947 . . . . 0.0 109.678 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.8 t70 72.3 4.18 4.92 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 127.671 2.389 . . . . 0.0 113.337 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -67.44 145.46 54.99 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.594 1.158 . . . . 0.0 109.387 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 25.4 m -73.24 129.0 37.09 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 179.36 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 26.2 mm -87.1 131.05 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' MET . . . . . 0.49 ' H ' HD12 ' A' ' 63' ' ' LEU . 82.0 mmm -124.55 161.02 27.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 126.235 1.814 . . . . 0.0 106.948 179.255 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.421 ' H ' ' CD ' ' A' ' 61' ' ' GLU . 1.1 pm0 -72.31 -27.25 62.32 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.825 1.65 . . . . 0.0 111.332 179.592 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.41 -14.42 62.91 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 124.419 1.088 . . . . 0.0 112.816 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.49 HD12 ' H ' ' A' ' 60' ' ' MET . 19.8 mt -93.29 -1.09 56.43 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 126.203 1.801 . . . . 0.0 112.148 -179.401 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.4 m -126.68 160.47 34.76 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 CA-C-N 119.707 1.14 . . . . 0.0 113.22 -178.479 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.541 0.606 0 C-N-CA 125.345 1.458 . . . . 0.0 109.091 178.593 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.301 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 10.7 p -94.02 134.12 36.76 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 118.264 1.032 . . . . 0.0 113.224 -178.373 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 98.9 t -68.27 132.67 32.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 176.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.29 155.6 40.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.533 0 C-N-CA 124.048 0.939 . . . . 0.0 109.174 179.098 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.72 117.04 12.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 177.536 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 42.6 tttp -63.58 -31.57 72.78 Favored 'General case' 0 C--N 1.33 -0.25 0 O-C-N 121.426 -0.796 . . . . 0.0 112.498 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m -142.3 169.99 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 C-N-CA 126.567 1.947 . . . . 0.0 107.012 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 39.1 tttt -64.17 127.18 30.33 Favored 'General case' 0 N--CA 1.454 -0.265 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.699 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.3 mt -111.89 100.69 49.54 Favored Pre-proline 0 CA--C 1.532 0.278 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 -179.425 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -65.16 151.43 85.54 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 N-CA-C 109.062 -1.168 . . . . 0.0 109.062 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -50.75 151.81 2.28 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.27 1.028 . . . . 0.0 111.384 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.62 -3.67 62.97 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 123.962 0.791 . . . . 0.0 113.971 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 99.1 m -81.42 145.89 30.56 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 118.191 0.995 . . . . 0.0 109.524 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.5 mm -88.74 130.86 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 178.045 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.555 ' HB3' HD11 ' A' ' 26' ' ' LEU . 30.7 mt -69.33 137.24 52.76 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 124.399 1.079 . . . . 0.0 110.734 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 73.4 p -135.39 159.03 42.86 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.383 1.073 . . . . 0.0 108.621 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 12.0 mmt -64.15 -17.86 63.89 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 118.114 0.415 . . . . 0.0 110.523 179.083 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -79.07 -16.45 56.77 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.966 0.906 . . . . 0.0 112.177 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 75.3 mtm -118.94 15.09 13.36 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.378 1.071 . . . . 0.0 109.971 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.555 HD11 ' HB3' ' A' ' 21' ' ' LEU . 42.9 mt -137.0 154.46 50.4 Favored 'General case' 0 CA--C 1.511 -0.553 0 O-C-N 120.959 -1.088 . . . . 0.0 110.034 -178.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.6 t -164.33 -179.54 6.14 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.449 HG21 ' HB3' ' A' ' 38' ' ' PRO . 1.2 p -134.01 112.6 16.7 Favored 'Isoleucine or valine' 0 C--O 1.234 0.287 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -73.99 114.86 12.78 Favored 'General case' 0 CA--C 1.511 -0.556 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.1 p -51.81 139.75 7.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 O-C-N 124.196 0.935 . . . . 0.0 109.702 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 138.0 -131.34 5.4 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.2 pm0 -75.66 133.92 73.09 Favored Pre-proline 0 CA--C 1.541 0.602 0 C-N-CA 125.211 1.404 . . . . 0.0 112.847 -179.19 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.06 61.3 7.17 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 124.673 3.582 . . . . 0.0 111.123 179.217 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -88.24 172.06 9.73 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 125.122 1.369 . . . . 0.0 107.866 178.38 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.05 -77.0 1.18 Allowed Glycine 0 N--CA 1.445 -0.715 0 N-CA-C 113.822 0.289 . . . . 0.0 113.822 178.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -149.07 139.97 13.87 Favored Pre-proline 0 N--CA 1.443 -0.789 0 C-N-CA 126.315 1.846 . . . . 0.0 107.016 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.38 136.91 48.95 Favored 'Trans proline' 0 N--CA 1.451 -0.98 0 N-CA-C 109.106 -1.152 . . . . 0.0 109.106 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.449 ' HB3' HG21 ' A' ' 28' ' ' VAL . 74.4 Cg_endo -68.76 -15.25 40.55 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 122.479 2.119 . . . . 0.0 113.354 -179.233 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -69.47 -27.49 65.26 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 119.959 1.254 . . . . 0.0 109.85 178.332 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -98.27 10.43 40.67 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.644 1.578 . . . . 0.0 111.382 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.8 tt -52.54 -38.87 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 C-N-CA 124.831 1.252 . . . . 0.0 111.672 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -68.91 -21.14 64.24 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.74 1.216 . . . . 0.0 112.661 -179.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -79.88 -38.04 33.53 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 119.087 0.858 . . . . 0.0 110.746 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.54 -30.0 70.36 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 123.032 0.533 . . . . 0.0 110.078 178.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 45.3 t -66.52 107.13 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.47 -11.95 10.37 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 126.503 2.002 . . . . 0.0 112.696 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.0 mttm -79.91 156.87 27.09 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-N 118.562 1.181 . . . . 0.0 109.215 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -101.51 138.57 38.34 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.182 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.7 m -78.05 138.77 19.68 Favored 'Isoleucine or valine' 0 C--O 1.24 0.605 0 N-CA-C 109.082 -0.711 . . . . 0.0 109.082 178.328 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 82.6 mt -84.85 -16.77 40.17 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.587 1.555 . . . . 0.0 111.636 179.489 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 15.3 m -149.69 163.5 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.175 0 C-N-CA 126.342 1.857 . . . . 0.0 108.648 -178.694 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 16.7 m -72.45 125.94 28.64 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 177.693 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 87.6 t -105.03 131.12 54.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -76.25 170.43 16.34 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-O 122.413 1.102 . . . . 0.0 112.759 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -65.67 136.91 56.91 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 63.14 7.98 3.06 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 126.035 1.734 . . . . 0.0 112.803 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -72.45 157.28 37.93 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 119.428 1.013 . . . . 0.0 111.286 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.1 m -79.75 119.34 22.53 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 123.944 0.898 . . . . 0.0 111.27 -178.802 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.6 mm -76.13 139.82 18.29 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 178.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 26.8 mtp -138.88 160.49 39.6 Favored 'General case' 0 C--O 1.231 0.094 0 C-N-CA 123.655 0.782 . . . . 0.0 109.474 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -60.77 -40.77 93.77 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 123.304 0.641 . . . . 0.0 109.456 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -65.66 4.33 0.6 Allowed 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 126.215 1.806 . . . . 0.0 114.551 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 34.9 mt -118.28 0.01 11.61 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.113 1.365 . . . . 0.0 109.694 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.5 m -131.23 162.58 39.01 Favored 'Isoleucine or valine' 0 C--N 1.343 0.285 0 C-N-CA 124.321 1.048 . . . . 0.0 111.148 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 36.4 t0 . . . . . 0 C--O 1.239 0.526 0 C-N-CA 124.975 1.31 . . . . 0.0 112.056 179.726 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.669 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 45.4 p -142.57 159.02 43.05 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.472 0.709 . . . . 0.0 109.794 -178.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 78.2 t -84.11 124.55 39.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 178.435 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.9 m -123.07 148.71 26.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.535 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.5 111.73 4.28 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 125.686 1.595 . . . . 0.0 107.997 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 81.1 tttt -64.95 -24.8 67.63 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 123.434 0.694 . . . . 0.0 112.714 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.6 m -148.92 165.79 3.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 127.116 2.167 . . . . 0.0 106.944 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -64.69 130.58 44.11 Favored 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 178.654 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 32.2 mt -118.78 101.27 50.59 Favored Pre-proline 0 CA--C 1.533 0.311 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.442 ' HA ' HG23 ' A' ' 52' ' ' THR . 36.6 Cg_endo -67.35 153.15 77.81 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 121.944 1.763 . . . . 0.0 112.346 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.4 ' HA ' HG23 ' A' ' 49' ' ' VAL . 9.6 tm-20 -58.17 146.03 35.02 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 122.289 1.042 . . . . 0.0 108.617 178.516 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.95 19.99 56.52 Favored Glycine 0 CA--C 1.53 0.995 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.953 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.1 m -117.44 156.25 28.27 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 125.976 1.71 . . . . 0.0 107.734 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 34.1 mm -101.5 143.25 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 C-N-CA 123.867 0.867 . . . . 0.0 108.716 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 23.0 mt -76.03 135.88 39.94 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 67.1 p -130.57 158.15 40.76 Favored 'General case' 0 C--O 1.238 0.477 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 13.4 mmt -63.22 -20.51 65.5 Favored 'General case' 0 CA--C 1.536 0.408 0 O-C-N 121.926 -0.484 . . . . 0.0 109.713 178.409 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -79.99 -18.41 50.36 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 126.27 1.828 . . . . 0.0 114.185 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 69.8 mtm -112.46 16.15 19.95 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 119.162 0.892 . . . . 0.0 111.697 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.1 mt -133.64 147.92 51.49 Favored 'General case' 0 C--O 1.238 0.456 0 C-N-CA 124.019 0.927 . . . . 0.0 110.666 -179.076 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.9 t -147.7 144.62 28.45 Favored 'General case' 0 CA--C 1.54 0.572 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 56.8 t -89.06 117.52 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 31.7 ttpt -59.84 -29.63 68.4 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 115.01 1.485 . . . . 0.0 115.01 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.6 t 47.65 66.42 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 CA-C-O 122.665 1.221 . . . . 0.0 109.278 -179.092 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.97 -66.24 0.01 OUTLIER Glycine 0 CA--C 1.521 0.435 0 C-N-CA 124.647 1.118 . . . . 0.0 111.042 -179.482 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -133.9 152.8 79.28 Favored Pre-proline 0 CA--C 1.529 0.158 0 C-N-CA 123.583 0.753 . . . . 0.0 111.598 -178.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.18 5.4 4.59 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 123.686 2.924 . . . . 0.0 113.131 179.209 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -72.26 115.12 11.13 Favored 'General case' 0 CA--C 1.518 -0.251 0 O-C-N 119.946 -1.721 . . . . 0.0 106.413 178.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.36 171.71 15.73 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.344 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -54.94 135.71 66.59 Favored Pre-proline 0 CA--C 1.541 0.61 0 CA-C-O 118.993 -0.527 . . . . 0.0 110.716 -179.216 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -67.94 150.73 78.26 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.806 2.337 . . . . 0.0 113.557 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -79.41 -4.34 13.6 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 123.437 2.758 . . . . 0.0 114.93 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 24.2 tp10 -82.43 -46.14 13.89 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 119.918 1.235 . . . . 0.0 108.124 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -79.71 7.38 8.62 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 125.86 1.664 . . . . 0.0 111.63 -179.575 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.7 tt -46.82 -43.13 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 C-N-CA 126.19 1.796 . . . . 0.0 112.909 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -58.91 -27.95 65.74 Favored 'General case' 0 C--O 1.227 -0.126 0 C-N-CA 123.1 0.56 . . . . 0.0 111.657 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -73.35 -36.82 66.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 49.2 mt -66.65 -38.96 87.94 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 119.123 0.874 . . . . 0.0 109.705 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 73.5 t -61.63 131.45 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.09 -11.09 69.69 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 118.792 -1.004 . . . . 0.0 111.699 -178.806 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 26.5 mttm -84.05 154.36 23.28 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-N 119.556 1.678 . . . . 0.0 110.615 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 39.4 ttmt -95.04 131.08 41.41 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 178.634 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.4 HG23 ' HA ' ' A' ' 17' ' ' GLU . 4.4 m -66.76 168.66 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 176.512 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 46.3 mt -114.28 -7.08 12.97 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 123.913 0.885 . . . . 0.0 112.44 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.8 m -156.83 162.31 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 126.952 2.101 . . . . 0.0 108.418 -178.781 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.442 HG23 ' HA ' ' A' ' 16' ' ' PRO . 31.9 m -72.94 109.66 6.66 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.003 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 57.4 t -85.96 131.04 35.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 179.291 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -78.05 167.49 21.37 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 123.652 0.781 . . . . 0.0 109.721 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -69.92 149.86 47.35 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 177.821 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 60.94 10.01 2.58 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 127.948 2.499 . . . . 0.0 111.59 -179.569 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -75.73 153.33 37.11 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 178.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 99.2 m -88.47 121.88 31.34 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.179 0.514 . . . . 0.0 110.932 -178.662 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 mm -74.18 138.51 21.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 178.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -131.37 157.92 42.13 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 124.368 1.067 . . . . 0.0 108.595 179.31 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -59.35 -27.8 66.26 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 124.715 1.206 . . . . 0.0 111.669 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -89.26 -4.15 58.27 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 119.173 0.897 . . . . 0.0 113.095 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 57.4 mt -96.57 15.8 20.61 Favored 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 124.352 1.061 . . . . 0.0 109.4 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.1 m -139.22 140.84 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 37.2 t70 . . . . . 0 C--N 1.327 -0.389 0 C-N-CA 125.598 1.559 . . . . 0.0 110.387 179.787 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.321 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -146.91 162.0 39.58 Favored 'General case' 0 C--O 1.239 0.513 0 C-N-CA 126.081 1.753 . . . . 0.0 110.963 179.046 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.2 t -70.0 140.47 18.54 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 C-N-CA 126.188 1.795 . . . . 0.0 112.282 -178.417 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.7 m -139.59 159.53 27.8 Favored 'Isoleucine or valine' 0 C--O 1.24 0.584 0 C-N-CA 126.601 1.961 . . . . 0.0 107.078 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -81.25 138.28 35.78 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.096 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -81.6 -22.33 37.78 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 123.447 0.699 . . . . 0.0 111.567 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.8 m -145.76 170.38 5.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 124.842 1.257 . . . . 0.0 108.254 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.6 tttm -72.41 104.05 3.65 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 105.549 -2.019 . . . . 0.0 105.549 177.74 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 7.3 mt -88.32 109.04 25.54 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-O 118.122 -0.942 . . . . 0.0 109.063 -178.758 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -69.67 149.39 67.4 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 CA-C-N 120.981 1.386 . . . . 0.0 109.983 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.422 ' HA ' HG23 ' A' ' 49' ' ' VAL . 27.9 tt0 -51.14 143.88 10.11 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.454 1.102 . . . . 0.0 110.565 179.434 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.38 2.0 90.27 Favored Glycine 0 C--N 1.338 0.641 0 CA-C-O 118.979 -0.901 . . . . 0.0 114.53 179.037 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 65.4 m -91.03 142.63 27.57 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 118.741 1.271 . . . . 0.0 109.708 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 5.0 mm -78.7 135.45 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.375 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 50.4 mt -74.29 141.85 45.26 Favored 'General case' 0 C--O 1.237 0.446 0 C-N-CA 124.774 1.23 . . . . 0.0 109.352 178.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 41.7 p -141.36 165.51 27.31 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 106.951 -1.499 . . . . 0.0 106.951 178.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -65.02 -22.2 66.96 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-N 118.116 0.416 . . . . 0.0 110.459 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -67.93 -30.5 69.82 Favored 'General case' 0 N--CA 1.464 0.263 0 C-N-CA 124.48 1.112 . . . . 0.0 111.495 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 71.1 mtm -105.92 10.52 32.37 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.491 1.117 . . . . 0.0 112.67 -177.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.0 mt -131.93 162.51 30.48 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 123.958 0.903 . . . . 0.0 109.013 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.5 t -169.84 174.86 5.45 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 179.113 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.4 t -114.99 156.75 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 177.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 23.8 ttpp -126.98 111.68 14.37 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 103.423 -2.806 . . . . 0.0 103.423 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.7 m -62.63 158.88 3.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 120.238 -0.585 . . . . 0.0 110.209 -179.113 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 130.76 -96.69 0.35 Allowed Glycine 0 C--N 1.333 0.371 0 CA-C-O 119.078 -0.846 . . . . 0.0 112.277 179.168 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -115.76 157.28 44.97 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 125.559 1.544 . . . . 0.0 113.486 -177.677 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -77.32 15.19 1.24 Allowed 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 124.562 3.508 . . . . 0.0 113.366 179.514 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 25.6 tptp -55.68 113.55 1.51 Allowed 'General case' 0 N--CA 1.465 0.311 0 O-C-N 120.699 -1.251 . . . . 0.0 108.5 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.33 -170.47 21.43 Favored Glycine 0 N--CA 1.451 -0.348 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.4 t80 -58.02 130.32 82.98 Favored Pre-proline 0 CA--C 1.544 0.719 0 CA-C-O 118.505 -0.76 . . . . 0.0 110.257 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -66.05 153.12 79.39 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.897 2.398 . . . . 0.0 111.797 -178.719 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_endo -77.23 -22.96 10.7 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 121.606 1.537 . . . . 0.0 113.893 -178.664 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -63.12 -40.92 99.01 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 119.83 1.195 . . . . 0.0 109.933 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -82.96 4.34 26.26 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-O 117.906 -1.045 . . . . 0.0 113.313 -178.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.6 tt -48.25 -35.03 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 CA-C-N 120.719 1.6 . . . . 0.0 113.763 -178.82 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -58.82 -28.49 66.07 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.508 0.723 . . . . 0.0 111.701 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 30.0 m-80 -71.53 -41.99 68.5 Favored 'General case' 0 CA--C 1.521 -0.161 0 C-N-CA 124.001 0.921 . . . . 0.0 109.234 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 38.1 mt -65.0 -42.17 94.73 Favored 'General case' 0 CA--C 1.519 -0.216 0 C-N-CA 123.054 0.541 . . . . 0.0 110.171 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.78 98.7 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 C-N-CA 124.345 1.058 . . . . 0.0 108.786 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.99 -14.19 6.65 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 126.321 1.915 . . . . 0.0 114.178 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -79.62 167.79 20.24 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 118.861 1.331 . . . . 0.0 110.426 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.05 137.82 42.22 Favored 'General case' 0 CA--C 1.512 -0.516 0 CA-C-O 118.075 -0.964 . . . . 0.0 109.599 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.422 HG23 ' HA ' ' A' ' 17' ' ' GLU . 3.3 m -77.02 138.14 21.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.37 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 78.3 mt -85.33 -15.88 41.84 Favored 'General case' 0 N--CA 1.462 0.148 0 C-N-CA 123.452 0.701 . . . . 0.0 112.182 179.689 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.2 m -148.04 164.47 5.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 30.7 m -69.66 140.86 53.68 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.077 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 84.9 t -115.14 152.8 16.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -110.71 166.69 10.81 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 123.966 0.907 . . . . 0.0 111.194 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -63.26 128.57 36.43 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 30.6 t70 68.73 8.21 6.61 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 128.09 2.556 . . . . 0.0 112.908 -179.399 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -67.25 162.6 22.28 Favored 'General case' 0 CA--C 1.533 0.298 0 O-C-N 121.005 -1.059 . . . . 0.0 108.438 179.26 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 77.7 m -95.08 123.0 38.32 Favored 'General case' 0 N--CA 1.468 0.435 0 O-C-N 120.131 -1.606 . . . . 0.0 113.181 -178.289 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 13.3 mm -74.38 146.41 9.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 3.3 mmt -140.26 158.56 43.85 Favored 'General case' 0 C--O 1.233 0.214 0 C-N-CA 126.404 1.882 . . . . 0.0 107.299 179.235 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.34 -32.32 73.71 Favored 'General case' 0 CA--C 1.528 0.123 0 O-C-N 122.141 -0.349 . . . . 0.0 111.762 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -72.07 -5.27 34.07 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -179.107 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 56.7 mt -103.77 9.57 36.99 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 124.24 1.016 . . . . 0.0 111.05 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.5 m -131.93 155.28 41.45 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 CA-C-N 119.758 1.163 . . . . 0.0 112.3 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 . . . . . 0 C--O 1.234 0.285 0 C-N-CA 125.608 1.563 . . . . 0.0 113.85 -179.547 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 CA-C-O 121.053 0.252 . . . . 0.0 113.234 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.411 ' HB3' ' O ' ' A' ' 34' ' ' LYS . 0.2 OUTLIER -122.52 134.32 54.56 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 127.245 2.218 . . . . 0.0 111.997 -177.877 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 61.2 t -67.73 129.44 32.29 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 28.2 m -132.88 151.42 34.31 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.23 128.4 36.11 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.474 ' HE3' ' HB ' ' A' ' 27' ' ' THR . 6.7 ttmt -72.75 -28.15 62.46 Favored 'General case' 0 C--N 1.327 -0.377 0 O-C-N 121.399 -0.813 . . . . 0.0 111.695 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.71 169.88 18.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 C-N-CA 125.762 1.625 . . . . 0.0 107.093 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 58.7 tttt -71.88 114.91 10.48 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 49.8 mt -100.2 106.77 43.88 Favored Pre-proline 0 CA--C 1.534 0.339 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.483 ' HA ' HG23 ' A' ' 52' ' ' THR . 42.8 Cg_endo -66.55 148.7 83.96 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 121.569 1.513 . . . . 0.0 110.72 179.297 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.45 ' HA ' HG23 ' A' ' 49' ' ' VAL . 52.0 tt0 -48.54 142.29 6.06 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 126.168 1.787 . . . . 0.0 110.38 179.476 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.36 0.46 86.76 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-O 118.012 -1.438 . . . . 0.0 113.768 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.1 m -91.3 154.88 18.93 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 120.355 2.078 . . . . 0.0 107.857 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.8 mm -89.29 145.91 6.82 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-N 119.509 1.05 . . . . 0.0 109.097 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 15.2 mt -80.36 137.7 36.59 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.245 0.618 . . . . 0.0 109.811 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 29.0 p -131.22 154.95 47.89 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 125.952 1.701 . . . . 0.0 107.342 179.261 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 12.4 mmt -60.82 -35.46 76.58 Favored 'General case' 0 CA--C 1.538 0.484 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -61.2 -19.16 61.29 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 127.987 2.515 . . . . 0.0 113.051 178.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.6 mtm -115.66 16.31 16.45 Favored 'General case' 0 N--CA 1.466 0.355 0 O-C-N 121.195 -0.941 . . . . 0.0 110.979 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 70.7 mt -129.26 170.5 13.53 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 121.998 0.904 . . . . 0.0 113.263 -179.113 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.474 ' HB ' ' HE3' ' A' ' 12' ' ' LYS . 4.3 t -171.88 173.26 4.54 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 128.343 2.657 . . . . 0.0 107.221 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -129.88 110.56 19.83 Favored 'Isoleucine or valine' 0 C--O 1.24 0.568 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 178.571 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 20.6 ttpt -69.8 112.6 6.36 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.192 1.397 . . . . 0.0 107.498 179.616 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.8 p -66.93 130.96 32.76 Favored 'Isoleucine or valine' 0 C--O 1.239 0.513 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 178.424 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.64 -89.27 0.1 OUTLIER Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 -179.139 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -134.5 158.5 75.01 Favored Pre-proline 0 CA--C 1.539 0.553 0 CA-C-O 118.532 -0.747 . . . . 0.0 110.698 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -73.3 31.65 0.31 Allowed 'Trans proline' 0 CA--C 1.544 0.981 1 C-N-CA 126.149 4.566 . . . . 0.0 116.093 -179.152 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.411 ' O ' ' HB3' ' A' ' 8' ' ' SER . 39.9 ttmt -60.6 139.04 57.96 Favored 'General case' 0 C--O 1.225 -0.225 0 O-C-N 120.676 -1.265 . . . . 0.0 110.968 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.41 -72.67 0.78 Allowed Glycine 0 CA--C 1.524 0.62 0 CA-C-O 118.526 -1.152 . . . . 0.0 115.754 178.497 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.415 ' CG ' HD11 ' A' ' 44' ' ' LEU . 1.7 t80 -151.09 147.77 21.31 Favored Pre-proline 0 CA--C 1.544 0.737 0 CA-C-N 119.596 1.698 . . . . 0.0 114.82 -176.515 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -83.99 163.4 13.67 Favored 'Trans proline' 0 C--N 1.354 0.868 0 C-N-CA 124.203 3.269 . . . . 0.0 114.347 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -79.61 -10.36 14.5 Favored 'Trans proline' 0 C--N 1.349 0.605 0 C-N-CA 122.482 2.121 . . . . 0.0 111.873 179.268 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -76.73 -19.85 57.2 Favored 'General case' 0 CA--C 1.535 0.39 0 O-C-N 121.248 -0.907 . . . . 0.0 110.922 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -117.47 8.78 13.07 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 124.04 0.936 . . . . 0.0 112.69 -178.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.6 tt -51.45 -35.5 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 124.041 0.936 . . . . 0.0 111.569 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -61.83 -28.17 69.29 Favored 'General case' 0 N--CA 1.461 0.123 0 C-N-CA 125.245 1.418 . . . . 0.0 111.74 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 37.7 m-80 -78.37 -30.26 47.86 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-O 118.977 -0.535 . . . . 0.0 109.622 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.415 HD11 ' CG ' ' A' ' 36' ' ' TYR . 53.4 mt -76.03 -37.47 58.33 Favored 'General case' 0 C--N 1.339 0.12 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.559 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.1 t -63.54 121.28 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 104.617 -2.364 . . . . 0.0 104.617 178.241 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.45 -9.72 38.59 Favored Glycine 0 CA--C 1.534 1.266 0 CA-C-O 118.846 -0.975 . . . . 0.0 111.404 -178.113 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 72.2 mttt -85.18 169.16 14.12 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-N 119.721 1.761 . . . . 0.0 107.751 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.1 ttmp? -116.01 130.07 56.65 Favored 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 125.813 1.645 . . . . 0.0 108.027 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.45 HG23 ' HA ' ' A' ' 17' ' ' GLU . 3.9 m -73.2 144.02 13.21 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 55.7 mt -90.59 -13.88 33.58 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 124.198 0.999 . . . . 0.0 112.093 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 31.6 m -147.99 162.88 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 125.89 1.676 . . . . 0.0 107.208 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.483 HG23 ' HA ' ' A' ' 16' ' ' PRO . 51.5 m -72.85 133.83 44.6 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.8 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 96.9 t -112.61 124.48 69.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 125.808 1.643 . . . . 0.0 107.519 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -78.65 171.85 14.54 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.49 0.662 . . . . 0.0 111.866 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 49.1 tt0 -63.25 143.68 57.59 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 105.389 -2.078 . . . . 0.0 105.389 177.482 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 25.8 t0 61.36 8.23 2.06 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.334 2.254 . . . . 0.0 112.883 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.82 150.52 32.28 Favored 'General case' 0 C--N 1.344 0.365 0 O-C-N 120.905 -1.122 . . . . 0.0 110.287 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.5 118.02 17.92 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 125.124 1.369 . . . . 0.0 113.961 -176.556 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 mm -75.87 146.32 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 104.564 -2.384 . . . . 0.0 104.564 177.407 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 10.0 mtt -141.92 157.19 45.26 Favored 'General case' 0 CA--C 1.518 -0.272 0 C-N-CA 123.956 0.903 . . . . 0.0 109.207 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -67.63 -14.74 63.2 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 122.473 0.309 . . . . 0.0 111.267 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 20.5 tt0 -84.52 -33.02 23.61 Favored 'General case' 0 CA--C 1.535 0.4 0 O-C-N 121.127 -0.983 . . . . 0.0 110.89 179.195 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 43.5 mt -81.33 6.27 14.83 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.722 1.609 . . . . 0.0 113.826 -178.393 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.6 m -126.66 154.26 36.28 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 CA-C-N 119.267 0.94 . . . . 0.0 110.997 -179.224 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 . . . . . 0 C--O 1.238 0.46 0 C-N-CA 125.351 1.46 . . . . 0.0 109.618 179.108 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.878 0 N-CA-C 107.262 -2.335 . . . . 0.0 107.262 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.1 t -141.94 174.03 10.97 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 118.377 1.089 . . . . 0.0 112.506 -178.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.438 HG11 ' CD1' ' A' ' 44' ' ' LEU . 68.3 t -78.33 119.78 27.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 C-N-CA 127.664 2.386 . . . . 0.0 108.578 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.6 m -128.96 147.5 33.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.582 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.17 115.43 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 124.356 1.062 . . . . 0.0 108.267 179.335 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 41.0 tttm -64.68 -30.55 71.56 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.845 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.7 m -147.74 168.67 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 128.413 2.685 . . . . 0.0 105.804 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 65.9 tttt -63.64 130.47 44.42 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 9.4 mt -114.63 101.14 54.18 Favored Pre-proline 0 N--CA 1.454 -0.26 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -70.56 148.3 59.6 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 122.381 2.054 . . . . 0.0 109.235 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 -51.9 146.25 8.65 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.678 1.191 . . . . 0.0 113.228 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 79.74 -2.87 71.78 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 125.059 1.314 . . . . 0.0 113.525 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.4 m -82.19 151.68 26.78 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 119.0 1.4 . . . . 0.0 109.637 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 17.4 mm -91.31 128.5 43.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 178.307 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 63.3 mt -67.56 146.91 53.44 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.084 1.354 . . . . 0.0 108.964 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 64.9 p -141.27 160.29 40.43 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.9 mmt -64.27 -26.86 68.68 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 178.043 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -63.69 -16.0 59.91 Favored 'General case' 0 CA--C 1.536 0.426 0 O-C-N 121.494 -0.754 . . . . 0.0 112.48 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 38.0 mtm -120.09 4.99 10.84 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 124.878 1.271 . . . . 0.0 112.375 -179.637 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 92.1 mt -124.94 118.82 27.12 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 120.006 1.275 . . . . 0.0 109.163 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 t -123.82 171.77 9.4 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 124.921 1.288 . . . . 0.0 109.369 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 17.9 t -119.81 151.4 22.36 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 39.1 mmtm -109.83 -172.22 2.0 Allowed 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 124.995 1.318 . . . . 0.0 109.795 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 23.2 m -131.57 16.77 1.82 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 C-N-CA 124.979 1.312 . . . . 0.0 111.565 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -78.64 -92.42 0.32 Allowed Glycine 0 C--N 1.334 0.451 0 C-N-CA 124.107 0.86 . . . . 0.0 113.255 -179.034 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -133.54 157.59 77.63 Favored Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 126.279 1.831 . . . . 0.0 109.004 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -73.05 -1.99 11.35 Favored 'Trans proline' 0 CA--C 1.535 0.55 0 C-N-CA 123.873 3.048 . . . . 0.0 114.233 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.4 ttpt -52.49 127.78 23.67 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.634 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.97 -170.74 13.44 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 -178.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -64.61 128.45 93.49 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -64.3 134.85 43.9 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.247 1.965 . . . . 0.0 111.337 -179.225 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -68.55 -17.65 43.28 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 121.631 1.554 . . . . 0.0 113.482 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -64.39 -25.62 68.1 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 120.311 1.414 . . . . 0.0 110.241 179.235 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -109.04 12.51 25.17 Favored 'General case' 0 N--CA 1.464 0.237 0 O-C-N 121.15 -0.969 . . . . 0.0 112.121 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.5 tt -48.6 -35.48 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 124.847 1.259 . . . . 0.0 111.895 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 40.0 m-85 -51.81 -30.17 22.22 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 126.111 1.764 . . . . 0.0 112.144 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 67.4 m-80 -81.96 -21.39 37.23 Favored 'General case' 0 CA--C 1.519 -0.214 0 C-N-CA 124.327 1.051 . . . . 0.0 113.093 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.438 ' CD1' HG11 ' A' ' 9' ' ' VAL . 96.2 mt -78.05 -35.53 49.51 Favored 'General case' 0 CA--C 1.521 -0.145 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.17 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.85 125.49 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.41 -11.5 68.71 Favored Glycine 0 CA--C 1.529 0.949 0 CA-C-O 117.842 -1.532 . . . . 0.0 113.369 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 43.1 mtmt -83.42 164.24 20.05 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 120.814 2.307 . . . . 0.0 109.558 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.7 ttmp? -102.54 145.52 29.48 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.8 m -85.36 140.23 16.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 O-C-N 123.346 0.404 . . . . 0.0 110.397 179.212 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 16.9 mt -86.89 -18.07 31.75 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-O 117.718 -1.134 . . . . 0.0 111.527 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 17.7 m -150.02 165.36 3.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 C-N-CA 123.958 0.903 . . . . 0.0 109.052 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.0 m -74.76 143.2 44.18 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 105.609 -1.997 . . . . 0.0 105.609 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 75.1 t -129.08 123.26 58.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 C-N-CA 125.8 1.64 . . . . 0.0 106.664 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -72.54 160.98 31.39 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 122.626 1.203 . . . . 0.0 108.867 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -65.76 134.32 52.9 Favored 'General case' 0 C--O 1.24 0.581 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.2 t70 82.87 1.2 1.17 Allowed 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 128.886 2.874 . . . . 0.0 113.901 179.285 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -71.76 156.97 38.74 Favored 'General case' 0 C--N 1.341 0.226 0 CA-C-N 118.228 0.467 . . . . 0.0 110.631 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.3 m -80.67 116.9 20.92 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 125.965 1.706 . . . . 0.0 109.775 179.172 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 16.0 mm -73.95 143.53 13.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 N-CA-C 107.243 -1.391 . . . . 0.0 107.243 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -135.47 153.75 51.65 Favored 'General case' 0 CA--C 1.521 -0.147 0 C-N-CA 125.574 1.55 . . . . 0.0 107.411 179.177 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -60.72 -29.34 69.3 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -179.192 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 22.2 tp10 -67.65 -22.7 65.3 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 122.714 0.406 . . . . 0.0 111.252 -179.147 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 17.4 mt -86.52 4.06 41.53 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 124.759 1.224 . . . . 0.0 112.276 -178.848 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.4 m -131.4 117.25 35.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 120.182 1.355 . . . . 0.0 112.292 -178.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 11.3 t70 . . . . . 0 C--O 1.238 0.488 0 C-N-CA 125.651 1.58 . . . . 0.0 108.263 179.263 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.548 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 48.4 t -136.95 154.92 50.31 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 123.823 0.849 . . . . 0.0 110.916 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 99.2 t -75.76 142.52 14.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.3 m -141.83 161.81 20.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.568 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 178.381 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.91 121.72 20.47 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 54.1 tttm -74.8 -21.7 59.16 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 118.862 -0.59 . . . . 0.0 110.96 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.4 m -145.31 168.04 8.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 C-N-CA 125.873 1.669 . . . . 0.0 108.765 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -73.34 113.68 10.7 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 178.037 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.3 mt -105.56 104.12 46.68 Favored Pre-proline 0 CA--C 1.533 0.299 0 C-N-CA 124.977 1.311 . . . . 0.0 108.311 -178.282 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -67.82 155.39 70.06 Favored 'Trans proline' 0 N--CA 1.454 -0.83 0 C-N-CA 121.559 1.506 . . . . 0.0 110.382 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.416 ' HA ' HG23 ' A' ' 49' ' ' VAL . 5.8 tm-20 -52.08 147.34 7.53 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-O 121.899 0.856 . . . . 0.0 111.164 179.515 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.27 -4.1 82.36 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 123.77 0.7 . . . . 0.0 114.151 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 26.9 m -84.98 144.76 28.1 Favored 'General case' 0 CA--C 1.538 0.485 0 CA-C-N 118.9 1.35 . . . . 0.0 111.355 -179.166 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 27.5 mm -87.13 129.85 37.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.859 1.664 . . . . 0.0 107.712 178.782 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 38.6 mt -71.33 150.49 45.07 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.808 1.243 . . . . 0.0 112.323 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 46.5 p -145.57 161.72 39.13 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 126.826 2.05 . . . . 0.0 107.396 179.1 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 21.6 mmt -62.11 -38.51 89.17 Favored 'General case' 0 C--O 1.223 -0.327 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 178.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.9 t0 -59.32 -23.61 62.62 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 125.014 1.326 . . . . 0.0 112.651 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 25.5 mtm -104.36 7.71 35.71 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 121.34 -0.85 . . . . 0.0 111.919 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.1 mt -126.19 151.19 47.69 Favored 'General case' 0 CA--C 1.521 -0.135 0 O-C-N 120.948 -1.095 . . . . 0.0 109.124 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.3 t -149.28 174.06 12.81 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 179.119 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.1 t -128.77 122.78 57.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.212 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 22.5 mmmt -92.84 116.46 29.05 Favored 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 p -65.2 136.03 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 178.601 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 154.76 -87.48 0.13 Allowed Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.5 pm0 -145.11 156.78 54.56 Favored Pre-proline 0 CA--C 1.54 0.591 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -82.35 57.35 6.12 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 124.965 3.777 . . . . 0.0 111.589 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.51 10.26 3.31 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 124.642 1.177 . . . . 0.0 113.254 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.48 -155.6 7.57 Favored Glycine 0 CA--C 1.524 0.633 0 C-N-CA 125.12 1.343 . . . . 0.0 109.98 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 20.1 t80 -59.66 141.03 89.04 Favored Pre-proline 0 CA--C 1.547 0.85 0 C-N-CA 123.669 0.788 . . . . 0.0 109.926 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.25 143.34 58.41 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 123.728 2.952 . . . . 0.0 115.287 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -76.17 -9.06 19.07 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.145 1.896 . . . . 0.0 113.144 179.124 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -79.23 -59.81 2.62 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -71.13 6.58 1.57 Allowed 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 125.817 1.647 . . . . 0.0 113.35 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 15.6 tt -47.65 -33.41 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 C-N-CA 126.385 1.874 . . . . 0.0 112.767 -179.263 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -57.53 -26.34 61.22 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 123.687 0.795 . . . . 0.0 111.753 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -78.01 -28.2 49.13 Favored 'General case' 0 CA--C 1.528 0.11 0 C-N-CA 123.532 0.733 . . . . 0.0 111.437 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.8 mt -70.58 -37.33 73.93 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 118.679 0.672 . . . . 0.0 109.458 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 43.1 t -61.44 109.29 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 C-N-CA 124.794 1.238 . . . . 0.0 109.382 -179.319 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.14 -14.44 18.88 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 125.582 1.563 . . . . 0.0 111.389 -178.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.2 mttt -74.64 156.0 37.19 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 118.76 1.28 . . . . 0.0 108.318 179.048 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.7 ttmp? -103.45 133.2 48.9 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.309 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.416 HG23 ' HA ' ' A' ' 17' ' ' GLU . 6.5 m -73.89 141.59 15.97 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 178.744 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 93.3 mt -87.37 -20.77 26.24 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 125.658 1.583 . . . . 0.0 110.806 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.6 m -142.29 166.42 16.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.241 0 C-N-CA 125.076 1.35 . . . . 0.0 110.18 -178.386 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 54.4 m -74.11 106.74 5.92 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 91.3 t -90.22 136.1 24.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 178.623 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -92.69 175.31 6.86 Favored 'General case' 0 C--O 1.226 -0.18 0 O-C-N 121.618 -0.676 . . . . 0.0 111.853 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -70.13 136.87 50.59 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.0 t70 67.22 9.46 6.98 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 126.952 2.101 . . . . 0.0 111.508 -178.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.9 t0 -70.96 147.67 48.46 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 178.382 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 39.4 m -81.31 115.09 20.52 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.888 0.851 . . . . 0.0 110.535 -178.123 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.8 mm -72.14 111.47 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -106.79 152.61 23.62 Favored 'General case' 0 C--O 1.238 0.481 0 N-CA-C 104.409 -2.441 . . . . 0.0 104.409 177.33 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -62.93 -24.45 67.87 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.606 -0.684 . . . . 0.0 111.707 -179.646 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -75.13 -6.01 47.32 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 46.3 mt -95.6 -2.79 47.6 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 119.501 1.046 . . . . 0.0 111.437 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.8 m -130.5 151.5 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 125.251 1.42 . . . . 0.0 107.574 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 13.6 t0 . . . . . 0 CA--C 1.541 0.6 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.767 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.394 0 N-CA-C 107.019 -2.432 . . . . 0.0 107.019 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 96.8 p -138.55 151.19 47.09 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 118.701 1.25 . . . . 0.0 110.924 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.6 t -76.57 125.83 36.69 Favored 'Isoleucine or valine' 0 C--O 1.234 0.259 0 O-C-N 121.307 -0.87 . . . . 0.0 110.159 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 33.3 m -124.9 155.8 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-O 122.445 1.117 . . . . 0.0 108.355 177.825 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.71 118.7 10.63 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 125.204 1.402 . . . . 0.0 107.43 178.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 34.8 tttp -69.84 -27.31 64.75 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.4 m -151.75 169.77 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 125.729 1.612 . . . . 0.0 107.71 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -61.28 135.27 57.67 Favored 'General case' 0 C--O 1.241 0.62 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.06 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.1 mt -123.09 114.92 29.21 Favored Pre-proline 0 C--O 1.237 0.427 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.469 ' HA ' HG23 ' A' ' 52' ' ' THR . 22.1 Cg_endo -68.35 145.46 65.61 Favored 'Trans proline' 0 N--CA 1.448 -1.174 0 C-N-CA 120.752 0.968 . . . . 0.0 109.993 178.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.6 tt0 -57.27 146.07 29.82 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.442 0.697 . . . . 0.0 110.8 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.36 -0.05 88.48 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 123.849 0.738 . . . . 0.0 112.854 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.6 m -91.71 155.34 18.36 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 118.311 1.055 . . . . 0.0 111.742 -178.691 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 37.1 mm -89.77 130.12 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 125.332 1.453 . . . . 0.0 108.634 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 29.8 mt -70.25 151.99 44.72 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 124.486 1.114 . . . . 0.0 109.047 178.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 74.2 p -140.63 163.22 33.47 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 124.205 1.002 . . . . 0.0 108.458 -179.313 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 6.2 mmt -63.58 -40.44 96.97 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 177.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -57.71 -30.75 65.77 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 125.683 1.593 . . . . 0.0 113.801 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 63.7 mtm -101.12 13.96 33.48 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 120.379 1.445 . . . . 0.0 112.737 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.4 mt -126.75 136.65 52.7 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -179.445 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.3 t -140.43 131.2 25.82 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.6 m -90.01 125.82 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 CA-C-N 120.179 1.354 . . . . 0.0 107.881 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 11.1 mttp -84.64 105.33 15.36 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 178.298 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 8.0 p -59.48 143.03 14.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.517 0 C-N-CA 123.922 0.889 . . . . 0.0 108.966 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 143.7 -81.36 0.22 Allowed Glycine 0 N--CA 1.448 -0.541 0 CA-C-N 118.081 0.4 . . . . 0.0 113.645 179.277 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -125.6 151.0 69.86 Favored Pre-proline 0 CA--C 1.533 0.293 0 C-N-CA 124.439 1.095 . . . . 0.0 113.102 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -77.8 28.8 0.44 Allowed 'Trans proline' 0 CA--C 1.545 1.051 0 C-N-CA 124.762 3.642 . . . . 0.0 111.936 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 47.7 tttm -80.52 92.99 5.97 Favored 'General case' 0 C--O 1.237 0.444 0 O-C-N 119.826 -1.796 . . . . 0.0 106.944 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 142.66 -149.42 21.27 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 108.501 -1.84 . . . . 0.0 108.501 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -84.68 140.5 38.12 Favored Pre-proline 0 C--O 1.24 0.596 0 C-N-CA 126.328 1.851 . . . . 0.0 108.76 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -55.58 136.05 72.21 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.191 2.594 . . . . 0.0 111.942 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -75.55 -11.02 20.51 Favored 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 123.364 2.709 . . . . 0.0 113.878 -178.587 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -87.99 -40.02 14.22 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 124.375 1.07 . . . . 0.0 110.074 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -74.36 4.53 5.72 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 124.523 1.129 . . . . 0.0 112.077 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.0 tt -44.5 -39.48 1.72 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 128.049 2.54 . . . . 0.0 112.756 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -53.64 -30.6 43.7 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 123.791 0.836 . . . . 0.0 112.15 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 73.6 m-80 -75.38 -44.97 41.95 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.803 179.397 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 36.6 mt -56.58 -42.63 78.97 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 79.9 t -60.6 107.55 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 179.437 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.74 -15.12 26.73 Favored Glycine 0 CA--C 1.528 0.847 0 C-N-CA 125.019 1.295 . . . . 0.0 112.692 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -76.76 157.42 31.65 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-N 120.157 1.979 . . . . 0.0 108.086 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 4.0 ttmp? -98.69 137.96 36.55 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 105.217 -2.142 . . . . 0.0 105.217 177.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 9.2 m -68.13 171.75 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 177.64 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 61.1 mt -116.46 -11.38 11.15 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 125.019 1.328 . . . . 0.0 111.097 178.364 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.8 m -153.3 166.68 1.35 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.372 0 C-N-CA 125.91 1.684 . . . . 0.0 107.958 -178.312 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.469 HG23 ' HA ' ' A' ' 16' ' ' PRO . 3.3 m -74.13 135.96 42.91 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 104.843 -2.281 . . . . 0.0 104.843 178.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 95.2 t -121.06 150.83 24.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -106.96 168.18 9.37 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.114 1.366 . . . . 0.0 108.85 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -65.65 147.94 52.57 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.24 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 50.1 m-20 72.47 -6.18 1.65 Allowed 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 128.377 2.671 . . . . 0.0 113.236 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -64.62 152.51 41.98 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-O 121.924 0.868 . . . . 0.0 112.652 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -84.0 99.16 10.24 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 123.827 0.851 . . . . 0.0 110.903 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 10.5 mm -67.26 93.73 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 29.9 mtp -96.05 160.96 14.19 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 119.363 0.983 . . . . 0.0 109.577 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -60.36 -22.4 63.23 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.712 0.805 . . . . 0.0 113.107 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -74.97 -16.02 60.65 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.041 0.936 . . . . 0.0 111.865 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 27.8 mt -99.16 9.07 44.18 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 126.447 1.899 . . . . 0.0 113.959 -178.175 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.92 149.8 33.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 120.138 1.335 . . . . 0.0 112.38 -179.095 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 15.7 t0 . . . . . 0 C--O 1.236 0.379 0 C-N-CA 126.036 1.734 . . . . 0.0 107.659 178.681 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.849 0 N-CA-C 112.091 -0.403 . . . . 0.0 112.091 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 23.0 t -102.32 156.73 17.39 Favored 'General case' 0 C--O 1.244 0.779 0 C-N-CA 123.94 0.896 . . . . 0.0 110.732 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 85.9 t -75.52 127.86 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.2 m -127.69 146.59 33.13 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.073 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.25 124.02 18.61 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 124.429 1.092 . . . . 0.0 109.054 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 46.6 tttm -67.92 -31.71 71.66 Favored 'General case' 0 C--O 1.225 -0.23 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.421 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.3 m -147.02 174.87 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 126.48 1.912 . . . . 0.0 107.585 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 81.1 tttt -69.38 138.38 53.59 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 178.097 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 23.8 mt -129.25 107.35 17.7 Favored Pre-proline 0 CA--C 1.532 0.262 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -178.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.424 ' HA ' HG23 ' A' ' 52' ' ' THR . 36.6 Cg_endo -69.52 155.51 66.53 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 121.661 1.574 . . . . 0.0 110.532 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.401 ' HA ' HG23 ' A' ' 49' ' ' VAL . 22.7 tt0 -53.39 147.27 10.84 Favored 'General case' 0 C--O 1.238 0.466 0 C-N-CA 124.942 1.297 . . . . 0.0 109.88 179.297 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.0 0.27 75.35 Favored Glycine 0 CA--C 1.53 0.989 0 CA-C-O 118.825 -0.986 . . . . 0.0 113.926 179.187 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 28.5 m -86.67 137.7 32.25 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 119.608 1.704 . . . . 0.0 108.956 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 11.4 mm -80.51 128.71 38.46 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 178.394 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 74.6 mt -67.19 145.18 55.51 Favored 'General case' 0 C--O 1.237 0.442 0 C-N-CA 125.28 1.432 . . . . 0.0 110.307 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.57 ' HA ' HG23 ' A' ' 45' ' ' VAL . 17.6 p -143.25 152.35 41.6 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.371 1.468 . . . . 0.0 107.457 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -56.65 -27.09 57.88 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 118.869 0.758 . . . . 0.0 109.319 178.559 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -56.39 -29.27 61.28 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 126.418 1.887 . . . . 0.0 111.574 177.729 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 48.6 mtm -114.04 3.01 15.14 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 124.616 1.166 . . . . 0.0 111.168 -178.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 70.7 mt -105.52 147.89 27.85 Favored 'General case' 0 C--N 1.343 0.296 0 CA-C-N 120.081 1.31 . . . . 0.0 109.188 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.0 t -159.74 171.97 18.56 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 125.241 1.417 . . . . 0.0 107.613 178.461 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 77.0 t -125.57 152.19 32.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 8.3 mmmt -127.45 109.49 11.8 Favored 'General case' 0 CA--C 1.508 -0.646 0 N-CA-C 105.797 -1.927 . . . . 0.0 105.797 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 29.5 m -59.52 151.43 5.12 Favored 'Isoleucine or valine' 0 C--O 1.24 0.563 0 O-C-N 123.573 0.545 . . . . 0.0 109.532 179.694 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 152.09 -95.24 0.15 Allowed Glycine 0 N--CA 1.442 -0.925 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.53 163.38 50.02 Favored Pre-proline 0 C--N 1.326 -0.419 0 C-N-CA 126.562 1.945 . . . . 0.0 110.147 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -85.88 53.87 3.37 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 122.761 2.307 . . . . 0.0 110.16 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 32.9 pttt -73.81 70.65 1.44 Allowed 'General case' 0 C--O 1.221 -0.417 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 178.393 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.69 -152.8 18.07 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -178.366 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -55.07 134.17 68.07 Favored Pre-proline 0 CA--C 1.545 0.766 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -178.17 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -74.17 156.36 46.78 Favored 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 123.367 2.711 . . . . 0.0 111.251 179.306 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -71.18 -24.72 23.09 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.045 1.83 . . . . 0.0 113.942 -178.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 18.8 mp0 -83.68 2.32 38.22 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 -177.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -124.79 -5.46 7.5 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 119.949 1.25 . . . . 0.0 111.957 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 18.2 tt -40.38 -34.8 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 128.401 2.68 . . . . 0.0 114.327 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -57.91 -11.96 2.81 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.43 1.492 . . . . 0.0 114.139 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -97.4 -24.8 15.46 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 120.298 1.408 . . . . 0.0 110.82 178.31 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 85.8 mt -64.23 -37.94 89.27 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.57 HG23 ' HA ' ' A' ' 22' ' ' THR . 0.7 OUTLIER -68.08 118.88 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 179.556 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.82 -16.78 23.21 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 125.325 1.44 . . . . 0.0 112.337 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -85.6 158.68 20.05 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 119.034 1.417 . . . . 0.0 107.593 178.607 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt -103.45 139.74 38.42 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.793 -0.818 . . . . 0.0 108.793 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.401 HG23 ' HA ' ' A' ' 17' ' ' GLU . 3.2 m -77.29 135.12 27.16 Favored 'Isoleucine or valine' 0 C--O 1.236 0.347 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.411 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 24.1 mt -81.27 -15.3 55.92 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 124.227 1.011 . . . . 0.0 112.028 179.46 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.2 m -146.92 164.03 7.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 127.059 2.144 . . . . 0.0 108.796 -178.353 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.424 HG23 ' HA ' ' A' ' 16' ' ' PRO . 24.0 m -77.34 132.28 38.5 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.025 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.496 HG12 ' H ' ' A' ' 54' ' ' GLU . 54.3 t -98.5 -178.48 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 C-N-CA 126.512 1.925 . . . . 0.0 106.803 178.818 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.496 ' H ' HG12 ' A' ' 53' ' ' VAL . 27.8 mt-10 -135.64 164.76 27.11 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 127.377 2.271 . . . . 0.0 107.73 177.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -65.91 141.43 58.24 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 105.7 -1.963 . . . . 0.0 105.7 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 68.22 4.88 4.37 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.168 1.787 . . . . 0.0 114.946 179.613 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -76.19 155.35 34.59 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 119.633 1.106 . . . . 0.0 109.515 179.005 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 29.7 m -77.32 135.74 38.41 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 121.166 -0.959 . . . . 0.0 109.871 -179.338 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 16.7 mm -97.5 133.94 37.42 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 N-CA-C 104.808 -2.293 . . . . 0.0 104.808 177.633 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 82.7 mtp -139.93 160.86 38.96 Favored 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 123.579 0.752 . . . . 0.0 110.703 -178.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -57.44 -33.62 68.12 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 124.778 1.231 . . . . 0.0 113.231 -179.667 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -75.32 -2.25 27.4 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.319 1.448 . . . . 0.0 113.601 -178.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 36.9 mt -108.92 3.59 22.45 Favored 'General case' 0 C--O 1.232 0.148 0 C-N-CA 125.06 1.344 . . . . 0.0 110.78 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.4 m -129.59 144.53 37.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 C-N-CA 124.174 0.99 . . . . 0.0 111.234 -179.385 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 27.3 t0 . . . . . 0 CA--C 1.535 0.394 0 C-N-CA 125.57 1.548 . . . . 0.0 110.704 -179.947 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.005 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 90.7 p -145.22 158.8 43.74 Favored 'General case' 0 C--O 1.237 0.431 0 O-C-N 121.764 -0.845 . . . . 0.0 111.412 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.11 137.17 24.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.083 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.4 m -136.49 160.62 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 C-N-CA 125.722 1.609 . . . . 0.0 107.778 178.698 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.74 118.27 18.38 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 178.566 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -62.48 -31.77 72.56 Favored 'General case' 0 N--CA 1.467 0.411 0 O-C-N 121.341 -0.85 . . . . 0.0 110.953 179.762 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m -138.32 172.0 14.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 126.708 2.003 . . . . 0.0 107.715 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.1 tttm -70.56 134.09 47.34 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.424 HD11 ' HB3' ' A' ' 25' ' ' MET . 73.9 mt -120.82 110.11 35.36 Favored Pre-proline 0 CA--C 1.53 0.208 0 C-N-CA 123.756 0.822 . . . . 0.0 110.031 -178.419 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -69.54 148.97 67.65 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 121.882 1.721 . . . . 0.0 111.086 178.742 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.406 ' HA ' HG23 ' A' ' 49' ' ' VAL . 60.4 tt0 -55.27 151.12 10.13 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 124.403 1.081 . . . . 0.0 110.166 178.429 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 68.99 30.47 72.22 Favored Glycine 0 CA--C 1.524 0.652 0 CA-C-O 119.441 -0.644 . . . . 0.0 113.847 178.717 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 59.9 m -118.04 150.87 38.58 Favored 'General case' 0 C--O 1.239 0.511 0 C-N-CA 125.737 1.615 . . . . 0.0 107.446 179.195 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 32.7 mm -92.4 123.93 44.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 CA-C-N 118.933 0.788 . . . . 0.0 109.443 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 62.2 mt -63.65 147.13 52.36 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.557 1.143 . . . . 0.0 110.858 -179.484 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.3 p -140.55 164.03 31.26 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 124.754 1.222 . . . . 0.0 107.715 178.892 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 5.7 mmt -62.82 -32.35 73.52 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.462 0.574 . . . . 0.0 110.281 179.211 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -59.24 -27.87 66.18 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 125.021 1.329 . . . . 0.0 113.357 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' MET . . . . . 0.424 ' HB3' HD11 ' A' ' 15' ' ' ILE . 57.9 mtm -105.08 9.2 34.39 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.528 1.131 . . . . 0.0 112.733 -178.525 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 78.5 mt -127.68 146.22 50.63 Favored 'General case' 0 CA--C 1.518 -0.28 0 O-C-N 120.85 -1.156 . . . . 0.0 110.579 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.6 t -153.48 177.92 10.38 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.66 119.52 38.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 179.163 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 47.8 mtpt -91.63 108.8 20.16 Favored 'General case' 0 CA--C 1.511 -0.527 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 179.637 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 31.9 t -58.64 133.86 23.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 N-CA-C 105.609 -1.997 . . . . 0.0 105.609 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.42 -83.4 0.12 Allowed Glycine 0 C--N 1.334 0.441 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.486 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -124.25 150.61 64.28 Favored Pre-proline 0 CA--C 1.532 0.252 0 C-N-CA 123.501 0.72 . . . . 0.0 111.025 -179.597 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -71.14 -15.59 31.98 Favored 'Trans proline' 0 N--CA 1.456 -0.715 0 C-N-CA 122.486 2.124 . . . . 0.0 113.192 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 18.7 ttmm -48.54 106.15 0.09 Allowed 'General case' 0 C--O 1.234 0.272 0 C-N-CA 126.314 1.846 . . . . 0.0 109.982 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.76 -173.51 20.88 Favored Glycine 0 CA--C 1.525 0.715 0 C-N-CA 126.314 1.911 . . . . 0.0 108.93 -179.043 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.5 t80 -65.79 140.19 97.2 Favored Pre-proline 0 CA--C 1.543 0.703 0 O-C-N 121.973 -0.722 . . . . 0.0 109.509 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -66.19 134.29 36.04 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 122.713 2.275 . . . . 0.0 111.579 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -71.56 -16.47 30.47 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.756 2.304 . . . . 0.0 115.215 -179.199 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -70.94 -22.5 62.21 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.555 1.07 . . . . 0.0 111.927 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -114.88 13.28 17.08 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 124.855 1.262 . . . . 0.0 113.269 -178.224 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 20.5 tt -45.44 -36.39 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 125.365 1.466 . . . . 0.0 113.79 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -58.73 -23.59 60.05 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.336 1.054 . . . . 0.0 113.518 -178.751 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -78.42 -32.94 48.89 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 120.385 1.448 . . . . 0.0 111.504 179.224 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.2 mt -62.87 -35.37 79.77 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.016 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 77.5 t -60.32 117.03 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.08 -6.71 51.4 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 118.302 -1.277 . . . . 0.0 113.91 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.0 mttm -86.52 158.63 19.5 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 120.717 2.258 . . . . 0.0 108.725 178.691 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -95.77 135.22 37.78 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 179.107 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.406 HG23 ' HA ' ' A' ' 17' ' ' GLU . 4.2 m -77.51 139.74 18.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 CA-C-N 118.239 0.472 . . . . 0.0 110.077 179.0 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 23.1 mt -85.08 -17.22 38.06 Favored 'General case' 0 N--CA 1.462 0.154 0 C-N-CA 125.278 1.431 . . . . 0.0 112.066 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.18 163.52 7.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 C-N-CA 124.816 1.247 . . . . 0.0 110.582 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 22.5 m -78.51 122.4 25.82 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 105.116 -2.179 . . . . 0.0 105.116 178.079 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 76.2 t -106.59 139.29 28.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 106.126 -1.805 . . . . 0.0 106.126 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -86.1 176.21 8.12 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 122.079 0.942 . . . . 0.0 112.211 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -71.32 132.37 44.78 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 123.648 0.779 . . . . 0.0 110.09 -179.153 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 68.02 9.75 7.37 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 126.252 1.821 . . . . 0.0 110.127 -179.112 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 35.1 t0 -73.54 153.38 40.29 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.573 1.149 . . . . 0.0 109.466 179.693 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 23.1 m -78.51 129.59 35.04 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 124.969 1.308 . . . . 0.0 111.809 -177.558 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 13.0 mm -90.39 148.01 4.84 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 179.013 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 38.1 mtp -142.17 163.56 32.54 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 124.777 1.231 . . . . 0.0 108.238 178.511 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -65.02 -26.35 68.24 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 124.128 0.971 . . . . 0.0 111.039 179.768 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -73.04 -14.84 61.49 Favored 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 123.62 0.768 . . . . 0.0 112.226 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 12.2 mt -94.11 6.59 48.1 Favored 'General case' 0 C--N 1.334 -0.069 0 CA-C-O 118.115 -0.945 . . . . 0.0 113.325 -177.598 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.4 m -127.88 125.33 64.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 120.139 1.336 . . . . 0.0 112.586 -178.632 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 50.5 t0 . . . . . 0 C--O 1.237 0.395 0 C-N-CA 125.779 1.632 . . . . 0.0 108.556 179.679 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.61 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.0 p -110.21 133.7 52.97 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.339 1.455 . . . . 0.0 110.78 -179.566 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.5 t -68.89 127.33 30.57 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 179.366 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.1 m -122.86 149.86 26.6 Favored 'Isoleucine or valine' 0 C--O 1.241 0.625 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.095 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.13 119.06 12.82 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 60.5 tttm -70.29 -21.53 62.94 Favored 'General case' 0 C--N 1.331 -0.206 0 O-C-N 121.529 -0.732 . . . . 0.0 112.099 -179.428 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.2 m -148.17 167.7 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 126.546 1.938 . . . . 0.0 107.501 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.3 tttm -76.43 99.8 5.0 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 178.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 7.6 mt -87.25 109.93 29.43 Favored Pre-proline 0 C--N 1.326 -0.431 0 C-N-CA 125.747 1.619 . . . . 0.0 107.677 -177.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.77 155.12 66.7 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 C-N-CA 121.387 1.391 . . . . 0.0 110.906 -179.519 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 61.8 tt0 -51.72 141.16 17.38 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 125.653 1.581 . . . . 0.0 109.399 179.607 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.1 -0.29 87.67 Favored Glycine 0 CA--C 1.535 1.3 0 CA-C-O 119.181 -0.788 . . . . 0.0 114.458 179.6 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.3 m -84.28 147.77 27.05 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 120.282 2.041 . . . . 0.0 109.668 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.5 mm -86.47 131.26 35.13 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 17.8 mt -68.98 148.16 50.55 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-O 121.607 0.717 . . . . 0.0 110.54 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.3 p -143.34 157.47 44.45 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 127.065 2.146 . . . . 0.0 107.331 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 15.9 mmt -64.98 -24.87 67.64 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.541 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -65.17 -14.73 61.3 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 128.791 2.837 . . . . 0.0 112.002 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 25.7 mtm -124.16 10.19 8.7 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.388 1.475 . . . . 0.0 111.933 -179.522 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 83.4 mt -128.66 152.86 47.9 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 119.728 1.149 . . . . 0.0 110.714 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.0 t -160.54 -179.15 7.41 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 105.434 -2.062 . . . . 0.0 105.434 178.133 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.47 131.11 39.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 O-C-N 120.766 -1.209 . . . . 0.0 108.07 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 2.4 tppp? -84.28 105.45 15.13 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 101.698 -3.445 . . . . 0.0 101.698 177.746 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.0 m -66.99 89.99 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 O-C-N 121.597 -0.689 . . . . 0.0 110.534 -179.154 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -145.06 -87.15 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 124.984 1.278 . . . . 0.0 110.565 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.9 148.44 39.92 Favored Pre-proline 0 C--N 1.326 -0.418 0 C-N-CA 125.884 1.674 . . . . 0.0 111.695 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -82.5 71.6 6.42 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.176 2.584 . . . . 0.0 108.166 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 40.1 tttp -114.24 166.2 11.9 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 123.537 0.735 . . . . 0.0 109.726 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 74.41 -87.65 0.71 Allowed Glycine 0 N--CA 1.444 -0.828 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -139.84 144.58 39.23 Favored Pre-proline 0 C--O 1.238 0.448 0 C-N-CA 124.919 1.288 . . . . 0.0 108.117 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.9 148.05 85.66 Favored 'Trans proline' 0 CA--C 1.539 0.75 0 C-N-CA 121.543 1.495 . . . . 0.0 109.358 179.065 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.05 -18.8 14.24 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.145 1.897 . . . . 0.0 111.989 -178.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -66.17 -33.09 74.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.46 -0.775 . . . . 0.0 111.391 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -92.24 10.78 28.13 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.18 1.792 . . . . 0.0 111.864 -178.873 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 13.9 tt -53.98 -34.65 26.5 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.718 0 O-C-N 119.801 -1.812 . . . . 0.0 111.201 179.234 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -60.64 -20.93 62.07 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.805 1.242 . . . . 0.0 113.605 179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -99.24 -17.99 17.83 Favored 'General case' 0 CA--C 1.515 -0.383 0 CA-C-N 119.732 1.151 . . . . 0.0 111.733 178.868 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 25.4 mt -68.27 -32.74 73.12 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 177.002 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 41.7 t -64.24 138.79 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 178.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 91.58 -16.2 59.68 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-O 118.823 -0.987 . . . . 0.0 112.277 -179.055 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.3 mttm -76.63 171.98 13.77 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-N 119.586 1.693 . . . . 0.0 107.368 178.198 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 24.7 ttmt -122.85 133.44 54.43 Favored 'General case' 0 CA--C 1.516 -0.355 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 1.8 m -74.6 148.47 7.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 O-C-N 124.258 0.974 . . . . 0.0 110.675 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.438 HD21 ' HB2' ' A' ' 65' ' ' ASP . 65.5 mt -97.93 -14.15 20.79 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 126.013 1.725 . . . . 0.0 112.696 179.7 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 15.7 m -144.42 161.81 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 C-N-CA 126.064 1.746 . . . . 0.0 108.461 179.105 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.1 m -74.98 96.0 3.1 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 87.0 t -70.79 127.13 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 178.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -74.29 170.28 15.91 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.584 0.707 . . . . 0.0 110.162 179.013 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -74.87 138.25 42.34 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 104.788 -2.301 . . . . 0.0 104.788 177.414 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 34.7 t0 72.34 10.94 5.85 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.781 2.032 . . . . 0.0 113.132 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -72.96 149.6 43.21 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 177.737 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 90.7 m -79.12 122.71 26.58 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 179.005 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.2 mm -76.51 126.52 37.26 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 48.7 mtp -128.09 155.43 44.4 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 122.469 1.128 . . . . 0.0 110.425 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -62.28 -20.18 64.02 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 126.696 1.998 . . . . 0.0 114.029 -179.131 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -89.21 -10.35 47.36 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 123.876 0.87 . . . . 0.0 111.687 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 84.1 mt -90.4 11.0 22.87 Favored 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 124.823 1.249 . . . . 0.0 110.729 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.5 m -133.34 151.2 33.27 Favored 'Isoleucine or valine' 0 C--O 1.232 0.166 0 CA-C-N 120.427 1.467 . . . . 0.0 114.239 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ASP . . . . . 0.438 ' HB2' HD21 ' A' ' 50' ' ' LEU . 35.1 t0 . . . . . 0 C--O 1.239 0.537 0 C-N-CA 124.641 1.176 . . . . 0.0 109.129 178.712 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.378 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 76.5 p -137.26 157.19 47.18 Favored 'General case' 0 C--O 1.238 0.451 0 C-N-CA 123.793 0.837 . . . . 0.0 109.704 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 28.9 t -75.57 130.75 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.446 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.3 m -128.98 157.85 41.76 Favored 'Isoleucine or valine' 0 C--O 1.24 0.593 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 178.023 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.31 130.99 42.77 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 178.689 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 64.7 tttt -75.59 -32.91 60.52 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 121.366 -0.834 . . . . 0.0 110.754 179.363 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 22.6 m -144.58 170.71 7.34 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 129.601 3.16 . . . . 0.0 108.945 -179.455 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 20.6 tttm -68.78 116.58 9.43 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 119.762 1.165 . . . . 0.0 108.79 179.681 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.438 HD13 ' CD2' ' A' ' 21' ' ' LEU . 40.2 mt -98.9 105.19 29.84 Favored Pre-proline 0 CA--C 1.534 0.365 0 C-N-CA 125.168 1.387 . . . . 0.0 110.983 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.408 ' HA ' HG23 ' A' ' 52' ' ' THR . 42.7 Cg_endo -67.99 145.39 67.6 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 121.609 1.539 . . . . 0.0 108.937 177.706 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -53.69 152.9 4.85 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 124.151 0.98 . . . . 0.0 110.966 178.862 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.87 24.89 76.15 Favored Glycine 0 CA--C 1.524 0.61 0 CA-C-O 118.543 -1.143 . . . . 0.0 113.892 178.661 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 56.9 m -118.62 143.82 46.55 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 119.112 1.456 . . . . 0.0 108.266 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 18.6 mm -74.39 136.26 25.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.363 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.515 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.438 ' CD2' HD13 ' A' ' 15' ' ' ILE . 25.4 mt -80.51 141.47 35.13 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 126.099 1.76 . . . . 0.0 107.805 179.199 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.0 p -135.92 165.32 25.93 Favored 'General case' 0 C--O 1.237 0.425 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 179.433 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -61.26 -25.87 67.38 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.55 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -78.17 -10.4 59.62 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.347 1.059 . . . . 0.0 113.164 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 58.9 mtm -119.97 16.07 12.51 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 126.029 1.731 . . . . 0.0 110.566 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.8 mt -141.55 137.88 32.3 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 179.322 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.1 t -148.28 155.08 40.89 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.626 HG11 ' HB3' ' A' ' 38' ' ' PRO . 2.9 t -111.25 102.04 13.41 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -179.586 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 27.7 ttpp -75.01 112.78 11.59 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.236 0.614 . . . . 0.0 109.794 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 90.1 t -61.83 121.92 11.28 Favored 'Isoleucine or valine' 0 C--O 1.239 0.504 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 176.19 -82.77 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -138.56 158.68 69.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 C-N-CA 123.442 0.697 . . . . 0.0 110.768 -179.238 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -74.63 11.63 1.3 Allowed 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.344 2.696 . . . . 0.0 113.182 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -67.47 95.32 0.45 Allowed 'General case' 0 C--O 1.232 0.155 0 O-C-N 120.281 -1.512 . . . . 0.0 108.136 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.7 -167.89 23.78 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 128.095 2.76 . . . . 0.0 109.316 -178.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.423 ' CE2' ' HB3' ' A' ' 40' ' ' ASP . 9.2 t80 -67.77 144.35 97.35 Favored Pre-proline 0 CA--C 1.545 0.752 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.199 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -72.35 154.35 56.07 Favored 'Trans proline' 0 CA--C 1.544 1.016 0 C-N-CA 122.432 2.088 . . . . 0.0 113.406 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.626 ' HB3' HG11 ' A' ' 28' ' ' VAL . 16.7 Cg_endo -66.2 -27.42 48.76 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 123.416 2.744 . . . . 0.0 116.223 -179.383 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -75.99 -25.06 55.44 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 120.233 1.379 . . . . 0.0 112.179 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.423 ' HB3' ' CE2' ' A' ' 36' ' ' TYR . 3.2 m-20 -88.86 -2.55 58.64 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.919 0.781 . . . . 0.0 112.563 -179.184 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.4 tt -51.12 -34.38 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 O-C-N 120.616 -1.302 . . . . 0.0 112.557 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -59.43 -22.9 62.15 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -95.29 -19.09 20.28 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-O 117.76 -1.115 . . . . 0.0 111.308 178.735 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 61.0 mt -72.68 -34.32 67.12 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 73.1 t -64.83 130.64 30.2 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 N-CA-C 105.62 -1.993 . . . . 0.0 105.62 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 93.82 -12.64 69.0 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-O 118.054 -1.414 . . . . 0.0 112.514 -179.305 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -75.49 173.14 11.36 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 119.565 1.682 . . . . 0.0 109.602 178.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.5 tppt? -127.07 101.58 6.6 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.204 1.402 . . . . 0.0 108.941 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 6.1 m -43.06 140.84 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 123.73 0.812 . . . . 0.0 112.508 -178.711 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 92.8 mt -86.84 -19.48 28.9 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.486 1.114 . . . . 0.0 112.307 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.1 m -143.89 165.69 13.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 C-N-CA 126.222 1.809 . . . . 0.0 107.974 -179.021 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.408 HG23 ' HA ' ' A' ' 16' ' ' PRO . 99.2 m -76.26 138.56 40.64 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 178.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 79.0 t -119.85 128.43 75.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -75.38 173.89 10.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 122.101 0.953 . . . . 0.0 110.565 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -69.83 145.53 52.02 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.235 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . 0.338 0.7 OUTLIER 58.63 8.29 0.88 Allowed 'General case' 0 C--O 1.236 0.348 0 C-N-CA 125.291 1.436 . . . . 0.0 114.374 179.333 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -74.38 158.78 33.32 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 178.407 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 18.4 m -84.77 126.82 33.75 Favored 'General case' 0 C--N 1.321 -0.638 0 O-C-N 120.69 -1.256 . . . . 0.0 112.131 -177.873 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.9 mm -84.04 134.9 25.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 N-CA-C 104.328 -2.471 . . . . 0.0 104.328 178.595 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 69.7 mtp -141.48 159.83 41.4 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 122.885 0.474 . . . . 0.0 110.642 -178.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -61.54 -20.68 63.52 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 125.057 1.343 . . . . 0.0 112.697 179.765 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -81.68 -12.68 58.57 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.457 1.103 . . . . 0.0 112.245 179.546 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 25.0 mt -103.34 0.23 31.08 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.345 1.058 . . . . 0.0 111.463 -179.474 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.6 m -132.24 147.23 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 CA-C-O 122.302 1.049 . . . . 0.0 112.368 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 20.4 t0 . . . . . 0 N--CA 1.445 -0.718 0 C-N-CA 126.692 1.997 . . . . 0.0 110.104 179.559 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.675 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -144.23 164.99 29.11 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 124.916 1.286 . . . . 0.0 109.665 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.0 t -81.41 134.05 27.95 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.6 m -133.23 159.39 43.01 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.066 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.77 120.35 17.23 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 178.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 75.5 tttt -69.04 -29.5 67.65 Favored 'General case' 0 C--N 1.327 -0.372 0 O-C-N 121.787 -0.571 . . . . 0.0 109.761 179.209 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.2 m -151.0 163.12 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 C-N-CA 128.081 2.552 . . . . 0.0 107.569 178.834 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -56.23 141.07 42.52 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 124.701 1.2 . . . . 0.0 108.718 178.389 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 8.3 mt -129.68 105.4 17.16 Favored Pre-proline 0 N--CA 1.465 0.281 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -178.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.682 ' HA ' HG23 ' A' ' 52' ' ' THR . 38.2 Cg_endo -65.79 146.06 82.48 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 121.47 1.446 . . . . 0.0 111.263 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.454 ' HA ' HG23 ' A' ' 49' ' ' VAL . 60.5 tt0 -56.71 141.97 41.91 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.561 0.696 . . . . 0.0 111.036 -179.335 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 90.91 2.77 71.32 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-O 119.137 -0.813 . . . . 0.0 113.376 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 30.0 m -97.38 151.26 20.12 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 125.603 1.561 . . . . 0.0 109.143 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 14.4 mm -91.98 141.15 14.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 37.6 mt -73.49 149.56 42.21 Favored 'General case' 0 C--O 1.238 0.468 0 C-N-CA 124.667 1.187 . . . . 0.0 110.69 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.9 p -144.51 158.11 43.91 Favored 'General case' 0 C--N 1.328 -0.361 0 C-N-CA 127.176 2.19 . . . . 0.0 108.096 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.6 mmt -63.74 -31.7 72.96 Favored 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.858 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -59.43 -17.44 30.93 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.987 1.315 . . . . 0.0 111.914 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 49.5 mtm -119.88 11.08 11.73 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.122 1.369 . . . . 0.0 111.849 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.5 mt -130.33 146.88 51.97 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 119.373 0.988 . . . . 0.0 110.256 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.7 t -152.95 163.83 39.08 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 55.3 t -107.75 101.49 12.6 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 1.1 mmtm -72.65 129.7 38.86 Favored 'General case' 0 N--CA 1.453 -0.287 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.3 m -73.24 123.04 27.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.826 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 168.33 -93.64 0.1 Allowed Glycine 0 C--N 1.335 0.473 0 C-N-CA 119.918 -1.134 . . . . 0.0 112.985 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -138.09 153.83 73.65 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 117.484 0.642 . . . . 0.0 111.577 -179.098 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -70.48 14.7 0.3 Allowed 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 124.588 3.525 . . . . 0.0 115.08 -179.032 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.42 114.2 6.65 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 105.31 -2.108 . . . . 0.0 105.31 178.768 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 119.74 -166.39 13.42 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -178.725 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -69.83 138.66 87.99 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-O 118.909 -0.567 . . . . 0.0 112.207 -178.839 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -60.79 135.18 58.26 Favored 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.643 2.229 . . . . 0.0 110.162 179.281 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.42 -13.84 36.19 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 121.963 1.775 . . . . 0.0 115.299 -179.271 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -78.23 -31.17 49.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 119.494 1.043 . . . . 0.0 108.929 179.021 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -81.39 3.98 22.5 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.379 1.072 . . . . 0.0 111.647 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.1 tt -53.2 -32.26 18.93 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 124.658 1.183 . . . . 0.0 112.244 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -57.27 -43.79 83.36 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 123.232 0.613 . . . . 0.0 109.384 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 18.3 m-80 -64.79 -36.76 85.36 Favored 'General case' 0 CA--C 1.522 -0.114 0 C-N-CA 124.176 0.991 . . . . 0.0 110.633 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 71.7 mt -64.42 -34.07 77.32 Favored 'General case' 0 C--O 1.227 -0.108 0 CA-C-O 118.837 -0.602 . . . . 0.0 110.495 179.645 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 96.8 t -71.98 82.11 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 CA-C-O 123.031 1.396 . . . . 0.0 109.245 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 147.24 -4.95 1.0 Allowed Glycine 0 CA--C 1.527 0.844 0 C-N-CA 127.032 2.253 . . . . 0.0 112.653 -179.587 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 78.7 mttt -91.92 156.33 17.54 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 119.427 1.613 . . . . 0.0 109.118 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -99.42 138.67 36.19 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 179.426 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.454 HG23 ' HA ' ' A' ' 17' ' ' GLU . 6.1 m -75.33 137.37 23.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.72 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 95.6 mt -88.81 -12.85 40.84 Favored 'General case' 0 C--N 1.334 -0.106 0 C-N-CA 124.575 1.15 . . . . 0.0 111.592 179.72 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 32.6 m -143.53 160.2 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.25 0 C-N-CA 124.343 1.057 . . . . 0.0 108.65 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.682 HG23 ' HA ' ' A' ' 16' ' ' PRO . 33.4 m -74.23 105.58 5.48 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 104.735 -2.32 . . . . 0.0 104.735 177.787 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 41.1 t -80.23 143.46 12.37 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 179.557 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -90.62 169.74 10.75 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 121.774 0.797 . . . . 0.0 109.08 178.617 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -69.35 136.91 52.4 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 178.053 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.6 t0 65.06 13.79 8.92 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 124.796 1.239 . . . . 0.0 113.813 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -77.01 157.14 31.35 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 124.004 0.922 . . . . 0.0 109.048 178.846 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.0 m -78.47 128.75 34.03 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 121.517 -0.74 . . . . 0.0 109.596 -179.264 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.0 mm -87.93 129.08 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 N-CA-C 103.143 -2.91 . . . . 0.0 103.143 177.766 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 46.6 mtp -133.24 159.92 38.8 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -63.4 -34.13 77.06 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 123.372 0.669 . . . . 0.0 109.904 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -60.75 -19.5 59.18 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 126.662 1.985 . . . . 0.0 110.741 179.699 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 10.7 mt -100.86 6.91 43.88 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 125.149 1.38 . . . . 0.0 112.532 -179.209 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.4 m -132.55 147.2 31.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 120.749 1.613 . . . . 0.0 111.814 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.237 0.398 0 C-N-CA 125.413 1.485 . . . . 0.0 109.57 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.623 0 N-CA-C 112.34 -0.304 . . . . 0.0 112.34 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 36.7 p -136.87 143.75 43.2 Favored 'General case' 0 C--O 1.234 0.255 0 C-N-CA 125.627 1.571 . . . . 0.0 110.872 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.7 t -69.24 123.07 21.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 CA-C-N 119.15 0.886 . . . . 0.0 110.869 179.486 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 35.5 m -125.41 154.64 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 125.043 1.337 . . . . 0.0 108.065 177.865 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.37 118.91 12.07 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -70.36 -29.93 66.72 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.389 -0.819 . . . . 0.0 110.85 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.6 m -147.21 161.85 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 127.816 2.447 . . . . 0.0 106.932 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 78.3 tttt -62.85 143.44 57.59 Favored 'General case' 0 C--O 1.24 0.577 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.499 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.1 mt -127.33 110.85 21.25 Favored Pre-proline 0 CA--C 1.538 0.486 0 C-N-CA 124.956 1.302 . . . . 0.0 109.201 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -66.35 149.5 84.9 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 121.663 1.575 . . . . 0.0 109.704 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.6 tm-20 -53.56 148.55 9.26 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 124.293 1.037 . . . . 0.0 110.905 179.503 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.22 -0.52 87.46 Favored Glycine 0 CA--C 1.526 0.747 0 C-N-CA 124.617 1.103 . . . . 0.0 115.219 178.879 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 72.5 m -83.6 144.53 29.39 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 118.213 1.006 . . . . 0.0 110.768 -179.07 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 30.0 mm -85.65 135.58 24.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 177.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 42.4 mt -72.29 151.98 42.43 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 124.008 0.923 . . . . 0.0 112.033 -179.123 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.617 ' HA ' HG13 ' A' ' 45' ' ' VAL . 47.7 p -144.0 159.02 43.32 Favored 'General case' 0 C--O 1.238 0.455 0 C-N-CA 127.285 2.234 . . . . 0.0 106.533 178.678 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' MET . . . . . 0.509 ' SD ' HG11 ' A' ' 45' ' ' VAL . 0.4 OUTLIER -65.69 -30.89 71.64 Favored 'General case' 0 C--O 1.224 -0.273 0 CA-C-N 119.377 0.99 . . . . 0.0 108.483 178.605 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -58.14 -30.58 66.45 Favored 'General case' 0 C--O 1.225 -0.209 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -179.436 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.8 mtm -95.69 9.67 39.53 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 118.861 0.755 . . . . 0.0 111.518 179.565 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.3 mt -130.83 158.22 40.76 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 123.898 0.879 . . . . 0.0 111.843 -178.261 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 t -159.32 152.06 21.7 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.351 -2.092 . . . . 0.0 105.351 177.735 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 m -103.01 120.51 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 119.828 1.194 . . . . 0.0 108.596 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 27.5 ttpp -68.84 113.67 6.48 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 104.784 -2.302 . . . . 0.0 104.784 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 60.7 t -74.56 85.73 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -144.02 -77.13 0.03 OUTLIER Glycine 0 CA--C 1.52 0.358 0 C-N-CA 125.395 1.474 . . . . 0.0 111.311 -179.118 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -147.62 161.59 34.98 Favored Pre-proline 0 CA--C 1.537 0.464 0 C-N-CA 124.88 1.272 . . . . 0.0 109.493 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -73.82 36.23 0.39 Allowed 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 124.61 3.54 . . . . 0.0 113.249 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -62.7 164.24 8.06 Favored 'General case' 0 N--CA 1.462 0.16 0 O-C-N 120.567 -1.333 . . . . 0.0 108.912 178.725 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 53.41 -132.09 42.7 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 179.312 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -86.45 135.88 35.89 Favored Pre-proline 0 CA--C 1.542 0.658 0 C-N-CA 125.026 1.33 . . . . 0.0 110.848 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.16 151.48 66.63 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.273 2.649 . . . . 0.0 112.592 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -80.04 -24.81 5.48 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.654 2.236 . . . . 0.0 112.989 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -65.48 -43.24 90.84 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 119.253 0.933 . . . . 0.0 110.638 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -71.05 8.33 0.97 Allowed 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 127.771 2.428 . . . . 0.0 114.15 -178.616 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.1 tt -50.27 -36.17 12.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 CA-C-N 119.3 0.955 . . . . 0.0 112.498 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -58.89 -32.37 69.44 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-O 118.976 -0.535 . . . . 0.0 111.706 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 70.9 m-80 -70.3 -49.6 47.98 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 20.8 mt -57.03 -46.23 82.54 Favored 'General case' 0 CA--C 1.515 -0.385 0 C-N-CA 123.52 0.728 . . . . 0.0 109.957 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.617 HG13 ' HA ' ' A' ' 22' ' ' THR . 74.8 t -68.05 99.19 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.693 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 131.46 -12.48 5.45 Favored Glycine 0 CA--C 1.529 0.926 0 C-N-CA 127.18 2.324 . . . . 0.0 110.687 -179.125 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 55.8 mttm -84.21 169.19 15.03 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 120.021 1.911 . . . . 0.0 108.053 178.273 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 20.4 ttmm -111.85 138.45 48.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 118.1 -0.952 . . . . 0.0 109.287 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.8 m -74.52 137.14 23.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.508 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.481 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 38.3 mt -83.2 -18.84 37.91 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 125.678 1.591 . . . . 0.0 112.268 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 22.8 m -145.21 167.94 9.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 126.198 1.799 . . . . 0.0 108.496 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.6 m -76.88 109.46 10.7 Favored 'General case' 0 N--CA 1.456 -0.149 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 178.628 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 86.7 t -86.48 126.07 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 C-N-CA 124.632 1.173 . . . . 0.0 107.863 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -77.45 172.8 12.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 122.18 0.991 . . . . 0.0 111.298 178.738 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -71.79 148.63 46.08 Favored 'General case' 0 N--CA 1.443 -0.782 0 O-C-N 121.616 -0.678 . . . . 0.0 109.509 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 29.2 t70 61.36 7.36 1.7 Allowed 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 127.554 2.342 . . . . 0.0 112.169 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -67.82 150.99 47.9 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.234 1.014 . . . . 0.0 108.895 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 47.3 m -82.64 111.84 18.97 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.048 -1.094 . . . . 0.0 108.048 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.8 mm -70.27 129.68 34.47 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 105.712 -1.959 . . . . 0.0 105.712 178.827 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 59.1 mtp -132.8 161.02 35.19 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 123.897 0.879 . . . . 0.0 109.316 -179.203 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -62.25 -30.55 71.19 Favored 'General case' 0 N--CA 1.466 0.329 0 C-N-CA 123.498 0.719 . . . . 0.0 111.031 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 19.2 pt-20 -66.51 -15.84 63.69 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 123.613 0.765 . . . . 0.0 111.474 179.339 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 38.5 mt -100.32 5.29 44.46 Favored 'General case' 0 C--N 1.341 0.234 0 C-N-CA 126.419 1.887 . . . . 0.0 112.692 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.06 140.41 47.97 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-N 121.665 2.029 . . . . 0.0 114.687 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 46.4 t0 . . . . . 0 C--O 1.239 0.514 0 C-N-CA 127.191 2.197 . . . . 0.0 108.869 178.893 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.742 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 46.4 p -136.33 163.04 31.37 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 117.251 0.525 . . . . 0.0 109.887 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 62.3 t -68.74 142.89 15.65 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.646 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.481 HG21 ' HG2' ' A' ' 29' ' ' LYS . 4.4 m -140.87 164.36 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 127.021 2.129 . . . . 0.0 106.547 178.354 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -81.13 133.15 35.42 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.062 -1.458 . . . . 0.0 107.062 177.728 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -75.51 -29.31 59.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 118.898 -0.572 . . . . 0.0 111.371 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.6 m -144.96 168.97 8.51 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 127.199 2.2 . . . . 0.0 107.854 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.4 tttm -71.86 123.86 23.6 Favored 'General case' 0 C--O 1.238 0.457 0 C-N-CA 124.966 1.306 . . . . 0.0 108.766 178.758 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 74.9 mt -115.64 119.82 37.06 Favored Pre-proline 0 CA--C 1.538 0.517 0 C-N-CA 125.111 1.365 . . . . 0.0 110.112 -178.621 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.6 152.03 53.28 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 121.783 1.655 . . . . 0.0 110.633 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -50.49 146.9 4.95 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.797 1.639 . . . . 0.0 110.844 179.435 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.12 -4.44 66.8 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 115.341 0.896 . . . . 0.0 115.341 178.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.5 m -82.6 149.65 27.32 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 118.561 1.18 . . . . 0.0 109.438 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.05 141.86 13.77 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 76.3 mt -82.98 144.35 30.04 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 123.607 0.763 . . . . 0.0 110.589 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 77.1 p -133.67 162.25 32.46 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 126.876 2.071 . . . . 0.0 108.114 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.0 mmt -63.03 -26.57 68.91 Favored 'General case' 0 N--CA 1.465 0.294 0 O-C-N 121.781 -0.574 . . . . 0.0 110.75 179.172 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -68.91 -43.92 74.19 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-O 117.82 -1.086 . . . . 0.0 112.782 -179.139 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 29.6 mtm -87.76 18.17 4.25 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 120.671 1.578 . . . . 0.0 111.58 -177.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 64.8 mt -125.65 133.61 52.14 Favored 'General case' 0 CA--C 1.516 -0.337 0 C-N-CA 126.169 1.788 . . . . 0.0 109.856 -179.187 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.0 t -146.77 174.08 11.8 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 178.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 40.9 t -129.86 100.22 5.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 CA-C-N 119.36 0.982 . . . . 0.0 108.585 -178.609 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.481 ' HG2' HG21 ' A' ' 10' ' ' VAL . 6.2 mmpt? -67.41 131.32 45.46 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.7 m -62.31 125.87 19.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 178.252 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.37 -134.0 3.13 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -99.66 156.19 35.64 Favored Pre-proline 0 C--O 1.236 0.374 0 C-N-CA 123.995 0.918 . . . . 0.0 112.781 -179.335 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -79.84 51.7 4.0 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 124.474 3.449 . . . . 0.0 111.526 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.0 pttt -72.21 -56.47 5.48 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 120.83 -1.169 . . . . 0.0 110.486 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -70.83 -169.61 8.86 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 125.3 1.428 . . . . 0.0 112.075 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -57.12 144.18 70.17 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 118.209 -0.9 . . . . 0.0 111.316 179.64 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -64.4 142.5 79.04 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.838 2.359 . . . . 0.0 112.089 179.729 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -77.26 7.82 3.55 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 123.638 2.892 . . . . 0.0 112.051 178.747 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -94.62 -43.09 8.45 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 126.405 1.882 . . . . 0.0 109.845 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -94.45 8.53 41.76 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 124.113 0.965 . . . . 0.0 111.193 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.2 tt -45.89 -35.78 2.16 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 126.644 1.977 . . . . 0.0 111.874 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -59.67 -25.15 64.49 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 125.374 1.47 . . . . 0.0 112.223 179.535 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -77.88 -36.14 50.07 Favored 'General case' 0 CA--C 1.518 -0.253 0 C-N-CA 124.068 0.947 . . . . 0.0 109.977 179.278 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 84.9 mt -57.38 -40.69 78.71 Favored 'General case' 0 CA--C 1.516 -0.335 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.227 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 94.4 t -60.39 104.71 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 178.761 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 118.67 -14.95 11.56 Favored Glycine 0 CA--C 1.526 0.748 0 CA-C-O 117.957 -1.468 . . . . 0.0 113.187 -179.474 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -81.06 168.5 18.57 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 119.564 1.682 . . . . 0.0 108.39 179.23 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -114.83 138.11 51.16 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 124.15 0.98 . . . . 0.0 109.316 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.1 m -74.06 151.94 7.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.596 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.28 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 13.1 mt -100.39 -13.99 18.53 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 126.018 1.727 . . . . 0.0 113.643 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 10.4 m -151.14 163.85 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 126.974 2.109 . . . . 0.0 107.915 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.6 m -73.25 102.53 3.68 Favored 'General case' 0 CA--C 1.534 0.349 0 O-C-N 121.085 -1.009 . . . . 0.0 108.665 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 64.1 t -78.4 144.28 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 N-CA-C 107.167 -1.419 . . . . 0.0 107.167 179.226 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 34.9 mm-40 -88.65 174.73 7.87 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 122.094 0.95 . . . . 0.0 110.082 179.4 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -77.14 143.35 39.19 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 177.49 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 69.63 -1.07 2.4 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 125.436 1.495 . . . . 0.0 112.698 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -67.2 151.34 47.72 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 127.177 2.191 . . . . 0.0 110.976 -178.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.6 m -80.51 127.58 32.6 Favored 'General case' 0 C--N 1.324 -0.535 0 C-N-CA 123.272 0.629 . . . . 0.0 110.431 -178.687 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.2 mm -85.08 96.4 4.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.264 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 179.113 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' MET . . . . . 0.536 ' H ' HD12 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -82.79 170.2 15.29 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 177.37 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.432 ' CD ' ' H ' ' A' ' 61' ' ' GLU . 17.8 mp0 -76.18 -34.69 59.33 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 125.198 1.399 . . . . 0.0 109.658 -179.558 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -64.56 -29.03 70.06 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 123.09 0.556 . . . . 0.0 111.334 179.144 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.536 HD12 ' H ' ' A' ' 60' ' ' MET . 73.9 mt -76.1 -0.18 21.01 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.79 1.236 . . . . 0.0 113.229 -179.385 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.36 147.2 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 121.466 1.939 . . . . 0.0 110.751 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.239 0.507 0 CA-C-O 123.256 1.503 . . . . 0.0 114.079 -179.014 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.439 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.4 t -137.37 163.17 31.69 Favored 'General case' 0 C--O 1.239 0.532 0 C-N-CA 123.94 0.896 . . . . 0.0 109.324 179.12 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.0 t -74.06 136.19 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.1 m -130.37 158.95 42.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 C-N-CA 125.426 1.49 . . . . 0.0 107.805 178.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.96 107.2 5.2 Favored 'General case' 0 N--CA 1.443 -0.797 0 N-CA-C 104.733 -2.321 . . . . 0.0 104.733 177.522 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 37.6 tttt -59.75 -24.09 63.76 Favored 'General case' 0 N--CA 1.464 0.239 0 O-C-N 121.6 -0.687 . . . . 0.0 111.857 -179.265 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.1 m -145.86 169.52 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 C-N-CA 125.679 1.592 . . . . 0.0 109.123 -178.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 36.8 tttm -72.71 128.32 35.19 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 103.386 -2.82 . . . . 0.0 103.386 176.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.5 mt -122.69 115.22 29.64 Favored Pre-proline 0 C--N 1.333 -0.143 0 C-N-CA 125.09 1.356 . . . . 0.0 111.122 -176.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -70.65 153.98 64.49 Favored 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 121.077 1.185 . . . . 0.0 110.463 178.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.471 ' HA ' HG23 ' A' ' 49' ' ' VAL . 37.3 tt0 -54.2 149.36 9.81 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.671 1.588 . . . . 0.0 111.436 179.45 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.13 -2.7 64.54 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 123.798 0.714 . . . . 0.0 114.431 179.47 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 12.8 m -81.76 143.63 31.67 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 119.179 1.49 . . . . 0.0 109.809 -179.601 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 39.9 mm -84.41 125.99 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.916 -1.883 . . . . 0.0 105.916 178.07 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 45.4 mt -66.38 144.83 56.3 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 124.434 1.094 . . . . 0.0 110.893 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 40.1 p -139.3 165.88 26.02 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 178.482 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.6 mmt -67.08 -9.82 43.46 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.914 -0.492 . . . . 0.0 110.507 178.619 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -88.83 -2.83 58.78 Favored 'General case' 0 N--CA 1.471 0.579 0 O-C-N 120.353 -1.467 . . . . 0.0 110.88 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 36.7 mtm -125.11 4.81 7.89 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 124.944 1.298 . . . . 0.0 110.961 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.8 mt -135.8 147.33 48.29 Favored 'General case' 0 CA--C 1.512 -0.506 0 O-C-N 121.163 -0.961 . . . . 0.0 109.326 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.9 t -159.46 177.98 10.39 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 178.745 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.1 132.82 68.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 178.713 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 25.1 mmtp -91.51 -173.04 3.44 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 178.719 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.86 96.83 4.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 O-C-N 120.948 -1.095 . . . . 0.0 108.856 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.16 -82.71 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -157.02 160.7 30.51 Favored Pre-proline 0 CA--C 1.546 0.816 0 C-N-CA 125.529 1.532 . . . . 0.0 109.132 -179.04 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -66.46 13.02 0.14 Allowed 'Trans proline' 0 CA--C 1.54 0.781 1 C-N-CA 126.321 4.681 . . . . 0.0 116.94 -179.039 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.0 ptmt -54.06 114.38 1.58 Allowed 'General case' 0 C--O 1.221 -0.412 0 CA-C-N 119.287 0.949 . . . . 0.0 110.853 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 116.56 -81.03 0.3 Allowed Glycine 0 C--N 1.332 0.321 0 CA-C-N 119.625 1.102 . . . . 0.0 112.366 179.125 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -151.17 138.36 11.99 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 123.147 0.579 . . . . 0.0 111.822 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -68.13 134.77 32.6 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.357 2.038 . . . . 0.0 111.707 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -63.71 -22.49 69.76 Favored 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 122.439 2.093 . . . . 0.0 113.191 179.136 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -69.4 -8.6 48.0 Favored 'General case' 0 CA--C 1.534 0.341 0 CA-C-N 119.323 0.965 . . . . 0.0 112.404 179.461 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -119.78 10.39 11.62 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 124.794 1.238 . . . . 0.0 112.414 -178.508 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.3 tt -51.84 -31.17 13.05 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 O-C-N 121.326 -0.859 . . . . 0.0 113.078 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -54.63 -37.49 65.71 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 125.248 1.419 . . . . 0.0 112.278 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -77.95 -29.28 49.77 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 118.467 0.576 . . . . 0.0 111.042 179.182 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 78.0 mt -66.46 -34.54 78.18 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 179.541 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.1 t -69.58 105.18 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -179.004 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 119.81 -10.08 11.32 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.894 1.711 . . . . 0.0 112.587 -179.426 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 3.3 mtpp -82.16 154.39 25.52 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 119.228 1.514 . . . . 0.0 108.026 178.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.2 ttmt -95.69 135.15 37.76 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.471 HG23 ' HA ' ' A' ' 17' ' ' GLU . 5.1 m -75.81 143.45 13.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 177.782 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 73.4 mt -89.27 -14.94 34.71 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 124.399 1.08 . . . . 0.0 111.248 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.4 m -145.9 163.81 10.55 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 C-N-CA 126.395 1.878 . . . . 0.0 109.309 -178.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 4.9 m -75.76 127.4 32.96 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 105.731 -1.951 . . . . 0.0 105.731 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 89.2 t -105.93 148.74 10.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -98.66 170.55 8.71 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 123.626 0.77 . . . . 0.0 111.603 -179.066 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -67.78 132.75 48.01 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.4 t70 67.91 9.39 7.1 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 129.327 3.051 . . . . 0.0 114.201 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -68.06 154.64 41.23 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 123.429 0.692 . . . . 0.0 110.253 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -84.81 124.97 32.18 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 123.246 0.618 . . . . 0.0 110.97 -178.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.9 mm -85.84 146.95 5.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 178.073 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 32.9 mtp -134.01 151.76 51.57 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 105.47 -2.048 . . . . 0.0 105.47 178.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.26 -26.96 61.63 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 123.562 0.745 . . . . 0.0 112.885 -178.765 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -76.62 -0.58 23.91 Favored 'General case' 0 N--CA 1.451 -0.408 0 C-N-CA 126.0 1.72 . . . . 0.0 114.768 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 61.6 mt -113.53 3.18 15.63 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.204 1.402 . . . . 0.0 112.364 -179.402 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.2 m -132.52 152.9 37.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-N 119.462 1.028 . . . . 0.0 112.453 -178.025 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.531 0.217 0 C-N-CA 123.594 0.758 . . . . 0.0 110.109 179.292 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.426 ' HA3' ' HA ' ' A' ' 30' ' ' VAL . . . . . . . . 0 CA--C 1.52 0.387 0 N-CA-C 111.995 -0.442 . . . . 0.0 111.995 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 55.7 p -137.74 155.58 48.92 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 124.224 1.01 . . . . 0.0 110.842 179.586 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 43.4 t -75.93 130.61 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 178.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 m -129.74 157.68 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 N-CA-C 105.122 -2.177 . . . . 0.0 105.122 177.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.05 128.9 36.62 Favored 'General case' 0 N--CA 1.444 -0.731 0 O-C-N 121.356 -0.84 . . . . 0.0 109.38 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 52.6 tttt -72.44 -27.49 62.36 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.075 0.55 . . . . 0.0 111.309 179.686 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.6 m -146.87 171.65 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 C-N-CA 127.092 2.157 . . . . 0.0 108.083 -179.473 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.3 tttt -70.58 124.67 24.79 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 178.58 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.3 mt -116.16 101.81 53.82 Favored Pre-proline 0 C--N 1.327 -0.384 0 N-CA-C 105.788 -1.93 . . . . 0.0 105.788 -178.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.689 ' HA ' HG23 ' A' ' 52' ' ' THR . 33.3 Cg_endo -63.31 159.05 41.53 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 120.896 1.064 . . . . 0.0 110.627 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 71.4 tt0 -54.83 149.03 11.96 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 179.512 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.94 4.89 73.46 Favored Glycine 0 CA--C 1.533 1.212 0 CA-C-O 119.045 -0.864 . . . . 0.0 114.576 179.357 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 18.9 m -92.11 150.85 20.71 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 119.667 1.734 . . . . 0.0 109.425 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 36.5 mm -89.5 135.97 24.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.439 0 C-N-CA 124.149 0.98 . . . . 0.0 110.108 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 25.9 mt -75.56 143.4 42.43 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.172 0.51 . . . . 0.0 109.808 178.86 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 33.2 p -138.55 154.13 48.74 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 17.4 mmt -59.71 -34.48 72.97 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-O 121.834 0.826 . . . . 0.0 110.332 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -64.81 -12.45 48.16 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 126.633 1.973 . . . . 0.0 114.055 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 33.1 mtm -117.74 6.26 12.34 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.22 1.008 . . . . 0.0 111.238 179.291 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.9 mt -119.41 153.21 35.56 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 179.429 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.7 t -151.93 172.59 16.0 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 105.558 -2.015 . . . . 0.0 105.558 178.842 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.65 122.0 46.21 Favored 'Isoleucine or valine' 0 C--O 1.237 0.424 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.203 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 15.3 ttmm -87.39 103.57 15.62 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.072 -2.196 . . . . 0.0 105.072 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.426 ' HA ' ' HA3' ' A' ' 7' ' ' GLY . 14.8 m -65.55 132.96 31.19 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 179.609 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.52 -64.62 0.27 Allowed Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -145.4 157.69 52.17 Favored Pre-proline 0 N--CA 1.453 -0.3 0 CA-C-O 118.604 -0.712 . . . . 0.0 111.712 -178.689 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -78.93 11.97 2.39 Favored 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 123.433 2.755 . . . . 0.0 112.599 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -51.74 110.07 0.43 Allowed 'General case' 0 N--CA 1.463 0.202 0 C-N-CA 125.455 1.502 . . . . 0.0 110.126 179.776 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.63 -99.33 0.56 Allowed Glycine 0 C--N 1.333 0.374 0 CA-C-N 119.193 0.906 . . . . 0.0 111.931 179.164 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -139.18 134.76 16.86 Favored Pre-proline 0 C--O 1.239 0.543 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.615 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -61.0 133.44 47.33 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.557 2.838 . . . . 0.0 111.554 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -72.52 -16.22 27.35 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 123.466 2.777 . . . . 0.0 113.408 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -67.42 -23.39 65.54 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 119.399 1.0 . . . . 0.0 110.028 178.301 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 47.1 m-20 -99.71 7.86 44.77 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 126.125 1.77 . . . . 0.0 111.167 -179.31 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.4 tt -51.72 -33.84 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 CA-C-N 120.395 1.452 . . . . 0.0 112.712 -179.141 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -60.98 -19.26 60.92 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 123.97 0.908 . . . . 0.0 112.006 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 -92.43 -27.58 17.39 Favored 'General case' 0 CA--C 1.52 -0.189 0 C-N-CA 124.701 1.2 . . . . 0.0 110.364 179.189 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 19.5 mt -67.97 -37.77 81.92 Favored 'General case' 0 CA--C 1.52 -0.188 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.1 t -58.98 137.72 21.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.09 -14.02 63.25 Favored Glycine 0 CA--C 1.53 0.996 0 CA-C-O 118.121 -1.377 . . . . 0.0 112.824 -179.188 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 40.8 mttm -75.41 166.66 23.25 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 120.458 2.129 . . . . 0.0 108.812 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -119.76 132.42 55.62 Favored 'General case' 0 CA--C 1.521 -0.165 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.333 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -74.99 157.12 6.09 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-N 118.438 0.563 . . . . 0.0 112.461 179.81 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.08 -19.14 16.64 Favored 'General case' 0 C--O 1.225 -0.229 0 C-N-CA 126.628 1.971 . . . . 0.0 110.49 178.422 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 35.4 m -142.43 158.74 19.46 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 124.208 1.003 . . . . 0.0 109.445 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.689 HG23 ' HA ' ' A' ' 16' ' ' PRO . 58.0 m -72.23 99.51 2.39 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.919 1.688 . . . . 0.0 109.562 179.163 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 47.4 t -78.83 151.99 5.01 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 179.294 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -100.86 169.44 8.98 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 126.072 1.749 . . . . 0.0 110.655 179.371 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -69.33 141.62 54.22 Favored 'General case' 0 C--O 1.239 0.52 0 N-CA-C 106.001 -1.851 . . . . 0.0 106.001 176.637 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 67.13 1.22 2.3 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 128.182 2.593 . . . . 0.0 112.413 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.44 149.55 48.2 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.15 0.98 . . . . 0.0 109.938 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 94.6 m -85.26 124.51 31.97 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-O 122.326 1.06 . . . . 0.0 110.94 -177.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 mm -82.18 142.01 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 33.6 mtp -142.25 155.14 45.22 Favored 'General case' 0 C--O 1.237 0.399 0 C-N-CA 125.018 1.327 . . . . 0.0 108.008 179.072 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -61.22 -34.7 75.53 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 124.519 1.128 . . . . 0.0 112.388 -179.106 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -69.56 -2.85 12.56 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 113.688 0.996 . . . . 0.0 113.688 -179.497 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 54.3 mt -105.04 5.77 32.8 Favored 'General case' 0 C--O 1.234 0.285 0 C-N-CA 125.696 1.598 . . . . 0.0 112.827 -178.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 36.0 m -124.79 160.35 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 120.272 1.396 . . . . 0.0 112.068 -179.158 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 46.7 t0 . . . . . 0 C--O 1.238 0.49 0 C-N-CA 127.079 2.151 . . . . 0.0 110.434 -179.21 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.709 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.2 m -146.61 145.19 29.99 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.206 0.527 . . . . 0.0 111.982 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 21.8 t -69.88 128.82 33.79 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 C-N-CA 123.994 0.918 . . . . 0.0 109.837 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.3 m -123.62 152.68 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 178.178 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.486 ' HB2' HD11 ' A' ' 59' ' ' ILE . . . -68.01 111.57 4.49 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 178.632 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 18.6 tttp -59.59 -30.56 68.76 Favored 'General case' 0 CA--C 1.536 0.426 0 O-C-N 121.068 -1.02 . . . . 0.0 113.561 -178.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.8 m -141.98 170.82 11.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 128.747 2.819 . . . . 0.0 106.91 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 42.9 tttm -66.59 137.77 56.99 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 178.401 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.1 mt -121.7 103.43 40.61 Favored Pre-proline 0 N--CA 1.462 0.155 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -179.304 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -66.65 149.99 83.82 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 121.085 1.19 . . . . 0.0 109.561 179.281 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -52.32 146.17 9.84 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 125.448 1.499 . . . . 0.0 110.749 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.65 3.13 86.68 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 123.724 0.678 . . . . 0.0 114.508 178.749 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 22.6 m -91.49 147.67 22.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 118.361 1.081 . . . . 0.0 109.779 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 49.3 mm -87.09 135.59 24.89 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 C-N-CA 123.982 0.913 . . . . 0.0 108.611 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 13.9 mt -74.16 147.09 42.94 Favored 'General case' 0 CA--C 1.519 -0.226 0 C-N-CA 125.288 1.435 . . . . 0.0 110.841 179.252 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.691 ' HA ' HG23 ' A' ' 45' ' ' VAL . 53.8 p -140.96 157.69 44.99 Favored 'General case' 0 C--O 1.238 0.47 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.167 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 7.6 mmt -62.93 -20.43 65.19 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.266 0.939 . . . . 0.0 110.881 178.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -72.0 -21.28 61.58 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.226 0.921 . . . . 0.0 110.25 178.51 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.7 mtm -105.51 4.98 31.08 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 126.328 1.851 . . . . 0.0 111.62 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 80.3 mt -122.94 141.26 52.12 Favored 'General case' 0 CA--C 1.516 -0.339 0 O-C-N 121.135 -0.978 . . . . 0.0 108.647 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.6 t -153.22 115.48 4.39 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.729 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 9' ' ' VAL . 0.2 OUTLIER -71.4 139.04 20.52 Favored 'Isoleucine or valine' 0 C--O 1.238 0.479 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.16 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.53 112.33 25.38 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 104.542 -2.392 . . . . 0.0 104.542 177.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.79 127.83 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 178.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 171.27 -85.86 0.08 OUTLIER Glycine 0 C--N 1.334 0.468 0 C-N-CA 119.955 -1.117 . . . . 0.0 113.356 -179.04 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -138.91 160.78 61.48 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 118.162 0.981 . . . . 0.0 111.562 -178.645 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -72.78 5.85 2.72 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.406 2.737 . . . . 0.0 114.818 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 23.7 tttp -68.63 92.91 0.48 Allowed 'General case' 0 C--O 1.233 0.21 0 C-N-CA 124.928 1.291 . . . . 0.0 109.476 179.377 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 148.21 -91.78 0.15 Allowed Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.785 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -157.27 141.38 11.67 Favored Pre-proline 0 C--O 1.238 0.454 0 C-N-CA 124.974 1.31 . . . . 0.0 110.308 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -68.64 150.39 74.59 Favored 'Trans proline' 0 CA--C 1.538 0.699 0 C-N-CA 122.447 2.098 . . . . 0.0 112.737 -179.403 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 80.7 Cg_endo -79.59 -3.28 12.82 Favored 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 123.098 2.532 . . . . 0.0 113.639 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -73.15 -59.11 2.86 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -71.31 4.95 2.49 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 128.762 2.825 . . . . 0.0 113.748 -179.395 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.559 ' HA ' HD12 ' A' ' 44' ' ' LEU . 17.4 tt -48.88 -37.11 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.568 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -178.153 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -63.38 -13.95 44.95 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.083 0.953 . . . . 0.0 113.49 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -87.29 -30.38 20.91 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 123.381 0.672 . . . . 0.0 110.989 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.559 HD12 ' HA ' ' A' ' 41' ' ' ILE . 21.2 mt -67.66 -44.54 77.59 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.331 1.052 . . . . 0.0 108.775 -179.13 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.691 HG23 ' HA ' ' A' ' 22' ' ' THR . 1.4 p -66.4 124.01 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.534 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.68 -15.47 29.21 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 125.664 1.602 . . . . 0.0 112.3 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 61.7 mttm -81.84 158.25 24.11 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 119.073 1.437 . . . . 0.0 110.469 179.292 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -97.89 142.55 29.49 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 177.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.0 m -86.1 144.0 10.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 CA-C-N 119.397 0.999 . . . . 0.0 109.228 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 62.2 mt -92.92 -3.84 53.83 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 125.446 1.498 . . . . 0.0 112.96 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 28.7 m -148.93 161.98 5.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 C-N-CA 125.81 1.644 . . . . 0.0 109.715 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.4 m -85.28 100.64 11.93 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 104.118 -2.549 . . . . 0.0 104.118 176.706 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.444 HG11 HD11 ' A' ' 59' ' ' ILE . 44.7 t -82.4 143.34 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 179.389 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -88.94 176.52 6.98 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 123.73 0.812 . . . . 0.0 110.605 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -72.41 143.42 48.53 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.496 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 59.23 11.58 2.17 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 128.946 2.898 . . . . 0.0 113.806 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -75.04 154.25 38.06 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.09 1.356 . . . . 0.0 109.099 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.0 m -82.61 132.86 35.18 Favored 'General case' 0 C--N 1.33 -0.276 0 O-C-N 120.886 -1.134 . . . . 0.0 112.379 -178.329 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.486 HD11 ' HB2' ' A' ' 11' ' ' ALA . 41.4 mm -100.2 127.52 53.08 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.72 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 30.9 mtp -122.58 167.37 13.47 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -61.09 -23.65 65.64 Favored 'General case' 0 CA--C 1.538 0.505 0 O-C-N 120.929 -1.107 . . . . 0.0 113.95 -179.565 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -76.56 -4.79 44.7 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 125.54 1.536 . . . . 0.0 113.065 -179.538 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 19.1 mt -107.61 2.08 23.69 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.721 0.809 . . . . 0.0 112.249 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.4 m -127.22 159.05 37.98 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 CA-C-N 119.37 0.986 . . . . 0.0 111.704 -178.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 C--O 1.239 0.504 0 C-N-CA 125.622 1.569 . . . . 0.0 113.569 -179.396 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.97 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -80.82 -55.65 4.67 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.441 0.697 . . . . 0.0 110.099 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.6 t -53.12 132.02 37.6 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 124.006 0.922 . . . . 0.0 109.318 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -158.3 90.12 0.11 Allowed Glycine 0 N--CA 1.442 -0.952 0 N-CA-C 107.546 -2.222 . . . . 0.0 107.546 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 74.3 m -75.04 41.0 0.16 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.184 1.394 . . . . 0.0 109.797 178.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.3 p -45.06 -38.23 4.77 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 127.584 2.353 . . . . 0.0 111.683 -179.367 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.15 -173.77 30.6 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 124.001 0.81 . . . . 0.0 111.1 179.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 84.7 p -129.14 151.32 49.94 Favored 'General case' 0 C--O 1.24 0.593 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -75.24 105.69 4.41 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 O-C-N 122.014 -0.429 . . . . 0.0 111.109 -179.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.0 m -102.86 152.82 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-O 122.654 1.216 . . . . 0.0 107.769 178.088 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.58 128.28 35.31 Favored 'General case' 0 C--N 1.319 -0.722 0 C-N-CA 124.958 1.303 . . . . 0.0 107.94 178.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.52 ' HE2' ' HB ' ' A' ' 27' ' ' THR . 20.1 ttmm -75.86 -23.92 55.69 Favored 'General case' 0 C--N 1.327 -0.378 0 O-C-N 121.012 -1.055 . . . . 0.0 111.099 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.7 m -148.15 173.25 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 C-N-CA 126.589 1.956 . . . . 0.0 107.678 -179.329 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 54.5 tttp -67.42 127.87 34.3 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 177.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.3 mt -111.48 96.43 31.73 Favored Pre-proline 0 C--N 1.331 -0.206 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -61.09 145.29 99.1 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 121.576 1.518 . . . . 0.0 110.496 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.588 ' HA ' HG23 ' A' ' 49' ' ' VAL . 4.9 tm-20 -50.77 146.2 6.11 Favored 'General case' 0 C--O 1.238 0.486 0 C-N-CA 124.936 1.294 . . . . 0.0 110.799 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.55 -3.64 81.6 Favored Glycine 0 CA--C 1.531 1.051 0 CA-C-O 119.327 -0.707 . . . . 0.0 113.153 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 20.0 m -88.22 143.78 26.84 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 118.956 1.378 . . . . 0.0 110.704 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 13.2 mm -83.98 140.24 16.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 71.0 mt -73.83 149.4 41.64 Favored 'General case' 0 C--O 1.238 0.489 0 C-N-CA 123.515 0.726 . . . . 0.0 112.452 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 22.6 p -146.94 157.4 43.62 Favored 'General case' 0 C--O 1.238 0.49 0 C-N-CA 127.526 2.33 . . . . 0.0 107.073 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 19.9 mmt -67.58 -24.15 65.47 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 118.826 0.739 . . . . 0.0 110.571 179.179 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -67.72 -12.67 61.01 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.476 -0.765 . . . . 0.0 112.207 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 47.7 mtm -115.45 10.78 15.83 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.078 0.951 . . . . 0.0 110.915 179.181 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -132.16 161.77 32.52 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 119.655 1.116 . . . . 0.0 112.53 -179.026 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.52 ' HB ' ' HE2' ' A' ' 12' ' ' LYS . 12.6 t -159.31 170.93 20.76 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 127.847 2.459 . . . . 0.0 107.294 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -125.36 110.87 25.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 178.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -76.68 91.73 3.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.8 p -54.53 125.54 9.43 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 C-N-CA 126.288 1.835 . . . . 0.0 106.591 178.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.65 -61.73 0.28 Allowed Glycine 0 N--CA 1.45 -0.417 0 CA-C-O 119.687 -0.507 . . . . 0.0 112.155 -179.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -148.7 148.65 28.63 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-N 118.313 1.056 . . . . 0.0 110.419 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -80.47 44.02 1.65 Allowed 'Trans proline' 0 CA--C 1.548 1.191 0 C-N-CA 123.645 2.896 . . . . 0.0 110.729 179.358 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 24.5 ttmt -84.85 92.8 8.35 Favored 'General case' 0 CA--C 1.521 -0.16 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.14 -132.59 6.74 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 179.633 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.462 ' CD2' ' HD2' ' A' ' 37' ' ' PRO . 0.6 OUTLIER -94.02 139.93 22.75 Favored Pre-proline 0 C--O 1.238 0.462 0 C-N-CA 124.805 1.242 . . . . 0.0 110.215 -179.727 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.462 ' HD2' ' CD2' ' A' ' 36' ' ' TYR . 83.9 Cg_endo -75.17 148.77 35.1 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.022 1.815 . . . . 0.0 112.104 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -75.99 -0.82 10.7 Favored 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 122.962 2.441 . . . . 0.0 111.709 178.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -81.55 -49.79 10.14 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.629 1.572 . . . . 0.0 108.794 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 -85.65 6.28 28.21 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.767 1.227 . . . . 0.0 111.344 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.0 tt -44.1 -41.66 1.81 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 C-N-CA 126.506 1.922 . . . . 0.0 114.607 -178.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -60.49 -32.61 71.6 Favored 'General case' 0 C--N 1.333 -0.138 0 O-C-N 121.575 -0.703 . . . . 0.0 112.003 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 33.7 m-80 -63.63 -30.42 71.53 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 123.377 0.671 . . . . 0.0 110.95 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.3 mt -71.93 -42.57 66.51 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 123.377 0.671 . . . . 0.0 109.828 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.2 t -67.2 93.73 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-O 122.212 1.006 . . . . 0.0 109.18 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 137.05 -11.7 3.88 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 126.202 1.858 . . . . 0.0 112.286 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -84.39 166.4 17.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 118.924 1.362 . . . . 0.0 109.069 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -110.3 139.58 45.35 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.588 HG23 ' HA ' ' A' ' 17' ' ' GLU . 13.5 m -81.99 150.35 4.49 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 O-C-N 123.583 0.552 . . . . 0.0 110.301 179.046 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 91.9 mt -101.01 -10.43 20.55 Favored 'General case' 0 C--O 1.233 0.226 0 C-N-CA 125.364 1.466 . . . . 0.0 111.88 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.4 160.56 14.99 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 C-N-CA 124.529 1.132 . . . . 0.0 109.154 178.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 11.6 m -78.65 99.88 6.77 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 14.9 t -73.2 150.41 7.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 179.036 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -102.55 168.12 9.49 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 123.589 0.756 . . . . 0.0 109.265 178.358 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 72.4 tt0 -61.51 144.18 54.7 Favored 'General case' 0 CA--C 1.538 0.495 0 O-C-N 121.413 -0.804 . . . . 0.0 108.834 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . 0.349 0.1 OUTLIER 56.92 13.06 1.35 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 128.077 2.551 . . . . 0.0 114.543 179.699 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -78.33 153.72 31.46 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 124.077 0.951 . . . . 0.0 112.403 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 20.0 m -81.43 113.07 19.25 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 124.75 1.22 . . . . 0.0 111.771 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.4 mm -76.88 144.31 11.83 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 3.0 mmt -134.53 161.21 35.7 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 125.877 1.671 . . . . 0.0 110.637 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -67.46 -29.15 68.53 Favored 'General case' 0 N--CA 1.467 0.378 0 O-C-N 121.354 -0.841 . . . . 0.0 111.773 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -74.01 -11.31 60.29 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 119.305 0.957 . . . . 0.0 112.486 179.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 69.6 mt -94.56 -4.43 47.94 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.341 1.057 . . . . 0.0 111.646 -179.339 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 m -122.54 140.36 46.59 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-N 120.162 1.346 . . . . 0.0 108.642 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 48.1 t0 -74.32 165.23 25.53 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -68.78 170.11 10.12 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 124.49 1.116 . . . . 0.0 108.192 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -68.12 151.49 46.93 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -116.78 59.07 0.47 Allowed Glycine 0 CA--C 1.518 0.271 0 N-CA-C 105.916 -2.873 . . . . 0.0 105.916 179.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 17.6 tppt? -99.14 -65.03 0.99 Allowed 'General case' 0 CA--C 1.52 -0.187 0 C-N-CA 124.164 0.986 . . . . 0.0 110.908 -178.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 42.1 tptt -50.07 122.04 6.23 Favored 'General case' 0 CA--C 1.514 -0.414 0 C-N-CA 124.379 1.072 . . . . 0.0 112.792 -177.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 28.0 pt -74.93 39.6 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 126.387 1.875 . . . . 0.0 110.78 178.567 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 19.6 tptm -151.67 142.03 22.47 Favored 'General case' 0 C--N 1.346 0.427 0 O-C-N 119.829 -1.794 . . . . 0.0 113.418 -178.214 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 32.6 m -79.98 100.09 7.94 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.534 1.134 . . . . 0.0 110.129 178.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 44.8 m -163.04 159.35 23.2 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 126.5 1.92 . . . . 0.0 106.825 178.462 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 112.22 93.04 2.1 Favored Glycine 0 C--N 1.335 0.477 0 CA-C-O 117.855 -1.525 . . . . 0.0 109.843 179.491 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -74.78 150.18 38.9 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.7 2.267 . . . . 0.0 109.293 179.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 32.9 t -61.98 143.66 56.21 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 116.643 -0.253 . . . . 0.0 110.902 -179.357 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 81.1 p -94.34 -10.33 33.04 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 123.672 0.789 . . . . 0.0 108.872 177.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.012 0 N-CA-C 106.562 -2.615 . . . . 0.0 106.562 179.177 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.599 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.6 p -85.23 124.84 32.33 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.71 1.604 . . . . 0.0 107.938 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 58.0 p -71.41 176.39 4.69 Favored 'General case' 0 C--O 1.243 0.749 0 CA-C-N 119.279 0.945 . . . . 0.0 110.918 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 137.7 86.43 0.17 Allowed Glycine 0 C--N 1.333 0.401 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.062 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.3 t -125.5 163.27 23.03 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.1 p -137.31 9.34 2.95 Favored 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 114.072 1.138 . . . . 0.0 114.072 -179.543 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -171.1 -164.0 26.08 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 120.09 1.313 . . . . 0.0 111.515 -179.061 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.5 p -139.83 161.46 37.52 Favored 'General case' 0 C--O 1.241 0.617 0 C-N-CA 125.758 1.623 . . . . 0.0 109.303 -179.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.2 t -85.88 133.17 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.8 m -129.38 160.62 40.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 178.184 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.4 118.78 12.71 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 126.38 1.872 . . . . 0.0 109.106 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.8 ttmm -68.01 -28.41 67.39 Favored 'General case' 0 N--CA 1.469 0.524 0 O-C-N 120.937 -1.102 . . . . 0.0 111.011 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.9 m -145.75 168.14 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 C-N-CA 127.778 2.431 . . . . 0.0 106.98 -179.399 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 80.9 tttt -68.81 128.78 37.88 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.76 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 8.2 mt -111.61 103.88 55.54 Favored Pre-proline 0 CA--C 1.538 0.507 0 C-N-CA 124.967 1.307 . . . . 0.0 108.552 -178.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -69.96 147.74 62.21 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 121.949 1.766 . . . . 0.0 110.704 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 7.3 tm-20 -49.22 139.65 10.83 Favored 'General case' 0 C--O 1.237 0.425 0 C-N-CA 123.909 0.884 . . . . 0.0 111.413 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.04 -3.57 84.56 Favored Glycine 0 CA--C 1.523 0.551 0 CA-C-N 115.571 -0.74 . . . . 0.0 112.942 179.575 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.4 m -82.53 140.37 33.34 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 118.756 1.278 . . . . 0.0 109.591 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.4 mm -78.73 135.35 26.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 105.424 -2.065 . . . . 0.0 105.424 178.119 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 32.2 mt -75.35 131.52 40.31 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.751 0.82 . . . . 0.0 109.304 179.628 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.4 p -127.83 161.36 29.21 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.759 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 13.2 mmt -61.76 -27.49 68.77 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 121.878 -0.514 . . . . 0.0 111.257 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -74.58 -7.9 54.62 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.884 0.874 . . . . 0.0 113.06 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 70.4 mtm -113.94 7.7 16.99 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 119.27 0.941 . . . . 0.0 111.25 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -123.64 152.68 41.71 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 124.368 1.067 . . . . 0.0 109.36 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.9 t -150.3 161.73 41.89 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 98.5 t -111.67 103.73 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 -178.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 9.5 tppt? -78.15 102.84 7.73 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 178.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.0 t -67.1 122.99 19.21 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 N-CA-C 104.438 -2.431 . . . . 0.0 104.438 178.131 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 170.18 -64.19 0.17 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-O 118.89 -0.95 . . . . 0.0 114.397 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -147.94 156.92 44.07 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 118.852 1.326 . . . . 0.0 110.421 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -79.31 0.72 9.79 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 123.666 2.911 . . . . 0.0 113.532 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.6 ttmt -60.44 106.99 0.6 Allowed 'General case' 0 CA--C 1.529 0.155 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 142.37 -105.56 0.41 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 123.758 0.694 . . . . 0.0 111.819 179.683 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -144.67 143.05 20.04 Favored Pre-proline 0 C--O 1.238 0.485 0 N-CA-C 106.347 -1.723 . . . . 0.0 106.347 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.45 132.11 23.13 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.735 2.29 . . . . 0.0 113.162 -178.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -71.15 -19.49 29.61 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 122.193 1.929 . . . . 0.0 112.257 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 24.5 mp0 -65.04 -31.92 73.38 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 119.586 1.085 . . . . 0.0 110.191 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -106.28 17.57 23.26 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 125.148 1.379 . . . . 0.0 111.998 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.8 tt -50.33 -32.84 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 125.146 1.379 . . . . 0.0 112.366 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -56.73 -25.01 53.62 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 124.193 0.997 . . . . 0.0 112.089 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -81.39 -17.33 49.35 Favored 'General case' 0 C--N 1.339 0.127 0 C-N-CA 123.487 0.715 . . . . 0.0 112.101 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 72.3 mt -76.65 -34.55 58.27 Favored 'General case' 0 C--O 1.225 -0.221 0 CA-C-N 119.219 0.918 . . . . 0.0 108.701 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 63.3 t -62.7 128.98 25.46 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 98.1 -16.78 59.64 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 125.484 1.516 . . . . 0.0 111.09 -178.391 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 82.6 mttt -75.4 168.75 19.4 Favored 'General case' 0 C--N 1.344 0.354 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 178.617 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.5 ttmp? -125.69 135.01 51.65 Favored 'General case' 0 CA--C 1.508 -0.656 0 O-C-N 121.236 -0.915 . . . . 0.0 108.785 -179.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.7 m -67.7 141.13 18.12 Favored 'Isoleucine or valine' 0 C--O 1.24 0.602 0 O-C-N 123.97 0.794 . . . . 0.0 110.113 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 86.5 mt -93.74 -14.44 26.28 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 126.12 1.768 . . . . 0.0 112.256 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 22.7 m -146.63 158.85 10.51 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 C-N-CA 126.317 1.847 . . . . 0.0 108.2 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 88.6 m -70.84 101.36 2.11 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 178.235 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 45.5 t -79.77 119.81 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -72.36 166.9 21.59 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 122.399 1.095 . . . . 0.0 109.401 178.633 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 52.6 tt0 -61.03 143.77 54.71 Favored 'General case' 0 N--CA 1.449 -0.52 0 O-C-N 121.438 -0.789 . . . . 0.0 109.521 -179.392 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.8 t70 64.15 3.71 1.84 Allowed 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.52 1.928 . . . . 0.0 113.587 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -71.71 155.12 40.83 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.866 0.841 . . . . 0.0 109.338 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.2 m -71.83 127.0 31.17 Favored 'General case' 0 N--CA 1.436 -1.151 0 C-N-CA 126.057 1.743 . . . . 0.0 110.797 -178.595 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.4 mm -90.7 137.58 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 N-CA-C 103.812 -2.662 . . . . 0.0 103.812 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 34.7 mtp -140.92 -170.89 3.13 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 123.662 0.785 . . . . 0.0 110.501 -178.67 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -86.27 -37.58 18.43 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 6.2 pm0 -64.45 -11.76 36.71 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.446 1.098 . . . . 0.0 112.779 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 71.4 mt -101.19 2.4 40.02 Favored 'General case' 0 C--O 1.227 -0.124 0 C-N-CA 125.436 1.494 . . . . 0.0 112.319 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 10.3 m -135.35 155.13 36.7 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-N 121.435 1.925 . . . . 0.0 114.399 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 49.9 p30 -76.87 164.49 25.76 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.394 178.269 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -70.89 121.62 18.44 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -50.77 -32.03 18.61 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 114.326 1.232 . . . . 0.0 114.326 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -62.82 -31.63 80.97 Favored Glycine 0 CA--C 1.529 0.937 0 CA-C-O 119.012 -0.882 . . . . 0.0 114.983 -179.181 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -175.97 153.86 1.39 Allowed 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 119.024 1.412 . . . . 0.0 109.807 178.597 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.0 ptmm? -98.08 128.48 44.62 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 7.9 pt -139.02 62.12 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 123.91 0.884 . . . . 0.0 111.175 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 15.3 mmmt -71.3 95.02 1.26 Allowed 'General case' 0 N--CA 1.47 0.575 0 N-CA-C 106.166 -1.79 . . . . 0.0 106.166 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.5 m -141.86 177.56 8.1 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 124.556 1.142 . . . . 0.0 111.66 -179.188 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.23 86.81 1.93 Allowed 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 127.85 2.46 . . . . 0.0 109.484 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 177.71 164.82 31.75 Favored Glycine 0 CA--C 1.529 0.956 0 C-N-CA 123.647 0.642 . . . . 0.0 111.649 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 75.4 Cg_endo -71.36 170.24 18.87 Favored 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.93 2.42 . . . . 0.0 111.184 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 46.6 p -104.3 -122.9 0.21 Allowed 'General case' 0 C--O 1.235 0.298 0 C-N-CA 124.723 1.209 . . . . 0.0 110.332 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -171.08 170.62 6.1 Favored 'General case' 0 N--CA 1.441 -0.892 0 C-N-CA 129.111 2.964 . . . . 0.0 106.371 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.035 0 N-CA-C 106.413 -2.675 . . . . 0.0 106.413 179.882 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.643 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.96 130.08 41.24 Favored 'General case' 0 C--O 1.236 0.367 0 C-N-CA 124.015 0.926 . . . . 0.0 111.065 -178.302 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 34.3 t -69.28 143.64 53.8 Favored 'General case' 0 C--O 1.237 0.414 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 179.096 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 68.9 40.13 84.81 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 119.557 -0.58 . . . . 0.0 112.122 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.7 m -82.8 90.27 6.89 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 117.72 0.76 . . . . 0.0 109.752 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.0 m -53.28 -67.2 0.27 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 125.666 1.586 . . . . 0.0 113.32 -179.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 77.68 178.66 48.66 Favored Glycine 0 CA--C 1.535 1.293 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 79.5 p -144.31 159.04 43.38 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-N 117.853 0.826 . . . . 0.0 111.353 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 97.6 t -71.73 133.31 32.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.37 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.496 HG11 ' HE3' ' A' ' 29' ' ' LYS . 14.6 m -136.02 157.88 38.48 Favored 'Isoleucine or valine' 0 C--O 1.24 0.601 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 178.283 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.87 124.46 24.38 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 44.2 tttt -77.14 -27.11 53.77 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 121.911 -0.493 . . . . 0.0 111.653 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.4 m -144.29 168.15 10.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 C-N-CA 127.602 2.361 . . . . 0.0 106.824 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 78.6 tttt -69.06 117.81 11.17 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 178.076 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 19.9 mt -102.75 112.26 65.53 Favored Pre-proline 0 CA--C 1.533 0.307 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.509 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.93 148.95 32.41 Favored 'Trans proline' 0 N--CA 1.445 -1.342 0 C-N-CA 121.7 1.6 . . . . 0.0 109.428 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 tm-20 -51.68 145.61 9.0 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 124.135 0.974 . . . . 0.0 110.384 179.101 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.38 -3.58 86.47 Favored Glycine 0 CA--C 1.529 0.927 0 CA-C-O 119.105 -0.83 . . . . 0.0 114.89 178.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.6 m -89.78 152.4 21.32 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 118.389 1.095 . . . . 0.0 110.054 -179.283 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 48.7 mm -90.01 141.54 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.478 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 65.9 mt -75.9 139.29 41.56 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.373 0.606 . . . . 0.0 111.489 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 68.3 p -134.28 155.59 49.94 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 126.12 1.768 . . . . 0.0 106.393 178.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 25.8 mtp -67.47 -12.45 60.32 Favored 'General case' 0 CA--C 1.545 0.766 0 CA-C-N 119.594 1.088 . . . . 0.0 110.16 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.6 m-20 -72.84 -19.9 61.23 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 120.828 -1.17 . . . . 0.0 112.147 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 56.1 mtm -115.08 10.37 16.15 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 124.691 1.196 . . . . 0.0 111.59 -178.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 36.0 mt -130.82 148.74 52.63 Favored 'General case' 0 CA--C 1.515 -0.37 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -178.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.8 t -157.14 179.14 9.56 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.4 t -124.56 113.52 36.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 118.826 0.739 . . . . 0.0 109.76 -178.742 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.496 ' HE3' HG11 ' A' ' 10' ' ' VAL . 2.7 ttpp -79.37 93.4 5.33 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 179.118 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 t -59.63 98.62 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -172.17 -46.13 0.04 OUTLIER Glycine 0 C--N 1.339 0.716 0 CA-C-O 117.494 -1.725 . . . . 0.0 115.559 -178.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -151.43 154.33 33.41 Favored Pre-proline 0 N--CA 1.464 0.241 0 CA-C-N 120.251 2.026 . . . . 0.0 110.6 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -76.49 -3.89 14.36 Favored 'Trans proline' 0 CA--C 1.534 0.504 0 C-N-CA 123.195 2.597 . . . . 0.0 113.066 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 3.6 tmmm? -63.73 107.05 1.09 Allowed 'General case' 0 CA--C 1.518 -0.252 0 O-C-N 121.132 -0.98 . . . . 0.0 108.419 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.429 ' HA2' ' SD ' ' A' ' 60' ' ' MET . . . 131.36 178.49 15.5 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 126.26 1.886 . . . . 0.0 109.889 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.526 ' CG ' HD11 ' A' ' 44' ' ' LEU . 7.3 t80 -57.07 134.02 80.45 Favored Pre-proline 0 C--O 1.24 0.603 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -61.98 131.04 33.13 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.168 1.912 . . . . 0.0 108.997 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.64 -19.06 48.39 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.261 1.974 . . . . 0.0 112.351 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -70.67 -10.85 60.32 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 113.304 0.853 . . . . 0.0 113.304 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -121.33 10.92 10.66 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 126.044 1.738 . . . . 0.0 111.582 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.5 tt -41.33 -37.42 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 C-N-CA 128.194 2.598 . . . . 0.0 113.792 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -60.39 -34.99 74.7 Favored 'General case' 0 CA--C 1.528 0.133 0 C-N-CA 125.58 1.552 . . . . 0.0 113.927 -179.165 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -59.46 -38.96 82.13 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 119.675 1.125 . . . . 0.0 112.044 -178.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.526 HD11 ' CG ' ' A' ' 36' ' ' TYR . 85.0 mt -72.55 -33.93 67.17 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 124.681 1.192 . . . . 0.0 111.9 -179.026 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 69.3 t -67.68 91.29 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 124.521 1.128 . . . . 0.0 108.302 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 139.12 -9.38 3.29 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 126.437 1.97 . . . . 0.0 112.629 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 92.1 mttt -82.41 171.14 14.5 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 119.039 1.419 . . . . 0.0 108.437 178.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 33.8 ttmt -110.15 136.93 48.61 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 178.117 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.4 m -80.74 146.27 7.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 O-C-N 121.786 -0.572 . . . . 0.0 109.961 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 92.8 mt -97.21 -14.19 21.57 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 125.906 1.682 . . . . 0.0 113.453 -178.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 16.7 m -146.32 158.0 11.41 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.0 m -77.23 101.6 6.29 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 70.8 t -80.23 138.89 19.04 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -85.12 170.03 13.32 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-O 122.054 0.93 . . . . 0.0 110.283 178.664 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -71.22 138.99 49.94 Favored 'General case' 0 N--CA 1.447 -0.597 0 O-C-N 121.184 -0.947 . . . . 0.0 109.678 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.8 t70 72.3 4.18 4.92 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 127.671 2.389 . . . . 0.0 113.337 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -67.44 145.46 54.99 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.594 1.158 . . . . 0.0 109.387 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 25.4 m -73.24 129.0 37.09 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 179.36 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 26.2 mm -87.1 131.05 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' MET . . . . . 0.49 ' H ' HD12 ' A' ' 63' ' ' LEU . 82.0 mmm -124.55 161.02 27.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 126.235 1.814 . . . . 0.0 106.948 179.255 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.421 ' H ' ' CD ' ' A' ' 61' ' ' GLU . 1.1 pm0 -72.31 -27.25 62.32 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.825 1.65 . . . . 0.0 111.332 179.592 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.41 -14.42 62.91 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 124.419 1.088 . . . . 0.0 112.816 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.49 HD12 ' H ' ' A' ' 60' ' ' MET . 19.8 mt -93.29 -1.09 56.43 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 126.203 1.801 . . . . 0.0 112.148 -179.401 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.4 m -126.68 160.47 34.76 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 CA-C-N 119.707 1.14 . . . . 0.0 113.22 -178.479 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.78 -172.02 3.14 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.345 1.458 . . . . 0.0 109.091 178.593 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 17.2 t-20 -128.35 129.56 46.44 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 106.028 -1.841 . . . . 0.0 106.028 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -43.66 110.87 0.23 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 124.342 1.057 . . . . 0.0 111.452 -179.108 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 166.59 -150.15 16.86 Favored Glycine 0 N--CA 1.443 -0.876 0 C-N-CA 119.8 -1.191 . . . . 0.0 113.417 -178.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.34 166.26 10.78 Favored 'General case' 0 CA--C 1.516 -0.347 0 C-N-CA 124.44 1.096 . . . . 0.0 111.119 -179.414 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 8.1 pttm -152.66 162.16 41.62 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 123.951 0.9 . . . . 0.0 108.926 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 8.1 pt -88.75 170.22 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 122.119 0.962 . . . . 0.0 110.087 179.056 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.505 ' H ' ' HD2' ' A' ' 72' ' ' LYS . 0.0 OUTLIER -81.29 127.48 32.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 104.865 -2.272 . . . . 0.0 104.865 177.691 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 26.8 m -172.76 154.34 2.94 Favored 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 127.753 2.421 . . . . 0.0 107.209 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 7.0 t -114.22 -170.37 1.71 Allowed 'General case' 0 C--O 1.241 0.608 0 C-N-CA 124.547 1.139 . . . . 0.0 108.565 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -74.12 -179.06 39.72 Favored Glycine 0 CA--C 1.533 1.167 0 C-N-CA 124.485 1.04 . . . . 0.0 111.293 179.036 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -67.52 165.49 27.08 Favored 'Trans proline' 0 N--CA 1.45 -1.06 0 C-N-CA 121.951 1.767 . . . . 0.0 109.54 179.078 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.4 m -131.37 14.48 5.05 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.645 0.778 . . . . 0.0 110.534 179.507 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.3 t -144.71 153.07 41.33 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 124.642 1.177 . . . . 0.0 109.946 -178.222 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.223 0 N-CA-C 106.192 -2.763 . . . . 0.0 106.192 -179.706 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.971 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.4 m -72.67 166.41 22.84 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 117.714 0.757 . . . . 0.0 110.176 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.5 m -86.43 -28.05 23.77 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 123.925 0.89 . . . . 0.0 110.431 179.05 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 132.58 163.22 10.56 Favored Glycine 0 CA--C 1.522 0.526 0 C-N-CA 127.725 2.583 . . . . 0.0 109.197 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.5 p -80.69 167.82 19.56 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 117.581 0.691 . . . . 0.0 109.266 179.098 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 m -154.5 147.6 24.71 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.451 1.5 . . . . 0.0 107.006 179.101 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 166.07 -170.12 40.62 Favored Glycine 0 CA--C 1.519 0.301 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 10.7 p -94.02 134.12 36.76 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 118.264 1.032 . . . . 0.0 113.224 -178.373 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 98.9 t -68.27 132.67 32.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 176.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.29 155.6 40.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.533 0 C-N-CA 124.048 0.939 . . . . 0.0 109.174 179.098 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.72 117.04 12.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 177.536 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 42.6 tttp -63.58 -31.57 72.78 Favored 'General case' 0 C--N 1.33 -0.25 0 O-C-N 121.426 -0.796 . . . . 0.0 112.498 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m -142.3 169.99 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 C-N-CA 126.567 1.947 . . . . 0.0 107.012 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 39.1 tttt -64.17 127.18 30.33 Favored 'General case' 0 N--CA 1.454 -0.265 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.699 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.3 mt -111.89 100.69 49.54 Favored Pre-proline 0 CA--C 1.532 0.278 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 -179.425 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -65.16 151.43 85.54 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 N-CA-C 109.062 -1.168 . . . . 0.0 109.062 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -50.75 151.81 2.28 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.27 1.028 . . . . 0.0 111.384 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.62 -3.67 62.97 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 123.962 0.791 . . . . 0.0 113.971 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 99.1 m -81.42 145.89 30.56 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 118.191 0.995 . . . . 0.0 109.524 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.5 mm -88.74 130.86 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 178.045 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.555 ' HB3' HD11 ' A' ' 26' ' ' LEU . 30.7 mt -69.33 137.24 52.76 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 124.399 1.079 . . . . 0.0 110.734 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 73.4 p -135.39 159.03 42.86 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.383 1.073 . . . . 0.0 108.621 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 12.0 mmt -64.15 -17.86 63.89 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 118.114 0.415 . . . . 0.0 110.523 179.083 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -79.07 -16.45 56.77 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.966 0.906 . . . . 0.0 112.177 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 75.3 mtm -118.94 15.09 13.36 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.378 1.071 . . . . 0.0 109.971 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.555 HD11 ' HB3' ' A' ' 21' ' ' LEU . 42.9 mt -137.0 154.46 50.4 Favored 'General case' 0 CA--C 1.511 -0.553 0 O-C-N 120.959 -1.088 . . . . 0.0 110.034 -178.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.6 t -164.33 -179.54 6.14 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.449 HG21 ' HB3' ' A' ' 38' ' ' PRO . 1.2 p -134.01 112.6 16.7 Favored 'Isoleucine or valine' 0 C--O 1.234 0.287 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -73.99 114.86 12.78 Favored 'General case' 0 CA--C 1.511 -0.556 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.1 p -51.81 139.75 7.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 O-C-N 124.196 0.935 . . . . 0.0 109.702 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 138.0 -131.34 5.4 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.2 pm0 -75.66 133.92 73.09 Favored Pre-proline 0 CA--C 1.541 0.602 0 C-N-CA 125.211 1.404 . . . . 0.0 112.847 -179.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.06 61.3 7.17 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 124.673 3.582 . . . . 0.0 111.123 179.217 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -88.24 172.06 9.73 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 125.122 1.369 . . . . 0.0 107.866 178.38 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.05 -77.0 1.18 Allowed Glycine 0 N--CA 1.445 -0.715 0 N-CA-C 113.822 0.289 . . . . 0.0 113.822 178.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -149.07 139.97 13.87 Favored Pre-proline 0 N--CA 1.443 -0.789 0 C-N-CA 126.315 1.846 . . . . 0.0 107.016 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.38 136.91 48.95 Favored 'Trans proline' 0 N--CA 1.451 -0.98 0 N-CA-C 109.106 -1.152 . . . . 0.0 109.106 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.449 ' HB3' HG21 ' A' ' 28' ' ' VAL . 74.4 Cg_endo -68.76 -15.25 40.55 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 122.479 2.119 . . . . 0.0 113.354 -179.233 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -69.47 -27.49 65.26 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 119.959 1.254 . . . . 0.0 109.85 178.332 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -98.27 10.43 40.67 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.644 1.578 . . . . 0.0 111.382 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.8 tt -52.54 -38.87 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 C-N-CA 124.831 1.252 . . . . 0.0 111.672 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -68.91 -21.14 64.24 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.74 1.216 . . . . 0.0 112.661 -179.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -79.88 -38.04 33.53 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 119.087 0.858 . . . . 0.0 110.746 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.54 -30.0 70.36 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 123.032 0.533 . . . . 0.0 110.078 178.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 45.3 t -66.52 107.13 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.47 -11.95 10.37 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 126.503 2.002 . . . . 0.0 112.696 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.0 mttm -79.91 156.87 27.09 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-N 118.562 1.181 . . . . 0.0 109.215 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -101.51 138.57 38.34 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.182 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.7 m -78.05 138.77 19.68 Favored 'Isoleucine or valine' 0 C--O 1.24 0.605 0 N-CA-C 109.082 -0.711 . . . . 0.0 109.082 178.328 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 82.6 mt -84.85 -16.77 40.17 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.587 1.555 . . . . 0.0 111.636 179.489 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 15.3 m -149.69 163.5 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.175 0 C-N-CA 126.342 1.857 . . . . 0.0 108.648 -178.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 16.7 m -72.45 125.94 28.64 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 177.693 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 87.6 t -105.03 131.12 54.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -76.25 170.43 16.34 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-O 122.413 1.102 . . . . 0.0 112.759 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -65.67 136.91 56.91 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 63.14 7.98 3.06 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 126.035 1.734 . . . . 0.0 112.803 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -72.45 157.28 37.93 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 119.428 1.013 . . . . 0.0 111.286 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.1 m -79.75 119.34 22.53 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 123.944 0.898 . . . . 0.0 111.27 -178.802 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.6 mm -76.13 139.82 18.29 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 178.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 26.8 mtp -138.88 160.49 39.6 Favored 'General case' 0 C--O 1.231 0.094 0 C-N-CA 123.655 0.782 . . . . 0.0 109.474 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -60.77 -40.77 93.77 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 123.304 0.641 . . . . 0.0 109.456 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -65.66 4.33 0.6 Allowed 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 126.215 1.806 . . . . 0.0 114.551 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 34.9 mt -118.28 0.01 11.61 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.113 1.365 . . . . 0.0 109.694 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.5 m -131.23 162.58 39.01 Favored 'Isoleucine or valine' 0 C--N 1.343 0.285 0 C-N-CA 124.321 1.048 . . . . 0.0 111.148 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -77.82 99.69 6.02 Favored 'General case' 0 C--O 1.239 0.526 0 C-N-CA 124.975 1.31 . . . . 0.0 112.056 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 179.73 135.55 0.1 Allowed 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 126.731 2.012 . . . . 0.0 108.002 178.138 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 27.6 m-70 -138.24 106.6 5.8 Favored 'General case' 0 CA--C 1.519 -0.213 0 N-CA-C 105.406 -2.072 . . . . 0.0 105.406 178.614 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -111.29 -115.75 3.56 Favored Glycine 0 N--CA 1.45 -0.408 0 O-C-N 123.184 0.303 . . . . 0.0 113.155 -178.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 54.7 tptt -101.59 100.82 11.28 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 106.006 -1.85 . . . . 0.0 106.006 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 36.1 tttp -145.26 171.64 14.28 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.325 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 25.8 pt -132.87 168.91 23.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 C-N-CA 124.989 1.315 . . . . 0.0 109.796 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 2.4 mmmp? -71.55 146.51 48.42 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 178.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 46.11 45.32 12.5 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 125.112 1.365 . . . . 0.0 111.627 -179.395 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.1 t -62.85 123.09 17.57 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 178.771 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 170.41 154.86 9.79 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 119.019 -0.878 . . . . 0.0 111.542 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -68.72 -39.78 8.25 Favored 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 123.51 2.807 . . . . 0.0 111.389 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 6.7 t -156.89 157.87 35.65 Favored 'General case' 0 N--CA 1.442 -0.851 0 C-N-CA 127.42 2.288 . . . . 0.0 105.564 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 1.7 t -159.89 -178.36 6.98 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 126.041 1.737 . . . . 0.0 106.855 179.322 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.675 0 N-CA-C 107.983 -2.047 . . . . 0.0 107.983 -178.924 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.431 0 N-CA-C 112.471 -0.251 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 6.0 t -155.2 152.25 29.13 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 179.131 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -163.75 168.2 20.0 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-O 121.827 0.822 . . . . 0.0 112.922 -179.115 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.72 -168.43 12.57 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 106.53 -2.628 . . . . 0.0 106.53 178.076 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.5 m -147.16 149.03 32.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 118.276 1.038 . . . . 0.0 108.846 178.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 69.7 m -125.25 118.49 26.12 Favored 'General case' 0 CA--C 1.516 -0.353 0 N-CA-C 105.828 -1.915 . . . . 0.0 105.828 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.06 -174.45 36.94 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 45.4 p -142.57 159.02 43.05 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.472 0.709 . . . . 0.0 109.794 -178.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 78.2 t -84.11 124.55 39.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 178.435 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.9 m -123.07 148.71 26.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.535 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.5 111.73 4.28 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 125.686 1.595 . . . . 0.0 107.997 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 81.1 tttt -64.95 -24.8 67.63 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 123.434 0.694 . . . . 0.0 112.714 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.6 m -148.92 165.79 3.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 127.116 2.167 . . . . 0.0 106.944 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -64.69 130.58 44.11 Favored 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 178.654 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 32.2 mt -118.78 101.27 50.59 Favored Pre-proline 0 CA--C 1.533 0.311 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.442 ' HA ' HG23 ' A' ' 52' ' ' THR . 36.6 Cg_endo -67.35 153.15 77.81 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 121.944 1.763 . . . . 0.0 112.346 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.4 ' HA ' HG23 ' A' ' 49' ' ' VAL . 9.6 tm-20 -58.17 146.03 35.02 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 122.289 1.042 . . . . 0.0 108.617 178.516 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.95 19.99 56.52 Favored Glycine 0 CA--C 1.53 0.995 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.953 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.1 m -117.44 156.25 28.27 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 125.976 1.71 . . . . 0.0 107.734 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 34.1 mm -101.5 143.25 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 C-N-CA 123.867 0.867 . . . . 0.0 108.716 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 23.0 mt -76.03 135.88 39.94 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 67.1 p -130.57 158.15 40.76 Favored 'General case' 0 C--O 1.238 0.477 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 13.4 mmt -63.22 -20.51 65.5 Favored 'General case' 0 CA--C 1.536 0.408 0 O-C-N 121.926 -0.484 . . . . 0.0 109.713 178.409 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -79.99 -18.41 50.36 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 126.27 1.828 . . . . 0.0 114.185 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 69.8 mtm -112.46 16.15 19.95 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 119.162 0.892 . . . . 0.0 111.697 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.1 mt -133.64 147.92 51.49 Favored 'General case' 0 C--O 1.238 0.456 0 C-N-CA 124.019 0.927 . . . . 0.0 110.666 -179.076 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.9 t -147.7 144.62 28.45 Favored 'General case' 0 CA--C 1.54 0.572 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 56.8 t -89.06 117.52 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 31.7 ttpt -59.84 -29.63 68.4 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 115.01 1.485 . . . . 0.0 115.01 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.6 t 47.65 66.42 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 CA-C-O 122.665 1.221 . . . . 0.0 109.278 -179.092 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.97 -66.24 0.01 OUTLIER Glycine 0 CA--C 1.521 0.435 0 C-N-CA 124.647 1.118 . . . . 0.0 111.042 -179.482 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -133.9 152.8 79.28 Favored Pre-proline 0 CA--C 1.529 0.158 0 C-N-CA 123.583 0.753 . . . . 0.0 111.598 -178.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.18 5.4 4.59 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 123.686 2.924 . . . . 0.0 113.131 179.209 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -72.26 115.12 11.13 Favored 'General case' 0 CA--C 1.518 -0.251 0 O-C-N 119.946 -1.721 . . . . 0.0 106.413 178.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.36 171.71 15.73 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.344 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -54.94 135.71 66.59 Favored Pre-proline 0 CA--C 1.541 0.61 0 CA-C-O 118.993 -0.527 . . . . 0.0 110.716 -179.216 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -67.94 150.73 78.26 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.806 2.337 . . . . 0.0 113.557 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -79.41 -4.34 13.6 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 123.437 2.758 . . . . 0.0 114.93 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 24.2 tp10 -82.43 -46.14 13.89 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 119.918 1.235 . . . . 0.0 108.124 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -79.71 7.38 8.62 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 125.86 1.664 . . . . 0.0 111.63 -179.575 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.7 tt -46.82 -43.13 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 C-N-CA 126.19 1.796 . . . . 0.0 112.909 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -58.91 -27.95 65.74 Favored 'General case' 0 C--O 1.227 -0.126 0 C-N-CA 123.1 0.56 . . . . 0.0 111.657 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -73.35 -36.82 66.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 49.2 mt -66.65 -38.96 87.94 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 119.123 0.874 . . . . 0.0 109.705 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 73.5 t -61.63 131.45 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.09 -11.09 69.69 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 118.792 -1.004 . . . . 0.0 111.699 -178.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 26.5 mttm -84.05 154.36 23.28 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-N 119.556 1.678 . . . . 0.0 110.615 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 39.4 ttmt -95.04 131.08 41.41 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 178.634 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.4 HG23 ' HA ' ' A' ' 17' ' ' GLU . 4.4 m -66.76 168.66 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 176.512 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 46.3 mt -114.28 -7.08 12.97 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 123.913 0.885 . . . . 0.0 112.44 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.8 m -156.83 162.31 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 126.952 2.101 . . . . 0.0 108.418 -178.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.442 HG23 ' HA ' ' A' ' 16' ' ' PRO . 31.9 m -72.94 109.66 6.66 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.003 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 57.4 t -85.96 131.04 35.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 179.291 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -78.05 167.49 21.37 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 123.652 0.781 . . . . 0.0 109.721 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -69.92 149.86 47.35 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 177.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 60.94 10.01 2.58 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 127.948 2.499 . . . . 0.0 111.59 -179.569 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -75.73 153.33 37.11 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 178.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 99.2 m -88.47 121.88 31.34 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.179 0.514 . . . . 0.0 110.932 -178.662 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 mm -74.18 138.51 21.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 178.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -131.37 157.92 42.13 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 124.368 1.067 . . . . 0.0 108.595 179.31 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -59.35 -27.8 66.26 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 124.715 1.206 . . . . 0.0 111.669 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -89.26 -4.15 58.27 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 119.173 0.897 . . . . 0.0 113.095 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 57.4 mt -96.57 15.8 20.61 Favored 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 124.352 1.061 . . . . 0.0 109.4 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.1 m -139.22 140.84 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -75.46 66.82 1.92 Allowed 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 125.598 1.559 . . . . 0.0 110.387 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -147.64 141.36 25.65 Favored 'General case' 0 CA--C 1.516 -0.338 0 C-N-CA 125.215 1.406 . . . . 0.0 108.372 -179.268 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . 0.263 5.5 m-70 64.43 -67.28 0.11 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 126.518 1.927 . . . . 0.0 109.057 -178.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -76.55 168.55 54.8 Favored Glycine 0 CA--C 1.538 1.506 0 N-CA-C 106.455 -2.658 . . . . 0.0 106.455 176.071 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 154.68 -4.48 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 130.186 3.394 . . . . 0.0 112.07 -179.424 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -79.8 106.45 11.84 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 120.665 -1.272 . . . . 0.0 107.696 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 23.4 pt -73.56 5.21 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 CA-C-N 118.295 0.498 . . . . 0.0 111.859 179.201 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -87.75 97.31 10.83 Favored 'General case' 0 N--CA 1.449 -0.483 0 O-C-N 120.724 -1.235 . . . . 0.0 108.498 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 2.2 p -62.4 92.87 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 126.655 1.982 . . . . 0.0 108.396 178.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 7.2 t -162.08 132.75 4.95 Favored 'General case' 0 C--O 1.236 0.394 0 O-C-N 120.709 -1.245 . . . . 0.0 110.749 -179.092 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.35 137.47 23.77 Favored Glycine 0 CA--C 1.534 1.224 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 179.627 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -73.0 168.05 25.76 Favored 'Trans proline' 0 N--CA 1.462 -0.38 0 C-N-CA 123.325 2.683 . . . . 0.0 111.784 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 50.3 m -64.95 109.19 2.02 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 177.723 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 12.7 m -154.62 80.34 1.09 Allowed 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 -178.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.967 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.615 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.755 0 N-CA-C 107.794 -2.122 . . . . 0.0 107.794 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.1 t -132.04 -9.32 3.43 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.495 1.518 . . . . 0.0 109.333 177.772 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.5 m -74.78 160.74 30.33 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 124.545 1.138 . . . . 0.0 109.671 178.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.75 161.27 28.52 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 108.041 -2.024 . . . . 0.0 108.041 179.073 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.1 p -140.79 24.92 2.18 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.292 1.437 . . . . 0.0 111.709 -178.691 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.1 m -54.74 127.26 27.51 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 124.173 0.989 . . . . 0.0 110.214 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.66 -171.75 24.26 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 126.917 2.199 . . . . 0.0 109.869 -178.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -146.91 162.0 39.58 Favored 'General case' 0 C--O 1.239 0.513 0 C-N-CA 126.081 1.753 . . . . 0.0 110.963 179.046 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.2 t -70.0 140.47 18.54 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 C-N-CA 126.188 1.795 . . . . 0.0 112.282 -178.417 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.7 m -139.59 159.53 27.8 Favored 'Isoleucine or valine' 0 C--O 1.24 0.584 0 C-N-CA 126.601 1.961 . . . . 0.0 107.078 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -81.25 138.28 35.78 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.096 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -81.6 -22.33 37.78 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 123.447 0.699 . . . . 0.0 111.567 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.8 m -145.76 170.38 5.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 124.842 1.257 . . . . 0.0 108.254 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.6 tttm -72.41 104.05 3.65 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 105.549 -2.019 . . . . 0.0 105.549 177.74 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 7.3 mt -88.32 109.04 25.54 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-O 118.122 -0.942 . . . . 0.0 109.063 -178.758 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -69.67 149.39 67.4 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 CA-C-N 120.981 1.386 . . . . 0.0 109.983 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.422 ' HA ' HG23 ' A' ' 49' ' ' VAL . 27.9 tt0 -51.14 143.88 10.11 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.454 1.102 . . . . 0.0 110.565 179.434 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.38 2.0 90.27 Favored Glycine 0 C--N 1.338 0.641 0 CA-C-O 118.979 -0.901 . . . . 0.0 114.53 179.037 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 65.4 m -91.03 142.63 27.57 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 118.741 1.271 . . . . 0.0 109.708 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 5.0 mm -78.7 135.45 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.375 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 50.4 mt -74.29 141.85 45.26 Favored 'General case' 0 C--O 1.237 0.446 0 C-N-CA 124.774 1.23 . . . . 0.0 109.352 178.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 41.7 p -141.36 165.51 27.31 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 106.951 -1.499 . . . . 0.0 106.951 178.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -65.02 -22.2 66.96 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-N 118.116 0.416 . . . . 0.0 110.459 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -67.93 -30.5 69.82 Favored 'General case' 0 N--CA 1.464 0.263 0 C-N-CA 124.48 1.112 . . . . 0.0 111.495 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 71.1 mtm -105.92 10.52 32.37 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.491 1.117 . . . . 0.0 112.67 -177.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.0 mt -131.93 162.51 30.48 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 123.958 0.903 . . . . 0.0 109.013 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.5 t -169.84 174.86 5.45 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 179.113 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.4 t -114.99 156.75 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 177.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 23.8 ttpp -126.98 111.68 14.37 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 103.423 -2.806 . . . . 0.0 103.423 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.7 m -62.63 158.88 3.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 120.238 -0.585 . . . . 0.0 110.209 -179.113 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 130.76 -96.69 0.35 Allowed Glycine 0 C--N 1.333 0.371 0 CA-C-O 119.078 -0.846 . . . . 0.0 112.277 179.168 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -115.76 157.28 44.97 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 125.559 1.544 . . . . 0.0 113.486 -177.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -77.32 15.19 1.24 Allowed 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 124.562 3.508 . . . . 0.0 113.366 179.514 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 25.6 tptp -55.68 113.55 1.51 Allowed 'General case' 0 N--CA 1.465 0.311 0 O-C-N 120.699 -1.251 . . . . 0.0 108.5 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.33 -170.47 21.43 Favored Glycine 0 N--CA 1.451 -0.348 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.4 t80 -58.02 130.32 82.98 Favored Pre-proline 0 CA--C 1.544 0.719 0 CA-C-O 118.505 -0.76 . . . . 0.0 110.257 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -66.05 153.12 79.39 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.897 2.398 . . . . 0.0 111.797 -178.719 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_endo -77.23 -22.96 10.7 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 121.606 1.537 . . . . 0.0 113.893 -178.664 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -63.12 -40.92 99.01 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 119.83 1.195 . . . . 0.0 109.933 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -82.96 4.34 26.26 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-O 117.906 -1.045 . . . . 0.0 113.313 -178.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.6 tt -48.25 -35.03 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 CA-C-N 120.719 1.6 . . . . 0.0 113.763 -178.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -58.82 -28.49 66.07 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.508 0.723 . . . . 0.0 111.701 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 30.0 m-80 -71.53 -41.99 68.5 Favored 'General case' 0 CA--C 1.521 -0.161 0 C-N-CA 124.001 0.921 . . . . 0.0 109.234 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 38.1 mt -65.0 -42.17 94.73 Favored 'General case' 0 CA--C 1.519 -0.216 0 C-N-CA 123.054 0.541 . . . . 0.0 110.171 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.78 98.7 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 C-N-CA 124.345 1.058 . . . . 0.0 108.786 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.99 -14.19 6.65 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 126.321 1.915 . . . . 0.0 114.178 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -79.62 167.79 20.24 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 118.861 1.331 . . . . 0.0 110.426 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.05 137.82 42.22 Favored 'General case' 0 CA--C 1.512 -0.516 0 CA-C-O 118.075 -0.964 . . . . 0.0 109.599 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.422 HG23 ' HA ' ' A' ' 17' ' ' GLU . 3.3 m -77.02 138.14 21.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.37 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 78.3 mt -85.33 -15.88 41.84 Favored 'General case' 0 N--CA 1.462 0.148 0 C-N-CA 123.452 0.701 . . . . 0.0 112.182 179.689 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.2 m -148.04 164.47 5.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 30.7 m -69.66 140.86 53.68 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.077 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 84.9 t -115.14 152.8 16.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -110.71 166.69 10.81 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 123.966 0.907 . . . . 0.0 111.194 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -63.26 128.57 36.43 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 30.6 t70 68.73 8.21 6.61 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 128.09 2.556 . . . . 0.0 112.908 -179.399 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -67.25 162.6 22.28 Favored 'General case' 0 CA--C 1.533 0.298 0 O-C-N 121.005 -1.059 . . . . 0.0 108.438 179.26 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 77.7 m -95.08 123.0 38.32 Favored 'General case' 0 N--CA 1.468 0.435 0 O-C-N 120.131 -1.606 . . . . 0.0 113.181 -178.289 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 13.3 mm -74.38 146.41 9.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 3.3 mmt -140.26 158.56 43.85 Favored 'General case' 0 C--O 1.233 0.214 0 C-N-CA 126.404 1.882 . . . . 0.0 107.299 179.235 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.34 -32.32 73.71 Favored 'General case' 0 CA--C 1.528 0.123 0 O-C-N 122.141 -0.349 . . . . 0.0 111.762 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -72.07 -5.27 34.07 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -179.107 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 56.7 mt -103.77 9.57 36.99 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 124.24 1.016 . . . . 0.0 111.05 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.5 m -131.93 155.28 41.45 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 CA-C-N 119.758 1.163 . . . . 0.0 112.3 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -62.15 167.67 3.84 Favored 'General case' 0 C--O 1.234 0.285 0 C-N-CA 125.608 1.563 . . . . 0.0 113.85 -179.547 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -85.8 84.13 7.65 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 106.633 -1.618 . . . . 0.0 106.633 178.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -63.33 -9.57 12.56 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 125.973 1.709 . . . . 0.0 112.598 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -146.58 -167.33 12.8 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 126.203 1.859 . . . . 0.0 109.926 179.235 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 48.7 tttp -89.39 111.11 21.89 Favored 'General case' 0 N--CA 1.443 -0.795 0 C-N-CA 127.557 2.343 . . . . 0.0 107.993 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 7.8 ptmm? -133.07 -177.86 4.7 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 36.9 mm -117.37 169.78 7.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 105.6 -2.0 . . . . 0.0 105.6 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 35.2 pttt -60.86 108.89 0.92 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.842 1.257 . . . . 0.0 108.045 178.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.1 t -154.89 147.34 24.07 Favored 'General case' 0 C--O 1.233 0.187 0 C-N-CA 124.036 0.934 . . . . 0.0 109.645 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.5 p -90.43 -2.65 57.95 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 126.28 1.832 . . . . 0.0 113.031 179.549 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 45.34 61.7 3.5 Favored Glycine 0 CA--C 1.536 1.368 0 CA-C-O 118.302 -1.277 . . . . 0.0 110.544 -179.076 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -57.49 -36.02 98.77 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 123.209 2.606 . . . . 0.0 114.734 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 9.7 p -153.51 -172.55 4.27 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-N 119.272 0.942 . . . . 0.0 109.456 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -155.04 134.28 12.43 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.254 1.394 0 CA-C-O 118.074 -1.403 . . . . 0.0 110.407 -179.706 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.725 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 34.7 t -131.41 -67.12 0.71 Allowed 'General case' 0 CA--C 1.53 0.199 0 N-CA-C 105.423 -2.066 . . . . 0.0 105.423 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.2 p -90.65 93.41 9.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 178.756 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 130.56 134.52 3.68 Favored Glycine 0 N--CA 1.453 -0.216 0 N-CA-C 107.318 -2.313 . . . . 0.0 107.318 -179.023 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.7 p -153.97 79.44 1.13 Allowed 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 -179.393 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.1 t -81.51 103.19 11.07 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 102.146 -3.279 . . . . 0.0 102.146 178.077 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -161.75 177.62 37.93 Favored Glycine 0 C--N 1.333 0.366 0 O-C-N 121.284 -0.885 . . . . 0.0 113.234 -178.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.411 ' HB3' ' O ' ' A' ' 34' ' ' LYS . 0.2 OUTLIER -122.52 134.32 54.56 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 127.245 2.218 . . . . 0.0 111.997 -177.877 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 61.2 t -67.73 129.44 32.29 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 28.2 m -132.88 151.42 34.31 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.23 128.4 36.11 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.474 ' HE3' ' HB ' ' A' ' 27' ' ' THR . 6.7 ttmt -72.75 -28.15 62.46 Favored 'General case' 0 C--N 1.327 -0.377 0 O-C-N 121.399 -0.813 . . . . 0.0 111.695 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.71 169.88 18.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 C-N-CA 125.762 1.625 . . . . 0.0 107.093 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 58.7 tttt -71.88 114.91 10.48 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 49.8 mt -100.2 106.77 43.88 Favored Pre-proline 0 CA--C 1.534 0.339 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.483 ' HA ' HG23 ' A' ' 52' ' ' THR . 42.8 Cg_endo -66.55 148.7 83.96 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 121.569 1.513 . . . . 0.0 110.72 179.297 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.45 ' HA ' HG23 ' A' ' 49' ' ' VAL . 52.0 tt0 -48.54 142.29 6.06 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 126.168 1.787 . . . . 0.0 110.38 179.476 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.36 0.46 86.76 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-O 118.012 -1.438 . . . . 0.0 113.768 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.1 m -91.3 154.88 18.93 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 120.355 2.078 . . . . 0.0 107.857 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.8 mm -89.29 145.91 6.82 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-N 119.509 1.05 . . . . 0.0 109.097 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 15.2 mt -80.36 137.7 36.59 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.245 0.618 . . . . 0.0 109.811 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 29.0 p -131.22 154.95 47.89 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 125.952 1.701 . . . . 0.0 107.342 179.261 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 12.4 mmt -60.82 -35.46 76.58 Favored 'General case' 0 CA--C 1.538 0.484 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -61.2 -19.16 61.29 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 127.987 2.515 . . . . 0.0 113.051 178.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.6 mtm -115.66 16.31 16.45 Favored 'General case' 0 N--CA 1.466 0.355 0 O-C-N 121.195 -0.941 . . . . 0.0 110.979 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 70.7 mt -129.26 170.5 13.53 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 121.998 0.904 . . . . 0.0 113.263 -179.113 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.474 ' HB ' ' HE3' ' A' ' 12' ' ' LYS . 4.3 t -171.88 173.26 4.54 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 128.343 2.657 . . . . 0.0 107.221 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -129.88 110.56 19.83 Favored 'Isoleucine or valine' 0 C--O 1.24 0.568 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 178.571 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 20.6 ttpt -69.8 112.6 6.36 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.192 1.397 . . . . 0.0 107.498 179.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.8 p -66.93 130.96 32.76 Favored 'Isoleucine or valine' 0 C--O 1.239 0.513 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 178.424 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.64 -89.27 0.1 OUTLIER Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 -179.139 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -134.5 158.5 75.01 Favored Pre-proline 0 CA--C 1.539 0.553 0 CA-C-O 118.532 -0.747 . . . . 0.0 110.698 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -73.3 31.65 0.31 Allowed 'Trans proline' 0 CA--C 1.544 0.981 1 C-N-CA 126.149 4.566 . . . . 0.0 116.093 -179.152 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.411 ' O ' ' HB3' ' A' ' 8' ' ' SER . 39.9 ttmt -60.6 139.04 57.96 Favored 'General case' 0 C--O 1.225 -0.225 0 O-C-N 120.676 -1.265 . . . . 0.0 110.968 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.41 -72.67 0.78 Allowed Glycine 0 CA--C 1.524 0.62 0 CA-C-O 118.526 -1.152 . . . . 0.0 115.754 178.497 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.415 ' CG ' HD11 ' A' ' 44' ' ' LEU . 1.7 t80 -151.09 147.77 21.31 Favored Pre-proline 0 CA--C 1.544 0.737 0 CA-C-N 119.596 1.698 . . . . 0.0 114.82 -176.515 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -83.99 163.4 13.67 Favored 'Trans proline' 0 C--N 1.354 0.868 0 C-N-CA 124.203 3.269 . . . . 0.0 114.347 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -79.61 -10.36 14.5 Favored 'Trans proline' 0 C--N 1.349 0.605 0 C-N-CA 122.482 2.121 . . . . 0.0 111.873 179.268 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -76.73 -19.85 57.2 Favored 'General case' 0 CA--C 1.535 0.39 0 O-C-N 121.248 -0.907 . . . . 0.0 110.922 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -117.47 8.78 13.07 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 124.04 0.936 . . . . 0.0 112.69 -178.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.6 tt -51.45 -35.5 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 124.041 0.936 . . . . 0.0 111.569 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -61.83 -28.17 69.29 Favored 'General case' 0 N--CA 1.461 0.123 0 C-N-CA 125.245 1.418 . . . . 0.0 111.74 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 37.7 m-80 -78.37 -30.26 47.86 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-O 118.977 -0.535 . . . . 0.0 109.622 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.415 HD11 ' CG ' ' A' ' 36' ' ' TYR . 53.4 mt -76.03 -37.47 58.33 Favored 'General case' 0 C--N 1.339 0.12 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.559 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.1 t -63.54 121.28 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 104.617 -2.364 . . . . 0.0 104.617 178.241 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.45 -9.72 38.59 Favored Glycine 0 CA--C 1.534 1.266 0 CA-C-O 118.846 -0.975 . . . . 0.0 111.404 -178.113 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 72.2 mttt -85.18 169.16 14.12 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-N 119.721 1.761 . . . . 0.0 107.751 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.1 ttmp? -116.01 130.07 56.65 Favored 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 125.813 1.645 . . . . 0.0 108.027 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.45 HG23 ' HA ' ' A' ' 17' ' ' GLU . 3.9 m -73.2 144.02 13.21 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 55.7 mt -90.59 -13.88 33.58 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 124.198 0.999 . . . . 0.0 112.093 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 31.6 m -147.99 162.88 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 125.89 1.676 . . . . 0.0 107.208 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.483 HG23 ' HA ' ' A' ' 16' ' ' PRO . 51.5 m -72.85 133.83 44.6 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 96.9 t -112.61 124.48 69.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 125.808 1.643 . . . . 0.0 107.519 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -78.65 171.85 14.54 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.49 0.662 . . . . 0.0 111.866 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 49.1 tt0 -63.25 143.68 57.59 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 105.389 -2.078 . . . . 0.0 105.389 177.482 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 25.8 t0 61.36 8.23 2.06 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.334 2.254 . . . . 0.0 112.883 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.82 150.52 32.28 Favored 'General case' 0 C--N 1.344 0.365 0 O-C-N 120.905 -1.122 . . . . 0.0 110.287 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.5 118.02 17.92 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 125.124 1.369 . . . . 0.0 113.961 -176.556 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 mm -75.87 146.32 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 104.564 -2.384 . . . . 0.0 104.564 177.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 10.0 mtt -141.92 157.19 45.26 Favored 'General case' 0 CA--C 1.518 -0.272 0 C-N-CA 123.956 0.903 . . . . 0.0 109.207 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -67.63 -14.74 63.2 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 122.473 0.309 . . . . 0.0 111.267 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 20.5 tt0 -84.52 -33.02 23.61 Favored 'General case' 0 CA--C 1.535 0.4 0 O-C-N 121.127 -0.983 . . . . 0.0 110.89 179.195 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 43.5 mt -81.33 6.27 14.83 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.722 1.609 . . . . 0.0 113.826 -178.393 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.6 m -126.66 154.26 36.28 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 CA-C-N 119.267 0.94 . . . . 0.0 110.997 -179.224 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -74.38 -179.1 3.78 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 125.351 1.46 . . . . 0.0 109.618 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -73.63 144.99 45.69 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 120.982 -1.074 . . . . 0.0 110.52 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 17.6 t-80 -63.63 94.34 0.09 Allowed 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 178.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.98 155.72 11.05 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 125.176 1.37 . . . . 0.0 110.718 -178.5 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 80.6 tttt -132.24 122.92 25.96 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 125.867 1.667 . . . . 0.0 106.607 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.94 143.49 17.01 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 118.164 0.438 . . . . 0.0 110.807 -179.685 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 29.1 pt -79.23 158.12 4.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 106.63 -1.618 . . . . 0.0 106.63 177.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 5.1 ptpt -105.42 152.66 22.71 Favored 'General case' 0 C--O 1.234 0.248 0 C-N-CA 123.613 0.765 . . . . 0.0 109.326 179.058 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.8 m -95.78 164.37 12.78 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 123.299 0.64 . . . . 0.0 109.879 179.546 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 5.7 t -170.23 -170.7 1.0 Allowed 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 127.338 2.255 . . . . 0.0 105.909 179.118 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -123.31 163.59 16.72 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.479 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -76.91 1.79 8.24 Favored 'Trans proline' 0 CA--C 1.54 0.805 0 C-N-CA 123.64 2.893 . . . . 0.0 112.775 179.608 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 9.0 t -146.57 156.16 43.03 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 105.839 -1.911 . . . . 0.0 105.839 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 57.4 m -158.32 177.66 11.02 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 126.055 1.742 . . . . 0.0 107.528 179.554 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.257 1.552 0 C-N-CA 128.211 2.815 . . . . 0.0 106.527 179.797 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.51 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.0 m -142.23 -168.4 2.71 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 124.433 1.093 . . . . 0.0 108.844 -179.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.2 t -138.96 157.78 45.39 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.454 1.102 . . . . 0.0 108.191 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 70.77 48.08 36.65 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 108.886 -1.686 . . . . 0.0 108.886 -179.208 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.4 p -60.58 157.73 13.8 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.421 1.488 . . . . 0.0 112.438 -179.312 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 43.9 t -102.83 -105.42 0.27 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 124.856 1.262 . . . . 0.0 108.292 179.491 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -175.94 -165.06 31.24 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 107.262 -2.335 . . . . 0.0 107.262 -179.504 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.1 t -141.94 174.03 10.97 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 118.377 1.089 . . . . 0.0 112.506 -178.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.438 HG11 ' CD1' ' A' ' 44' ' ' LEU . 68.3 t -78.33 119.78 27.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 C-N-CA 127.664 2.386 . . . . 0.0 108.578 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.6 m -128.96 147.5 33.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.582 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.17 115.43 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 124.356 1.062 . . . . 0.0 108.267 179.335 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 41.0 tttm -64.68 -30.55 71.56 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.7 m -147.74 168.67 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 128.413 2.685 . . . . 0.0 105.804 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 65.9 tttt -63.64 130.47 44.42 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 9.4 mt -114.63 101.14 54.18 Favored Pre-proline 0 N--CA 1.454 -0.26 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -70.56 148.3 59.6 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 122.381 2.054 . . . . 0.0 109.235 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 -51.9 146.25 8.65 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.678 1.191 . . . . 0.0 113.228 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 79.74 -2.87 71.78 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 125.059 1.314 . . . . 0.0 113.525 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.4 m -82.19 151.68 26.78 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 119.0 1.4 . . . . 0.0 109.637 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 17.4 mm -91.31 128.5 43.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 178.307 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 63.3 mt -67.56 146.91 53.44 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.084 1.354 . . . . 0.0 108.964 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 64.9 p -141.27 160.29 40.43 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.9 mmt -64.27 -26.86 68.68 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 178.043 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -63.69 -16.0 59.91 Favored 'General case' 0 CA--C 1.536 0.426 0 O-C-N 121.494 -0.754 . . . . 0.0 112.48 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 38.0 mtm -120.09 4.99 10.84 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 124.878 1.271 . . . . 0.0 112.375 -179.637 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 92.1 mt -124.94 118.82 27.12 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 120.006 1.275 . . . . 0.0 109.163 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 t -123.82 171.77 9.4 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 124.921 1.288 . . . . 0.0 109.369 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 17.9 t -119.81 151.4 22.36 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 39.1 mmtm -109.83 -172.22 2.0 Allowed 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 124.995 1.318 . . . . 0.0 109.795 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 23.2 m -131.57 16.77 1.82 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 C-N-CA 124.979 1.312 . . . . 0.0 111.565 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -78.64 -92.42 0.32 Allowed Glycine 0 C--N 1.334 0.451 0 C-N-CA 124.107 0.86 . . . . 0.0 113.255 -179.034 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -133.54 157.59 77.63 Favored Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 126.279 1.831 . . . . 0.0 109.004 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -73.05 -1.99 11.35 Favored 'Trans proline' 0 CA--C 1.535 0.55 0 C-N-CA 123.873 3.048 . . . . 0.0 114.233 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.4 ttpt -52.49 127.78 23.67 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.97 -170.74 13.44 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 -178.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -64.61 128.45 93.49 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -64.3 134.85 43.9 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.247 1.965 . . . . 0.0 111.337 -179.225 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -68.55 -17.65 43.28 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 121.631 1.554 . . . . 0.0 113.482 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -64.39 -25.62 68.1 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 120.311 1.414 . . . . 0.0 110.241 179.235 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -109.04 12.51 25.17 Favored 'General case' 0 N--CA 1.464 0.237 0 O-C-N 121.15 -0.969 . . . . 0.0 112.121 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.5 tt -48.6 -35.48 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 124.847 1.259 . . . . 0.0 111.895 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 40.0 m-85 -51.81 -30.17 22.22 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 126.111 1.764 . . . . 0.0 112.144 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 67.4 m-80 -81.96 -21.39 37.23 Favored 'General case' 0 CA--C 1.519 -0.214 0 C-N-CA 124.327 1.051 . . . . 0.0 113.093 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.438 ' CD1' HG11 ' A' ' 9' ' ' VAL . 96.2 mt -78.05 -35.53 49.51 Favored 'General case' 0 CA--C 1.521 -0.145 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.17 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.85 125.49 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.41 -11.5 68.71 Favored Glycine 0 CA--C 1.529 0.949 0 CA-C-O 117.842 -1.532 . . . . 0.0 113.369 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 43.1 mtmt -83.42 164.24 20.05 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 120.814 2.307 . . . . 0.0 109.558 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.7 ttmp? -102.54 145.52 29.48 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.8 m -85.36 140.23 16.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 O-C-N 123.346 0.404 . . . . 0.0 110.397 179.212 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 16.9 mt -86.89 -18.07 31.75 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-O 117.718 -1.134 . . . . 0.0 111.527 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 17.7 m -150.02 165.36 3.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 C-N-CA 123.958 0.903 . . . . 0.0 109.052 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.0 m -74.76 143.2 44.18 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 105.609 -1.997 . . . . 0.0 105.609 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 75.1 t -129.08 123.26 58.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 C-N-CA 125.8 1.64 . . . . 0.0 106.664 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -72.54 160.98 31.39 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 122.626 1.203 . . . . 0.0 108.867 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -65.76 134.32 52.9 Favored 'General case' 0 C--O 1.24 0.581 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.2 t70 82.87 1.2 1.17 Allowed 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 128.886 2.874 . . . . 0.0 113.901 179.285 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -71.76 156.97 38.74 Favored 'General case' 0 C--N 1.341 0.226 0 CA-C-N 118.228 0.467 . . . . 0.0 110.631 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.3 m -80.67 116.9 20.92 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 125.965 1.706 . . . . 0.0 109.775 179.172 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 16.0 mm -73.95 143.53 13.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 N-CA-C 107.243 -1.391 . . . . 0.0 107.243 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -135.47 153.75 51.65 Favored 'General case' 0 CA--C 1.521 -0.147 0 C-N-CA 125.574 1.55 . . . . 0.0 107.411 179.177 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -60.72 -29.34 69.3 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -179.192 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 22.2 tp10 -67.65 -22.7 65.3 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 122.714 0.406 . . . . 0.0 111.252 -179.147 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 17.4 mt -86.52 4.06 41.53 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 124.759 1.224 . . . . 0.0 112.276 -178.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.4 m -131.4 117.25 35.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 120.182 1.355 . . . . 0.0 112.292 -178.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -72.89 118.55 15.98 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 125.651 1.58 . . . . 0.0 108.263 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 173.18 114.94 0.02 OUTLIER 'General case' 0 C--O 1.233 0.226 0 C-N-CA 126.054 1.742 . . . . 0.0 110.108 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 72.7 m-70 -79.42 61.44 3.47 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.226 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 46.5 -139.61 7.07 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 126.227 1.87 . . . . 0.0 110.58 -179.169 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 25.4 ttpp -101.85 142.7 32.76 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 178.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 60.5 tttp -155.64 124.59 6.11 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 106.345 -1.724 . . . . 0.0 106.345 178.464 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 62.7 mt -60.5 153.98 4.47 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.698 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 20.8 mmtp -111.82 -39.83 4.45 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 125.21 1.404 . . . . 0.0 109.529 179.282 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.3 t -75.47 -168.36 0.81 Allowed 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.151 1.381 . . . . 0.0 110.032 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -144.51 170.25 16.41 Favored 'General case' 0 C--O 1.237 0.42 0 C-N-CA 127.296 2.238 . . . . 0.0 108.432 179.325 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 130.65 -72.9 0.47 Allowed Glycine 0 CA--C 1.525 0.7 0 CA-C-O 117.919 -1.489 . . . . 0.0 111.839 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -74.68 158.71 43.19 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 122.028 1.818 . . . . 0.0 112.734 -179.058 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 6.5 m -63.34 157.7 22.34 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 125.451 1.5 . . . . 0.0 110.005 178.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 5.7 m -51.55 -37.78 51.22 Favored 'General case' 0 C--O 1.228 -0.067 0 C-N-CA 125.101 1.36 . . . . 0.0 113.156 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.983 0 N-CA-C 104.378 -3.489 . . . . 0.0 104.378 -179.863 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.98 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.9 m -75.16 122.81 24.18 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.228 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.9 t -74.48 69.39 1.67 Allowed 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 119.535 1.061 . . . . 0.0 110.091 -179.551 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.0 160.27 31.44 Favored Glycine 0 N--CA 1.45 -0.372 0 O-C-N 120.789 -1.195 . . . . 0.0 114.053 -179.228 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -161.46 -68.11 0.06 Allowed 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 129.124 2.969 . . . . 0.0 105.984 178.623 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.9 m -75.99 97.32 3.98 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 124.714 1.206 . . . . 0.0 108.303 178.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 178.85 -168.79 39.92 Favored Glycine 0 CA--C 1.523 0.548 0 O-C-N 120.238 -1.539 . . . . 0.0 111.44 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 48.4 t -136.95 154.92 50.31 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 123.823 0.849 . . . . 0.0 110.916 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 99.2 t -75.76 142.52 14.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.3 m -141.83 161.81 20.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.568 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 178.381 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.91 121.72 20.47 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 54.1 tttm -74.8 -21.7 59.16 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 118.862 -0.59 . . . . 0.0 110.96 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.4 m -145.31 168.04 8.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 C-N-CA 125.873 1.669 . . . . 0.0 108.765 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -73.34 113.68 10.7 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 178.037 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.3 mt -105.56 104.12 46.68 Favored Pre-proline 0 CA--C 1.533 0.299 0 C-N-CA 124.977 1.311 . . . . 0.0 108.311 -178.282 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -67.82 155.39 70.06 Favored 'Trans proline' 0 N--CA 1.454 -0.83 0 C-N-CA 121.559 1.506 . . . . 0.0 110.382 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.416 ' HA ' HG23 ' A' ' 49' ' ' VAL . 5.8 tm-20 -52.08 147.34 7.53 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-O 121.899 0.856 . . . . 0.0 111.164 179.515 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.27 -4.1 82.36 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 123.77 0.7 . . . . 0.0 114.151 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 26.9 m -84.98 144.76 28.1 Favored 'General case' 0 CA--C 1.538 0.485 0 CA-C-N 118.9 1.35 . . . . 0.0 111.355 -179.166 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 27.5 mm -87.13 129.85 37.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.859 1.664 . . . . 0.0 107.712 178.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 38.6 mt -71.33 150.49 45.07 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.808 1.243 . . . . 0.0 112.323 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 46.5 p -145.57 161.72 39.13 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 126.826 2.05 . . . . 0.0 107.396 179.1 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 21.6 mmt -62.11 -38.51 89.17 Favored 'General case' 0 C--O 1.223 -0.327 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 178.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.9 t0 -59.32 -23.61 62.62 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 125.014 1.326 . . . . 0.0 112.651 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 25.5 mtm -104.36 7.71 35.71 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 121.34 -0.85 . . . . 0.0 111.919 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.1 mt -126.19 151.19 47.69 Favored 'General case' 0 CA--C 1.521 -0.135 0 O-C-N 120.948 -1.095 . . . . 0.0 109.124 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.3 t -149.28 174.06 12.81 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 179.119 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.1 t -128.77 122.78 57.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.212 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 22.5 mmmt -92.84 116.46 29.05 Favored 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 p -65.2 136.03 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 178.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 154.76 -87.48 0.13 Allowed Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.5 pm0 -145.11 156.78 54.56 Favored Pre-proline 0 CA--C 1.54 0.591 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -82.35 57.35 6.12 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 124.965 3.777 . . . . 0.0 111.589 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.51 10.26 3.31 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 124.642 1.177 . . . . 0.0 113.254 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.48 -155.6 7.57 Favored Glycine 0 CA--C 1.524 0.633 0 C-N-CA 125.12 1.343 . . . . 0.0 109.98 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 20.1 t80 -59.66 141.03 89.04 Favored Pre-proline 0 CA--C 1.547 0.85 0 C-N-CA 123.669 0.788 . . . . 0.0 109.926 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.25 143.34 58.41 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 123.728 2.952 . . . . 0.0 115.287 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -76.17 -9.06 19.07 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.145 1.896 . . . . 0.0 113.144 179.124 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -79.23 -59.81 2.62 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -71.13 6.58 1.57 Allowed 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 125.817 1.647 . . . . 0.0 113.35 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 15.6 tt -47.65 -33.41 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 C-N-CA 126.385 1.874 . . . . 0.0 112.767 -179.263 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -57.53 -26.34 61.22 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 123.687 0.795 . . . . 0.0 111.753 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -78.01 -28.2 49.13 Favored 'General case' 0 CA--C 1.528 0.11 0 C-N-CA 123.532 0.733 . . . . 0.0 111.437 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.8 mt -70.58 -37.33 73.93 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 118.679 0.672 . . . . 0.0 109.458 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 43.1 t -61.44 109.29 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 C-N-CA 124.794 1.238 . . . . 0.0 109.382 -179.319 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.14 -14.44 18.88 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 125.582 1.563 . . . . 0.0 111.389 -178.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.2 mttt -74.64 156.0 37.19 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 118.76 1.28 . . . . 0.0 108.318 179.048 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.7 ttmp? -103.45 133.2 48.9 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.309 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.416 HG23 ' HA ' ' A' ' 17' ' ' GLU . 6.5 m -73.89 141.59 15.97 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 178.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 93.3 mt -87.37 -20.77 26.24 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 125.658 1.583 . . . . 0.0 110.806 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.6 m -142.29 166.42 16.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.241 0 C-N-CA 125.076 1.35 . . . . 0.0 110.18 -178.386 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 54.4 m -74.11 106.74 5.92 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 91.3 t -90.22 136.1 24.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 178.623 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -92.69 175.31 6.86 Favored 'General case' 0 C--O 1.226 -0.18 0 O-C-N 121.618 -0.676 . . . . 0.0 111.853 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -70.13 136.87 50.59 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.0 t70 67.22 9.46 6.98 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 126.952 2.101 . . . . 0.0 111.508 -178.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.9 t0 -70.96 147.67 48.46 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 178.382 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 39.4 m -81.31 115.09 20.52 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.888 0.851 . . . . 0.0 110.535 -178.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.8 mm -72.14 111.47 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -106.79 152.61 23.62 Favored 'General case' 0 C--O 1.238 0.481 0 N-CA-C 104.409 -2.441 . . . . 0.0 104.409 177.33 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -62.93 -24.45 67.87 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.606 -0.684 . . . . 0.0 111.707 -179.646 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -75.13 -6.01 47.32 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 46.3 mt -95.6 -2.79 47.6 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 119.501 1.046 . . . . 0.0 111.437 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.8 m -130.5 151.5 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 125.251 1.42 . . . . 0.0 107.574 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -70.34 166.54 20.03 Favored 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.767 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -61.04 -52.39 65.18 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 179.086 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -149.55 160.25 43.64 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 126.491 1.916 . . . . 0.0 107.245 178.877 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -114.84 167.63 12.36 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 108.19 -1.964 . . . . 0.0 108.19 178.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.06 -2.79 4.56 Favored 'General case' 0 N--CA 1.466 0.375 0 O-C-N 121.571 -0.958 . . . . 0.0 111.269 178.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 51.4 tttm -59.08 109.38 0.83 Allowed 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 106.113 -1.81 . . . . 0.0 106.113 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.3 pp -67.43 175.55 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 124.681 1.193 . . . . 0.0 110.789 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 30.5 ttmt -96.36 146.37 24.81 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.219 1.008 . . . . 0.0 109.986 179.574 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.9 p -78.6 -77.7 0.16 Allowed 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 105.504 -2.036 . . . . 0.0 105.504 178.106 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.8 m -137.92 171.52 14.3 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 125.864 1.666 . . . . 0.0 108.153 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -128.35 -149.65 7.05 Favored Glycine 0 CA--C 1.531 1.092 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -68.88 9.65 0.44 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 123.564 2.843 . . . . 0.0 113.445 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.4 p -63.07 137.86 58.38 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 119.904 1.229 . . . . 0.0 107.929 178.662 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' SER . . . . . 0.406 ' H ' ' H ' ' A' ' 79' ' ' GLY . 35.9 t -169.92 -26.01 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.074 1.75 . . . . 0.0 109.287 -179.673 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.406 ' H ' ' H ' ' A' ' 78' ' ' SER . . . . . . . . 0 C--O 1.251 1.2 0 C-N-CA 128.785 3.088 . . . . 0.0 105.918 179.494 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.636 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.2 p -76.81 171.5 14.62 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 178.638 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.2 p -147.29 142.32 27.05 Favored 'General case' 0 C--O 1.235 0.338 0 O-C-N 121.17 -0.956 . . . . 0.0 110.524 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -110.21 120.87 5.77 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 106.34 -2.704 . . . . 0.0 106.34 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.7 108.08 5.55 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 -178.38 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 89.6 p -139.86 154.4 47.29 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.807 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.96 -146.63 11.23 Favored Glycine 0 CA--C 1.52 0.394 0 N-CA-C 107.019 -2.432 . . . . 0.0 107.019 -178.533 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 96.8 p -138.55 151.19 47.09 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 118.701 1.25 . . . . 0.0 110.924 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.6 t -76.57 125.83 36.69 Favored 'Isoleucine or valine' 0 C--O 1.234 0.259 0 O-C-N 121.307 -0.87 . . . . 0.0 110.159 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 33.3 m -124.9 155.8 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-O 122.445 1.117 . . . . 0.0 108.355 177.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.71 118.7 10.63 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 125.204 1.402 . . . . 0.0 107.43 178.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 34.8 tttp -69.84 -27.31 64.75 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.4 m -151.75 169.77 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 125.729 1.612 . . . . 0.0 107.71 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -61.28 135.27 57.67 Favored 'General case' 0 C--O 1.241 0.62 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.06 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.1 mt -123.09 114.92 29.21 Favored Pre-proline 0 C--O 1.237 0.427 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.469 ' HA ' HG23 ' A' ' 52' ' ' THR . 22.1 Cg_endo -68.35 145.46 65.61 Favored 'Trans proline' 0 N--CA 1.448 -1.174 0 C-N-CA 120.752 0.968 . . . . 0.0 109.993 178.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.6 tt0 -57.27 146.07 29.82 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.442 0.697 . . . . 0.0 110.8 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.36 -0.05 88.48 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 123.849 0.738 . . . . 0.0 112.854 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.6 m -91.71 155.34 18.36 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 118.311 1.055 . . . . 0.0 111.742 -178.691 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 37.1 mm -89.77 130.12 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 125.332 1.453 . . . . 0.0 108.634 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 29.8 mt -70.25 151.99 44.72 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 124.486 1.114 . . . . 0.0 109.047 178.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 74.2 p -140.63 163.22 33.47 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 124.205 1.002 . . . . 0.0 108.458 -179.313 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 6.2 mmt -63.58 -40.44 96.97 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 177.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -57.71 -30.75 65.77 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 125.683 1.593 . . . . 0.0 113.801 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 63.7 mtm -101.12 13.96 33.48 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 120.379 1.445 . . . . 0.0 112.737 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.4 mt -126.75 136.65 52.7 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -179.445 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.3 t -140.43 131.2 25.82 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.6 m -90.01 125.82 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 CA-C-N 120.179 1.354 . . . . 0.0 107.881 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 11.1 mttp -84.64 105.33 15.36 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 178.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 8.0 p -59.48 143.03 14.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.517 0 C-N-CA 123.922 0.889 . . . . 0.0 108.966 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 143.7 -81.36 0.22 Allowed Glycine 0 N--CA 1.448 -0.541 0 CA-C-N 118.081 0.4 . . . . 0.0 113.645 179.277 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -125.6 151.0 69.86 Favored Pre-proline 0 CA--C 1.533 0.293 0 C-N-CA 124.439 1.095 . . . . 0.0 113.102 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -77.8 28.8 0.44 Allowed 'Trans proline' 0 CA--C 1.545 1.051 0 C-N-CA 124.762 3.642 . . . . 0.0 111.936 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 47.7 tttm -80.52 92.99 5.97 Favored 'General case' 0 C--O 1.237 0.444 0 O-C-N 119.826 -1.796 . . . . 0.0 106.944 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 142.66 -149.42 21.27 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 108.501 -1.84 . . . . 0.0 108.501 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -84.68 140.5 38.12 Favored Pre-proline 0 C--O 1.24 0.596 0 C-N-CA 126.328 1.851 . . . . 0.0 108.76 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -55.58 136.05 72.21 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.191 2.594 . . . . 0.0 111.942 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -75.55 -11.02 20.51 Favored 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 123.364 2.709 . . . . 0.0 113.878 -178.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -87.99 -40.02 14.22 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 124.375 1.07 . . . . 0.0 110.074 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -74.36 4.53 5.72 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 124.523 1.129 . . . . 0.0 112.077 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.0 tt -44.5 -39.48 1.72 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 128.049 2.54 . . . . 0.0 112.756 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -53.64 -30.6 43.7 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 123.791 0.836 . . . . 0.0 112.15 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 73.6 m-80 -75.38 -44.97 41.95 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.803 179.397 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 36.6 mt -56.58 -42.63 78.97 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 79.9 t -60.6 107.55 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 179.437 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.74 -15.12 26.73 Favored Glycine 0 CA--C 1.528 0.847 0 C-N-CA 125.019 1.295 . . . . 0.0 112.692 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -76.76 157.42 31.65 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-N 120.157 1.979 . . . . 0.0 108.086 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 4.0 ttmp? -98.69 137.96 36.55 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 105.217 -2.142 . . . . 0.0 105.217 177.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 9.2 m -68.13 171.75 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 177.64 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 61.1 mt -116.46 -11.38 11.15 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 125.019 1.328 . . . . 0.0 111.097 178.364 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.8 m -153.3 166.68 1.35 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.372 0 C-N-CA 125.91 1.684 . . . . 0.0 107.958 -178.312 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.469 HG23 ' HA ' ' A' ' 16' ' ' PRO . 3.3 m -74.13 135.96 42.91 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 104.843 -2.281 . . . . 0.0 104.843 178.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 95.2 t -121.06 150.83 24.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -106.96 168.18 9.37 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.114 1.366 . . . . 0.0 108.85 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -65.65 147.94 52.57 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.24 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 50.1 m-20 72.47 -6.18 1.65 Allowed 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 128.377 2.671 . . . . 0.0 113.236 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -64.62 152.51 41.98 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-O 121.924 0.868 . . . . 0.0 112.652 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -84.0 99.16 10.24 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 123.827 0.851 . . . . 0.0 110.903 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 10.5 mm -67.26 93.73 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 29.9 mtp -96.05 160.96 14.19 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 119.363 0.983 . . . . 0.0 109.577 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -60.36 -22.4 63.23 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.712 0.805 . . . . 0.0 113.107 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -74.97 -16.02 60.65 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.041 0.936 . . . . 0.0 111.865 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 27.8 mt -99.16 9.07 44.18 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 126.447 1.899 . . . . 0.0 113.959 -178.175 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.92 149.8 33.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 120.138 1.335 . . . . 0.0 112.38 -179.095 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -100.32 164.05 12.11 Favored 'General case' 0 C--O 1.236 0.379 0 C-N-CA 126.036 1.734 . . . . 0.0 107.659 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -71.43 139.98 49.9 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -69.81 -0.03 6.5 Favored 'General case' 0 CA--C 1.545 0.768 0 O-C-N 121.35 -0.844 . . . . 0.0 112.255 179.789 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -64.58 165.37 32.71 Favored Glycine 0 CA--C 1.531 1.039 0 O-C-N 119.684 -1.885 . . . . 0.0 109.69 178.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.18 5.52 51.49 Favored 'General case' 0 C--O 1.239 0.542 0 O-C-N 121.646 -0.914 . . . . 0.0 112.9 -179.366 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.7 tptp -59.79 159.01 9.45 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 119.059 0.845 . . . . 0.0 109.254 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 40.9 pt -82.48 167.32 2.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 178.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 20.7 ttmm -60.26 151.48 27.35 Favored 'General case' 0 C--O 1.239 0.527 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -153.5 170.52 20.56 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-O 122.125 0.964 . . . . 0.0 112.861 179.646 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.2 p -78.21 56.83 1.74 Allowed 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 128.999 2.92 . . . . 0.0 109.245 179.279 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.66 80.07 0.48 Allowed Glycine 0 CA--C 1.523 0.566 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.259 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -68.36 -15.9 42.79 Favored 'Trans proline' 0 CA--C 1.534 0.519 0 C-N-CA 122.424 2.083 . . . . 0.0 111.895 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.5 m -160.85 173.71 14.94 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 125.827 1.651 . . . . 0.0 107.331 179.139 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 43.4 m -118.1 113.9 22.29 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 104.918 -2.253 . . . . 0.0 104.918 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.74 0 CA-C-O 116.921 -2.044 . . . . 0.0 110.252 -179.957 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.862 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -135.15 153.68 51.9 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 124.689 1.196 . . . . 0.0 108.385 -179.567 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.9 m -145.04 171.13 14.91 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 125.507 1.523 . . . . 0.0 109.019 -179.255 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.16 -9.42 42.69 Favored Glycine 0 CA--C 1.523 0.587 0 CA-C-O 117.976 -1.458 . . . . 0.0 113.638 179.755 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.6 t -171.71 127.91 0.63 Allowed 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.828 1.314 . . . . 0.0 108.254 178.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -121.31 81.16 1.75 Allowed 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 103.955 -2.609 . . . . 0.0 103.955 178.355 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.81 -179.99 16.53 Favored Glycine 0 CA--C 1.528 0.849 0 CA-C-N 114.666 -1.152 . . . . 0.0 112.091 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 23.0 t -102.32 156.73 17.39 Favored 'General case' 0 C--O 1.244 0.779 0 C-N-CA 123.94 0.896 . . . . 0.0 110.732 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 85.9 t -75.52 127.86 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.2 m -127.69 146.59 33.13 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.073 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.25 124.02 18.61 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 124.429 1.092 . . . . 0.0 109.054 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 46.6 tttm -67.92 -31.71 71.66 Favored 'General case' 0 C--O 1.225 -0.23 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.421 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.3 m -147.02 174.87 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 126.48 1.912 . . . . 0.0 107.585 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 81.1 tttt -69.38 138.38 53.59 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 178.097 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 23.8 mt -129.25 107.35 17.7 Favored Pre-proline 0 CA--C 1.532 0.262 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -178.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.424 ' HA ' HG23 ' A' ' 52' ' ' THR . 36.6 Cg_endo -69.52 155.51 66.53 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 121.661 1.574 . . . . 0.0 110.532 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.401 ' HA ' HG23 ' A' ' 49' ' ' VAL . 22.7 tt0 -53.39 147.27 10.84 Favored 'General case' 0 C--O 1.238 0.466 0 C-N-CA 124.942 1.297 . . . . 0.0 109.88 179.297 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.0 0.27 75.35 Favored Glycine 0 CA--C 1.53 0.989 0 CA-C-O 118.825 -0.986 . . . . 0.0 113.926 179.187 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 28.5 m -86.67 137.7 32.25 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 119.608 1.704 . . . . 0.0 108.956 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 11.4 mm -80.51 128.71 38.46 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 178.394 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 74.6 mt -67.19 145.18 55.51 Favored 'General case' 0 C--O 1.237 0.442 0 C-N-CA 125.28 1.432 . . . . 0.0 110.307 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.57 ' HA ' HG23 ' A' ' 45' ' ' VAL . 17.6 p -143.25 152.35 41.6 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.371 1.468 . . . . 0.0 107.457 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -56.65 -27.09 57.88 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 118.869 0.758 . . . . 0.0 109.319 178.559 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -56.39 -29.27 61.28 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 126.418 1.887 . . . . 0.0 111.574 177.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 48.6 mtm -114.04 3.01 15.14 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 124.616 1.166 . . . . 0.0 111.168 -178.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 70.7 mt -105.52 147.89 27.85 Favored 'General case' 0 C--N 1.343 0.296 0 CA-C-N 120.081 1.31 . . . . 0.0 109.188 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.0 t -159.74 171.97 18.56 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 125.241 1.417 . . . . 0.0 107.613 178.461 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 77.0 t -125.57 152.19 32.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 8.3 mmmt -127.45 109.49 11.8 Favored 'General case' 0 CA--C 1.508 -0.646 0 N-CA-C 105.797 -1.927 . . . . 0.0 105.797 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 29.5 m -59.52 151.43 5.12 Favored 'Isoleucine or valine' 0 C--O 1.24 0.563 0 O-C-N 123.573 0.545 . . . . 0.0 109.532 179.694 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 152.09 -95.24 0.15 Allowed Glycine 0 N--CA 1.442 -0.925 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.53 163.38 50.02 Favored Pre-proline 0 C--N 1.326 -0.419 0 C-N-CA 126.562 1.945 . . . . 0.0 110.147 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -85.88 53.87 3.37 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 122.761 2.307 . . . . 0.0 110.16 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 32.9 pttt -73.81 70.65 1.44 Allowed 'General case' 0 C--O 1.221 -0.417 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 178.393 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.69 -152.8 18.07 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -178.366 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -55.07 134.17 68.07 Favored Pre-proline 0 CA--C 1.545 0.766 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -178.17 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -74.17 156.36 46.78 Favored 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 123.367 2.711 . . . . 0.0 111.251 179.306 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -71.18 -24.72 23.09 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.045 1.83 . . . . 0.0 113.942 -178.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 18.8 mp0 -83.68 2.32 38.22 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 -177.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -124.79 -5.46 7.5 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 119.949 1.25 . . . . 0.0 111.957 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 18.2 tt -40.38 -34.8 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 128.401 2.68 . . . . 0.0 114.327 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -57.91 -11.96 2.81 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.43 1.492 . . . . 0.0 114.139 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -97.4 -24.8 15.46 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 120.298 1.408 . . . . 0.0 110.82 178.31 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 85.8 mt -64.23 -37.94 89.27 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.57 HG23 ' HA ' ' A' ' 22' ' ' THR . 0.7 OUTLIER -68.08 118.88 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 179.556 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.82 -16.78 23.21 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 125.325 1.44 . . . . 0.0 112.337 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -85.6 158.68 20.05 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 119.034 1.417 . . . . 0.0 107.593 178.607 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt -103.45 139.74 38.42 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.793 -0.818 . . . . 0.0 108.793 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.401 HG23 ' HA ' ' A' ' 17' ' ' GLU . 3.2 m -77.29 135.12 27.16 Favored 'Isoleucine or valine' 0 C--O 1.236 0.347 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.411 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 24.1 mt -81.27 -15.3 55.92 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 124.227 1.011 . . . . 0.0 112.028 179.46 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.2 m -146.92 164.03 7.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 127.059 2.144 . . . . 0.0 108.796 -178.353 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.424 HG23 ' HA ' ' A' ' 16' ' ' PRO . 24.0 m -77.34 132.28 38.5 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.025 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.496 HG12 ' H ' ' A' ' 54' ' ' GLU . 54.3 t -98.5 -178.48 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 C-N-CA 126.512 1.925 . . . . 0.0 106.803 178.818 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.496 ' H ' HG12 ' A' ' 53' ' ' VAL . 27.8 mt-10 -135.64 164.76 27.11 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 127.377 2.271 . . . . 0.0 107.73 177.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -65.91 141.43 58.24 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 105.7 -1.963 . . . . 0.0 105.7 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 68.22 4.88 4.37 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.168 1.787 . . . . 0.0 114.946 179.613 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -76.19 155.35 34.59 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 119.633 1.106 . . . . 0.0 109.515 179.005 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 29.7 m -77.32 135.74 38.41 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 121.166 -0.959 . . . . 0.0 109.871 -179.338 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 16.7 mm -97.5 133.94 37.42 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 N-CA-C 104.808 -2.293 . . . . 0.0 104.808 177.633 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 82.7 mtp -139.93 160.86 38.96 Favored 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 123.579 0.752 . . . . 0.0 110.703 -178.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -57.44 -33.62 68.12 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 124.778 1.231 . . . . 0.0 113.231 -179.667 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -75.32 -2.25 27.4 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.319 1.448 . . . . 0.0 113.601 -178.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 36.9 mt -108.92 3.59 22.45 Favored 'General case' 0 C--O 1.232 0.148 0 C-N-CA 125.06 1.344 . . . . 0.0 110.78 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.4 m -129.59 144.53 37.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 C-N-CA 124.174 0.99 . . . . 0.0 111.234 -179.385 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -91.07 173.66 7.82 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.57 1.548 . . . . 0.0 110.704 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 31.5 t30 -57.04 157.39 5.9 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 125.036 1.334 . . . . 0.0 110.056 178.798 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 50.7 p-80 -119.45 166.85 12.56 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 124.14 0.976 . . . . 0.0 113.268 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 120.4 -164.36 13.92 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 125.864 1.697 . . . . 0.0 109.076 -179.235 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -114.62 166.14 12.04 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 125.847 1.659 . . . . 0.0 108.155 179.589 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.9 157.75 43.29 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 125.851 1.66 . . . . 0.0 106.785 177.358 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 8.2 pt -68.38 124.62 24.38 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 CA-C-N 118.635 0.652 . . . . 0.0 109.454 179.566 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.6 tptm -82.05 58.16 3.82 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.073 1.349 . . . . 0.0 111.002 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 5.0 t -141.89 145.61 34.8 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.3 t -68.43 170.95 8.04 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-O 122.061 0.934 . . . . 0.0 112.258 -179.255 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -155.02 -164.14 12.73 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 126.908 2.194 . . . . 0.0 109.277 -179.665 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -64.3 172.65 6.15 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 122.568 2.178 . . . . 0.0 112.344 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 10.9 t -136.42 149.0 48.06 Favored 'General case' 0 C--O 1.238 0.453 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 179.34 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -87.75 178.92 6.6 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 121.597 0.713 . . . . 0.0 109.978 179.548 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.735 0 N-CA-C 105.095 -3.202 . . . . 0.0 105.095 178.76 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.895 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 6.4 t -148.32 -48.69 0.16 Allowed 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 118.177 -0.915 . . . . 0.0 110.537 179.118 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.2 t -64.0 154.66 33.46 Favored 'General case' 0 C--O 1.238 0.451 0 CA-C-N 119.118 0.872 . . . . 0.0 111.148 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 101.17 132.31 7.71 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 106.664 -2.574 . . . . 0.0 106.664 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.1 m -153.61 162.6 41.1 Favored 'General case' 0 C--O 1.238 0.483 0 O-C-N 121.213 -1.169 . . . . 0.0 108.723 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.2 m -119.47 4.59 11.16 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 124.95 1.3 . . . . 0.0 112.04 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 75.03 -159.24 51.78 Favored Glycine 0 CA--C 1.53 1.005 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 90.7 p -145.22 158.8 43.74 Favored 'General case' 0 C--O 1.237 0.431 0 O-C-N 121.764 -0.845 . . . . 0.0 111.412 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.11 137.17 24.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.083 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.4 m -136.49 160.62 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 C-N-CA 125.722 1.609 . . . . 0.0 107.778 178.698 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.74 118.27 18.38 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 178.566 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -62.48 -31.77 72.56 Favored 'General case' 0 N--CA 1.467 0.411 0 O-C-N 121.341 -0.85 . . . . 0.0 110.953 179.762 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m -138.32 172.0 14.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 126.708 2.003 . . . . 0.0 107.715 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.1 tttm -70.56 134.09 47.34 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.424 HD11 ' HB3' ' A' ' 25' ' ' MET . 73.9 mt -120.82 110.11 35.36 Favored Pre-proline 0 CA--C 1.53 0.208 0 C-N-CA 123.756 0.822 . . . . 0.0 110.031 -178.419 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -69.54 148.97 67.65 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 121.882 1.721 . . . . 0.0 111.086 178.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.406 ' HA ' HG23 ' A' ' 49' ' ' VAL . 60.4 tt0 -55.27 151.12 10.13 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 124.403 1.081 . . . . 0.0 110.166 178.429 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 68.99 30.47 72.22 Favored Glycine 0 CA--C 1.524 0.652 0 CA-C-O 119.441 -0.644 . . . . 0.0 113.847 178.717 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 59.9 m -118.04 150.87 38.58 Favored 'General case' 0 C--O 1.239 0.511 0 C-N-CA 125.737 1.615 . . . . 0.0 107.446 179.195 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 32.7 mm -92.4 123.93 44.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 CA-C-N 118.933 0.788 . . . . 0.0 109.443 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 62.2 mt -63.65 147.13 52.36 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.557 1.143 . . . . 0.0 110.858 -179.484 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.3 p -140.55 164.03 31.26 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 124.754 1.222 . . . . 0.0 107.715 178.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 5.7 mmt -62.82 -32.35 73.52 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.462 0.574 . . . . 0.0 110.281 179.211 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -59.24 -27.87 66.18 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 125.021 1.329 . . . . 0.0 113.357 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' MET . . . . . 0.424 ' HB3' HD11 ' A' ' 15' ' ' ILE . 57.9 mtm -105.08 9.2 34.39 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.528 1.131 . . . . 0.0 112.733 -178.525 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 78.5 mt -127.68 146.22 50.63 Favored 'General case' 0 CA--C 1.518 -0.28 0 O-C-N 120.85 -1.156 . . . . 0.0 110.579 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.6 t -153.48 177.92 10.38 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.66 119.52 38.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 179.163 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 47.8 mtpt -91.63 108.8 20.16 Favored 'General case' 0 CA--C 1.511 -0.527 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 179.637 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 31.9 t -58.64 133.86 23.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 N-CA-C 105.609 -1.997 . . . . 0.0 105.609 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.42 -83.4 0.12 Allowed Glycine 0 C--N 1.334 0.441 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.486 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -124.25 150.61 64.28 Favored Pre-proline 0 CA--C 1.532 0.252 0 C-N-CA 123.501 0.72 . . . . 0.0 111.025 -179.597 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -71.14 -15.59 31.98 Favored 'Trans proline' 0 N--CA 1.456 -0.715 0 C-N-CA 122.486 2.124 . . . . 0.0 113.192 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 18.7 ttmm -48.54 106.15 0.09 Allowed 'General case' 0 C--O 1.234 0.272 0 C-N-CA 126.314 1.846 . . . . 0.0 109.982 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.76 -173.51 20.88 Favored Glycine 0 CA--C 1.525 0.715 0 C-N-CA 126.314 1.911 . . . . 0.0 108.93 -179.043 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.5 t80 -65.79 140.19 97.2 Favored Pre-proline 0 CA--C 1.543 0.703 0 O-C-N 121.973 -0.722 . . . . 0.0 109.509 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -66.19 134.29 36.04 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 122.713 2.275 . . . . 0.0 111.579 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -71.56 -16.47 30.47 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.756 2.304 . . . . 0.0 115.215 -179.199 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -70.94 -22.5 62.21 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.555 1.07 . . . . 0.0 111.927 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -114.88 13.28 17.08 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 124.855 1.262 . . . . 0.0 113.269 -178.224 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 20.5 tt -45.44 -36.39 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 125.365 1.466 . . . . 0.0 113.79 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -58.73 -23.59 60.05 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.336 1.054 . . . . 0.0 113.518 -178.751 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -78.42 -32.94 48.89 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 120.385 1.448 . . . . 0.0 111.504 179.224 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.2 mt -62.87 -35.37 79.77 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.016 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 77.5 t -60.32 117.03 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.08 -6.71 51.4 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 118.302 -1.277 . . . . 0.0 113.91 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.0 mttm -86.52 158.63 19.5 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 120.717 2.258 . . . . 0.0 108.725 178.691 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -95.77 135.22 37.78 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 179.107 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.406 HG23 ' HA ' ' A' ' 17' ' ' GLU . 4.2 m -77.51 139.74 18.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 CA-C-N 118.239 0.472 . . . . 0.0 110.077 179.0 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 23.1 mt -85.08 -17.22 38.06 Favored 'General case' 0 N--CA 1.462 0.154 0 C-N-CA 125.278 1.431 . . . . 0.0 112.066 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.18 163.52 7.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 C-N-CA 124.816 1.247 . . . . 0.0 110.582 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 22.5 m -78.51 122.4 25.82 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 105.116 -2.179 . . . . 0.0 105.116 178.079 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 76.2 t -106.59 139.29 28.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 106.126 -1.805 . . . . 0.0 106.126 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -86.1 176.21 8.12 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 122.079 0.942 . . . . 0.0 112.211 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -71.32 132.37 44.78 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 123.648 0.779 . . . . 0.0 110.09 -179.153 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 68.02 9.75 7.37 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 126.252 1.821 . . . . 0.0 110.127 -179.112 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 35.1 t0 -73.54 153.38 40.29 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.573 1.149 . . . . 0.0 109.466 179.693 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 23.1 m -78.51 129.59 35.04 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 124.969 1.308 . . . . 0.0 111.809 -177.558 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 13.0 mm -90.39 148.01 4.84 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 179.013 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 38.1 mtp -142.17 163.56 32.54 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 124.777 1.231 . . . . 0.0 108.238 178.511 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -65.02 -26.35 68.24 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 124.128 0.971 . . . . 0.0 111.039 179.768 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -73.04 -14.84 61.49 Favored 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 123.62 0.768 . . . . 0.0 112.226 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 12.2 mt -94.11 6.59 48.1 Favored 'General case' 0 C--N 1.334 -0.069 0 CA-C-O 118.115 -0.945 . . . . 0.0 113.325 -177.598 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.4 m -127.88 125.33 64.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 120.139 1.336 . . . . 0.0 112.586 -178.632 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -75.26 102.39 5.01 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 125.779 1.632 . . . . 0.0 108.556 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -169.32 158.8 8.36 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 123.087 0.555 . . . . 0.0 110.747 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -147.2 -55.72 0.24 Allowed 'General case' 0 N--CA 1.465 0.325 0 C-N-CA 124.067 0.947 . . . . 0.0 111.085 179.238 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 164.94 107.96 0.21 Allowed Glycine 0 C--N 1.337 0.626 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.58 -57.36 0.79 Allowed 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 123.864 0.866 . . . . 0.0 110.328 -179.634 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 44.8 mttm -70.37 -21.13 62.9 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 118.795 0.725 . . . . 0.0 112.847 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 3.3 mp -136.06 152.49 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 179.753 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 12.5 ptmm? -124.16 172.74 8.8 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 123.498 0.719 . . . . 0.0 110.56 179.096 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -70.44 96.85 1.2 Allowed 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 126.938 2.095 . . . . 0.0 107.113 178.791 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.8 p -88.54 169.61 11.59 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.289 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 74.88 -169.83 54.38 Favored Glycine 0 CA--C 1.528 0.896 0 O-C-N 121.188 -0.945 . . . . 0.0 112.218 179.539 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -67.73 15.36 0.14 Allowed 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 125.095 3.863 . . . . 0.0 115.644 -178.632 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 73.19 3.37 4.62 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.513 1.525 . . . . 0.0 113.69 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.26 157.33 22.88 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.501 1.12 . . . . 0.0 108.719 179.512 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.898 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.704 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.698 0 CA-C-O 119.248 -0.751 . . . . 0.0 111.692 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -120.03 18.88 12.4 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 119.092 1.446 . . . . 0.0 113.231 -179.409 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 m -59.66 145.2 45.62 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 119.313 0.96 . . . . 0.0 109.989 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.66 -72.7 0.27 Allowed Glycine 0 C--O 1.237 0.343 0 N-CA-C 108.389 -1.884 . . . . 0.0 108.389 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 32.4 p -154.12 178.78 9.59 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.28 1.032 . . . . 0.0 111.684 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 26.8 t -167.32 169.39 12.46 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 128.82 2.848 . . . . 0.0 106.655 179.054 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 166.31 -164.4 37.57 Favored Glycine 0 CA--C 1.524 0.61 0 O-C-N 120.757 -1.214 . . . . 0.0 110.864 -179.57 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.0 p -110.21 133.7 52.97 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.339 1.455 . . . . 0.0 110.78 -179.566 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.5 t -68.89 127.33 30.57 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 179.366 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.1 m -122.86 149.86 26.6 Favored 'Isoleucine or valine' 0 C--O 1.241 0.625 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.095 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.13 119.06 12.82 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 60.5 tttm -70.29 -21.53 62.94 Favored 'General case' 0 C--N 1.331 -0.206 0 O-C-N 121.529 -0.732 . . . . 0.0 112.099 -179.428 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.2 m -148.17 167.7 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 126.546 1.938 . . . . 0.0 107.501 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.3 tttm -76.43 99.8 5.0 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 178.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 7.6 mt -87.25 109.93 29.43 Favored Pre-proline 0 C--N 1.326 -0.431 0 C-N-CA 125.747 1.619 . . . . 0.0 107.677 -177.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.77 155.12 66.7 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 C-N-CA 121.387 1.391 . . . . 0.0 110.906 -179.519 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 61.8 tt0 -51.72 141.16 17.38 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 125.653 1.581 . . . . 0.0 109.399 179.607 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.1 -0.29 87.67 Favored Glycine 0 CA--C 1.535 1.3 0 CA-C-O 119.181 -0.788 . . . . 0.0 114.458 179.6 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.3 m -84.28 147.77 27.05 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 120.282 2.041 . . . . 0.0 109.668 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.5 mm -86.47 131.26 35.13 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 17.8 mt -68.98 148.16 50.55 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-O 121.607 0.717 . . . . 0.0 110.54 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.3 p -143.34 157.47 44.45 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 127.065 2.146 . . . . 0.0 107.331 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 15.9 mmt -64.98 -24.87 67.64 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.541 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -65.17 -14.73 61.3 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 128.791 2.837 . . . . 0.0 112.002 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 25.7 mtm -124.16 10.19 8.7 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.388 1.475 . . . . 0.0 111.933 -179.522 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 83.4 mt -128.66 152.86 47.9 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 119.728 1.149 . . . . 0.0 110.714 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.0 t -160.54 -179.15 7.41 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 105.434 -2.062 . . . . 0.0 105.434 178.133 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.47 131.11 39.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 O-C-N 120.766 -1.209 . . . . 0.0 108.07 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 2.4 tppp? -84.28 105.45 15.13 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 101.698 -3.445 . . . . 0.0 101.698 177.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.0 m -66.99 89.99 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 O-C-N 121.597 -0.689 . . . . 0.0 110.534 -179.154 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -145.06 -87.15 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 124.984 1.278 . . . . 0.0 110.565 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.9 148.44 39.92 Favored Pre-proline 0 C--N 1.326 -0.418 0 C-N-CA 125.884 1.674 . . . . 0.0 111.695 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -82.5 71.6 6.42 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.176 2.584 . . . . 0.0 108.166 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 40.1 tttp -114.24 166.2 11.9 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 123.537 0.735 . . . . 0.0 109.726 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 74.41 -87.65 0.71 Allowed Glycine 0 N--CA 1.444 -0.828 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -139.84 144.58 39.23 Favored Pre-proline 0 C--O 1.238 0.448 0 C-N-CA 124.919 1.288 . . . . 0.0 108.117 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.9 148.05 85.66 Favored 'Trans proline' 0 CA--C 1.539 0.75 0 C-N-CA 121.543 1.495 . . . . 0.0 109.358 179.065 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.05 -18.8 14.24 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.145 1.897 . . . . 0.0 111.989 -178.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -66.17 -33.09 74.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.46 -0.775 . . . . 0.0 111.391 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -92.24 10.78 28.13 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.18 1.792 . . . . 0.0 111.864 -178.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 13.9 tt -53.98 -34.65 26.5 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.718 0 O-C-N 119.801 -1.812 . . . . 0.0 111.201 179.234 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -60.64 -20.93 62.07 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.805 1.242 . . . . 0.0 113.605 179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -99.24 -17.99 17.83 Favored 'General case' 0 CA--C 1.515 -0.383 0 CA-C-N 119.732 1.151 . . . . 0.0 111.733 178.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 25.4 mt -68.27 -32.74 73.12 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 177.002 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 41.7 t -64.24 138.79 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 178.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 91.58 -16.2 59.68 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-O 118.823 -0.987 . . . . 0.0 112.277 -179.055 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.3 mttm -76.63 171.98 13.77 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-N 119.586 1.693 . . . . 0.0 107.368 178.198 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 24.7 ttmt -122.85 133.44 54.43 Favored 'General case' 0 CA--C 1.516 -0.355 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 1.8 m -74.6 148.47 7.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 O-C-N 124.258 0.974 . . . . 0.0 110.675 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.438 HD21 ' HB2' ' A' ' 65' ' ' ASP . 65.5 mt -97.93 -14.15 20.79 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 126.013 1.725 . . . . 0.0 112.696 179.7 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 15.7 m -144.42 161.81 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 C-N-CA 126.064 1.746 . . . . 0.0 108.461 179.105 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.1 m -74.98 96.0 3.1 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 87.0 t -70.79 127.13 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 178.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -74.29 170.28 15.91 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.584 0.707 . . . . 0.0 110.162 179.013 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -74.87 138.25 42.34 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 104.788 -2.301 . . . . 0.0 104.788 177.414 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 34.7 t0 72.34 10.94 5.85 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.781 2.032 . . . . 0.0 113.132 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -72.96 149.6 43.21 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 177.737 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 90.7 m -79.12 122.71 26.58 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 179.005 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.2 mm -76.51 126.52 37.26 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 48.7 mtp -128.09 155.43 44.4 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 122.469 1.128 . . . . 0.0 110.425 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -62.28 -20.18 64.02 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 126.696 1.998 . . . . 0.0 114.029 -179.131 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -89.21 -10.35 47.36 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 123.876 0.87 . . . . 0.0 111.687 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 84.1 mt -90.4 11.0 22.87 Favored 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 124.823 1.249 . . . . 0.0 110.729 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.5 m -133.34 151.2 33.27 Favored 'Isoleucine or valine' 0 C--O 1.232 0.166 0 CA-C-N 120.427 1.467 . . . . 0.0 114.239 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ASP . . . . . 0.438 ' HB2' HD21 ' A' ' 50' ' ' LEU . 35.1 t0 -90.85 169.99 10.46 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 124.641 1.176 . . . . 0.0 109.129 178.712 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -72.09 136.85 46.73 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 121.753 -0.592 . . . . 0.0 109.793 178.704 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 54.0 t-80 -60.11 134.96 57.55 Favored 'General case' 0 C--O 1.24 0.592 0 C-N-CA 124.025 0.93 . . . . 0.0 111.751 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.44 -178.12 15.07 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 124.428 1.013 . . . . 0.0 111.586 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.17 -8.71 1.32 Allowed 'General case' 0 N--CA 1.47 0.538 0 O-C-N 121.986 -0.714 . . . . 0.0 112.655 178.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -54.51 155.62 3.9 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.961 1.305 . . . . 0.0 110.67 179.027 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 33.1 pt -111.95 28.8 2.1 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 C-N-CA 125.712 1.605 . . . . 0.0 111.442 -179.08 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 48.2 tttp -66.63 -34.55 78.12 Favored 'General case' 0 C--O 1.237 0.414 0 O-C-N 120.852 -1.155 . . . . 0.0 110.805 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 33.1 t -77.41 150.64 35.02 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 125.102 1.361 . . . . 0.0 109.487 179.31 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 21.9 t -71.11 -67.8 0.48 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 104.452 -2.425 . . . . 0.0 104.452 177.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -172.99 147.91 10.05 Favored Glycine 0 CA--C 1.53 1.001 0 N-CA-C 106.791 -2.524 . . . . 0.0 106.791 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -71.63 -17.16 29.98 Favored 'Trans proline' 0 CA--C 1.534 0.477 0 C-N-CA 123.073 2.516 . . . . 0.0 113.835 -179.118 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.6 m 66.64 8.71 6.08 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.037 1.335 . . . . 0.0 114.133 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 39.0 p -79.12 -167.57 1.2 Allowed 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.493 1.517 . . . . 0.0 109.857 179.108 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.858 0 N-CA-C 106.761 -2.536 . . . . 0.0 106.761 178.639 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.356 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.5 p -67.5 177.85 1.81 Allowed 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 126.908 2.083 . . . . 0.0 111.274 178.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 65.1 m -105.06 97.6 7.43 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 101.248 -3.612 . . . . 0.0 101.248 177.332 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.2 120.33 0.7 Allowed Glycine 0 CA--C 1.527 0.837 0 N-CA-C 106.854 -2.499 . . . . 0.0 106.854 -177.822 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 79.7 p -126.6 175.23 8.09 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 124.687 1.195 . . . . 0.0 109.977 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 48.7 m -119.44 178.32 4.59 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 124.776 1.231 . . . . 0.0 109.162 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -140.74 -158.48 7.57 Favored Glycine 0 N--CA 1.45 -0.378 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 -179.317 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 76.5 p -137.26 157.19 47.18 Favored 'General case' 0 C--O 1.238 0.451 0 C-N-CA 123.793 0.837 . . . . 0.0 109.704 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 28.9 t -75.57 130.75 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.446 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.3 m -128.98 157.85 41.76 Favored 'Isoleucine or valine' 0 C--O 1.24 0.593 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 178.023 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.31 130.99 42.77 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 178.689 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 64.7 tttt -75.59 -32.91 60.52 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 121.366 -0.834 . . . . 0.0 110.754 179.363 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 22.6 m -144.58 170.71 7.34 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 129.601 3.16 . . . . 0.0 108.945 -179.455 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 20.6 tttm -68.78 116.58 9.43 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 119.762 1.165 . . . . 0.0 108.79 179.681 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.438 HD13 ' CD2' ' A' ' 21' ' ' LEU . 40.2 mt -98.9 105.19 29.84 Favored Pre-proline 0 CA--C 1.534 0.365 0 C-N-CA 125.168 1.387 . . . . 0.0 110.983 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.408 ' HA ' HG23 ' A' ' 52' ' ' THR . 42.7 Cg_endo -67.99 145.39 67.6 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 121.609 1.539 . . . . 0.0 108.937 177.706 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -53.69 152.9 4.85 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 124.151 0.98 . . . . 0.0 110.966 178.862 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.87 24.89 76.15 Favored Glycine 0 CA--C 1.524 0.61 0 CA-C-O 118.543 -1.143 . . . . 0.0 113.892 178.661 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 56.9 m -118.62 143.82 46.55 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 119.112 1.456 . . . . 0.0 108.266 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 18.6 mm -74.39 136.26 25.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.363 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.515 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.438 ' CD2' HD13 ' A' ' 15' ' ' ILE . 25.4 mt -80.51 141.47 35.13 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 126.099 1.76 . . . . 0.0 107.805 179.199 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.0 p -135.92 165.32 25.93 Favored 'General case' 0 C--O 1.237 0.425 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 179.433 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -61.26 -25.87 67.38 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.55 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -78.17 -10.4 59.62 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.347 1.059 . . . . 0.0 113.164 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 58.9 mtm -119.97 16.07 12.51 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 126.029 1.731 . . . . 0.0 110.566 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.8 mt -141.55 137.88 32.3 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 179.322 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.1 t -148.28 155.08 40.89 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.626 HG11 ' HB3' ' A' ' 38' ' ' PRO . 2.9 t -111.25 102.04 13.41 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -179.586 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 27.7 ttpp -75.01 112.78 11.59 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.236 0.614 . . . . 0.0 109.794 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 90.1 t -61.83 121.92 11.28 Favored 'Isoleucine or valine' 0 C--O 1.239 0.504 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 176.19 -82.77 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -138.56 158.68 69.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 C-N-CA 123.442 0.697 . . . . 0.0 110.768 -179.238 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -74.63 11.63 1.3 Allowed 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.344 2.696 . . . . 0.0 113.182 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -67.47 95.32 0.45 Allowed 'General case' 0 C--O 1.232 0.155 0 O-C-N 120.281 -1.512 . . . . 0.0 108.136 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.7 -167.89 23.78 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 128.095 2.76 . . . . 0.0 109.316 -178.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.423 ' CE2' ' HB3' ' A' ' 40' ' ' ASP . 9.2 t80 -67.77 144.35 97.35 Favored Pre-proline 0 CA--C 1.545 0.752 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.199 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -72.35 154.35 56.07 Favored 'Trans proline' 0 CA--C 1.544 1.016 0 C-N-CA 122.432 2.088 . . . . 0.0 113.406 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.626 ' HB3' HG11 ' A' ' 28' ' ' VAL . 16.7 Cg_endo -66.2 -27.42 48.76 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 123.416 2.744 . . . . 0.0 116.223 -179.383 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -75.99 -25.06 55.44 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 120.233 1.379 . . . . 0.0 112.179 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.423 ' HB3' ' CE2' ' A' ' 36' ' ' TYR . 3.2 m-20 -88.86 -2.55 58.64 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.919 0.781 . . . . 0.0 112.563 -179.184 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.4 tt -51.12 -34.38 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 O-C-N 120.616 -1.302 . . . . 0.0 112.557 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -59.43 -22.9 62.15 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -95.29 -19.09 20.28 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-O 117.76 -1.115 . . . . 0.0 111.308 178.735 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 61.0 mt -72.68 -34.32 67.12 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 73.1 t -64.83 130.64 30.2 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 N-CA-C 105.62 -1.993 . . . . 0.0 105.62 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 93.82 -12.64 69.0 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-O 118.054 -1.414 . . . . 0.0 112.514 -179.305 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -75.49 173.14 11.36 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 119.565 1.682 . . . . 0.0 109.602 178.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.5 tppt? -127.07 101.58 6.6 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.204 1.402 . . . . 0.0 108.941 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 6.1 m -43.06 140.84 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 123.73 0.812 . . . . 0.0 112.508 -178.711 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 92.8 mt -86.84 -19.48 28.9 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.486 1.114 . . . . 0.0 112.307 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.1 m -143.89 165.69 13.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 C-N-CA 126.222 1.809 . . . . 0.0 107.974 -179.021 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.408 HG23 ' HA ' ' A' ' 16' ' ' PRO . 99.2 m -76.26 138.56 40.64 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 178.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 79.0 t -119.85 128.43 75.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -75.38 173.89 10.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 122.101 0.953 . . . . 0.0 110.565 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -69.83 145.53 52.02 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.235 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . 0.338 0.7 OUTLIER 58.63 8.29 0.88 Allowed 'General case' 0 C--O 1.236 0.348 0 C-N-CA 125.291 1.436 . . . . 0.0 114.374 179.333 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -74.38 158.78 33.32 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 178.407 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 18.4 m -84.77 126.82 33.75 Favored 'General case' 0 C--N 1.321 -0.638 0 O-C-N 120.69 -1.256 . . . . 0.0 112.131 -177.873 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.9 mm -84.04 134.9 25.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 N-CA-C 104.328 -2.471 . . . . 0.0 104.328 178.595 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 69.7 mtp -141.48 159.83 41.4 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 122.885 0.474 . . . . 0.0 110.642 -178.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -61.54 -20.68 63.52 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 125.057 1.343 . . . . 0.0 112.697 179.765 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -81.68 -12.68 58.57 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.457 1.103 . . . . 0.0 112.245 179.546 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 25.0 mt -103.34 0.23 31.08 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.345 1.058 . . . . 0.0 111.463 -179.474 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.6 m -132.24 147.23 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 CA-C-O 122.302 1.049 . . . . 0.0 112.368 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -81.67 163.08 22.76 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 126.692 1.997 . . . . 0.0 110.104 179.559 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -67.5 149.23 50.46 Favored 'General case' 0 N--CA 1.444 -0.755 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.115 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -148.85 135.31 19.49 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 178.488 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.38 75.65 0.42 Allowed Glycine 0 CA--C 1.529 0.921 0 C-N-CA 123.567 0.603 . . . . 0.0 112.827 179.786 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 51.8 tptt -142.65 165.98 25.92 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 126.617 1.967 . . . . 0.0 107.451 178.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.1 ptpm? -149.56 121.62 8.27 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 179.565 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 98.0 mt -69.26 158.6 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 4.7 ttpm? -155.41 101.32 2.19 Favored 'General case' 0 CA--C 1.517 -0.317 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 14.5 p -65.53 -31.51 72.6 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 122.653 0.381 . . . . 0.0 111.796 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.1 m -62.14 115.84 4.46 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 124.81 1.244 . . . . 0.0 112.821 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 88.08 174.86 47.87 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.069 0.842 . . . . 0.0 114.085 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -61.72 148.69 92.48 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 123.372 2.715 . . . . 0.0 110.878 -179.467 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 24.1 m -79.66 -178.22 6.25 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 125.107 1.363 . . . . 0.0 110.839 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -57.76 -58.57 7.77 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 123.628 0.771 . . . . 0.0 109.142 178.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.961 0 N-CA-C 106.81 -2.516 . . . . 0.0 106.81 -179.417 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.947 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.1 t -54.09 -71.18 0.08 Allowed 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.76 1.224 . . . . 0.0 111.196 -179.54 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -74.96 163.9 27.13 Favored 'General case' 0 C--O 1.237 0.421 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.406 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 101.14 137.72 9.9 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 -179.376 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.5 m -63.32 163.49 10.49 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 117.338 0.569 . . . . 0.0 110.929 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.3 t -80.16 -175.71 5.19 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-O 121.7 0.762 . . . . 0.0 109.19 178.659 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -153.91 -172.51 22.02 Favored Glycine 0 CA--C 1.525 0.675 0 C-N-CA 125.412 1.482 . . . . 0.0 109.507 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -144.23 164.99 29.11 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 124.916 1.286 . . . . 0.0 109.665 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.0 t -81.41 134.05 27.95 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.6 m -133.23 159.39 43.01 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.066 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.77 120.35 17.23 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 178.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 75.5 tttt -69.04 -29.5 67.65 Favored 'General case' 0 C--N 1.327 -0.372 0 O-C-N 121.787 -0.571 . . . . 0.0 109.761 179.209 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.2 m -151.0 163.12 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 C-N-CA 128.081 2.552 . . . . 0.0 107.569 178.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -56.23 141.07 42.52 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 124.701 1.2 . . . . 0.0 108.718 178.389 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 8.3 mt -129.68 105.4 17.16 Favored Pre-proline 0 N--CA 1.465 0.281 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -178.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.682 ' HA ' HG23 ' A' ' 52' ' ' THR . 38.2 Cg_endo -65.79 146.06 82.48 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 121.47 1.446 . . . . 0.0 111.263 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.454 ' HA ' HG23 ' A' ' 49' ' ' VAL . 60.5 tt0 -56.71 141.97 41.91 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.561 0.696 . . . . 0.0 111.036 -179.335 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 90.91 2.77 71.32 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-O 119.137 -0.813 . . . . 0.0 113.376 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 30.0 m -97.38 151.26 20.12 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 125.603 1.561 . . . . 0.0 109.143 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 14.4 mm -91.98 141.15 14.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 37.6 mt -73.49 149.56 42.21 Favored 'General case' 0 C--O 1.238 0.468 0 C-N-CA 124.667 1.187 . . . . 0.0 110.69 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.9 p -144.51 158.11 43.91 Favored 'General case' 0 C--N 1.328 -0.361 0 C-N-CA 127.176 2.19 . . . . 0.0 108.096 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.6 mmt -63.74 -31.7 72.96 Favored 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -59.43 -17.44 30.93 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.987 1.315 . . . . 0.0 111.914 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 49.5 mtm -119.88 11.08 11.73 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.122 1.369 . . . . 0.0 111.849 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.5 mt -130.33 146.88 51.97 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 119.373 0.988 . . . . 0.0 110.256 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.7 t -152.95 163.83 39.08 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 55.3 t -107.75 101.49 12.6 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 1.1 mmtm -72.65 129.7 38.86 Favored 'General case' 0 N--CA 1.453 -0.287 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.3 m -73.24 123.04 27.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.826 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 168.33 -93.64 0.1 Allowed Glycine 0 C--N 1.335 0.473 0 C-N-CA 119.918 -1.134 . . . . 0.0 112.985 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -138.09 153.83 73.65 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 117.484 0.642 . . . . 0.0 111.577 -179.098 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -70.48 14.7 0.3 Allowed 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 124.588 3.525 . . . . 0.0 115.08 -179.032 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.42 114.2 6.65 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 105.31 -2.108 . . . . 0.0 105.31 178.768 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 119.74 -166.39 13.42 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -178.725 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -69.83 138.66 87.99 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-O 118.909 -0.567 . . . . 0.0 112.207 -178.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -60.79 135.18 58.26 Favored 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.643 2.229 . . . . 0.0 110.162 179.281 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.42 -13.84 36.19 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 121.963 1.775 . . . . 0.0 115.299 -179.271 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -78.23 -31.17 49.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 119.494 1.043 . . . . 0.0 108.929 179.021 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -81.39 3.98 22.5 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.379 1.072 . . . . 0.0 111.647 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.1 tt -53.2 -32.26 18.93 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 124.658 1.183 . . . . 0.0 112.244 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -57.27 -43.79 83.36 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 123.232 0.613 . . . . 0.0 109.384 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 18.3 m-80 -64.79 -36.76 85.36 Favored 'General case' 0 CA--C 1.522 -0.114 0 C-N-CA 124.176 0.991 . . . . 0.0 110.633 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 71.7 mt -64.42 -34.07 77.32 Favored 'General case' 0 C--O 1.227 -0.108 0 CA-C-O 118.837 -0.602 . . . . 0.0 110.495 179.645 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 96.8 t -71.98 82.11 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 CA-C-O 123.031 1.396 . . . . 0.0 109.245 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 147.24 -4.95 1.0 Allowed Glycine 0 CA--C 1.527 0.844 0 C-N-CA 127.032 2.253 . . . . 0.0 112.653 -179.587 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 78.7 mttt -91.92 156.33 17.54 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 119.427 1.613 . . . . 0.0 109.118 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -99.42 138.67 36.19 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 179.426 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.454 HG23 ' HA ' ' A' ' 17' ' ' GLU . 6.1 m -75.33 137.37 23.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.72 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 95.6 mt -88.81 -12.85 40.84 Favored 'General case' 0 C--N 1.334 -0.106 0 C-N-CA 124.575 1.15 . . . . 0.0 111.592 179.72 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 32.6 m -143.53 160.2 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.25 0 C-N-CA 124.343 1.057 . . . . 0.0 108.65 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.682 HG23 ' HA ' ' A' ' 16' ' ' PRO . 33.4 m -74.23 105.58 5.48 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 104.735 -2.32 . . . . 0.0 104.735 177.787 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 41.1 t -80.23 143.46 12.37 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 179.557 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -90.62 169.74 10.75 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 121.774 0.797 . . . . 0.0 109.08 178.617 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -69.35 136.91 52.4 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 178.053 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.6 t0 65.06 13.79 8.92 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 124.796 1.239 . . . . 0.0 113.813 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -77.01 157.14 31.35 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 124.004 0.922 . . . . 0.0 109.048 178.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.0 m -78.47 128.75 34.03 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 121.517 -0.74 . . . . 0.0 109.596 -179.264 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.0 mm -87.93 129.08 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 N-CA-C 103.143 -2.91 . . . . 0.0 103.143 177.766 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 46.6 mtp -133.24 159.92 38.8 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -63.4 -34.13 77.06 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 123.372 0.669 . . . . 0.0 109.904 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -60.75 -19.5 59.18 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 126.662 1.985 . . . . 0.0 110.741 179.699 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 10.7 mt -100.86 6.91 43.88 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 125.149 1.38 . . . . 0.0 112.532 -179.209 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.4 m -132.55 147.2 31.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 120.749 1.613 . . . . 0.0 111.814 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -57.45 143.1 41.73 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 125.413 1.485 . . . . 0.0 109.57 179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -61.42 -35.27 77.09 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 124.325 1.05 . . . . 0.0 112.102 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -147.78 174.5 11.76 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 124.793 1.237 . . . . 0.0 108.082 178.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.46 108.3 0.37 Allowed Glycine 0 N--CA 1.452 -0.237 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.43 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 19.3 ptmt -138.04 155.34 48.91 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 123.541 0.737 . . . . 0.0 109.179 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 6.2 ttpm? -161.67 105.98 1.26 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.4 pp -76.79 -2.36 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 N-CA-C 113.595 0.961 . . . . 0.0 113.595 -179.344 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -70.81 97.98 1.48 Allowed 'General case' 0 C--N 1.342 0.27 0 CA-C-N 119.996 1.271 . . . . 0.0 110.381 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 19.5 t -123.38 -67.64 0.93 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 20.1 m -68.27 167.56 14.16 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 124.17 0.988 . . . . 0.0 111.914 -179.602 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -169.98 172.94 44.02 Favored Glycine 0 CA--C 1.533 1.167 0 C-N-CA 125.558 1.551 . . . . 0.0 109.269 179.46 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -74.29 -10.22 22.28 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 123.02 2.48 . . . . 0.0 111.4 179.066 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.4 p -73.79 48.86 0.3 Allowed 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 129.265 3.026 . . . . 0.0 110.681 179.715 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 51.1 m -145.69 84.03 1.66 Allowed 'General case' 0 N--CA 1.453 -0.314 0 O-C-N 120.573 -1.329 . . . . 0.0 108.085 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.775 0 C-N-CA 129.649 3.5 . . . . 0.0 106.159 179.716 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.891 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.1 t -129.44 136.94 50.55 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.333 1.453 . . . . 0.0 107.937 179.74 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 m -75.39 128.18 34.8 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.37 0.668 . . . . 0.0 109.863 179.803 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -100.89 -172.91 29.06 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 73.3 m -86.37 124.44 32.72 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 178.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -52.89 139.11 28.2 Favored 'General case' 0 C--O 1.237 0.408 0 C-N-CA 123.863 0.865 . . . . 0.0 111.23 -179.061 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -175.98 -168.32 36.08 Favored Glycine 0 CA--C 1.524 0.623 0 O-C-N 121.613 -0.68 . . . . 0.0 112.34 -179.03 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 36.7 p -136.87 143.75 43.2 Favored 'General case' 0 C--O 1.234 0.255 0 C-N-CA 125.627 1.571 . . . . 0.0 110.872 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.7 t -69.24 123.07 21.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 CA-C-N 119.15 0.886 . . . . 0.0 110.869 179.486 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 35.5 m -125.41 154.64 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 125.043 1.337 . . . . 0.0 108.065 177.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.37 118.91 12.07 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -70.36 -29.93 66.72 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.389 -0.819 . . . . 0.0 110.85 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.6 m -147.21 161.85 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 127.816 2.447 . . . . 0.0 106.932 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 78.3 tttt -62.85 143.44 57.59 Favored 'General case' 0 C--O 1.24 0.577 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.499 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.1 mt -127.33 110.85 21.25 Favored Pre-proline 0 CA--C 1.538 0.486 0 C-N-CA 124.956 1.302 . . . . 0.0 109.201 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -66.35 149.5 84.9 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 121.663 1.575 . . . . 0.0 109.704 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.6 tm-20 -53.56 148.55 9.26 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 124.293 1.037 . . . . 0.0 110.905 179.503 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.22 -0.52 87.46 Favored Glycine 0 CA--C 1.526 0.747 0 C-N-CA 124.617 1.103 . . . . 0.0 115.219 178.879 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 72.5 m -83.6 144.53 29.39 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 118.213 1.006 . . . . 0.0 110.768 -179.07 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 30.0 mm -85.65 135.58 24.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 177.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 42.4 mt -72.29 151.98 42.43 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 124.008 0.923 . . . . 0.0 112.033 -179.123 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.617 ' HA ' HG13 ' A' ' 45' ' ' VAL . 47.7 p -144.0 159.02 43.32 Favored 'General case' 0 C--O 1.238 0.455 0 C-N-CA 127.285 2.234 . . . . 0.0 106.533 178.678 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' MET . . . . . 0.509 ' SD ' HG11 ' A' ' 45' ' ' VAL . 0.4 OUTLIER -65.69 -30.89 71.64 Favored 'General case' 0 C--O 1.224 -0.273 0 CA-C-N 119.377 0.99 . . . . 0.0 108.483 178.605 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -58.14 -30.58 66.45 Favored 'General case' 0 C--O 1.225 -0.209 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -179.436 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.8 mtm -95.69 9.67 39.53 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 118.861 0.755 . . . . 0.0 111.518 179.565 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.3 mt -130.83 158.22 40.76 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 123.898 0.879 . . . . 0.0 111.843 -178.261 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 t -159.32 152.06 21.7 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.351 -2.092 . . . . 0.0 105.351 177.735 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 m -103.01 120.51 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 119.828 1.194 . . . . 0.0 108.596 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 27.5 ttpp -68.84 113.67 6.48 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 104.784 -2.302 . . . . 0.0 104.784 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 60.7 t -74.56 85.73 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -144.02 -77.13 0.03 OUTLIER Glycine 0 CA--C 1.52 0.358 0 C-N-CA 125.395 1.474 . . . . 0.0 111.311 -179.118 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -147.62 161.59 34.98 Favored Pre-proline 0 CA--C 1.537 0.464 0 C-N-CA 124.88 1.272 . . . . 0.0 109.493 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -73.82 36.23 0.39 Allowed 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 124.61 3.54 . . . . 0.0 113.249 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -62.7 164.24 8.06 Favored 'General case' 0 N--CA 1.462 0.16 0 O-C-N 120.567 -1.333 . . . . 0.0 108.912 178.725 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 53.41 -132.09 42.7 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 179.312 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -86.45 135.88 35.89 Favored Pre-proline 0 CA--C 1.542 0.658 0 C-N-CA 125.026 1.33 . . . . 0.0 110.848 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.16 151.48 66.63 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.273 2.649 . . . . 0.0 112.592 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -80.04 -24.81 5.48 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.654 2.236 . . . . 0.0 112.989 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -65.48 -43.24 90.84 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 119.253 0.933 . . . . 0.0 110.638 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -71.05 8.33 0.97 Allowed 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 127.771 2.428 . . . . 0.0 114.15 -178.616 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.1 tt -50.27 -36.17 12.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 CA-C-N 119.3 0.955 . . . . 0.0 112.498 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -58.89 -32.37 69.44 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-O 118.976 -0.535 . . . . 0.0 111.706 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 70.9 m-80 -70.3 -49.6 47.98 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 20.8 mt -57.03 -46.23 82.54 Favored 'General case' 0 CA--C 1.515 -0.385 0 C-N-CA 123.52 0.728 . . . . 0.0 109.957 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.617 HG13 ' HA ' ' A' ' 22' ' ' THR . 74.8 t -68.05 99.19 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.693 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 131.46 -12.48 5.45 Favored Glycine 0 CA--C 1.529 0.926 0 C-N-CA 127.18 2.324 . . . . 0.0 110.687 -179.125 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 55.8 mttm -84.21 169.19 15.03 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 120.021 1.911 . . . . 0.0 108.053 178.273 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 20.4 ttmm -111.85 138.45 48.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 118.1 -0.952 . . . . 0.0 109.287 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.8 m -74.52 137.14 23.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.508 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.481 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 38.3 mt -83.2 -18.84 37.91 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 125.678 1.591 . . . . 0.0 112.268 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 22.8 m -145.21 167.94 9.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 126.198 1.799 . . . . 0.0 108.496 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.6 m -76.88 109.46 10.7 Favored 'General case' 0 N--CA 1.456 -0.149 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 178.628 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 86.7 t -86.48 126.07 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 C-N-CA 124.632 1.173 . . . . 0.0 107.863 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -77.45 172.8 12.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 122.18 0.991 . . . . 0.0 111.298 178.738 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -71.79 148.63 46.08 Favored 'General case' 0 N--CA 1.443 -0.782 0 O-C-N 121.616 -0.678 . . . . 0.0 109.509 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 29.2 t70 61.36 7.36 1.7 Allowed 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 127.554 2.342 . . . . 0.0 112.169 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -67.82 150.99 47.9 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.234 1.014 . . . . 0.0 108.895 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 47.3 m -82.64 111.84 18.97 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.048 -1.094 . . . . 0.0 108.048 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.8 mm -70.27 129.68 34.47 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 105.712 -1.959 . . . . 0.0 105.712 178.827 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 59.1 mtp -132.8 161.02 35.19 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 123.897 0.879 . . . . 0.0 109.316 -179.203 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -62.25 -30.55 71.19 Favored 'General case' 0 N--CA 1.466 0.329 0 C-N-CA 123.498 0.719 . . . . 0.0 111.031 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 19.2 pt-20 -66.51 -15.84 63.69 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 123.613 0.765 . . . . 0.0 111.474 179.339 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 38.5 mt -100.32 5.29 44.46 Favored 'General case' 0 C--N 1.341 0.234 0 C-N-CA 126.419 1.887 . . . . 0.0 112.692 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.06 140.41 47.97 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-N 121.665 2.029 . . . . 0.0 114.687 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -101.01 161.15 13.8 Favored 'General case' 0 C--O 1.239 0.514 0 C-N-CA 127.191 2.197 . . . . 0.0 108.869 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -64.92 143.43 57.96 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 127.183 2.193 . . . . 0.0 111.598 179.568 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 34.5 t-80 -76.88 107.8 9.47 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 178.531 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -76.24 178.11 49.87 Favored Glycine 0 CA--C 1.532 1.154 0 N-CA-C 109.289 -1.525 . . . . 0.0 109.289 178.653 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.6 ttmp? -125.89 -77.2 0.58 Allowed 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 179.161 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -78.33 72.45 4.86 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 178.688 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 30.2 pt -79.91 175.01 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 125.407 1.483 . . . . 0.0 110.718 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 24.0 tptp -147.14 113.2 5.82 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 107.046 -1.464 . . . . 0.0 107.046 178.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.9 t -57.4 104.43 0.17 Allowed 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 125.256 1.422 . . . . 0.0 110.418 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.1 p -74.54 -58.36 3.34 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 178.298 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 163.42 161.61 12.97 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 127.019 2.247 . . . . 0.0 108.962 179.522 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -81.5 -179.02 4.62 Favored 'Trans proline' 0 CA--C 1.538 0.69 0 C-N-CA 123.402 2.735 . . . . 0.0 109.48 179.469 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 38.0 p -130.91 134.9 47.18 Favored 'General case' 0 C--O 1.236 0.383 0 O-C-N 121.194 -0.941 . . . . 0.0 109.263 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 44.1 t -84.66 -65.35 1.02 Allowed 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 105.913 -1.884 . . . . 0.0 105.913 178.314 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.579 0 N-CA-C 106.392 -2.683 . . . . 0.0 106.392 -179.207 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.669 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.0 p -64.4 147.97 51.48 Favored 'General case' 0 CA--C 1.535 0.367 0 CA-C-N 118.629 1.215 . . . . 0.0 109.177 179.044 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.5 m -54.32 -38.78 66.38 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 123.623 0.769 . . . . 0.0 113.074 -179.387 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.71 124.78 15.66 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 111.524 -0.631 . . . . 0.0 111.524 -179.426 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.2 m -83.19 76.51 9.87 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 124.142 0.977 . . . . 0.0 109.885 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.9 p -80.99 72.57 8.02 Favored 'General case' 0 CA--C 1.542 0.661 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 178.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 124.33 -175.79 16.98 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 127.251 2.358 . . . . 0.0 109.188 -179.16 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 46.4 p -136.33 163.04 31.37 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 117.251 0.525 . . . . 0.0 109.887 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 62.3 t -68.74 142.89 15.65 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.646 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.481 HG21 ' HG2' ' A' ' 29' ' ' LYS . 4.4 m -140.87 164.36 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 127.021 2.129 . . . . 0.0 106.547 178.354 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -81.13 133.15 35.42 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.062 -1.458 . . . . 0.0 107.062 177.728 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -75.51 -29.31 59.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 118.898 -0.572 . . . . 0.0 111.371 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.6 m -144.96 168.97 8.51 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 127.199 2.2 . . . . 0.0 107.854 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.4 tttm -71.86 123.86 23.6 Favored 'General case' 0 C--O 1.238 0.457 0 C-N-CA 124.966 1.306 . . . . 0.0 108.766 178.758 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 74.9 mt -115.64 119.82 37.06 Favored Pre-proline 0 CA--C 1.538 0.517 0 C-N-CA 125.111 1.365 . . . . 0.0 110.112 -178.621 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.6 152.03 53.28 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 121.783 1.655 . . . . 0.0 110.633 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -50.49 146.9 4.95 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.797 1.639 . . . . 0.0 110.844 179.435 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.12 -4.44 66.8 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 115.341 0.896 . . . . 0.0 115.341 178.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.5 m -82.6 149.65 27.32 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 118.561 1.18 . . . . 0.0 109.438 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.05 141.86 13.77 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 76.3 mt -82.98 144.35 30.04 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 123.607 0.763 . . . . 0.0 110.589 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 77.1 p -133.67 162.25 32.46 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 126.876 2.071 . . . . 0.0 108.114 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.0 mmt -63.03 -26.57 68.91 Favored 'General case' 0 N--CA 1.465 0.294 0 O-C-N 121.781 -0.574 . . . . 0.0 110.75 179.172 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -68.91 -43.92 74.19 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-O 117.82 -1.086 . . . . 0.0 112.782 -179.139 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 29.6 mtm -87.76 18.17 4.25 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 120.671 1.578 . . . . 0.0 111.58 -177.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 64.8 mt -125.65 133.61 52.14 Favored 'General case' 0 CA--C 1.516 -0.337 0 C-N-CA 126.169 1.788 . . . . 0.0 109.856 -179.187 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.0 t -146.77 174.08 11.8 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 178.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 40.9 t -129.86 100.22 5.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 CA-C-N 119.36 0.982 . . . . 0.0 108.585 -178.609 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.481 ' HG2' HG21 ' A' ' 10' ' ' VAL . 6.2 mmpt? -67.41 131.32 45.46 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.7 m -62.31 125.87 19.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 178.252 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.37 -134.0 3.13 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -99.66 156.19 35.64 Favored Pre-proline 0 C--O 1.236 0.374 0 C-N-CA 123.995 0.918 . . . . 0.0 112.781 -179.335 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -79.84 51.7 4.0 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 124.474 3.449 . . . . 0.0 111.526 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.0 pttt -72.21 -56.47 5.48 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 120.83 -1.169 . . . . 0.0 110.486 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -70.83 -169.61 8.86 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 125.3 1.428 . . . . 0.0 112.075 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -57.12 144.18 70.17 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 118.209 -0.9 . . . . 0.0 111.316 179.64 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -64.4 142.5 79.04 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.838 2.359 . . . . 0.0 112.089 179.729 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -77.26 7.82 3.55 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 123.638 2.892 . . . . 0.0 112.051 178.747 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -94.62 -43.09 8.45 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 126.405 1.882 . . . . 0.0 109.845 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -94.45 8.53 41.76 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 124.113 0.965 . . . . 0.0 111.193 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.2 tt -45.89 -35.78 2.16 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 126.644 1.977 . . . . 0.0 111.874 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -59.67 -25.15 64.49 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 125.374 1.47 . . . . 0.0 112.223 179.535 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -77.88 -36.14 50.07 Favored 'General case' 0 CA--C 1.518 -0.253 0 C-N-CA 124.068 0.947 . . . . 0.0 109.977 179.278 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 84.9 mt -57.38 -40.69 78.71 Favored 'General case' 0 CA--C 1.516 -0.335 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.227 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 94.4 t -60.39 104.71 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 178.761 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 118.67 -14.95 11.56 Favored Glycine 0 CA--C 1.526 0.748 0 CA-C-O 117.957 -1.468 . . . . 0.0 113.187 -179.474 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -81.06 168.5 18.57 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 119.564 1.682 . . . . 0.0 108.39 179.23 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -114.83 138.11 51.16 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 124.15 0.98 . . . . 0.0 109.316 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.1 m -74.06 151.94 7.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.596 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.28 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 13.1 mt -100.39 -13.99 18.53 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 126.018 1.727 . . . . 0.0 113.643 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 10.4 m -151.14 163.85 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 126.974 2.109 . . . . 0.0 107.915 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.6 m -73.25 102.53 3.68 Favored 'General case' 0 CA--C 1.534 0.349 0 O-C-N 121.085 -1.009 . . . . 0.0 108.665 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 64.1 t -78.4 144.28 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 N-CA-C 107.167 -1.419 . . . . 0.0 107.167 179.226 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 34.9 mm-40 -88.65 174.73 7.87 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 122.094 0.95 . . . . 0.0 110.082 179.4 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -77.14 143.35 39.19 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 177.49 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 69.63 -1.07 2.4 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 125.436 1.495 . . . . 0.0 112.698 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -67.2 151.34 47.72 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 127.177 2.191 . . . . 0.0 110.976 -178.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.6 m -80.51 127.58 32.6 Favored 'General case' 0 C--N 1.324 -0.535 0 C-N-CA 123.272 0.629 . . . . 0.0 110.431 -178.687 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.2 mm -85.08 96.4 4.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.264 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 179.113 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' MET . . . . . 0.536 ' H ' HD12 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -82.79 170.2 15.29 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 177.37 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.432 ' CD ' ' H ' ' A' ' 61' ' ' GLU . 17.8 mp0 -76.18 -34.69 59.33 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 125.198 1.399 . . . . 0.0 109.658 -179.558 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -64.56 -29.03 70.06 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 123.09 0.556 . . . . 0.0 111.334 179.144 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.536 HD12 ' H ' ' A' ' 60' ' ' MET . 73.9 mt -76.1 -0.18 21.01 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.79 1.236 . . . . 0.0 113.229 -179.385 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.36 147.2 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 121.466 1.939 . . . . 0.0 110.751 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.45 164.43 11.54 Favored 'General case' 0 C--O 1.239 0.507 0 CA-C-O 123.256 1.503 . . . . 0.0 114.079 -179.014 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -81.49 96.55 7.45 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.117 179.35 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 52.7 t-80 -71.18 88.17 0.81 Allowed 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 124.061 0.944 . . . . 0.0 108.821 179.622 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -178.95 142.02 5.16 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 107.593 -2.203 . . . . 0.0 107.593 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -157.01 -24.91 0.09 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 179.212 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 22.4 ttmm -70.11 134.43 48.17 Favored 'General case' 0 C--O 1.236 0.342 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.582 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 80.1 mt -130.98 149.52 33.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -142.67 74.29 1.44 Allowed 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 125.706 1.602 . . . . 0.0 106.939 179.556 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 11.4 m -72.38 63.77 0.56 Allowed 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.05 1.34 . . . . 0.0 110.527 179.561 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 34.4 t -158.96 174.09 15.5 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 125.35 1.46 . . . . 0.0 108.03 -179.535 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -173.35 177.39 45.77 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 127.203 2.335 . . . . 0.0 107.693 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -68.76 155.36 68.98 Favored 'Trans proline' 0 N--CA 1.456 -0.706 0 C-N-CA 121.683 1.588 . . . . 0.0 109.342 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 67.3 m -152.3 35.67 0.52 Allowed 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.318 1.047 . . . . 0.0 109.718 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 12.2 m -154.16 169.47 23.5 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 126.01 1.724 . . . . 0.0 107.175 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.452 0 C-N-CA 127.589 2.519 . . . . 0.0 106.918 -179.756 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.698 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.5 t -67.99 -178.64 1.04 Allowed 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.419 1.488 . . . . 0.0 112.077 -179.532 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.2 t -70.79 131.42 43.79 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 125.279 1.431 . . . . 0.0 109.827 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.16 149.28 20.4 Favored Glycine 0 N--CA 1.446 -0.693 0 N-CA-C 107.703 -2.159 . . . . 0.0 107.703 178.599 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.0 p -106.78 -6.28 17.87 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 126.006 1.722 . . . . 0.0 113.012 -179.251 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.7 t -66.29 -10.55 43.6 Favored 'General case' 0 CA--C 1.535 0.381 0 N-CA-C 115.848 1.796 . . . . 0.0 115.848 -178.625 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.2 -160.47 36.49 Favored Glycine 0 CA--C 1.521 0.439 0 CA-C-N 119.636 1.107 . . . . 0.0 110.753 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.4 t -137.37 163.17 31.69 Favored 'General case' 0 C--O 1.239 0.532 0 C-N-CA 123.94 0.896 . . . . 0.0 109.324 179.12 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.0 t -74.06 136.19 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.1 m -130.37 158.95 42.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 C-N-CA 125.426 1.49 . . . . 0.0 107.805 178.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.96 107.2 5.2 Favored 'General case' 0 N--CA 1.443 -0.797 0 N-CA-C 104.733 -2.321 . . . . 0.0 104.733 177.522 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 37.6 tttt -59.75 -24.09 63.76 Favored 'General case' 0 N--CA 1.464 0.239 0 O-C-N 121.6 -0.687 . . . . 0.0 111.857 -179.265 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.1 m -145.86 169.52 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 C-N-CA 125.679 1.592 . . . . 0.0 109.123 -178.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 36.8 tttm -72.71 128.32 35.19 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 103.386 -2.82 . . . . 0.0 103.386 176.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.5 mt -122.69 115.22 29.64 Favored Pre-proline 0 C--N 1.333 -0.143 0 C-N-CA 125.09 1.356 . . . . 0.0 111.122 -176.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -70.65 153.98 64.49 Favored 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 121.077 1.185 . . . . 0.0 110.463 178.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.471 ' HA ' HG23 ' A' ' 49' ' ' VAL . 37.3 tt0 -54.2 149.36 9.81 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.671 1.588 . . . . 0.0 111.436 179.45 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.13 -2.7 64.54 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 123.798 0.714 . . . . 0.0 114.431 179.47 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 12.8 m -81.76 143.63 31.67 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 119.179 1.49 . . . . 0.0 109.809 -179.601 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 39.9 mm -84.41 125.99 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.916 -1.883 . . . . 0.0 105.916 178.07 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 45.4 mt -66.38 144.83 56.3 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 124.434 1.094 . . . . 0.0 110.893 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 40.1 p -139.3 165.88 26.02 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 178.482 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.6 mmt -67.08 -9.82 43.46 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.914 -0.492 . . . . 0.0 110.507 178.619 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -88.83 -2.83 58.78 Favored 'General case' 0 N--CA 1.471 0.579 0 O-C-N 120.353 -1.467 . . . . 0.0 110.88 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 36.7 mtm -125.11 4.81 7.89 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 124.944 1.298 . . . . 0.0 110.961 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.8 mt -135.8 147.33 48.29 Favored 'General case' 0 CA--C 1.512 -0.506 0 O-C-N 121.163 -0.961 . . . . 0.0 109.326 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.9 t -159.46 177.98 10.39 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 178.745 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.1 132.82 68.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 178.713 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 25.1 mmtp -91.51 -173.04 3.44 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 178.719 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.86 96.83 4.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 O-C-N 120.948 -1.095 . . . . 0.0 108.856 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.16 -82.71 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -157.02 160.7 30.51 Favored Pre-proline 0 CA--C 1.546 0.816 0 C-N-CA 125.529 1.532 . . . . 0.0 109.132 -179.04 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -66.46 13.02 0.14 Allowed 'Trans proline' 0 CA--C 1.54 0.781 1 C-N-CA 126.321 4.681 . . . . 0.0 116.94 -179.039 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.0 ptmt -54.06 114.38 1.58 Allowed 'General case' 0 C--O 1.221 -0.412 0 CA-C-N 119.287 0.949 . . . . 0.0 110.853 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 116.56 -81.03 0.3 Allowed Glycine 0 C--N 1.332 0.321 0 CA-C-N 119.625 1.102 . . . . 0.0 112.366 179.125 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -151.17 138.36 11.99 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 123.147 0.579 . . . . 0.0 111.822 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -68.13 134.77 32.6 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.357 2.038 . . . . 0.0 111.707 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -63.71 -22.49 69.76 Favored 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 122.439 2.093 . . . . 0.0 113.191 179.136 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -69.4 -8.6 48.0 Favored 'General case' 0 CA--C 1.534 0.341 0 CA-C-N 119.323 0.965 . . . . 0.0 112.404 179.461 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -119.78 10.39 11.62 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 124.794 1.238 . . . . 0.0 112.414 -178.508 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.3 tt -51.84 -31.17 13.05 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 O-C-N 121.326 -0.859 . . . . 0.0 113.078 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -54.63 -37.49 65.71 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 125.248 1.419 . . . . 0.0 112.278 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -77.95 -29.28 49.77 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 118.467 0.576 . . . . 0.0 111.042 179.182 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 78.0 mt -66.46 -34.54 78.18 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 179.541 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.1 t -69.58 105.18 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -179.004 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 119.81 -10.08 11.32 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.894 1.711 . . . . 0.0 112.587 -179.426 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 3.3 mtpp -82.16 154.39 25.52 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 119.228 1.514 . . . . 0.0 108.026 178.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.2 ttmt -95.69 135.15 37.76 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.471 HG23 ' HA ' ' A' ' 17' ' ' GLU . 5.1 m -75.81 143.45 13.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 177.782 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 73.4 mt -89.27 -14.94 34.71 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 124.399 1.08 . . . . 0.0 111.248 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.4 m -145.9 163.81 10.55 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 C-N-CA 126.395 1.878 . . . . 0.0 109.309 -178.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 4.9 m -75.76 127.4 32.96 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 105.731 -1.951 . . . . 0.0 105.731 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 89.2 t -105.93 148.74 10.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -98.66 170.55 8.71 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 123.626 0.77 . . . . 0.0 111.603 -179.066 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -67.78 132.75 48.01 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.4 t70 67.91 9.39 7.1 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 129.327 3.051 . . . . 0.0 114.201 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -68.06 154.64 41.23 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 123.429 0.692 . . . . 0.0 110.253 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -84.81 124.97 32.18 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 123.246 0.618 . . . . 0.0 110.97 -178.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.9 mm -85.84 146.95 5.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 178.073 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 32.9 mtp -134.01 151.76 51.57 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 105.47 -2.048 . . . . 0.0 105.47 178.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.26 -26.96 61.63 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 123.562 0.745 . . . . 0.0 112.885 -178.765 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -76.62 -0.58 23.91 Favored 'General case' 0 N--CA 1.451 -0.408 0 C-N-CA 126.0 1.72 . . . . 0.0 114.768 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 61.6 mt -113.53 3.18 15.63 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.204 1.402 . . . . 0.0 112.364 -179.402 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.2 m -132.52 152.9 37.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-N 119.462 1.028 . . . . 0.0 112.453 -178.025 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -61.8 150.78 36.08 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.594 0.758 . . . . 0.0 110.109 179.292 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -95.88 -42.48 8.29 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 116.453 2.02 . . . . 0.0 116.453 -177.559 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 -136.05 73.2 1.45 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 124.266 1.026 . . . . 0.0 112.237 -177.712 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -75.38 169.17 54.75 Favored Glycine 0 CA--C 1.526 0.764 0 C-N-CA 124.227 0.918 . . . . 0.0 113.356 -178.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.02 144.6 20.18 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 126.855 2.062 . . . . 0.0 106.234 178.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 51.1 tttp -148.44 130.4 15.29 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 177.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 31.7 pt -60.76 152.68 5.46 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.46 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 3.0 ttmp? -149.72 153.56 37.12 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 126.958 2.103 . . . . 0.0 107.236 178.792 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 73.3 m -140.8 126.08 18.62 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 104.131 -2.544 . . . . 0.0 104.131 178.34 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 12.4 m -91.91 168.54 11.35 Favored 'General case' 0 C--O 1.239 0.511 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 179.39 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.91 78.38 0.25 Allowed Glycine 0 CA--C 1.527 0.818 0 CA-C-O 118.055 -1.414 . . . . 0.0 112.265 -179.168 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -69.99 167.96 23.24 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.695 2.263 . . . . 0.0 110.18 179.075 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 46.5 t -143.56 -173.27 3.91 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.81 1.644 . . . . 0.0 107.344 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 33.7 m -129.35 16.48 6.04 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 127.02 2.128 . . . . 0.0 109.898 179.168 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.254 1.346 0 C-N-CA 130.388 3.851 . . . . 0.0 106.108 179.736 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.358 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 42.7 p -80.33 109.07 14.47 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 179.245 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.3 t -64.86 174.83 1.7 Allowed 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.933 0.873 . . . . 0.0 110.713 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 153.08 89.46 0.07 OUTLIER Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 105.618 -2.993 . . . . 0.0 105.618 -179.37 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.9 m -123.49 95.38 4.56 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 125.331 1.452 . . . . 0.0 108.786 -179.208 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.4 m -168.6 173.82 7.14 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 127.861 2.464 . . . . 0.0 108.301 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.426 ' HA3' ' HA ' ' A' ' 30' ' ' VAL . . . 81.25 -164.74 46.13 Favored Glycine 0 C--N 1.336 0.541 0 C-N-CA 123.939 0.781 . . . . 0.0 111.995 179.731 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 55.7 p -137.74 155.58 48.92 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 124.224 1.01 . . . . 0.0 110.842 179.586 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 43.4 t -75.93 130.61 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 178.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 m -129.74 157.68 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 N-CA-C 105.122 -2.177 . . . . 0.0 105.122 177.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.05 128.9 36.62 Favored 'General case' 0 N--CA 1.444 -0.731 0 O-C-N 121.356 -0.84 . . . . 0.0 109.38 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 52.6 tttt -72.44 -27.49 62.36 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.075 0.55 . . . . 0.0 111.309 179.686 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.6 m -146.87 171.65 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 C-N-CA 127.092 2.157 . . . . 0.0 108.083 -179.473 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.3 tttt -70.58 124.67 24.79 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 178.58 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.3 mt -116.16 101.81 53.82 Favored Pre-proline 0 C--N 1.327 -0.384 0 N-CA-C 105.788 -1.93 . . . . 0.0 105.788 -178.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.689 ' HA ' HG23 ' A' ' 52' ' ' THR . 33.3 Cg_endo -63.31 159.05 41.53 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 120.896 1.064 . . . . 0.0 110.627 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 71.4 tt0 -54.83 149.03 11.96 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 179.512 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.94 4.89 73.46 Favored Glycine 0 CA--C 1.533 1.212 0 CA-C-O 119.045 -0.864 . . . . 0.0 114.576 179.357 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 18.9 m -92.11 150.85 20.71 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 119.667 1.734 . . . . 0.0 109.425 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 36.5 mm -89.5 135.97 24.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.439 0 C-N-CA 124.149 0.98 . . . . 0.0 110.108 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 25.9 mt -75.56 143.4 42.43 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.172 0.51 . . . . 0.0 109.808 178.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 33.2 p -138.55 154.13 48.74 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 17.4 mmt -59.71 -34.48 72.97 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-O 121.834 0.826 . . . . 0.0 110.332 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -64.81 -12.45 48.16 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 126.633 1.973 . . . . 0.0 114.055 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 33.1 mtm -117.74 6.26 12.34 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.22 1.008 . . . . 0.0 111.238 179.291 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.9 mt -119.41 153.21 35.56 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 179.429 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.7 t -151.93 172.59 16.0 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 105.558 -2.015 . . . . 0.0 105.558 178.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.65 122.0 46.21 Favored 'Isoleucine or valine' 0 C--O 1.237 0.424 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.203 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 15.3 ttmm -87.39 103.57 15.62 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.072 -2.196 . . . . 0.0 105.072 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.426 ' HA ' ' HA3' ' A' ' 7' ' ' GLY . 14.8 m -65.55 132.96 31.19 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 179.609 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.52 -64.62 0.27 Allowed Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -145.4 157.69 52.17 Favored Pre-proline 0 N--CA 1.453 -0.3 0 CA-C-O 118.604 -0.712 . . . . 0.0 111.712 -178.689 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -78.93 11.97 2.39 Favored 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 123.433 2.755 . . . . 0.0 112.599 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -51.74 110.07 0.43 Allowed 'General case' 0 N--CA 1.463 0.202 0 C-N-CA 125.455 1.502 . . . . 0.0 110.126 179.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.63 -99.33 0.56 Allowed Glycine 0 C--N 1.333 0.374 0 CA-C-N 119.193 0.906 . . . . 0.0 111.931 179.164 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -139.18 134.76 16.86 Favored Pre-proline 0 C--O 1.239 0.543 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.615 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -61.0 133.44 47.33 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.557 2.838 . . . . 0.0 111.554 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -72.52 -16.22 27.35 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 123.466 2.777 . . . . 0.0 113.408 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -67.42 -23.39 65.54 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 119.399 1.0 . . . . 0.0 110.028 178.301 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 47.1 m-20 -99.71 7.86 44.77 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 126.125 1.77 . . . . 0.0 111.167 -179.31 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.4 tt -51.72 -33.84 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 CA-C-N 120.395 1.452 . . . . 0.0 112.712 -179.141 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -60.98 -19.26 60.92 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 123.97 0.908 . . . . 0.0 112.006 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 -92.43 -27.58 17.39 Favored 'General case' 0 CA--C 1.52 -0.189 0 C-N-CA 124.701 1.2 . . . . 0.0 110.364 179.189 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 19.5 mt -67.97 -37.77 81.92 Favored 'General case' 0 CA--C 1.52 -0.188 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.1 t -58.98 137.72 21.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.09 -14.02 63.25 Favored Glycine 0 CA--C 1.53 0.996 0 CA-C-O 118.121 -1.377 . . . . 0.0 112.824 -179.188 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 40.8 mttm -75.41 166.66 23.25 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 120.458 2.129 . . . . 0.0 108.812 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -119.76 132.42 55.62 Favored 'General case' 0 CA--C 1.521 -0.165 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.333 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -74.99 157.12 6.09 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-N 118.438 0.563 . . . . 0.0 112.461 179.81 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.08 -19.14 16.64 Favored 'General case' 0 C--O 1.225 -0.229 0 C-N-CA 126.628 1.971 . . . . 0.0 110.49 178.422 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 35.4 m -142.43 158.74 19.46 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 124.208 1.003 . . . . 0.0 109.445 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.689 HG23 ' HA ' ' A' ' 16' ' ' PRO . 58.0 m -72.23 99.51 2.39 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.919 1.688 . . . . 0.0 109.562 179.163 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 47.4 t -78.83 151.99 5.01 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 179.294 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -100.86 169.44 8.98 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 126.072 1.749 . . . . 0.0 110.655 179.371 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -69.33 141.62 54.22 Favored 'General case' 0 C--O 1.239 0.52 0 N-CA-C 106.001 -1.851 . . . . 0.0 106.001 176.637 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 67.13 1.22 2.3 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 128.182 2.593 . . . . 0.0 112.413 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.44 149.55 48.2 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.15 0.98 . . . . 0.0 109.938 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 94.6 m -85.26 124.51 31.97 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-O 122.326 1.06 . . . . 0.0 110.94 -177.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 mm -82.18 142.01 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 33.6 mtp -142.25 155.14 45.22 Favored 'General case' 0 C--O 1.237 0.399 0 C-N-CA 125.018 1.327 . . . . 0.0 108.008 179.072 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -61.22 -34.7 75.53 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 124.519 1.128 . . . . 0.0 112.388 -179.106 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -69.56 -2.85 12.56 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 113.688 0.996 . . . . 0.0 113.688 -179.497 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 54.3 mt -105.04 5.77 32.8 Favored 'General case' 0 C--O 1.234 0.285 0 C-N-CA 125.696 1.598 . . . . 0.0 112.827 -178.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 36.0 m -124.79 160.35 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 120.272 1.396 . . . . 0.0 112.068 -179.158 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -124.71 173.05 8.81 Favored 'General case' 0 C--O 1.238 0.49 0 C-N-CA 127.079 2.151 . . . . 0.0 110.434 -179.21 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 53.7 t-20 -62.85 135.5 57.36 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.409 1.884 . . . . 0.0 109.402 179.215 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -56.51 -40.31 74.79 Favored 'General case' 0 CA--C 1.537 0.474 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.451 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -123.95 81.07 0.35 Allowed Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 126.386 1.946 . . . . 0.0 109.337 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -72.22 38.21 0.07 Allowed 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 124.982 1.313 . . . . 0.0 111.487 179.052 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 20.7 ptmt -66.73 170.97 5.67 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 120.561 -1.337 . . . . 0.0 109.838 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 4.7 mp -125.59 147.53 30.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 C-N-CA 123.509 0.723 . . . . 0.0 109.377 -178.616 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 80.6 tttt -131.77 -78.32 0.51 Allowed 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 127.203 2.201 . . . . 0.0 105.246 179.198 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -67.8 153.59 43.39 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 124.484 1.114 . . . . 0.0 110.193 179.386 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.7 t -65.73 -37.73 87.21 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.043 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 89.92 93.13 1.19 Allowed Glycine 0 CA--C 1.527 0.789 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_endo -76.9 15.38 1.12 Allowed 'Trans proline' 0 CA--C 1.543 0.967 0 C-N-CA 123.676 2.917 . . . . 0.0 112.473 179.512 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.7 t -59.43 162.15 5.1 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 125.141 1.376 . . . . 0.0 111.06 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.8 t -149.21 173.33 13.58 Favored 'General case' 0 N--CA 1.447 -0.609 0 C-N-CA 124.832 1.253 . . . . 0.0 108.521 179.422 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.175 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 -179.884 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.668 0 N-CA-C 109.971 -1.252 . . . . 0.0 109.971 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.4 m -136.16 52.33 1.98 Allowed 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.774 1.23 . . . . 0.0 109.871 -179.574 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 m -64.24 173.04 2.15 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 125.41 1.484 . . . . 0.0 112.392 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -74.97 -37.96 42.26 Favored Glycine 0 CA--C 1.53 0.986 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 179.182 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 62.9 m -63.0 160.93 13.95 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 125.507 1.523 . . . . 0.0 112.253 -179.618 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.5 t 166.5 160.35 0.03 OUTLIER 'General case' 0 C--O 1.236 0.358 1 C-N-CA 132.101 4.161 . . . . 0.0 103.372 179.627 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 73.38 175.86 31.09 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.23 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.2 m -146.61 145.19 29.99 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.206 0.527 . . . . 0.0 111.982 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 21.8 t -69.88 128.82 33.79 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 C-N-CA 123.994 0.918 . . . . 0.0 109.837 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.3 m -123.62 152.68 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 178.178 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.486 ' HB2' HD11 ' A' ' 59' ' ' ILE . . . -68.01 111.57 4.49 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 178.632 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 18.6 tttp -59.59 -30.56 68.76 Favored 'General case' 0 CA--C 1.536 0.426 0 O-C-N 121.068 -1.02 . . . . 0.0 113.561 -178.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.8 m -141.98 170.82 11.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 128.747 2.819 . . . . 0.0 106.91 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 42.9 tttm -66.59 137.77 56.99 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 178.401 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.1 mt -121.7 103.43 40.61 Favored Pre-proline 0 N--CA 1.462 0.155 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -179.304 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -66.65 149.99 83.82 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 121.085 1.19 . . . . 0.0 109.561 179.281 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -52.32 146.17 9.84 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 125.448 1.499 . . . . 0.0 110.749 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.65 3.13 86.68 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 123.724 0.678 . . . . 0.0 114.508 178.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 22.6 m -91.49 147.67 22.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 118.361 1.081 . . . . 0.0 109.779 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 49.3 mm -87.09 135.59 24.89 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 C-N-CA 123.982 0.913 . . . . 0.0 108.611 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 13.9 mt -74.16 147.09 42.94 Favored 'General case' 0 CA--C 1.519 -0.226 0 C-N-CA 125.288 1.435 . . . . 0.0 110.841 179.252 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.691 ' HA ' HG23 ' A' ' 45' ' ' VAL . 53.8 p -140.96 157.69 44.99 Favored 'General case' 0 C--O 1.238 0.47 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.167 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 7.6 mmt -62.93 -20.43 65.19 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.266 0.939 . . . . 0.0 110.881 178.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -72.0 -21.28 61.58 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.226 0.921 . . . . 0.0 110.25 178.51 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.7 mtm -105.51 4.98 31.08 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 126.328 1.851 . . . . 0.0 111.62 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 80.3 mt -122.94 141.26 52.12 Favored 'General case' 0 CA--C 1.516 -0.339 0 O-C-N 121.135 -0.978 . . . . 0.0 108.647 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.6 t -153.22 115.48 4.39 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.729 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 9' ' ' VAL . 0.2 OUTLIER -71.4 139.04 20.52 Favored 'Isoleucine or valine' 0 C--O 1.238 0.479 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.16 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.53 112.33 25.38 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 104.542 -2.392 . . . . 0.0 104.542 177.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.79 127.83 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 178.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 171.27 -85.86 0.08 OUTLIER Glycine 0 C--N 1.334 0.468 0 C-N-CA 119.955 -1.117 . . . . 0.0 113.356 -179.04 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -138.91 160.78 61.48 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 118.162 0.981 . . . . 0.0 111.562 -178.645 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -72.78 5.85 2.72 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.406 2.737 . . . . 0.0 114.818 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 23.7 tttp -68.63 92.91 0.48 Allowed 'General case' 0 C--O 1.233 0.21 0 C-N-CA 124.928 1.291 . . . . 0.0 109.476 179.377 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 148.21 -91.78 0.15 Allowed Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -157.27 141.38 11.67 Favored Pre-proline 0 C--O 1.238 0.454 0 C-N-CA 124.974 1.31 . . . . 0.0 110.308 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -68.64 150.39 74.59 Favored 'Trans proline' 0 CA--C 1.538 0.699 0 C-N-CA 122.447 2.098 . . . . 0.0 112.737 -179.403 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 80.7 Cg_endo -79.59 -3.28 12.82 Favored 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 123.098 2.532 . . . . 0.0 113.639 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -73.15 -59.11 2.86 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -71.31 4.95 2.49 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 128.762 2.825 . . . . 0.0 113.748 -179.395 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.559 ' HA ' HD12 ' A' ' 44' ' ' LEU . 17.4 tt -48.88 -37.11 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.568 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -178.153 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -63.38 -13.95 44.95 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.083 0.953 . . . . 0.0 113.49 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -87.29 -30.38 20.91 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 123.381 0.672 . . . . 0.0 110.989 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.559 HD12 ' HA ' ' A' ' 41' ' ' ILE . 21.2 mt -67.66 -44.54 77.59 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.331 1.052 . . . . 0.0 108.775 -179.13 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.691 HG23 ' HA ' ' A' ' 22' ' ' THR . 1.4 p -66.4 124.01 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.534 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.68 -15.47 29.21 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 125.664 1.602 . . . . 0.0 112.3 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 61.7 mttm -81.84 158.25 24.11 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 119.073 1.437 . . . . 0.0 110.469 179.292 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -97.89 142.55 29.49 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 177.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.0 m -86.1 144.0 10.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 CA-C-N 119.397 0.999 . . . . 0.0 109.228 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 62.2 mt -92.92 -3.84 53.83 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 125.446 1.498 . . . . 0.0 112.96 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 28.7 m -148.93 161.98 5.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 C-N-CA 125.81 1.644 . . . . 0.0 109.715 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.4 m -85.28 100.64 11.93 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 104.118 -2.549 . . . . 0.0 104.118 176.706 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.444 HG11 HD11 ' A' ' 59' ' ' ILE . 44.7 t -82.4 143.34 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 179.389 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -88.94 176.52 6.98 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 123.73 0.812 . . . . 0.0 110.605 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -72.41 143.42 48.53 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.496 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 59.23 11.58 2.17 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 128.946 2.898 . . . . 0.0 113.806 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -75.04 154.25 38.06 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.09 1.356 . . . . 0.0 109.099 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.0 m -82.61 132.86 35.18 Favored 'General case' 0 C--N 1.33 -0.276 0 O-C-N 120.886 -1.134 . . . . 0.0 112.379 -178.329 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.486 HD11 ' HB2' ' A' ' 11' ' ' ALA . 41.4 mm -100.2 127.52 53.08 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.72 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 30.9 mtp -122.58 167.37 13.47 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -61.09 -23.65 65.64 Favored 'General case' 0 CA--C 1.538 0.505 0 O-C-N 120.929 -1.107 . . . . 0.0 113.95 -179.565 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -76.56 -4.79 44.7 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 125.54 1.536 . . . . 0.0 113.065 -179.538 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 19.1 mt -107.61 2.08 23.69 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.721 0.809 . . . . 0.0 112.249 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.4 m -127.22 159.05 37.98 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 CA-C-N 119.37 0.986 . . . . 0.0 111.704 -178.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -70.99 159.66 34.34 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 125.622 1.569 . . . . 0.0 113.569 -179.396 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 21.2 t30 -95.55 105.53 17.51 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 105.23 -2.137 . . . . 0.0 105.23 177.602 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 31.2 p-80 -39.58 -45.04 1.55 Allowed 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 127.503 2.321 . . . . 0.0 110.2 179.088 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.85 82.45 0.18 Allowed Glycine 0 C--N 1.337 0.639 0 C-N-CA 123.804 0.716 . . . . 0.0 112.004 178.521 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 18.0 ttmt -116.79 50.14 1.1 Allowed 'General case' 0 CA--C 1.518 -0.253 0 O-C-N 122.132 -0.628 . . . . 0.0 111.064 179.636 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 5.0 tmmm? -149.12 123.07 9.38 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 104.141 -2.54 . . . . 0.0 104.141 177.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 97.4 mt -139.0 136.29 42.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 104.685 -2.339 . . . . 0.0 104.685 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -140.58 150.15 43.27 Favored 'General case' 0 C--O 1.235 0.301 0 C-N-CA 124.847 1.259 . . . . 0.0 108.092 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.0 p -146.43 69.46 1.19 Allowed 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 179.142 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 61.41 8.75 2.3 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.571 1.548 . . . . 0.0 114.78 -179.154 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.4 177.98 52.73 Favored Glycine 0 CA--C 1.534 1.271 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 178.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -69.29 163.62 37.21 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 123.157 2.571 . . . . 0.0 113.108 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.8 p -83.43 73.18 10.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.358 1.463 . . . . 0.0 109.803 179.472 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 34.2 p -62.52 -18.23 61.48 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 123.113 0.565 . . . . 0.0 110.887 178.615 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.439 -1.123 0 C-N-CA 130.294 3.807 . . . . 0.0 105.121 179.512 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.786 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 84.7 p -129.14 151.32 49.94 Favored 'General case' 0 C--O 1.24 0.593 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -75.24 105.69 4.41 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 O-C-N 122.014 -0.429 . . . . 0.0 111.109 -179.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.0 m -102.86 152.82 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-O 122.654 1.216 . . . . 0.0 107.769 178.088 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.58 128.28 35.31 Favored 'General case' 0 C--N 1.319 -0.722 0 C-N-CA 124.958 1.303 . . . . 0.0 107.94 178.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.52 ' HE2' ' HB ' ' A' ' 27' ' ' THR . 20.1 ttmm -75.86 -23.92 55.69 Favored 'General case' 0 C--N 1.327 -0.378 0 O-C-N 121.012 -1.055 . . . . 0.0 111.099 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.7 m -148.15 173.25 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 C-N-CA 126.589 1.956 . . . . 0.0 107.678 -179.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 54.5 tttp -67.42 127.87 34.3 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 177.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.3 mt -111.48 96.43 31.73 Favored Pre-proline 0 C--N 1.331 -0.206 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -61.09 145.29 99.1 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 121.576 1.518 . . . . 0.0 110.496 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.588 ' HA ' HG23 ' A' ' 49' ' ' VAL . 4.9 tm-20 -50.77 146.2 6.11 Favored 'General case' 0 C--O 1.238 0.486 0 C-N-CA 124.936 1.294 . . . . 0.0 110.799 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.55 -3.64 81.6 Favored Glycine 0 CA--C 1.531 1.051 0 CA-C-O 119.327 -0.707 . . . . 0.0 113.153 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 20.0 m -88.22 143.78 26.84 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 118.956 1.378 . . . . 0.0 110.704 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 13.2 mm -83.98 140.24 16.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 71.0 mt -73.83 149.4 41.64 Favored 'General case' 0 C--O 1.238 0.489 0 C-N-CA 123.515 0.726 . . . . 0.0 112.452 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 22.6 p -146.94 157.4 43.62 Favored 'General case' 0 C--O 1.238 0.49 0 C-N-CA 127.526 2.33 . . . . 0.0 107.073 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 19.9 mmt -67.58 -24.15 65.47 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 118.826 0.739 . . . . 0.0 110.571 179.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -67.72 -12.67 61.01 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.476 -0.765 . . . . 0.0 112.207 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 47.7 mtm -115.45 10.78 15.83 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.078 0.951 . . . . 0.0 110.915 179.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -132.16 161.77 32.52 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 119.655 1.116 . . . . 0.0 112.53 -179.026 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.52 ' HB ' ' HE2' ' A' ' 12' ' ' LYS . 12.6 t -159.31 170.93 20.76 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 127.847 2.459 . . . . 0.0 107.294 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -125.36 110.87 25.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 178.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -76.68 91.73 3.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.8 p -54.53 125.54 9.43 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 C-N-CA 126.288 1.835 . . . . 0.0 106.591 178.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.65 -61.73 0.28 Allowed Glycine 0 N--CA 1.45 -0.417 0 CA-C-O 119.687 -0.507 . . . . 0.0 112.155 -179.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -148.7 148.65 28.63 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-N 118.313 1.056 . . . . 0.0 110.419 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -80.47 44.02 1.65 Allowed 'Trans proline' 0 CA--C 1.548 1.191 0 C-N-CA 123.645 2.896 . . . . 0.0 110.729 179.358 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 24.5 ttmt -84.85 92.8 8.35 Favored 'General case' 0 CA--C 1.521 -0.16 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.14 -132.59 6.74 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 179.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.462 ' CD2' ' HD2' ' A' ' 37' ' ' PRO . 0.6 OUTLIER -94.02 139.93 22.75 Favored Pre-proline 0 C--O 1.238 0.462 0 C-N-CA 124.805 1.242 . . . . 0.0 110.215 -179.727 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.462 ' HD2' ' CD2' ' A' ' 36' ' ' TYR . 83.9 Cg_endo -75.17 148.77 35.1 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.022 1.815 . . . . 0.0 112.104 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -75.99 -0.82 10.7 Favored 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 122.962 2.441 . . . . 0.0 111.709 178.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -81.55 -49.79 10.14 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.629 1.572 . . . . 0.0 108.794 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 -85.65 6.28 28.21 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.767 1.227 . . . . 0.0 111.344 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.0 tt -44.1 -41.66 1.81 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 C-N-CA 126.506 1.922 . . . . 0.0 114.607 -178.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -60.49 -32.61 71.6 Favored 'General case' 0 C--N 1.333 -0.138 0 O-C-N 121.575 -0.703 . . . . 0.0 112.003 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 33.7 m-80 -63.63 -30.42 71.53 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 123.377 0.671 . . . . 0.0 110.95 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.3 mt -71.93 -42.57 66.51 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 123.377 0.671 . . . . 0.0 109.828 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.2 t -67.2 93.73 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-O 122.212 1.006 . . . . 0.0 109.18 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 137.05 -11.7 3.88 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 126.202 1.858 . . . . 0.0 112.286 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -84.39 166.4 17.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 118.924 1.362 . . . . 0.0 109.069 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -110.3 139.58 45.35 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.588 HG23 ' HA ' ' A' ' 17' ' ' GLU . 13.5 m -81.99 150.35 4.49 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 O-C-N 123.583 0.552 . . . . 0.0 110.301 179.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 91.9 mt -101.01 -10.43 20.55 Favored 'General case' 0 C--O 1.233 0.226 0 C-N-CA 125.364 1.466 . . . . 0.0 111.88 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.4 160.56 14.99 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 C-N-CA 124.529 1.132 . . . . 0.0 109.154 178.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 11.6 m -78.65 99.88 6.77 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 14.9 t -73.2 150.41 7.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 179.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -102.55 168.12 9.49 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 123.589 0.756 . . . . 0.0 109.265 178.358 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 72.4 tt0 -61.51 144.18 54.7 Favored 'General case' 0 CA--C 1.538 0.495 0 O-C-N 121.413 -0.804 . . . . 0.0 108.834 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . 0.349 0.1 OUTLIER 56.92 13.06 1.35 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 128.077 2.551 . . . . 0.0 114.543 179.699 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -78.33 153.72 31.46 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 124.077 0.951 . . . . 0.0 112.403 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 20.0 m -81.43 113.07 19.25 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 124.75 1.22 . . . . 0.0 111.771 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.4 mm -76.88 144.31 11.83 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 3.0 mmt -134.53 161.21 35.7 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 125.877 1.671 . . . . 0.0 110.637 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -67.46 -29.15 68.53 Favored 'General case' 0 N--CA 1.467 0.378 0 O-C-N 121.354 -0.841 . . . . 0.0 111.773 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -74.01 -11.31 60.29 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 119.305 0.957 . . . . 0.0 112.486 179.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 69.6 mt -94.56 -4.43 47.94 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.341 1.057 . . . . 0.0 111.646 -179.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 m -122.54 140.36 46.59 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-N 120.162 1.346 . . . . 0.0 108.642 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 48.1 t0 . . . . . 0 C--O 1.24 0.59 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.902 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.5 p -139.83 161.46 37.52 Favored 'General case' 0 C--O 1.241 0.617 0 C-N-CA 125.758 1.623 . . . . 0.0 109.303 -179.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.2 t -85.88 133.17 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.8 m -129.38 160.62 40.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 178.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.4 118.78 12.71 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 126.38 1.872 . . . . 0.0 109.106 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.8 ttmm -68.01 -28.41 67.39 Favored 'General case' 0 N--CA 1.469 0.524 0 O-C-N 120.937 -1.102 . . . . 0.0 111.011 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.9 m -145.75 168.14 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 C-N-CA 127.778 2.431 . . . . 0.0 106.98 -179.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 80.9 tttt -68.81 128.78 37.88 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 8.2 mt -111.61 103.88 55.54 Favored Pre-proline 0 CA--C 1.538 0.507 0 C-N-CA 124.967 1.307 . . . . 0.0 108.552 -178.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -69.96 147.74 62.21 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 121.949 1.766 . . . . 0.0 110.704 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 7.3 tm-20 -49.22 139.65 10.83 Favored 'General case' 0 C--O 1.237 0.425 0 C-N-CA 123.909 0.884 . . . . 0.0 111.413 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.04 -3.57 84.56 Favored Glycine 0 CA--C 1.523 0.551 0 CA-C-N 115.571 -0.74 . . . . 0.0 112.942 179.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.4 m -82.53 140.37 33.34 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 118.756 1.278 . . . . 0.0 109.591 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.4 mm -78.73 135.35 26.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 105.424 -2.065 . . . . 0.0 105.424 178.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 32.2 mt -75.35 131.52 40.31 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.751 0.82 . . . . 0.0 109.304 179.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.4 p -127.83 161.36 29.21 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 13.2 mmt -61.76 -27.49 68.77 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 121.878 -0.514 . . . . 0.0 111.257 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -74.58 -7.9 54.62 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.884 0.874 . . . . 0.0 113.06 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 70.4 mtm -113.94 7.7 16.99 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 119.27 0.941 . . . . 0.0 111.25 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -123.64 152.68 41.71 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 124.368 1.067 . . . . 0.0 109.36 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.9 t -150.3 161.73 41.89 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 98.5 t -111.67 103.73 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 -178.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 9.5 tppt? -78.15 102.84 7.73 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 178.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.0 t -67.1 122.99 19.21 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 N-CA-C 104.438 -2.431 . . . . 0.0 104.438 178.131 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 170.18 -64.19 0.17 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-O 118.89 -0.95 . . . . 0.0 114.397 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -147.94 156.92 44.07 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 118.852 1.326 . . . . 0.0 110.421 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -79.31 0.72 9.79 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 123.666 2.911 . . . . 0.0 113.532 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.6 ttmt -60.44 106.99 0.6 Allowed 'General case' 0 CA--C 1.529 0.155 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 142.37 -105.56 0.41 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 123.758 0.694 . . . . 0.0 111.819 179.683 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -144.67 143.05 20.04 Favored Pre-proline 0 C--O 1.238 0.485 0 N-CA-C 106.347 -1.723 . . . . 0.0 106.347 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.45 132.11 23.13 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.735 2.29 . . . . 0.0 113.162 -178.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -71.15 -19.49 29.61 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 122.193 1.929 . . . . 0.0 112.257 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 24.5 mp0 -65.04 -31.92 73.38 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 119.586 1.085 . . . . 0.0 110.191 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -106.28 17.57 23.26 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 125.148 1.379 . . . . 0.0 111.998 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.8 tt -50.33 -32.84 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 125.146 1.379 . . . . 0.0 112.366 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -56.73 -25.01 53.62 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 124.193 0.997 . . . . 0.0 112.089 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 74.2 m-80 -81.39 -17.33 49.35 Favored 'General case' 0 C--N 1.339 0.127 0 C-N-CA 123.487 0.715 . . . . 0.0 112.101 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 72.3 mt -76.65 -34.55 58.27 Favored 'General case' 0 C--O 1.225 -0.221 0 CA-C-N 119.219 0.918 . . . . 0.0 108.701 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 63.3 t -62.7 128.98 25.46 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 98.1 -16.78 59.64 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 125.484 1.516 . . . . 0.0 111.09 -178.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 82.6 mttt -75.4 168.75 19.4 Favored 'General case' 0 C--N 1.344 0.354 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 178.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.5 ttmp? -125.69 135.01 51.65 Favored 'General case' 0 CA--C 1.508 -0.656 0 O-C-N 121.236 -0.915 . . . . 0.0 108.785 -179.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.7 m -67.7 141.13 18.12 Favored 'Isoleucine or valine' 0 C--O 1.24 0.602 0 O-C-N 123.97 0.794 . . . . 0.0 110.113 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 86.5 mt -93.74 -14.44 26.28 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 126.12 1.768 . . . . 0.0 112.256 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 22.7 m -146.63 158.85 10.51 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 C-N-CA 126.317 1.847 . . . . 0.0 108.2 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 88.6 m -70.84 101.36 2.11 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 178.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 45.5 t -79.77 119.81 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -72.36 166.9 21.59 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 122.399 1.095 . . . . 0.0 109.401 178.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 52.6 tt0 -61.03 143.77 54.71 Favored 'General case' 0 N--CA 1.449 -0.52 0 O-C-N 121.438 -0.789 . . . . 0.0 109.521 -179.392 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.8 t70 64.15 3.71 1.84 Allowed 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.52 1.928 . . . . 0.0 113.587 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -71.71 155.12 40.83 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.866 0.841 . . . . 0.0 109.338 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.2 m -71.83 127.0 31.17 Favored 'General case' 0 N--CA 1.436 -1.151 0 C-N-CA 126.057 1.743 . . . . 0.0 110.797 -178.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.4 mm -90.7 137.58 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 N-CA-C 103.812 -2.662 . . . . 0.0 103.812 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 34.7 mtp -140.92 -170.89 3.13 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 123.662 0.785 . . . . 0.0 110.501 -178.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -86.27 -37.58 18.43 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 6.2 pm0 -64.45 -11.76 36.71 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.446 1.098 . . . . 0.0 112.779 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 71.4 mt -101.19 2.4 40.02 Favored 'General case' 0 C--O 1.227 -0.124 0 C-N-CA 125.436 1.494 . . . . 0.0 112.319 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 10.3 m -135.35 155.13 36.7 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-N 121.435 1.925 . . . . 0.0 114.399 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 49.9 p30 . . . . . 0 C--O 1.236 0.394 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.394 178.269 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.293 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 79.5 p -144.31 159.04 43.38 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-N 117.853 0.826 . . . . 0.0 111.353 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 97.6 t -71.73 133.31 32.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.496 HG11 ' HE3' ' A' ' 29' ' ' LYS . 14.6 m -136.02 157.88 38.48 Favored 'Isoleucine or valine' 0 C--O 1.24 0.601 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 178.283 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.87 124.46 24.38 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 44.2 tttt -77.14 -27.11 53.77 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 121.911 -0.493 . . . . 0.0 111.653 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.4 m -144.29 168.15 10.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 C-N-CA 127.602 2.361 . . . . 0.0 106.824 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 78.6 tttt -69.06 117.81 11.17 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 178.076 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 19.9 mt -102.75 112.26 65.53 Favored Pre-proline 0 CA--C 1.533 0.307 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.93 148.95 32.41 Favored 'Trans proline' 0 N--CA 1.445 -1.342 0 C-N-CA 121.7 1.6 . . . . 0.0 109.428 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 tm-20 -51.68 145.61 9.0 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 124.135 0.974 . . . . 0.0 110.384 179.101 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.38 -3.58 86.47 Favored Glycine 0 CA--C 1.529 0.927 0 CA-C-O 119.105 -0.83 . . . . 0.0 114.89 178.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.6 m -89.78 152.4 21.32 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 118.389 1.095 . . . . 0.0 110.054 -179.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 48.7 mm -90.01 141.54 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 65.9 mt -75.9 139.29 41.56 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.373 0.606 . . . . 0.0 111.489 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 68.3 p -134.28 155.59 49.94 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 126.12 1.768 . . . . 0.0 106.393 178.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 25.8 mtp -67.47 -12.45 60.32 Favored 'General case' 0 CA--C 1.545 0.766 0 CA-C-N 119.594 1.088 . . . . 0.0 110.16 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.6 m-20 -72.84 -19.9 61.23 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 120.828 -1.17 . . . . 0.0 112.147 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 56.1 mtm -115.08 10.37 16.15 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 124.691 1.196 . . . . 0.0 111.59 -178.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 36.0 mt -130.82 148.74 52.63 Favored 'General case' 0 CA--C 1.515 -0.37 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -178.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.8 t -157.14 179.14 9.56 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.4 t -124.56 113.52 36.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 118.826 0.739 . . . . 0.0 109.76 -178.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.496 ' HE3' HG11 ' A' ' 10' ' ' VAL . 2.7 ttpp -79.37 93.4 5.33 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 179.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 t -59.63 98.62 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -172.17 -46.13 0.04 OUTLIER Glycine 0 C--N 1.339 0.716 0 CA-C-O 117.494 -1.725 . . . . 0.0 115.559 -178.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -151.43 154.33 33.41 Favored Pre-proline 0 N--CA 1.464 0.241 0 CA-C-N 120.251 2.026 . . . . 0.0 110.6 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -76.49 -3.89 14.36 Favored 'Trans proline' 0 CA--C 1.534 0.504 0 C-N-CA 123.195 2.597 . . . . 0.0 113.066 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 3.6 tmmm? -63.73 107.05 1.09 Allowed 'General case' 0 CA--C 1.518 -0.252 0 O-C-N 121.132 -0.98 . . . . 0.0 108.419 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.429 ' HA2' ' SD ' ' A' ' 60' ' ' MET . . . 131.36 178.49 15.5 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 126.26 1.886 . . . . 0.0 109.889 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.526 ' CG ' HD11 ' A' ' 44' ' ' LEU . 7.3 t80 -57.07 134.02 80.45 Favored Pre-proline 0 C--O 1.24 0.603 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -61.98 131.04 33.13 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.168 1.912 . . . . 0.0 108.997 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.64 -19.06 48.39 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.261 1.974 . . . . 0.0 112.351 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -70.67 -10.85 60.32 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 113.304 0.853 . . . . 0.0 113.304 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -121.33 10.92 10.66 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 126.044 1.738 . . . . 0.0 111.582 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.5 tt -41.33 -37.42 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 C-N-CA 128.194 2.598 . . . . 0.0 113.792 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -60.39 -34.99 74.7 Favored 'General case' 0 CA--C 1.528 0.133 0 C-N-CA 125.58 1.552 . . . . 0.0 113.927 -179.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -59.46 -38.96 82.13 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 119.675 1.125 . . . . 0.0 112.044 -178.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.526 HD11 ' CG ' ' A' ' 36' ' ' TYR . 85.0 mt -72.55 -33.93 67.17 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 124.681 1.192 . . . . 0.0 111.9 -179.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 69.3 t -67.68 91.29 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 124.521 1.128 . . . . 0.0 108.302 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 139.12 -9.38 3.29 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 126.437 1.97 . . . . 0.0 112.629 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 92.1 mttt -82.41 171.14 14.5 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 119.039 1.419 . . . . 0.0 108.437 178.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 33.8 ttmt -110.15 136.93 48.61 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 178.117 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.4 m -80.74 146.27 7.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 O-C-N 121.786 -0.572 . . . . 0.0 109.961 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 92.8 mt -97.21 -14.19 21.57 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 125.906 1.682 . . . . 0.0 113.453 -178.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 16.7 m -146.32 158.0 11.41 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.0 m -77.23 101.6 6.29 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 70.8 t -80.23 138.89 19.04 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -85.12 170.03 13.32 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-O 122.054 0.93 . . . . 0.0 110.283 178.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -71.22 138.99 49.94 Favored 'General case' 0 N--CA 1.447 -0.597 0 O-C-N 121.184 -0.947 . . . . 0.0 109.678 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.8 t70 72.3 4.18 4.92 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 127.671 2.389 . . . . 0.0 113.337 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -67.44 145.46 54.99 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.594 1.158 . . . . 0.0 109.387 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 25.4 m -73.24 129.0 37.09 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 179.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 26.2 mm -87.1 131.05 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . 0.49 ' H ' HD12 ' A' ' 63' ' ' LEU . 82.0 mmm -124.55 161.02 27.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 126.235 1.814 . . . . 0.0 106.948 179.255 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.421 ' H ' ' CD ' ' A' ' 61' ' ' GLU . 1.1 pm0 -72.31 -27.25 62.32 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.825 1.65 . . . . 0.0 111.332 179.592 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.41 -14.42 62.91 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 124.419 1.088 . . . . 0.0 112.816 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.49 HD12 ' H ' ' A' ' 60' ' ' MET . 19.8 mt -93.29 -1.09 56.43 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 126.203 1.801 . . . . 0.0 112.148 -179.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.4 m -126.68 160.47 34.76 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 CA-C-N 119.707 1.14 . . . . 0.0 113.22 -178.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.541 0.606 0 C-N-CA 125.345 1.458 . . . . 0.0 109.091 178.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.301 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 10.7 p -94.02 134.12 36.76 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 118.264 1.032 . . . . 0.0 113.224 -178.373 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 98.9 t -68.27 132.67 32.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 176.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.29 155.6 40.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.533 0 C-N-CA 124.048 0.939 . . . . 0.0 109.174 179.098 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.72 117.04 12.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 177.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 42.6 tttp -63.58 -31.57 72.78 Favored 'General case' 0 C--N 1.33 -0.25 0 O-C-N 121.426 -0.796 . . . . 0.0 112.498 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m -142.3 169.99 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 C-N-CA 126.567 1.947 . . . . 0.0 107.012 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 39.1 tttt -64.17 127.18 30.33 Favored 'General case' 0 N--CA 1.454 -0.265 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.3 mt -111.89 100.69 49.54 Favored Pre-proline 0 CA--C 1.532 0.278 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 -179.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -65.16 151.43 85.54 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 N-CA-C 109.062 -1.168 . . . . 0.0 109.062 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -50.75 151.81 2.28 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.27 1.028 . . . . 0.0 111.384 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.62 -3.67 62.97 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 123.962 0.791 . . . . 0.0 113.971 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 99.1 m -81.42 145.89 30.56 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 118.191 0.995 . . . . 0.0 109.524 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.5 mm -88.74 130.86 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 178.045 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.555 ' HB3' HD11 ' A' ' 26' ' ' LEU . 30.7 mt -69.33 137.24 52.76 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 124.399 1.079 . . . . 0.0 110.734 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 73.4 p -135.39 159.03 42.86 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.383 1.073 . . . . 0.0 108.621 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 12.0 mmt -64.15 -17.86 63.89 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 118.114 0.415 . . . . 0.0 110.523 179.083 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -79.07 -16.45 56.77 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.966 0.906 . . . . 0.0 112.177 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 75.3 mtm -118.94 15.09 13.36 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.378 1.071 . . . . 0.0 109.971 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.555 HD11 ' HB3' ' A' ' 21' ' ' LEU . 42.9 mt -137.0 154.46 50.4 Favored 'General case' 0 CA--C 1.511 -0.553 0 O-C-N 120.959 -1.088 . . . . 0.0 110.034 -178.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.6 t -164.33 -179.54 6.14 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.449 HG21 ' HB3' ' A' ' 38' ' ' PRO . 1.2 p -134.01 112.6 16.7 Favored 'Isoleucine or valine' 0 C--O 1.234 0.287 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -73.99 114.86 12.78 Favored 'General case' 0 CA--C 1.511 -0.556 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.1 p -51.81 139.75 7.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 O-C-N 124.196 0.935 . . . . 0.0 109.702 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 138.0 -131.34 5.4 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.2 pm0 -75.66 133.92 73.09 Favored Pre-proline 0 CA--C 1.541 0.602 0 C-N-CA 125.211 1.404 . . . . 0.0 112.847 -179.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.06 61.3 7.17 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 124.673 3.582 . . . . 0.0 111.123 179.217 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -88.24 172.06 9.73 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 125.122 1.369 . . . . 0.0 107.866 178.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.05 -77.0 1.18 Allowed Glycine 0 N--CA 1.445 -0.715 0 N-CA-C 113.822 0.289 . . . . 0.0 113.822 178.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -149.07 139.97 13.87 Favored Pre-proline 0 N--CA 1.443 -0.789 0 C-N-CA 126.315 1.846 . . . . 0.0 107.016 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.38 136.91 48.95 Favored 'Trans proline' 0 N--CA 1.451 -0.98 0 N-CA-C 109.106 -1.152 . . . . 0.0 109.106 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.449 ' HB3' HG21 ' A' ' 28' ' ' VAL . 74.4 Cg_endo -68.76 -15.25 40.55 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 122.479 2.119 . . . . 0.0 113.354 -179.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -69.47 -27.49 65.26 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 119.959 1.254 . . . . 0.0 109.85 178.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -98.27 10.43 40.67 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.644 1.578 . . . . 0.0 111.382 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.8 tt -52.54 -38.87 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 C-N-CA 124.831 1.252 . . . . 0.0 111.672 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -68.91 -21.14 64.24 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.74 1.216 . . . . 0.0 112.661 -179.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -79.88 -38.04 33.53 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 119.087 0.858 . . . . 0.0 110.746 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.54 -30.0 70.36 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 123.032 0.533 . . . . 0.0 110.078 178.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 45.3 t -66.52 107.13 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.47 -11.95 10.37 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 126.503 2.002 . . . . 0.0 112.696 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.0 mttm -79.91 156.87 27.09 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-N 118.562 1.181 . . . . 0.0 109.215 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -101.51 138.57 38.34 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.182 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.7 m -78.05 138.77 19.68 Favored 'Isoleucine or valine' 0 C--O 1.24 0.605 0 N-CA-C 109.082 -0.711 . . . . 0.0 109.082 178.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 82.6 mt -84.85 -16.77 40.17 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.587 1.555 . . . . 0.0 111.636 179.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 15.3 m -149.69 163.5 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.175 0 C-N-CA 126.342 1.857 . . . . 0.0 108.648 -178.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 16.7 m -72.45 125.94 28.64 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 177.693 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 87.6 t -105.03 131.12 54.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -76.25 170.43 16.34 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-O 122.413 1.102 . . . . 0.0 112.759 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -65.67 136.91 56.91 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 63.14 7.98 3.06 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 126.035 1.734 . . . . 0.0 112.803 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -72.45 157.28 37.93 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 119.428 1.013 . . . . 0.0 111.286 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.1 m -79.75 119.34 22.53 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 123.944 0.898 . . . . 0.0 111.27 -178.802 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.6 mm -76.13 139.82 18.29 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 178.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 26.8 mtp -138.88 160.49 39.6 Favored 'General case' 0 C--O 1.231 0.094 0 C-N-CA 123.655 0.782 . . . . 0.0 109.474 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -60.77 -40.77 93.77 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 123.304 0.641 . . . . 0.0 109.456 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -65.66 4.33 0.6 Allowed 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 126.215 1.806 . . . . 0.0 114.551 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 34.9 mt -118.28 0.01 11.61 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.113 1.365 . . . . 0.0 109.694 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.5 m -131.23 162.58 39.01 Favored 'Isoleucine or valine' 0 C--N 1.343 0.285 0 C-N-CA 124.321 1.048 . . . . 0.0 111.148 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 36.4 t0 . . . . . 0 C--O 1.239 0.526 0 C-N-CA 124.975 1.31 . . . . 0.0 112.056 179.726 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.669 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 45.4 p -142.57 159.02 43.05 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.472 0.709 . . . . 0.0 109.794 -178.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 78.2 t -84.11 124.55 39.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 178.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.9 m -123.07 148.71 26.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.535 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.5 111.73 4.28 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 125.686 1.595 . . . . 0.0 107.997 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 81.1 tttt -64.95 -24.8 67.63 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 123.434 0.694 . . . . 0.0 112.714 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.6 m -148.92 165.79 3.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 127.116 2.167 . . . . 0.0 106.944 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -64.69 130.58 44.11 Favored 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 178.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 32.2 mt -118.78 101.27 50.59 Favored Pre-proline 0 CA--C 1.533 0.311 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.442 ' HA ' HG23 ' A' ' 52' ' ' THR . 36.6 Cg_endo -67.35 153.15 77.81 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 121.944 1.763 . . . . 0.0 112.346 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.4 ' HA ' HG23 ' A' ' 49' ' ' VAL . 9.6 tm-20 -58.17 146.03 35.02 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 122.289 1.042 . . . . 0.0 108.617 178.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.95 19.99 56.52 Favored Glycine 0 CA--C 1.53 0.995 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.953 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.1 m -117.44 156.25 28.27 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 125.976 1.71 . . . . 0.0 107.734 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 34.1 mm -101.5 143.25 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 C-N-CA 123.867 0.867 . . . . 0.0 108.716 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 23.0 mt -76.03 135.88 39.94 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 67.1 p -130.57 158.15 40.76 Favored 'General case' 0 C--O 1.238 0.477 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 13.4 mmt -63.22 -20.51 65.5 Favored 'General case' 0 CA--C 1.536 0.408 0 O-C-N 121.926 -0.484 . . . . 0.0 109.713 178.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -79.99 -18.41 50.36 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 126.27 1.828 . . . . 0.0 114.185 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 69.8 mtm -112.46 16.15 19.95 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 119.162 0.892 . . . . 0.0 111.697 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.1 mt -133.64 147.92 51.49 Favored 'General case' 0 C--O 1.238 0.456 0 C-N-CA 124.019 0.927 . . . . 0.0 110.666 -179.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.9 t -147.7 144.62 28.45 Favored 'General case' 0 CA--C 1.54 0.572 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 56.8 t -89.06 117.52 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 31.7 ttpt -59.84 -29.63 68.4 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 115.01 1.485 . . . . 0.0 115.01 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.6 t 47.65 66.42 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 CA-C-O 122.665 1.221 . . . . 0.0 109.278 -179.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.97 -66.24 0.01 OUTLIER Glycine 0 CA--C 1.521 0.435 0 C-N-CA 124.647 1.118 . . . . 0.0 111.042 -179.482 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -133.9 152.8 79.28 Favored Pre-proline 0 CA--C 1.529 0.158 0 C-N-CA 123.583 0.753 . . . . 0.0 111.598 -178.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.18 5.4 4.59 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 123.686 2.924 . . . . 0.0 113.131 179.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -72.26 115.12 11.13 Favored 'General case' 0 CA--C 1.518 -0.251 0 O-C-N 119.946 -1.721 . . . . 0.0 106.413 178.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.36 171.71 15.73 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -54.94 135.71 66.59 Favored Pre-proline 0 CA--C 1.541 0.61 0 CA-C-O 118.993 -0.527 . . . . 0.0 110.716 -179.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -67.94 150.73 78.26 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.806 2.337 . . . . 0.0 113.557 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -79.41 -4.34 13.6 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 123.437 2.758 . . . . 0.0 114.93 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 24.2 tp10 -82.43 -46.14 13.89 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 119.918 1.235 . . . . 0.0 108.124 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -79.71 7.38 8.62 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 125.86 1.664 . . . . 0.0 111.63 -179.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.7 tt -46.82 -43.13 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 C-N-CA 126.19 1.796 . . . . 0.0 112.909 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -58.91 -27.95 65.74 Favored 'General case' 0 C--O 1.227 -0.126 0 C-N-CA 123.1 0.56 . . . . 0.0 111.657 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -73.35 -36.82 66.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 49.2 mt -66.65 -38.96 87.94 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 119.123 0.874 . . . . 0.0 109.705 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 73.5 t -61.63 131.45 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.09 -11.09 69.69 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 118.792 -1.004 . . . . 0.0 111.699 -178.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 26.5 mttm -84.05 154.36 23.28 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-N 119.556 1.678 . . . . 0.0 110.615 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 39.4 ttmt -95.04 131.08 41.41 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 178.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.4 HG23 ' HA ' ' A' ' 17' ' ' GLU . 4.4 m -66.76 168.66 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 176.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 46.3 mt -114.28 -7.08 12.97 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 123.913 0.885 . . . . 0.0 112.44 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.8 m -156.83 162.31 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 126.952 2.101 . . . . 0.0 108.418 -178.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.442 HG23 ' HA ' ' A' ' 16' ' ' PRO . 31.9 m -72.94 109.66 6.66 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.003 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 57.4 t -85.96 131.04 35.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 179.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -78.05 167.49 21.37 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 123.652 0.781 . . . . 0.0 109.721 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -69.92 149.86 47.35 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 177.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 60.94 10.01 2.58 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 127.948 2.499 . . . . 0.0 111.59 -179.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -75.73 153.33 37.11 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 178.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 99.2 m -88.47 121.88 31.34 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.179 0.514 . . . . 0.0 110.932 -178.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 mm -74.18 138.51 21.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 178.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -131.37 157.92 42.13 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 124.368 1.067 . . . . 0.0 108.595 179.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -59.35 -27.8 66.26 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 124.715 1.206 . . . . 0.0 111.669 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -89.26 -4.15 58.27 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 119.173 0.897 . . . . 0.0 113.095 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 57.4 mt -96.57 15.8 20.61 Favored 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 124.352 1.061 . . . . 0.0 109.4 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.1 m -139.22 140.84 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 37.2 t70 . . . . . 0 C--N 1.327 -0.389 0 C-N-CA 125.598 1.559 . . . . 0.0 110.387 179.787 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.321 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -146.91 162.0 39.58 Favored 'General case' 0 C--O 1.239 0.513 0 C-N-CA 126.081 1.753 . . . . 0.0 110.963 179.046 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.2 t -70.0 140.47 18.54 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 C-N-CA 126.188 1.795 . . . . 0.0 112.282 -178.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.7 m -139.59 159.53 27.8 Favored 'Isoleucine or valine' 0 C--O 1.24 0.584 0 C-N-CA 126.601 1.961 . . . . 0.0 107.078 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -81.25 138.28 35.78 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.096 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -81.6 -22.33 37.78 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 123.447 0.699 . . . . 0.0 111.567 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.8 m -145.76 170.38 5.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 124.842 1.257 . . . . 0.0 108.254 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.6 tttm -72.41 104.05 3.65 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 105.549 -2.019 . . . . 0.0 105.549 177.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 7.3 mt -88.32 109.04 25.54 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-O 118.122 -0.942 . . . . 0.0 109.063 -178.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -69.67 149.39 67.4 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 CA-C-N 120.981 1.386 . . . . 0.0 109.983 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.422 ' HA ' HG23 ' A' ' 49' ' ' VAL . 27.9 tt0 -51.14 143.88 10.11 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.454 1.102 . . . . 0.0 110.565 179.434 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.38 2.0 90.27 Favored Glycine 0 C--N 1.338 0.641 0 CA-C-O 118.979 -0.901 . . . . 0.0 114.53 179.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 65.4 m -91.03 142.63 27.57 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 118.741 1.271 . . . . 0.0 109.708 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 5.0 mm -78.7 135.45 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 50.4 mt -74.29 141.85 45.26 Favored 'General case' 0 C--O 1.237 0.446 0 C-N-CA 124.774 1.23 . . . . 0.0 109.352 178.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 41.7 p -141.36 165.51 27.31 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 106.951 -1.499 . . . . 0.0 106.951 178.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -65.02 -22.2 66.96 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-N 118.116 0.416 . . . . 0.0 110.459 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -67.93 -30.5 69.82 Favored 'General case' 0 N--CA 1.464 0.263 0 C-N-CA 124.48 1.112 . . . . 0.0 111.495 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 71.1 mtm -105.92 10.52 32.37 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.491 1.117 . . . . 0.0 112.67 -177.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.0 mt -131.93 162.51 30.48 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 123.958 0.903 . . . . 0.0 109.013 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.5 t -169.84 174.86 5.45 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 179.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.4 t -114.99 156.75 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 177.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 23.8 ttpp -126.98 111.68 14.37 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 103.423 -2.806 . . . . 0.0 103.423 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.7 m -62.63 158.88 3.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 120.238 -0.585 . . . . 0.0 110.209 -179.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 130.76 -96.69 0.35 Allowed Glycine 0 C--N 1.333 0.371 0 CA-C-O 119.078 -0.846 . . . . 0.0 112.277 179.168 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -115.76 157.28 44.97 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 125.559 1.544 . . . . 0.0 113.486 -177.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -77.32 15.19 1.24 Allowed 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 124.562 3.508 . . . . 0.0 113.366 179.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 25.6 tptp -55.68 113.55 1.51 Allowed 'General case' 0 N--CA 1.465 0.311 0 O-C-N 120.699 -1.251 . . . . 0.0 108.5 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.33 -170.47 21.43 Favored Glycine 0 N--CA 1.451 -0.348 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.4 t80 -58.02 130.32 82.98 Favored Pre-proline 0 CA--C 1.544 0.719 0 CA-C-O 118.505 -0.76 . . . . 0.0 110.257 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -66.05 153.12 79.39 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.897 2.398 . . . . 0.0 111.797 -178.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_endo -77.23 -22.96 10.7 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 121.606 1.537 . . . . 0.0 113.893 -178.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -63.12 -40.92 99.01 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 119.83 1.195 . . . . 0.0 109.933 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -82.96 4.34 26.26 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-O 117.906 -1.045 . . . . 0.0 113.313 -178.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.6 tt -48.25 -35.03 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 CA-C-N 120.719 1.6 . . . . 0.0 113.763 -178.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -58.82 -28.49 66.07 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.508 0.723 . . . . 0.0 111.701 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 30.0 m-80 -71.53 -41.99 68.5 Favored 'General case' 0 CA--C 1.521 -0.161 0 C-N-CA 124.001 0.921 . . . . 0.0 109.234 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 38.1 mt -65.0 -42.17 94.73 Favored 'General case' 0 CA--C 1.519 -0.216 0 C-N-CA 123.054 0.541 . . . . 0.0 110.171 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.78 98.7 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 C-N-CA 124.345 1.058 . . . . 0.0 108.786 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.99 -14.19 6.65 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 126.321 1.915 . . . . 0.0 114.178 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -79.62 167.79 20.24 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 118.861 1.331 . . . . 0.0 110.426 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.05 137.82 42.22 Favored 'General case' 0 CA--C 1.512 -0.516 0 CA-C-O 118.075 -0.964 . . . . 0.0 109.599 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.422 HG23 ' HA ' ' A' ' 17' ' ' GLU . 3.3 m -77.02 138.14 21.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 78.3 mt -85.33 -15.88 41.84 Favored 'General case' 0 N--CA 1.462 0.148 0 C-N-CA 123.452 0.701 . . . . 0.0 112.182 179.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.2 m -148.04 164.47 5.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 30.7 m -69.66 140.86 53.68 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.077 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 84.9 t -115.14 152.8 16.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -110.71 166.69 10.81 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 123.966 0.907 . . . . 0.0 111.194 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -63.26 128.57 36.43 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 30.6 t70 68.73 8.21 6.61 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 128.09 2.556 . . . . 0.0 112.908 -179.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -67.25 162.6 22.28 Favored 'General case' 0 CA--C 1.533 0.298 0 O-C-N 121.005 -1.059 . . . . 0.0 108.438 179.26 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 77.7 m -95.08 123.0 38.32 Favored 'General case' 0 N--CA 1.468 0.435 0 O-C-N 120.131 -1.606 . . . . 0.0 113.181 -178.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 13.3 mm -74.38 146.41 9.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 3.3 mmt -140.26 158.56 43.85 Favored 'General case' 0 C--O 1.233 0.214 0 C-N-CA 126.404 1.882 . . . . 0.0 107.299 179.235 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.34 -32.32 73.71 Favored 'General case' 0 CA--C 1.528 0.123 0 O-C-N 122.141 -0.349 . . . . 0.0 111.762 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -72.07 -5.27 34.07 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -179.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 56.7 mt -103.77 9.57 36.99 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 124.24 1.016 . . . . 0.0 111.05 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.5 m -131.93 155.28 41.45 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 CA-C-N 119.758 1.163 . . . . 0.0 112.3 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 . . . . . 0 C--O 1.234 0.285 0 C-N-CA 125.608 1.563 . . . . 0.0 113.85 -179.547 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 CA-C-O 121.053 0.252 . . . . 0.0 113.234 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.411 ' HB3' ' O ' ' A' ' 34' ' ' LYS . 0.2 OUTLIER -122.52 134.32 54.56 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 127.245 2.218 . . . . 0.0 111.997 -177.877 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 61.2 t -67.73 129.44 32.29 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 28.2 m -132.88 151.42 34.31 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.23 128.4 36.11 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.474 ' HE3' ' HB ' ' A' ' 27' ' ' THR . 6.7 ttmt -72.75 -28.15 62.46 Favored 'General case' 0 C--N 1.327 -0.377 0 O-C-N 121.399 -0.813 . . . . 0.0 111.695 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.71 169.88 18.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 C-N-CA 125.762 1.625 . . . . 0.0 107.093 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 58.7 tttt -71.88 114.91 10.48 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 49.8 mt -100.2 106.77 43.88 Favored Pre-proline 0 CA--C 1.534 0.339 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.483 ' HA ' HG23 ' A' ' 52' ' ' THR . 42.8 Cg_endo -66.55 148.7 83.96 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 121.569 1.513 . . . . 0.0 110.72 179.297 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.45 ' HA ' HG23 ' A' ' 49' ' ' VAL . 52.0 tt0 -48.54 142.29 6.06 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 126.168 1.787 . . . . 0.0 110.38 179.476 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.36 0.46 86.76 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-O 118.012 -1.438 . . . . 0.0 113.768 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.1 m -91.3 154.88 18.93 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 120.355 2.078 . . . . 0.0 107.857 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.8 mm -89.29 145.91 6.82 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-N 119.509 1.05 . . . . 0.0 109.097 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 15.2 mt -80.36 137.7 36.59 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.245 0.618 . . . . 0.0 109.811 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 29.0 p -131.22 154.95 47.89 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 125.952 1.701 . . . . 0.0 107.342 179.261 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 12.4 mmt -60.82 -35.46 76.58 Favored 'General case' 0 CA--C 1.538 0.484 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -61.2 -19.16 61.29 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 127.987 2.515 . . . . 0.0 113.051 178.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.6 mtm -115.66 16.31 16.45 Favored 'General case' 0 N--CA 1.466 0.355 0 O-C-N 121.195 -0.941 . . . . 0.0 110.979 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 70.7 mt -129.26 170.5 13.53 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 121.998 0.904 . . . . 0.0 113.263 -179.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.474 ' HB ' ' HE3' ' A' ' 12' ' ' LYS . 4.3 t -171.88 173.26 4.54 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 128.343 2.657 . . . . 0.0 107.221 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -129.88 110.56 19.83 Favored 'Isoleucine or valine' 0 C--O 1.24 0.568 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 178.571 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 20.6 ttpt -69.8 112.6 6.36 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.192 1.397 . . . . 0.0 107.498 179.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.8 p -66.93 130.96 32.76 Favored 'Isoleucine or valine' 0 C--O 1.239 0.513 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 178.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.64 -89.27 0.1 OUTLIER Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 -179.139 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -134.5 158.5 75.01 Favored Pre-proline 0 CA--C 1.539 0.553 0 CA-C-O 118.532 -0.747 . . . . 0.0 110.698 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -73.3 31.65 0.31 Allowed 'Trans proline' 0 CA--C 1.544 0.981 1 C-N-CA 126.149 4.566 . . . . 0.0 116.093 -179.152 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.411 ' O ' ' HB3' ' A' ' 8' ' ' SER . 39.9 ttmt -60.6 139.04 57.96 Favored 'General case' 0 C--O 1.225 -0.225 0 O-C-N 120.676 -1.265 . . . . 0.0 110.968 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.41 -72.67 0.78 Allowed Glycine 0 CA--C 1.524 0.62 0 CA-C-O 118.526 -1.152 . . . . 0.0 115.754 178.497 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.415 ' CG ' HD11 ' A' ' 44' ' ' LEU . 1.7 t80 -151.09 147.77 21.31 Favored Pre-proline 0 CA--C 1.544 0.737 0 CA-C-N 119.596 1.698 . . . . 0.0 114.82 -176.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -83.99 163.4 13.67 Favored 'Trans proline' 0 C--N 1.354 0.868 0 C-N-CA 124.203 3.269 . . . . 0.0 114.347 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -79.61 -10.36 14.5 Favored 'Trans proline' 0 C--N 1.349 0.605 0 C-N-CA 122.482 2.121 . . . . 0.0 111.873 179.268 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -76.73 -19.85 57.2 Favored 'General case' 0 CA--C 1.535 0.39 0 O-C-N 121.248 -0.907 . . . . 0.0 110.922 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -117.47 8.78 13.07 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 124.04 0.936 . . . . 0.0 112.69 -178.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.6 tt -51.45 -35.5 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 124.041 0.936 . . . . 0.0 111.569 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -61.83 -28.17 69.29 Favored 'General case' 0 N--CA 1.461 0.123 0 C-N-CA 125.245 1.418 . . . . 0.0 111.74 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 37.7 m-80 -78.37 -30.26 47.86 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-O 118.977 -0.535 . . . . 0.0 109.622 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.415 HD11 ' CG ' ' A' ' 36' ' ' TYR . 53.4 mt -76.03 -37.47 58.33 Favored 'General case' 0 C--N 1.339 0.12 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.559 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.1 t -63.54 121.28 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 104.617 -2.364 . . . . 0.0 104.617 178.241 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.45 -9.72 38.59 Favored Glycine 0 CA--C 1.534 1.266 0 CA-C-O 118.846 -0.975 . . . . 0.0 111.404 -178.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 72.2 mttt -85.18 169.16 14.12 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-N 119.721 1.761 . . . . 0.0 107.751 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.1 ttmp? -116.01 130.07 56.65 Favored 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 125.813 1.645 . . . . 0.0 108.027 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.45 HG23 ' HA ' ' A' ' 17' ' ' GLU . 3.9 m -73.2 144.02 13.21 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 55.7 mt -90.59 -13.88 33.58 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 124.198 0.999 . . . . 0.0 112.093 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 31.6 m -147.99 162.88 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 125.89 1.676 . . . . 0.0 107.208 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.483 HG23 ' HA ' ' A' ' 16' ' ' PRO . 51.5 m -72.85 133.83 44.6 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 96.9 t -112.61 124.48 69.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 125.808 1.643 . . . . 0.0 107.519 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -78.65 171.85 14.54 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.49 0.662 . . . . 0.0 111.866 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 49.1 tt0 -63.25 143.68 57.59 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 105.389 -2.078 . . . . 0.0 105.389 177.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 25.8 t0 61.36 8.23 2.06 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.334 2.254 . . . . 0.0 112.883 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.82 150.52 32.28 Favored 'General case' 0 C--N 1.344 0.365 0 O-C-N 120.905 -1.122 . . . . 0.0 110.287 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.5 118.02 17.92 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 125.124 1.369 . . . . 0.0 113.961 -176.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 mm -75.87 146.32 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 104.564 -2.384 . . . . 0.0 104.564 177.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 10.0 mtt -141.92 157.19 45.26 Favored 'General case' 0 CA--C 1.518 -0.272 0 C-N-CA 123.956 0.903 . . . . 0.0 109.207 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -67.63 -14.74 63.2 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 122.473 0.309 . . . . 0.0 111.267 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 20.5 tt0 -84.52 -33.02 23.61 Favored 'General case' 0 CA--C 1.535 0.4 0 O-C-N 121.127 -0.983 . . . . 0.0 110.89 179.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 43.5 mt -81.33 6.27 14.83 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.722 1.609 . . . . 0.0 113.826 -178.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.6 m -126.66 154.26 36.28 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 CA-C-N 119.267 0.94 . . . . 0.0 110.997 -179.224 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 . . . . . 0 C--O 1.238 0.46 0 C-N-CA 125.351 1.46 . . . . 0.0 109.618 179.108 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.878 0 N-CA-C 107.262 -2.335 . . . . 0.0 107.262 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.1 t -141.94 174.03 10.97 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 118.377 1.089 . . . . 0.0 112.506 -178.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.438 HG11 ' CD1' ' A' ' 44' ' ' LEU . 68.3 t -78.33 119.78 27.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 C-N-CA 127.664 2.386 . . . . 0.0 108.578 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.6 m -128.96 147.5 33.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.17 115.43 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 124.356 1.062 . . . . 0.0 108.267 179.335 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 41.0 tttm -64.68 -30.55 71.56 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.7 m -147.74 168.67 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 128.413 2.685 . . . . 0.0 105.804 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 65.9 tttt -63.64 130.47 44.42 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 9.4 mt -114.63 101.14 54.18 Favored Pre-proline 0 N--CA 1.454 -0.26 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -70.56 148.3 59.6 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 122.381 2.054 . . . . 0.0 109.235 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 -51.9 146.25 8.65 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.678 1.191 . . . . 0.0 113.228 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 79.74 -2.87 71.78 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 125.059 1.314 . . . . 0.0 113.525 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.4 m -82.19 151.68 26.78 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 119.0 1.4 . . . . 0.0 109.637 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 17.4 mm -91.31 128.5 43.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 178.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 63.3 mt -67.56 146.91 53.44 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.084 1.354 . . . . 0.0 108.964 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 64.9 p -141.27 160.29 40.43 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.9 mmt -64.27 -26.86 68.68 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 178.043 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -63.69 -16.0 59.91 Favored 'General case' 0 CA--C 1.536 0.426 0 O-C-N 121.494 -0.754 . . . . 0.0 112.48 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 38.0 mtm -120.09 4.99 10.84 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 124.878 1.271 . . . . 0.0 112.375 -179.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 92.1 mt -124.94 118.82 27.12 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 120.006 1.275 . . . . 0.0 109.163 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 t -123.82 171.77 9.4 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 124.921 1.288 . . . . 0.0 109.369 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 17.9 t -119.81 151.4 22.36 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 39.1 mmtm -109.83 -172.22 2.0 Allowed 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 124.995 1.318 . . . . 0.0 109.795 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 23.2 m -131.57 16.77 1.82 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 C-N-CA 124.979 1.312 . . . . 0.0 111.565 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -78.64 -92.42 0.32 Allowed Glycine 0 C--N 1.334 0.451 0 C-N-CA 124.107 0.86 . . . . 0.0 113.255 -179.034 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -133.54 157.59 77.63 Favored Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 126.279 1.831 . . . . 0.0 109.004 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -73.05 -1.99 11.35 Favored 'Trans proline' 0 CA--C 1.535 0.55 0 C-N-CA 123.873 3.048 . . . . 0.0 114.233 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.4 ttpt -52.49 127.78 23.67 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.97 -170.74 13.44 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 -178.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -64.61 128.45 93.49 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -64.3 134.85 43.9 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.247 1.965 . . . . 0.0 111.337 -179.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -68.55 -17.65 43.28 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 121.631 1.554 . . . . 0.0 113.482 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -64.39 -25.62 68.1 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 120.311 1.414 . . . . 0.0 110.241 179.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -109.04 12.51 25.17 Favored 'General case' 0 N--CA 1.464 0.237 0 O-C-N 121.15 -0.969 . . . . 0.0 112.121 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.5 tt -48.6 -35.48 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 124.847 1.259 . . . . 0.0 111.895 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 40.0 m-85 -51.81 -30.17 22.22 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 126.111 1.764 . . . . 0.0 112.144 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 67.4 m-80 -81.96 -21.39 37.23 Favored 'General case' 0 CA--C 1.519 -0.214 0 C-N-CA 124.327 1.051 . . . . 0.0 113.093 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.438 ' CD1' HG11 ' A' ' 9' ' ' VAL . 96.2 mt -78.05 -35.53 49.51 Favored 'General case' 0 CA--C 1.521 -0.145 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.85 125.49 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.41 -11.5 68.71 Favored Glycine 0 CA--C 1.529 0.949 0 CA-C-O 117.842 -1.532 . . . . 0.0 113.369 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 43.1 mtmt -83.42 164.24 20.05 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 120.814 2.307 . . . . 0.0 109.558 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.7 ttmp? -102.54 145.52 29.48 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.8 m -85.36 140.23 16.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 O-C-N 123.346 0.404 . . . . 0.0 110.397 179.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 16.9 mt -86.89 -18.07 31.75 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-O 117.718 -1.134 . . . . 0.0 111.527 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 17.7 m -150.02 165.36 3.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 C-N-CA 123.958 0.903 . . . . 0.0 109.052 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.0 m -74.76 143.2 44.18 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 105.609 -1.997 . . . . 0.0 105.609 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 75.1 t -129.08 123.26 58.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 C-N-CA 125.8 1.64 . . . . 0.0 106.664 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -72.54 160.98 31.39 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 122.626 1.203 . . . . 0.0 108.867 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -65.76 134.32 52.9 Favored 'General case' 0 C--O 1.24 0.581 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.2 t70 82.87 1.2 1.17 Allowed 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 128.886 2.874 . . . . 0.0 113.901 179.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -71.76 156.97 38.74 Favored 'General case' 0 C--N 1.341 0.226 0 CA-C-N 118.228 0.467 . . . . 0.0 110.631 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.3 m -80.67 116.9 20.92 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 125.965 1.706 . . . . 0.0 109.775 179.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 16.0 mm -73.95 143.53 13.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 N-CA-C 107.243 -1.391 . . . . 0.0 107.243 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -135.47 153.75 51.65 Favored 'General case' 0 CA--C 1.521 -0.147 0 C-N-CA 125.574 1.55 . . . . 0.0 107.411 179.177 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -60.72 -29.34 69.3 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -179.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 22.2 tp10 -67.65 -22.7 65.3 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 122.714 0.406 . . . . 0.0 111.252 -179.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 17.4 mt -86.52 4.06 41.53 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 124.759 1.224 . . . . 0.0 112.276 -178.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.4 m -131.4 117.25 35.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 120.182 1.355 . . . . 0.0 112.292 -178.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 11.3 t70 . . . . . 0 C--O 1.238 0.488 0 C-N-CA 125.651 1.58 . . . . 0.0 108.263 179.263 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.548 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 48.4 t -136.95 154.92 50.31 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 123.823 0.849 . . . . 0.0 110.916 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 99.2 t -75.76 142.52 14.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.3 m -141.83 161.81 20.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.568 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 178.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.91 121.72 20.47 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 54.1 tttm -74.8 -21.7 59.16 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 118.862 -0.59 . . . . 0.0 110.96 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.4 m -145.31 168.04 8.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 C-N-CA 125.873 1.669 . . . . 0.0 108.765 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -73.34 113.68 10.7 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 178.037 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.3 mt -105.56 104.12 46.68 Favored Pre-proline 0 CA--C 1.533 0.299 0 C-N-CA 124.977 1.311 . . . . 0.0 108.311 -178.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -67.82 155.39 70.06 Favored 'Trans proline' 0 N--CA 1.454 -0.83 0 C-N-CA 121.559 1.506 . . . . 0.0 110.382 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.416 ' HA ' HG23 ' A' ' 49' ' ' VAL . 5.8 tm-20 -52.08 147.34 7.53 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-O 121.899 0.856 . . . . 0.0 111.164 179.515 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.27 -4.1 82.36 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 123.77 0.7 . . . . 0.0 114.151 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 26.9 m -84.98 144.76 28.1 Favored 'General case' 0 CA--C 1.538 0.485 0 CA-C-N 118.9 1.35 . . . . 0.0 111.355 -179.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 27.5 mm -87.13 129.85 37.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.859 1.664 . . . . 0.0 107.712 178.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 38.6 mt -71.33 150.49 45.07 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.808 1.243 . . . . 0.0 112.323 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 46.5 p -145.57 161.72 39.13 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 126.826 2.05 . . . . 0.0 107.396 179.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 21.6 mmt -62.11 -38.51 89.17 Favored 'General case' 0 C--O 1.223 -0.327 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 178.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.9 t0 -59.32 -23.61 62.62 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 125.014 1.326 . . . . 0.0 112.651 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 25.5 mtm -104.36 7.71 35.71 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 121.34 -0.85 . . . . 0.0 111.919 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.1 mt -126.19 151.19 47.69 Favored 'General case' 0 CA--C 1.521 -0.135 0 O-C-N 120.948 -1.095 . . . . 0.0 109.124 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.3 t -149.28 174.06 12.81 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 179.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.1 t -128.77 122.78 57.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 22.5 mmmt -92.84 116.46 29.05 Favored 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 p -65.2 136.03 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 178.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 154.76 -87.48 0.13 Allowed Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.5 pm0 -145.11 156.78 54.56 Favored Pre-proline 0 CA--C 1.54 0.591 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -82.35 57.35 6.12 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 124.965 3.777 . . . . 0.0 111.589 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.51 10.26 3.31 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 124.642 1.177 . . . . 0.0 113.254 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.48 -155.6 7.57 Favored Glycine 0 CA--C 1.524 0.633 0 C-N-CA 125.12 1.343 . . . . 0.0 109.98 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 20.1 t80 -59.66 141.03 89.04 Favored Pre-proline 0 CA--C 1.547 0.85 0 C-N-CA 123.669 0.788 . . . . 0.0 109.926 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.25 143.34 58.41 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 123.728 2.952 . . . . 0.0 115.287 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -76.17 -9.06 19.07 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.145 1.896 . . . . 0.0 113.144 179.124 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -79.23 -59.81 2.62 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -71.13 6.58 1.57 Allowed 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 125.817 1.647 . . . . 0.0 113.35 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 15.6 tt -47.65 -33.41 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 C-N-CA 126.385 1.874 . . . . 0.0 112.767 -179.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -57.53 -26.34 61.22 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 123.687 0.795 . . . . 0.0 111.753 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -78.01 -28.2 49.13 Favored 'General case' 0 CA--C 1.528 0.11 0 C-N-CA 123.532 0.733 . . . . 0.0 111.437 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.8 mt -70.58 -37.33 73.93 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 118.679 0.672 . . . . 0.0 109.458 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 43.1 t -61.44 109.29 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 C-N-CA 124.794 1.238 . . . . 0.0 109.382 -179.319 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.14 -14.44 18.88 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 125.582 1.563 . . . . 0.0 111.389 -178.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.2 mttt -74.64 156.0 37.19 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 118.76 1.28 . . . . 0.0 108.318 179.048 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.7 ttmp? -103.45 133.2 48.9 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.416 HG23 ' HA ' ' A' ' 17' ' ' GLU . 6.5 m -73.89 141.59 15.97 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 178.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 93.3 mt -87.37 -20.77 26.24 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 125.658 1.583 . . . . 0.0 110.806 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.6 m -142.29 166.42 16.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.241 0 C-N-CA 125.076 1.35 . . . . 0.0 110.18 -178.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 54.4 m -74.11 106.74 5.92 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 91.3 t -90.22 136.1 24.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 178.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -92.69 175.31 6.86 Favored 'General case' 0 C--O 1.226 -0.18 0 O-C-N 121.618 -0.676 . . . . 0.0 111.853 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -70.13 136.87 50.59 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.0 t70 67.22 9.46 6.98 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 126.952 2.101 . . . . 0.0 111.508 -178.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.9 t0 -70.96 147.67 48.46 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 178.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 39.4 m -81.31 115.09 20.52 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.888 0.851 . . . . 0.0 110.535 -178.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.8 mm -72.14 111.47 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -106.79 152.61 23.62 Favored 'General case' 0 C--O 1.238 0.481 0 N-CA-C 104.409 -2.441 . . . . 0.0 104.409 177.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -62.93 -24.45 67.87 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.606 -0.684 . . . . 0.0 111.707 -179.646 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -75.13 -6.01 47.32 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 46.3 mt -95.6 -2.79 47.6 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 119.501 1.046 . . . . 0.0 111.437 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.8 m -130.5 151.5 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 125.251 1.42 . . . . 0.0 107.574 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 13.6 t0 . . . . . 0 CA--C 1.541 0.6 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.767 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.394 0 N-CA-C 107.019 -2.432 . . . . 0.0 107.019 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 96.8 p -138.55 151.19 47.09 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 118.701 1.25 . . . . 0.0 110.924 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.6 t -76.57 125.83 36.69 Favored 'Isoleucine or valine' 0 C--O 1.234 0.259 0 O-C-N 121.307 -0.87 . . . . 0.0 110.159 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 33.3 m -124.9 155.8 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-O 122.445 1.117 . . . . 0.0 108.355 177.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.71 118.7 10.63 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 125.204 1.402 . . . . 0.0 107.43 178.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 34.8 tttp -69.84 -27.31 64.75 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.4 m -151.75 169.77 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 125.729 1.612 . . . . 0.0 107.71 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -61.28 135.27 57.67 Favored 'General case' 0 C--O 1.241 0.62 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.06 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.1 mt -123.09 114.92 29.21 Favored Pre-proline 0 C--O 1.237 0.427 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.469 ' HA ' HG23 ' A' ' 52' ' ' THR . 22.1 Cg_endo -68.35 145.46 65.61 Favored 'Trans proline' 0 N--CA 1.448 -1.174 0 C-N-CA 120.752 0.968 . . . . 0.0 109.993 178.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.6 tt0 -57.27 146.07 29.82 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.442 0.697 . . . . 0.0 110.8 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.36 -0.05 88.48 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 123.849 0.738 . . . . 0.0 112.854 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.6 m -91.71 155.34 18.36 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 118.311 1.055 . . . . 0.0 111.742 -178.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 37.1 mm -89.77 130.12 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 125.332 1.453 . . . . 0.0 108.634 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 29.8 mt -70.25 151.99 44.72 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 124.486 1.114 . . . . 0.0 109.047 178.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 74.2 p -140.63 163.22 33.47 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 124.205 1.002 . . . . 0.0 108.458 -179.313 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 6.2 mmt -63.58 -40.44 96.97 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 177.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -57.71 -30.75 65.77 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 125.683 1.593 . . . . 0.0 113.801 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 63.7 mtm -101.12 13.96 33.48 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 120.379 1.445 . . . . 0.0 112.737 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.4 mt -126.75 136.65 52.7 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -179.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.3 t -140.43 131.2 25.82 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.6 m -90.01 125.82 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 CA-C-N 120.179 1.354 . . . . 0.0 107.881 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 11.1 mttp -84.64 105.33 15.36 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 178.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 8.0 p -59.48 143.03 14.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.517 0 C-N-CA 123.922 0.889 . . . . 0.0 108.966 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 143.7 -81.36 0.22 Allowed Glycine 0 N--CA 1.448 -0.541 0 CA-C-N 118.081 0.4 . . . . 0.0 113.645 179.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -125.6 151.0 69.86 Favored Pre-proline 0 CA--C 1.533 0.293 0 C-N-CA 124.439 1.095 . . . . 0.0 113.102 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -77.8 28.8 0.44 Allowed 'Trans proline' 0 CA--C 1.545 1.051 0 C-N-CA 124.762 3.642 . . . . 0.0 111.936 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 47.7 tttm -80.52 92.99 5.97 Favored 'General case' 0 C--O 1.237 0.444 0 O-C-N 119.826 -1.796 . . . . 0.0 106.944 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 142.66 -149.42 21.27 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 108.501 -1.84 . . . . 0.0 108.501 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -84.68 140.5 38.12 Favored Pre-proline 0 C--O 1.24 0.596 0 C-N-CA 126.328 1.851 . . . . 0.0 108.76 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -55.58 136.05 72.21 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.191 2.594 . . . . 0.0 111.942 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -75.55 -11.02 20.51 Favored 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 123.364 2.709 . . . . 0.0 113.878 -178.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -87.99 -40.02 14.22 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 124.375 1.07 . . . . 0.0 110.074 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -74.36 4.53 5.72 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 124.523 1.129 . . . . 0.0 112.077 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.0 tt -44.5 -39.48 1.72 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 128.049 2.54 . . . . 0.0 112.756 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -53.64 -30.6 43.7 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 123.791 0.836 . . . . 0.0 112.15 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 73.6 m-80 -75.38 -44.97 41.95 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.803 179.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 36.6 mt -56.58 -42.63 78.97 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 79.9 t -60.6 107.55 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 179.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.74 -15.12 26.73 Favored Glycine 0 CA--C 1.528 0.847 0 C-N-CA 125.019 1.295 . . . . 0.0 112.692 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -76.76 157.42 31.65 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-N 120.157 1.979 . . . . 0.0 108.086 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 4.0 ttmp? -98.69 137.96 36.55 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 105.217 -2.142 . . . . 0.0 105.217 177.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 9.2 m -68.13 171.75 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 177.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 61.1 mt -116.46 -11.38 11.15 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 125.019 1.328 . . . . 0.0 111.097 178.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.8 m -153.3 166.68 1.35 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.372 0 C-N-CA 125.91 1.684 . . . . 0.0 107.958 -178.312 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.469 HG23 ' HA ' ' A' ' 16' ' ' PRO . 3.3 m -74.13 135.96 42.91 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 104.843 -2.281 . . . . 0.0 104.843 178.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 95.2 t -121.06 150.83 24.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -106.96 168.18 9.37 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.114 1.366 . . . . 0.0 108.85 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -65.65 147.94 52.57 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 50.1 m-20 72.47 -6.18 1.65 Allowed 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 128.377 2.671 . . . . 0.0 113.236 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -64.62 152.51 41.98 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-O 121.924 0.868 . . . . 0.0 112.652 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -84.0 99.16 10.24 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 123.827 0.851 . . . . 0.0 110.903 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 10.5 mm -67.26 93.73 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 29.9 mtp -96.05 160.96 14.19 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 119.363 0.983 . . . . 0.0 109.577 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -60.36 -22.4 63.23 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.712 0.805 . . . . 0.0 113.107 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -74.97 -16.02 60.65 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.041 0.936 . . . . 0.0 111.865 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 27.8 mt -99.16 9.07 44.18 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 126.447 1.899 . . . . 0.0 113.959 -178.175 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.92 149.8 33.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 120.138 1.335 . . . . 0.0 112.38 -179.095 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 15.7 t0 . . . . . 0 C--O 1.236 0.379 0 C-N-CA 126.036 1.734 . . . . 0.0 107.659 178.681 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.849 0 N-CA-C 112.091 -0.403 . . . . 0.0 112.091 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 23.0 t -102.32 156.73 17.39 Favored 'General case' 0 C--O 1.244 0.779 0 C-N-CA 123.94 0.896 . . . . 0.0 110.732 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 85.9 t -75.52 127.86 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.2 m -127.69 146.59 33.13 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.25 124.02 18.61 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 124.429 1.092 . . . . 0.0 109.054 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 46.6 tttm -67.92 -31.71 71.66 Favored 'General case' 0 C--O 1.225 -0.23 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.421 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.3 m -147.02 174.87 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 126.48 1.912 . . . . 0.0 107.585 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 81.1 tttt -69.38 138.38 53.59 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 178.097 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 23.8 mt -129.25 107.35 17.7 Favored Pre-proline 0 CA--C 1.532 0.262 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -178.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.424 ' HA ' HG23 ' A' ' 52' ' ' THR . 36.6 Cg_endo -69.52 155.51 66.53 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 121.661 1.574 . . . . 0.0 110.532 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.401 ' HA ' HG23 ' A' ' 49' ' ' VAL . 22.7 tt0 -53.39 147.27 10.84 Favored 'General case' 0 C--O 1.238 0.466 0 C-N-CA 124.942 1.297 . . . . 0.0 109.88 179.297 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.0 0.27 75.35 Favored Glycine 0 CA--C 1.53 0.989 0 CA-C-O 118.825 -0.986 . . . . 0.0 113.926 179.187 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 28.5 m -86.67 137.7 32.25 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 119.608 1.704 . . . . 0.0 108.956 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 11.4 mm -80.51 128.71 38.46 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 178.394 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 74.6 mt -67.19 145.18 55.51 Favored 'General case' 0 C--O 1.237 0.442 0 C-N-CA 125.28 1.432 . . . . 0.0 110.307 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.57 ' HA ' HG23 ' A' ' 45' ' ' VAL . 17.6 p -143.25 152.35 41.6 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.371 1.468 . . . . 0.0 107.457 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -56.65 -27.09 57.88 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 118.869 0.758 . . . . 0.0 109.319 178.559 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -56.39 -29.27 61.28 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 126.418 1.887 . . . . 0.0 111.574 177.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 48.6 mtm -114.04 3.01 15.14 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 124.616 1.166 . . . . 0.0 111.168 -178.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 70.7 mt -105.52 147.89 27.85 Favored 'General case' 0 C--N 1.343 0.296 0 CA-C-N 120.081 1.31 . . . . 0.0 109.188 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.0 t -159.74 171.97 18.56 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 125.241 1.417 . . . . 0.0 107.613 178.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 77.0 t -125.57 152.19 32.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 8.3 mmmt -127.45 109.49 11.8 Favored 'General case' 0 CA--C 1.508 -0.646 0 N-CA-C 105.797 -1.927 . . . . 0.0 105.797 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 29.5 m -59.52 151.43 5.12 Favored 'Isoleucine or valine' 0 C--O 1.24 0.563 0 O-C-N 123.573 0.545 . . . . 0.0 109.532 179.694 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 152.09 -95.24 0.15 Allowed Glycine 0 N--CA 1.442 -0.925 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.53 163.38 50.02 Favored Pre-proline 0 C--N 1.326 -0.419 0 C-N-CA 126.562 1.945 . . . . 0.0 110.147 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -85.88 53.87 3.37 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 122.761 2.307 . . . . 0.0 110.16 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 32.9 pttt -73.81 70.65 1.44 Allowed 'General case' 0 C--O 1.221 -0.417 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 178.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.69 -152.8 18.07 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -178.366 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -55.07 134.17 68.07 Favored Pre-proline 0 CA--C 1.545 0.766 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -178.17 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -74.17 156.36 46.78 Favored 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 123.367 2.711 . . . . 0.0 111.251 179.306 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -71.18 -24.72 23.09 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.045 1.83 . . . . 0.0 113.942 -178.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 18.8 mp0 -83.68 2.32 38.22 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 -177.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -124.79 -5.46 7.5 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 119.949 1.25 . . . . 0.0 111.957 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 18.2 tt -40.38 -34.8 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 128.401 2.68 . . . . 0.0 114.327 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -57.91 -11.96 2.81 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.43 1.492 . . . . 0.0 114.139 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -97.4 -24.8 15.46 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 120.298 1.408 . . . . 0.0 110.82 178.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 85.8 mt -64.23 -37.94 89.27 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.57 HG23 ' HA ' ' A' ' 22' ' ' THR . 0.7 OUTLIER -68.08 118.88 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 179.556 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.82 -16.78 23.21 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 125.325 1.44 . . . . 0.0 112.337 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -85.6 158.68 20.05 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 119.034 1.417 . . . . 0.0 107.593 178.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt -103.45 139.74 38.42 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.793 -0.818 . . . . 0.0 108.793 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.401 HG23 ' HA ' ' A' ' 17' ' ' GLU . 3.2 m -77.29 135.12 27.16 Favored 'Isoleucine or valine' 0 C--O 1.236 0.347 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 24.1 mt -81.27 -15.3 55.92 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 124.227 1.011 . . . . 0.0 112.028 179.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.2 m -146.92 164.03 7.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 127.059 2.144 . . . . 0.0 108.796 -178.353 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.424 HG23 ' HA ' ' A' ' 16' ' ' PRO . 24.0 m -77.34 132.28 38.5 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.025 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.496 HG12 ' H ' ' A' ' 54' ' ' GLU . 54.3 t -98.5 -178.48 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 C-N-CA 126.512 1.925 . . . . 0.0 106.803 178.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.496 ' H ' HG12 ' A' ' 53' ' ' VAL . 27.8 mt-10 -135.64 164.76 27.11 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 127.377 2.271 . . . . 0.0 107.73 177.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -65.91 141.43 58.24 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 105.7 -1.963 . . . . 0.0 105.7 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 68.22 4.88 4.37 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.168 1.787 . . . . 0.0 114.946 179.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -76.19 155.35 34.59 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 119.633 1.106 . . . . 0.0 109.515 179.005 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 29.7 m -77.32 135.74 38.41 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 121.166 -0.959 . . . . 0.0 109.871 -179.338 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 16.7 mm -97.5 133.94 37.42 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 N-CA-C 104.808 -2.293 . . . . 0.0 104.808 177.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 82.7 mtp -139.93 160.86 38.96 Favored 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 123.579 0.752 . . . . 0.0 110.703 -178.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -57.44 -33.62 68.12 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 124.778 1.231 . . . . 0.0 113.231 -179.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -75.32 -2.25 27.4 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.319 1.448 . . . . 0.0 113.601 -178.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 36.9 mt -108.92 3.59 22.45 Favored 'General case' 0 C--O 1.232 0.148 0 C-N-CA 125.06 1.344 . . . . 0.0 110.78 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.4 m -129.59 144.53 37.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 C-N-CA 124.174 0.99 . . . . 0.0 111.234 -179.385 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 27.3 t0 . . . . . 0 CA--C 1.535 0.394 0 C-N-CA 125.57 1.548 . . . . 0.0 110.704 -179.947 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.005 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 90.7 p -145.22 158.8 43.74 Favored 'General case' 0 C--O 1.237 0.431 0 O-C-N 121.764 -0.845 . . . . 0.0 111.412 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.11 137.17 24.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.083 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.4 m -136.49 160.62 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 C-N-CA 125.722 1.609 . . . . 0.0 107.778 178.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.74 118.27 18.38 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 178.566 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -62.48 -31.77 72.56 Favored 'General case' 0 N--CA 1.467 0.411 0 O-C-N 121.341 -0.85 . . . . 0.0 110.953 179.762 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m -138.32 172.0 14.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 126.708 2.003 . . . . 0.0 107.715 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.1 tttm -70.56 134.09 47.34 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.424 HD11 ' HB3' ' A' ' 25' ' ' MET . 73.9 mt -120.82 110.11 35.36 Favored Pre-proline 0 CA--C 1.53 0.208 0 C-N-CA 123.756 0.822 . . . . 0.0 110.031 -178.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -69.54 148.97 67.65 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 121.882 1.721 . . . . 0.0 111.086 178.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.406 ' HA ' HG23 ' A' ' 49' ' ' VAL . 60.4 tt0 -55.27 151.12 10.13 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 124.403 1.081 . . . . 0.0 110.166 178.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 68.99 30.47 72.22 Favored Glycine 0 CA--C 1.524 0.652 0 CA-C-O 119.441 -0.644 . . . . 0.0 113.847 178.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 59.9 m -118.04 150.87 38.58 Favored 'General case' 0 C--O 1.239 0.511 0 C-N-CA 125.737 1.615 . . . . 0.0 107.446 179.195 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 32.7 mm -92.4 123.93 44.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 CA-C-N 118.933 0.788 . . . . 0.0 109.443 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 62.2 mt -63.65 147.13 52.36 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.557 1.143 . . . . 0.0 110.858 -179.484 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.3 p -140.55 164.03 31.26 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 124.754 1.222 . . . . 0.0 107.715 178.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 5.7 mmt -62.82 -32.35 73.52 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.462 0.574 . . . . 0.0 110.281 179.211 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -59.24 -27.87 66.18 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 125.021 1.329 . . . . 0.0 113.357 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . 0.424 ' HB3' HD11 ' A' ' 15' ' ' ILE . 57.9 mtm -105.08 9.2 34.39 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.528 1.131 . . . . 0.0 112.733 -178.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 78.5 mt -127.68 146.22 50.63 Favored 'General case' 0 CA--C 1.518 -0.28 0 O-C-N 120.85 -1.156 . . . . 0.0 110.579 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.6 t -153.48 177.92 10.38 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.66 119.52 38.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 179.163 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 47.8 mtpt -91.63 108.8 20.16 Favored 'General case' 0 CA--C 1.511 -0.527 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 179.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 31.9 t -58.64 133.86 23.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 N-CA-C 105.609 -1.997 . . . . 0.0 105.609 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.42 -83.4 0.12 Allowed Glycine 0 C--N 1.334 0.441 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.486 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -124.25 150.61 64.28 Favored Pre-proline 0 CA--C 1.532 0.252 0 C-N-CA 123.501 0.72 . . . . 0.0 111.025 -179.597 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -71.14 -15.59 31.98 Favored 'Trans proline' 0 N--CA 1.456 -0.715 0 C-N-CA 122.486 2.124 . . . . 0.0 113.192 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 18.7 ttmm -48.54 106.15 0.09 Allowed 'General case' 0 C--O 1.234 0.272 0 C-N-CA 126.314 1.846 . . . . 0.0 109.982 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.76 -173.51 20.88 Favored Glycine 0 CA--C 1.525 0.715 0 C-N-CA 126.314 1.911 . . . . 0.0 108.93 -179.043 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.5 t80 -65.79 140.19 97.2 Favored Pre-proline 0 CA--C 1.543 0.703 0 O-C-N 121.973 -0.722 . . . . 0.0 109.509 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -66.19 134.29 36.04 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 122.713 2.275 . . . . 0.0 111.579 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -71.56 -16.47 30.47 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.756 2.304 . . . . 0.0 115.215 -179.199 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -70.94 -22.5 62.21 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.555 1.07 . . . . 0.0 111.927 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -114.88 13.28 17.08 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 124.855 1.262 . . . . 0.0 113.269 -178.224 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 20.5 tt -45.44 -36.39 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 125.365 1.466 . . . . 0.0 113.79 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -58.73 -23.59 60.05 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.336 1.054 . . . . 0.0 113.518 -178.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -78.42 -32.94 48.89 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 120.385 1.448 . . . . 0.0 111.504 179.224 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.2 mt -62.87 -35.37 79.77 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.016 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 77.5 t -60.32 117.03 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.08 -6.71 51.4 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 118.302 -1.277 . . . . 0.0 113.91 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.0 mttm -86.52 158.63 19.5 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 120.717 2.258 . . . . 0.0 108.725 178.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -95.77 135.22 37.78 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 179.107 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.406 HG23 ' HA ' ' A' ' 17' ' ' GLU . 4.2 m -77.51 139.74 18.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 CA-C-N 118.239 0.472 . . . . 0.0 110.077 179.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 23.1 mt -85.08 -17.22 38.06 Favored 'General case' 0 N--CA 1.462 0.154 0 C-N-CA 125.278 1.431 . . . . 0.0 112.066 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.18 163.52 7.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 C-N-CA 124.816 1.247 . . . . 0.0 110.582 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 22.5 m -78.51 122.4 25.82 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 105.116 -2.179 . . . . 0.0 105.116 178.079 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 76.2 t -106.59 139.29 28.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 106.126 -1.805 . . . . 0.0 106.126 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -86.1 176.21 8.12 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 122.079 0.942 . . . . 0.0 112.211 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -71.32 132.37 44.78 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 123.648 0.779 . . . . 0.0 110.09 -179.153 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 68.02 9.75 7.37 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 126.252 1.821 . . . . 0.0 110.127 -179.112 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 35.1 t0 -73.54 153.38 40.29 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.573 1.149 . . . . 0.0 109.466 179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 23.1 m -78.51 129.59 35.04 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 124.969 1.308 . . . . 0.0 111.809 -177.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 13.0 mm -90.39 148.01 4.84 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 179.013 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 38.1 mtp -142.17 163.56 32.54 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 124.777 1.231 . . . . 0.0 108.238 178.511 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -65.02 -26.35 68.24 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 124.128 0.971 . . . . 0.0 111.039 179.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -73.04 -14.84 61.49 Favored 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 123.62 0.768 . . . . 0.0 112.226 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 12.2 mt -94.11 6.59 48.1 Favored 'General case' 0 C--N 1.334 -0.069 0 CA-C-O 118.115 -0.945 . . . . 0.0 113.325 -177.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.4 m -127.88 125.33 64.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 120.139 1.336 . . . . 0.0 112.586 -178.632 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 50.5 t0 . . . . . 0 C--O 1.237 0.395 0 C-N-CA 125.779 1.632 . . . . 0.0 108.556 179.679 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.61 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.0 p -110.21 133.7 52.97 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.339 1.455 . . . . 0.0 110.78 -179.566 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.5 t -68.89 127.33 30.57 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 179.366 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.1 m -122.86 149.86 26.6 Favored 'Isoleucine or valine' 0 C--O 1.241 0.625 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.13 119.06 12.82 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 60.5 tttm -70.29 -21.53 62.94 Favored 'General case' 0 C--N 1.331 -0.206 0 O-C-N 121.529 -0.732 . . . . 0.0 112.099 -179.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.2 m -148.17 167.7 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 126.546 1.938 . . . . 0.0 107.501 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.3 tttm -76.43 99.8 5.0 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 178.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 7.6 mt -87.25 109.93 29.43 Favored Pre-proline 0 C--N 1.326 -0.431 0 C-N-CA 125.747 1.619 . . . . 0.0 107.677 -177.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.77 155.12 66.7 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 C-N-CA 121.387 1.391 . . . . 0.0 110.906 -179.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 61.8 tt0 -51.72 141.16 17.38 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 125.653 1.581 . . . . 0.0 109.399 179.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.1 -0.29 87.67 Favored Glycine 0 CA--C 1.535 1.3 0 CA-C-O 119.181 -0.788 . . . . 0.0 114.458 179.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.3 m -84.28 147.77 27.05 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 120.282 2.041 . . . . 0.0 109.668 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.5 mm -86.47 131.26 35.13 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 17.8 mt -68.98 148.16 50.55 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-O 121.607 0.717 . . . . 0.0 110.54 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.3 p -143.34 157.47 44.45 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 127.065 2.146 . . . . 0.0 107.331 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 15.9 mmt -64.98 -24.87 67.64 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -65.17 -14.73 61.3 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 128.791 2.837 . . . . 0.0 112.002 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 25.7 mtm -124.16 10.19 8.7 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.388 1.475 . . . . 0.0 111.933 -179.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 83.4 mt -128.66 152.86 47.9 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 119.728 1.149 . . . . 0.0 110.714 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.0 t -160.54 -179.15 7.41 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 105.434 -2.062 . . . . 0.0 105.434 178.133 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.47 131.11 39.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 O-C-N 120.766 -1.209 . . . . 0.0 108.07 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 2.4 tppp? -84.28 105.45 15.13 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 101.698 -3.445 . . . . 0.0 101.698 177.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.0 m -66.99 89.99 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 O-C-N 121.597 -0.689 . . . . 0.0 110.534 -179.154 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -145.06 -87.15 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 124.984 1.278 . . . . 0.0 110.565 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.9 148.44 39.92 Favored Pre-proline 0 C--N 1.326 -0.418 0 C-N-CA 125.884 1.674 . . . . 0.0 111.695 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -82.5 71.6 6.42 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.176 2.584 . . . . 0.0 108.166 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 40.1 tttp -114.24 166.2 11.9 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 123.537 0.735 . . . . 0.0 109.726 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 74.41 -87.65 0.71 Allowed Glycine 0 N--CA 1.444 -0.828 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -139.84 144.58 39.23 Favored Pre-proline 0 C--O 1.238 0.448 0 C-N-CA 124.919 1.288 . . . . 0.0 108.117 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.9 148.05 85.66 Favored 'Trans proline' 0 CA--C 1.539 0.75 0 C-N-CA 121.543 1.495 . . . . 0.0 109.358 179.065 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.05 -18.8 14.24 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.145 1.897 . . . . 0.0 111.989 -178.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -66.17 -33.09 74.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.46 -0.775 . . . . 0.0 111.391 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -92.24 10.78 28.13 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.18 1.792 . . . . 0.0 111.864 -178.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 13.9 tt -53.98 -34.65 26.5 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.718 0 O-C-N 119.801 -1.812 . . . . 0.0 111.201 179.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -60.64 -20.93 62.07 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.805 1.242 . . . . 0.0 113.605 179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -99.24 -17.99 17.83 Favored 'General case' 0 CA--C 1.515 -0.383 0 CA-C-N 119.732 1.151 . . . . 0.0 111.733 178.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 25.4 mt -68.27 -32.74 73.12 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 177.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 41.7 t -64.24 138.79 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 178.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 91.58 -16.2 59.68 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-O 118.823 -0.987 . . . . 0.0 112.277 -179.055 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.3 mttm -76.63 171.98 13.77 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-N 119.586 1.693 . . . . 0.0 107.368 178.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 24.7 ttmt -122.85 133.44 54.43 Favored 'General case' 0 CA--C 1.516 -0.355 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 1.8 m -74.6 148.47 7.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 O-C-N 124.258 0.974 . . . . 0.0 110.675 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.438 HD21 ' HB2' ' A' ' 65' ' ' ASP . 65.5 mt -97.93 -14.15 20.79 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 126.013 1.725 . . . . 0.0 112.696 179.7 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 15.7 m -144.42 161.81 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 C-N-CA 126.064 1.746 . . . . 0.0 108.461 179.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.1 m -74.98 96.0 3.1 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 87.0 t -70.79 127.13 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 178.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -74.29 170.28 15.91 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.584 0.707 . . . . 0.0 110.162 179.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -74.87 138.25 42.34 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 104.788 -2.301 . . . . 0.0 104.788 177.414 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 34.7 t0 72.34 10.94 5.85 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.781 2.032 . . . . 0.0 113.132 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -72.96 149.6 43.21 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 177.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 90.7 m -79.12 122.71 26.58 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 179.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.2 mm -76.51 126.52 37.26 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 48.7 mtp -128.09 155.43 44.4 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 122.469 1.128 . . . . 0.0 110.425 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -62.28 -20.18 64.02 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 126.696 1.998 . . . . 0.0 114.029 -179.131 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -89.21 -10.35 47.36 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 123.876 0.87 . . . . 0.0 111.687 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 84.1 mt -90.4 11.0 22.87 Favored 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 124.823 1.249 . . . . 0.0 110.729 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.5 m -133.34 151.2 33.27 Favored 'Isoleucine or valine' 0 C--O 1.232 0.166 0 CA-C-N 120.427 1.467 . . . . 0.0 114.239 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . 0.438 ' HB2' HD21 ' A' ' 50' ' ' LEU . 35.1 t0 . . . . . 0 C--O 1.239 0.537 0 C-N-CA 124.641 1.176 . . . . 0.0 109.129 178.712 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.378 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 76.5 p -137.26 157.19 47.18 Favored 'General case' 0 C--O 1.238 0.451 0 C-N-CA 123.793 0.837 . . . . 0.0 109.704 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 28.9 t -75.57 130.75 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.3 m -128.98 157.85 41.76 Favored 'Isoleucine or valine' 0 C--O 1.24 0.593 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 178.023 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.31 130.99 42.77 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 178.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 64.7 tttt -75.59 -32.91 60.52 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 121.366 -0.834 . . . . 0.0 110.754 179.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 22.6 m -144.58 170.71 7.34 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 129.601 3.16 . . . . 0.0 108.945 -179.455 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 20.6 tttm -68.78 116.58 9.43 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 119.762 1.165 . . . . 0.0 108.79 179.681 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.438 HD13 ' CD2' ' A' ' 21' ' ' LEU . 40.2 mt -98.9 105.19 29.84 Favored Pre-proline 0 CA--C 1.534 0.365 0 C-N-CA 125.168 1.387 . . . . 0.0 110.983 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.408 ' HA ' HG23 ' A' ' 52' ' ' THR . 42.7 Cg_endo -67.99 145.39 67.6 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 121.609 1.539 . . . . 0.0 108.937 177.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -53.69 152.9 4.85 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 124.151 0.98 . . . . 0.0 110.966 178.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.87 24.89 76.15 Favored Glycine 0 CA--C 1.524 0.61 0 CA-C-O 118.543 -1.143 . . . . 0.0 113.892 178.661 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 56.9 m -118.62 143.82 46.55 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 119.112 1.456 . . . . 0.0 108.266 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 18.6 mm -74.39 136.26 25.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.363 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.438 ' CD2' HD13 ' A' ' 15' ' ' ILE . 25.4 mt -80.51 141.47 35.13 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 126.099 1.76 . . . . 0.0 107.805 179.199 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.0 p -135.92 165.32 25.93 Favored 'General case' 0 C--O 1.237 0.425 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 179.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -61.26 -25.87 67.38 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.55 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -78.17 -10.4 59.62 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.347 1.059 . . . . 0.0 113.164 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 58.9 mtm -119.97 16.07 12.51 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 126.029 1.731 . . . . 0.0 110.566 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.8 mt -141.55 137.88 32.3 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 179.322 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.1 t -148.28 155.08 40.89 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.626 HG11 ' HB3' ' A' ' 38' ' ' PRO . 2.9 t -111.25 102.04 13.41 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -179.586 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 27.7 ttpp -75.01 112.78 11.59 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.236 0.614 . . . . 0.0 109.794 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 90.1 t -61.83 121.92 11.28 Favored 'Isoleucine or valine' 0 C--O 1.239 0.504 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 176.19 -82.77 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -138.56 158.68 69.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 C-N-CA 123.442 0.697 . . . . 0.0 110.768 -179.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -74.63 11.63 1.3 Allowed 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.344 2.696 . . . . 0.0 113.182 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -67.47 95.32 0.45 Allowed 'General case' 0 C--O 1.232 0.155 0 O-C-N 120.281 -1.512 . . . . 0.0 108.136 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.7 -167.89 23.78 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 128.095 2.76 . . . . 0.0 109.316 -178.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.423 ' CE2' ' HB3' ' A' ' 40' ' ' ASP . 9.2 t80 -67.77 144.35 97.35 Favored Pre-proline 0 CA--C 1.545 0.752 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.199 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -72.35 154.35 56.07 Favored 'Trans proline' 0 CA--C 1.544 1.016 0 C-N-CA 122.432 2.088 . . . . 0.0 113.406 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.626 ' HB3' HG11 ' A' ' 28' ' ' VAL . 16.7 Cg_endo -66.2 -27.42 48.76 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 123.416 2.744 . . . . 0.0 116.223 -179.383 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -75.99 -25.06 55.44 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 120.233 1.379 . . . . 0.0 112.179 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.423 ' HB3' ' CE2' ' A' ' 36' ' ' TYR . 3.2 m-20 -88.86 -2.55 58.64 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.919 0.781 . . . . 0.0 112.563 -179.184 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.4 tt -51.12 -34.38 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 O-C-N 120.616 -1.302 . . . . 0.0 112.557 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -59.43 -22.9 62.15 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -95.29 -19.09 20.28 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-O 117.76 -1.115 . . . . 0.0 111.308 178.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 61.0 mt -72.68 -34.32 67.12 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 73.1 t -64.83 130.64 30.2 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 N-CA-C 105.62 -1.993 . . . . 0.0 105.62 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 93.82 -12.64 69.0 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-O 118.054 -1.414 . . . . 0.0 112.514 -179.305 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -75.49 173.14 11.36 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 119.565 1.682 . . . . 0.0 109.602 178.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.5 tppt? -127.07 101.58 6.6 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.204 1.402 . . . . 0.0 108.941 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 6.1 m -43.06 140.84 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 123.73 0.812 . . . . 0.0 112.508 -178.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 92.8 mt -86.84 -19.48 28.9 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.486 1.114 . . . . 0.0 112.307 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.1 m -143.89 165.69 13.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 C-N-CA 126.222 1.809 . . . . 0.0 107.974 -179.021 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.408 HG23 ' HA ' ' A' ' 16' ' ' PRO . 99.2 m -76.26 138.56 40.64 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 178.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 79.0 t -119.85 128.43 75.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -75.38 173.89 10.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 122.101 0.953 . . . . 0.0 110.565 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -69.83 145.53 52.02 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . 0.338 0.7 OUTLIER 58.63 8.29 0.88 Allowed 'General case' 0 C--O 1.236 0.348 0 C-N-CA 125.291 1.436 . . . . 0.0 114.374 179.333 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -74.38 158.78 33.32 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 178.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 18.4 m -84.77 126.82 33.75 Favored 'General case' 0 C--N 1.321 -0.638 0 O-C-N 120.69 -1.256 . . . . 0.0 112.131 -177.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.9 mm -84.04 134.9 25.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 N-CA-C 104.328 -2.471 . . . . 0.0 104.328 178.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 69.7 mtp -141.48 159.83 41.4 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 122.885 0.474 . . . . 0.0 110.642 -178.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -61.54 -20.68 63.52 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 125.057 1.343 . . . . 0.0 112.697 179.765 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -81.68 -12.68 58.57 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.457 1.103 . . . . 0.0 112.245 179.546 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 25.0 mt -103.34 0.23 31.08 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.345 1.058 . . . . 0.0 111.463 -179.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.6 m -132.24 147.23 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 CA-C-O 122.302 1.049 . . . . 0.0 112.368 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 20.4 t0 . . . . . 0 N--CA 1.445 -0.718 0 C-N-CA 126.692 1.997 . . . . 0.0 110.104 179.559 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.675 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -144.23 164.99 29.11 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 124.916 1.286 . . . . 0.0 109.665 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.0 t -81.41 134.05 27.95 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.6 m -133.23 159.39 43.01 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.77 120.35 17.23 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 178.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 75.5 tttt -69.04 -29.5 67.65 Favored 'General case' 0 C--N 1.327 -0.372 0 O-C-N 121.787 -0.571 . . . . 0.0 109.761 179.209 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.2 m -151.0 163.12 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 C-N-CA 128.081 2.552 . . . . 0.0 107.569 178.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -56.23 141.07 42.52 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 124.701 1.2 . . . . 0.0 108.718 178.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 8.3 mt -129.68 105.4 17.16 Favored Pre-proline 0 N--CA 1.465 0.281 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -178.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.682 ' HA ' HG23 ' A' ' 52' ' ' THR . 38.2 Cg_endo -65.79 146.06 82.48 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 121.47 1.446 . . . . 0.0 111.263 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.454 ' HA ' HG23 ' A' ' 49' ' ' VAL . 60.5 tt0 -56.71 141.97 41.91 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.561 0.696 . . . . 0.0 111.036 -179.335 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 90.91 2.77 71.32 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-O 119.137 -0.813 . . . . 0.0 113.376 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 30.0 m -97.38 151.26 20.12 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 125.603 1.561 . . . . 0.0 109.143 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 14.4 mm -91.98 141.15 14.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 37.6 mt -73.49 149.56 42.21 Favored 'General case' 0 C--O 1.238 0.468 0 C-N-CA 124.667 1.187 . . . . 0.0 110.69 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.9 p -144.51 158.11 43.91 Favored 'General case' 0 C--N 1.328 -0.361 0 C-N-CA 127.176 2.19 . . . . 0.0 108.096 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.6 mmt -63.74 -31.7 72.96 Favored 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -59.43 -17.44 30.93 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.987 1.315 . . . . 0.0 111.914 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 49.5 mtm -119.88 11.08 11.73 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.122 1.369 . . . . 0.0 111.849 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.5 mt -130.33 146.88 51.97 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 119.373 0.988 . . . . 0.0 110.256 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.7 t -152.95 163.83 39.08 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 55.3 t -107.75 101.49 12.6 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 1.1 mmtm -72.65 129.7 38.86 Favored 'General case' 0 N--CA 1.453 -0.287 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.3 m -73.24 123.04 27.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 168.33 -93.64 0.1 Allowed Glycine 0 C--N 1.335 0.473 0 C-N-CA 119.918 -1.134 . . . . 0.0 112.985 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -138.09 153.83 73.65 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 117.484 0.642 . . . . 0.0 111.577 -179.098 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -70.48 14.7 0.3 Allowed 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 124.588 3.525 . . . . 0.0 115.08 -179.032 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.42 114.2 6.65 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 105.31 -2.108 . . . . 0.0 105.31 178.768 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 119.74 -166.39 13.42 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -178.725 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -69.83 138.66 87.99 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-O 118.909 -0.567 . . . . 0.0 112.207 -178.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -60.79 135.18 58.26 Favored 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.643 2.229 . . . . 0.0 110.162 179.281 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.42 -13.84 36.19 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 121.963 1.775 . . . . 0.0 115.299 -179.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -78.23 -31.17 49.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 119.494 1.043 . . . . 0.0 108.929 179.021 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -81.39 3.98 22.5 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.379 1.072 . . . . 0.0 111.647 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.1 tt -53.2 -32.26 18.93 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 124.658 1.183 . . . . 0.0 112.244 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -57.27 -43.79 83.36 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 123.232 0.613 . . . . 0.0 109.384 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 18.3 m-80 -64.79 -36.76 85.36 Favored 'General case' 0 CA--C 1.522 -0.114 0 C-N-CA 124.176 0.991 . . . . 0.0 110.633 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 71.7 mt -64.42 -34.07 77.32 Favored 'General case' 0 C--O 1.227 -0.108 0 CA-C-O 118.837 -0.602 . . . . 0.0 110.495 179.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 96.8 t -71.98 82.11 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 CA-C-O 123.031 1.396 . . . . 0.0 109.245 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 147.24 -4.95 1.0 Allowed Glycine 0 CA--C 1.527 0.844 0 C-N-CA 127.032 2.253 . . . . 0.0 112.653 -179.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 78.7 mttt -91.92 156.33 17.54 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 119.427 1.613 . . . . 0.0 109.118 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -99.42 138.67 36.19 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 179.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.454 HG23 ' HA ' ' A' ' 17' ' ' GLU . 6.1 m -75.33 137.37 23.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 95.6 mt -88.81 -12.85 40.84 Favored 'General case' 0 C--N 1.334 -0.106 0 C-N-CA 124.575 1.15 . . . . 0.0 111.592 179.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 32.6 m -143.53 160.2 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.25 0 C-N-CA 124.343 1.057 . . . . 0.0 108.65 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.682 HG23 ' HA ' ' A' ' 16' ' ' PRO . 33.4 m -74.23 105.58 5.48 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 104.735 -2.32 . . . . 0.0 104.735 177.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 41.1 t -80.23 143.46 12.37 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 179.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -90.62 169.74 10.75 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 121.774 0.797 . . . . 0.0 109.08 178.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -69.35 136.91 52.4 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 178.053 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.6 t0 65.06 13.79 8.92 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 124.796 1.239 . . . . 0.0 113.813 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -77.01 157.14 31.35 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 124.004 0.922 . . . . 0.0 109.048 178.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.0 m -78.47 128.75 34.03 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 121.517 -0.74 . . . . 0.0 109.596 -179.264 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.0 mm -87.93 129.08 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 N-CA-C 103.143 -2.91 . . . . 0.0 103.143 177.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 46.6 mtp -133.24 159.92 38.8 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -63.4 -34.13 77.06 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 123.372 0.669 . . . . 0.0 109.904 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -60.75 -19.5 59.18 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 126.662 1.985 . . . . 0.0 110.741 179.699 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 10.7 mt -100.86 6.91 43.88 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 125.149 1.38 . . . . 0.0 112.532 -179.209 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.4 m -132.55 147.2 31.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 120.749 1.613 . . . . 0.0 111.814 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.237 0.398 0 C-N-CA 125.413 1.485 . . . . 0.0 109.57 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.623 0 N-CA-C 112.34 -0.304 . . . . 0.0 112.34 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 36.7 p -136.87 143.75 43.2 Favored 'General case' 0 C--O 1.234 0.255 0 C-N-CA 125.627 1.571 . . . . 0.0 110.872 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.7 t -69.24 123.07 21.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 CA-C-N 119.15 0.886 . . . . 0.0 110.869 179.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 35.5 m -125.41 154.64 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 125.043 1.337 . . . . 0.0 108.065 177.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.37 118.91 12.07 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -70.36 -29.93 66.72 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.389 -0.819 . . . . 0.0 110.85 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.6 m -147.21 161.85 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 127.816 2.447 . . . . 0.0 106.932 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 78.3 tttt -62.85 143.44 57.59 Favored 'General case' 0 C--O 1.24 0.577 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.1 mt -127.33 110.85 21.25 Favored Pre-proline 0 CA--C 1.538 0.486 0 C-N-CA 124.956 1.302 . . . . 0.0 109.201 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -66.35 149.5 84.9 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 121.663 1.575 . . . . 0.0 109.704 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.6 tm-20 -53.56 148.55 9.26 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 124.293 1.037 . . . . 0.0 110.905 179.503 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.22 -0.52 87.46 Favored Glycine 0 CA--C 1.526 0.747 0 C-N-CA 124.617 1.103 . . . . 0.0 115.219 178.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 72.5 m -83.6 144.53 29.39 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 118.213 1.006 . . . . 0.0 110.768 -179.07 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 30.0 mm -85.65 135.58 24.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 177.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 42.4 mt -72.29 151.98 42.43 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 124.008 0.923 . . . . 0.0 112.033 -179.123 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.617 ' HA ' HG13 ' A' ' 45' ' ' VAL . 47.7 p -144.0 159.02 43.32 Favored 'General case' 0 C--O 1.238 0.455 0 C-N-CA 127.285 2.234 . . . . 0.0 106.533 178.678 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . 0.509 ' SD ' HG11 ' A' ' 45' ' ' VAL . 0.4 OUTLIER -65.69 -30.89 71.64 Favored 'General case' 0 C--O 1.224 -0.273 0 CA-C-N 119.377 0.99 . . . . 0.0 108.483 178.605 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -58.14 -30.58 66.45 Favored 'General case' 0 C--O 1.225 -0.209 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -179.436 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.8 mtm -95.69 9.67 39.53 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 118.861 0.755 . . . . 0.0 111.518 179.565 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.3 mt -130.83 158.22 40.76 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 123.898 0.879 . . . . 0.0 111.843 -178.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 t -159.32 152.06 21.7 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.351 -2.092 . . . . 0.0 105.351 177.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 m -103.01 120.51 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 119.828 1.194 . . . . 0.0 108.596 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 27.5 ttpp -68.84 113.67 6.48 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 104.784 -2.302 . . . . 0.0 104.784 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 60.7 t -74.56 85.73 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -144.02 -77.13 0.03 OUTLIER Glycine 0 CA--C 1.52 0.358 0 C-N-CA 125.395 1.474 . . . . 0.0 111.311 -179.118 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -147.62 161.59 34.98 Favored Pre-proline 0 CA--C 1.537 0.464 0 C-N-CA 124.88 1.272 . . . . 0.0 109.493 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -73.82 36.23 0.39 Allowed 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 124.61 3.54 . . . . 0.0 113.249 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -62.7 164.24 8.06 Favored 'General case' 0 N--CA 1.462 0.16 0 O-C-N 120.567 -1.333 . . . . 0.0 108.912 178.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 53.41 -132.09 42.7 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 179.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -86.45 135.88 35.89 Favored Pre-proline 0 CA--C 1.542 0.658 0 C-N-CA 125.026 1.33 . . . . 0.0 110.848 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.16 151.48 66.63 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.273 2.649 . . . . 0.0 112.592 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -80.04 -24.81 5.48 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.654 2.236 . . . . 0.0 112.989 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -65.48 -43.24 90.84 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 119.253 0.933 . . . . 0.0 110.638 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -71.05 8.33 0.97 Allowed 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 127.771 2.428 . . . . 0.0 114.15 -178.616 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.1 tt -50.27 -36.17 12.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 CA-C-N 119.3 0.955 . . . . 0.0 112.498 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -58.89 -32.37 69.44 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-O 118.976 -0.535 . . . . 0.0 111.706 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 70.9 m-80 -70.3 -49.6 47.98 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 20.8 mt -57.03 -46.23 82.54 Favored 'General case' 0 CA--C 1.515 -0.385 0 C-N-CA 123.52 0.728 . . . . 0.0 109.957 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.617 HG13 ' HA ' ' A' ' 22' ' ' THR . 74.8 t -68.05 99.19 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 131.46 -12.48 5.45 Favored Glycine 0 CA--C 1.529 0.926 0 C-N-CA 127.18 2.324 . . . . 0.0 110.687 -179.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 55.8 mttm -84.21 169.19 15.03 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 120.021 1.911 . . . . 0.0 108.053 178.273 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 20.4 ttmm -111.85 138.45 48.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 118.1 -0.952 . . . . 0.0 109.287 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.8 m -74.52 137.14 23.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.508 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.481 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 38.3 mt -83.2 -18.84 37.91 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 125.678 1.591 . . . . 0.0 112.268 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 22.8 m -145.21 167.94 9.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 126.198 1.799 . . . . 0.0 108.496 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.6 m -76.88 109.46 10.7 Favored 'General case' 0 N--CA 1.456 -0.149 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 178.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 86.7 t -86.48 126.07 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 C-N-CA 124.632 1.173 . . . . 0.0 107.863 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -77.45 172.8 12.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 122.18 0.991 . . . . 0.0 111.298 178.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -71.79 148.63 46.08 Favored 'General case' 0 N--CA 1.443 -0.782 0 O-C-N 121.616 -0.678 . . . . 0.0 109.509 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 29.2 t70 61.36 7.36 1.7 Allowed 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 127.554 2.342 . . . . 0.0 112.169 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -67.82 150.99 47.9 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.234 1.014 . . . . 0.0 108.895 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 47.3 m -82.64 111.84 18.97 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.048 -1.094 . . . . 0.0 108.048 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.8 mm -70.27 129.68 34.47 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 105.712 -1.959 . . . . 0.0 105.712 178.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 59.1 mtp -132.8 161.02 35.19 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 123.897 0.879 . . . . 0.0 109.316 -179.203 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -62.25 -30.55 71.19 Favored 'General case' 0 N--CA 1.466 0.329 0 C-N-CA 123.498 0.719 . . . . 0.0 111.031 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 19.2 pt-20 -66.51 -15.84 63.69 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 123.613 0.765 . . . . 0.0 111.474 179.339 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 38.5 mt -100.32 5.29 44.46 Favored 'General case' 0 C--N 1.341 0.234 0 C-N-CA 126.419 1.887 . . . . 0.0 112.692 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.06 140.41 47.97 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-N 121.665 2.029 . . . . 0.0 114.687 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 46.4 t0 . . . . . 0 C--O 1.239 0.514 0 C-N-CA 127.191 2.197 . . . . 0.0 108.869 178.893 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.742 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 46.4 p -136.33 163.04 31.37 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 117.251 0.525 . . . . 0.0 109.887 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 62.3 t -68.74 142.89 15.65 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.481 HG21 ' HG2' ' A' ' 29' ' ' LYS . 4.4 m -140.87 164.36 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 127.021 2.129 . . . . 0.0 106.547 178.354 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -81.13 133.15 35.42 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.062 -1.458 . . . . 0.0 107.062 177.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -75.51 -29.31 59.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 118.898 -0.572 . . . . 0.0 111.371 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.6 m -144.96 168.97 8.51 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 127.199 2.2 . . . . 0.0 107.854 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.4 tttm -71.86 123.86 23.6 Favored 'General case' 0 C--O 1.238 0.457 0 C-N-CA 124.966 1.306 . . . . 0.0 108.766 178.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 74.9 mt -115.64 119.82 37.06 Favored Pre-proline 0 CA--C 1.538 0.517 0 C-N-CA 125.111 1.365 . . . . 0.0 110.112 -178.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.6 152.03 53.28 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 121.783 1.655 . . . . 0.0 110.633 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -50.49 146.9 4.95 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.797 1.639 . . . . 0.0 110.844 179.435 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.12 -4.44 66.8 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 115.341 0.896 . . . . 0.0 115.341 178.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.5 m -82.6 149.65 27.32 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 118.561 1.18 . . . . 0.0 109.438 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.05 141.86 13.77 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 76.3 mt -82.98 144.35 30.04 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 123.607 0.763 . . . . 0.0 110.589 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 77.1 p -133.67 162.25 32.46 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 126.876 2.071 . . . . 0.0 108.114 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.0 mmt -63.03 -26.57 68.91 Favored 'General case' 0 N--CA 1.465 0.294 0 O-C-N 121.781 -0.574 . . . . 0.0 110.75 179.172 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -68.91 -43.92 74.19 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-O 117.82 -1.086 . . . . 0.0 112.782 -179.139 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 29.6 mtm -87.76 18.17 4.25 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 120.671 1.578 . . . . 0.0 111.58 -177.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 64.8 mt -125.65 133.61 52.14 Favored 'General case' 0 CA--C 1.516 -0.337 0 C-N-CA 126.169 1.788 . . . . 0.0 109.856 -179.187 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.0 t -146.77 174.08 11.8 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 178.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 40.9 t -129.86 100.22 5.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 CA-C-N 119.36 0.982 . . . . 0.0 108.585 -178.609 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.481 ' HG2' HG21 ' A' ' 10' ' ' VAL . 6.2 mmpt? -67.41 131.32 45.46 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.7 m -62.31 125.87 19.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 178.252 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.37 -134.0 3.13 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -99.66 156.19 35.64 Favored Pre-proline 0 C--O 1.236 0.374 0 C-N-CA 123.995 0.918 . . . . 0.0 112.781 -179.335 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -79.84 51.7 4.0 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 124.474 3.449 . . . . 0.0 111.526 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.0 pttt -72.21 -56.47 5.48 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 120.83 -1.169 . . . . 0.0 110.486 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -70.83 -169.61 8.86 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 125.3 1.428 . . . . 0.0 112.075 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -57.12 144.18 70.17 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 118.209 -0.9 . . . . 0.0 111.316 179.64 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -64.4 142.5 79.04 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.838 2.359 . . . . 0.0 112.089 179.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -77.26 7.82 3.55 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 123.638 2.892 . . . . 0.0 112.051 178.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -94.62 -43.09 8.45 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 126.405 1.882 . . . . 0.0 109.845 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -94.45 8.53 41.76 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 124.113 0.965 . . . . 0.0 111.193 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.2 tt -45.89 -35.78 2.16 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 126.644 1.977 . . . . 0.0 111.874 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -59.67 -25.15 64.49 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 125.374 1.47 . . . . 0.0 112.223 179.535 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -77.88 -36.14 50.07 Favored 'General case' 0 CA--C 1.518 -0.253 0 C-N-CA 124.068 0.947 . . . . 0.0 109.977 179.278 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 84.9 mt -57.38 -40.69 78.71 Favored 'General case' 0 CA--C 1.516 -0.335 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.227 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 94.4 t -60.39 104.71 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 178.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 118.67 -14.95 11.56 Favored Glycine 0 CA--C 1.526 0.748 0 CA-C-O 117.957 -1.468 . . . . 0.0 113.187 -179.474 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -81.06 168.5 18.57 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 119.564 1.682 . . . . 0.0 108.39 179.23 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -114.83 138.11 51.16 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 124.15 0.98 . . . . 0.0 109.316 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.1 m -74.06 151.94 7.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.596 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 13.1 mt -100.39 -13.99 18.53 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 126.018 1.727 . . . . 0.0 113.643 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 10.4 m -151.14 163.85 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 126.974 2.109 . . . . 0.0 107.915 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.6 m -73.25 102.53 3.68 Favored 'General case' 0 CA--C 1.534 0.349 0 O-C-N 121.085 -1.009 . . . . 0.0 108.665 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 64.1 t -78.4 144.28 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 N-CA-C 107.167 -1.419 . . . . 0.0 107.167 179.226 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 34.9 mm-40 -88.65 174.73 7.87 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 122.094 0.95 . . . . 0.0 110.082 179.4 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -77.14 143.35 39.19 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 177.49 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 69.63 -1.07 2.4 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 125.436 1.495 . . . . 0.0 112.698 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -67.2 151.34 47.72 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 127.177 2.191 . . . . 0.0 110.976 -178.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.6 m -80.51 127.58 32.6 Favored 'General case' 0 C--N 1.324 -0.535 0 C-N-CA 123.272 0.629 . . . . 0.0 110.431 -178.687 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.2 mm -85.08 96.4 4.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.264 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 179.113 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . 0.536 ' H ' HD12 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -82.79 170.2 15.29 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 177.37 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.432 ' CD ' ' H ' ' A' ' 61' ' ' GLU . 17.8 mp0 -76.18 -34.69 59.33 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 125.198 1.399 . . . . 0.0 109.658 -179.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -64.56 -29.03 70.06 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 123.09 0.556 . . . . 0.0 111.334 179.144 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.536 HD12 ' H ' ' A' ' 60' ' ' MET . 73.9 mt -76.1 -0.18 21.01 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.79 1.236 . . . . 0.0 113.229 -179.385 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.36 147.2 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 121.466 1.939 . . . . 0.0 110.751 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.239 0.507 0 CA-C-O 123.256 1.503 . . . . 0.0 114.079 -179.014 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.439 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.4 t -137.37 163.17 31.69 Favored 'General case' 0 C--O 1.239 0.532 0 C-N-CA 123.94 0.896 . . . . 0.0 109.324 179.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.0 t -74.06 136.19 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.1 m -130.37 158.95 42.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 C-N-CA 125.426 1.49 . . . . 0.0 107.805 178.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.96 107.2 5.2 Favored 'General case' 0 N--CA 1.443 -0.797 0 N-CA-C 104.733 -2.321 . . . . 0.0 104.733 177.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 37.6 tttt -59.75 -24.09 63.76 Favored 'General case' 0 N--CA 1.464 0.239 0 O-C-N 121.6 -0.687 . . . . 0.0 111.857 -179.265 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.1 m -145.86 169.52 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 C-N-CA 125.679 1.592 . . . . 0.0 109.123 -178.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 36.8 tttm -72.71 128.32 35.19 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 103.386 -2.82 . . . . 0.0 103.386 176.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.5 mt -122.69 115.22 29.64 Favored Pre-proline 0 C--N 1.333 -0.143 0 C-N-CA 125.09 1.356 . . . . 0.0 111.122 -176.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -70.65 153.98 64.49 Favored 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 121.077 1.185 . . . . 0.0 110.463 178.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.471 ' HA ' HG23 ' A' ' 49' ' ' VAL . 37.3 tt0 -54.2 149.36 9.81 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.671 1.588 . . . . 0.0 111.436 179.45 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.13 -2.7 64.54 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 123.798 0.714 . . . . 0.0 114.431 179.47 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 12.8 m -81.76 143.63 31.67 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 119.179 1.49 . . . . 0.0 109.809 -179.601 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 39.9 mm -84.41 125.99 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.916 -1.883 . . . . 0.0 105.916 178.07 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 45.4 mt -66.38 144.83 56.3 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 124.434 1.094 . . . . 0.0 110.893 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 40.1 p -139.3 165.88 26.02 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 178.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.6 mmt -67.08 -9.82 43.46 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.914 -0.492 . . . . 0.0 110.507 178.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -88.83 -2.83 58.78 Favored 'General case' 0 N--CA 1.471 0.579 0 O-C-N 120.353 -1.467 . . . . 0.0 110.88 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 36.7 mtm -125.11 4.81 7.89 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 124.944 1.298 . . . . 0.0 110.961 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.8 mt -135.8 147.33 48.29 Favored 'General case' 0 CA--C 1.512 -0.506 0 O-C-N 121.163 -0.961 . . . . 0.0 109.326 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.9 t -159.46 177.98 10.39 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 178.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.1 132.82 68.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 178.713 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 25.1 mmtp -91.51 -173.04 3.44 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 178.719 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.86 96.83 4.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 O-C-N 120.948 -1.095 . . . . 0.0 108.856 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.16 -82.71 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -157.02 160.7 30.51 Favored Pre-proline 0 CA--C 1.546 0.816 0 C-N-CA 125.529 1.532 . . . . 0.0 109.132 -179.04 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -66.46 13.02 0.14 Allowed 'Trans proline' 0 CA--C 1.54 0.781 1 C-N-CA 126.321 4.681 . . . . 0.0 116.94 -179.039 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.0 ptmt -54.06 114.38 1.58 Allowed 'General case' 0 C--O 1.221 -0.412 0 CA-C-N 119.287 0.949 . . . . 0.0 110.853 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 116.56 -81.03 0.3 Allowed Glycine 0 C--N 1.332 0.321 0 CA-C-N 119.625 1.102 . . . . 0.0 112.366 179.125 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -151.17 138.36 11.99 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 123.147 0.579 . . . . 0.0 111.822 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -68.13 134.77 32.6 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.357 2.038 . . . . 0.0 111.707 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -63.71 -22.49 69.76 Favored 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 122.439 2.093 . . . . 0.0 113.191 179.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -69.4 -8.6 48.0 Favored 'General case' 0 CA--C 1.534 0.341 0 CA-C-N 119.323 0.965 . . . . 0.0 112.404 179.461 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -119.78 10.39 11.62 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 124.794 1.238 . . . . 0.0 112.414 -178.508 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.3 tt -51.84 -31.17 13.05 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 O-C-N 121.326 -0.859 . . . . 0.0 113.078 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -54.63 -37.49 65.71 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 125.248 1.419 . . . . 0.0 112.278 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -77.95 -29.28 49.77 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 118.467 0.576 . . . . 0.0 111.042 179.182 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 78.0 mt -66.46 -34.54 78.18 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 179.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.1 t -69.58 105.18 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -179.004 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 119.81 -10.08 11.32 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.894 1.711 . . . . 0.0 112.587 -179.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 3.3 mtpp -82.16 154.39 25.52 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 119.228 1.514 . . . . 0.0 108.026 178.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.2 ttmt -95.69 135.15 37.76 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.471 HG23 ' HA ' ' A' ' 17' ' ' GLU . 5.1 m -75.81 143.45 13.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 177.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 73.4 mt -89.27 -14.94 34.71 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 124.399 1.08 . . . . 0.0 111.248 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.4 m -145.9 163.81 10.55 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 C-N-CA 126.395 1.878 . . . . 0.0 109.309 -178.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 4.9 m -75.76 127.4 32.96 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 105.731 -1.951 . . . . 0.0 105.731 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 89.2 t -105.93 148.74 10.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -98.66 170.55 8.71 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 123.626 0.77 . . . . 0.0 111.603 -179.066 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -67.78 132.75 48.01 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.4 t70 67.91 9.39 7.1 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 129.327 3.051 . . . . 0.0 114.201 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -68.06 154.64 41.23 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 123.429 0.692 . . . . 0.0 110.253 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -84.81 124.97 32.18 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 123.246 0.618 . . . . 0.0 110.97 -178.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.9 mm -85.84 146.95 5.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 178.073 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 32.9 mtp -134.01 151.76 51.57 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 105.47 -2.048 . . . . 0.0 105.47 178.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.26 -26.96 61.63 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 123.562 0.745 . . . . 0.0 112.885 -178.765 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -76.62 -0.58 23.91 Favored 'General case' 0 N--CA 1.451 -0.408 0 C-N-CA 126.0 1.72 . . . . 0.0 114.768 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 61.6 mt -113.53 3.18 15.63 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.204 1.402 . . . . 0.0 112.364 -179.402 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.2 m -132.52 152.9 37.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-N 119.462 1.028 . . . . 0.0 112.453 -178.025 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.531 0.217 0 C-N-CA 123.594 0.758 . . . . 0.0 110.109 179.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.426 ' HA3' ' HA ' ' A' ' 30' ' ' VAL . . . . . . . . 0 CA--C 1.52 0.387 0 N-CA-C 111.995 -0.442 . . . . 0.0 111.995 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 55.7 p -137.74 155.58 48.92 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 124.224 1.01 . . . . 0.0 110.842 179.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 43.4 t -75.93 130.61 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 178.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 m -129.74 157.68 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 N-CA-C 105.122 -2.177 . . . . 0.0 105.122 177.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.05 128.9 36.62 Favored 'General case' 0 N--CA 1.444 -0.731 0 O-C-N 121.356 -0.84 . . . . 0.0 109.38 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 52.6 tttt -72.44 -27.49 62.36 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.075 0.55 . . . . 0.0 111.309 179.686 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.6 m -146.87 171.65 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 C-N-CA 127.092 2.157 . . . . 0.0 108.083 -179.473 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.3 tttt -70.58 124.67 24.79 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 178.58 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.3 mt -116.16 101.81 53.82 Favored Pre-proline 0 C--N 1.327 -0.384 0 N-CA-C 105.788 -1.93 . . . . 0.0 105.788 -178.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.689 ' HA ' HG23 ' A' ' 52' ' ' THR . 33.3 Cg_endo -63.31 159.05 41.53 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 120.896 1.064 . . . . 0.0 110.627 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 71.4 tt0 -54.83 149.03 11.96 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 179.512 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.94 4.89 73.46 Favored Glycine 0 CA--C 1.533 1.212 0 CA-C-O 119.045 -0.864 . . . . 0.0 114.576 179.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 18.9 m -92.11 150.85 20.71 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 119.667 1.734 . . . . 0.0 109.425 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 36.5 mm -89.5 135.97 24.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.439 0 C-N-CA 124.149 0.98 . . . . 0.0 110.108 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 25.9 mt -75.56 143.4 42.43 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.172 0.51 . . . . 0.0 109.808 178.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 33.2 p -138.55 154.13 48.74 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 17.4 mmt -59.71 -34.48 72.97 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-O 121.834 0.826 . . . . 0.0 110.332 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -64.81 -12.45 48.16 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 126.633 1.973 . . . . 0.0 114.055 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 33.1 mtm -117.74 6.26 12.34 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.22 1.008 . . . . 0.0 111.238 179.291 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.9 mt -119.41 153.21 35.56 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 179.429 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.7 t -151.93 172.59 16.0 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 105.558 -2.015 . . . . 0.0 105.558 178.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.65 122.0 46.21 Favored 'Isoleucine or valine' 0 C--O 1.237 0.424 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.203 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 15.3 ttmm -87.39 103.57 15.62 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.072 -2.196 . . . . 0.0 105.072 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.426 ' HA ' ' HA3' ' A' ' 7' ' ' GLY . 14.8 m -65.55 132.96 31.19 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 179.609 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.52 -64.62 0.27 Allowed Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -145.4 157.69 52.17 Favored Pre-proline 0 N--CA 1.453 -0.3 0 CA-C-O 118.604 -0.712 . . . . 0.0 111.712 -178.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -78.93 11.97 2.39 Favored 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 123.433 2.755 . . . . 0.0 112.599 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -51.74 110.07 0.43 Allowed 'General case' 0 N--CA 1.463 0.202 0 C-N-CA 125.455 1.502 . . . . 0.0 110.126 179.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.63 -99.33 0.56 Allowed Glycine 0 C--N 1.333 0.374 0 CA-C-N 119.193 0.906 . . . . 0.0 111.931 179.164 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -139.18 134.76 16.86 Favored Pre-proline 0 C--O 1.239 0.543 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.615 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -61.0 133.44 47.33 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.557 2.838 . . . . 0.0 111.554 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -72.52 -16.22 27.35 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 123.466 2.777 . . . . 0.0 113.408 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -67.42 -23.39 65.54 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 119.399 1.0 . . . . 0.0 110.028 178.301 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 47.1 m-20 -99.71 7.86 44.77 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 126.125 1.77 . . . . 0.0 111.167 -179.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.4 tt -51.72 -33.84 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 CA-C-N 120.395 1.452 . . . . 0.0 112.712 -179.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -60.98 -19.26 60.92 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 123.97 0.908 . . . . 0.0 112.006 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 -92.43 -27.58 17.39 Favored 'General case' 0 CA--C 1.52 -0.189 0 C-N-CA 124.701 1.2 . . . . 0.0 110.364 179.189 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 19.5 mt -67.97 -37.77 81.92 Favored 'General case' 0 CA--C 1.52 -0.188 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.1 t -58.98 137.72 21.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.09 -14.02 63.25 Favored Glycine 0 CA--C 1.53 0.996 0 CA-C-O 118.121 -1.377 . . . . 0.0 112.824 -179.188 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 40.8 mttm -75.41 166.66 23.25 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 120.458 2.129 . . . . 0.0 108.812 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -119.76 132.42 55.62 Favored 'General case' 0 CA--C 1.521 -0.165 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.333 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -74.99 157.12 6.09 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-N 118.438 0.563 . . . . 0.0 112.461 179.81 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.08 -19.14 16.64 Favored 'General case' 0 C--O 1.225 -0.229 0 C-N-CA 126.628 1.971 . . . . 0.0 110.49 178.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 35.4 m -142.43 158.74 19.46 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 124.208 1.003 . . . . 0.0 109.445 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.689 HG23 ' HA ' ' A' ' 16' ' ' PRO . 58.0 m -72.23 99.51 2.39 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.919 1.688 . . . . 0.0 109.562 179.163 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 47.4 t -78.83 151.99 5.01 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 179.294 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -100.86 169.44 8.98 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 126.072 1.749 . . . . 0.0 110.655 179.371 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -69.33 141.62 54.22 Favored 'General case' 0 C--O 1.239 0.52 0 N-CA-C 106.001 -1.851 . . . . 0.0 106.001 176.637 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 67.13 1.22 2.3 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 128.182 2.593 . . . . 0.0 112.413 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.44 149.55 48.2 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.15 0.98 . . . . 0.0 109.938 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 94.6 m -85.26 124.51 31.97 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-O 122.326 1.06 . . . . 0.0 110.94 -177.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 mm -82.18 142.01 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 33.6 mtp -142.25 155.14 45.22 Favored 'General case' 0 C--O 1.237 0.399 0 C-N-CA 125.018 1.327 . . . . 0.0 108.008 179.072 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -61.22 -34.7 75.53 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 124.519 1.128 . . . . 0.0 112.388 -179.106 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -69.56 -2.85 12.56 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 113.688 0.996 . . . . 0.0 113.688 -179.497 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 54.3 mt -105.04 5.77 32.8 Favored 'General case' 0 C--O 1.234 0.285 0 C-N-CA 125.696 1.598 . . . . 0.0 112.827 -178.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 36.0 m -124.79 160.35 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 120.272 1.396 . . . . 0.0 112.068 -179.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 46.7 t0 . . . . . 0 C--O 1.238 0.49 0 C-N-CA 127.079 2.151 . . . . 0.0 110.434 -179.21 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.709 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.2 m -146.61 145.19 29.99 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.206 0.527 . . . . 0.0 111.982 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 21.8 t -69.88 128.82 33.79 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 C-N-CA 123.994 0.918 . . . . 0.0 109.837 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.3 m -123.62 152.68 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 178.178 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.486 ' HB2' HD11 ' A' ' 59' ' ' ILE . . . -68.01 111.57 4.49 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 178.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 18.6 tttp -59.59 -30.56 68.76 Favored 'General case' 0 CA--C 1.536 0.426 0 O-C-N 121.068 -1.02 . . . . 0.0 113.561 -178.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.8 m -141.98 170.82 11.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 128.747 2.819 . . . . 0.0 106.91 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 42.9 tttm -66.59 137.77 56.99 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 178.401 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.1 mt -121.7 103.43 40.61 Favored Pre-proline 0 N--CA 1.462 0.155 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -179.304 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -66.65 149.99 83.82 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 121.085 1.19 . . . . 0.0 109.561 179.281 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -52.32 146.17 9.84 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 125.448 1.499 . . . . 0.0 110.749 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.65 3.13 86.68 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 123.724 0.678 . . . . 0.0 114.508 178.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 22.6 m -91.49 147.67 22.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 118.361 1.081 . . . . 0.0 109.779 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 49.3 mm -87.09 135.59 24.89 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 C-N-CA 123.982 0.913 . . . . 0.0 108.611 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 13.9 mt -74.16 147.09 42.94 Favored 'General case' 0 CA--C 1.519 -0.226 0 C-N-CA 125.288 1.435 . . . . 0.0 110.841 179.252 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.691 ' HA ' HG23 ' A' ' 45' ' ' VAL . 53.8 p -140.96 157.69 44.99 Favored 'General case' 0 C--O 1.238 0.47 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.167 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 7.6 mmt -62.93 -20.43 65.19 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.266 0.939 . . . . 0.0 110.881 178.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -72.0 -21.28 61.58 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.226 0.921 . . . . 0.0 110.25 178.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.7 mtm -105.51 4.98 31.08 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 126.328 1.851 . . . . 0.0 111.62 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 80.3 mt -122.94 141.26 52.12 Favored 'General case' 0 CA--C 1.516 -0.339 0 O-C-N 121.135 -0.978 . . . . 0.0 108.647 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.6 t -153.22 115.48 4.39 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.729 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 9' ' ' VAL . 0.2 OUTLIER -71.4 139.04 20.52 Favored 'Isoleucine or valine' 0 C--O 1.238 0.479 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.16 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.53 112.33 25.38 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 104.542 -2.392 . . . . 0.0 104.542 177.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.79 127.83 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 178.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 171.27 -85.86 0.08 OUTLIER Glycine 0 C--N 1.334 0.468 0 C-N-CA 119.955 -1.117 . . . . 0.0 113.356 -179.04 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -138.91 160.78 61.48 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 118.162 0.981 . . . . 0.0 111.562 -178.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -72.78 5.85 2.72 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.406 2.737 . . . . 0.0 114.818 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 23.7 tttp -68.63 92.91 0.48 Allowed 'General case' 0 C--O 1.233 0.21 0 C-N-CA 124.928 1.291 . . . . 0.0 109.476 179.377 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 148.21 -91.78 0.15 Allowed Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -157.27 141.38 11.67 Favored Pre-proline 0 C--O 1.238 0.454 0 C-N-CA 124.974 1.31 . . . . 0.0 110.308 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -68.64 150.39 74.59 Favored 'Trans proline' 0 CA--C 1.538 0.699 0 C-N-CA 122.447 2.098 . . . . 0.0 112.737 -179.403 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 80.7 Cg_endo -79.59 -3.28 12.82 Favored 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 123.098 2.532 . . . . 0.0 113.639 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -73.15 -59.11 2.86 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -71.31 4.95 2.49 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 128.762 2.825 . . . . 0.0 113.748 -179.395 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.559 ' HA ' HD12 ' A' ' 44' ' ' LEU . 17.4 tt -48.88 -37.11 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.568 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -178.153 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -63.38 -13.95 44.95 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.083 0.953 . . . . 0.0 113.49 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -87.29 -30.38 20.91 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 123.381 0.672 . . . . 0.0 110.989 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.559 HD12 ' HA ' ' A' ' 41' ' ' ILE . 21.2 mt -67.66 -44.54 77.59 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.331 1.052 . . . . 0.0 108.775 -179.13 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.691 HG23 ' HA ' ' A' ' 22' ' ' THR . 1.4 p -66.4 124.01 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.68 -15.47 29.21 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 125.664 1.602 . . . . 0.0 112.3 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 61.7 mttm -81.84 158.25 24.11 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 119.073 1.437 . . . . 0.0 110.469 179.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -97.89 142.55 29.49 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 177.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.0 m -86.1 144.0 10.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 CA-C-N 119.397 0.999 . . . . 0.0 109.228 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 62.2 mt -92.92 -3.84 53.83 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 125.446 1.498 . . . . 0.0 112.96 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 28.7 m -148.93 161.98 5.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 C-N-CA 125.81 1.644 . . . . 0.0 109.715 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.4 m -85.28 100.64 11.93 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 104.118 -2.549 . . . . 0.0 104.118 176.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.444 HG11 HD11 ' A' ' 59' ' ' ILE . 44.7 t -82.4 143.34 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 179.389 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -88.94 176.52 6.98 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 123.73 0.812 . . . . 0.0 110.605 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -72.41 143.42 48.53 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.496 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 59.23 11.58 2.17 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 128.946 2.898 . . . . 0.0 113.806 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -75.04 154.25 38.06 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.09 1.356 . . . . 0.0 109.099 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.0 m -82.61 132.86 35.18 Favored 'General case' 0 C--N 1.33 -0.276 0 O-C-N 120.886 -1.134 . . . . 0.0 112.379 -178.329 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.486 HD11 ' HB2' ' A' ' 11' ' ' ALA . 41.4 mm -100.2 127.52 53.08 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.72 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 30.9 mtp -122.58 167.37 13.47 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -61.09 -23.65 65.64 Favored 'General case' 0 CA--C 1.538 0.505 0 O-C-N 120.929 -1.107 . . . . 0.0 113.95 -179.565 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -76.56 -4.79 44.7 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 125.54 1.536 . . . . 0.0 113.065 -179.538 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 19.1 mt -107.61 2.08 23.69 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.721 0.809 . . . . 0.0 112.249 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.4 m -127.22 159.05 37.98 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 CA-C-N 119.37 0.986 . . . . 0.0 111.704 -178.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 C--O 1.239 0.504 0 C-N-CA 125.622 1.569 . . . . 0.0 113.569 -179.396 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.97 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -80.82 -55.65 4.67 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.441 0.697 . . . . 0.0 110.099 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.6 t -53.12 132.02 37.6 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 124.006 0.922 . . . . 0.0 109.318 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -158.3 90.12 0.11 Allowed Glycine 0 N--CA 1.442 -0.952 0 N-CA-C 107.546 -2.222 . . . . 0.0 107.546 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 74.3 m -75.04 41.0 0.16 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.184 1.394 . . . . 0.0 109.797 178.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.3 p -45.06 -38.23 4.77 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 127.584 2.353 . . . . 0.0 111.683 -179.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.15 -173.77 30.6 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 124.001 0.81 . . . . 0.0 111.1 179.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 84.7 p -129.14 151.32 49.94 Favored 'General case' 0 C--O 1.24 0.593 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -75.24 105.69 4.41 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 O-C-N 122.014 -0.429 . . . . 0.0 111.109 -179.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.0 m -102.86 152.82 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-O 122.654 1.216 . . . . 0.0 107.769 178.088 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.58 128.28 35.31 Favored 'General case' 0 C--N 1.319 -0.722 0 C-N-CA 124.958 1.303 . . . . 0.0 107.94 178.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.52 ' HE2' ' HB ' ' A' ' 27' ' ' THR . 20.1 ttmm -75.86 -23.92 55.69 Favored 'General case' 0 C--N 1.327 -0.378 0 O-C-N 121.012 -1.055 . . . . 0.0 111.099 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.7 m -148.15 173.25 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 C-N-CA 126.589 1.956 . . . . 0.0 107.678 -179.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 54.5 tttp -67.42 127.87 34.3 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 177.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.3 mt -111.48 96.43 31.73 Favored Pre-proline 0 C--N 1.331 -0.206 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -61.09 145.29 99.1 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 121.576 1.518 . . . . 0.0 110.496 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.588 ' HA ' HG23 ' A' ' 49' ' ' VAL . 4.9 tm-20 -50.77 146.2 6.11 Favored 'General case' 0 C--O 1.238 0.486 0 C-N-CA 124.936 1.294 . . . . 0.0 110.799 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.55 -3.64 81.6 Favored Glycine 0 CA--C 1.531 1.051 0 CA-C-O 119.327 -0.707 . . . . 0.0 113.153 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 20.0 m -88.22 143.78 26.84 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 118.956 1.378 . . . . 0.0 110.704 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 13.2 mm -83.98 140.24 16.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 71.0 mt -73.83 149.4 41.64 Favored 'General case' 0 C--O 1.238 0.489 0 C-N-CA 123.515 0.726 . . . . 0.0 112.452 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 22.6 p -146.94 157.4 43.62 Favored 'General case' 0 C--O 1.238 0.49 0 C-N-CA 127.526 2.33 . . . . 0.0 107.073 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 19.9 mmt -67.58 -24.15 65.47 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 118.826 0.739 . . . . 0.0 110.571 179.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -67.72 -12.67 61.01 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 121.476 -0.765 . . . . 0.0 112.207 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 47.7 mtm -115.45 10.78 15.83 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.078 0.951 . . . . 0.0 110.915 179.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -132.16 161.77 32.52 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 119.655 1.116 . . . . 0.0 112.53 -179.026 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.52 ' HB ' ' HE2' ' A' ' 12' ' ' LYS . 12.6 t -159.31 170.93 20.76 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 127.847 2.459 . . . . 0.0 107.294 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -125.36 110.87 25.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 178.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 1.1 mptp? -76.68 91.73 3.47 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.8 p -54.53 125.54 9.43 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 C-N-CA 126.288 1.835 . . . . 0.0 106.591 178.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.65 -61.73 0.28 Allowed Glycine 0 N--CA 1.45 -0.417 0 CA-C-O 119.687 -0.507 . . . . 0.0 112.155 -179.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -148.7 148.65 28.63 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-N 118.313 1.056 . . . . 0.0 110.419 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -80.47 44.02 1.65 Allowed 'Trans proline' 0 CA--C 1.548 1.191 0 C-N-CA 123.645 2.896 . . . . 0.0 110.729 179.358 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 24.5 ttmt -84.85 92.8 8.35 Favored 'General case' 0 CA--C 1.521 -0.16 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.14 -132.59 6.74 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 179.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.462 ' CD2' ' HD2' ' A' ' 37' ' ' PRO . 0.6 OUTLIER -94.02 139.93 22.75 Favored Pre-proline 0 C--O 1.238 0.462 0 C-N-CA 124.805 1.242 . . . . 0.0 110.215 -179.727 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.462 ' HD2' ' CD2' ' A' ' 36' ' ' TYR . 83.9 Cg_endo -75.17 148.77 35.1 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.022 1.815 . . . . 0.0 112.104 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -75.99 -0.82 10.7 Favored 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 122.962 2.441 . . . . 0.0 111.709 178.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -81.55 -49.79 10.14 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.629 1.572 . . . . 0.0 108.794 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 -85.65 6.28 28.21 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.767 1.227 . . . . 0.0 111.344 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.0 tt -44.1 -41.66 1.81 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 C-N-CA 126.506 1.922 . . . . 0.0 114.607 -178.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -60.49 -32.61 71.6 Favored 'General case' 0 C--N 1.333 -0.138 0 O-C-N 121.575 -0.703 . . . . 0.0 112.003 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 33.7 m-80 -63.63 -30.42 71.53 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 123.377 0.671 . . . . 0.0 110.95 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.3 mt -71.93 -42.57 66.51 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 123.377 0.671 . . . . 0.0 109.828 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.2 t -67.2 93.73 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-O 122.212 1.006 . . . . 0.0 109.18 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 137.05 -11.7 3.88 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 126.202 1.858 . . . . 0.0 112.286 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -84.39 166.4 17.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 118.924 1.362 . . . . 0.0 109.069 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 28.2 ttmt -110.3 139.58 45.35 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.588 HG23 ' HA ' ' A' ' 17' ' ' GLU . 13.5 m -81.99 150.35 4.49 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 O-C-N 123.583 0.552 . . . . 0.0 110.301 179.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 91.9 mt -101.01 -10.43 20.55 Favored 'General case' 0 C--O 1.233 0.226 0 C-N-CA 125.364 1.466 . . . . 0.0 111.88 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.4 160.56 14.99 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 C-N-CA 124.529 1.132 . . . . 0.0 109.154 178.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 11.6 m -78.65 99.88 6.77 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 14.9 t -73.2 150.41 7.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 179.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -102.55 168.12 9.49 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 123.589 0.756 . . . . 0.0 109.265 178.358 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 72.4 tt0 -61.51 144.18 54.7 Favored 'General case' 0 CA--C 1.538 0.495 0 O-C-N 121.413 -0.804 . . . . 0.0 108.834 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . 0.349 0.1 OUTLIER 56.92 13.06 1.35 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 128.077 2.551 . . . . 0.0 114.543 179.699 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -78.33 153.72 31.46 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 124.077 0.951 . . . . 0.0 112.403 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 20.0 m -81.43 113.07 19.25 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 124.75 1.22 . . . . 0.0 111.771 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.4 mm -76.88 144.31 11.83 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 3.0 mmt -134.53 161.21 35.7 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 125.877 1.671 . . . . 0.0 110.637 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -67.46 -29.15 68.53 Favored 'General case' 0 N--CA 1.467 0.378 0 O-C-N 121.354 -0.841 . . . . 0.0 111.773 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -74.01 -11.31 60.29 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 119.305 0.957 . . . . 0.0 112.486 179.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 69.6 mt -94.56 -4.43 47.94 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.341 1.057 . . . . 0.0 111.646 -179.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 m -122.54 140.36 46.59 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-N 120.162 1.346 . . . . 0.0 108.642 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 48.1 t0 -74.32 165.23 25.53 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -68.78 170.11 10.12 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 124.49 1.116 . . . . 0.0 108.192 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -68.12 151.49 46.93 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -116.78 59.07 0.47 Allowed Glycine 0 CA--C 1.518 0.271 0 N-CA-C 105.916 -2.873 . . . . 0.0 105.916 179.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 17.6 tppt? -99.14 -65.03 0.99 Allowed 'General case' 0 CA--C 1.52 -0.187 0 C-N-CA 124.164 0.986 . . . . 0.0 110.908 -178.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 42.1 tptt -50.07 122.04 6.23 Favored 'General case' 0 CA--C 1.514 -0.414 0 C-N-CA 124.379 1.072 . . . . 0.0 112.792 -177.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 28.0 pt -74.93 39.6 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 126.387 1.875 . . . . 0.0 110.78 178.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 19.6 tptm -151.67 142.03 22.47 Favored 'General case' 0 C--N 1.346 0.427 0 O-C-N 119.829 -1.794 . . . . 0.0 113.418 -178.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 32.6 m -79.98 100.09 7.94 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.534 1.134 . . . . 0.0 110.129 178.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 44.8 m -163.04 159.35 23.2 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 126.5 1.92 . . . . 0.0 106.825 178.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 112.22 93.04 2.1 Favored Glycine 0 C--N 1.335 0.477 0 CA-C-O 117.855 -1.525 . . . . 0.0 109.843 179.491 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -74.78 150.18 38.9 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.7 2.267 . . . . 0.0 109.293 179.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 32.9 t -61.98 143.66 56.21 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 116.643 -0.253 . . . . 0.0 110.902 -179.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 81.1 p -94.34 -10.33 33.04 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 123.672 0.789 . . . . 0.0 108.872 177.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.012 0 N-CA-C 106.562 -2.615 . . . . 0.0 106.562 179.177 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.599 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.6 p -85.23 124.84 32.33 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 125.71 1.604 . . . . 0.0 107.938 179.366 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 58.0 p -71.41 176.39 4.69 Favored 'General case' 0 C--O 1.243 0.749 0 CA-C-N 119.279 0.945 . . . . 0.0 110.918 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 137.7 86.43 0.17 Allowed Glycine 0 C--N 1.333 0.401 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.062 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.3 t -125.5 163.27 23.03 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.1 p -137.31 9.34 2.95 Favored 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 114.072 1.138 . . . . 0.0 114.072 -179.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -171.1 -164.0 26.08 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 120.09 1.313 . . . . 0.0 111.515 -179.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.5 p -139.83 161.46 37.52 Favored 'General case' 0 C--O 1.241 0.617 0 C-N-CA 125.758 1.623 . . . . 0.0 109.303 -179.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.2 t -85.88 133.17 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.8 m -129.38 160.62 40.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 178.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.4 118.78 12.71 Favored 'General case' 0 N--CA 1.448 -0.572 0 C-N-CA 126.38 1.872 . . . . 0.0 109.106 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.8 ttmm -68.01 -28.41 67.39 Favored 'General case' 0 N--CA 1.469 0.524 0 O-C-N 120.937 -1.102 . . . . 0.0 111.011 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.9 m -145.75 168.14 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 C-N-CA 127.778 2.431 . . . . 0.0 106.98 -179.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 80.9 tttt -68.81 128.78 37.88 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 8.2 mt -111.61 103.88 55.54 Favored Pre-proline 0 CA--C 1.538 0.507 0 C-N-CA 124.967 1.307 . . . . 0.0 108.552 -178.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -69.96 147.74 62.21 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 121.949 1.766 . . . . 0.0 110.704 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 7.3 tm-20 -49.22 139.65 10.83 Favored 'General case' 0 C--O 1.237 0.425 0 C-N-CA 123.909 0.884 . . . . 0.0 111.413 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.04 -3.57 84.56 Favored Glycine 0 CA--C 1.523 0.551 0 CA-C-N 115.571 -0.74 . . . . 0.0 112.942 179.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 53.4 m -82.53 140.37 33.34 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 118.756 1.278 . . . . 0.0 109.591 179.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.4 mm -78.73 135.35 26.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 105.424 -2.065 . . . . 0.0 105.424 178.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 32.2 mt -75.35 131.52 40.31 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.751 0.82 . . . . 0.0 109.304 179.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.4 p -127.83 161.36 29.21 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 13.2 mmt -61.76 -27.49 68.77 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 121.878 -0.514 . . . . 0.0 111.257 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -74.58 -7.9 54.62 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.884 0.874 . . . . 0.0 113.06 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 70.4 mtm -113.94 7.7 16.99 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 119.27 0.941 . . . . 0.0 111.25 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.8 mt -123.64 152.68 41.71 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 124.368 1.067 . . . . 0.0 109.36 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.9 t -150.3 161.73 41.89 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 98.5 t -111.67 103.73 15.93 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 -178.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 9.5 tppt? -78.15 102.84 7.73 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 178.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.0 t -67.1 122.99 19.21 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 N-CA-C 104.438 -2.431 . . . . 0.0 104.438 178.131 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 170.18 -64.19 0.17 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-O 118.89 -0.95 . . . . 0.0 114.397 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -147.94 156.92 44.07 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 118.852 1.326 . . . . 0.0 110.421 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -79.31 0.72 9.79 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 123.666 2.911 . . . . 0.0 113.532 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.6 ttmt -60.44 106.99 0.6 Allowed 'General case' 0 CA--C 1.529 0.155 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 142.37 -105.56 0.41 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 123.758 0.694 . . . . 0.0 111.819 179.683 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -144.67 143.05 20.04 Favored Pre-proline 0 C--O 1.238 0.485 0 N-CA-C 106.347 -1.723 . . . . 0.0 106.347 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.45 132.11 23.13 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.735 2.29 . . . . 0.0 113.162 -178.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -71.15 -19.49 29.61 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 122.193 1.929 . . . . 0.0 112.257 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 24.5 mp0 -65.04 -31.92 73.38 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 119.586 1.085 . . . . 0.0 110.191 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -106.28 17.57 23.26 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 125.148 1.379 . . . . 0.0 111.998 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.8 tt -50.33 -32.84 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 125.146 1.379 . . . . 0.0 112.366 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -56.73 -25.01 53.62 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 124.193 0.997 . . . . 0.0 112.089 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 74.2 m-80 -81.39 -17.33 49.35 Favored 'General case' 0 C--N 1.339 0.127 0 C-N-CA 123.487 0.715 . . . . 0.0 112.101 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 72.3 mt -76.65 -34.55 58.27 Favored 'General case' 0 C--O 1.225 -0.221 0 CA-C-N 119.219 0.918 . . . . 0.0 108.701 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 63.3 t -62.7 128.98 25.46 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 98.1 -16.78 59.64 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 125.484 1.516 . . . . 0.0 111.09 -178.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 82.6 mttt -75.4 168.75 19.4 Favored 'General case' 0 C--N 1.344 0.354 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 178.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.5 ttmp? -125.69 135.01 51.65 Favored 'General case' 0 CA--C 1.508 -0.656 0 O-C-N 121.236 -0.915 . . . . 0.0 108.785 -179.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.7 m -67.7 141.13 18.12 Favored 'Isoleucine or valine' 0 C--O 1.24 0.602 0 O-C-N 123.97 0.794 . . . . 0.0 110.113 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 86.5 mt -93.74 -14.44 26.28 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 126.12 1.768 . . . . 0.0 112.256 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 22.7 m -146.63 158.85 10.51 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 C-N-CA 126.317 1.847 . . . . 0.0 108.2 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 88.6 m -70.84 101.36 2.11 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 178.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 45.5 t -79.77 119.81 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -72.36 166.9 21.59 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 122.399 1.095 . . . . 0.0 109.401 178.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 52.6 tt0 -61.03 143.77 54.71 Favored 'General case' 0 N--CA 1.449 -0.52 0 O-C-N 121.438 -0.789 . . . . 0.0 109.521 -179.392 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.8 t70 64.15 3.71 1.84 Allowed 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.52 1.928 . . . . 0.0 113.587 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -71.71 155.12 40.83 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-O 121.866 0.841 . . . . 0.0 109.338 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.2 m -71.83 127.0 31.17 Favored 'General case' 0 N--CA 1.436 -1.151 0 C-N-CA 126.057 1.743 . . . . 0.0 110.797 -178.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.4 mm -90.7 137.58 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 N-CA-C 103.812 -2.662 . . . . 0.0 103.812 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 34.7 mtp -140.92 -170.89 3.13 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 123.662 0.785 . . . . 0.0 110.501 -178.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -86.27 -37.58 18.43 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 6.2 pm0 -64.45 -11.76 36.71 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.446 1.098 . . . . 0.0 112.779 179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 71.4 mt -101.19 2.4 40.02 Favored 'General case' 0 C--O 1.227 -0.124 0 C-N-CA 125.436 1.494 . . . . 0.0 112.319 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 10.3 m -135.35 155.13 36.7 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.173 0 CA-C-N 121.435 1.925 . . . . 0.0 114.399 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 49.9 p30 -76.87 164.49 25.76 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.394 178.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -70.89 121.62 18.44 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -50.77 -32.03 18.61 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 114.326 1.232 . . . . 0.0 114.326 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -62.82 -31.63 80.97 Favored Glycine 0 CA--C 1.529 0.937 0 CA-C-O 119.012 -0.882 . . . . 0.0 114.983 -179.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -175.97 153.86 1.39 Allowed 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 119.024 1.412 . . . . 0.0 109.807 178.597 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.0 ptmm? -98.08 128.48 44.62 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 7.9 pt -139.02 62.12 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 123.91 0.884 . . . . 0.0 111.175 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 15.3 mmmt -71.3 95.02 1.26 Allowed 'General case' 0 N--CA 1.47 0.575 0 N-CA-C 106.166 -1.79 . . . . 0.0 106.166 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.5 m -141.86 177.56 8.1 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 124.556 1.142 . . . . 0.0 111.66 -179.188 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.23 86.81 1.93 Allowed 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 127.85 2.46 . . . . 0.0 109.484 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 177.71 164.82 31.75 Favored Glycine 0 CA--C 1.529 0.956 0 C-N-CA 123.647 0.642 . . . . 0.0 111.649 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 75.4 Cg_endo -71.36 170.24 18.87 Favored 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.93 2.42 . . . . 0.0 111.184 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 46.6 p -104.3 -122.9 0.21 Allowed 'General case' 0 C--O 1.235 0.298 0 C-N-CA 124.723 1.209 . . . . 0.0 110.332 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -171.08 170.62 6.1 Favored 'General case' 0 N--CA 1.441 -0.892 0 C-N-CA 129.111 2.964 . . . . 0.0 106.371 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.035 0 N-CA-C 106.413 -2.675 . . . . 0.0 106.413 179.882 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.643 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.96 130.08 41.24 Favored 'General case' 0 C--O 1.236 0.367 0 C-N-CA 124.015 0.926 . . . . 0.0 111.065 -178.302 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 34.3 t -69.28 143.64 53.8 Favored 'General case' 0 C--O 1.237 0.414 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 179.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 68.9 40.13 84.81 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-O 119.557 -0.58 . . . . 0.0 112.122 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.7 m -82.8 90.27 6.89 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 117.72 0.76 . . . . 0.0 109.752 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.0 m -53.28 -67.2 0.27 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 125.666 1.586 . . . . 0.0 113.32 -179.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 77.68 178.66 48.66 Favored Glycine 0 CA--C 1.535 1.293 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 79.5 p -144.31 159.04 43.38 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-N 117.853 0.826 . . . . 0.0 111.353 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 97.6 t -71.73 133.31 32.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.496 HG11 ' HE3' ' A' ' 29' ' ' LYS . 14.6 m -136.02 157.88 38.48 Favored 'Isoleucine or valine' 0 C--O 1.24 0.601 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 178.283 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.87 124.46 24.38 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 44.2 tttt -77.14 -27.11 53.77 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 121.911 -0.493 . . . . 0.0 111.653 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.4 m -144.29 168.15 10.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 C-N-CA 127.602 2.361 . . . . 0.0 106.824 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 78.6 tttt -69.06 117.81 11.17 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 178.076 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 19.9 mt -102.75 112.26 65.53 Favored Pre-proline 0 CA--C 1.533 0.307 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.93 148.95 32.41 Favored 'Trans proline' 0 N--CA 1.445 -1.342 0 C-N-CA 121.7 1.6 . . . . 0.0 109.428 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 tm-20 -51.68 145.61 9.0 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 124.135 0.974 . . . . 0.0 110.384 179.101 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.38 -3.58 86.47 Favored Glycine 0 CA--C 1.529 0.927 0 CA-C-O 119.105 -0.83 . . . . 0.0 114.89 178.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.6 m -89.78 152.4 21.32 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 118.389 1.095 . . . . 0.0 110.054 -179.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 48.7 mm -90.01 141.54 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 65.9 mt -75.9 139.29 41.56 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.373 0.606 . . . . 0.0 111.489 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 68.3 p -134.28 155.59 49.94 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 126.12 1.768 . . . . 0.0 106.393 178.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 25.8 mtp -67.47 -12.45 60.32 Favored 'General case' 0 CA--C 1.545 0.766 0 CA-C-N 119.594 1.088 . . . . 0.0 110.16 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.6 m-20 -72.84 -19.9 61.23 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 120.828 -1.17 . . . . 0.0 112.147 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 56.1 mtm -115.08 10.37 16.15 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 124.691 1.196 . . . . 0.0 111.59 -178.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 36.0 mt -130.82 148.74 52.63 Favored 'General case' 0 CA--C 1.515 -0.37 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -178.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 3.8 t -157.14 179.14 9.56 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.4 t -124.56 113.52 36.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-N 118.826 0.739 . . . . 0.0 109.76 -178.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.496 ' HE3' HG11 ' A' ' 10' ' ' VAL . 2.7 ttpp -79.37 93.4 5.33 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 179.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 16.0 t -59.63 98.62 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -172.17 -46.13 0.04 OUTLIER Glycine 0 C--N 1.339 0.716 0 CA-C-O 117.494 -1.725 . . . . 0.0 115.559 -178.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -151.43 154.33 33.41 Favored Pre-proline 0 N--CA 1.464 0.241 0 CA-C-N 120.251 2.026 . . . . 0.0 110.6 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -76.49 -3.89 14.36 Favored 'Trans proline' 0 CA--C 1.534 0.504 0 C-N-CA 123.195 2.597 . . . . 0.0 113.066 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 3.6 tmmm? -63.73 107.05 1.09 Allowed 'General case' 0 CA--C 1.518 -0.252 0 O-C-N 121.132 -0.98 . . . . 0.0 108.419 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.429 ' HA2' ' SD ' ' A' ' 60' ' ' MET . . . 131.36 178.49 15.5 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 126.26 1.886 . . . . 0.0 109.889 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.526 ' CG ' HD11 ' A' ' 44' ' ' LEU . 7.3 t80 -57.07 134.02 80.45 Favored Pre-proline 0 C--O 1.24 0.603 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -61.98 131.04 33.13 Favored 'Trans proline' 0 N--CA 1.453 -0.888 0 C-N-CA 122.168 1.912 . . . . 0.0 108.997 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.64 -19.06 48.39 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.261 1.974 . . . . 0.0 112.351 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -70.67 -10.85 60.32 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 113.304 0.853 . . . . 0.0 113.304 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -121.33 10.92 10.66 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 126.044 1.738 . . . . 0.0 111.582 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.5 tt -41.33 -37.42 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.547 0 C-N-CA 128.194 2.598 . . . . 0.0 113.792 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -60.39 -34.99 74.7 Favored 'General case' 0 CA--C 1.528 0.133 0 C-N-CA 125.58 1.552 . . . . 0.0 113.927 -179.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -59.46 -38.96 82.13 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 119.675 1.125 . . . . 0.0 112.044 -178.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.526 HD11 ' CG ' ' A' ' 36' ' ' TYR . 85.0 mt -72.55 -33.93 67.17 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 124.681 1.192 . . . . 0.0 111.9 -179.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 69.3 t -67.68 91.29 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 124.521 1.128 . . . . 0.0 108.302 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 139.12 -9.38 3.29 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 126.437 1.97 . . . . 0.0 112.629 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 92.1 mttt -82.41 171.14 14.5 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 119.039 1.419 . . . . 0.0 108.437 178.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 33.8 ttmt -110.15 136.93 48.61 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 178.117 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.4 m -80.74 146.27 7.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 O-C-N 121.786 -0.572 . . . . 0.0 109.961 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 92.8 mt -97.21 -14.19 21.57 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 125.906 1.682 . . . . 0.0 113.453 -178.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 16.7 m -146.32 158.0 11.41 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.0 m -77.23 101.6 6.29 Favored 'General case' 0 CA--C 1.534 0.35 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 70.8 t -80.23 138.89 19.04 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -85.12 170.03 13.32 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-O 122.054 0.93 . . . . 0.0 110.283 178.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -71.22 138.99 49.94 Favored 'General case' 0 N--CA 1.447 -0.597 0 O-C-N 121.184 -0.947 . . . . 0.0 109.678 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.8 t70 72.3 4.18 4.92 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 127.671 2.389 . . . . 0.0 113.337 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -67.44 145.46 54.99 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.594 1.158 . . . . 0.0 109.387 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 25.4 m -73.24 129.0 37.09 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 179.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 26.2 mm -87.1 131.05 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . 0.49 ' H ' HD12 ' A' ' 63' ' ' LEU . 82.0 mmm -124.55 161.02 27.06 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 126.235 1.814 . . . . 0.0 106.948 179.255 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.421 ' H ' ' CD ' ' A' ' 61' ' ' GLU . 1.1 pm0 -72.31 -27.25 62.32 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.825 1.65 . . . . 0.0 111.332 179.592 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.41 -14.42 62.91 Favored 'General case' 0 CA--C 1.54 0.58 0 C-N-CA 124.419 1.088 . . . . 0.0 112.816 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.49 HD12 ' H ' ' A' ' 60' ' ' MET . 19.8 mt -93.29 -1.09 56.43 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 126.203 1.801 . . . . 0.0 112.148 -179.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.4 m -126.68 160.47 34.76 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 CA-C-N 119.707 1.14 . . . . 0.0 113.22 -178.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.78 -172.02 3.14 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.345 1.458 . . . . 0.0 109.091 178.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 17.2 t-20 -128.35 129.56 46.44 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 106.028 -1.841 . . . . 0.0 106.028 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -43.66 110.87 0.23 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 124.342 1.057 . . . . 0.0 111.452 -179.108 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 166.59 -150.15 16.86 Favored Glycine 0 N--CA 1.443 -0.876 0 C-N-CA 119.8 -1.191 . . . . 0.0 113.417 -178.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.34 166.26 10.78 Favored 'General case' 0 CA--C 1.516 -0.347 0 C-N-CA 124.44 1.096 . . . . 0.0 111.119 -179.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 8.1 pttm -152.66 162.16 41.62 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 123.951 0.9 . . . . 0.0 108.926 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 8.1 pt -88.75 170.22 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 122.119 0.962 . . . . 0.0 110.087 179.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.505 ' H ' ' HD2' ' A' ' 72' ' ' LYS . 0.0 OUTLIER -81.29 127.48 32.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 104.865 -2.272 . . . . 0.0 104.865 177.691 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 26.8 m -172.76 154.34 2.94 Favored 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 127.753 2.421 . . . . 0.0 107.209 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 7.0 t -114.22 -170.37 1.71 Allowed 'General case' 0 C--O 1.241 0.608 0 C-N-CA 124.547 1.139 . . . . 0.0 108.565 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -74.12 -179.06 39.72 Favored Glycine 0 CA--C 1.533 1.167 0 C-N-CA 124.485 1.04 . . . . 0.0 111.293 179.036 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -67.52 165.49 27.08 Favored 'Trans proline' 0 N--CA 1.45 -1.06 0 C-N-CA 121.951 1.767 . . . . 0.0 109.54 179.078 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.4 m -131.37 14.48 5.05 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.645 0.778 . . . . 0.0 110.534 179.507 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.3 t -144.71 153.07 41.33 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 124.642 1.177 . . . . 0.0 109.946 -178.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.223 0 N-CA-C 106.192 -2.763 . . . . 0.0 106.192 -179.706 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.971 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.4 m -72.67 166.41 22.84 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 117.714 0.757 . . . . 0.0 110.176 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.5 m -86.43 -28.05 23.77 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 123.925 0.89 . . . . 0.0 110.431 179.05 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 132.58 163.22 10.56 Favored Glycine 0 CA--C 1.522 0.526 0 C-N-CA 127.725 2.583 . . . . 0.0 109.197 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.5 p -80.69 167.82 19.56 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 117.581 0.691 . . . . 0.0 109.266 179.098 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 m -154.5 147.6 24.71 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.451 1.5 . . . . 0.0 107.006 179.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 166.07 -170.12 40.62 Favored Glycine 0 CA--C 1.519 0.301 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 10.7 p -94.02 134.12 36.76 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 118.264 1.032 . . . . 0.0 113.224 -178.373 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 98.9 t -68.27 132.67 32.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 176.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.29 155.6 40.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.533 0 C-N-CA 124.048 0.939 . . . . 0.0 109.174 179.098 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.72 117.04 12.79 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 177.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 42.6 tttp -63.58 -31.57 72.78 Favored 'General case' 0 C--N 1.33 -0.25 0 O-C-N 121.426 -0.796 . . . . 0.0 112.498 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m -142.3 169.99 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 C-N-CA 126.567 1.947 . . . . 0.0 107.012 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 39.1 tttt -64.17 127.18 30.33 Favored 'General case' 0 N--CA 1.454 -0.265 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.3 mt -111.89 100.69 49.54 Favored Pre-proline 0 CA--C 1.532 0.278 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 -179.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -65.16 151.43 85.54 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 N-CA-C 109.062 -1.168 . . . . 0.0 109.062 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -50.75 151.81 2.28 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 124.27 1.028 . . . . 0.0 111.384 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.62 -3.67 62.97 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 123.962 0.791 . . . . 0.0 113.971 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 99.1 m -81.42 145.89 30.56 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 118.191 0.995 . . . . 0.0 109.524 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.5 mm -88.74 130.86 37.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 178.045 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.555 ' HB3' HD11 ' A' ' 26' ' ' LEU . 30.7 mt -69.33 137.24 52.76 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 124.399 1.079 . . . . 0.0 110.734 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 73.4 p -135.39 159.03 42.86 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.383 1.073 . . . . 0.0 108.621 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 12.0 mmt -64.15 -17.86 63.89 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 118.114 0.415 . . . . 0.0 110.523 179.083 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -79.07 -16.45 56.77 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.966 0.906 . . . . 0.0 112.177 179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 75.3 mtm -118.94 15.09 13.36 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.378 1.071 . . . . 0.0 109.971 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.555 HD11 ' HB3' ' A' ' 21' ' ' LEU . 42.9 mt -137.0 154.46 50.4 Favored 'General case' 0 CA--C 1.511 -0.553 0 O-C-N 120.959 -1.088 . . . . 0.0 110.034 -178.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.6 t -164.33 -179.54 6.14 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.449 HG21 ' HB3' ' A' ' 38' ' ' PRO . 1.2 p -134.01 112.6 16.7 Favored 'Isoleucine or valine' 0 C--O 1.234 0.287 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -73.99 114.86 12.78 Favored 'General case' 0 CA--C 1.511 -0.556 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.1 p -51.81 139.75 7.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 O-C-N 124.196 0.935 . . . . 0.0 109.702 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 138.0 -131.34 5.4 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.2 pm0 -75.66 133.92 73.09 Favored Pre-proline 0 CA--C 1.541 0.602 0 C-N-CA 125.211 1.404 . . . . 0.0 112.847 -179.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.06 61.3 7.17 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 124.673 3.582 . . . . 0.0 111.123 179.217 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -88.24 172.06 9.73 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 125.122 1.369 . . . . 0.0 107.866 178.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.05 -77.0 1.18 Allowed Glycine 0 N--CA 1.445 -0.715 0 N-CA-C 113.822 0.289 . . . . 0.0 113.822 178.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -149.07 139.97 13.87 Favored Pre-proline 0 N--CA 1.443 -0.789 0 C-N-CA 126.315 1.846 . . . . 0.0 107.016 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.38 136.91 48.95 Favored 'Trans proline' 0 N--CA 1.451 -0.98 0 N-CA-C 109.106 -1.152 . . . . 0.0 109.106 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.449 ' HB3' HG21 ' A' ' 28' ' ' VAL . 74.4 Cg_endo -68.76 -15.25 40.55 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 122.479 2.119 . . . . 0.0 113.354 -179.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -69.47 -27.49 65.26 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 119.959 1.254 . . . . 0.0 109.85 178.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -98.27 10.43 40.67 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.644 1.578 . . . . 0.0 111.382 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.8 tt -52.54 -38.87 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 C-N-CA 124.831 1.252 . . . . 0.0 111.672 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 -68.91 -21.14 64.24 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.74 1.216 . . . . 0.0 112.661 -179.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -79.88 -38.04 33.53 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 119.087 0.858 . . . . 0.0 110.746 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.54 -30.0 70.36 Favored 'General case' 0 CA--C 1.528 0.126 0 C-N-CA 123.032 0.533 . . . . 0.0 110.078 178.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 45.3 t -66.52 107.13 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.47 -11.95 10.37 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 126.503 2.002 . . . . 0.0 112.696 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.0 mttm -79.91 156.87 27.09 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-N 118.562 1.181 . . . . 0.0 109.215 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -101.51 138.57 38.34 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.182 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 3.7 m -78.05 138.77 19.68 Favored 'Isoleucine or valine' 0 C--O 1.24 0.605 0 N-CA-C 109.082 -0.711 . . . . 0.0 109.082 178.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 82.6 mt -84.85 -16.77 40.17 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.587 1.555 . . . . 0.0 111.636 179.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 15.3 m -149.69 163.5 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.175 0 C-N-CA 126.342 1.857 . . . . 0.0 108.648 -178.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 16.7 m -72.45 125.94 28.64 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 177.693 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 87.6 t -105.03 131.12 54.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 106.026 -1.842 . . . . 0.0 106.026 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -76.25 170.43 16.34 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-O 122.413 1.102 . . . . 0.0 112.759 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 -65.67 136.91 56.91 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 63.14 7.98 3.06 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 126.035 1.734 . . . . 0.0 112.803 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -72.45 157.28 37.93 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 119.428 1.013 . . . . 0.0 111.286 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 12.1 m -79.75 119.34 22.53 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 123.944 0.898 . . . . 0.0 111.27 -178.802 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.6 mm -76.13 139.82 18.29 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 178.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 26.8 mtp -138.88 160.49 39.6 Favored 'General case' 0 C--O 1.231 0.094 0 C-N-CA 123.655 0.782 . . . . 0.0 109.474 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -60.77 -40.77 93.77 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 123.304 0.641 . . . . 0.0 109.456 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -65.66 4.33 0.6 Allowed 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 126.215 1.806 . . . . 0.0 114.551 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 34.9 mt -118.28 0.01 11.61 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 125.113 1.365 . . . . 0.0 109.694 179.065 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.5 m -131.23 162.58 39.01 Favored 'Isoleucine or valine' 0 C--N 1.343 0.285 0 C-N-CA 124.321 1.048 . . . . 0.0 111.148 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 36.4 t0 -77.82 99.69 6.02 Favored 'General case' 0 C--O 1.239 0.526 0 C-N-CA 124.975 1.31 . . . . 0.0 112.056 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 179.73 135.55 0.1 Allowed 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 126.731 2.012 . . . . 0.0 108.002 178.138 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 27.6 m-70 -138.24 106.6 5.8 Favored 'General case' 0 CA--C 1.519 -0.213 0 N-CA-C 105.406 -2.072 . . . . 0.0 105.406 178.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -111.29 -115.75 3.56 Favored Glycine 0 N--CA 1.45 -0.408 0 O-C-N 123.184 0.303 . . . . 0.0 113.155 -178.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 54.7 tptt -101.59 100.82 11.28 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 106.006 -1.85 . . . . 0.0 106.006 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 36.1 tttp -145.26 171.64 14.28 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.325 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 25.8 pt -132.87 168.91 23.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.348 0 C-N-CA 124.989 1.315 . . . . 0.0 109.796 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 2.4 mmmp? -71.55 146.51 48.42 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 178.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 46.11 45.32 12.5 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 125.112 1.365 . . . . 0.0 111.627 -179.395 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.1 t -62.85 123.09 17.57 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 178.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 170.41 154.86 9.79 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 119.019 -0.878 . . . . 0.0 111.542 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -68.72 -39.78 8.25 Favored 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 123.51 2.807 . . . . 0.0 111.389 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 6.7 t -156.89 157.87 35.65 Favored 'General case' 0 N--CA 1.442 -0.851 0 C-N-CA 127.42 2.288 . . . . 0.0 105.564 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 1.7 t -159.89 -178.36 6.98 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 126.041 1.737 . . . . 0.0 106.855 179.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.675 0 N-CA-C 107.983 -2.047 . . . . 0.0 107.983 -178.924 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.431 0 N-CA-C 112.471 -0.251 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 6.0 t -155.2 152.25 29.13 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 179.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -163.75 168.2 20.0 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-O 121.827 0.822 . . . . 0.0 112.922 -179.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.72 -168.43 12.57 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 106.53 -2.628 . . . . 0.0 106.53 178.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.5 m -147.16 149.03 32.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 118.276 1.038 . . . . 0.0 108.846 178.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 69.7 m -125.25 118.49 26.12 Favored 'General case' 0 CA--C 1.516 -0.353 0 N-CA-C 105.828 -1.915 . . . . 0.0 105.828 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.06 -174.45 36.94 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 45.4 p -142.57 159.02 43.05 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 123.472 0.709 . . . . 0.0 109.794 -178.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 78.2 t -84.11 124.55 39.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 178.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.9 m -123.07 148.71 26.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.535 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.5 111.73 4.28 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 125.686 1.595 . . . . 0.0 107.997 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 81.1 tttt -64.95 -24.8 67.63 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 123.434 0.694 . . . . 0.0 112.714 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.6 m -148.92 165.79 3.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 127.116 2.167 . . . . 0.0 106.944 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -64.69 130.58 44.11 Favored 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 178.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 32.2 mt -118.78 101.27 50.59 Favored Pre-proline 0 CA--C 1.533 0.311 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.442 ' HA ' HG23 ' A' ' 52' ' ' THR . 36.6 Cg_endo -67.35 153.15 77.81 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 121.944 1.763 . . . . 0.0 112.346 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.4 ' HA ' HG23 ' A' ' 49' ' ' VAL . 9.6 tm-20 -58.17 146.03 35.02 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 122.289 1.042 . . . . 0.0 108.617 178.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.95 19.99 56.52 Favored Glycine 0 CA--C 1.53 0.995 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.953 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.1 m -117.44 156.25 28.27 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 125.976 1.71 . . . . 0.0 107.734 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 34.1 mm -101.5 143.25 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 C-N-CA 123.867 0.867 . . . . 0.0 108.716 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 23.0 mt -76.03 135.88 39.94 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 67.1 p -130.57 158.15 40.76 Favored 'General case' 0 C--O 1.238 0.477 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 13.4 mmt -63.22 -20.51 65.5 Favored 'General case' 0 CA--C 1.536 0.408 0 O-C-N 121.926 -0.484 . . . . 0.0 109.713 178.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -79.99 -18.41 50.36 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 126.27 1.828 . . . . 0.0 114.185 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 69.8 mtm -112.46 16.15 19.95 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 119.162 0.892 . . . . 0.0 111.697 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.1 mt -133.64 147.92 51.49 Favored 'General case' 0 C--O 1.238 0.456 0 C-N-CA 124.019 0.927 . . . . 0.0 110.666 -179.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.9 t -147.7 144.62 28.45 Favored 'General case' 0 CA--C 1.54 0.572 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 56.8 t -89.06 117.52 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 31.7 ttpt -59.84 -29.63 68.4 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 115.01 1.485 . . . . 0.0 115.01 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.6 t 47.65 66.42 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 CA-C-O 122.665 1.221 . . . . 0.0 109.278 -179.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.97 -66.24 0.01 OUTLIER Glycine 0 CA--C 1.521 0.435 0 C-N-CA 124.647 1.118 . . . . 0.0 111.042 -179.482 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -133.9 152.8 79.28 Favored Pre-proline 0 CA--C 1.529 0.158 0 C-N-CA 123.583 0.753 . . . . 0.0 111.598 -178.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.18 5.4 4.59 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 123.686 2.924 . . . . 0.0 113.131 179.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -72.26 115.12 11.13 Favored 'General case' 0 CA--C 1.518 -0.251 0 O-C-N 119.946 -1.721 . . . . 0.0 106.413 178.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.36 171.71 15.73 Favored Glycine 0 N--CA 1.45 -0.42 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -54.94 135.71 66.59 Favored Pre-proline 0 CA--C 1.541 0.61 0 CA-C-O 118.993 -0.527 . . . . 0.0 110.716 -179.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -67.94 150.73 78.26 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.806 2.337 . . . . 0.0 113.557 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -79.41 -4.34 13.6 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 123.437 2.758 . . . . 0.0 114.93 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 24.2 tp10 -82.43 -46.14 13.89 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 119.918 1.235 . . . . 0.0 108.124 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -79.71 7.38 8.62 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 125.86 1.664 . . . . 0.0 111.63 -179.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.7 tt -46.82 -43.13 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 C-N-CA 126.19 1.796 . . . . 0.0 112.909 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -58.91 -27.95 65.74 Favored 'General case' 0 C--O 1.227 -0.126 0 C-N-CA 123.1 0.56 . . . . 0.0 111.657 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -73.35 -36.82 66.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 49.2 mt -66.65 -38.96 87.94 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 119.123 0.874 . . . . 0.0 109.705 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 73.5 t -61.63 131.45 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.325 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.09 -11.09 69.69 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 118.792 -1.004 . . . . 0.0 111.699 -178.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 26.5 mttm -84.05 154.36 23.28 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-N 119.556 1.678 . . . . 0.0 110.615 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 39.4 ttmt -95.04 131.08 41.41 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 178.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.4 HG23 ' HA ' ' A' ' 17' ' ' GLU . 4.4 m -66.76 168.66 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 176.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 46.3 mt -114.28 -7.08 12.97 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 123.913 0.885 . . . . 0.0 112.44 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 2.8 m -156.83 162.31 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 C-N-CA 126.952 2.101 . . . . 0.0 108.418 -178.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.442 HG23 ' HA ' ' A' ' 16' ' ' PRO . 31.9 m -72.94 109.66 6.66 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.003 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 57.4 t -85.96 131.04 35.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 179.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -78.05 167.49 21.37 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 123.652 0.781 . . . . 0.0 109.721 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -69.92 149.86 47.35 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 177.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 60.94 10.01 2.58 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 127.948 2.499 . . . . 0.0 111.59 -179.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -75.73 153.33 37.11 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 178.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 99.2 m -88.47 121.88 31.34 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.179 0.514 . . . . 0.0 110.932 -178.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 mm -74.18 138.51 21.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 178.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -131.37 157.92 42.13 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 124.368 1.067 . . . . 0.0 108.595 179.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -59.35 -27.8 66.26 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 124.715 1.206 . . . . 0.0 111.669 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -89.26 -4.15 58.27 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 119.173 0.897 . . . . 0.0 113.095 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 57.4 mt -96.57 15.8 20.61 Favored 'General case' 0 N--CA 1.466 0.331 0 C-N-CA 124.352 1.061 . . . . 0.0 109.4 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.1 m -139.22 140.84 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -75.46 66.82 1.92 Allowed 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 125.598 1.559 . . . . 0.0 110.387 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -147.64 141.36 25.65 Favored 'General case' 0 CA--C 1.516 -0.338 0 C-N-CA 125.215 1.406 . . . . 0.0 108.372 -179.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . 0.263 5.5 m-70 64.43 -67.28 0.11 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 126.518 1.927 . . . . 0.0 109.057 -178.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -76.55 168.55 54.8 Favored Glycine 0 CA--C 1.538 1.506 0 N-CA-C 106.455 -2.658 . . . . 0.0 106.455 176.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 154.68 -4.48 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 130.186 3.394 . . . . 0.0 112.07 -179.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -79.8 106.45 11.84 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 120.665 -1.272 . . . . 0.0 107.696 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 23.4 pt -73.56 5.21 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 CA-C-N 118.295 0.498 . . . . 0.0 111.859 179.201 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -87.75 97.31 10.83 Favored 'General case' 0 N--CA 1.449 -0.483 0 O-C-N 120.724 -1.235 . . . . 0.0 108.498 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 2.2 p -62.4 92.87 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 126.655 1.982 . . . . 0.0 108.396 178.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 7.2 t -162.08 132.75 4.95 Favored 'General case' 0 C--O 1.236 0.394 0 O-C-N 120.709 -1.245 . . . . 0.0 110.749 -179.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -73.35 137.47 23.77 Favored Glycine 0 CA--C 1.534 1.224 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 179.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -73.0 168.05 25.76 Favored 'Trans proline' 0 N--CA 1.462 -0.38 0 C-N-CA 123.325 2.683 . . . . 0.0 111.784 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 50.3 m -64.95 109.19 2.02 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 177.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 12.7 m -154.62 80.34 1.09 Allowed 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 -178.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.967 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.615 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.755 0 N-CA-C 107.794 -2.122 . . . . 0.0 107.794 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.1 t -132.04 -9.32 3.43 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.495 1.518 . . . . 0.0 109.333 177.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.5 m -74.78 160.74 30.33 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 124.545 1.138 . . . . 0.0 109.671 178.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.75 161.27 28.52 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 108.041 -2.024 . . . . 0.0 108.041 179.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.1 p -140.79 24.92 2.18 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 125.292 1.437 . . . . 0.0 111.709 -178.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.1 m -54.74 127.26 27.51 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 124.173 0.989 . . . . 0.0 110.214 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.66 -171.75 24.26 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 126.917 2.199 . . . . 0.0 109.869 -178.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -146.91 162.0 39.58 Favored 'General case' 0 C--O 1.239 0.513 0 C-N-CA 126.081 1.753 . . . . 0.0 110.963 179.046 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.2 t -70.0 140.47 18.54 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 C-N-CA 126.188 1.795 . . . . 0.0 112.282 -178.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.7 m -139.59 159.53 27.8 Favored 'Isoleucine or valine' 0 C--O 1.24 0.584 0 C-N-CA 126.601 1.961 . . . . 0.0 107.078 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -81.25 138.28 35.78 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.096 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -81.6 -22.33 37.78 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 123.447 0.699 . . . . 0.0 111.567 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.8 m -145.76 170.38 5.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 C-N-CA 124.842 1.257 . . . . 0.0 108.254 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.6 tttm -72.41 104.05 3.65 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 105.549 -2.019 . . . . 0.0 105.549 177.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 7.3 mt -88.32 109.04 25.54 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-O 118.122 -0.942 . . . . 0.0 109.063 -178.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -69.67 149.39 67.4 Favored 'Trans proline' 0 N--CA 1.454 -0.798 0 CA-C-N 120.981 1.386 . . . . 0.0 109.983 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.422 ' HA ' HG23 ' A' ' 49' ' ' VAL . 27.9 tt0 -51.14 143.88 10.11 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.454 1.102 . . . . 0.0 110.565 179.434 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.38 2.0 90.27 Favored Glycine 0 C--N 1.338 0.641 0 CA-C-O 118.979 -0.901 . . . . 0.0 114.53 179.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 65.4 m -91.03 142.63 27.57 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 118.741 1.271 . . . . 0.0 109.708 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 5.0 mm -78.7 135.45 25.87 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 178.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 50.4 mt -74.29 141.85 45.26 Favored 'General case' 0 C--O 1.237 0.446 0 C-N-CA 124.774 1.23 . . . . 0.0 109.352 178.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 41.7 p -141.36 165.51 27.31 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 106.951 -1.499 . . . . 0.0 106.951 178.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -65.02 -22.2 66.96 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-N 118.116 0.416 . . . . 0.0 110.459 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -67.93 -30.5 69.82 Favored 'General case' 0 N--CA 1.464 0.263 0 C-N-CA 124.48 1.112 . . . . 0.0 111.495 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 71.1 mtm -105.92 10.52 32.37 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 124.491 1.117 . . . . 0.0 112.67 -177.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.0 mt -131.93 162.51 30.48 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 123.958 0.903 . . . . 0.0 109.013 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.5 t -169.84 174.86 5.45 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 179.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 57.4 t -114.99 156.75 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.568 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 177.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 23.8 ttpp -126.98 111.68 14.37 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 103.423 -2.806 . . . . 0.0 103.423 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 35.7 m -62.63 158.88 3.1 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 120.238 -0.585 . . . . 0.0 110.209 -179.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 130.76 -96.69 0.35 Allowed Glycine 0 C--N 1.333 0.371 0 CA-C-O 119.078 -0.846 . . . . 0.0 112.277 179.168 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -115.76 157.28 44.97 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 125.559 1.544 . . . . 0.0 113.486 -177.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -77.32 15.19 1.24 Allowed 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 124.562 3.508 . . . . 0.0 113.366 179.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 25.6 tptp -55.68 113.55 1.51 Allowed 'General case' 0 N--CA 1.465 0.311 0 O-C-N 120.699 -1.251 . . . . 0.0 108.5 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.33 -170.47 21.43 Favored Glycine 0 N--CA 1.451 -0.348 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.4 t80 -58.02 130.32 82.98 Favored Pre-proline 0 CA--C 1.544 0.719 0 CA-C-O 118.505 -0.76 . . . . 0.0 110.257 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -66.05 153.12 79.39 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.897 2.398 . . . . 0.0 111.797 -178.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_endo -77.23 -22.96 10.7 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 121.606 1.537 . . . . 0.0 113.893 -178.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -63.12 -40.92 99.01 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 119.83 1.195 . . . . 0.0 109.933 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -82.96 4.34 26.26 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-O 117.906 -1.045 . . . . 0.0 113.313 -178.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.6 tt -48.25 -35.03 5.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 CA-C-N 120.719 1.6 . . . . 0.0 113.763 -178.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -58.82 -28.49 66.07 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.508 0.723 . . . . 0.0 111.701 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 30.0 m-80 -71.53 -41.99 68.5 Favored 'General case' 0 CA--C 1.521 -0.161 0 C-N-CA 124.001 0.921 . . . . 0.0 109.234 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 38.1 mt -65.0 -42.17 94.73 Favored 'General case' 0 CA--C 1.519 -0.216 0 C-N-CA 123.054 0.541 . . . . 0.0 110.171 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.78 98.7 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 C-N-CA 124.345 1.058 . . . . 0.0 108.786 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.99 -14.19 6.65 Favored Glycine 0 CA--C 1.526 0.739 0 C-N-CA 126.321 1.915 . . . . 0.0 114.178 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -79.62 167.79 20.24 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 118.861 1.331 . . . . 0.0 110.426 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.05 137.82 42.22 Favored 'General case' 0 CA--C 1.512 -0.516 0 CA-C-O 118.075 -0.964 . . . . 0.0 109.599 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.422 HG23 ' HA ' ' A' ' 17' ' ' GLU . 3.3 m -77.02 138.14 21.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 78.3 mt -85.33 -15.88 41.84 Favored 'General case' 0 N--CA 1.462 0.148 0 C-N-CA 123.452 0.701 . . . . 0.0 112.182 179.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.2 m -148.04 164.47 5.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 30.7 m -69.66 140.86 53.68 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.077 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 84.9 t -115.14 152.8 16.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -110.71 166.69 10.81 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 123.966 0.907 . . . . 0.0 111.194 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -63.26 128.57 36.43 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 30.6 t70 68.73 8.21 6.61 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 128.09 2.556 . . . . 0.0 112.908 -179.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -67.25 162.6 22.28 Favored 'General case' 0 CA--C 1.533 0.298 0 O-C-N 121.005 -1.059 . . . . 0.0 108.438 179.26 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 77.7 m -95.08 123.0 38.32 Favored 'General case' 0 N--CA 1.468 0.435 0 O-C-N 120.131 -1.606 . . . . 0.0 113.181 -178.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 13.3 mm -74.38 146.41 9.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 3.3 mmt -140.26 158.56 43.85 Favored 'General case' 0 C--O 1.233 0.214 0 C-N-CA 126.404 1.882 . . . . 0.0 107.299 179.235 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.34 -32.32 73.71 Favored 'General case' 0 CA--C 1.528 0.123 0 O-C-N 122.141 -0.349 . . . . 0.0 111.762 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -72.07 -5.27 34.07 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -179.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 56.7 mt -103.77 9.57 36.99 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 124.24 1.016 . . . . 0.0 111.05 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.5 m -131.93 155.28 41.45 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 CA-C-N 119.758 1.163 . . . . 0.0 112.3 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -62.15 167.67 3.84 Favored 'General case' 0 C--O 1.234 0.285 0 C-N-CA 125.608 1.563 . . . . 0.0 113.85 -179.547 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -85.8 84.13 7.65 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 106.633 -1.618 . . . . 0.0 106.633 178.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -63.33 -9.57 12.56 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 125.973 1.709 . . . . 0.0 112.598 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -146.58 -167.33 12.8 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 126.203 1.859 . . . . 0.0 109.926 179.235 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 48.7 tttp -89.39 111.11 21.89 Favored 'General case' 0 N--CA 1.443 -0.795 0 C-N-CA 127.557 2.343 . . . . 0.0 107.993 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 7.8 ptmm? -133.07 -177.86 4.7 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 36.9 mm -117.37 169.78 7.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 105.6 -2.0 . . . . 0.0 105.6 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 35.2 pttt -60.86 108.89 0.92 Allowed 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.842 1.257 . . . . 0.0 108.045 178.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.1 t -154.89 147.34 24.07 Favored 'General case' 0 C--O 1.233 0.187 0 C-N-CA 124.036 0.934 . . . . 0.0 109.645 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.5 p -90.43 -2.65 57.95 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 126.28 1.832 . . . . 0.0 113.031 179.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 45.34 61.7 3.5 Favored Glycine 0 CA--C 1.536 1.368 0 CA-C-O 118.302 -1.277 . . . . 0.0 110.544 -179.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -57.49 -36.02 98.77 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 123.209 2.606 . . . . 0.0 114.734 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 9.7 p -153.51 -172.55 4.27 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-N 119.272 0.942 . . . . 0.0 109.456 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -155.04 134.28 12.43 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.254 1.394 0 CA-C-O 118.074 -1.403 . . . . 0.0 110.407 -179.706 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.725 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 34.7 t -131.41 -67.12 0.71 Allowed 'General case' 0 CA--C 1.53 0.199 0 N-CA-C 105.423 -2.066 . . . . 0.0 105.423 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.2 p -90.65 93.41 9.25 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 178.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 130.56 134.52 3.68 Favored Glycine 0 N--CA 1.453 -0.216 0 N-CA-C 107.318 -2.313 . . . . 0.0 107.318 -179.023 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.7 p -153.97 79.44 1.13 Allowed 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 -179.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.1 t -81.51 103.19 11.07 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 102.146 -3.279 . . . . 0.0 102.146 178.077 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -161.75 177.62 37.93 Favored Glycine 0 C--N 1.333 0.366 0 O-C-N 121.284 -0.885 . . . . 0.0 113.234 -178.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.411 ' HB3' ' O ' ' A' ' 34' ' ' LYS . 0.2 OUTLIER -122.52 134.32 54.56 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 127.245 2.218 . . . . 0.0 111.997 -177.877 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 61.2 t -67.73 129.44 32.29 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 28.2 m -132.88 151.42 34.31 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.23 128.4 36.11 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.474 ' HE3' ' HB ' ' A' ' 27' ' ' THR . 6.7 ttmt -72.75 -28.15 62.46 Favored 'General case' 0 C--N 1.327 -0.377 0 O-C-N 121.399 -0.813 . . . . 0.0 111.695 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.71 169.88 18.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 C-N-CA 125.762 1.625 . . . . 0.0 107.093 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 58.7 tttt -71.88 114.91 10.48 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 49.8 mt -100.2 106.77 43.88 Favored Pre-proline 0 CA--C 1.534 0.339 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.483 ' HA ' HG23 ' A' ' 52' ' ' THR . 42.8 Cg_endo -66.55 148.7 83.96 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 121.569 1.513 . . . . 0.0 110.72 179.297 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.45 ' HA ' HG23 ' A' ' 49' ' ' VAL . 52.0 tt0 -48.54 142.29 6.06 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 126.168 1.787 . . . . 0.0 110.38 179.476 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.36 0.46 86.76 Favored Glycine 0 CA--C 1.529 0.929 0 CA-C-O 118.012 -1.438 . . . . 0.0 113.768 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.1 m -91.3 154.88 18.93 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 120.355 2.078 . . . . 0.0 107.857 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.8 mm -89.29 145.91 6.82 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-N 119.509 1.05 . . . . 0.0 109.097 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 15.2 mt -80.36 137.7 36.59 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.245 0.618 . . . . 0.0 109.811 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 29.0 p -131.22 154.95 47.89 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 125.952 1.701 . . . . 0.0 107.342 179.261 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 12.4 mmt -60.82 -35.46 76.58 Favored 'General case' 0 CA--C 1.538 0.484 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -61.2 -19.16 61.29 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 127.987 2.515 . . . . 0.0 113.051 178.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.6 mtm -115.66 16.31 16.45 Favored 'General case' 0 N--CA 1.466 0.355 0 O-C-N 121.195 -0.941 . . . . 0.0 110.979 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 70.7 mt -129.26 170.5 13.53 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 121.998 0.904 . . . . 0.0 113.263 -179.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.474 ' HB ' ' HE3' ' A' ' 12' ' ' LYS . 4.3 t -171.88 173.26 4.54 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 128.343 2.657 . . . . 0.0 107.221 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -129.88 110.56 19.83 Favored 'Isoleucine or valine' 0 C--O 1.24 0.568 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 178.571 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 20.6 ttpt -69.8 112.6 6.36 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 125.192 1.397 . . . . 0.0 107.498 179.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.8 p -66.93 130.96 32.76 Favored 'Isoleucine or valine' 0 C--O 1.239 0.513 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 178.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.64 -89.27 0.1 OUTLIER Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 -179.139 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -134.5 158.5 75.01 Favored Pre-proline 0 CA--C 1.539 0.553 0 CA-C-O 118.532 -0.747 . . . . 0.0 110.698 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -73.3 31.65 0.31 Allowed 'Trans proline' 0 CA--C 1.544 0.981 1 C-N-CA 126.149 4.566 . . . . 0.0 116.093 -179.152 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.411 ' O ' ' HB3' ' A' ' 8' ' ' SER . 39.9 ttmt -60.6 139.04 57.96 Favored 'General case' 0 C--O 1.225 -0.225 0 O-C-N 120.676 -1.265 . . . . 0.0 110.968 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.41 -72.67 0.78 Allowed Glycine 0 CA--C 1.524 0.62 0 CA-C-O 118.526 -1.152 . . . . 0.0 115.754 178.497 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.415 ' CG ' HD11 ' A' ' 44' ' ' LEU . 1.7 t80 -151.09 147.77 21.31 Favored Pre-proline 0 CA--C 1.544 0.737 0 CA-C-N 119.596 1.698 . . . . 0.0 114.82 -176.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -83.99 163.4 13.67 Favored 'Trans proline' 0 C--N 1.354 0.868 0 C-N-CA 124.203 3.269 . . . . 0.0 114.347 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -79.61 -10.36 14.5 Favored 'Trans proline' 0 C--N 1.349 0.605 0 C-N-CA 122.482 2.121 . . . . 0.0 111.873 179.268 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -76.73 -19.85 57.2 Favored 'General case' 0 CA--C 1.535 0.39 0 O-C-N 121.248 -0.907 . . . . 0.0 110.922 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -117.47 8.78 13.07 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 124.04 0.936 . . . . 0.0 112.69 -178.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.6 tt -51.45 -35.5 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 124.041 0.936 . . . . 0.0 111.569 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -61.83 -28.17 69.29 Favored 'General case' 0 N--CA 1.461 0.123 0 C-N-CA 125.245 1.418 . . . . 0.0 111.74 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 37.7 m-80 -78.37 -30.26 47.86 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-O 118.977 -0.535 . . . . 0.0 109.622 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.415 HD11 ' CG ' ' A' ' 36' ' ' TYR . 53.4 mt -76.03 -37.47 58.33 Favored 'General case' 0 C--N 1.339 0.12 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.559 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.1 t -63.54 121.28 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 N-CA-C 104.617 -2.364 . . . . 0.0 104.617 178.241 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 107.45 -9.72 38.59 Favored Glycine 0 CA--C 1.534 1.266 0 CA-C-O 118.846 -0.975 . . . . 0.0 111.404 -178.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 72.2 mttt -85.18 169.16 14.12 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-N 119.721 1.761 . . . . 0.0 107.751 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.1 ttmp? -116.01 130.07 56.65 Favored 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 125.813 1.645 . . . . 0.0 108.027 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.45 HG23 ' HA ' ' A' ' 17' ' ' GLU . 3.9 m -73.2 144.02 13.21 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 55.7 mt -90.59 -13.88 33.58 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 124.198 0.999 . . . . 0.0 112.093 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 31.6 m -147.99 162.88 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 125.89 1.676 . . . . 0.0 107.208 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.483 HG23 ' HA ' ' A' ' 16' ' ' PRO . 51.5 m -72.85 133.83 44.6 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 96.9 t -112.61 124.48 69.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 125.808 1.643 . . . . 0.0 107.519 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -78.65 171.85 14.54 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.49 0.662 . . . . 0.0 111.866 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 49.1 tt0 -63.25 143.68 57.59 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 105.389 -2.078 . . . . 0.0 105.389 177.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 25.8 t0 61.36 8.23 2.06 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.334 2.254 . . . . 0.0 112.883 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -78.82 150.52 32.28 Favored 'General case' 0 C--N 1.344 0.365 0 O-C-N 120.905 -1.122 . . . . 0.0 110.287 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.5 118.02 17.92 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 125.124 1.369 . . . . 0.0 113.961 -176.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 mm -75.87 146.32 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 104.564 -2.384 . . . . 0.0 104.564 177.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 10.0 mtt -141.92 157.19 45.26 Favored 'General case' 0 CA--C 1.518 -0.272 0 C-N-CA 123.956 0.903 . . . . 0.0 109.207 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -67.63 -14.74 63.2 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 122.473 0.309 . . . . 0.0 111.267 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 20.5 tt0 -84.52 -33.02 23.61 Favored 'General case' 0 CA--C 1.535 0.4 0 O-C-N 121.127 -0.983 . . . . 0.0 110.89 179.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 43.5 mt -81.33 6.27 14.83 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.722 1.609 . . . . 0.0 113.826 -178.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.6 m -126.66 154.26 36.28 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 CA-C-N 119.267 0.94 . . . . 0.0 110.997 -179.224 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -74.38 -179.1 3.78 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 125.351 1.46 . . . . 0.0 109.618 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -73.63 144.99 45.69 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 120.982 -1.074 . . . . 0.0 110.52 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 17.6 t-80 -63.63 94.34 0.09 Allowed 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 178.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.98 155.72 11.05 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 125.176 1.37 . . . . 0.0 110.718 -178.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 80.6 tttt -132.24 122.92 25.96 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 125.867 1.667 . . . . 0.0 106.607 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.94 143.49 17.01 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 118.164 0.438 . . . . 0.0 110.807 -179.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 29.1 pt -79.23 158.12 4.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 106.63 -1.618 . . . . 0.0 106.63 177.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 5.1 ptpt -105.42 152.66 22.71 Favored 'General case' 0 C--O 1.234 0.248 0 C-N-CA 123.613 0.765 . . . . 0.0 109.326 179.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.8 m -95.78 164.37 12.78 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 123.299 0.64 . . . . 0.0 109.879 179.546 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 5.7 t -170.23 -170.7 1.0 Allowed 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 127.338 2.255 . . . . 0.0 105.909 179.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -123.31 163.59 16.72 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -76.91 1.79 8.24 Favored 'Trans proline' 0 CA--C 1.54 0.805 0 C-N-CA 123.64 2.893 . . . . 0.0 112.775 179.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 9.0 t -146.57 156.16 43.03 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 105.839 -1.911 . . . . 0.0 105.839 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 57.4 m -158.32 177.66 11.02 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 126.055 1.742 . . . . 0.0 107.528 179.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.257 1.552 0 C-N-CA 128.211 2.815 . . . . 0.0 106.527 179.797 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.51 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.0 m -142.23 -168.4 2.71 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 124.433 1.093 . . . . 0.0 108.844 -179.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.2 t -138.96 157.78 45.39 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.454 1.102 . . . . 0.0 108.191 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 70.77 48.08 36.65 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 108.886 -1.686 . . . . 0.0 108.886 -179.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.4 p -60.58 157.73 13.8 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.421 1.488 . . . . 0.0 112.438 -179.312 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 43.9 t -102.83 -105.42 0.27 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 124.856 1.262 . . . . 0.0 108.292 179.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -175.94 -165.06 31.24 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 107.262 -2.335 . . . . 0.0 107.262 -179.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.1 t -141.94 174.03 10.97 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 118.377 1.089 . . . . 0.0 112.506 -178.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.438 HG11 ' CD1' ' A' ' 44' ' ' LEU . 68.3 t -78.33 119.78 27.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 C-N-CA 127.664 2.386 . . . . 0.0 108.578 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.6 m -128.96 147.5 33.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.17 115.43 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 124.356 1.062 . . . . 0.0 108.267 179.335 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 41.0 tttm -64.68 -30.55 71.56 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.7 m -147.74 168.67 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 128.413 2.685 . . . . 0.0 105.804 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 65.9 tttt -63.64 130.47 44.42 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 9.4 mt -114.63 101.14 54.18 Favored Pre-proline 0 N--CA 1.454 -0.26 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -70.56 148.3 59.6 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 122.381 2.054 . . . . 0.0 109.235 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 -51.9 146.25 8.65 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.678 1.191 . . . . 0.0 113.228 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 79.74 -2.87 71.78 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 125.059 1.314 . . . . 0.0 113.525 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.4 m -82.19 151.68 26.78 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 119.0 1.4 . . . . 0.0 109.637 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 17.4 mm -91.31 128.5 43.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 178.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 63.3 mt -67.56 146.91 53.44 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.084 1.354 . . . . 0.0 108.964 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 64.9 p -141.27 160.29 40.43 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.9 mmt -64.27 -26.86 68.68 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 178.043 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -63.69 -16.0 59.91 Favored 'General case' 0 CA--C 1.536 0.426 0 O-C-N 121.494 -0.754 . . . . 0.0 112.48 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 38.0 mtm -120.09 4.99 10.84 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 124.878 1.271 . . . . 0.0 112.375 -179.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 92.1 mt -124.94 118.82 27.12 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 120.006 1.275 . . . . 0.0 109.163 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 t -123.82 171.77 9.4 Favored 'General case' 0 C--O 1.238 0.484 0 C-N-CA 124.921 1.288 . . . . 0.0 109.369 179.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 17.9 t -119.81 151.4 22.36 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 39.1 mmtm -109.83 -172.22 2.0 Allowed 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 124.995 1.318 . . . . 0.0 109.795 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 23.2 m -131.57 16.77 1.82 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 C-N-CA 124.979 1.312 . . . . 0.0 111.565 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -78.64 -92.42 0.32 Allowed Glycine 0 C--N 1.334 0.451 0 C-N-CA 124.107 0.86 . . . . 0.0 113.255 -179.034 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -133.54 157.59 77.63 Favored Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 126.279 1.831 . . . . 0.0 109.004 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -73.05 -1.99 11.35 Favored 'Trans proline' 0 CA--C 1.535 0.55 0 C-N-CA 123.873 3.048 . . . . 0.0 114.233 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.4 ttpt -52.49 127.78 23.67 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.97 -170.74 13.44 Favored Glycine 0 N--CA 1.45 -0.425 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 -178.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -64.61 128.45 93.49 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -64.3 134.85 43.9 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.247 1.965 . . . . 0.0 111.337 -179.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -68.55 -17.65 43.28 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 121.631 1.554 . . . . 0.0 113.482 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -64.39 -25.62 68.1 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 120.311 1.414 . . . . 0.0 110.241 179.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -109.04 12.51 25.17 Favored 'General case' 0 N--CA 1.464 0.237 0 O-C-N 121.15 -0.969 . . . . 0.0 112.121 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.5 tt -48.6 -35.48 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 124.847 1.259 . . . . 0.0 111.895 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 40.0 m-85 -51.81 -30.17 22.22 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 126.111 1.764 . . . . 0.0 112.144 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 67.4 m-80 -81.96 -21.39 37.23 Favored 'General case' 0 CA--C 1.519 -0.214 0 C-N-CA 124.327 1.051 . . . . 0.0 113.093 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.438 ' CD1' HG11 ' A' ' 9' ' ' VAL . 96.2 mt -78.05 -35.53 49.51 Favored 'General case' 0 CA--C 1.521 -0.145 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.7 t -60.85 125.49 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.41 -11.5 68.71 Favored Glycine 0 CA--C 1.529 0.949 0 CA-C-O 117.842 -1.532 . . . . 0.0 113.369 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 43.1 mtmt -83.42 164.24 20.05 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 120.814 2.307 . . . . 0.0 109.558 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.7 ttmp? -102.54 145.52 29.48 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.8 m -85.36 140.23 16.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 O-C-N 123.346 0.404 . . . . 0.0 110.397 179.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 16.9 mt -86.89 -18.07 31.75 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-O 117.718 -1.134 . . . . 0.0 111.527 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 17.7 m -150.02 165.36 3.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 C-N-CA 123.958 0.903 . . . . 0.0 109.052 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.0 m -74.76 143.2 44.18 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 105.609 -1.997 . . . . 0.0 105.609 178.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 75.1 t -129.08 123.26 58.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 C-N-CA 125.8 1.64 . . . . 0.0 106.664 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -72.54 160.98 31.39 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 122.626 1.203 . . . . 0.0 108.867 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -65.76 134.32 52.9 Favored 'General case' 0 C--O 1.24 0.581 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.391 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.2 t70 82.87 1.2 1.17 Allowed 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 128.886 2.874 . . . . 0.0 113.901 179.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -71.76 156.97 38.74 Favored 'General case' 0 C--N 1.341 0.226 0 CA-C-N 118.228 0.467 . . . . 0.0 110.631 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.3 m -80.67 116.9 20.92 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 125.965 1.706 . . . . 0.0 109.775 179.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 16.0 mm -73.95 143.53 13.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 N-CA-C 107.243 -1.391 . . . . 0.0 107.243 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -135.47 153.75 51.65 Favored 'General case' 0 CA--C 1.521 -0.147 0 C-N-CA 125.574 1.55 . . . . 0.0 107.411 179.177 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -60.72 -29.34 69.3 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -179.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 22.2 tp10 -67.65 -22.7 65.3 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 122.714 0.406 . . . . 0.0 111.252 -179.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 17.4 mt -86.52 4.06 41.53 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 124.759 1.224 . . . . 0.0 112.276 -178.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.4 m -131.4 117.25 35.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 120.182 1.355 . . . . 0.0 112.292 -178.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -72.89 118.55 15.98 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 125.651 1.58 . . . . 0.0 108.263 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 173.18 114.94 0.02 OUTLIER 'General case' 0 C--O 1.233 0.226 0 C-N-CA 126.054 1.742 . . . . 0.0 110.108 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 72.7 m-70 -79.42 61.44 3.47 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 46.5 -139.61 7.07 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 126.227 1.87 . . . . 0.0 110.58 -179.169 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 25.4 ttpp -101.85 142.7 32.76 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 178.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 60.5 tttp -155.64 124.59 6.11 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 106.345 -1.724 . . . . 0.0 106.345 178.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 62.7 mt -60.5 153.98 4.47 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 20.8 mmtp -111.82 -39.83 4.45 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 125.21 1.404 . . . . 0.0 109.529 179.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.3 t -75.47 -168.36 0.81 Allowed 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.151 1.381 . . . . 0.0 110.032 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -144.51 170.25 16.41 Favored 'General case' 0 C--O 1.237 0.42 0 C-N-CA 127.296 2.238 . . . . 0.0 108.432 179.325 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 130.65 -72.9 0.47 Allowed Glycine 0 CA--C 1.525 0.7 0 CA-C-O 117.919 -1.489 . . . . 0.0 111.839 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -74.68 158.71 43.19 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 122.028 1.818 . . . . 0.0 112.734 -179.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 6.5 m -63.34 157.7 22.34 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 125.451 1.5 . . . . 0.0 110.005 178.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 5.7 m -51.55 -37.78 51.22 Favored 'General case' 0 C--O 1.228 -0.067 0 C-N-CA 125.101 1.36 . . . . 0.0 113.156 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.983 0 N-CA-C 104.378 -3.489 . . . . 0.0 104.378 -179.863 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.98 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.9 m -75.16 122.81 24.18 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.9 t -74.48 69.39 1.67 Allowed 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 119.535 1.061 . . . . 0.0 110.091 -179.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.0 160.27 31.44 Favored Glycine 0 N--CA 1.45 -0.372 0 O-C-N 120.789 -1.195 . . . . 0.0 114.053 -179.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -161.46 -68.11 0.06 Allowed 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 129.124 2.969 . . . . 0.0 105.984 178.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.9 m -75.99 97.32 3.98 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 124.714 1.206 . . . . 0.0 108.303 178.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 178.85 -168.79 39.92 Favored Glycine 0 CA--C 1.523 0.548 0 O-C-N 120.238 -1.539 . . . . 0.0 111.44 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 48.4 t -136.95 154.92 50.31 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 123.823 0.849 . . . . 0.0 110.916 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 99.2 t -75.76 142.52 14.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.3 m -141.83 161.81 20.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.568 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 178.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.91 121.72 20.47 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 54.1 tttm -74.8 -21.7 59.16 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 118.862 -0.59 . . . . 0.0 110.96 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.4 m -145.31 168.04 8.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 C-N-CA 125.873 1.669 . . . . 0.0 108.765 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -73.34 113.68 10.7 Favored 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 178.037 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.3 mt -105.56 104.12 46.68 Favored Pre-proline 0 CA--C 1.533 0.299 0 C-N-CA 124.977 1.311 . . . . 0.0 108.311 -178.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -67.82 155.39 70.06 Favored 'Trans proline' 0 N--CA 1.454 -0.83 0 C-N-CA 121.559 1.506 . . . . 0.0 110.382 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.416 ' HA ' HG23 ' A' ' 49' ' ' VAL . 5.8 tm-20 -52.08 147.34 7.53 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-O 121.899 0.856 . . . . 0.0 111.164 179.515 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.27 -4.1 82.36 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 123.77 0.7 . . . . 0.0 114.151 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 26.9 m -84.98 144.76 28.1 Favored 'General case' 0 CA--C 1.538 0.485 0 CA-C-N 118.9 1.35 . . . . 0.0 111.355 -179.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 27.5 mm -87.13 129.85 37.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.859 1.664 . . . . 0.0 107.712 178.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 38.6 mt -71.33 150.49 45.07 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.808 1.243 . . . . 0.0 112.323 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 46.5 p -145.57 161.72 39.13 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 126.826 2.05 . . . . 0.0 107.396 179.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 21.6 mmt -62.11 -38.51 89.17 Favored 'General case' 0 C--O 1.223 -0.327 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 178.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.9 t0 -59.32 -23.61 62.62 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 125.014 1.326 . . . . 0.0 112.651 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 25.5 mtm -104.36 7.71 35.71 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 121.34 -0.85 . . . . 0.0 111.919 -179.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.1 mt -126.19 151.19 47.69 Favored 'General case' 0 CA--C 1.521 -0.135 0 O-C-N 120.948 -1.095 . . . . 0.0 109.124 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.3 t -149.28 174.06 12.81 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 179.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.1 t -128.77 122.78 57.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 22.5 mmmt -92.84 116.46 29.05 Favored 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 p -65.2 136.03 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 178.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 154.76 -87.48 0.13 Allowed Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.5 pm0 -145.11 156.78 54.56 Favored Pre-proline 0 CA--C 1.54 0.591 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -82.35 57.35 6.12 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 124.965 3.777 . . . . 0.0 111.589 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.51 10.26 3.31 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 124.642 1.177 . . . . 0.0 113.254 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -157.48 -155.6 7.57 Favored Glycine 0 CA--C 1.524 0.633 0 C-N-CA 125.12 1.343 . . . . 0.0 109.98 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 20.1 t80 -59.66 141.03 89.04 Favored Pre-proline 0 CA--C 1.547 0.85 0 C-N-CA 123.669 0.788 . . . . 0.0 109.926 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.25 143.34 58.41 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 123.728 2.952 . . . . 0.0 115.287 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -76.17 -9.06 19.07 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.145 1.896 . . . . 0.0 113.144 179.124 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -79.23 -59.81 2.62 Favored 'General case' 0 N--CA 1.451 -0.396 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -71.13 6.58 1.57 Allowed 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 125.817 1.647 . . . . 0.0 113.35 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 15.6 tt -47.65 -33.41 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 C-N-CA 126.385 1.874 . . . . 0.0 112.767 -179.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -57.53 -26.34 61.22 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 123.687 0.795 . . . . 0.0 111.753 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -78.01 -28.2 49.13 Favored 'General case' 0 CA--C 1.528 0.11 0 C-N-CA 123.532 0.733 . . . . 0.0 111.437 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.8 mt -70.58 -37.33 73.93 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 118.679 0.672 . . . . 0.0 109.458 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 43.1 t -61.44 109.29 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 C-N-CA 124.794 1.238 . . . . 0.0 109.382 -179.319 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.14 -14.44 18.88 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 125.582 1.563 . . . . 0.0 111.389 -178.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.2 mttt -74.64 156.0 37.19 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 118.76 1.28 . . . . 0.0 108.318 179.048 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 2.7 ttmp? -103.45 133.2 48.9 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.416 HG23 ' HA ' ' A' ' 17' ' ' GLU . 6.5 m -73.89 141.59 15.97 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 178.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 93.3 mt -87.37 -20.77 26.24 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 125.658 1.583 . . . . 0.0 110.806 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 27.6 m -142.29 166.42 16.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.241 0 C-N-CA 125.076 1.35 . . . . 0.0 110.18 -178.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 54.4 m -74.11 106.74 5.92 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 91.3 t -90.22 136.1 24.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 178.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -92.69 175.31 6.86 Favored 'General case' 0 C--O 1.226 -0.18 0 O-C-N 121.618 -0.676 . . . . 0.0 111.853 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -70.13 136.87 50.59 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.0 t70 67.22 9.46 6.98 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 126.952 2.101 . . . . 0.0 111.508 -178.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.9 t0 -70.96 147.67 48.46 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 178.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 39.4 m -81.31 115.09 20.52 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.888 0.851 . . . . 0.0 110.535 -178.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.8 mm -72.14 111.47 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -106.79 152.61 23.62 Favored 'General case' 0 C--O 1.238 0.481 0 N-CA-C 104.409 -2.441 . . . . 0.0 104.409 177.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -62.93 -24.45 67.87 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 121.606 -0.684 . . . . 0.0 111.707 -179.646 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -75.13 -6.01 47.32 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 113.843 1.053 . . . . 0.0 113.843 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 46.3 mt -95.6 -2.79 47.6 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 119.501 1.046 . . . . 0.0 111.437 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.8 m -130.5 151.5 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 C-N-CA 125.251 1.42 . . . . 0.0 107.574 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 13.6 t0 -70.34 166.54 20.03 Favored 'General case' 0 CA--C 1.541 0.6 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -61.04 -52.39 65.18 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 179.086 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -149.55 160.25 43.64 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 126.491 1.916 . . . . 0.0 107.245 178.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -114.84 167.63 12.36 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 108.19 -1.964 . . . . 0.0 108.19 178.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.06 -2.79 4.56 Favored 'General case' 0 N--CA 1.466 0.375 0 O-C-N 121.571 -0.958 . . . . 0.0 111.269 178.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 51.4 tttm -59.08 109.38 0.83 Allowed 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 106.113 -1.81 . . . . 0.0 106.113 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 1.3 pp -67.43 175.55 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 124.681 1.193 . . . . 0.0 110.789 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 30.5 ttmt -96.36 146.37 24.81 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.219 1.008 . . . . 0.0 109.986 179.574 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.9 p -78.6 -77.7 0.16 Allowed 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 105.504 -2.036 . . . . 0.0 105.504 178.106 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.8 m -137.92 171.52 14.3 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 125.864 1.666 . . . . 0.0 108.153 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -128.35 -149.65 7.05 Favored Glycine 0 CA--C 1.531 1.092 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -68.88 9.65 0.44 Allowed 'Trans proline' 0 CA--C 1.544 0.985 0 C-N-CA 123.564 2.843 . . . . 0.0 113.445 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.4 p -63.07 137.86 58.38 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 119.904 1.229 . . . . 0.0 107.929 178.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . 0.406 ' H ' ' H ' ' A' ' 79' ' ' GLY . 35.9 t -169.92 -26.01 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.074 1.75 . . . . 0.0 109.287 -179.673 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.406 ' H ' ' H ' ' A' ' 78' ' ' SER . . . . . . . . 0 C--O 1.251 1.2 0 C-N-CA 128.785 3.088 . . . . 0.0 105.918 179.494 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.636 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.2 p -76.81 171.5 14.62 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 178.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.2 p -147.29 142.32 27.05 Favored 'General case' 0 C--O 1.235 0.338 0 O-C-N 121.17 -0.956 . . . . 0.0 110.524 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -110.21 120.87 5.77 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 106.34 -2.704 . . . . 0.0 106.34 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.7 108.08 5.55 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 -178.38 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 89.6 p -139.86 154.4 47.29 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.96 -146.63 11.23 Favored Glycine 0 CA--C 1.52 0.394 0 N-CA-C 107.019 -2.432 . . . . 0.0 107.019 -178.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 96.8 p -138.55 151.19 47.09 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 118.701 1.25 . . . . 0.0 110.924 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.6 t -76.57 125.83 36.69 Favored 'Isoleucine or valine' 0 C--O 1.234 0.259 0 O-C-N 121.307 -0.87 . . . . 0.0 110.159 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 33.3 m -124.9 155.8 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.454 0 CA-C-O 122.445 1.117 . . . . 0.0 108.355 177.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.71 118.7 10.63 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 125.204 1.402 . . . . 0.0 107.43 178.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 34.8 tttp -69.84 -27.31 64.75 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.4 m -151.75 169.77 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 125.729 1.612 . . . . 0.0 107.71 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -61.28 135.27 57.67 Favored 'General case' 0 C--O 1.241 0.62 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.06 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.1 mt -123.09 114.92 29.21 Favored Pre-proline 0 C--O 1.237 0.427 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.469 ' HA ' HG23 ' A' ' 52' ' ' THR . 22.1 Cg_endo -68.35 145.46 65.61 Favored 'Trans proline' 0 N--CA 1.448 -1.174 0 C-N-CA 120.752 0.968 . . . . 0.0 109.993 178.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 17.6 tt0 -57.27 146.07 29.82 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.442 0.697 . . . . 0.0 110.8 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.36 -0.05 88.48 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 123.849 0.738 . . . . 0.0 112.854 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.6 m -91.71 155.34 18.36 Favored 'General case' 0 C--O 1.234 0.275 0 CA-C-N 118.311 1.055 . . . . 0.0 111.742 -178.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 37.1 mm -89.77 130.12 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 125.332 1.453 . . . . 0.0 108.634 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 29.8 mt -70.25 151.99 44.72 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 124.486 1.114 . . . . 0.0 109.047 178.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 74.2 p -140.63 163.22 33.47 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 124.205 1.002 . . . . 0.0 108.458 -179.313 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 6.2 mmt -63.58 -40.44 96.97 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 177.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -57.71 -30.75 65.77 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 125.683 1.593 . . . . 0.0 113.801 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 63.7 mtm -101.12 13.96 33.48 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 120.379 1.445 . . . . 0.0 112.737 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.4 mt -126.75 136.65 52.7 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -179.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.3 t -140.43 131.2 25.82 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.6 m -90.01 125.82 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 CA-C-N 120.179 1.354 . . . . 0.0 107.881 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 11.1 mttp -84.64 105.33 15.36 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 178.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 8.0 p -59.48 143.03 14.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.517 0 C-N-CA 123.922 0.889 . . . . 0.0 108.966 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 143.7 -81.36 0.22 Allowed Glycine 0 N--CA 1.448 -0.541 0 CA-C-N 118.081 0.4 . . . . 0.0 113.645 179.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -125.6 151.0 69.86 Favored Pre-proline 0 CA--C 1.533 0.293 0 C-N-CA 124.439 1.095 . . . . 0.0 113.102 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -77.8 28.8 0.44 Allowed 'Trans proline' 0 CA--C 1.545 1.051 0 C-N-CA 124.762 3.642 . . . . 0.0 111.936 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 47.7 tttm -80.52 92.99 5.97 Favored 'General case' 0 C--O 1.237 0.444 0 O-C-N 119.826 -1.796 . . . . 0.0 106.944 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 142.66 -149.42 21.27 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 108.501 -1.84 . . . . 0.0 108.501 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -84.68 140.5 38.12 Favored Pre-proline 0 C--O 1.24 0.596 0 C-N-CA 126.328 1.851 . . . . 0.0 108.76 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -55.58 136.05 72.21 Favored 'Trans proline' 0 CA--C 1.543 0.932 0 C-N-CA 123.191 2.594 . . . . 0.0 111.942 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -75.55 -11.02 20.51 Favored 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 123.364 2.709 . . . . 0.0 113.878 -178.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -87.99 -40.02 14.22 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 124.375 1.07 . . . . 0.0 110.074 179.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -74.36 4.53 5.72 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 124.523 1.129 . . . . 0.0 112.077 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.0 tt -44.5 -39.48 1.72 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 128.049 2.54 . . . . 0.0 112.756 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -53.64 -30.6 43.7 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 123.791 0.836 . . . . 0.0 112.15 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 73.6 m-80 -75.38 -44.97 41.95 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.803 179.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 36.6 mt -56.58 -42.63 78.97 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 79.9 t -60.6 107.55 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 179.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.74 -15.12 26.73 Favored Glycine 0 CA--C 1.528 0.847 0 C-N-CA 125.019 1.295 . . . . 0.0 112.692 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -76.76 157.42 31.65 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-N 120.157 1.979 . . . . 0.0 108.086 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 4.0 ttmp? -98.69 137.96 36.55 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 105.217 -2.142 . . . . 0.0 105.217 177.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 9.2 m -68.13 171.75 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 177.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 61.1 mt -116.46 -11.38 11.15 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 125.019 1.328 . . . . 0.0 111.097 178.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.8 m -153.3 166.68 1.35 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.372 0 C-N-CA 125.91 1.684 . . . . 0.0 107.958 -178.312 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.469 HG23 ' HA ' ' A' ' 16' ' ' PRO . 3.3 m -74.13 135.96 42.91 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 104.843 -2.281 . . . . 0.0 104.843 178.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 95.2 t -121.06 150.83 24.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 70.4 mt-10 -106.96 168.18 9.37 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 125.114 1.366 . . . . 0.0 108.85 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -65.65 147.94 52.57 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 50.1 m-20 72.47 -6.18 1.65 Allowed 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 128.377 2.671 . . . . 0.0 113.236 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -64.62 152.51 41.98 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-O 121.924 0.868 . . . . 0.0 112.652 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -84.0 99.16 10.24 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 123.827 0.851 . . . . 0.0 110.903 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 10.5 mm -67.26 93.73 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 29.9 mtp -96.05 160.96 14.19 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 119.363 0.983 . . . . 0.0 109.577 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -60.36 -22.4 63.23 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.712 0.805 . . . . 0.0 113.107 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -74.97 -16.02 60.65 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.041 0.936 . . . . 0.0 111.865 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 27.8 mt -99.16 9.07 44.18 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 126.447 1.899 . . . . 0.0 113.959 -178.175 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.92 149.8 33.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 120.138 1.335 . . . . 0.0 112.38 -179.095 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -100.32 164.05 12.11 Favored 'General case' 0 C--O 1.236 0.379 0 C-N-CA 126.036 1.734 . . . . 0.0 107.659 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -71.43 139.98 49.9 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -69.81 -0.03 6.5 Favored 'General case' 0 CA--C 1.545 0.768 0 O-C-N 121.35 -0.844 . . . . 0.0 112.255 179.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -64.58 165.37 32.71 Favored Glycine 0 CA--C 1.531 1.039 0 O-C-N 119.684 -1.885 . . . . 0.0 109.69 178.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.18 5.52 51.49 Favored 'General case' 0 C--O 1.239 0.542 0 O-C-N 121.646 -0.914 . . . . 0.0 112.9 -179.366 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.7 tptp -59.79 159.01 9.45 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 119.059 0.845 . . . . 0.0 109.254 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 40.9 pt -82.48 167.32 2.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 178.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 20.7 ttmm -60.26 151.48 27.35 Favored 'General case' 0 C--O 1.239 0.527 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -153.5 170.52 20.56 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-O 122.125 0.964 . . . . 0.0 112.861 179.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.2 p -78.21 56.83 1.74 Allowed 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 128.999 2.92 . . . . 0.0 109.245 179.279 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.66 80.07 0.48 Allowed Glycine 0 CA--C 1.523 0.566 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -68.36 -15.9 42.79 Favored 'Trans proline' 0 CA--C 1.534 0.519 0 C-N-CA 122.424 2.083 . . . . 0.0 111.895 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.5 m -160.85 173.71 14.94 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 125.827 1.651 . . . . 0.0 107.331 179.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 43.4 m -118.1 113.9 22.29 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 104.918 -2.253 . . . . 0.0 104.918 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.74 0 CA-C-O 116.921 -2.044 . . . . 0.0 110.252 -179.957 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.862 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -135.15 153.68 51.9 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 124.689 1.196 . . . . 0.0 108.385 -179.567 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.9 m -145.04 171.13 14.91 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 125.507 1.523 . . . . 0.0 109.019 -179.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.16 -9.42 42.69 Favored Glycine 0 CA--C 1.523 0.587 0 CA-C-O 117.976 -1.458 . . . . 0.0 113.638 179.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.6 t -171.71 127.91 0.63 Allowed 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.828 1.314 . . . . 0.0 108.254 178.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -121.31 81.16 1.75 Allowed 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 103.955 -2.609 . . . . 0.0 103.955 178.355 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.81 -179.99 16.53 Favored Glycine 0 CA--C 1.528 0.849 0 CA-C-N 114.666 -1.152 . . . . 0.0 112.091 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 23.0 t -102.32 156.73 17.39 Favored 'General case' 0 C--O 1.244 0.779 0 C-N-CA 123.94 0.896 . . . . 0.0 110.732 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 85.9 t -75.52 127.86 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.2 m -127.69 146.59 33.13 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.25 124.02 18.61 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 124.429 1.092 . . . . 0.0 109.054 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 46.6 tttm -67.92 -31.71 71.66 Favored 'General case' 0 C--O 1.225 -0.23 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.421 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.3 m -147.02 174.87 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 126.48 1.912 . . . . 0.0 107.585 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 81.1 tttt -69.38 138.38 53.59 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 178.097 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 23.8 mt -129.25 107.35 17.7 Favored Pre-proline 0 CA--C 1.532 0.262 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -178.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.424 ' HA ' HG23 ' A' ' 52' ' ' THR . 36.6 Cg_endo -69.52 155.51 66.53 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 121.661 1.574 . . . . 0.0 110.532 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.401 ' HA ' HG23 ' A' ' 49' ' ' VAL . 22.7 tt0 -53.39 147.27 10.84 Favored 'General case' 0 C--O 1.238 0.466 0 C-N-CA 124.942 1.297 . . . . 0.0 109.88 179.297 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.0 0.27 75.35 Favored Glycine 0 CA--C 1.53 0.989 0 CA-C-O 118.825 -0.986 . . . . 0.0 113.926 179.187 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 28.5 m -86.67 137.7 32.25 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 119.608 1.704 . . . . 0.0 108.956 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 11.4 mm -80.51 128.71 38.46 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 178.394 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 74.6 mt -67.19 145.18 55.51 Favored 'General case' 0 C--O 1.237 0.442 0 C-N-CA 125.28 1.432 . . . . 0.0 110.307 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.57 ' HA ' HG23 ' A' ' 45' ' ' VAL . 17.6 p -143.25 152.35 41.6 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.371 1.468 . . . . 0.0 107.457 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -56.65 -27.09 57.88 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 118.869 0.758 . . . . 0.0 109.319 178.559 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -56.39 -29.27 61.28 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 126.418 1.887 . . . . 0.0 111.574 177.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 48.6 mtm -114.04 3.01 15.14 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 124.616 1.166 . . . . 0.0 111.168 -178.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 70.7 mt -105.52 147.89 27.85 Favored 'General case' 0 C--N 1.343 0.296 0 CA-C-N 120.081 1.31 . . . . 0.0 109.188 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.0 t -159.74 171.97 18.56 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 125.241 1.417 . . . . 0.0 107.613 178.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 77.0 t -125.57 152.19 32.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 8.3 mmmt -127.45 109.49 11.8 Favored 'General case' 0 CA--C 1.508 -0.646 0 N-CA-C 105.797 -1.927 . . . . 0.0 105.797 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 29.5 m -59.52 151.43 5.12 Favored 'Isoleucine or valine' 0 C--O 1.24 0.563 0 O-C-N 123.573 0.545 . . . . 0.0 109.532 179.694 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 152.09 -95.24 0.15 Allowed Glycine 0 N--CA 1.442 -0.925 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.53 163.38 50.02 Favored Pre-proline 0 C--N 1.326 -0.419 0 C-N-CA 126.562 1.945 . . . . 0.0 110.147 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -85.88 53.87 3.37 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 122.761 2.307 . . . . 0.0 110.16 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 32.9 pttt -73.81 70.65 1.44 Allowed 'General case' 0 C--O 1.221 -0.417 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 178.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.69 -152.8 18.07 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -178.366 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -55.07 134.17 68.07 Favored Pre-proline 0 CA--C 1.545 0.766 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -178.17 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -74.17 156.36 46.78 Favored 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 123.367 2.711 . . . . 0.0 111.251 179.306 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -71.18 -24.72 23.09 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.045 1.83 . . . . 0.0 113.942 -178.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 18.8 mp0 -83.68 2.32 38.22 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 -177.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -124.79 -5.46 7.5 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 119.949 1.25 . . . . 0.0 111.957 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 18.2 tt -40.38 -34.8 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 128.401 2.68 . . . . 0.0 114.327 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -57.91 -11.96 2.81 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 125.43 1.492 . . . . 0.0 114.139 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -97.4 -24.8 15.46 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 120.298 1.408 . . . . 0.0 110.82 178.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 85.8 mt -64.23 -37.94 89.27 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.57 HG23 ' HA ' ' A' ' 22' ' ' THR . 0.7 OUTLIER -68.08 118.88 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 179.556 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 112.82 -16.78 23.21 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 125.325 1.44 . . . . 0.0 112.337 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -85.6 158.68 20.05 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 119.034 1.417 . . . . 0.0 107.593 178.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt -103.45 139.74 38.42 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.793 -0.818 . . . . 0.0 108.793 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.401 HG23 ' HA ' ' A' ' 17' ' ' GLU . 3.2 m -77.29 135.12 27.16 Favored 'Isoleucine or valine' 0 C--O 1.236 0.347 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 24.1 mt -81.27 -15.3 55.92 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 124.227 1.011 . . . . 0.0 112.028 179.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.2 m -146.92 164.03 7.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 127.059 2.144 . . . . 0.0 108.796 -178.353 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.424 HG23 ' HA ' ' A' ' 16' ' ' PRO . 24.0 m -77.34 132.28 38.5 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.025 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.496 HG12 ' H ' ' A' ' 54' ' ' GLU . 54.3 t -98.5 -178.48 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 C-N-CA 126.512 1.925 . . . . 0.0 106.803 178.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.496 ' H ' HG12 ' A' ' 53' ' ' VAL . 27.8 mt-10 -135.64 164.76 27.11 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 127.377 2.271 . . . . 0.0 107.73 177.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -65.91 141.43 58.24 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 105.7 -1.963 . . . . 0.0 105.7 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 68.22 4.88 4.37 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.168 1.787 . . . . 0.0 114.946 179.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -76.19 155.35 34.59 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 119.633 1.106 . . . . 0.0 109.515 179.005 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 29.7 m -77.32 135.74 38.41 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 121.166 -0.959 . . . . 0.0 109.871 -179.338 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 16.7 mm -97.5 133.94 37.42 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 N-CA-C 104.808 -2.293 . . . . 0.0 104.808 177.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 82.7 mtp -139.93 160.86 38.96 Favored 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 123.579 0.752 . . . . 0.0 110.703 -178.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -57.44 -33.62 68.12 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 124.778 1.231 . . . . 0.0 113.231 -179.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -75.32 -2.25 27.4 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.319 1.448 . . . . 0.0 113.601 -178.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 36.9 mt -108.92 3.59 22.45 Favored 'General case' 0 C--O 1.232 0.148 0 C-N-CA 125.06 1.344 . . . . 0.0 110.78 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.4 m -129.59 144.53 37.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 C-N-CA 124.174 0.99 . . . . 0.0 111.234 -179.385 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -91.07 173.66 7.82 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 125.57 1.548 . . . . 0.0 110.704 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 31.5 t30 -57.04 157.39 5.9 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 125.036 1.334 . . . . 0.0 110.056 178.798 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 50.7 p-80 -119.45 166.85 12.56 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 124.14 0.976 . . . . 0.0 113.268 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 120.4 -164.36 13.92 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 125.864 1.697 . . . . 0.0 109.076 -179.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -114.62 166.14 12.04 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 125.847 1.659 . . . . 0.0 108.155 179.589 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.9 157.75 43.29 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 125.851 1.66 . . . . 0.0 106.785 177.358 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 8.2 pt -68.38 124.62 24.38 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 CA-C-N 118.635 0.652 . . . . 0.0 109.454 179.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.6 tptm -82.05 58.16 3.82 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.073 1.349 . . . . 0.0 111.002 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 5.0 t -141.89 145.61 34.8 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.3 t -68.43 170.95 8.04 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-O 122.061 0.934 . . . . 0.0 112.258 -179.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -155.02 -164.14 12.73 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 126.908 2.194 . . . . 0.0 109.277 -179.665 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -64.3 172.65 6.15 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 122.568 2.178 . . . . 0.0 112.344 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 10.9 t -136.42 149.0 48.06 Favored 'General case' 0 C--O 1.238 0.453 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 179.34 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -87.75 178.92 6.6 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 121.597 0.713 . . . . 0.0 109.978 179.548 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.735 0 N-CA-C 105.095 -3.202 . . . . 0.0 105.095 178.76 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.895 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 6.4 t -148.32 -48.69 0.16 Allowed 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 118.177 -0.915 . . . . 0.0 110.537 179.118 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.2 t -64.0 154.66 33.46 Favored 'General case' 0 C--O 1.238 0.451 0 CA-C-N 119.118 0.872 . . . . 0.0 111.148 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 101.17 132.31 7.71 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 106.664 -2.574 . . . . 0.0 106.664 -179.039 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.1 m -153.61 162.6 41.1 Favored 'General case' 0 C--O 1.238 0.483 0 O-C-N 121.213 -1.169 . . . . 0.0 108.723 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.2 m -119.47 4.59 11.16 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 124.95 1.3 . . . . 0.0 112.04 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 75.03 -159.24 51.78 Favored Glycine 0 CA--C 1.53 1.005 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 90.7 p -145.22 158.8 43.74 Favored 'General case' 0 C--O 1.237 0.431 0 O-C-N 121.764 -0.845 . . . . 0.0 111.412 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.11 137.17 24.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.083 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.4 m -136.49 160.62 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 C-N-CA 125.722 1.609 . . . . 0.0 107.778 178.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.74 118.27 18.38 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 178.566 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -62.48 -31.77 72.56 Favored 'General case' 0 N--CA 1.467 0.411 0 O-C-N 121.341 -0.85 . . . . 0.0 110.953 179.762 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m -138.32 172.0 14.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 126.708 2.003 . . . . 0.0 107.715 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.1 tttm -70.56 134.09 47.34 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.424 HD11 ' HB3' ' A' ' 25' ' ' MET . 73.9 mt -120.82 110.11 35.36 Favored Pre-proline 0 CA--C 1.53 0.208 0 C-N-CA 123.756 0.822 . . . . 0.0 110.031 -178.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -69.54 148.97 67.65 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 121.882 1.721 . . . . 0.0 111.086 178.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.406 ' HA ' HG23 ' A' ' 49' ' ' VAL . 60.4 tt0 -55.27 151.12 10.13 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 124.403 1.081 . . . . 0.0 110.166 178.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 68.99 30.47 72.22 Favored Glycine 0 CA--C 1.524 0.652 0 CA-C-O 119.441 -0.644 . . . . 0.0 113.847 178.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 59.9 m -118.04 150.87 38.58 Favored 'General case' 0 C--O 1.239 0.511 0 C-N-CA 125.737 1.615 . . . . 0.0 107.446 179.195 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 32.7 mm -92.4 123.93 44.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 CA-C-N 118.933 0.788 . . . . 0.0 109.443 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 62.2 mt -63.65 147.13 52.36 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.557 1.143 . . . . 0.0 110.858 -179.484 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.3 p -140.55 164.03 31.26 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 124.754 1.222 . . . . 0.0 107.715 178.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 5.7 mmt -62.82 -32.35 73.52 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.462 0.574 . . . . 0.0 110.281 179.211 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -59.24 -27.87 66.18 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 125.021 1.329 . . . . 0.0 113.357 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . 0.424 ' HB3' HD11 ' A' ' 15' ' ' ILE . 57.9 mtm -105.08 9.2 34.39 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.528 1.131 . . . . 0.0 112.733 -178.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 78.5 mt -127.68 146.22 50.63 Favored 'General case' 0 CA--C 1.518 -0.28 0 O-C-N 120.85 -1.156 . . . . 0.0 110.579 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.6 t -153.48 177.92 10.38 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.66 119.52 38.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 179.163 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 47.8 mtpt -91.63 108.8 20.16 Favored 'General case' 0 CA--C 1.511 -0.527 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 179.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 31.9 t -58.64 133.86 23.67 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 N-CA-C 105.609 -1.997 . . . . 0.0 105.609 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.42 -83.4 0.12 Allowed Glycine 0 C--N 1.334 0.441 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.486 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -124.25 150.61 64.28 Favored Pre-proline 0 CA--C 1.532 0.252 0 C-N-CA 123.501 0.72 . . . . 0.0 111.025 -179.597 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -71.14 -15.59 31.98 Favored 'Trans proline' 0 N--CA 1.456 -0.715 0 C-N-CA 122.486 2.124 . . . . 0.0 113.192 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 18.7 ttmm -48.54 106.15 0.09 Allowed 'General case' 0 C--O 1.234 0.272 0 C-N-CA 126.314 1.846 . . . . 0.0 109.982 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.76 -173.51 20.88 Favored Glycine 0 CA--C 1.525 0.715 0 C-N-CA 126.314 1.911 . . . . 0.0 108.93 -179.043 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.5 t80 -65.79 140.19 97.2 Favored Pre-proline 0 CA--C 1.543 0.703 0 O-C-N 121.973 -0.722 . . . . 0.0 109.509 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -66.19 134.29 36.04 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 122.713 2.275 . . . . 0.0 111.579 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -71.56 -16.47 30.47 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.756 2.304 . . . . 0.0 115.215 -179.199 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -70.94 -22.5 62.21 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 119.555 1.07 . . . . 0.0 111.927 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -114.88 13.28 17.08 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 124.855 1.262 . . . . 0.0 113.269 -178.224 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 20.5 tt -45.44 -36.39 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 125.365 1.466 . . . . 0.0 113.79 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -58.73 -23.59 60.05 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.336 1.054 . . . . 0.0 113.518 -178.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -78.42 -32.94 48.89 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 120.385 1.448 . . . . 0.0 111.504 179.224 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 53.2 mt -62.87 -35.37 79.77 Favored 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.016 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 77.5 t -60.32 117.03 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.08 -6.71 51.4 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 118.302 -1.277 . . . . 0.0 113.91 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.0 mttm -86.52 158.63 19.5 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 120.717 2.258 . . . . 0.0 108.725 178.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -95.77 135.22 37.78 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 179.107 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.406 HG23 ' HA ' ' A' ' 17' ' ' GLU . 4.2 m -77.51 139.74 18.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 CA-C-N 118.239 0.472 . . . . 0.0 110.077 179.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 23.1 mt -85.08 -17.22 38.06 Favored 'General case' 0 N--CA 1.462 0.154 0 C-N-CA 125.278 1.431 . . . . 0.0 112.066 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.18 163.52 7.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 C-N-CA 124.816 1.247 . . . . 0.0 110.582 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 22.5 m -78.51 122.4 25.82 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 105.116 -2.179 . . . . 0.0 105.116 178.079 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 76.2 t -106.59 139.29 28.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 106.126 -1.805 . . . . 0.0 106.126 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -86.1 176.21 8.12 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 122.079 0.942 . . . . 0.0 112.211 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -71.32 132.37 44.78 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 123.648 0.779 . . . . 0.0 110.09 -179.153 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 68.02 9.75 7.37 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 126.252 1.821 . . . . 0.0 110.127 -179.112 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 35.1 t0 -73.54 153.38 40.29 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.573 1.149 . . . . 0.0 109.466 179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 23.1 m -78.51 129.59 35.04 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 124.969 1.308 . . . . 0.0 111.809 -177.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 13.0 mm -90.39 148.01 4.84 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 179.013 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 38.1 mtp -142.17 163.56 32.54 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 124.777 1.231 . . . . 0.0 108.238 178.511 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -65.02 -26.35 68.24 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 124.128 0.971 . . . . 0.0 111.039 179.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -73.04 -14.84 61.49 Favored 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 123.62 0.768 . . . . 0.0 112.226 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 12.2 mt -94.11 6.59 48.1 Favored 'General case' 0 C--N 1.334 -0.069 0 CA-C-O 118.115 -0.945 . . . . 0.0 113.325 -177.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.4 m -127.88 125.33 64.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 120.139 1.336 . . . . 0.0 112.586 -178.632 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -75.26 102.39 5.01 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 125.779 1.632 . . . . 0.0 108.556 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -169.32 158.8 8.36 Favored 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 123.087 0.555 . . . . 0.0 110.747 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -147.2 -55.72 0.24 Allowed 'General case' 0 N--CA 1.465 0.325 0 C-N-CA 124.067 0.947 . . . . 0.0 111.085 179.238 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 164.94 107.96 0.21 Allowed Glycine 0 C--N 1.337 0.626 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 -179.316 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.58 -57.36 0.79 Allowed 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 123.864 0.866 . . . . 0.0 110.328 -179.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 44.8 mttm -70.37 -21.13 62.9 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 118.795 0.725 . . . . 0.0 112.847 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 3.3 mp -136.06 152.49 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 179.753 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 12.5 ptmm? -124.16 172.74 8.8 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 123.498 0.719 . . . . 0.0 110.56 179.096 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -70.44 96.85 1.2 Allowed 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 126.938 2.095 . . . . 0.0 107.113 178.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.8 p -88.54 169.61 11.59 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 74.88 -169.83 54.38 Favored Glycine 0 CA--C 1.528 0.896 0 O-C-N 121.188 -0.945 . . . . 0.0 112.218 179.539 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -67.73 15.36 0.14 Allowed 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 125.095 3.863 . . . . 0.0 115.644 -178.632 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 73.19 3.37 4.62 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.513 1.525 . . . . 0.0 113.69 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.26 157.33 22.88 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.501 1.12 . . . . 0.0 108.719 179.512 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.898 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.704 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.698 0 CA-C-O 119.248 -0.751 . . . . 0.0 111.692 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -120.03 18.88 12.4 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 119.092 1.446 . . . . 0.0 113.231 -179.409 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 m -59.66 145.2 45.62 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 119.313 0.96 . . . . 0.0 109.989 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.66 -72.7 0.27 Allowed Glycine 0 C--O 1.237 0.343 0 N-CA-C 108.389 -1.884 . . . . 0.0 108.389 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 32.4 p -154.12 178.78 9.59 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.28 1.032 . . . . 0.0 111.684 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 26.8 t -167.32 169.39 12.46 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 128.82 2.848 . . . . 0.0 106.655 179.054 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 166.31 -164.4 37.57 Favored Glycine 0 CA--C 1.524 0.61 0 O-C-N 120.757 -1.214 . . . . 0.0 110.864 -179.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.0 p -110.21 133.7 52.97 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 125.339 1.455 . . . . 0.0 110.78 -179.566 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.5 t -68.89 127.33 30.57 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 179.366 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.1 m -122.86 149.86 26.6 Favored 'Isoleucine or valine' 0 C--O 1.241 0.625 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.13 119.06 12.82 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 60.5 tttm -70.29 -21.53 62.94 Favored 'General case' 0 C--N 1.331 -0.206 0 O-C-N 121.529 -0.732 . . . . 0.0 112.099 -179.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.2 m -148.17 167.7 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 126.546 1.938 . . . . 0.0 107.501 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.3 tttm -76.43 99.8 5.0 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 178.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 7.6 mt -87.25 109.93 29.43 Favored Pre-proline 0 C--N 1.326 -0.431 0 C-N-CA 125.747 1.619 . . . . 0.0 107.677 -177.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.77 155.12 66.7 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 C-N-CA 121.387 1.391 . . . . 0.0 110.906 -179.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 61.8 tt0 -51.72 141.16 17.38 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 125.653 1.581 . . . . 0.0 109.399 179.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.1 -0.29 87.67 Favored Glycine 0 CA--C 1.535 1.3 0 CA-C-O 119.181 -0.788 . . . . 0.0 114.458 179.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.3 m -84.28 147.77 27.05 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 120.282 2.041 . . . . 0.0 109.668 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 28.5 mm -86.47 131.26 35.13 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 17.8 mt -68.98 148.16 50.55 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-O 121.607 0.717 . . . . 0.0 110.54 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 12.3 p -143.34 157.47 44.45 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 127.065 2.146 . . . . 0.0 107.331 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 15.9 mmt -64.98 -24.87 67.64 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -65.17 -14.73 61.3 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 128.791 2.837 . . . . 0.0 112.002 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 25.7 mtm -124.16 10.19 8.7 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.388 1.475 . . . . 0.0 111.933 -179.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 83.4 mt -128.66 152.86 47.9 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 119.728 1.149 . . . . 0.0 110.714 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 10.0 t -160.54 -179.15 7.41 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 105.434 -2.062 . . . . 0.0 105.434 178.133 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.47 131.11 39.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 O-C-N 120.766 -1.209 . . . . 0.0 108.07 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 2.4 tppp? -84.28 105.45 15.13 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 101.698 -3.445 . . . . 0.0 101.698 177.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.0 m -66.99 89.99 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 O-C-N 121.597 -0.689 . . . . 0.0 110.534 -179.154 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -145.06 -87.15 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 124.984 1.278 . . . . 0.0 110.565 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.9 148.44 39.92 Favored Pre-proline 0 C--N 1.326 -0.418 0 C-N-CA 125.884 1.674 . . . . 0.0 111.695 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -82.5 71.6 6.42 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.176 2.584 . . . . 0.0 108.166 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 40.1 tttp -114.24 166.2 11.9 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 123.537 0.735 . . . . 0.0 109.726 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 74.41 -87.65 0.71 Allowed Glycine 0 N--CA 1.444 -0.828 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -139.84 144.58 39.23 Favored Pre-proline 0 C--O 1.238 0.448 0 C-N-CA 124.919 1.288 . . . . 0.0 108.117 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.9 148.05 85.66 Favored 'Trans proline' 0 CA--C 1.539 0.75 0 C-N-CA 121.543 1.495 . . . . 0.0 109.358 179.065 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.05 -18.8 14.24 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.145 1.897 . . . . 0.0 111.989 -178.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -66.17 -33.09 74.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.46 -0.775 . . . . 0.0 111.391 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -92.24 10.78 28.13 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.18 1.792 . . . . 0.0 111.864 -178.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 13.9 tt -53.98 -34.65 26.5 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.718 0 O-C-N 119.801 -1.812 . . . . 0.0 111.201 179.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -60.64 -20.93 62.07 Favored 'General case' 0 C--O 1.235 0.317 0 C-N-CA 124.805 1.242 . . . . 0.0 113.605 179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -99.24 -17.99 17.83 Favored 'General case' 0 CA--C 1.515 -0.383 0 CA-C-N 119.732 1.151 . . . . 0.0 111.733 178.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 25.4 mt -68.27 -32.74 73.12 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 177.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 41.7 t -64.24 138.79 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 178.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 91.58 -16.2 59.68 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-O 118.823 -0.987 . . . . 0.0 112.277 -179.055 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.3 mttm -76.63 171.98 13.77 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-N 119.586 1.693 . . . . 0.0 107.368 178.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 24.7 ttmt -122.85 133.44 54.43 Favored 'General case' 0 CA--C 1.516 -0.355 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 1.8 m -74.6 148.47 7.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 O-C-N 124.258 0.974 . . . . 0.0 110.675 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.438 HD21 ' HB2' ' A' ' 65' ' ' ASP . 65.5 mt -97.93 -14.15 20.79 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 126.013 1.725 . . . . 0.0 112.696 179.7 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 15.7 m -144.42 161.81 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 C-N-CA 126.064 1.746 . . . . 0.0 108.461 179.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.1 m -74.98 96.0 3.1 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 87.0 t -70.79 127.13 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 178.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -74.29 170.28 15.91 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.584 0.707 . . . . 0.0 110.162 179.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -74.87 138.25 42.34 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 104.788 -2.301 . . . . 0.0 104.788 177.414 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 34.7 t0 72.34 10.94 5.85 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.781 2.032 . . . . 0.0 113.132 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -72.96 149.6 43.21 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 177.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 90.7 m -79.12 122.71 26.58 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 179.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.2 mm -76.51 126.52 37.26 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 179.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 48.7 mtp -128.09 155.43 44.4 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 122.469 1.128 . . . . 0.0 110.425 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -62.28 -20.18 64.02 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 126.696 1.998 . . . . 0.0 114.029 -179.131 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -89.21 -10.35 47.36 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 123.876 0.87 . . . . 0.0 111.687 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 84.1 mt -90.4 11.0 22.87 Favored 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 124.823 1.249 . . . . 0.0 110.729 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.5 m -133.34 151.2 33.27 Favored 'Isoleucine or valine' 0 C--O 1.232 0.166 0 CA-C-N 120.427 1.467 . . . . 0.0 114.239 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . 0.438 ' HB2' HD21 ' A' ' 50' ' ' LEU . 35.1 t0 -90.85 169.99 10.46 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 124.641 1.176 . . . . 0.0 109.129 178.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -72.09 136.85 46.73 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 121.753 -0.592 . . . . 0.0 109.793 178.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 54.0 t-80 -60.11 134.96 57.55 Favored 'General case' 0 C--O 1.24 0.592 0 C-N-CA 124.025 0.93 . . . . 0.0 111.751 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.44 -178.12 15.07 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 124.428 1.013 . . . . 0.0 111.586 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.17 -8.71 1.32 Allowed 'General case' 0 N--CA 1.47 0.538 0 O-C-N 121.986 -0.714 . . . . 0.0 112.655 178.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -54.51 155.62 3.9 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.961 1.305 . . . . 0.0 110.67 179.027 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 33.1 pt -111.95 28.8 2.1 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 C-N-CA 125.712 1.605 . . . . 0.0 111.442 -179.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 48.2 tttp -66.63 -34.55 78.12 Favored 'General case' 0 C--O 1.237 0.414 0 O-C-N 120.852 -1.155 . . . . 0.0 110.805 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 33.1 t -77.41 150.64 35.02 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 125.102 1.361 . . . . 0.0 109.487 179.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 21.9 t -71.11 -67.8 0.48 Allowed 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 104.452 -2.425 . . . . 0.0 104.452 177.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -172.99 147.91 10.05 Favored Glycine 0 CA--C 1.53 1.001 0 N-CA-C 106.791 -2.524 . . . . 0.0 106.791 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -71.63 -17.16 29.98 Favored 'Trans proline' 0 CA--C 1.534 0.477 0 C-N-CA 123.073 2.516 . . . . 0.0 113.835 -179.118 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.6 m 66.64 8.71 6.08 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.037 1.335 . . . . 0.0 114.133 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 39.0 p -79.12 -167.57 1.2 Allowed 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.493 1.517 . . . . 0.0 109.857 179.108 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.858 0 N-CA-C 106.761 -2.536 . . . . 0.0 106.761 178.639 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.356 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.5 p -67.5 177.85 1.81 Allowed 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 126.908 2.083 . . . . 0.0 111.274 178.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 65.1 m -105.06 97.6 7.43 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 101.248 -3.612 . . . . 0.0 101.248 177.332 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.2 120.33 0.7 Allowed Glycine 0 CA--C 1.527 0.837 0 N-CA-C 106.854 -2.499 . . . . 0.0 106.854 -177.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 79.7 p -126.6 175.23 8.09 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 124.687 1.195 . . . . 0.0 109.977 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 48.7 m -119.44 178.32 4.59 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 124.776 1.231 . . . . 0.0 109.162 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -140.74 -158.48 7.57 Favored Glycine 0 N--CA 1.45 -0.378 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 -179.317 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 76.5 p -137.26 157.19 47.18 Favored 'General case' 0 C--O 1.238 0.451 0 C-N-CA 123.793 0.837 . . . . 0.0 109.704 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 28.9 t -75.57 130.75 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.3 m -128.98 157.85 41.76 Favored 'Isoleucine or valine' 0 C--O 1.24 0.593 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 178.023 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.31 130.99 42.77 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 178.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 64.7 tttt -75.59 -32.91 60.52 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 121.366 -0.834 . . . . 0.0 110.754 179.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 22.6 m -144.58 170.71 7.34 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 129.601 3.16 . . . . 0.0 108.945 -179.455 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 20.6 tttm -68.78 116.58 9.43 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 119.762 1.165 . . . . 0.0 108.79 179.681 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.438 HD13 ' CD2' ' A' ' 21' ' ' LEU . 40.2 mt -98.9 105.19 29.84 Favored Pre-proline 0 CA--C 1.534 0.365 0 C-N-CA 125.168 1.387 . . . . 0.0 110.983 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.408 ' HA ' HG23 ' A' ' 52' ' ' THR . 42.7 Cg_endo -67.99 145.39 67.6 Favored 'Trans proline' 0 N--CA 1.452 -0.951 0 C-N-CA 121.609 1.539 . . . . 0.0 108.937 177.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -53.69 152.9 4.85 Favored 'General case' 0 CA--C 1.539 0.558 0 C-N-CA 124.151 0.98 . . . . 0.0 110.966 178.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.87 24.89 76.15 Favored Glycine 0 CA--C 1.524 0.61 0 CA-C-O 118.543 -1.143 . . . . 0.0 113.892 178.661 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 56.9 m -118.62 143.82 46.55 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 119.112 1.456 . . . . 0.0 108.266 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 18.6 mm -74.39 136.26 25.63 Favored 'Isoleucine or valine' 0 C--O 1.236 0.363 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.438 ' CD2' HD13 ' A' ' 15' ' ' ILE . 25.4 mt -80.51 141.47 35.13 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 126.099 1.76 . . . . 0.0 107.805 179.199 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 82.0 p -135.92 165.32 25.93 Favored 'General case' 0 C--O 1.237 0.425 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 179.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 8.5 mmt -61.26 -25.87 67.38 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.55 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -78.17 -10.4 59.62 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.347 1.059 . . . . 0.0 113.164 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 58.9 mtm -119.97 16.07 12.51 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 126.029 1.731 . . . . 0.0 110.566 -179.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.8 mt -141.55 137.88 32.3 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 179.322 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 15.1 t -148.28 155.08 40.89 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.626 HG11 ' HB3' ' A' ' 38' ' ' PRO . 2.9 t -111.25 102.04 13.41 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -179.586 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 27.7 ttpp -75.01 112.78 11.59 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.236 0.614 . . . . 0.0 109.794 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 90.1 t -61.83 121.92 11.28 Favored 'Isoleucine or valine' 0 C--O 1.239 0.504 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 176.19 -82.77 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -138.56 158.68 69.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 C-N-CA 123.442 0.697 . . . . 0.0 110.768 -179.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -74.63 11.63 1.3 Allowed 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.344 2.696 . . . . 0.0 113.182 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -67.47 95.32 0.45 Allowed 'General case' 0 C--O 1.232 0.155 0 O-C-N 120.281 -1.512 . . . . 0.0 108.136 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.7 -167.89 23.78 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 128.095 2.76 . . . . 0.0 109.316 -178.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.423 ' CE2' ' HB3' ' A' ' 40' ' ' ASP . 9.2 t80 -67.77 144.35 97.35 Favored Pre-proline 0 CA--C 1.545 0.752 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.199 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -72.35 154.35 56.07 Favored 'Trans proline' 0 CA--C 1.544 1.016 0 C-N-CA 122.432 2.088 . . . . 0.0 113.406 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.626 ' HB3' HG11 ' A' ' 28' ' ' VAL . 16.7 Cg_endo -66.2 -27.42 48.76 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 123.416 2.744 . . . . 0.0 116.223 -179.383 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -75.99 -25.06 55.44 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 120.233 1.379 . . . . 0.0 112.179 -178.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.423 ' HB3' ' CE2' ' A' ' 36' ' ' TYR . 3.2 m-20 -88.86 -2.55 58.64 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.919 0.781 . . . . 0.0 112.563 -179.184 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.4 tt -51.12 -34.38 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 O-C-N 120.616 -1.302 . . . . 0.0 112.557 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -59.43 -22.9 62.15 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -95.29 -19.09 20.28 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-O 117.76 -1.115 . . . . 0.0 111.308 178.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 61.0 mt -72.68 -34.32 67.12 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 73.1 t -64.83 130.64 30.2 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 N-CA-C 105.62 -1.993 . . . . 0.0 105.62 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 93.82 -12.64 69.0 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-O 118.054 -1.414 . . . . 0.0 112.514 -179.305 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -75.49 173.14 11.36 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 119.565 1.682 . . . . 0.0 109.602 178.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.5 tppt? -127.07 101.58 6.6 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.204 1.402 . . . . 0.0 108.941 -179.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 6.1 m -43.06 140.84 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 123.73 0.812 . . . . 0.0 112.508 -178.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 92.8 mt -86.84 -19.48 28.9 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.486 1.114 . . . . 0.0 112.307 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.1 m -143.89 165.69 13.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 C-N-CA 126.222 1.809 . . . . 0.0 107.974 -179.021 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.408 HG23 ' HA ' ' A' ' 16' ' ' PRO . 99.2 m -76.26 138.56 40.64 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 178.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 79.0 t -119.85 128.43 75.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -75.38 173.89 10.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 122.101 0.953 . . . . 0.0 110.565 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 53.0 tt0 -69.83 145.53 52.02 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . 0.338 0.7 OUTLIER 58.63 8.29 0.88 Allowed 'General case' 0 C--O 1.236 0.348 0 C-N-CA 125.291 1.436 . . . . 0.0 114.374 179.333 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -74.38 158.78 33.32 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 178.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 18.4 m -84.77 126.82 33.75 Favored 'General case' 0 C--N 1.321 -0.638 0 O-C-N 120.69 -1.256 . . . . 0.0 112.131 -177.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.9 mm -84.04 134.9 25.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.415 0 N-CA-C 104.328 -2.471 . . . . 0.0 104.328 178.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 69.7 mtp -141.48 159.83 41.4 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 122.885 0.474 . . . . 0.0 110.642 -178.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -61.54 -20.68 63.52 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 125.057 1.343 . . . . 0.0 112.697 179.765 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -81.68 -12.68 58.57 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.457 1.103 . . . . 0.0 112.245 179.546 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 25.0 mt -103.34 0.23 31.08 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.345 1.058 . . . . 0.0 111.463 -179.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.6 m -132.24 147.23 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 CA-C-O 122.302 1.049 . . . . 0.0 112.368 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -81.67 163.08 22.76 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 126.692 1.997 . . . . 0.0 110.104 179.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -67.5 149.23 50.46 Favored 'General case' 0 N--CA 1.444 -0.755 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.115 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -148.85 135.31 19.49 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 178.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.38 75.65 0.42 Allowed Glycine 0 CA--C 1.529 0.921 0 C-N-CA 123.567 0.603 . . . . 0.0 112.827 179.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 51.8 tptt -142.65 165.98 25.92 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 126.617 1.967 . . . . 0.0 107.451 178.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.1 ptpm? -149.56 121.62 8.27 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 179.565 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 98.0 mt -69.26 158.6 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 4.7 ttpm? -155.41 101.32 2.19 Favored 'General case' 0 CA--C 1.517 -0.317 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 14.5 p -65.53 -31.51 72.6 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 122.653 0.381 . . . . 0.0 111.796 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.1 m -62.14 115.84 4.46 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 124.81 1.244 . . . . 0.0 112.821 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 88.08 174.86 47.87 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.069 0.842 . . . . 0.0 114.085 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -61.72 148.69 92.48 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 123.372 2.715 . . . . 0.0 110.878 -179.467 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 24.1 m -79.66 -178.22 6.25 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 125.107 1.363 . . . . 0.0 110.839 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -57.76 -58.57 7.77 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 123.628 0.771 . . . . 0.0 109.142 178.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.961 0 N-CA-C 106.81 -2.516 . . . . 0.0 106.81 -179.417 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.947 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.1 t -54.09 -71.18 0.08 Allowed 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.76 1.224 . . . . 0.0 111.196 -179.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -74.96 163.9 27.13 Favored 'General case' 0 C--O 1.237 0.421 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.406 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 101.14 137.72 9.9 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 -179.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.5 m -63.32 163.49 10.49 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 117.338 0.569 . . . . 0.0 110.929 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.3 t -80.16 -175.71 5.19 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-O 121.7 0.762 . . . . 0.0 109.19 178.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -153.91 -172.51 22.02 Favored Glycine 0 CA--C 1.525 0.675 0 C-N-CA 125.412 1.482 . . . . 0.0 109.507 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -144.23 164.99 29.11 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 124.916 1.286 . . . . 0.0 109.665 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 40.0 t -81.41 134.05 27.95 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.6 m -133.23 159.39 43.01 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.77 120.35 17.23 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 178.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 75.5 tttt -69.04 -29.5 67.65 Favored 'General case' 0 C--N 1.327 -0.372 0 O-C-N 121.787 -0.571 . . . . 0.0 109.761 179.209 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.2 m -151.0 163.12 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 C-N-CA 128.081 2.552 . . . . 0.0 107.569 178.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -56.23 141.07 42.52 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 124.701 1.2 . . . . 0.0 108.718 178.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 8.3 mt -129.68 105.4 17.16 Favored Pre-proline 0 N--CA 1.465 0.281 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -178.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.682 ' HA ' HG23 ' A' ' 52' ' ' THR . 38.2 Cg_endo -65.79 146.06 82.48 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 121.47 1.446 . . . . 0.0 111.263 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.454 ' HA ' HG23 ' A' ' 49' ' ' VAL . 60.5 tt0 -56.71 141.97 41.91 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.561 0.696 . . . . 0.0 111.036 -179.335 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 90.91 2.77 71.32 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-O 119.137 -0.813 . . . . 0.0 113.376 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 30.0 m -97.38 151.26 20.12 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 125.603 1.561 . . . . 0.0 109.143 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 14.4 mm -91.98 141.15 14.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 37.6 mt -73.49 149.56 42.21 Favored 'General case' 0 C--O 1.238 0.468 0 C-N-CA 124.667 1.187 . . . . 0.0 110.69 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 18.9 p -144.51 158.11 43.91 Favored 'General case' 0 C--N 1.328 -0.361 0 C-N-CA 127.176 2.19 . . . . 0.0 108.096 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.6 mmt -63.74 -31.7 72.96 Favored 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -59.43 -17.44 30.93 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.987 1.315 . . . . 0.0 111.914 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 49.5 mtm -119.88 11.08 11.73 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.122 1.369 . . . . 0.0 111.849 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.5 mt -130.33 146.88 51.97 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 119.373 0.988 . . . . 0.0 110.256 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.7 t -152.95 163.83 39.08 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 55.3 t -107.75 101.49 12.6 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 1.1 mmtm -72.65 129.7 38.86 Favored 'General case' 0 N--CA 1.453 -0.287 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.3 m -73.24 123.04 27.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 168.33 -93.64 0.1 Allowed Glycine 0 C--N 1.335 0.473 0 C-N-CA 119.918 -1.134 . . . . 0.0 112.985 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -138.09 153.83 73.65 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 117.484 0.642 . . . . 0.0 111.577 -179.098 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -70.48 14.7 0.3 Allowed 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 124.588 3.525 . . . . 0.0 115.08 -179.032 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.42 114.2 6.65 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 105.31 -2.108 . . . . 0.0 105.31 178.768 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 119.74 -166.39 13.42 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 -178.725 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -69.83 138.66 87.99 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-O 118.909 -0.567 . . . . 0.0 112.207 -178.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -60.79 135.18 58.26 Favored 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.643 2.229 . . . . 0.0 110.162 179.281 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.42 -13.84 36.19 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 121.963 1.775 . . . . 0.0 115.299 -179.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -78.23 -31.17 49.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 119.494 1.043 . . . . 0.0 108.929 179.021 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -81.39 3.98 22.5 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.379 1.072 . . . . 0.0 111.647 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.1 tt -53.2 -32.26 18.93 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 124.658 1.183 . . . . 0.0 112.244 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -57.27 -43.79 83.36 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 123.232 0.613 . . . . 0.0 109.384 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 18.3 m-80 -64.79 -36.76 85.36 Favored 'General case' 0 CA--C 1.522 -0.114 0 C-N-CA 124.176 0.991 . . . . 0.0 110.633 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 71.7 mt -64.42 -34.07 77.32 Favored 'General case' 0 C--O 1.227 -0.108 0 CA-C-O 118.837 -0.602 . . . . 0.0 110.495 179.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 96.8 t -71.98 82.11 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 CA-C-O 123.031 1.396 . . . . 0.0 109.245 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 147.24 -4.95 1.0 Allowed Glycine 0 CA--C 1.527 0.844 0 C-N-CA 127.032 2.253 . . . . 0.0 112.653 -179.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 78.7 mttt -91.92 156.33 17.54 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 119.427 1.613 . . . . 0.0 109.118 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -99.42 138.67 36.19 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 179.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.454 HG23 ' HA ' ' A' ' 17' ' ' GLU . 6.1 m -75.33 137.37 23.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.398 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 95.6 mt -88.81 -12.85 40.84 Favored 'General case' 0 C--N 1.334 -0.106 0 C-N-CA 124.575 1.15 . . . . 0.0 111.592 179.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 32.6 m -143.53 160.2 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.25 0 C-N-CA 124.343 1.057 . . . . 0.0 108.65 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.682 HG23 ' HA ' ' A' ' 16' ' ' PRO . 33.4 m -74.23 105.58 5.48 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 104.735 -2.32 . . . . 0.0 104.735 177.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 41.1 t -80.23 143.46 12.37 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 179.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -90.62 169.74 10.75 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 121.774 0.797 . . . . 0.0 109.08 178.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -69.35 136.91 52.4 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 178.053 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.6 t0 65.06 13.79 8.92 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 124.796 1.239 . . . . 0.0 113.813 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 45.0 t0 -77.01 157.14 31.35 Favored 'General case' 0 C--O 1.233 0.203 0 C-N-CA 124.004 0.922 . . . . 0.0 109.048 178.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.0 m -78.47 128.75 34.03 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 121.517 -0.74 . . . . 0.0 109.596 -179.264 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.0 mm -87.93 129.08 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 N-CA-C 103.143 -2.91 . . . . 0.0 103.143 177.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 46.6 mtp -133.24 159.92 38.8 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -63.4 -34.13 77.06 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 123.372 0.669 . . . . 0.0 109.904 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -60.75 -19.5 59.18 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 126.662 1.985 . . . . 0.0 110.741 179.699 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 10.7 mt -100.86 6.91 43.88 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 125.149 1.38 . . . . 0.0 112.532 -179.209 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.4 m -132.55 147.2 31.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 120.749 1.613 . . . . 0.0 111.814 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -57.45 143.1 41.73 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 125.413 1.485 . . . . 0.0 109.57 179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -61.42 -35.27 77.09 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 124.325 1.05 . . . . 0.0 112.102 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -147.78 174.5 11.76 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 124.793 1.237 . . . . 0.0 108.082 178.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.46 108.3 0.37 Allowed Glycine 0 N--CA 1.452 -0.237 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 -179.43 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 19.3 ptmt -138.04 155.34 48.91 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 123.541 0.737 . . . . 0.0 109.179 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 6.2 ttpm? -161.67 105.98 1.26 Allowed 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.4 pp -76.79 -2.36 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 N-CA-C 113.595 0.961 . . . . 0.0 113.595 -179.344 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -70.81 97.98 1.48 Allowed 'General case' 0 C--N 1.342 0.27 0 CA-C-N 119.996 1.271 . . . . 0.0 110.381 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 19.5 t -123.38 -67.64 0.93 Allowed 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 179.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 20.1 m -68.27 167.56 14.16 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 124.17 0.988 . . . . 0.0 111.914 -179.602 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -169.98 172.94 44.02 Favored Glycine 0 CA--C 1.533 1.167 0 C-N-CA 125.558 1.551 . . . . 0.0 109.269 179.46 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -74.29 -10.22 22.28 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 123.02 2.48 . . . . 0.0 111.4 179.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.4 p -73.79 48.86 0.3 Allowed 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 129.265 3.026 . . . . 0.0 110.681 179.715 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 51.1 m -145.69 84.03 1.66 Allowed 'General case' 0 N--CA 1.453 -0.314 0 O-C-N 120.573 -1.329 . . . . 0.0 108.085 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.775 0 C-N-CA 129.649 3.5 . . . . 0.0 106.159 179.716 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.891 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.1 t -129.44 136.94 50.55 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 125.333 1.453 . . . . 0.0 107.937 179.74 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 m -75.39 128.18 34.8 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.37 0.668 . . . . 0.0 109.863 179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -100.89 -172.91 29.06 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 73.3 m -86.37 124.44 32.72 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 178.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -52.89 139.11 28.2 Favored 'General case' 0 C--O 1.237 0.408 0 C-N-CA 123.863 0.865 . . . . 0.0 111.23 -179.061 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -175.98 -168.32 36.08 Favored Glycine 0 CA--C 1.524 0.623 0 O-C-N 121.613 -0.68 . . . . 0.0 112.34 -179.03 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 36.7 p -136.87 143.75 43.2 Favored 'General case' 0 C--O 1.234 0.255 0 C-N-CA 125.627 1.571 . . . . 0.0 110.872 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 35.7 t -69.24 123.07 21.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 CA-C-N 119.15 0.886 . . . . 0.0 110.869 179.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 35.5 m -125.41 154.64 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 125.043 1.337 . . . . 0.0 108.065 177.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.37 118.91 12.07 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -70.36 -29.93 66.72 Favored 'General case' 0 N--CA 1.465 0.281 0 O-C-N 121.389 -0.819 . . . . 0.0 110.85 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.6 m -147.21 161.85 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 127.816 2.447 . . . . 0.0 106.932 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 78.3 tttt -62.85 143.44 57.59 Favored 'General case' 0 C--O 1.24 0.577 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.1 mt -127.33 110.85 21.25 Favored Pre-proline 0 CA--C 1.538 0.486 0 C-N-CA 124.956 1.302 . . . . 0.0 109.201 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -66.35 149.5 84.9 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 121.663 1.575 . . . . 0.0 109.704 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.6 tm-20 -53.56 148.55 9.26 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 124.293 1.037 . . . . 0.0 110.905 179.503 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 81.22 -0.52 87.46 Favored Glycine 0 CA--C 1.526 0.747 0 C-N-CA 124.617 1.103 . . . . 0.0 115.219 178.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 72.5 m -83.6 144.53 29.39 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 118.213 1.006 . . . . 0.0 110.768 -179.07 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 30.0 mm -85.65 135.58 24.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 177.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 42.4 mt -72.29 151.98 42.43 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 124.008 0.923 . . . . 0.0 112.033 -179.123 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.617 ' HA ' HG13 ' A' ' 45' ' ' VAL . 47.7 p -144.0 159.02 43.32 Favored 'General case' 0 C--O 1.238 0.455 0 C-N-CA 127.285 2.234 . . . . 0.0 106.533 178.678 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . 0.509 ' SD ' HG11 ' A' ' 45' ' ' VAL . 0.4 OUTLIER -65.69 -30.89 71.64 Favored 'General case' 0 C--O 1.224 -0.273 0 CA-C-N 119.377 0.99 . . . . 0.0 108.483 178.605 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -58.14 -30.58 66.45 Favored 'General case' 0 C--O 1.225 -0.209 0 N-CA-C 114.578 1.325 . . . . 0.0 114.578 -179.436 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.8 mtm -95.69 9.67 39.53 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 118.861 0.755 . . . . 0.0 111.518 179.565 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 97.3 mt -130.83 158.22 40.76 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 123.898 0.879 . . . . 0.0 111.843 -178.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.1 t -159.32 152.06 21.7 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.351 -2.092 . . . . 0.0 105.351 177.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 m -103.01 120.51 52.95 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 119.828 1.194 . . . . 0.0 108.596 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 27.5 ttpp -68.84 113.67 6.48 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 104.784 -2.302 . . . . 0.0 104.784 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 60.7 t -74.56 85.73 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -144.02 -77.13 0.03 OUTLIER Glycine 0 CA--C 1.52 0.358 0 C-N-CA 125.395 1.474 . . . . 0.0 111.311 -179.118 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -147.62 161.59 34.98 Favored Pre-proline 0 CA--C 1.537 0.464 0 C-N-CA 124.88 1.272 . . . . 0.0 109.493 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -73.82 36.23 0.39 Allowed 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 124.61 3.54 . . . . 0.0 113.249 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -62.7 164.24 8.06 Favored 'General case' 0 N--CA 1.462 0.16 0 O-C-N 120.567 -1.333 . . . . 0.0 108.912 178.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 53.41 -132.09 42.7 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 179.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -86.45 135.88 35.89 Favored Pre-proline 0 CA--C 1.542 0.658 0 C-N-CA 125.026 1.33 . . . . 0.0 110.848 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -59.16 151.48 66.63 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.273 2.649 . . . . 0.0 112.592 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -80.04 -24.81 5.48 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 122.654 2.236 . . . . 0.0 112.989 -178.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -65.48 -43.24 90.84 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 119.253 0.933 . . . . 0.0 110.638 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -71.05 8.33 0.97 Allowed 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 127.771 2.428 . . . . 0.0 114.15 -178.616 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.1 tt -50.27 -36.17 12.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 CA-C-N 119.3 0.955 . . . . 0.0 112.498 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -58.89 -32.37 69.44 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-O 118.976 -0.535 . . . . 0.0 111.706 179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 70.9 m-80 -70.3 -49.6 47.98 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 20.8 mt -57.03 -46.23 82.54 Favored 'General case' 0 CA--C 1.515 -0.385 0 C-N-CA 123.52 0.728 . . . . 0.0 109.957 -179.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.617 HG13 ' HA ' ' A' ' 22' ' ' THR . 74.8 t -68.05 99.19 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 131.46 -12.48 5.45 Favored Glycine 0 CA--C 1.529 0.926 0 C-N-CA 127.18 2.324 . . . . 0.0 110.687 -179.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 55.8 mttm -84.21 169.19 15.03 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 120.021 1.911 . . . . 0.0 108.053 178.273 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 20.4 ttmm -111.85 138.45 48.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 118.1 -0.952 . . . . 0.0 109.287 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.8 m -74.52 137.14 23.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.508 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.481 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 38.3 mt -83.2 -18.84 37.91 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 125.678 1.591 . . . . 0.0 112.268 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 22.8 m -145.21 167.94 9.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 126.198 1.799 . . . . 0.0 108.496 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.6 m -76.88 109.46 10.7 Favored 'General case' 0 N--CA 1.456 -0.149 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 178.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 86.7 t -86.48 126.07 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 C-N-CA 124.632 1.173 . . . . 0.0 107.863 -179.393 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -77.45 172.8 12.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 122.18 0.991 . . . . 0.0 111.298 178.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -71.79 148.63 46.08 Favored 'General case' 0 N--CA 1.443 -0.782 0 O-C-N 121.616 -0.678 . . . . 0.0 109.509 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 29.2 t70 61.36 7.36 1.7 Allowed 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 127.554 2.342 . . . . 0.0 112.169 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -67.82 150.99 47.9 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.234 1.014 . . . . 0.0 108.895 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 47.3 m -82.64 111.84 18.97 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.048 -1.094 . . . . 0.0 108.048 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.8 mm -70.27 129.68 34.47 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 105.712 -1.959 . . . . 0.0 105.712 178.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 59.1 mtp -132.8 161.02 35.19 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 123.897 0.879 . . . . 0.0 109.316 -179.203 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -62.25 -30.55 71.19 Favored 'General case' 0 N--CA 1.466 0.329 0 C-N-CA 123.498 0.719 . . . . 0.0 111.031 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 19.2 pt-20 -66.51 -15.84 63.69 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 123.613 0.765 . . . . 0.0 111.474 179.339 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 38.5 mt -100.32 5.29 44.46 Favored 'General case' 0 C--N 1.341 0.234 0 C-N-CA 126.419 1.887 . . . . 0.0 112.692 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.06 140.41 47.97 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-N 121.665 2.029 . . . . 0.0 114.687 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -101.01 161.15 13.8 Favored 'General case' 0 C--O 1.239 0.514 0 C-N-CA 127.191 2.197 . . . . 0.0 108.869 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -64.92 143.43 57.96 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 127.183 2.193 . . . . 0.0 111.598 179.568 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 34.5 t-80 -76.88 107.8 9.47 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 178.531 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -76.24 178.11 49.87 Favored Glycine 0 CA--C 1.532 1.154 0 N-CA-C 109.289 -1.525 . . . . 0.0 109.289 178.653 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.6 ttmp? -125.89 -77.2 0.58 Allowed 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 179.161 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -78.33 72.45 4.86 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 178.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 30.2 pt -79.91 175.01 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 125.407 1.483 . . . . 0.0 110.718 -179.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 24.0 tptp -147.14 113.2 5.82 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 107.046 -1.464 . . . . 0.0 107.046 178.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.9 t -57.4 104.43 0.17 Allowed 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 125.256 1.422 . . . . 0.0 110.418 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.1 p -74.54 -58.36 3.34 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 178.298 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 163.42 161.61 12.97 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 127.019 2.247 . . . . 0.0 108.962 179.522 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -81.5 -179.02 4.62 Favored 'Trans proline' 0 CA--C 1.538 0.69 0 C-N-CA 123.402 2.735 . . . . 0.0 109.48 179.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 38.0 p -130.91 134.9 47.18 Favored 'General case' 0 C--O 1.236 0.383 0 O-C-N 121.194 -0.941 . . . . 0.0 109.263 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 44.1 t -84.66 -65.35 1.02 Allowed 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 105.913 -1.884 . . . . 0.0 105.913 178.314 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.579 0 N-CA-C 106.392 -2.683 . . . . 0.0 106.392 -179.207 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.669 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.0 p -64.4 147.97 51.48 Favored 'General case' 0 CA--C 1.535 0.367 0 CA-C-N 118.629 1.215 . . . . 0.0 109.177 179.044 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.5 m -54.32 -38.78 66.38 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 123.623 0.769 . . . . 0.0 113.074 -179.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.71 124.78 15.66 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 111.524 -0.631 . . . . 0.0 111.524 -179.426 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.2 m -83.19 76.51 9.87 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 124.142 0.977 . . . . 0.0 109.885 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.9 p -80.99 72.57 8.02 Favored 'General case' 0 CA--C 1.542 0.661 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 178.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 124.33 -175.79 16.98 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 127.251 2.358 . . . . 0.0 109.188 -179.16 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 46.4 p -136.33 163.04 31.37 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 117.251 0.525 . . . . 0.0 109.887 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 62.3 t -68.74 142.89 15.65 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.481 HG21 ' HG2' ' A' ' 29' ' ' LYS . 4.4 m -140.87 164.36 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 127.021 2.129 . . . . 0.0 106.547 178.354 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -81.13 133.15 35.42 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 107.062 -1.458 . . . . 0.0 107.062 177.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 54.1 tttp -75.51 -29.31 59.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 118.898 -0.572 . . . . 0.0 111.371 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.6 m -144.96 168.97 8.51 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 127.199 2.2 . . . . 0.0 107.854 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.4 tttm -71.86 123.86 23.6 Favored 'General case' 0 C--O 1.238 0.457 0 C-N-CA 124.966 1.306 . . . . 0.0 108.766 178.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 74.9 mt -115.64 119.82 37.06 Favored Pre-proline 0 CA--C 1.538 0.517 0 C-N-CA 125.111 1.365 . . . . 0.0 110.112 -178.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.6 152.03 53.28 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 121.783 1.655 . . . . 0.0 110.633 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -50.49 146.9 4.95 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.797 1.639 . . . . 0.0 110.844 179.435 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.12 -4.44 66.8 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 115.341 0.896 . . . . 0.0 115.341 178.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 54.5 m -82.6 149.65 27.32 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 118.561 1.18 . . . . 0.0 109.438 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.05 141.86 13.77 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 76.3 mt -82.98 144.35 30.04 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 123.607 0.763 . . . . 0.0 110.589 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 77.1 p -133.67 162.25 32.46 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 126.876 2.071 . . . . 0.0 108.114 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.0 mmt -63.03 -26.57 68.91 Favored 'General case' 0 N--CA 1.465 0.294 0 O-C-N 121.781 -0.574 . . . . 0.0 110.75 179.172 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -68.91 -43.92 74.19 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-O 117.82 -1.086 . . . . 0.0 112.782 -179.139 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 29.6 mtm -87.76 18.17 4.25 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 120.671 1.578 . . . . 0.0 111.58 -177.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 64.8 mt -125.65 133.61 52.14 Favored 'General case' 0 CA--C 1.516 -0.337 0 C-N-CA 126.169 1.788 . . . . 0.0 109.856 -179.187 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 14.0 t -146.77 174.08 11.8 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 178.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 40.9 t -129.86 100.22 5.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 CA-C-N 119.36 0.982 . . . . 0.0 108.585 -178.609 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.481 ' HG2' HG21 ' A' ' 10' ' ' VAL . 6.2 mmpt? -67.41 131.32 45.46 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.7 m -62.31 125.87 19.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 178.252 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.37 -134.0 3.13 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -99.66 156.19 35.64 Favored Pre-proline 0 C--O 1.236 0.374 0 C-N-CA 123.995 0.918 . . . . 0.0 112.781 -179.335 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -79.84 51.7 4.0 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 124.474 3.449 . . . . 0.0 111.526 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.0 pttt -72.21 -56.47 5.48 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 120.83 -1.169 . . . . 0.0 110.486 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -70.83 -169.61 8.86 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 125.3 1.428 . . . . 0.0 112.075 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -57.12 144.18 70.17 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 118.209 -0.9 . . . . 0.0 111.316 179.64 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -64.4 142.5 79.04 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.838 2.359 . . . . 0.0 112.089 179.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -77.26 7.82 3.55 Favored 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 123.638 2.892 . . . . 0.0 112.051 178.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -94.62 -43.09 8.45 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 126.405 1.882 . . . . 0.0 109.845 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -94.45 8.53 41.76 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 124.113 0.965 . . . . 0.0 111.193 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 17.2 tt -45.89 -35.78 2.16 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 126.644 1.977 . . . . 0.0 111.874 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -59.67 -25.15 64.49 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 125.374 1.47 . . . . 0.0 112.223 179.535 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -77.88 -36.14 50.07 Favored 'General case' 0 CA--C 1.518 -0.253 0 C-N-CA 124.068 0.947 . . . . 0.0 109.977 179.278 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 84.9 mt -57.38 -40.69 78.71 Favored 'General case' 0 CA--C 1.516 -0.335 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.227 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 94.4 t -60.39 104.71 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 178.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 118.67 -14.95 11.56 Favored Glycine 0 CA--C 1.526 0.748 0 CA-C-O 117.957 -1.468 . . . . 0.0 113.187 -179.474 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -81.06 168.5 18.57 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 119.564 1.682 . . . . 0.0 108.39 179.23 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -114.83 138.11 51.16 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 124.15 0.98 . . . . 0.0 109.316 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.1 m -74.06 151.94 7.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.596 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 13.1 mt -100.39 -13.99 18.53 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 126.018 1.727 . . . . 0.0 113.643 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 10.4 m -151.14 163.85 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 126.974 2.109 . . . . 0.0 107.915 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 20.6 m -73.25 102.53 3.68 Favored 'General case' 0 CA--C 1.534 0.349 0 O-C-N 121.085 -1.009 . . . . 0.0 108.665 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 64.1 t -78.4 144.28 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 N-CA-C 107.167 -1.419 . . . . 0.0 107.167 179.226 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 34.9 mm-40 -88.65 174.73 7.87 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 122.094 0.95 . . . . 0.0 110.082 179.4 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -77.14 143.35 39.19 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 177.49 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 69.63 -1.07 2.4 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 125.436 1.495 . . . . 0.0 112.698 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.4 t0 -67.2 151.34 47.72 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 127.177 2.191 . . . . 0.0 110.976 -178.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 15.6 m -80.51 127.58 32.6 Favored 'General case' 0 C--N 1.324 -0.535 0 C-N-CA 123.272 0.629 . . . . 0.0 110.431 -178.687 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.2 mm -85.08 96.4 4.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.264 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 179.113 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . 0.536 ' H ' HD12 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -82.79 170.2 15.29 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 177.37 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.432 ' CD ' ' H ' ' A' ' 61' ' ' GLU . 17.8 mp0 -76.18 -34.69 59.33 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 125.198 1.399 . . . . 0.0 109.658 -179.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -64.56 -29.03 70.06 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 123.09 0.556 . . . . 0.0 111.334 179.144 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.536 HD12 ' H ' ' A' ' 60' ' ' MET . 73.9 mt -76.1 -0.18 21.01 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.79 1.236 . . . . 0.0 113.229 -179.385 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.36 147.2 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 121.466 1.939 . . . . 0.0 110.751 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.45 164.43 11.54 Favored 'General case' 0 C--O 1.239 0.507 0 CA-C-O 123.256 1.503 . . . . 0.0 114.079 -179.014 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -81.49 96.55 7.45 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.117 179.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 52.7 t-80 -71.18 88.17 0.81 Allowed 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 124.061 0.944 . . . . 0.0 108.821 179.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -178.95 142.02 5.16 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 107.593 -2.203 . . . . 0.0 107.593 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -157.01 -24.91 0.09 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 179.212 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 22.4 ttmm -70.11 134.43 48.17 Favored 'General case' 0 C--O 1.236 0.342 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 80.1 mt -130.98 149.52 33.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 37.3 ttpt -142.67 74.29 1.44 Allowed 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 125.706 1.602 . . . . 0.0 106.939 179.556 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 11.4 m -72.38 63.77 0.56 Allowed 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.05 1.34 . . . . 0.0 110.527 179.561 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 34.4 t -158.96 174.09 15.5 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 125.35 1.46 . . . . 0.0 108.03 -179.535 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -173.35 177.39 45.77 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 127.203 2.335 . . . . 0.0 107.693 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -68.76 155.36 68.98 Favored 'Trans proline' 0 N--CA 1.456 -0.706 0 C-N-CA 121.683 1.588 . . . . 0.0 109.342 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 67.3 m -152.3 35.67 0.52 Allowed 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.318 1.047 . . . . 0.0 109.718 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 12.2 m -154.16 169.47 23.5 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 126.01 1.724 . . . . 0.0 107.175 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.452 0 C-N-CA 127.589 2.519 . . . . 0.0 106.918 -179.756 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.698 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.5 t -67.99 -178.64 1.04 Allowed 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.419 1.488 . . . . 0.0 112.077 -179.532 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.2 t -70.79 131.42 43.79 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 125.279 1.431 . . . . 0.0 109.827 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.16 149.28 20.4 Favored Glycine 0 N--CA 1.446 -0.693 0 N-CA-C 107.703 -2.159 . . . . 0.0 107.703 178.599 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.0 p -106.78 -6.28 17.87 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 126.006 1.722 . . . . 0.0 113.012 -179.251 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.7 t -66.29 -10.55 43.6 Favored 'General case' 0 CA--C 1.535 0.381 0 N-CA-C 115.848 1.796 . . . . 0.0 115.848 -178.625 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.2 -160.47 36.49 Favored Glycine 0 CA--C 1.521 0.439 0 CA-C-N 119.636 1.107 . . . . 0.0 110.753 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.4 t -137.37 163.17 31.69 Favored 'General case' 0 C--O 1.239 0.532 0 C-N-CA 123.94 0.896 . . . . 0.0 109.324 179.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.0 t -74.06 136.19 25.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.1 m -130.37 158.95 42.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 C-N-CA 125.426 1.49 . . . . 0.0 107.805 178.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.96 107.2 5.2 Favored 'General case' 0 N--CA 1.443 -0.797 0 N-CA-C 104.733 -2.321 . . . . 0.0 104.733 177.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 37.6 tttt -59.75 -24.09 63.76 Favored 'General case' 0 N--CA 1.464 0.239 0 O-C-N 121.6 -0.687 . . . . 0.0 111.857 -179.265 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.1 m -145.86 169.52 6.41 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 C-N-CA 125.679 1.592 . . . . 0.0 109.123 -178.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 36.8 tttm -72.71 128.32 35.19 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 103.386 -2.82 . . . . 0.0 103.386 176.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.5 mt -122.69 115.22 29.64 Favored Pre-proline 0 C--N 1.333 -0.143 0 C-N-CA 125.09 1.356 . . . . 0.0 111.122 -176.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -70.65 153.98 64.49 Favored 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 121.077 1.185 . . . . 0.0 110.463 178.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.471 ' HA ' HG23 ' A' ' 49' ' ' VAL . 37.3 tt0 -54.2 149.36 9.81 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 125.671 1.588 . . . . 0.0 111.436 179.45 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.13 -2.7 64.54 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 123.798 0.714 . . . . 0.0 114.431 179.47 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 12.8 m -81.76 143.63 31.67 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 119.179 1.49 . . . . 0.0 109.809 -179.601 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 39.9 mm -84.41 125.99 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.916 -1.883 . . . . 0.0 105.916 178.07 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 45.4 mt -66.38 144.83 56.3 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 124.434 1.094 . . . . 0.0 110.893 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 40.1 p -139.3 165.88 26.02 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 106.679 -1.601 . . . . 0.0 106.679 178.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.6 mmt -67.08 -9.82 43.46 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.914 -0.492 . . . . 0.0 110.507 178.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -88.83 -2.83 58.78 Favored 'General case' 0 N--CA 1.471 0.579 0 O-C-N 120.353 -1.467 . . . . 0.0 110.88 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 36.7 mtm -125.11 4.81 7.89 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 124.944 1.298 . . . . 0.0 110.961 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.8 mt -135.8 147.33 48.29 Favored 'General case' 0 CA--C 1.512 -0.506 0 O-C-N 121.163 -0.961 . . . . 0.0 109.326 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 4.9 t -159.46 177.98 10.39 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 178.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.1 132.82 68.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 106.603 -1.629 . . . . 0.0 106.603 178.713 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 25.1 mmtp -91.51 -173.04 3.44 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 178.719 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.86 96.83 4.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 O-C-N 120.948 -1.095 . . . . 0.0 108.856 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.16 -82.71 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -157.02 160.7 30.51 Favored Pre-proline 0 CA--C 1.546 0.816 0 C-N-CA 125.529 1.532 . . . . 0.0 109.132 -179.04 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -66.46 13.02 0.14 Allowed 'Trans proline' 0 CA--C 1.54 0.781 1 C-N-CA 126.321 4.681 . . . . 0.0 116.94 -179.039 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 19.0 ptmt -54.06 114.38 1.58 Allowed 'General case' 0 C--O 1.221 -0.412 0 CA-C-N 119.287 0.949 . . . . 0.0 110.853 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 116.56 -81.03 0.3 Allowed Glycine 0 C--N 1.332 0.321 0 CA-C-N 119.625 1.102 . . . . 0.0 112.366 179.125 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -151.17 138.36 11.99 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 123.147 0.579 . . . . 0.0 111.822 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -68.13 134.77 32.6 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.357 2.038 . . . . 0.0 111.707 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -63.71 -22.49 69.76 Favored 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 122.439 2.093 . . . . 0.0 113.191 179.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -69.4 -8.6 48.0 Favored 'General case' 0 CA--C 1.534 0.341 0 CA-C-N 119.323 0.965 . . . . 0.0 112.404 179.461 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 30.1 t0 -119.78 10.39 11.62 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 124.794 1.238 . . . . 0.0 112.414 -178.508 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 19.3 tt -51.84 -31.17 13.05 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 O-C-N 121.326 -0.859 . . . . 0.0 113.078 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -54.63 -37.49 65.71 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 125.248 1.419 . . . . 0.0 112.278 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -77.95 -29.28 49.77 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 118.467 0.576 . . . . 0.0 111.042 179.182 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 78.0 mt -66.46 -34.54 78.18 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 179.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 56.1 t -69.58 105.18 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -179.004 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 119.81 -10.08 11.32 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.894 1.711 . . . . 0.0 112.587 -179.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 3.3 mtpp -82.16 154.39 25.52 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 119.228 1.514 . . . . 0.0 108.026 178.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.2 ttmt -95.69 135.15 37.76 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.471 HG23 ' HA ' ' A' ' 17' ' ' GLU . 5.1 m -75.81 143.45 13.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 177.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 73.4 mt -89.27 -14.94 34.71 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 124.399 1.08 . . . . 0.0 111.248 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 30.4 m -145.9 163.81 10.55 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 C-N-CA 126.395 1.878 . . . . 0.0 109.309 -178.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 4.9 m -75.76 127.4 32.96 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 105.731 -1.951 . . . . 0.0 105.731 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 89.2 t -105.93 148.74 10.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -98.66 170.55 8.71 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 123.626 0.77 . . . . 0.0 111.603 -179.066 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -67.78 132.75 48.01 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.4 t70 67.91 9.39 7.1 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 129.327 3.051 . . . . 0.0 114.201 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -68.06 154.64 41.23 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 123.429 0.692 . . . . 0.0 110.253 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -84.81 124.97 32.18 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 123.246 0.618 . . . . 0.0 110.97 -178.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.9 mm -85.84 146.95 5.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 178.073 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 32.9 mtp -134.01 151.76 51.57 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 105.47 -2.048 . . . . 0.0 105.47 178.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.26 -26.96 61.63 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 123.562 0.745 . . . . 0.0 112.885 -178.765 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -76.62 -0.58 23.91 Favored 'General case' 0 N--CA 1.451 -0.408 0 C-N-CA 126.0 1.72 . . . . 0.0 114.768 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 61.6 mt -113.53 3.18 15.63 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.204 1.402 . . . . 0.0 112.364 -179.402 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 3.2 m -132.52 152.9 37.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-N 119.462 1.028 . . . . 0.0 112.453 -178.025 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -61.8 150.78 36.08 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.594 0.758 . . . . 0.0 110.109 179.292 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -95.88 -42.48 8.29 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 116.453 2.02 . . . . 0.0 116.453 -177.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 -136.05 73.2 1.45 Allowed 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 124.266 1.026 . . . . 0.0 112.237 -177.712 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -75.38 169.17 54.75 Favored Glycine 0 CA--C 1.526 0.764 0 C-N-CA 124.227 0.918 . . . . 0.0 113.356 -178.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.02 144.6 20.18 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 126.855 2.062 . . . . 0.0 106.234 178.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 51.1 tttp -148.44 130.4 15.29 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 177.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 31.7 pt -60.76 152.68 5.46 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.46 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 3.0 ttmp? -149.72 153.56 37.12 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 126.958 2.103 . . . . 0.0 107.236 178.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 73.3 m -140.8 126.08 18.62 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 104.131 -2.544 . . . . 0.0 104.131 178.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 12.4 m -91.91 168.54 11.35 Favored 'General case' 0 C--O 1.239 0.511 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 179.39 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -112.91 78.38 0.25 Allowed Glycine 0 CA--C 1.527 0.818 0 CA-C-O 118.055 -1.414 . . . . 0.0 112.265 -179.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -69.99 167.96 23.24 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.695 2.263 . . . . 0.0 110.18 179.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 46.5 t -143.56 -173.27 3.91 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.81 1.644 . . . . 0.0 107.344 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 33.7 m -129.35 16.48 6.04 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 127.02 2.128 . . . . 0.0 109.898 179.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.254 1.346 0 C-N-CA 130.388 3.851 . . . . 0.0 106.108 179.736 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.358 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 42.7 p -80.33 109.07 14.47 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 179.245 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.3 t -64.86 174.83 1.7 Allowed 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.933 0.873 . . . . 0.0 110.713 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 153.08 89.46 0.07 OUTLIER Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 105.618 -2.993 . . . . 0.0 105.618 -179.37 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.9 m -123.49 95.38 4.56 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 125.331 1.452 . . . . 0.0 108.786 -179.208 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.4 m -168.6 173.82 7.14 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 127.861 2.464 . . . . 0.0 108.301 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.426 ' HA3' ' HA ' ' A' ' 30' ' ' VAL . . . 81.25 -164.74 46.13 Favored Glycine 0 C--N 1.336 0.541 0 C-N-CA 123.939 0.781 . . . . 0.0 111.995 179.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 55.7 p -137.74 155.58 48.92 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 124.224 1.01 . . . . 0.0 110.842 179.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 43.4 t -75.93 130.61 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 178.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 m -129.74 157.68 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 N-CA-C 105.122 -2.177 . . . . 0.0 105.122 177.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.05 128.9 36.62 Favored 'General case' 0 N--CA 1.444 -0.731 0 O-C-N 121.356 -0.84 . . . . 0.0 109.38 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 52.6 tttt -72.44 -27.49 62.36 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.075 0.55 . . . . 0.0 111.309 179.686 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.6 m -146.87 171.65 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 C-N-CA 127.092 2.157 . . . . 0.0 108.083 -179.473 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.3 tttt -70.58 124.67 24.79 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 178.58 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.3 mt -116.16 101.81 53.82 Favored Pre-proline 0 C--N 1.327 -0.384 0 N-CA-C 105.788 -1.93 . . . . 0.0 105.788 -178.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.689 ' HA ' HG23 ' A' ' 52' ' ' THR . 33.3 Cg_endo -63.31 159.05 41.53 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 120.896 1.064 . . . . 0.0 110.627 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 71.4 tt0 -54.83 149.03 11.96 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 179.512 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 74.94 4.89 73.46 Favored Glycine 0 CA--C 1.533 1.212 0 CA-C-O 119.045 -0.864 . . . . 0.0 114.576 179.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 18.9 m -92.11 150.85 20.71 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 119.667 1.734 . . . . 0.0 109.425 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 36.5 mm -89.5 135.97 24.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.439 0 C-N-CA 124.149 0.98 . . . . 0.0 110.108 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 25.9 mt -75.56 143.4 42.43 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.172 0.51 . . . . 0.0 109.808 178.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 33.2 p -138.55 154.13 48.74 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 179.475 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 17.4 mmt -59.71 -34.48 72.97 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-O 121.834 0.826 . . . . 0.0 110.332 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -64.81 -12.45 48.16 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 126.633 1.973 . . . . 0.0 114.055 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 33.1 mtm -117.74 6.26 12.34 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.22 1.008 . . . . 0.0 111.238 179.291 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.9 mt -119.41 153.21 35.56 Favored 'General case' 0 CA--C 1.52 -0.211 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 179.429 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.7 t -151.93 172.59 16.0 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 105.558 -2.015 . . . . 0.0 105.558 178.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.65 122.0 46.21 Favored 'Isoleucine or valine' 0 C--O 1.237 0.424 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.203 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 15.3 ttmm -87.39 103.57 15.62 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.072 -2.196 . . . . 0.0 105.072 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.426 ' HA ' ' HA3' ' A' ' 7' ' ' GLY . 14.8 m -65.55 132.96 31.19 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 179.609 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 161.52 -64.62 0.27 Allowed Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -145.4 157.69 52.17 Favored Pre-proline 0 N--CA 1.453 -0.3 0 CA-C-O 118.604 -0.712 . . . . 0.0 111.712 -178.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -78.93 11.97 2.39 Favored 'Trans proline' 0 CA--C 1.542 0.914 0 C-N-CA 123.433 2.755 . . . . 0.0 112.599 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -51.74 110.07 0.43 Allowed 'General case' 0 N--CA 1.463 0.202 0 C-N-CA 125.455 1.502 . . . . 0.0 110.126 179.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.63 -99.33 0.56 Allowed Glycine 0 C--N 1.333 0.374 0 CA-C-N 119.193 0.906 . . . . 0.0 111.931 179.164 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -139.18 134.76 16.86 Favored Pre-proline 0 C--O 1.239 0.543 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.615 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -61.0 133.44 47.33 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.557 2.838 . . . . 0.0 111.554 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -72.52 -16.22 27.35 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 123.466 2.777 . . . . 0.0 113.408 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -67.42 -23.39 65.54 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 119.399 1.0 . . . . 0.0 110.028 178.301 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 47.1 m-20 -99.71 7.86 44.77 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 126.125 1.77 . . . . 0.0 111.167 -179.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.4 tt -51.72 -33.84 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 CA-C-N 120.395 1.452 . . . . 0.0 112.712 -179.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -60.98 -19.26 60.92 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 123.97 0.908 . . . . 0.0 112.006 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 35.1 m-80 -92.43 -27.58 17.39 Favored 'General case' 0 CA--C 1.52 -0.189 0 C-N-CA 124.701 1.2 . . . . 0.0 110.364 179.189 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 19.5 mt -67.97 -37.77 81.92 Favored 'General case' 0 CA--C 1.52 -0.188 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.1 t -58.98 137.72 21.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 90.09 -14.02 63.25 Favored Glycine 0 CA--C 1.53 0.996 0 CA-C-O 118.121 -1.377 . . . . 0.0 112.824 -179.188 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 40.8 mttm -75.41 166.66 23.25 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 120.458 2.129 . . . . 0.0 108.812 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -119.76 132.42 55.62 Favored 'General case' 0 CA--C 1.521 -0.165 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.333 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -74.99 157.12 6.09 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-N 118.438 0.563 . . . . 0.0 112.461 179.81 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 40.4 mt -100.08 -19.14 16.64 Favored 'General case' 0 C--O 1.225 -0.229 0 C-N-CA 126.628 1.971 . . . . 0.0 110.49 178.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 35.4 m -142.43 158.74 19.46 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 C-N-CA 124.208 1.003 . . . . 0.0 109.445 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.689 HG23 ' HA ' ' A' ' 16' ' ' PRO . 58.0 m -72.23 99.51 2.39 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.919 1.688 . . . . 0.0 109.562 179.163 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 47.4 t -78.83 151.99 5.01 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 179.294 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -100.86 169.44 8.98 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 126.072 1.749 . . . . 0.0 110.655 179.371 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -69.33 141.62 54.22 Favored 'General case' 0 C--O 1.239 0.52 0 N-CA-C 106.001 -1.851 . . . . 0.0 106.001 176.637 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 67.13 1.22 2.3 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 128.182 2.593 . . . . 0.0 112.413 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.44 149.55 48.2 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.15 0.98 . . . . 0.0 109.938 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 94.6 m -85.26 124.51 31.97 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-O 122.326 1.06 . . . . 0.0 110.94 -177.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 mm -82.18 142.01 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 33.6 mtp -142.25 155.14 45.22 Favored 'General case' 0 C--O 1.237 0.399 0 C-N-CA 125.018 1.327 . . . . 0.0 108.008 179.072 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -61.22 -34.7 75.53 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 124.519 1.128 . . . . 0.0 112.388 -179.106 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -69.56 -2.85 12.56 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 113.688 0.996 . . . . 0.0 113.688 -179.497 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 54.3 mt -105.04 5.77 32.8 Favored 'General case' 0 C--O 1.234 0.285 0 C-N-CA 125.696 1.598 . . . . 0.0 112.827 -178.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 36.0 m -124.79 160.35 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 120.272 1.396 . . . . 0.0 112.068 -179.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -124.71 173.05 8.81 Favored 'General case' 0 C--O 1.238 0.49 0 C-N-CA 127.079 2.151 . . . . 0.0 110.434 -179.21 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 53.7 t-20 -62.85 135.5 57.36 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 126.409 1.884 . . . . 0.0 109.402 179.215 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -56.51 -40.31 74.79 Favored 'General case' 0 CA--C 1.537 0.474 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.451 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -123.95 81.07 0.35 Allowed Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 126.386 1.946 . . . . 0.0 109.337 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -72.22 38.21 0.07 Allowed 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 124.982 1.313 . . . . 0.0 111.487 179.052 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 20.7 ptmt -66.73 170.97 5.67 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 120.561 -1.337 . . . . 0.0 109.838 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 4.7 mp -125.59 147.53 30.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 C-N-CA 123.509 0.723 . . . . 0.0 109.377 -178.616 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 80.6 tttt -131.77 -78.32 0.51 Allowed 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 127.203 2.201 . . . . 0.0 105.246 179.198 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -67.8 153.59 43.39 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 124.484 1.114 . . . . 0.0 110.193 179.386 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.7 t -65.73 -37.73 87.21 Favored 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 89.92 93.13 1.19 Allowed Glycine 0 CA--C 1.527 0.789 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_endo -76.9 15.38 1.12 Allowed 'Trans proline' 0 CA--C 1.543 0.967 0 C-N-CA 123.676 2.917 . . . . 0.0 112.473 179.512 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.7 t -59.43 162.15 5.1 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 125.141 1.376 . . . . 0.0 111.06 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.8 t -149.21 173.33 13.58 Favored 'General case' 0 N--CA 1.447 -0.609 0 C-N-CA 124.832 1.253 . . . . 0.0 108.521 179.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.175 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 -179.884 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.668 0 N-CA-C 109.971 -1.252 . . . . 0.0 109.971 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.4 m -136.16 52.33 1.98 Allowed 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.774 1.23 . . . . 0.0 109.871 -179.574 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 m -64.24 173.04 2.15 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 125.41 1.484 . . . . 0.0 112.392 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -74.97 -37.96 42.26 Favored Glycine 0 CA--C 1.53 0.986 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 179.182 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 62.9 m -63.0 160.93 13.95 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 125.507 1.523 . . . . 0.0 112.253 -179.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.5 t 166.5 160.35 0.03 OUTLIER 'General case' 0 C--O 1.236 0.358 1 C-N-CA 132.101 4.161 . . . . 0.0 103.372 179.627 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 73.38 175.86 31.09 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.23 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.2 m -146.61 145.19 29.99 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.206 0.527 . . . . 0.0 111.982 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 21.8 t -69.88 128.82 33.79 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 C-N-CA 123.994 0.918 . . . . 0.0 109.837 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 32.3 m -123.62 152.68 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 178.178 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.486 ' HB2' HD11 ' A' ' 59' ' ' ILE . . . -68.01 111.57 4.49 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 178.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 18.6 tttp -59.59 -30.56 68.76 Favored 'General case' 0 CA--C 1.536 0.426 0 O-C-N 121.068 -1.02 . . . . 0.0 113.561 -178.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.8 m -141.98 170.82 11.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 128.747 2.819 . . . . 0.0 106.91 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 42.9 tttm -66.59 137.77 56.99 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 178.401 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.1 mt -121.7 103.43 40.61 Favored Pre-proline 0 N--CA 1.462 0.155 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -179.304 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -66.65 149.99 83.82 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 121.085 1.19 . . . . 0.0 109.561 179.281 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -52.32 146.17 9.84 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 125.448 1.499 . . . . 0.0 110.749 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 78.65 3.13 86.68 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 123.724 0.678 . . . . 0.0 114.508 178.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 22.6 m -91.49 147.67 22.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 118.361 1.081 . . . . 0.0 109.779 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 49.3 mm -87.09 135.59 24.89 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 C-N-CA 123.982 0.913 . . . . 0.0 108.611 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 13.9 mt -74.16 147.09 42.94 Favored 'General case' 0 CA--C 1.519 -0.226 0 C-N-CA 125.288 1.435 . . . . 0.0 110.841 179.252 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.691 ' HA ' HG23 ' A' ' 45' ' ' VAL . 53.8 p -140.96 157.69 44.99 Favored 'General case' 0 C--O 1.238 0.47 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.167 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 7.6 mmt -62.93 -20.43 65.19 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.266 0.939 . . . . 0.0 110.881 178.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -72.0 -21.28 61.58 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.226 0.921 . . . . 0.0 110.25 178.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 59.7 mtm -105.51 4.98 31.08 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 126.328 1.851 . . . . 0.0 111.62 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 80.3 mt -122.94 141.26 52.12 Favored 'General case' 0 CA--C 1.516 -0.339 0 O-C-N 121.135 -0.978 . . . . 0.0 108.647 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.6 t -153.22 115.48 4.39 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.729 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 9' ' ' VAL . 0.2 OUTLIER -71.4 139.04 20.52 Favored 'Isoleucine or valine' 0 C--O 1.238 0.479 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.16 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.53 112.33 25.38 Favored 'General case' 0 N--CA 1.438 -1.037 0 N-CA-C 104.542 -2.392 . . . . 0.0 104.542 177.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.79 127.83 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 178.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 171.27 -85.86 0.08 OUTLIER Glycine 0 C--N 1.334 0.468 0 C-N-CA 119.955 -1.117 . . . . 0.0 113.356 -179.04 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -138.91 160.78 61.48 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 118.162 0.981 . . . . 0.0 111.562 -178.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -72.78 5.85 2.72 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.406 2.737 . . . . 0.0 114.818 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 23.7 tttp -68.63 92.91 0.48 Allowed 'General case' 0 C--O 1.233 0.21 0 C-N-CA 124.928 1.291 . . . . 0.0 109.476 179.377 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 148.21 -91.78 0.15 Allowed Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -157.27 141.38 11.67 Favored Pre-proline 0 C--O 1.238 0.454 0 C-N-CA 124.974 1.31 . . . . 0.0 110.308 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -68.64 150.39 74.59 Favored 'Trans proline' 0 CA--C 1.538 0.699 0 C-N-CA 122.447 2.098 . . . . 0.0 112.737 -179.403 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 80.7 Cg_endo -79.59 -3.28 12.82 Favored 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 123.098 2.532 . . . . 0.0 113.639 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -73.15 -59.11 2.86 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -71.31 4.95 2.49 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 128.762 2.825 . . . . 0.0 113.748 -179.395 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.559 ' HA ' HD12 ' A' ' 44' ' ' LEU . 17.4 tt -48.88 -37.11 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.568 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -178.153 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -63.38 -13.95 44.95 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 124.083 0.953 . . . . 0.0 113.49 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -87.29 -30.38 20.91 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 123.381 0.672 . . . . 0.0 110.989 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.559 HD12 ' HA ' ' A' ' 41' ' ' ILE . 21.2 mt -67.66 -44.54 77.59 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.331 1.052 . . . . 0.0 108.775 -179.13 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.691 HG23 ' HA ' ' A' ' 22' ' ' THR . 1.4 p -66.4 124.01 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.68 -15.47 29.21 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 125.664 1.602 . . . . 0.0 112.3 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 61.7 mttm -81.84 158.25 24.11 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 119.073 1.437 . . . . 0.0 110.469 179.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -97.89 142.55 29.49 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 177.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.0 m -86.1 144.0 10.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 CA-C-N 119.397 0.999 . . . . 0.0 109.228 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 62.2 mt -92.92 -3.84 53.83 Favored 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 125.446 1.498 . . . . 0.0 112.96 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 28.7 m -148.93 161.98 5.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 C-N-CA 125.81 1.644 . . . . 0.0 109.715 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.4 m -85.28 100.64 11.93 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 104.118 -2.549 . . . . 0.0 104.118 176.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.444 HG11 HD11 ' A' ' 59' ' ' ILE . 44.7 t -82.4 143.34 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 179.389 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -88.94 176.52 6.98 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 123.73 0.812 . . . . 0.0 110.605 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -72.41 143.42 48.53 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.496 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 59.23 11.58 2.17 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 128.946 2.898 . . . . 0.0 113.806 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -75.04 154.25 38.06 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.09 1.356 . . . . 0.0 109.099 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.0 m -82.61 132.86 35.18 Favored 'General case' 0 C--N 1.33 -0.276 0 O-C-N 120.886 -1.134 . . . . 0.0 112.379 -178.329 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.486 HD11 ' HB2' ' A' ' 11' ' ' ALA . 41.4 mm -100.2 127.52 53.08 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.72 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' MET . . . . . . . . . . . . . 30.9 mtp -122.58 167.37 13.47 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 178.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -61.09 -23.65 65.64 Favored 'General case' 0 CA--C 1.538 0.505 0 O-C-N 120.929 -1.107 . . . . 0.0 113.95 -179.565 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -76.56 -4.79 44.7 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 125.54 1.536 . . . . 0.0 113.065 -179.538 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 19.1 mt -107.61 2.08 23.69 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.721 0.809 . . . . 0.0 112.249 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.4 m -127.22 159.05 37.98 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 CA-C-N 119.37 0.986 . . . . 0.0 111.704 -178.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -70.99 159.66 34.34 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 125.622 1.569 . . . . 0.0 113.569 -179.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 21.2 t30 -95.55 105.53 17.51 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 105.23 -2.137 . . . . 0.0 105.23 177.602 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 31.2 p-80 -39.58 -45.04 1.55 Allowed 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 127.503 2.321 . . . . 0.0 110.2 179.088 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.85 82.45 0.18 Allowed Glycine 0 C--N 1.337 0.639 0 C-N-CA 123.804 0.716 . . . . 0.0 112.004 178.521 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 18.0 ttmt -116.79 50.14 1.1 Allowed 'General case' 0 CA--C 1.518 -0.253 0 O-C-N 122.132 -0.628 . . . . 0.0 111.064 179.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 5.0 tmmm? -149.12 123.07 9.38 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 104.141 -2.54 . . . . 0.0 104.141 177.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 97.4 mt -139.0 136.29 42.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 104.685 -2.339 . . . . 0.0 104.685 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -140.58 150.15 43.27 Favored 'General case' 0 C--O 1.235 0.301 0 C-N-CA 124.847 1.259 . . . . 0.0 108.092 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.0 p -146.43 69.46 1.19 Allowed 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 179.142 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 61.41 8.75 2.3 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.571 1.548 . . . . 0.0 114.78 -179.154 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -83.4 177.98 52.73 Favored Glycine 0 CA--C 1.534 1.271 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 178.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -69.29 163.62 37.21 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 123.157 2.571 . . . . 0.0 113.108 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.8 p -83.43 73.18 10.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.358 1.463 . . . . 0.0 109.803 179.472 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 34.2 p -62.52 -18.23 61.48 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 123.113 0.565 . . . . 0.0 110.887 178.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.439 -1.123 0 C-N-CA 130.294 3.807 . . . . 0.0 105.121 179.512 . . . . . . . . 0 0 . 1 stop_ save_